action_type,activity_comment,activity_id,activity_properties,assay_chembl_id,assay_description,assay_type,assay_variant_accession,assay_variant_mutation,bao_endpoint,bao_format,bao_label,canonical_smiles,data_validity_comment,data_validity_description,document_chembl_id,document_journal,document_year,ligand_efficiency,molecule_chembl_id,molecule_pref_name,parent_molecule_chembl_id,pchembl_value,potential_duplicate,qudt_units,record_id,relation,src_id,standard_flag,standard_relation,standard_text_value,standard_type,standard_units,standard_upper_value,standard_value,target_chembl_id,target_organism,target_pref_name,target_tax_id,text_value,toid,type,units,uo_units,upper_value,value
,,305155,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,O=c1c2ccc(S(=O)(=O)c3ccc4c(=O)n5c6ccccc6nc5c5cccc3c45)c3cccc(c32)c2nc3ccccc3n12,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '8.05', 'le': '0.15', 'lle': '-1.48', 'sei': '4.72'}",CHEMBL337153,,CHEMBL337153,4.85,0,http://www.openphacts.org/units/Nanomolar,262350,=,1,1,=,,IC50,nM,,14000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,14.0
,Not Active,306440,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,CN1C(=O)c2ccc3c4ccc5c(=O)n6c7ccccc7nc6c6ccc(c7ccc(c2c37)C1=O)c4c56,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137528,,CHEMBL137528,,0,http://www.openphacts.org/units/Nanomolar,262333,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,307747,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,Brc1cccc[n+]1-c1ccc2cc(-[n+]3ccccc3Br)ccc2c1,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '11.15', 'le': '0.28', 'lle': '0.01', 'sei': '63.55'}",CHEMBL340270,,CHEMBL340270,4.93,0,http://www.openphacts.org/units/Nanomolar,262316,=,1,1,=,,IC50,nM,,11700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,11.7
,Not Active,307748,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc(-c2ccccc2)[nH]c2nc3ccccc3[n+]1-2,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137543,,CHEMBL137543,,0,http://www.openphacts.org/units/Nanomolar,262323,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,309225,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1c2ccc[n+]3c2-c2c1ccc[n+]2CC3,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL337147,,CHEMBL337147,,0,http://www.openphacts.org/units/Nanomolar,262329,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,310418,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,Nc1nc(-c2ccccc2)nc2c1[n+]([O-])c1ccccc1[n+]2[O-],,,CHEMBL1134645,J Med Chem,2001,"{'bei': '18.98', 'le': '0.34', 'lle': '4.50', 'sei': '5.48'}",CHEMBL443221,,CHEMBL443221,5.80,0,http://www.openphacts.org/units/Nanomolar,262314,=,1,1,=,,IC50,nM,,1600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.6
,Not Active,310419,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,CS1(C)=NC(=O)C2=C(N=1)c1ccccc1S2(=O)=O,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL343734,,CHEMBL343734,,0,http://www.openphacts.org/units/Nanomolar,262324,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,314458,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc2c(cc1C)[n+]([O-])c(-c1nc3ccccc3s1)c(N)[n+]2[O-],,,CHEMBL1134645,J Med Chem,2001,,CHEMBL136866,,CHEMBL136866,,0,http://www.openphacts.org/units/Nanomolar,262331,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,316813,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C(CSc1nc2ccccc2s1)c1sc2sc3ccccc3[n+]2c1O,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137246,,CHEMBL137246,,0,http://www.openphacts.org/units/Nanomolar,262327,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,320523,[],CHEMBL651291,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2,B,,,BAO_0000190,BAO_0000357,single protein format,O=C1c2cc(Br)ccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1cc(Br)ccc1-5,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '8.32', 'le': '0.18', 'lle': '-4.57', 'sei': '14.98'}",CHEMBL135934,,CHEMBL135934,5.11,0,http://www.openphacts.org/units/Nanomolar,262312,=,1,1,=,,IC50,nM,,7700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.7
,Not Active,320524,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,CN(C)CCNCCCNc1c2ccccc2nc2cccc([N+](=O)[O-])c12,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137215,,CHEMBL137215,,0,http://www.openphacts.org/units/Nanomolar,262348,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,324313,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,COc1ccc2c(c1)c[n+](C)c1c3cc(OC)c(OC)cc3ccc21,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL335782,,CHEMBL335782,,0,http://www.openphacts.org/units/Nanomolar,262322,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,324314,[],CHEMBL651293,Inhibitory activity against Bcl-2,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)C(C#N)C1c2cc(Br)ccc2OC(N)C1C(=O)OCC,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '12.27', 'le': '0.28', 'lle': '2.96', 'sei': '4.52'}",CHEMBL137135,,CHEMBL137135,5.05,0,http://www.openphacts.org/units/Nanomolar,262321,=,1,1,=,,IC50,nM,,9000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.0
,,324315,[],CHEMBL651293,Inhibitory activity against Bcl-2,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(Cl)cc(C(=O)Nc2cc(S(=O)(=O)c3ccc(Cl)cc3)ccc2Cl)c1O,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '11.64', 'le': '0.26', 'lle': '-0.27', 'sei': '6.57'}",CHEMBL334590,,CHEMBL334590,5.48,0,http://www.openphacts.org/units/Nanomolar,262319,=,1,1,=,,IC50,nM,,3300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.3
,Not Active,329523,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1c2ccccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1ccccc1-5,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL344254,,CHEMBL344254,,0,http://www.openphacts.org/units/Nanomolar,262317,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,329524,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,COc1cc2ccc3c4cc5c(cc4c[n+](C)c3c2cc1OC)OCO5,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137740,,CHEMBL137740,,0,http://www.openphacts.org/units/Nanomolar,262341,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,329525,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,Cn1c(=O)c2nc(-[n+]3ccc(-c4ccccc4)cc3)[nH]c2n(C)c1=O,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137744,,CHEMBL137744,,0,http://www.openphacts.org/units/Nanomolar,262330,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,330672,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,COc1ccc2c(c1)CCc1cc(OC)ccc1/[N+]([O-])=[N+]\2[O-],,,CHEMBL1134645,J Med Chem,2001,"{'bei': '16.59', 'le': '0.31', 'lle': '1.74', 'sei': '7.06'}",CHEMBL344184,,CHEMBL344184,4.98,0,http://www.openphacts.org/units/Nanomolar,262313,=,1,1,=,,IC50,nM,,10400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.4
,,330673,[],CHEMBL649021,Inhibitory activity against Bcl-2 using bromide assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2c(c1)CCc1cc(OC)ccc1/[N+]([O-])=[N+]\2[O-],,,CHEMBL1134645,J Med Chem,2001,"{'bei': '17.97', 'le': '0.34', 'lle': '2.16', 'sei': '7.65'}",CHEMBL344184,,CHEMBL344184,5.40,0,http://www.openphacts.org/units/Nanomolar,262313,=,1,1,=,,IC50,nM,,4000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.0
,Not Active,330674,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1c2cc([N+](=O)[O-])ccc2-c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1cc([N+](=O)[O-])ccc1-5,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137267,,CHEMBL137267,,0,http://www.openphacts.org/units/Nanomolar,262338,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,332035,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1c2ccccc2-c2cc(O)c3c4c(O)cc5c6c(ccc(c7ccc1c2c73)c64)C(=O)c1ccccc1-5,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL136987,,CHEMBL136987,,0,http://www.openphacts.org/units/Nanomolar,262339,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,332036,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,C[n+]1cc2c3cc4c(cc3ccc2c2ccc3c(c21)OCO3)OCO4,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL135315,,CHEMBL135315,,0,http://www.openphacts.org/units/Nanomolar,262344,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,334817,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,Cl.N=C(N)c1ccc(/N=N/c2c(O)ccc3c2[nH]c2ccccc23)cc1,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '15.90', 'le': '0.29', 'lle': '0.51', 'sei': '4.73'}",CHEMBL540363,,CHEMBL1190214,5.24,0,http://www.openphacts.org/units/Nanomolar,262349,=,1,1,=,,IC50,nM,,5800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.8
,Not Active,334818,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,[O-][n+]1c2c([n+]([O-])c3c4ccccc4ccc31)-c1cccc3cccc-2c13,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL336901,,CHEMBL336901,,0,http://www.openphacts.org/units/Nanomolar,262336,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,334819,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,[O-][n+]1c2c([n+]([O-])c3c4ccccc4ccc31)-c1cccc3cccc-2c13,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL336901,,CHEMBL336901,,0,http://www.openphacts.org/units/Nanomolar,262335,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,334820,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,NCC(=O)c1ccc2cc(Br)c3ccccc3c2c1,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL343743,,CHEMBL343743,,0,http://www.openphacts.org/units/Nanomolar,262332,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,334821,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,Nc1nc(N)c2c(n1)[n+]([O-])c1ccccc1[n+]2[O-],,,CHEMBL1134645,J Med Chem,2001,,CHEMBL335140,,CHEMBL335140,,0,http://www.openphacts.org/units/Nanomolar,262340,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,335994,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,COc1cc2ccc3c[n+]4ccccc4cc3c2cc1OC,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137796,,CHEMBL137796,,0,http://www.openphacts.org/units/Nanomolar,262342,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,337273,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1c2ccccc2C(=O)c2c1ccc1nc3c(ccc4c(O)c5ccccc5c(O)c43)nc21,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL337140,,CHEMBL337140,,0,http://www.openphacts.org/units/Nanomolar,262345,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,337274,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,CN1COc2ccc3ccc4c(c3c2C1)CN(C)CO4,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL136016,,CHEMBL136016,,0,http://www.openphacts.org/units/Nanomolar,262343,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,337275,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C(CSc1ccccn1)c1sc2cccc[n+]2c1O,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL342944,,CHEMBL342944,,0,http://www.openphacts.org/units/Nanomolar,262326,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,337276,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,COc1cc2cc[n+]3c4ccc([N+](=O)[O-])cc4ccc3c2cc1OC.[Cl-],,,CHEMBL1134645,J Med Chem,2001,,CHEMBL609717,,CHEMBL136983,,0,http://www.openphacts.org/units/Nanomolar,262325,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,338549,[],CHEMBL651292,In vitro inhibitory activity against Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60,B,,,BAO_0000190,BAO_0000019,assay format,COc1ccc2c(c1)C(=O)C1C=C([N+]#N)C=CC1N2.[Cl-],,,CHEMBL1134645,J Med Chem,2001,"{'bei': '19.60', 'le': '0.36', 'lle': '2.39', 'sei': '7.50'}",CHEMBL137800,,CHEMBL1180673,4.98,0,http://www.openphacts.org/units/Nanomolar,262315,=,1,1,=,,IC50,nM,,10400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.4
,Not Active,338550,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=C1NC(=O)c2ccc3c4ccc5c6c(ccc(c7ccc1c2c73)c64)C(=O)N(c1ccccc1)C5=O,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL342179,,CHEMBL342179,,0,http://www.openphacts.org/units/Nanomolar,262334,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,338551,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,c1cc[n+]2c(c1)-c1cccc[n+]1CCC2,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137177,,CHEMBL137177,,0,http://www.openphacts.org/units/Nanomolar,262347,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,338552,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,O=c1c2ccccc2c2nc3ccc4c(=O)c5ccccc5c5nc6ccc1c2c6c3c45,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137369,,CHEMBL137369,,0,http://www.openphacts.org/units/Nanomolar,262346,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,Not Active,338553,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,OC1C[n+]2cc3ccccn3c2-c2cccc[n+]21,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL343296,,CHEMBL343296,,0,http://www.openphacts.org/units/Nanomolar,262328,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,339975,[],CHEMBL651293,Inhibitory activity against Bcl-2,B,,,BAO_0000190,BAO_0000357,single protein format,CCCC[C@H]1C(=O)O[C@H](C)[C@H](NC(=O)c2cccc(NC=O)c2O)C(=O)O[C@@H](C)[C@@H]1OC(=O)CC(C)C,,,CHEMBL1134645,J Med Chem,2001,"{'bei': '10.95', 'le': '0.21', 'lle': '3.00', 'sei': '3.62'}",CHEMBL436605,ANTIMYCIN A3,CHEMBL436605,5.70,0,http://www.openphacts.org/units/Nanomolar,262318,=,1,1,=,,IC50,nM,,2000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.0
,Not Active,342354,[],CHEMBL875933,In vitro inhibition of Bak-Bh3 peptide binding to the Bcl-2 using human myeloid leukemia cell line HL-60; Inactive,B,,,BAO_0000190,BAO_0000019,assay format,c1cc[n+]2cc3ccc4c[n+]5ccccc5cc4c3cc2c1,,,CHEMBL1134645,J Med Chem,2001,,CHEMBL137306,,CHEMBL137306,,0,http://www.openphacts.org/units/Nanomolar,262337,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,1244283,[],CHEMBL649854,Inhibitory activity against Bcl-2 functioning,F,,,BAO_0000190,BAO_0000019,assay format,CCSCCCCC(c1ccc(O)cc1)C(C)(CC)c1ccc(O)cc1,,,CHEMBL1135909,J Med Chem,2002,,CHEMBL2374449,,CHEMBL2374449,,0,http://www.openphacts.org/units/Nanomolar,62824,~,1,1,~,,IC50,nM,,9000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.0
,,1617644,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.09', 'le': None, 'lle': None, 'sei': None}",CHEMBL411747,,CHEMBL411747,6.52,0,http://www.openphacts.org/units/Nanomolar,405278,=,1,1,=,,IC50,nM,,300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.3
,Not Active,1617645,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,,CHEMBL439314,,CHEMBL439314,,0,http://www.openphacts.org/units/Nanomolar,405279,,1,0,,,IC50,nM,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,
,,1617646,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.03', 'le': None, 'lle': None, 'sei': None}",CHEMBL269555,,CHEMBL269555,5.25,0,http://www.openphacts.org/units/Nanomolar,405280,=,1,1,=,,IC50,nM,,5600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.6
,,1617647,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CCC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.86', 'le': None, 'lle': None, 'sei': None}",CHEMBL411219,,CHEMBL411219,4.76,0,http://www.openphacts.org/units/Nanomolar,405281,=,1,1,=,,IC50,nM,,17500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,17.5
,,1617652,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.31', 'le': None, 'lle': None, 'sei': None}",CHEMBL437858,,CHEMBL437858,7.31,0,http://www.openphacts.org/units/Nanomolar,405283,=,1,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.049
,,1617653,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](C)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.13', 'le': None, 'lle': None, 'sei': None}",CHEMBL409227,,CHEMBL409227,6.39,0,http://www.openphacts.org/units/Nanomolar,405284,=,1,1,=,,IC50,nM,,410.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.41
,,1617654,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.97', 'le': None, 'lle': None, 'sei': None}",CHEMBL427653,,CHEMBL427653,6.10,0,http://www.openphacts.org/units/Nanomolar,405285,=,1,1,=,,IC50,nM,,800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.8
,,1617655,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CSCC[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCC(=O)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.93', 'le': None, 'lle': None, 'sei': None}",CHEMBL412528,,CHEMBL412528,5.87,0,http://www.openphacts.org/units/Nanomolar,405286,=,1,1,=,,IC50,nM,,1360.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.36
,,1617656,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CN)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)[C@@H](C)CC)[C@@H](C)CC,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.94', 'le': None, 'lle': None, 'sei': None}",CHEMBL441321,,CHEMBL441321,5.08,0,http://www.openphacts.org/units/Nanomolar,405287,=,1,1,=,,IC50,nM,,8360.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,8.36
,,1617657,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCSC)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H]1CCCN1)[C@@H](C)O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)O)C(=O)O)[C@@H](C)CC)[C@@H](C)CC,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.92', 'le': None, 'lle': None, 'sei': None}",CHEMBL440058,,CHEMBL440058,5.52,0,http://www.openphacts.org/units/Nanomolar,405288,=,1,1,=,,IC50,nM,,3030.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.03
,,1617658,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(C)C)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@H](C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)[C@@H](C)CC)[C@@H](C)CC,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.20', 'le': None, 'lle': None, 'sei': None}",CHEMBL409228,,CHEMBL409228,6.19,0,http://www.openphacts.org/units/Nanomolar,405289,=,1,1,=,,IC50,nM,,650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.65
,,1617659,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](N)CCCCN)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL414287,,CHEMBL414287,4.54,0,http://www.openphacts.org/units/Nanomolar,405290,=,1,1,=,,IC50,nM,,29070.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,29.07
,,1617660,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.88', 'le': None, 'lle': None, 'sei': None}",CHEMBL441574,,CHEMBL441574,5.54,0,http://www.openphacts.org/units/Nanomolar,405291,=,1,1,=,,IC50,nM,,2880.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.88
,,1617661,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.01', 'le': None, 'lle': None, 'sei': None}",CHEMBL265917,,CHEMBL265917,5.88,0,http://www.openphacts.org/units/Nanomolar,405292,=,1,1,=,,IC50,nM,,1330.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.33
,,1617665,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](N)CCCN=C(N)N)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)C(C)C,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '2.53', 'le': None, 'lle': None, 'sei': None}",CHEMBL413158,,CHEMBL413158,4.65,0,http://www.openphacts.org/units/Nanomolar,405294,=,1,1,=,,IC50,nM,,22340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,22.34
,,1617666,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCC(N)=O)[C@@H](C)CC)[C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N1CCC[C@H]1C(=O)N1CCC[C@H]1C(=O)NCC(=O)O)[C@@H](C)CC)C(C)C,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.68', 'le': None, 'lle': None, 'sei': None}",CHEMBL438732,,CHEMBL438732,4.85,0,http://www.openphacts.org/units/Nanomolar,405295,=,1,1,=,,IC50,nM,,14080.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,14.08
,,1617667,[],CHEMBL880570,Inhibition of BCL2 by fluorescence polarization based competitive binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](Cc1c[nH]cn1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CO)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)O)C(C)C,,,CHEMBL1142844,Bioorg Med Chem Lett,2005,"{'bei': '1.98', 'le': None, 'lle': None, 'sei': None}",CHEMBL442325,,CHEMBL442325,5.81,0,http://www.openphacts.org/units/Nanomolar,405296,=,1,1,=,,IC50,nM,,1560.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.56
,,1679650,[],CHEMBL858941,Inhibitory activity against Bcl-XL in presence of HSA3 from 1% human serum,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,,,CHEMBL1149415,J Med Chem,2006,"{'bei': '9.43', 'le': '0.19', 'lle': '-0.52', 'sei': '4.39'}",CHEMBL371861,,CHEMBL371861,5.20,0,http://www.openphacts.org/units/Nanomolar,425020,=,1,1,=,,IC50,nM,,6300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.3
,,1720432,[],CHEMBL866343,Displacement of Flu-Bid from human recombinant Bcl2 receptor,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)C[C@H]1N[C@@H](C(=O)NCCN2CCOCC2)[C@H](c2cccc(Cl)c2F)[C@@]12C(=O)Nc1cc(Cl)ccc12,,,CHEMBL1148527,J Med Chem,2006,,CHEMBL379173,,CHEMBL379173,,0,http://www.openphacts.org/units/Nanomolar,490991,>,1,1,>,,IC50,nM,,50000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,50.0
,,1771942,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '12.15', 'le': '0.23', 'lle': '-0.08', 'sei': '4.05'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,6.30,0,http://www.openphacts.org/units/Nanomolar,607811,=,1,1,=,,IC50,nM,,500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.5
,,1773930,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC[C@H](C)[C@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CCSC)NC(=O)[C@@H](N)CC(=O)O)[C@@H](C)CC)[C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](Cc1ccccc1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '2.43', 'le': None, 'lle': None, 'sei': None}",CHEMBL2371929,,CHEMBL2371929,7.96,0,http://www.openphacts.org/units/Nanomolar,607818,=,1,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.011
,,1773932,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '10.73', 'le': '0.21', 'lle': '-0.75', 'sei': '4.97'}",CHEMBL217354,,CHEMBL217354,6.16,0,http://www.openphacts.org/units/Nanomolar,607815,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
,,1773933,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '12.19', 'le': '0.23', 'lle': '1.32', 'sei': '4.68'}",CHEMBL217223,,CHEMBL217223,5.80,0,http://www.openphacts.org/units/Nanomolar,607814,=,1,1,=,,IC50,nM,,1600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.6
,,1773934,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(Nc1ccccc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '15.33', 'le': '0.28', 'lle': '1.49', 'sei': '5.73'}",CHEMBL214965,,CHEMBL214965,5.14,0,http://www.openphacts.org/units/Nanomolar,607813,=,1,1,=,,IC50,nM,,7200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.2
,,1773935,[],CHEMBL909445,Binding affinity to human Bcl2 by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)Nc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,"{'bei': '14.88', 'le': '0.28', 'lle': '1.09', 'sei': '4.76'}",CHEMBL214839,,CHEMBL214839,4.28,0,http://www.openphacts.org/units/Nanomolar,607812,=,1,1,=,,IC50,nM,,53100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,53.1
,,1773942,[],CHEMBL909448,Inhibition of growth of human PC3 cell overexpressing Bcl2,F,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)c1ccccc1Cc1cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,,CHEMBL217354,,CHEMBL217354,6.70,0,http://www.openphacts.org/units/Nanomolar,607815,=,1,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.2
,,1773943,[],CHEMBL909448,Inhibition of growth of human PC3 cell overexpressing Bcl2,F,,,BAO_0000190,BAO_0000219,cell-based format,COc1c(Cc2ccccc2C(C)C)cc(C(=O)Nc2ccc(S(=O)(=O)c3ccccc3C(C)(C)C)cc2)c(OC)c1OC,,,CHEMBL1137390,J Med Chem,2006,,CHEMBL216213,,CHEMBL216213,,0,http://www.openphacts.org/units/Nanomolar,607816,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,1773944,[],CHEMBL909448,Inhibition of growth of human PC3 cell overexpressing Bcl2,F,,,BAO_0000190,BAO_0000219,cell-based format,O=C(Nc1ccc(S(=O)(=O)c2ccccc2)cc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,,CHEMBL217223,,CHEMBL217223,5.40,0,http://www.openphacts.org/units/Nanomolar,607814,=,1,1,=,,IC50,nM,,4000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.0
,,1773945,[],CHEMBL909448,Inhibition of growth of human PC3 cell overexpressing Bcl2,F,,,BAO_0000190,BAO_0000219,cell-based format,O=C(Nc1ccccc1)c1cc(Cc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,,CHEMBL214965,,CHEMBL214965,5.30,0,http://www.openphacts.org/units/Nanomolar,607813,=,1,1,=,,IC50,nM,,5000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.0
,,1773946,[],CHEMBL909448,Inhibition of growth of human PC3 cell overexpressing Bcl2,F,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)c1cc(C(=O)Nc2ccccc2)c(O)c(O)c1O,,,CHEMBL1137390,J Med Chem,2006,,CHEMBL214839,,CHEMBL214839,5.16,0,http://www.openphacts.org/units/Nanomolar,607812,=,1,1,=,,IC50,nM,,7000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.0
,,1826035,[],CHEMBL918623,Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCCc1ccccc1)S(=O)(=O)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O,,,CHEMBL1144472,J Med Chem,2007,"{'bei': '9.53', 'le': '0.19', 'lle': '2.70', 'sei': '3.94'}",CHEMBL376055,,CHEMBL376055,6.48,0,http://www.openphacts.org/units/Nanomolar,629213,=,1,1,=,,IC50,nM,,330.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.33
,,1826036,[],CHEMBL918623,Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)N2CCc3ccc(S(=O)(=O)NCCc4ccccc4)cc3C2)c(O)c(O)c1O,,,CHEMBL1144472,J Med Chem,2007,"{'bei': '10.15', 'le': '0.20', 'lle': '1.53', 'sei': '4.07'}",CHEMBL219775,,CHEMBL219775,5.18,0,http://www.openphacts.org/units/Nanomolar,629212,=,1,1,=,,IC50,nM,,6600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.6
,,1826037,[],CHEMBL918623,Displacement of biotinylated Bim BH3 peptide from recombinant His-tagged Bcl2 by ELISA assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)N2CCc3ccccc3C2)c(O)c(O)c1O,,,CHEMBL1144472,J Med Chem,2007,"{'bei': '13.49', 'le': '0.25', 'lle': '1.29', 'sei': '5.45'}",CHEMBL220055,,CHEMBL220055,4.42,0,http://www.openphacts.org/units/Nanomolar,629211,=,1,1,=,,IC50,nM,,38200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,38.2
,,2103309,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)N2CCc3ccccc3C2)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '13.49', 'le': '0.25', 'lle': '1.29', 'sei': '5.45'}",CHEMBL220055,,CHEMBL220055,4.42,1,http://www.openphacts.org/units/Nanomolar,691257,=,1,1,=,,IC50,nM,,38200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,38.2
,,2103310,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2nc3ccccc3s2)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '14.00', 'le': '0.26', 'lle': '1.10', 'sei': '5.79'}",CHEMBL258819,,CHEMBL258819,6.77,0,http://www.openphacts.org/units/Nanomolar,691262,=,1,1,=,,IC50,nM,,170.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.17
,,2103311,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1ccc(Oc2ccccc2)cc1)c1cc(C(=O)c2cccc3ccccc23)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '13.72', 'le': '0.25', 'lle': '0.33', 'sei': '6.28'}",CHEMBL259034,,CHEMBL259034,6.54,0,http://www.openphacts.org/units/Nanomolar,691261,=,1,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.29
,,2103312,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)C(=O)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '14.23', 'le': '0.26', 'lle': '0.92', 'sei': '5.37'}",CHEMBL259033,,CHEMBL259033,5.58,0,http://www.openphacts.org/units/Nanomolar,691260,=,1,1,=,,IC50,nM,,2600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.6
,,2103313,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)c2ccc(Oc3ccccc3)cc2)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '15.01', 'le': '0.28', 'lle': '0.52', 'sei': '6.29'}",CHEMBL270268,,CHEMBL270268,5.47,0,http://www.openphacts.org/units/Nanomolar,691259,=,1,1,=,,IC50,nM,,3400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.4
,,2103314,[],CHEMBL932183,Inhibition of human Bcl-2 protein by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cc(C(=O)c2ccccc2)c(O)c(O)c1O,,,CHEMBL1141593,J Med Chem,2008,"{'bei': '16.09', 'le': '0.30', 'lle': '1.22', 'sei': '5.63'}",CHEMBL269836,,CHEMBL269836,4.38,0,http://www.openphacts.org/units/Nanomolar,691258,=,1,1,=,,IC50,nM,,41600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,41.6
,,2265032,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N2CCc3ccccc3C2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.22', 'le': '0.22', 'lle': '1.24', 'sei': '9.97'}",CHEMBL464268,,CHEMBL464268,5.82,0,http://www.openphacts.org/units/Nanomolar,749765,=,1,1,=,,IC50,nM,,1500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.5
,,2265033,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)Nc2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.85', 'le': '0.18', 'lle': '-0.33', 'sei': '6.40'}",CHEMBL464440,,CHEMBL464440,4.30,0,http://www.openphacts.org/units/Nanomolar,749766,=,1,1,=,,IC50,nM,,50000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,50.0
,,2265034,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(C)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.43', 'le': '0.23', 'lle': '0.94', 'sei': '9.59'}",CHEMBL466801,,CHEMBL466801,5.60,0,http://www.openphacts.org/units/Nanomolar,749682,=,1,1,=,,IC50,nM,,2500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.5
,,2265036,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(C)c2ccc(F)cc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.61', 'le': '0.19', 'lle': '0.18', 'sei': '8.51'}",CHEMBL469305,,CHEMBL469305,4.97,0,http://www.openphacts.org/units/Nanomolar,749684,=,1,1,=,,IC50,nM,,10700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.7
,,2265037,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(C)c2cccc(F)c2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.03', 'le': '0.22', 'lle': '0.85', 'sei': '9.65'}",CHEMBL518858,,CHEMBL518858,5.64,0,http://www.openphacts.org/units/Nanomolar,749767,=,1,1,=,,IC50,nM,,2300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.3
,,2265038,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(C)c2ccccc2F)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.79', 'le': '0.22', 'lle': '0.73', 'sei': '9.45'}",CHEMBL480008,,CHEMBL480008,5.52,0,http://www.openphacts.org/units/Nanomolar,749768,=,1,1,=,,IC50,nM,,3000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.0
,,2265039,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN(C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1)c1ccccc1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.32', 'le': '0.22', 'lle': '0.67', 'sei': '9.79'}",CHEMBL480009,,CHEMBL480009,5.72,0,http://www.openphacts.org/units/Nanomolar,749769,=,1,1,=,,IC50,nM,,1900.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.9
,,2265040,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)C(C)C)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.68', 'le': '0.19', 'lle': '-0.32', 'sei': '8.75'}",CHEMBL480010,,CHEMBL480010,5.11,0,http://www.openphacts.org/units/Nanomolar,749770,=,1,1,=,,IC50,nM,,7700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.7
,,2265041,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)C2CCCCC2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.29', 'le': '0.20', 'lle': '-0.51', 'sei': '10.02'}",CHEMBL516633,,CHEMBL516633,5.85,0,http://www.openphacts.org/units/Nanomolar,749686,=,1,1,=,,IC50,nM,,1400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.4
,,2265042,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1CCc2ccccc2C1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.89', 'le': '0.21', 'lle': '-0.26', 'sei': '10.43'}",CHEMBL517577,,CHEMBL517577,6.10,0,http://www.openphacts.org/units/Nanomolar,749687,=,1,1,=,,IC50,nM,,800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.8
,,2265043,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.39', 'le': '0.22', 'lle': '1.00', 'sei': '8.54'}",CHEMBL444140,,CHEMBL444140,6.72,0,http://www.openphacts.org/units/Nanomolar,749688,=,1,1,=,,IC50,nM,,190.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.19
,,2265044,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.85', 'le': '0.23', 'lle': '1.27', 'sei': '8.24'}",CHEMBL453380,,CHEMBL453380,6.96,0,http://www.openphacts.org/units/Nanomolar,749689,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.11
,,2265045,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,COC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.21', 'le': '0.22', 'lle': '0.43', 'sei': '10.04'}",CHEMBL501871,,CHEMBL501871,6.80,0,http://www.openphacts.org/units/Nanomolar,749690,=,1,1,=,,IC50,nM,,160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16
,,2265046,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.51', 'le': '0.19', 'lle': '0.28', 'sei': '7.01'}",CHEMBL510332,,CHEMBL510332,6.14,0,http://www.openphacts.org/units/Nanomolar,749691,=,1,1,=,,IC50,nM,,730.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.73
,,2265047,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CNS(C)(=O)=O,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.65', 'le': '0.18', 'lle': '0.70', 'sei': '5.72'}",CHEMBL446607,,CHEMBL446607,5.98,0,http://www.openphacts.org/units/Nanomolar,749692,=,1,1,=,,IC50,nM,,1050.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.05
,,2265048,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '8.98', 'le': '0.16', 'lle': '-1.04', 'sei': '6.20'}",CHEMBL446480,,CHEMBL446480,5.25,0,http://www.openphacts.org/units/Nanomolar,749693,=,1,1,=,,IC50,nM,,5610.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.61
,,2265049,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.21', 'le': '0.20', 'lle': '0.26', 'sei': '7.73'}",CHEMBL453466,,CHEMBL453466,6.55,0,http://www.openphacts.org/units/Nanomolar,749694,=,1,1,=,,IC50,nM,,280.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.28
,,2265050,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.98', 'le': '0.22', 'lle': '0.53', 'sei': '11.06'}",CHEMBL500574,,CHEMBL500574,6.82,0,http://www.openphacts.org/units/Nanomolar,749695,=,1,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.15
,,2265051,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CNC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)cc1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.33', 'le': '0.22', 'lle': '0.90', 'sei': '9.73'}",CHEMBL500866,,CHEMBL500866,6.85,0,http://www.openphacts.org/units/Nanomolar,749696,=,1,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.14
,,2265052,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1C,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '13.21', 'le': '0.24', 'lle': '0.21', 'sei': '11.91'}",CHEMBL514298,,CHEMBL514298,6.96,0,http://www.openphacts.org/units/Nanomolar,749771,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.11
,,2265053,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Br)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.90', 'le': '0.24', 'lle': '0.92', 'sei': '9.40'}",CHEMBL509788,,CHEMBL509788,7.40,0,http://www.openphacts.org/units/Nanomolar,749773,=,1,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.04
,,2265054,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.65', 'le': '0.24', 'lle': '0.93', 'sei': '9.28'}",CHEMBL460173,,CHEMBL460173,7.30,0,http://www.openphacts.org/units/Nanomolar,749774,=,1,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.05
,,2265055,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '13.06', 'le': '0.24', 'lle': '1.18', 'sei': '8.91'}",CHEMBL503454,,CHEMBL503454,7.52,0,http://www.openphacts.org/units/Nanomolar,749775,=,1,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.03
,,2265056,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Br,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.34', 'le': '0.22', 'lle': '1.46', 'sei': '6.91'}",CHEMBL520607,,CHEMBL520607,5.43,0,http://www.openphacts.org/units/Nanomolar,749776,=,1,1,=,,IC50,nM,,3670.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.67
,,2265057,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '14.05', 'le': '0.26', 'lle': '1.22', 'sei': '11.36'}",CHEMBL513318,,CHEMBL513318,6.64,0,http://www.openphacts.org/units/Nanomolar,749699,=,1,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.23
,,2265058,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '13.03', 'le': '0.25', 'lle': '1.56', 'sei': '8.90'}",CHEMBL467229,,CHEMBL467229,7.00,0,http://www.openphacts.org/units/Nanomolar,749700,=,1,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.1
,,2265059,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '14.36', 'le': '0.28', 'lle': '2.30', 'sei': '9.12'}",CHEMBL481581,,CHEMBL481581,7.70,0,http://www.openphacts.org/units/Nanomolar,749777,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.02
,,2265060,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '13.50', 'le': '0.26', 'lle': '1.39', 'sei': '8.34'}",CHEMBL481775,,CHEMBL481775,7.05,0,http://www.openphacts.org/units/Nanomolar,749778,=,1,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.09
,,2265061,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.73', 'le': '0.18', 'lle': '-1.24', 'sei': '6.96'}",CHEMBL446802,,CHEMBL446802,6.09,0,http://www.openphacts.org/units/Nanomolar,749779,=,1,1,=,,IC50,nM,,810.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.81
,,2265062,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.56', 'le': '0.22', 'lle': '0.14', 'sei': '8.45'}",CHEMBL449546,,CHEMBL449546,7.40,0,http://www.openphacts.org/units/Nanomolar,749780,=,1,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.04
,,2265063,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.27', 'le': '0.21', 'lle': '0.31', 'sei': '7.64'}",CHEMBL504480,,CHEMBL504480,7.40,0,http://www.openphacts.org/units/Nanomolar,749781,=,1,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.04
,,2265064,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.76', 'le': '0.19', 'lle': '-0.42', 'sei': '6.31'}",CHEMBL450954,,CHEMBL450954,6.60,0,http://www.openphacts.org/units/Nanomolar,749782,=,1,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.25
,,2265065,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.69', 'le': '0.23', 'lle': '1.02', 'sei': '9.09'}",CHEMBL509208,,CHEMBL509208,7.70,0,http://www.openphacts.org/units/Nanomolar,749783,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.02
,,2265066,[],CHEMBL1019892,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)O)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '14.63', 'le': '0.27', 'lle': '3.11', 'sei': '7.62'}",CHEMBL473446,,CHEMBL473446,8.00,0,http://www.openphacts.org/units/Nanomolar,749784,=,1,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,2265082,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Br)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.74', 'le': '0.22', 'lle': '0.20', 'sei': '8.49'}",CHEMBL509788,,CHEMBL509788,6.68,0,http://www.openphacts.org/units/Nanomolar,749773,=,1,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.21
,,2265083,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.95', 'le': '0.21', 'lle': '-0.05', 'sei': '8.03'}",CHEMBL460173,,CHEMBL460173,6.32,0,http://www.openphacts.org/units/Nanomolar,749774,=,1,1,=,,IC50,nM,,480.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.48
,,2265084,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.15', 'le': '0.23', 'lle': '0.66', 'sei': '8.29'}",CHEMBL503454,,CHEMBL503454,7.00,0,http://www.openphacts.org/units/Nanomolar,749775,=,1,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.1
,,2265085,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Br,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.06', 'le': '0.19', 'lle': '0.78', 'sei': '6.05'}",CHEMBL520607,,CHEMBL520607,4.76,0,http://www.openphacts.org/units/Nanomolar,749776,=,1,1,=,,IC50,nM,,17300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,17.3
,,2265086,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.05', 'le': '0.22', 'lle': '0.28', 'sei': '9.75'}",CHEMBL513318,,CHEMBL513318,5.70,0,http://www.openphacts.org/units/Nanomolar,749699,=,1,1,=,,IC50,nM,,2010.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.01
,,2265087,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.37', 'le': '0.22', 'lle': '0.67', 'sei': '7.76'}",CHEMBL467229,,CHEMBL467229,6.11,0,http://www.openphacts.org/units/Nanomolar,749700,=,1,1,=,,IC50,nM,,780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.78
,,2265088,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.68', 'le': '0.24', 'lle': '1.40', 'sei': '8.05'}",CHEMBL481581,,CHEMBL481581,6.80,0,http://www.openphacts.org/units/Nanomolar,749777,=,1,1,=,,IC50,nM,,160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16
,,2265089,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.79', 'le': '0.23', 'lle': '0.49', 'sei': '7.29'}",CHEMBL481775,,CHEMBL481775,6.16,0,http://www.openphacts.org/units/Nanomolar,749778,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
,,2265090,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '8.38', 'le': '0.16', 'lle': '-2.08', 'sei': '5.99'}",CHEMBL446802,,CHEMBL446802,5.25,0,http://www.openphacts.org/units/Nanomolar,749779,=,1,1,=,,IC50,nM,,5660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.66
,,2265091,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.26', 'le': '0.20', 'lle': '-0.69', 'sei': '7.50'}",CHEMBL449546,,CHEMBL449546,6.57,0,http://www.openphacts.org/units/Nanomolar,749780,=,1,1,=,,IC50,nM,,270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.27
,,2265092,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.49', 'le': '0.20', 'lle': '-0.20', 'sei': '7.12'}",CHEMBL504480,,CHEMBL504480,6.89,0,http://www.openphacts.org/units/Nanomolar,749781,=,1,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.13
,,2265093,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)Cc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '8.14', 'le': '0.16', 'lle': '-1.52', 'sei': '5.26'}",CHEMBL450954,,CHEMBL450954,5.50,0,http://www.openphacts.org/units/Nanomolar,749782,=,1,1,=,,IC50,nM,,3150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.15
,,2265094,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)c3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.68', 'le': '0.20', 'lle': '-0.20', 'sei': '7.65'}",CHEMBL509208,,CHEMBL509208,6.48,0,http://www.openphacts.org/units/Nanomolar,749783,=,1,1,=,,IC50,nM,,330.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.33
,,2265095,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(OCC(=O)O)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '12.60', 'le': '0.24', 'lle': '2.00', 'sei': '6.56'}",CHEMBL473446,,CHEMBL473446,6.89,0,http://www.openphacts.org/units/Nanomolar,749784,=,1,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.13
,,2265096,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)CSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.75', 'le': '0.18', 'lle': '-0.93', 'sei': '7.11'}",CHEMBL502066,,CHEMBL502066,6.22,0,http://www.openphacts.org/units/Nanomolar,749785,=,1,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.6
,,2265097,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.12', 'le': '0.19', 'lle': '-0.15', 'sei': '6.50'}",CHEMBL451856,,CHEMBL451856,6.29,0,http://www.openphacts.org/units/Nanomolar,749786,=,1,1,=,,IC50,nM,,510.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.51
,,2265098,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(N)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '11.65', 'le': '0.22', 'lle': '1.44', 'sei': '5.81'}",CHEMBL518649,,CHEMBL518649,6.42,0,http://www.openphacts.org/units/Nanomolar,749702,=,1,1,=,,IC50,nM,,380.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.38
,,2265099,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '10.98', 'le': '0.21', 'lle': '1.10', 'sei': '6.13'}",CHEMBL508392,,CHEMBL508392,7.52,0,http://www.openphacts.org/units/Nanomolar,749703,=,1,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.03
,,2265100,[],CHEMBL1019894,Inhibition of GST fused Bcl-2 binding to biotinylated 26 mer Bak-BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NCc3ccncc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1139292,Bioorg Med Chem Lett,2009,"{'bei': '9.63', 'le': '0.18', 'lle': '-0.22', 'sei': '5.66'}",CHEMBL498873,,CHEMBL498873,6.19,0,http://www.openphacts.org/units/Nanomolar,749704,=,1,1,=,,IC50,nM,,650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.65
,,2271390,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '13.10', 'le': '0.24', 'lle': '1.70', 'sei': '8.00'}",CHEMBL454406,,CHEMBL454406,6.76,0,http://www.openphacts.org/units/Nanomolar,730404,=,1,1,=,,IC50,nM,,175.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,175.0
,,2271391,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '11.51', 'le': '0.21', 'lle': '0.38', 'sei': '8.15'}",CHEMBL503783,,CHEMBL503783,6.41,0,http://www.openphacts.org/units/Nanomolar,730403,=,1,1,=,,IC50,nM,,390.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,390.0
,,2271392,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '9.37', 'le': '0.17', 'lle': '-0.82', 'sei': '6.63'}",CHEMBL503783,,CHEMBL503783,5.21,0,http://www.openphacts.org/units/Nanomolar,730402,=,1,1,=,,IC50,nM,,6100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6100.0
,,2271393,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@H]1CO,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '12.00', 'le': '0.22', 'lle': '0.65', 'sei': '8.49'}",CHEMBL508211,,CHEMBL508211,6.68,0,http://www.openphacts.org/units/Nanomolar,730401,=,1,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,210.0
,,2271394,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2C[C@@H]1CO,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '10.70', 'le': '0.19', 'lle': '-0.07', 'sei': '7.57'}",CHEMBL503783,,CHEMBL503783,5.96,0,http://www.openphacts.org/units/Nanomolar,730400,=,1,1,=,,IC50,nM,,1100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1100.0
,,2271395,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)cc2C)c1C(=O)N1Cc2ccccc2CC1CO,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '11.18', 'le': '0.20', 'lle': '0.19', 'sei': '7.91'}",CHEMBL509760,,CHEMBL509760,6.22,0,http://www.openphacts.org/units/Nanomolar,730399,=,1,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,600.0
,,2271396,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2cccc(C)c2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '13.41', 'le': '0.26', 'lle': '1.67', 'sei': '8.73'}",CHEMBL454411,,CHEMBL454411,7.38,0,http://www.openphacts.org/units/Nanomolar,730469,=,1,1,=,,IC50,nM,,42.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,42.0
,,2271397,[],CHEMBL1014486,Inhibition of GST fused Bcl-2 binding to biotinylated 16 mer BH3 peptide by HTRF-LANCE assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cccc(Cl)c2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL1153292,Bioorg Med Chem Lett,2009,"{'bei': '11.14', 'le': '0.21', 'lle': '0.57', 'sei': '7.07'}",CHEMBL452586,,CHEMBL452586,5.97,0,http://www.openphacts.org/units/Nanomolar,730470,=,1,1,=,,IC50,nM,,1070.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1070.0
,,2652232,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(CCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(CCc3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '10.77', 'le': '0.20', 'lle': '-1.76', 'sei': '5.21'}",CHEMBL552735,,CHEMBL552735,6.32,0,http://www.openphacts.org/units/Nanomolar,815471,=,1,1,=,,IC50,nM,,480.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.48
,,2652233,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC3Cc4ccccc4C3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '8.83', 'le': '0.16', 'lle': '-0.15', 'sei': '3.43'}",CHEMBL541427,,CHEMBL541427,6.16,0,http://www.openphacts.org/units/Nanomolar,815392,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
,,2652234,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '9.27', 'le': '0.17', 'lle': '-1.09', 'sei': '3.62'}",CHEMBL538616,,CHEMBL538616,6.50,0,http://www.openphacts.org/units/Nanomolar,815391,=,1,1,=,,IC50,nM,,320.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.32
,,2652235,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3cccc(Cl)c3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '7.22', 'le': '0.14', 'lle': '-2.40', 'sei': '2.98'}",CHEMBL553474,,CHEMBL553474,5.36,0,http://www.openphacts.org/units/Nanomolar,815389,=,1,1,=,,IC50,nM,,4400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.4
,,2652236,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCCc6ccc(CC)cc6)c(O)c(O)cc5c4O)c(C)cc23)cc1,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '8.47', 'le': '0.16', 'lle': '-1.41', 'sei': '3.44'}",CHEMBL541496,,CHEMBL541496,6.17,0,http://www.openphacts.org/units/Nanomolar,815390,=,1,1,=,,IC50,nM,,670.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.67
,,2652237,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCCc3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '10.14', 'le': '0.19', 'lle': '0.36', 'sei': '3.80'}",CHEMBL552287,,CHEMBL552287,6.82,0,http://www.openphacts.org/units/Nanomolar,815387,=,1,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.15
,,2652238,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC3CCCCC3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '9.36', 'le': '0.17', 'lle': '-0.98', 'sei': '3.42'}",CHEMBL541004,,CHEMBL541004,6.15,0,http://www.openphacts.org/units/Nanomolar,815386,=,1,1,=,,IC50,nM,,710.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.71
,,2652239,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC(C)c3ccc(Cl)cc3)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '8.51', 'le': '0.17', 'lle': '-2.49', 'sei': '3.51'}",CHEMBL539481,,CHEMBL539481,6.31,0,http://www.openphacts.org/units/Nanomolar,815384,=,1,1,=,,IC50,nM,,490.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.49
,,2652240,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C)c(CNC(=O)c2c(O)c(O)cc3c(O)c(-c4c(C)cc5c(C(=O)NCc6c(C)cc(C)cc6C)c(O)c(O)cc5c4O)c(C)cc23)c(C)c1,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '8.44', 'le': '0.16', 'lle': '-2.07', 'sei': '3.43'}",CHEMBL554545,,CHEMBL554545,6.16,0,http://www.openphacts.org/units/Nanomolar,815383,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
,,2652241,[],CHEMBL1031851,Displacement of F-BakBH3 from Bcl-2 by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)cc2c1O,,,CHEMBL1158469,J Med Chem,2009,"{'bei': '8.86', 'le': '0.16', 'lle': '-2.66', 'sei': '3.38'}",CHEMBL551288,APOGOSSYPOL,CHEMBL551288,4.10,0,http://www.openphacts.org/units/Nanomolar,815372,=,1,1,=,,IC50,nM,,80000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,80.0
,,3281646,[],CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1C1C2=C(N=c3s/c(=C\c4cccc(OCC(=O)O)c4)c(=O)n31)c1ccccc1CC2,,,CHEMBL1157133,J Med Chem,2010,"{'bei': '10.50', 'le': '0.20', 'lle': '1.72', 'sei': '6.11'}",CHEMBL1097075,,CHEMBL1097075,5.51,0,http://www.openphacts.org/units/Nanomolar,907420,=,1,1,=,,IC50,nM,,3100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.1
,,3281647,[],CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C2C3=C(N=c4s/c(=C\c5ccc(OCc6cccc(C(=O)O)c6)c(OC)c5)c(=O)n42)c2ccccc2CC3)cc1,,,CHEMBL1157133,J Med Chem,2010,"{'bei': '8.71', 'le': '0.16', 'lle': '-0.12', 'sei': '5.53'}",CHEMBL1098324,,CHEMBL1098324,5.50,0,http://www.openphacts.org/units/Nanomolar,907560,=,1,1,=,,IC50,nM,,3200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.2
,,3281648,[],CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cccc(-c2ccc(/C=c3\sc4n(c3=O)C(c3cccc(F)c3)C3=C(N=4)c4ccccc4CC3)o2)c1,,,CHEMBL1157133,J Med Chem,2010,"{'bei': '9.29', 'le': '0.17', 'lle': '-0.32', 'sei': '6.01'}",CHEMBL1096755,,CHEMBL1096755,5.10,0,http://www.openphacts.org/units/Nanomolar,907846,=,1,1,=,,IC50,nM,,8000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,8.0
,,3281649,[],CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C2C3=C(N=c4s/c(=C\c5ccc(-c6cccc(C(=O)O)c6)o5)c(=O)n42)c2ccccc2CC3)cc1,,,CHEMBL1157133,J Med Chem,2010,"{'bei': '8.84', 'le': '0.17', 'lle': '-0.34', 'sei': '5.27'}",CHEMBL1095309,,CHEMBL1095309,4.96,0,http://www.openphacts.org/units/Nanomolar,907925,=,1,1,=,,IC50,nM,,11100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,11.1
,,3281650,[],CHEMBL1120826,Displacement of FITC labeled BH3 peptide from His-tagged human BCL2 after 1 hr by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(C2C3=C(N=c4s/c(=C\c5ccc(-c6cccc(C(=O)O)c6)o5)c(=O)n42)c2ccccc2CC3)c1,,,CHEMBL1157133,J Med Chem,2010,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.58', 'sei': '5.01'}",CHEMBL1095310,,CHEMBL1095310,4.71,0,http://www.openphacts.org/units/Nanomolar,907926,=,1,1,=,,IC50,nM,,19400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,19.4
,,3283444,[],CHEMBL1107438,Displacement of FITC-conjugated BH3-Bim peptide from human recombinant Bcl-2 expressed in Escherichia coli BL21 (DE3) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Oc1cc(Cc2ccccc2)c(Cc2ccccc2)cc1O,,,CHEMBL1157820,J Med Chem,2010,"{'bei': '18.35', 'le': '0.33', 'lle': '1.05', 'sei': '13.17'}",CHEMBL481409,,CHEMBL481409,5.33,0,http://www.openphacts.org/units/Nanomolar,911186,=,1,1,=,,IC50,nM,,4700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.7
,,3287014,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '12.58', 'le': '0.23', 'lle': '0.14', 'sei': '4.19'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,6.52,0,http://www.openphacts.org/units/Nanomolar,911388,=,1,1,=,,IC50,nM,,300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.3
,,3287015,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '12.70', 'le': '0.24', 'lle': '0.21', 'sei': '4.23'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,6.58,0,http://www.openphacts.org/units/Nanomolar,911387,=,1,1,=,,IC50,nM,,260.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.26
,,3287016,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '8.82', 'le': '0.16', 'lle': '-1.40', 'sei': '3.44'}",CHEMBL538616,,CHEMBL538616,6.18,0,http://www.openphacts.org/units/Nanomolar,911382,=,1,1,=,,IC50,nM,,660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.66
,,3287017,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '9.08', 'le': '0.17', 'lle': '-1.21', 'sei': '3.55'}",CHEMBL1094366,"(S)-1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((S)-2-PHENYLPROPYL)-N5'-((S)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX)",CHEMBL1094366,6.37,0,http://www.openphacts.org/units/Nanomolar,911386,=,1,1,=,,IC50,nM,,430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.43
,,3287018,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '9.08', 'le': '0.17', 'lle': '-1.21', 'sei': '3.55'}",CHEMBL1094366,"(S)-1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((S)-2-PHENYLPROPYL)-N5'-((S)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX)",CHEMBL1094366,6.37,0,http://www.openphacts.org/units/Nanomolar,911383,=,1,1,=,,IC50,nM,,430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.43
,,3287019,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '8.48', 'le': '0.16', 'lle': '-1.64', 'sei': '3.31'}",CHEMBL1094250,"1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX)",CHEMBL1094250,5.94,0,http://www.openphacts.org/units/Nanomolar,911385,=,1,1,=,,IC50,nM,,1140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.14
,,3287020,[],CHEMBL1106537,Displacement of FITC-labeled Bak BH3 peptide from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL1157826,J Med Chem,2010,"{'bei': '9.27', 'le': '0.17', 'lle': '-1.09', 'sei': '3.62'}",CHEMBL1094250,"1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX)",CHEMBL1094250,6.50,0,http://www.openphacts.org/units/Nanomolar,911384,=,1,1,=,,IC50,nM,,320.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.32
,,3522860,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '13.11', 'le': '0.24', 'lle': '1.58', 'sei': '4.31'}",CHEMBL1272170,,CHEMBL1272170,6.43,0,http://www.openphacts.org/units/Nanomolar,968046,=,1,1,=,,IC50,nM,,370.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.37
,,3522861,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '9.11', 'le': '0.17', 'lle': '0.97', 'sei': '3.20'}",CHEMBL1269070,,CHEMBL1269070,6.64,0,http://www.openphacts.org/units/Nanomolar,964350,=,1,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.23
,,3522862,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '8.82', 'le': '0.16', 'lle': '1.01', 'sei': '3.22'}",CHEMBL1269012,,CHEMBL1269012,6.68,0,http://www.openphacts.org/units/Nanomolar,964352,=,1,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.21
,,3522863,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '10.36', 'le': '0.19', 'lle': '1.21', 'sei': '3.63'}",CHEMBL1269072,,CHEMBL1269072,6.66,0,http://www.openphacts.org/units/Nanomolar,964353,=,1,1,=,,IC50,nM,,220.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.22
,,3522864,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '12.73', 'le': '0.24', 'lle': '1.60', 'sei': '4.42'}",CHEMBL1272224,,CHEMBL1272224,6.60,0,http://www.openphacts.org/units/Nanomolar,968106,=,1,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.25
,,3522865,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '9.89', 'le': '0.18', 'lle': '-0.43', 'sei': '3.78'}",CHEMBL1269073,,CHEMBL1269073,5.64,0,http://www.openphacts.org/units/Nanomolar,964354,=,1,1,=,,IC50,nM,,2270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.27
,,3522866,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '8.25', 'le': '0.15', 'lle': '-2.46', 'sei': '3.47'}",CHEMBL1269074,,CHEMBL1269074,5.17,0,http://www.openphacts.org/units/Nanomolar,964355,=,1,1,=,,IC50,nM,,6730.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.73
,,3522867,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '9.09', 'le': '0.17', 'lle': '-0.58', 'sei': '3.75'}",CHEMBL1269075,,CHEMBL1269075,5.59,0,http://www.openphacts.org/units/Nanomolar,964356,=,1,1,=,,IC50,nM,,2570.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.57
,,3522868,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '8.57', 'le': '0.16', 'lle': '-1.28', 'sei': '3.69'}",CHEMBL1269076,,CHEMBL1269076,5.51,0,http://www.openphacts.org/units/Nanomolar,964357,=,1,1,=,,IC50,nM,,3120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.12
,,3522869,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '8.81', 'le': '0.16', 'lle': '-1.29', 'sei': '3.80'}",CHEMBL1269077,,CHEMBL1269077,5.66,0,http://www.openphacts.org/units/Nanomolar,964358,=,1,1,=,,IC50,nM,,2170.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.17
,,3522870,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '11.14', 'le': '0.20', 'lle': '0.76', 'sei': '4.38'}",CHEMBL1269107,,CHEMBL1269107,6.54,0,http://www.openphacts.org/units/Nanomolar,964402,=,1,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.29
,,3522871,[],CHEMBL1273517,Displacement of F-BakBH3 from Bcl-2 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O,,,CHEMBL1269007,J Med Chem,2010,"{'bei': '9.87', 'le': '0.19', 'lle': '-0.62', 'sei': '4.34'}",CHEMBL1269110,,CHEMBL1269110,6.47,0,http://www.openphacts.org/units/Nanomolar,964405,=,1,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.34
,,5232545,[],CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL1671783,J Med Chem,2011,"{'bei': '19.75', 'le': '0.37', 'lle': '3.54', 'sei': '11.59'}",CHEMBL595134,,CHEMBL595134,6.54,0,http://www.openphacts.org/units/Nanomolar,1330162,=,1,1,=,,IC50,nM,,285.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.285
,,5232547,[],CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCC(C)(C)c1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,CHEMBL1671783,J Med Chem,2011,"{'bei': '15.83', 'le': '0.29', 'lle': '0.17', 'sei': '12.15'}",CHEMBL1672080,,CHEMBL1672080,6.47,0,http://www.openphacts.org/units/Nanomolar,1330175,=,1,1,=,,IC50,nM,,342.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.342
,,5232549,[],CHEMBL1677787,Displacement of FAM-Bid from human recombinant Bcl-2 after 30 mins by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,CHEMBL1671783,J Med Chem,2011,"{'bei': '18.45', 'le': '0.34', 'lle': '2.33', 'sei': '8.23'}",CHEMBL1672082,,CHEMBL1672082,6.52,0,http://www.openphacts.org/units/Nanomolar,1330177,=,1,1,=,,IC50,nM,,302.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.302
,,5295800,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL1687940,J Med Chem,2011,"{'bei': '10.10', 'le': '0.20', 'lle': '0.33', 'sei': '6.41'}",CHEMBL376408,ABT 737,CHEMBL376408,8.21,0,http://www.openphacts.org/units/Nanomolar,1338691,=,1,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,,5295801,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1[N+](=O)[O-],,,CHEMBL1687940,J Med Chem,2011,"{'bei': '9.62', 'le': '0.19', 'lle': '-0.45', 'sei': '5.89'}",CHEMBL1689139,,CHEMBL1689139,8.06,0,http://www.openphacts.org/units/Nanomolar,1338683,=,1,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,,5295816,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=[N+]([O-])c1cc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '8.73', 'le': '0.17', 'lle': '-0.60', 'sei': '5.26'}",CHEMBL1689140,,CHEMBL1689140,7.68,0,http://www.openphacts.org/units/Nanomolar,1338684,=,1,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,,5295817,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '8.53', 'le': '0.17', 'lle': '-1.00', 'sei': '6.17'}",CHEMBL1689141,,CHEMBL1689141,7.89,0,http://www.openphacts.org/units/Nanomolar,1338685,=,1,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,,5295818,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=S(=O)(Nc1ncnc2cc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)ccc12)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '7.34', 'le': '0.15', 'lle': '-1.57', 'sei': '5.17'}",CHEMBL1689142,,CHEMBL1689142,7.09,0,http://www.openphacts.org/units/Nanomolar,1338686,=,1,1,=,,IC50,nM,,81.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,81.0
,,5295819,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1[N+](=O)[O-],,,CHEMBL1687940,J Med Chem,2011,"{'bei': '9.11', 'le': '0.18', 'lle': '-1.38', 'sei': '5.79'}",CHEMBL1689143,,CHEMBL1689143,7.92,0,http://www.openphacts.org/units/Nanomolar,1338687,=,1,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,,5295820,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c([N+](=O)[O-])c5)ncnc4c3)CC2)C1,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '8.42', 'le': '0.17', 'lle': '-1.39', 'sei': '5.26'}",CHEMBL1689144,,CHEMBL1689144,7.68,0,http://www.openphacts.org/units/Nanomolar,1338688,=,1,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,,5295821,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3cc(N4CCN(CC5=C(c6ccc(Cl)cc6)CCC(C)(C)C5)CC4)ccc23)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '8.68', 'le': '0.18', 'lle': '-1.39', 'sei': '6.49'}",CHEMBL1689145,,CHEMBL1689145,8.30,0,http://www.openphacts.org/units/Nanomolar,1338689,=,1,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,,5295822,[],CHEMBL1693055,Displacement of wild type mBimBH3 from human Bcl-2 by solution competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc4c(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ncnc4c3)CC2)C1,,,CHEMBL1687940,J Med Chem,2011,"{'bei': '7.09', 'le': '0.14', 'lle': '-2.38', 'sei': '5.16'}",CHEMBL1689146,,CHEMBL1689146,7.08,0,http://www.openphacts.org/units/Nanomolar,1338690,=,1,1,=,,IC50,nM,,84.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.0
,,10894262,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)c1nn(-c2ccccc2)c(C)c1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '7.70', 'le': '0.14', 'lle': '-1.11', 'sei': '4.21'}",CHEMBL2030844,,CHEMBL2030844,5.38,0,http://www.openphacts.org/units/Nanomolar,1642830,=,1,1,=,,IC50,nM,,4190.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.19
,,10894263,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.34', 'le': '0.16', 'lle': '-1.35', 'sei': '4.84'}",CHEMBL2030845,,CHEMBL2030845,6.18,0,http://www.openphacts.org/units/Nanomolar,1642831,=,1,1,=,,IC50,nM,,660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.66
,,10894265,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)O)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.50', 'le': '0.18', 'lle': '-0.28', 'sei': '4.88'}",CHEMBL2030846,,CHEMBL2030846,6.77,0,http://www.openphacts.org/units/Nanomolar,1642832,=,1,1,=,,IC50,nM,,170.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.17
,,10894267,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.32', 'le': '0.19', 'lle': '0.37', 'sei': '5.93'}",CHEMBL2030847,,CHEMBL2030847,7.21,0,http://www.openphacts.org/units/Nanomolar,1642833,=,1,1,=,,IC50,nM,,61.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.061
,,10894269,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(OC)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '7.46', 'le': '0.14', 'lle': '-1.79', 'sei': '4.20'}",CHEMBL2030848,,CHEMBL2030848,5.75,0,http://www.openphacts.org/units/Nanomolar,1642834,=,1,1,=,,IC50,nM,,1790.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.79
,,10894271,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1cccc(Oc2ccccc2)c1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.23', 'le': '0.15', 'lle': '-2.47', 'sei': '5.01'}",CHEMBL2030849,,CHEMBL2030849,6.85,0,http://www.openphacts.org/units/Nanomolar,1642835,=,1,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.14
,,10894273,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.40', 'le': '0.16', 'lle': '-2.32', 'sei': '5.11'}",CHEMBL2030850,,CHEMBL2030850,7.00,0,http://www.openphacts.org/units/Nanomolar,1642836,=,1,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.1
,,10894275,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.71', 'le': '0.16', 'lle': '-1.75', 'sei': '5.26'}",CHEMBL2030851,,CHEMBL2030851,6.89,0,http://www.openphacts.org/units/Nanomolar,1642837,=,1,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.13
,,10894277,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.28', 'le': '0.18', 'lle': '-1.63', 'sei': '5.85'}",CHEMBL2030852,,CHEMBL2030852,7.66,0,http://www.openphacts.org/units/Nanomolar,1642838,=,1,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.022
,,10894279,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.81', 'le': '0.19', 'lle': '-1.19', 'sei': '6.19'}",CHEMBL2030853,,CHEMBL2030853,8.10,0,http://www.openphacts.org/units/Nanomolar,1642839,=,1,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.008
,,10894281,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCOc1ccc(-n2nc(CO)c(-c3ccc(C(=O)NS(=O)(=O)c4ccc5ccccc5c4)cc3C(=O)N3CCc4ccccc4C3)c2CCCC)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.53', 'le': '0.18', 'lle': '-0.67', 'sei': '5.62'}",CHEMBL2030854,,CHEMBL2030854,7.35,0,http://www.openphacts.org/units/Nanomolar,1642840,=,1,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.045
,,10894283,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(-c2ccccc2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.52', 'le': '0.20', 'lle': '-0.36', 'sei': '6.71'}",CHEMBL2030855,,CHEMBL2030855,8.15,0,http://www.openphacts.org/units/Nanomolar,1642841,=,1,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.007
,,10894285,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.36', 'le': '0.19', 'lle': '1.32', 'sei': '5.43'}",CHEMBL2030856,,CHEMBL2030856,7.70,0,http://www.openphacts.org/units/Nanomolar,1642842,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.02
,,10894287,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCCO)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.38', 'le': '0.20', 'lle': '1.08', 'sei': '5.54'}",CHEMBL2030857,,CHEMBL2030857,7.85,0,http://www.openphacts.org/units/Nanomolar,1642843,=,1,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.014
,,10894289,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1cccc(CO)c1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.81', 'le': '0.18', 'lle': '0.81', 'sei': '5.04'}",CHEMBL2030858,,CHEMBL2030858,7.15,0,http://www.openphacts.org/units/Nanomolar,1642844,=,1,1,=,,IC50,nM,,71.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.071
,,10894291,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.92', 'le': '0.21', 'lle': '1.75', 'sei': '5.61'}",CHEMBL2030859,,CHEMBL2030859,7.96,0,http://www.openphacts.org/units/Nanomolar,1642845,=,1,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.011
,,10894293,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(CO)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.47', 'le': '0.20', 'lle': '1.45', 'sei': '5.16'}",CHEMBL2030860,,CHEMBL2030860,7.62,0,http://www.openphacts.org/units/Nanomolar,1642846,=,1,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.024
,,10894295,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccccc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.99', 'le': None, 'lle': None, 'sei': None}",CHEMBL2030861,,CHEMBL2030861,6.72,0,http://www.openphacts.org/units/Nanomolar,1642847,=,1,1,=,,IC50,nM,,190.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.19
,,10894297,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.24', 'le': '0.18', 'lle': '-0.38', 'sei': '5.14'}",CHEMBL2030862,,CHEMBL2030862,6.72,0,http://www.openphacts.org/units/Nanomolar,1642848,=,1,1,=,,IC50,nM,,190.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.19
,,10894299,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCCS(=O)(=O)NC(=O)c1ccc(-c2c(CO)nn(-c3ccc(Oc4cccc(Cl)c4)cc3)c2CCCC)c(C(=O)N2CCc3ccccc3C2)c1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.34', 'le': '0.18', 'lle': '-1.08', 'sei': '5.49'}",CHEMBL2030863,,CHEMBL2030863,7.19,0,http://www.openphacts.org/units/Nanomolar,1642849,=,1,1,=,,IC50,nM,,65.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.065
,,10894301,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.56', 'le': '0.19', 'lle': '-1.72', 'sei': '6.28'}",CHEMBL2030864,,CHEMBL2030864,8.22,0,http://www.openphacts.org/units/Nanomolar,1642850,=,1,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.006
,,10894303,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.11', 'le': '0.17', 'lle': '-0.87', 'sei': '5.47'}",CHEMBL2030865,,CHEMBL2030865,6.16,0,http://www.openphacts.org/units/Nanomolar,1642851,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
,,10894305,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.74', 'le': '0.19', 'lle': '-0.75', 'sei': '6.15'}",CHEMBL2030866,,CHEMBL2030866,6.92,0,http://www.openphacts.org/units/Nanomolar,1642852,=,1,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.12
,,10894307,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.55', 'le': '0.19', 'lle': '-0.78', 'sei': '6.09'}",CHEMBL2031001,,CHEMBL2031001,6.85,0,http://www.openphacts.org/units/Nanomolar,1642997,=,1,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.14
,,10894309,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '8.38', 'le': '0.17', 'lle': '-1.82', 'sei': '5.98'}",CHEMBL2031002,,CHEMBL2031002,6.92,0,http://www.openphacts.org/units/Nanomolar,1642998,=,1,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.12
,,10894311,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.03', 'le': '0.17', 'lle': '0.02', 'sei': '4.59'}",CHEMBL2031003,,CHEMBL2031003,6.37,0,http://www.openphacts.org/units/Nanomolar,1642999,=,1,1,=,,IC50,nM,,430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.43
,,10894313,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.18', 'le': '0.18', 'lle': '-0.23', 'sei': '5.12'}",CHEMBL2031004,,CHEMBL2031004,6.80,0,http://www.openphacts.org/units/Nanomolar,1643000,=,1,1,=,,IC50,nM,,160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16
,,10894315,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '9.57', 'le': '0.19', 'lle': '-0.87', 'sei': '6.04'}",CHEMBL2031005,,CHEMBL2031005,6.80,0,http://www.openphacts.org/units/Nanomolar,1643001,=,1,1,=,,IC50,nM,,160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16
,,10894317,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ncc(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.09', 'le': '0.19', 'lle': '-0.37', 'sei': '6.18'}",CHEMBL2031006,,CHEMBL2031006,6.96,0,http://www.openphacts.org/units/Nanomolar,1643002,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.11
,,10894319,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.53', 'le': '0.20', 'lle': '0.58', 'sei': '6.06'}",CHEMBL2031007,,CHEMBL2031007,6.82,0,http://www.openphacts.org/units/Nanomolar,1643003,=,1,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.15
,,10894321,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.49', 'le': '0.21', 'lle': '0.95', 'sei': '5.65'}",CHEMBL2031008,,CHEMBL2031008,7.82,0,http://www.openphacts.org/units/Nanomolar,1643004,=,1,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.015
,,10894323,[],CHEMBL2033942,Inhibition of GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL2029199,Bioorg Med Chem Lett,2012,"{'bei': '10.77', 'le': '0.22', 'lle': '1.14', 'sei': '6.06'}",CHEMBL2031009,,CHEMBL2031009,8.05,0,http://www.openphacts.org/units/Nanomolar,1643005,=,1,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.009
,,10894351,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1ccc(CN(Cc2ccc(F)cc2)S(=O)(=O)c2cc(Cl)cc(Cl)c2O)cc1)N(Cc1ccc(F)cc1)Cc1cc(Cl)cc(Cl)c1,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.93', 'le': '0.21', 'lle': '-2.06', 'sei': '9.57'}",CHEMBL2031010,,CHEMBL2031010,7.46,0,http://www.openphacts.org/units/Nanomolar,1643006,=,1,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.035
,,10894352,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(NS(=O)(=O)c3cc(Cl)cc(Cl)c3O)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.09', 'le': '0.17', 'lle': '-1.85', 'sei': '4.84'}",CHEMBL2031011,,CHEMBL2031011,6.04,0,http://www.openphacts.org/units/Nanomolar,1643007,=,1,1,=,,IC50,nM,,910.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.91
,,10894353,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '10.12', 'le': '0.20', 'lle': '0.14', 'sei': '6.16'}",CHEMBL2031012,,CHEMBL2031012,7.50,0,http://www.openphacts.org/units/Nanomolar,1643008,=,1,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,,10894354,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(S(=O)(=O)CC)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.10', 'le': '0.16', 'lle': '-0.40', 'sei': '4.33'}",CHEMBL2031013,,CHEMBL2031013,6.75,0,http://www.openphacts.org/units/Nanomolar,1643009,=,1,1,=,,IC50,nM,,180.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,180.0
,,10894355,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.00', 'le': '0.16', 'lle': '-0.10', 'sei': '4.85'}",CHEMBL2031014,,CHEMBL2031014,6.96,0,http://www.openphacts.org/units/Nanomolar,1643010,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,,10894356,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '7.36', 'le': '0.14', 'lle': '-0.66', 'sei': '4.46'}",CHEMBL2031015,,CHEMBL2031015,6.40,0,http://www.openphacts.org/units/Nanomolar,1643011,=,1,1,=,,IC50,nM,,400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,400.0
,,10894357,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCc5ccc(C(=O)O)cc5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.79', 'le': '0.17', 'lle': '-0.80', 'sei': '4.65'}",CHEMBL2031016,,CHEMBL2031016,7.82,0,http://www.openphacts.org/units/Nanomolar,1643012,=,1,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,,10894358,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.61', 'le': '0.19', 'lle': '-0.49', 'sei': '6.13'}",CHEMBL2031017,,CHEMBL2031017,7.46,0,http://www.openphacts.org/units/Nanomolar,1643013,=,1,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,,10894359,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.58', 'le': '0.19', 'lle': '-0.52', 'sei': '6.11'}",CHEMBL2031018,,CHEMBL2031018,7.43,0,http://www.openphacts.org/units/Nanomolar,1643014,=,1,1,=,,IC50,nM,,37.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,37.0
,,10894360,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '10.25', 'le': '0.20', 'lle': '1.33', 'sei': '5.61'}",CHEMBL2031019,,CHEMBL2031019,7.50,0,http://www.openphacts.org/units/Nanomolar,1643015,=,1,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,,10894361,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)c3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '7.25', 'le': '0.15', 'lle': '-2.15', 'sei': '4.62'}",CHEMBL2031020,,CHEMBL2031020,6.55,0,http://www.openphacts.org/units/Nanomolar,1643016,=,1,1,=,,IC50,nM,,280.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,280.0
,,10894362,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.36', 'le': '0.18', 'lle': '0.53', 'sei': '5.69'}",CHEMBL2031021,,CHEMBL2031021,7.11,0,http://www.openphacts.org/units/Nanomolar,1643017,=,1,1,=,,IC50,nM,,78.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,78.0
,,10894363,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.76', 'le': '0.18', 'lle': '-1.26', 'sei': '6.24'}",CHEMBL2031022,,CHEMBL2031022,7.80,0,http://www.openphacts.org/units/Nanomolar,1643018,=,1,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,,10894364,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2C)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.15', 'le': '0.16', 'lle': '-1.76', 'sei': '5.05'}",CHEMBL2031023,,CHEMBL2031023,6.15,0,http://www.openphacts.org/units/Nanomolar,1643019,=,1,1,=,,IC50,nM,,710.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,710.0
,,10894365,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.68', 'le': '0.19', 'lle': '0.75', 'sei': '5.25'}",CHEMBL2031024,,CHEMBL2031024,7.46,0,http://www.openphacts.org/units/Nanomolar,1643020,=,1,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,,10894366,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.09', 'le': '0.18', 'lle': '-0.11', 'sei': '5.46'}",CHEMBL2031025,,CHEMBL2031025,7.66,0,http://www.openphacts.org/units/Nanomolar,1643021,=,1,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,,10894367,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.83', 'le': '0.17', 'lle': '0.14', 'sei': '5.54'}",CHEMBL2031026,,CHEMBL2031026,7.43,0,http://www.openphacts.org/units/Nanomolar,1643022,=,1,1,=,,IC50,nM,,37.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,37.0
,,10894368,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '10.46', 'le': '0.20', 'lle': '1.38', 'sei': '5.45'}",CHEMBL2031027,,CHEMBL2031027,8.05,0,http://www.openphacts.org/units/Nanomolar,1643023,=,1,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,,10894369,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.04', 'le': '0.16', 'lle': '-0.11', 'sei': '5.35'}",CHEMBL2031028,,CHEMBL2031028,6.85,0,http://www.openphacts.org/units/Nanomolar,1643024,=,1,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,,10894370,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.36', 'le': '0.18', 'lle': '0.80', 'sei': '5.85'}",CHEMBL2031029,,CHEMBL2031029,7.85,0,http://www.openphacts.org/units/Nanomolar,1643025,=,1,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,,10894371,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCC2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '8.90', 'le': '0.17', 'lle': '-0.48', 'sei': '5.87'}",CHEMBL2031030,,CHEMBL2031030,7.33,0,http://www.openphacts.org/units/Nanomolar,1643026,=,1,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
,,10894372,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '9.32', 'le': '0.18', 'lle': '-0.22', 'sei': '5.29'}",CHEMBL2031031,,CHEMBL2031031,6.92,0,http://www.openphacts.org/units/Nanomolar,1643027,=,1,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,,10894373,[],CHEMBL2033953,Inhibition in GST-tagged Bcl2 using [FAM]-IWIAQELRRIGDEFNAYY-NH2 as substrate after 60 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CNc3ccccc3C2)c(C)c1Cl,,,CHEMBL2029223,Bioorg Med Chem Lett,2012,"{'bei': '10.23', 'le': '0.20', 'lle': '0.42', 'sei': '5.67'}",CHEMBL2031032,,CHEMBL2031032,7.58,0,http://www.openphacts.org/units/Nanomolar,1643028,=,1,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,,10943747,[],CHEMBL2050128,Inhibition of Bcl2,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2046328,Bioorg Med Chem,2012,,CHEMBL376408,ABT 737,CHEMBL376408,,0,http://www.openphacts.org/units/Nanomolar,1652113,<,1,1,<,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,,10970488,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN1CCN(CCCNC(=O)c2c(-c3ccccc3)c(-c3ccc(Cl)cc3)cn2CC[C@H](O)CO)CC1,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL2062483,J Med Chem,2012,,CHEMBL2063880,,CHEMBL2063880,,0,http://www.openphacts.org/units/Nanomolar,1659871,=,1,1,=,,IC50,nM,,213000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,213.0
,,10970489,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(N)(=O)=O)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,,CHEMBL2063881,,CHEMBL2063881,,0,http://www.openphacts.org/units/Nanomolar,1659872,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,10970490,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '7.10', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063882,,CHEMBL2063882,8.06,0,http://www.openphacts.org/units/Nanomolar,1659873,=,1,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,,10970491,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '8.02', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063883,,CHEMBL2063883,8.89,0,http://www.openphacts.org/units/Nanomolar,1659874,=,1,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,,10970492,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(-c3cn(-c4cccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)c4)nn3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '8.12', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063884,,CHEMBL2063884,8.85,0,http://www.openphacts.org/units/Nanomolar,1659875,=,1,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,,10970493,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '8.11', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063885,,CHEMBL2063885,8.72,0,http://www.openphacts.org/units/Nanomolar,1659876,=,1,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,,10970494,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(C#Cc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '7.81', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063886,,CHEMBL2063886,8.18,0,http://www.openphacts.org/units/Nanomolar,1659877,=,1,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,,10970495,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(NCCNc3cccc(-c4c(-c5ccc(Cl)cc5)cn(CC[C@H](O)CO)c4C(=O)NCCCN4CCN(C)CC4)c3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '6.67', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063887,,CHEMBL2063887,7.22,0,http://www.openphacts.org/units/Nanomolar,1659878,=,1,1,=,,IC50,nM,,60.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.6
,,10970496,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4ccc(-c5c(-c6ccc(Cl)cc6)cn(CC[C@H](O)CO)c5C(=O)NCCCN5CCN(C)CC5)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '6.74', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063888,,CHEMBL2063888,7.47,0,http://www.openphacts.org/units/Nanomolar,1659879,=,1,1,=,,IC50,nM,,33.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.9
,,10970497,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '9.00', 'le': '0.18', 'lle': '-1.49', 'sei': '6.37'}",CHEMBL2063889,,CHEMBL2063889,7.07,0,http://www.openphacts.org/units/Nanomolar,1659880,=,1,1,=,,IC50,nM,,85.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,85.3
,,10970498,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '10.69', 'le': '0.21', 'lle': '0.82', 'sei': '6.79'}",CHEMBL376408,ABT 737,CHEMBL376408,8.70,0,http://www.openphacts.org/units/Nanomolar,1659881,=,1,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,,10970499,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccccc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,,CHEMBL2063890,,CHEMBL2063890,,0,http://www.openphacts.org/units/Nanomolar,1659882,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,10970500,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCNCC3)cc2)cc1[N+](=O)[O-],Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL2062483,J Med Chem,2012,,CHEMBL2063891,,CHEMBL2063891,,0,http://www.openphacts.org/units/Nanomolar,1659883,=,1,1,=,,IC50,nM,,534000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,534.0
,,10971446,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)NCCCN5CCN(C)CC5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '8.92', 'le': None, 'lle': None, 'sei': None}",CHEMBL2063892,,CHEMBL2063892,9.22,0,http://www.openphacts.org/units/Nanomolar,1659884,=,1,1,=,,IC50,nM,,0.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.6
,,10971447,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C,,,CHEMBL2062483,J Med Chem,2012,"{'bei': '9.12', 'le': '0.18', 'lle': '-0.65', 'sei': '5.70'}",CHEMBL2063893,,CHEMBL2063893,8.28,0,http://www.openphacts.org/units/Nanomolar,1659885,=,1,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,,10971448,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)cc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '8.33', 'le': '0.16', 'lle': '-2.49', 'sei': '6.11'}",CHEMBL2063894,,CHEMBL2063894,7.08,0,http://www.openphacts.org/units/Nanomolar,1659886,=,1,1,=,,IC50,nM,,82.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,82.6
,,10971449,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CCOC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)cn1C,,,CHEMBL2062483,J Med Chem,2012,"{'bei': '7.96', 'le': '0.16', 'lle': '-2.41', 'sei': '5.16'}",CHEMBL2063895,,CHEMBL2063895,7.34,0,http://www.openphacts.org/units/Nanomolar,1659887,=,1,1,=,,IC50,nM,,45.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,45.8
,,10971450,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)cn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2062483,J Med Chem,2012,"{'bei': '9.80', 'le': '0.19', 'lle': '-0.50', 'sei': '5.72'}",CHEMBL2063896,,CHEMBL2063896,8.77,0,http://www.openphacts.org/units/Nanomolar,1659888,=,1,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,,10971451,[],CHEMBL2066619,Binding affinity to N-terminus 6X His-tagged human Bcl2 expressed in Escherichia coli BL21 (DE3) cells after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CCc1c(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(C(=O)O)n1C,,,CHEMBL2062483,J Med Chem,2012,"{'bei': '9.09', 'le': '0.18', 'lle': '-1.44', 'sei': '5.47'}",CHEMBL2063897,,CHEMBL2063897,8.39,0,http://www.openphacts.org/units/Nanomolar,1659889,=,1,1,=,,IC50,nM,,4.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.1
,,12098632,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.50', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170840,,CHEMBL2170840,7.11,0,http://www.openphacts.org/units/Nanomolar,1740686,=,1,1,=,,IC50,nM,,78.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,78.2
,,12098633,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.97', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170839,,CHEMBL2170839,7.52,0,http://www.openphacts.org/units/Nanomolar,1740685,=,1,1,=,,IC50,nM,,30.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.1
,,12098634,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.78', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170838,,CHEMBL2170838,8.40,0,http://www.openphacts.org/units/Nanomolar,1740684,=,1,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,,12098635,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.76', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170837,,CHEMBL2170837,8.27,0,http://www.openphacts.org/units/Nanomolar,1740683,=,1,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,,12098636,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(C)(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.25', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170836,,CHEMBL2170836,7.73,0,http://www.openphacts.org/units/Nanomolar,1740682,=,1,1,=,,IC50,nM,,18.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.6
,,12098637,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC(O)CC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.60', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170835,,CHEMBL2170835,7.99,0,http://www.openphacts.org/units/Nanomolar,1740681,=,1,1,=,,IC50,nM,,10.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.2
,,12098638,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CC(O)C6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.93', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170851,,CHEMBL2170851,8.11,0,http://www.openphacts.org/units/Nanomolar,1740697,=,1,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,,12098639,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.54', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170850,,CHEMBL2170850,7.81,0,http://www.openphacts.org/units/Nanomolar,1740696,=,1,1,=,,IC50,nM,,15.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.6
,,12098640,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.91', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170849,,CHEMBL2170849,8.08,0,http://www.openphacts.org/units/Nanomolar,1740695,=,1,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,,12098641,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '8.06', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170848,,CHEMBL2170848,8.12,0,http://www.openphacts.org/units/Nanomolar,1740694,=,1,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,,12098642,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.99', 'le': None, 'lle': None, 'sei': None}",CHEMBL2170847,,CHEMBL2170847,7.26,0,http://www.openphacts.org/units/Nanomolar,1740693,=,1,1,=,,IC50,nM,,55.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,55.2
,,12098643,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '8.07', 'le': '0.16', 'lle': '-1.92', 'sei': '5.57'}",CHEMBL2170846,,CHEMBL2170846,8.04,0,http://www.openphacts.org/units/Nanomolar,1740692,=,1,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
,,12098644,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C6CC6)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.87', 'le': '0.14', 'lle': '-0.68', 'sei': '4.77'}",CHEMBL2170845,,CHEMBL2170845,6.07,0,http://www.openphacts.org/units/Nanomolar,1740691,=,1,1,=,,IC50,nM,,844.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,844.0
,,12098645,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCS(=O)(=O)c1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.97', 'le': '0.14', 'lle': '-0.53', 'sei': '4.78'}",CHEMBL2170844,,CHEMBL2170844,6.08,0,http://www.openphacts.org/units/Nanomolar,1740690,=,1,1,=,,IC50,nM,,828.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,828.0
,,12098646,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(C)(=O)=O)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.52', 'le': '0.13', 'lle': '-0.63', 'sei': '4.39'}",CHEMBL2170843,,CHEMBL2170843,5.59,0,http://www.openphacts.org/units/Nanomolar,1740689,=,1,1,=,,IC50,nM,,2543.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2543.0
,,12098647,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(S(=O)(=O)C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.47', 'le': '0.15', 'lle': '-0.29', 'sei': '5.35'}",CHEMBL2170842,,CHEMBL2170842,6.82,0,http://www.openphacts.org/units/Nanomolar,1740688,=,1,1,=,,IC50,nM,,153.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,153.0
,,12098648,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.79', 'le': '0.13', 'lle': '-1.91', 'sei': '5.56'}",CHEMBL2170841,,CHEMBL2170841,5.69,0,http://www.openphacts.org/units/Nanomolar,1740687,=,1,1,=,,IC50,nM,,2021.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2021.0
,,12098649,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCOc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.02', 'le': '0.14', 'lle': '-1.42', 'sei': '5.65'}",CHEMBL2171011,,CHEMBL2171011,5.79,0,http://www.openphacts.org/units/Nanomolar,1740870,=,1,1,=,,IC50,nM,,1624.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1624.0
,,12098650,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.52', 'le': '0.15', 'lle': '-0.72', 'sei': '5.95'}",CHEMBL2169898,,CHEMBL2169898,6.10,0,http://www.openphacts.org/units/Nanomolar,1740869,=,1,1,=,,IC50,nM,,802.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,802.0
,,12098651,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(OC(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.08', 'le': '0.14', 'lle': '-1.59', 'sei': '5.97'}",CHEMBL2171010,,CHEMBL2171010,6.12,0,http://www.openphacts.org/units/Nanomolar,1740868,=,1,1,=,,IC50,nM,,763.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,763.0
,,12098652,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(C)(C)C)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '6.84', 'le': '0.13', 'lle': '-2.39', 'sei': '6.14'}",CHEMBL2171009,,CHEMBL2171009,5.72,0,http://www.openphacts.org/units/Nanomolar,1740867,=,1,1,=,,IC50,nM,,1908.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1908.0
,,12098653,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CCc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.68', 'le': '0.15', 'lle': '-1.17', 'sei': '6.66'}",CHEMBL2171008,,CHEMBL2171008,6.21,0,http://www.openphacts.org/units/Nanomolar,1740866,=,1,1,=,,IC50,nM,,621.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,621.0
,,12098654,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NCCCN6CCN(C)CC6)c(C)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)c1,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.76', 'le': '0.15', 'lle': '-0.96', 'sei': '6.61'}",CHEMBL2171007,,CHEMBL2171007,6.16,0,http://www.openphacts.org/units/Nanomolar,1740865,=,1,1,=,,IC50,nM,,689.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,689.0
,,12098655,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(C(F)(F)F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.35', 'le': '0.14', 'lle': '-1.59', 'sei': '6.69'}",CHEMBL2171006,,CHEMBL2171006,6.24,0,http://www.openphacts.org/units/Nanomolar,1740864,=,1,1,=,,IC50,nM,,582.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,582.0
,,12098656,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Br)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.67', 'le': '0.16', 'lle': '-0.99', 'sei': '7.08'}",CHEMBL2171005,,CHEMBL2171005,6.59,0,http://www.openphacts.org/units/Nanomolar,1740863,=,1,1,=,,IC50,nM,,255.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,255.0
,,12098657,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(Cl)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.58', 'le': '0.15', 'lle': '-1.29', 'sei': '6.63'}",CHEMBL2171004,,CHEMBL2171004,6.18,0,http://www.openphacts.org/units/Nanomolar,1740862,=,1,1,=,,IC50,nM,,660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,660.0
,,12098658,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc(F)c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.53', 'le': '0.15', 'lle': '-0.94', 'sei': '6.45'}",CHEMBL2171003,,CHEMBL2171003,6.01,0,http://www.openphacts.org/units/Nanomolar,1740861,=,1,1,=,,IC50,nM,,977.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,977.0
,,12098659,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccccc5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '7.25', 'le': '0.14', 'lle': '-1.16', 'sei': '6.07'}",CHEMBL2170853,,CHEMBL2170853,5.66,0,http://www.openphacts.org/units/Nanomolar,1740701,=,1,1,=,,IC50,nM,,2200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2200.0
,,12098660,[],CHEMBL2173962,Inhibition of N-terminal 6xHis-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c(C(=O)NCCCN2CCN(C)CC2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5cccc([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2169845,J Med Chem,2012,"{'bei': '8.40', 'le': '0.16', 'lle': '0.21', 'sei': '5.09'}",CHEMBL2170852,,CHEMBL2170852,6.93,0,http://www.openphacts.org/units/Nanomolar,1740700,=,1,1,=,,IC50,nM,,117.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,117.0
,,12165757,[],CHEMBL2208697,Binding affinity to Bcl2 by fluorescent polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,,,CHEMBL2203023,J Med Chem,2011,"{'bei': '12.75', 'le': '0.25', 'lle': '1.31', 'sei': '5.94'}",CHEMBL371861,,CHEMBL371861,7.03,0,http://www.openphacts.org/units/Nanomolar,1756145,=,1,1,=,,IC50,nM,,93.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,93.0
,,12165758,[],CHEMBL2208697,Binding affinity to Bcl2 by fluorescent polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Oc1cccc2c1CCCC2,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL2203023,J Med Chem,2011,,CHEMBL449132,,CHEMBL449132,,0,http://www.openphacts.org/units/Nanomolar,1756144,=,1,1,=,,IC50,nM,,4300000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4300.0
,,12167058,[],CHEMBL2208697,Binding affinity to Bcl2 by fluorescent polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1ccc(-c2ccc(F)cc2)cc1,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL2203023,J Med Chem,2011,,CHEMBL106708,,CHEMBL106708,,0,http://www.openphacts.org/units/Nanomolar,1756143,=,1,1,=,,IC50,nM,,300000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,300.0
,,12620188,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '14.47', 'le': '0.28', 'lle': '2.24', 'sei': '9.63'}",CHEMBL2312467,,CHEMBL2312467,5.68,0,http://www.openphacts.org/units/Nanomolar,1842075,=,1,1,=,,IC50,nM,,2100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.1
,,12620189,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)C1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '14.95', 'le': '0.29', 'lle': '2.61', 'sei': '9.59'}",CHEMBL2312468,,CHEMBL2312468,5.66,0,http://www.openphacts.org/units/Nanomolar,1842076,=,1,1,=,,IC50,nM,,2200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.2
,,12620190,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C1N=C2C(=C1NCCCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '12.59', 'le': '0.24', 'lle': '0.44', 'sei': '13.17'}",CHEMBL2312480,,CHEMBL2312480,5.89,0,http://www.openphacts.org/units/Nanomolar,1842090,=,1,1,=,,IC50,nM,,1300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.3
,,12620191,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C1N=C2C(=C1NCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,,CHEMBL2312479,,CHEMBL2312479,,0,http://www.openphacts.org/units/Nanomolar,1842089,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,12620192,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)NC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,,CHEMBL2312478,,CHEMBL2312478,,0,http://www.openphacts.org/units/Nanomolar,1842088,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,12620193,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.61', 'le': '0.28', 'lle': '0.35', 'sei': '14.55'}",CHEMBL2312476,,CHEMBL2312476,7.38,0,http://www.openphacts.org/units/Nanomolar,1842086,=,1,1,=,,IC50,nM,,42.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,42.0
,,12620194,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.36', 'le': '0.28', 'lle': '-0.24', 'sei': '13.29'}",CHEMBL2312475,,CHEMBL2312475,6.74,0,http://www.openphacts.org/units/Nanomolar,1842085,=,1,1,=,,IC50,nM,,184.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,184.0
,,12620195,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCNC1=C2C(=NC1=O)c1cccc3c(Oc4ccc(C(C)C)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.81', 'le': '0.29', 'lle': '0.29', 'sei': '12.81'}",CHEMBL2312474,,CHEMBL2312474,6.49,0,http://www.openphacts.org/units/Nanomolar,1842084,=,1,1,=,,IC50,nM,,322.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,322.0
,,12620196,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccc(Oc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.83', 'le': '0.30', 'lle': '0.75', 'sei': '9.82'}",CHEMBL1672071,,CHEMBL1672071,6.13,0,http://www.openphacts.org/units/Nanomolar,1842083,=,1,1,=,,IC50,nM,,739.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,739.0
,,12620197,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(Sc3ccc(OO)cc3)c3cccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.14', 'le': '0.28', 'lle': '1.12', 'sei': '10.21'}",CHEMBL2312473,,CHEMBL2312473,7.24,0,http://www.openphacts.org/units/Nanomolar,1842082,=,1,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
,,12620198,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.11', 'le': '0.29', 'lle': '0.47', 'sei': '13.19'}",CHEMBL2312472,,CHEMBL2312472,6.69,0,http://www.openphacts.org/units/Nanomolar,1842081,=,1,1,=,,IC50,nM,,206.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,206.0
,,12620199,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(OC)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '15.56', 'le': '0.29', 'lle': '1.01', 'sei': '12.72'}",CHEMBL2312471,,CHEMBL2312471,6.45,0,http://www.openphacts.org/units/Nanomolar,1842080,=,1,1,=,,IC50,nM,,356.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,356.0
,,12620200,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(C#N)=C23)cc1,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.35', 'le': '0.30', 'lle': '1.40', 'sei': '9.65'}",CHEMBL1672077,,CHEMBL1672077,6.03,0,http://www.openphacts.org/units/Nanomolar,1842079,=,1,1,=,,IC50,nM,,945.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,945.0
,,12620201,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,Nc1ccc(Sc2ccc3c4c(cccc24)C2=NC(=O)C(NCCCc4ccccc4)=C23)cc1,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.68', 'le': '0.31', 'lle': '1.85', 'sei': '11.41'}",CHEMBL2312470,,CHEMBL2312470,7.70,0,http://www.openphacts.org/units/Nanomolar,1842078,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,,12620202,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.60', 'le': '0.31', 'lle': '1.30', 'sei': '10.52'}",CHEMBL2312469,,CHEMBL2312469,7.10,0,http://www.openphacts.org/units/Nanomolar,1842077,=,1,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,,12620203,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCNC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.82', 'le': '0.32', 'lle': '1.70', 'sei': '9.96'}",CHEMBL2312484,,CHEMBL2312484,6.72,0,http://www.openphacts.org/units/Nanomolar,1842097,=,1,1,=,,IC50,nM,,190.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,190.0
,,12620204,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C2C(=NC1=O)c1cccc3c(Sc4ccc(N)cc4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '18.34', 'le': '0.34', 'lle': '2.29', 'sei': '8.18'}",CHEMBL1672082,,CHEMBL1672082,6.48,0,http://www.openphacts.org/units/Nanomolar,1842096,=,1,1,=,,IC50,nM,,331.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,331.0
,,12620205,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=C1N=C2C(=C1NCCCc1ccccc1)c1ccc(N3CCSCC3)c3cccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '16.63', 'le': '0.31', 'lle': '2.64', 'sei': '16.35'}",CHEMBL2312483,,CHEMBL2312483,7.31,0,http://www.openphacts.org/units/Nanomolar,1842095,=,1,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,,12620206,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '17.30', 'le': '0.33', 'lle': '2.40', 'sei': '15.70'}",CHEMBL2312482,,CHEMBL2312482,7.02,0,http://www.openphacts.org/units/Nanomolar,1842094,=,1,1,=,,IC50,nM,,96.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,96.0
,,12620207,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCNC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '17.76', 'le': '0.34', 'lle': '2.86', 'sei': '15.00'}",CHEMBL2312481,,CHEMBL2312481,6.70,0,http://www.openphacts.org/units/Nanomolar,1842093,=,1,1,=,,IC50,nM,,198.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,198.0
,,12620208,[],CHEMBL2318341,Binding affinity to human Bcl-2 (unknown origin) by biotin-Bim displacement based ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C2C(=NC1=O)c1cccc3c(N4CCSCC4)ccc2c13,,,CHEMBL2311285,Bioorg Med Chem,2013,"{'bei': '18.54', 'le': '0.35', 'lle': '3.14', 'sei': '10.89'}",CHEMBL595134,,CHEMBL595134,6.15,0,http://www.openphacts.org/units/Nanomolar,1842092,=,1,1,=,,IC50,nM,,715.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,715.0
,,12653912,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(C(F)(F)F)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '7.36', 'le': '0.15', 'lle': '-2.12', 'sei': '5.74'}",CHEMBL2322022,,CHEMBL2322022,7.34,0,http://www.openphacts.org/units/Nanomolar,1847702,=,1,1,=,,IC50,nM,,46.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,46.0
,,12653917,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nc(Cl)nc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '7.78', 'le': '0.16', 'lle': '-1.60', 'sei': '5.86'}",CHEMBL2322021,,CHEMBL2322021,7.50,0,http://www.openphacts.org/units/Nanomolar,1847701,=,1,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,,12653922,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3=O)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '7.13', 'le': '0.15', 'lle': '-1.37', 'sei': '4.73'}",CHEMBL2322020,,CHEMBL2322020,6.85,0,http://www.openphacts.org/units/Nanomolar,1847700,=,1,1,=,,IC50,nM,,142.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,142.0
,,12653931,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CC(c1ccccc1-c1ccc(Cl)cc1)N1CCC(N2CCc3c(ncnc3NS(=O)(=O)c3ccc(N[C@H](CCN(C)C)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)C2)CC1,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '7.91', 'le': '0.16', 'lle': '-1.54', 'sei': '5.83'}",CHEMBL2326747,,CHEMBL2326747,7.46,0,http://www.openphacts.org/units/Nanomolar,1853262,=,1,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,,12653936,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4cc(F)ccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '7.90', 'le': '0.16', 'lle': '-1.10', 'sei': '5.85'}",CHEMBL2326746,,CHEMBL2326746,7.48,0,http://www.openphacts.org/units/Nanomolar,1853261,=,1,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,,12653946,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ncnc3c2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)C3)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '8.32', 'le': '0.17', 'lle': '-0.72', 'sei': '6.04'}",CHEMBL2326745,,CHEMBL2326745,7.72,0,http://www.openphacts.org/units/Nanomolar,1853260,=,1,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,,12653950,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3n2CCN(C2CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC2)CC3)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '8.16', 'le': '0.17', 'lle': '-0.14', 'sei': '5.73'}",CHEMBL2326744,,CHEMBL2326744,7.60,0,http://www.openphacts.org/units/Nanomolar,1853259,=,1,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,,12653953,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,O=S(=O)(Nc1ncnc2c1CN(C1CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC1)C2)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '6.41', 'le': '0.13', 'lle': '-2.04', 'sei': '4.47'}",CHEMBL2322029,,CHEMBL2322029,6.13,0,http://www.openphacts.org/units/Nanomolar,1847710,=,1,1,=,,IC50,nM,,740.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,740.0
,,12653956,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,O=S(=O)(Nc1nnc2n1CCN(C1CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC1)C2)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,CHEMBL2321763,ACS Med Chem Lett,2013,,CHEMBL2322028,,CHEMBL2322028,,0,http://www.openphacts.org/units/Nanomolar,1847709,<,1,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,,12653965,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC2=NS(=O)(=O)c3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc32)cc1[N+](=O)[O-],,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '8.88', 'le': '0.18', 'lle': '0.58', 'sei': '4.93'}",CHEMBL2322027,,CHEMBL2322027,7.77,0,http://www.openphacts.org/units/Nanomolar,1847708,=,1,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,,12653970,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nnc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnn23)cc1[N+](=O)[O-],,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '9.19', 'le': '0.18', 'lle': '0.60', 'sei': '4.93'}",CHEMBL2322026,,CHEMBL2322026,7.60,0,http://www.openphacts.org/units/Nanomolar,1847707,=,1,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,,12653972,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2nn(C)c3nc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ncc23)cc1[N+](=O)[O-],,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '6.03', 'le': '0.12', 'lle': '-2.17', 'sei': '3.28'}",CHEMBL2322025,,CHEMBL2322025,5.07,0,http://www.openphacts.org/units/Nanomolar,1847706,=,1,1,=,,IC50,nM,,8500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8500.0
,,12653975,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2cccc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)cnc23)cc1[N+](=O)[O-],,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '8.57', 'le': '0.17', 'lle': '-1.94', 'sei': '5.78'}",CHEMBL2322024,,CHEMBL2322024,7.17,0,http://www.openphacts.org/units/Nanomolar,1847705,=,1,1,=,,IC50,nM,,68.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,68.0
,,12653978,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,O=[N+]([O-])c1cc(S(=O)(=O)Nc2cccc3cc(N4CCN(Cc5ccccc5-c5ccc(Cl)cc5)CC4)ccc23)ccc1N[C@H](CCN1CCOCC1)CSc1ccccc1,,,CHEMBL2321763,ACS Med Chem Lett,2013,,CHEMBL2322023,,CHEMBL2322023,,0,http://www.openphacts.org/units/Nanomolar,1847704,>,1,1,>,,IC50,nM,,4000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4000.0
,,12653982,[],CHEMBL2328210,Inhibition of Bcl-2/biotinylated BAK (unknown origin) interaction incubated for 1 hr by surface plasmon resonance analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321763,ACS Med Chem Lett,2013,"{'bei': '9.46', 'le': '0.19', 'lle': '-0.18', 'sei': '6.01'}",CHEMBL376408,ABT 737,CHEMBL376408,7.70,0,http://www.openphacts.org/units/Nanomolar,1847703,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,,12661041,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.63', 'le': None, 'lle': None, 'sei': None}",CHEMBL2325764,,CHEMBL2325764,8.74,0,http://www.openphacts.org/units/Nanomolar,1852132,=,1,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,,12661042,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(C)c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.75', 'le': '0.18', 'lle': '-0.31', 'sei': '4.88'}",CHEMBL2325763,,CHEMBL2325763,8.74,0,http://www.openphacts.org/units/Nanomolar,1852131,=,1,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,,12661043,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.03', 'le': '0.16', 'lle': '-3.20', 'sei': '4.98'}",CHEMBL2325762,,CHEMBL2325762,7.64,0,http://www.openphacts.org/units/Nanomolar,1852130,=,1,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,,12661044,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.54', 'le': '0.17', 'lle': '-2.45', 'sei': '5.22'}",CHEMBL2325761,,CHEMBL2325761,8.00,0,http://www.openphacts.org/units/Nanomolar,1852129,=,1,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,,12661045,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C(C)C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.45', 'le': '0.19', 'lle': '-1.77', 'sei': '5.78'}",CHEMBL2159740,,CHEMBL2159740,8.85,0,http://www.openphacts.org/units/Nanomolar,1852128,=,1,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,,12661046,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1oc(-c2ccc(Cl)cc2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1C(=O)O,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.40', 'le': '0.19', 'lle': '-1.41', 'sei': '5.21'}",CHEMBL2325760,,CHEMBL2325760,8.42,0,http://www.openphacts.org/units/Nanomolar,1852127,=,1,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,,12662228,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(-c6ccc(Cl)cc6)nn(C)c5C(=O)O)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.42', 'le': '0.19', 'lle': '-0.24', 'sei': '5.07'}",CHEMBL2325759,,CHEMBL2325759,8.43,0,http://www.openphacts.org/units/Nanomolar,1852126,=,1,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,,12662229,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)nn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.10', 'le': '0.18', 'lle': '-0.52', 'sei': '4.90'}",CHEMBL2325758,,CHEMBL2325758,8.15,0,http://www.openphacts.org/units/Nanomolar,1852125,=,1,1,=,,IC50,nM,,7.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.1
,,12662230,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)cnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.62', 'le': '0.17', 'lle': '0.83', 'sei': '4.30'}",CHEMBL2325757,,CHEMBL2325757,8.27,0,http://www.openphacts.org/units/Nanomolar,1852124,=,1,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,,12662231,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)NS(C)(=O)=O)ncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.78', 'le': '0.18', 'lle': '0.98', 'sei': '4.38'}",CHEMBL2326039,,CHEMBL2326039,8.42,0,http://www.openphacts.org/units/Nanomolar,1852454,=,1,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,,12662232,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnoc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '7.70', 'le': '0.15', 'lle': '-2.76', 'sei': '4.71'}",CHEMBL2326038,,CHEMBL2326038,6.46,0,http://www.openphacts.org/units/Nanomolar,1852453,=,1,1,=,,IC50,nM,,350.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,350.0
,,12662233,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cn(C)nc5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.05', 'le': '0.16', 'lle': '-2.12', 'sei': '5.32'}",CHEMBL2326037,,CHEMBL2326037,6.85,0,http://www.openphacts.org/units/Nanomolar,1852452,=,1,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,,12662234,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cnn(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '7.84', 'le': '0.15', 'lle': '-2.29', 'sei': '5.18'}",CHEMBL2325774,,CHEMBL2325774,6.68,0,http://www.openphacts.org/units/Nanomolar,1852142,=,1,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,210.0
,,12662235,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5ccnn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.31', 'le': '0.16', 'lle': '-1.79', 'sei': '5.40'}",CHEMBL2325773,,CHEMBL2325773,6.96,0,http://www.openphacts.org/units/Nanomolar,1852141,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,,12662236,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5cncn5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.76', 'le': '0.17', 'lle': '-1.41', 'sei': '5.69'}",CHEMBL2325772,,CHEMBL2325772,7.34,0,http://www.openphacts.org/units/Nanomolar,1852140,=,1,1,=,,IC50,nM,,46.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,46.0
,,12662237,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(Cl)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.50', 'le': '0.19', 'lle': '-1.10', 'sei': '5.76'}",CHEMBL2325771,,CHEMBL2325771,8.82,0,http://www.openphacts.org/units/Nanomolar,1852139,=,1,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,,12662238,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)Nc2ccc(N3CCN(c4cccc(-c5c(C(=O)O)c(C(F)(F)F)n(C)c5-c5ccc(Cl)cc5)c4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.31', 'le': '0.19', 'lle': '-1.33', 'sei': '5.84'}",CHEMBL2325770,,CHEMBL2325770,8.96,0,http://www.openphacts.org/units/Nanomolar,1852138,=,1,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,,12662239,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C#N)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.73', 'le': '0.17', 'lle': '-1.98', 'sei': '5.56'}",CHEMBL2325769,,CHEMBL2325769,7.77,0,http://www.openphacts.org/units/Nanomolar,1852137,=,1,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,,12662240,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(F)(F)F)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '7.04', 'le': '0.14', 'lle': '-4.33', 'sei': '5.66'}",CHEMBL2325768,,CHEMBL2325768,6.57,0,http://www.openphacts.org/units/Nanomolar,1852136,=,1,1,=,,IC50,nM,,271.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,271.0
,,12662241,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '7.32', 'le': '0.15', 'lle': '-3.94', 'sei': '5.68'}",CHEMBL2325767,,CHEMBL2325767,6.58,0,http://www.openphacts.org/units/Nanomolar,1852135,=,1,1,=,,IC50,nM,,260.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,260.0
,,12662242,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)NS(C)(=O)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.18', 'le': '0.18', 'lle': '0.48', 'sei': '5.05'}",CHEMBL2325766,,CHEMBL2325766,9.05,0,http://www.openphacts.org/units/Nanomolar,1852134,=,1,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,,12662243,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N2CC(C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.44', 'le': '0.17', 'lle': '-0.84', 'sei': '5.27'}",CHEMBL2325765,,CHEMBL2325765,8.25,0,http://www.openphacts.org/units/Nanomolar,1852133,=,1,1,=,,IC50,nM,,5.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.6
,,12662244,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N[C@H]2C[C@@](C)(O)C2)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.19', 'le': '0.16', 'lle': '-1.40', 'sei': '4.91'}",CHEMBL2326041,,CHEMBL2326041,8.12,0,http://www.openphacts.org/units/Nanomolar,1852460,=,1,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,,12662245,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(N)=O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.51', 'le': '0.17', 'lle': '-1.26', 'sei': '4.85'}",CHEMBL2326040,,CHEMBL2326040,7.72,0,http://www.openphacts.org/units/Nanomolar,1852459,=,1,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,,12662246,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CNC(=O)c1c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n(C)c1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.01', 'le': '0.18', 'lle': '-0.94', 'sei': '5.72'}",CHEMBL2159736,,CHEMBL2159736,8.30,0,http://www.openphacts.org/units/Nanomolar,1852458,=,1,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,,12662247,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '8.10', 'le': '0.16', 'lle': '-2.88', 'sei': '6.04'}",CHEMBL2159738,,CHEMBL2159738,7.00,0,http://www.openphacts.org/units/Nanomolar,1852457,=,1,1,=,,IC50,nM,,99.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,99.0
,,12662248,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(C)c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c1-c1ccc(Cl)cc1,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.43', 'le': '0.19', 'lle': '-1.36', 'sei': '5.67'}",CHEMBL2159739,,CHEMBL2159739,8.70,0,http://www.openphacts.org/units/Nanomolar,1852456,=,1,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,,12662249,[],CHEMBL2330000,Binding affinity to BCL2 (unknown origin) after 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)O)c(-c2cccc(N3CCN(c4ccc(NS(=O)(=O)c5ccc(N[C@H](CCN(C)C)CSc6ccccc6)c([N+](=O)[O-])c5)cc4)CC3)c2)c(-c2ccc(Cl)cc2)n1C,,,CHEMBL2321752,J Med Chem,2013,"{'bei': '9.78', 'le': '0.19', 'lle': '-0.69', 'sei': '5.80'}",CHEMBL2159737,,CHEMBL2159737,8.89,0,http://www.openphacts.org/units/Nanomolar,1852455,=,1,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,,13294104,[],CHEMBL2379960,Inhibition of Bcl-2 (unknown origin) after 15 hrs by FRET method,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL2375247,Bioorg Med Chem Lett,2013,"{'bei': '10.95', 'le': '0.20', 'lle': '-0.70', 'sei': '3.65'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,5.68,0,http://www.openphacts.org/units/Nanomolar,1891261,=,1,1,=,,IC50,nM,,2110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.11
,,13294105,[],CHEMBL2379961,Competitive binding affinity to his-tagged Bcl-2 (unknown origin) after 1 hr by ELISA in presence of Bim peptide,B,,,BAO_0000190,BAO_0000357,single protein format,Nn1c(SCc2cccc([N+](=O)[O-])c2)nnc1-c1c[nH]c2ccccc12,,,CHEMBL2375247,Bioorg Med Chem Lett,2013,"{'bei': '15.95', 'le': '0.31', 'lle': '2.50', 'sei': '5.05'}",CHEMBL2376835,,CHEMBL2376835,5.84,0,http://www.openphacts.org/units/Nanomolar,1891428,=,1,1,=,,IC50,nM,,1430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.43
,,13352591,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,C/C(=N\Nc1nc2ccccc2s1)c1ccc(-c2cccc(C(=O)O)n2)s1,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398170,,CHEMBL2398170,,0,http://www.openphacts.org/units/Nanomolar,1903758,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353866,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1ccnc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398262,,CHEMBL2398262,,0,http://www.openphacts.org/units/Nanomolar,1903864,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353867,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CC/C(=N/Nc2nc3ccccc3s2)c2cc(-c3cccc(C(=O)O)n3)ccc21,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398249,,CHEMBL2398249,,0,http://www.openphacts.org/units/Nanomolar,1903851,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353868,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cccc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398173,,CHEMBL2398173,,0,http://www.openphacts.org/units/Nanomolar,1903761,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353869,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,C/C(=N\Nc1nc2ccccc2s1)c1cccc(-c2cccc(C(=O)O)n2)c1,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398286,,CHEMBL2398286,,0,http://www.openphacts.org/units/Nanomolar,1903889,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353870,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,C/C(=N\Nc1nc2ccccc2s1)c1ccc(-c2cccc(C(=O)O)c2)o1,,,CHEMBL2396645,J Med Chem,2013,,CHEMBL2398292,,CHEMBL2398292,,0,http://www.openphacts.org/units/Nanomolar,1903897,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,13353892,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)ccn1,,,CHEMBL2396645,J Med Chem,2013,"{'bei': '12.79', 'le': '0.24', 'lle': '0.09', 'sei': '6.06'}",CHEMBL2398263,,CHEMBL2398263,5.30,0,http://www.openphacts.org/units/Nanomolar,1903865,=,1,1,=,,IC50,nM,,5000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.0
,,13353893,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1csc(-c2ccc3c(c2)/C(=N\Nc2nc4ccccc4s2)CCC3)n1,,,CHEMBL2396645,J Med Chem,2013,"{'bei': '12.61', 'le': '0.25', 'lle': '0.03', 'sei': '6.06'}",CHEMBL2398260,,CHEMBL2398260,5.30,0,http://www.openphacts.org/units/Nanomolar,1903862,=,1,1,=,,IC50,nM,,5000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.0
,,13353952,[],CHEMBL2399234,Binding affinity to Bcl-2 (unknown origin) by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL2396645,J Med Chem,2013,"{'bei': '10.03', 'le': '0.20', 'lle': '0.27', 'sei': '6.36'}",CHEMBL376408,ABT 737,CHEMBL376408,8.15,0,http://www.openphacts.org/units/Nanomolar,1903892,=,1,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.007
,,14733267,[],CHEMBL3291800,Antagonist activity at Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cccc(-c2ccc3c(c2)/C(=N/Nc2nc4ccccc4s2)CCC3)n1,,,CHEMBL3286340,ACS Med Chem Lett,2014,,CHEMBL3287282,,CHEMBL3287282,,0,http://www.openphacts.org/units/Nanomolar,2114588,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
,,14733268,[],CHEMBL3291800,Antagonist activity at Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1csc(-c2ccc3c(c2)/C(=N/Nc2nc4ccccc4s2)CCC3)n1,,,CHEMBL3286340,ACS Med Chem Lett,2014,"{'bei': '12.61', 'le': '0.25', 'lle': '0.03', 'sei': '6.06'}",CHEMBL3287283,,CHEMBL3287283,5.30,0,http://www.openphacts.org/units/Nanomolar,2114589,=,1,1,=,,IC50,nM,,5000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.0
,,15040106,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.44', 'le': '0.17', 'lle': '-0.08', 'sei': '6.20'}",CHEMBL3311329,,CHEMBL3311329,7.96,0,http://www.openphacts.org/units/Nanomolar,2254789,=,1,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.011
,,15040107,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.20', 'le': '0.17', 'lle': '-0.50', 'sei': '5.71'}",CHEMBL3311330,,CHEMBL3311330,7.72,0,http://www.openphacts.org/units/Nanomolar,2254790,=,1,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.019
,,15040108,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=S(=O)(NC(=C1COC1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3311331,,CHEMBL3311331,,0,http://www.openphacts.org/units/Nanomolar,2254791,>,1,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.0
,,15040109,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nn1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.95', 'le': '0.14', 'lle': '-0.26', 'sei': '4.26'}",CHEMBL3311479,,CHEMBL3311479,6.57,0,http://www.openphacts.org/units/Nanomolar,2254792,=,1,1,=,,IC50,nM,,270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.27
,,15040110,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1cnc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.20', 'le': '0.17', 'lle': '0.91', 'sei': '5.02'}",CHEMBL3311480,,CHEMBL3311480,7.75,0,http://www.openphacts.org/units/Nanomolar,2254793,=,1,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.018
,,15040111,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1csc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)n1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.29', 'le': '0.15', 'lle': '-0.57', 'sei': '4.90'}",CHEMBL3311481,,CHEMBL3311481,6.92,0,http://www.openphacts.org/units/Nanomolar,2254794,=,1,1,=,,IC50,nM,,119.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.119
,,15040112,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CC3(CN(Cc4ccccc4-c4ccc(Cl)cc4)C3)C2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3311482,,CHEMBL3311482,,0,http://www.openphacts.org/units/Nanomolar,2254795,>,1,1,>,,IC50,nM,,468.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.468
,,15040113,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(P2(=O)CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3311483,,CHEMBL3311483,,0,http://www.openphacts.org/units/Nanomolar,2254796,>,1,1,>,,IC50,nM,,1100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.1
,,15040114,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCP(=O)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.45', 'le': '0.16', 'lle': '-1.83', 'sei': '5.11'}",CHEMBL3311484,,CHEMBL3311484,7.27,0,http://www.openphacts.org/units/Nanomolar,2254797,=,1,1,=,,IC50,nM,,54.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.054
,,15040115,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Oc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.00', 'le': '0.14', 'lle': '-2.16', 'sei': '4.91'}",CHEMBL3311485,,CHEMBL3311485,6.60,0,http://www.openphacts.org/units/Nanomolar,2254798,=,1,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.25
,,15040116,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(C(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.52', 'le': '0.15', 'lle': '-1.62', 'sei': '5.05'}",CHEMBL3311486,,CHEMBL3311486,7.19,0,http://www.openphacts.org/units/Nanomolar,2254799,=,1,1,=,,IC50,nM,,65.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.065
,,15040117,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(Sc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.52', 'le': '0.16', 'lle': '-2.27', 'sei': '5.77'}",CHEMBL3311487,,CHEMBL3311487,7.21,0,http://www.openphacts.org/units/Nanomolar,2254800,=,1,1,=,,IC50,nM,,61.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.061
,,15040118,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.91', 'le': '0.16', 'lle': '-0.77', 'sei': '5.21'}",CHEMBL3311488,,CHEMBL3311488,7.72,0,http://www.openphacts.org/units/Nanomolar,2254801,=,1,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.019
,,15040119,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.42', 'le': '0.13', 'lle': '-2.23', 'sei': '4.23'}",CHEMBL3311489,,CHEMBL3311489,6.26,0,http://www.openphacts.org/units/Nanomolar,2254802,=,1,1,=,,IC50,nM,,545.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.545
,,15040120,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(S(=O)(=O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.12', 'le': '0.15', 'lle': '-1.10', 'sei': '4.43'}",CHEMBL3309283,,CHEMBL3309283,7.06,0,http://www.openphacts.org/units/Nanomolar,2254803,=,1,1,=,,IC50,nM,,87.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.087
,,15040121,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3311490,,CHEMBL3311490,,0,http://www.openphacts.org/units/Nanomolar,2254804,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040122,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,NCC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3311491,,CHEMBL3311491,,0,http://www.openphacts.org/units/Nanomolar,2254805,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040123,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)C1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.67', 'le': None, 'lle': None, 'sei': None}",CHEMBL3311492,,CHEMBL3311492,7.77,0,http://www.openphacts.org/units/Nanomolar,2254806,=,1,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.017
,,15040124,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC(CO)(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.44', 'le': '0.15', 'lle': '-1.31', 'sei': '4.97'}",CHEMBL3311493,,CHEMBL3311493,7.23,0,http://www.openphacts.org/units/Nanomolar,2254807,=,1,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.059
,,15040125,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ncc(Cl)cn3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.13', 'le': '0.17', 'lle': '0.85', 'sei': '4.98'}",CHEMBL3311494,,CHEMBL3311494,7.68,0,http://www.openphacts.org/units/Nanomolar,2254808,=,1,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.021
,,15040126,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccncc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309307,,CHEMBL3309307,,0,http://www.openphacts.org/units/Nanomolar,2254809,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040127,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cccnc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.04', 'le': '0.16', 'lle': '0.16', 'sei': '5.37'}",CHEMBL3309308,,CHEMBL3309308,7.58,0,http://www.openphacts.org/units/Nanomolar,2254810,=,1,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.026
,,15040128,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3cn[nH]c3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.93', 'le': '0.16', 'lle': '0.64', 'sei': '4.71'}",CHEMBL3309309,,CHEMBL3309309,7.40,0,http://www.openphacts.org/units/Nanomolar,2254811,=,1,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.04
,,15040129,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1-c1ccc(Cl)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309310,,CHEMBL3309310,,0,http://www.openphacts.org/units/Nanomolar,2254812,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040130,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C(=O)COc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309311,,CHEMBL3309311,,0,http://www.openphacts.org/units/Nanomolar,2254813,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040131,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C(=O)COc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309262,,CHEMBL3309262,,0,http://www.openphacts.org/units/Nanomolar,2254814,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040132,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCOc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309312,,CHEMBL3309312,,0,http://www.openphacts.org/units/Nanomolar,2254815,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040133,[],CHEMBL3369467,Inhibition of c-terminal 6xHis-tagged Bcl-2 (amino acids 1 to 204) (unknown origin) preincubated for 1 hr prior to substrate addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCOc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL3309313,,CHEMBL3309313,,0,http://www.openphacts.org/units/Nanomolar,2254816,<,1,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.01
,,15040219,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.33', 'le': '0.17', 'lle': '-0.19', 'sei': '6.12'}",CHEMBL3311329,,CHEMBL3311329,7.85,0,http://www.openphacts.org/units/Nanomolar,2254789,=,1,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.014
,,15040220,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1cnc(N2CCN(Cc3ccccc3-c3ccc(Cl)cc3)CC2)nc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.85', 'le': '0.14', 'lle': '-0.36', 'sei': '4.20'}",CHEMBL3311480,,CHEMBL3311480,6.47,0,http://www.openphacts.org/units/Nanomolar,2254793,=,1,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.34
,,15040221,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([S@@+]([O-])c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.52', 'le': '0.14', 'lle': '-2.13', 'sei': '4.29'}",CHEMBL3311488,,CHEMBL3311488,6.36,0,http://www.openphacts.org/units/Nanomolar,2254801,=,1,1,=,,IC50,nM,,434.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.434
,,15040222,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1(Cc2ccccc2-c2ccc(Cl)cc2)CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.48', 'le': '0.13', 'lle': '-2.81', 'sei': '4.21'}",CHEMBL3311490,,CHEMBL3311490,6.26,0,http://www.openphacts.org/units/Nanomolar,2254804,=,1,1,=,,IC50,nM,,545.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.545
,,15040223,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)C(=O)COc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.04', 'le': None, 'lle': None, 'sei': None}",CHEMBL3309311,,CHEMBL3309311,7.35,0,http://www.openphacts.org/units/Nanomolar,2254813,=,1,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.045
,,15040224,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)C(=O)COc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '6.45', 'le': None, 'lle': None, 'sei': None}",CHEMBL3309262,,CHEMBL3309262,6.73,0,http://www.openphacts.org/units/Nanomolar,2254814,=,1,1,=,,IC50,nM,,187.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.187
,,15040225,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CCOc1cccc(-c2ccc(Cl)cc2)c1CN1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '8.16', 'le': None, 'lle': None, 'sei': None}",CHEMBL3309312,,CHEMBL3309312,8.40,0,http://www.openphacts.org/units/Nanomolar,2254815,=,1,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.004
,,15040226,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CCOc1ccc(-c2ccc(Cl)cc2)c(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)c1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,"{'bei': '7.44', 'le': None, 'lle': None, 'sei': None}",CHEMBL3309313,,CHEMBL3309313,7.66,0,http://www.openphacts.org/units/Nanomolar,2254816,=,1,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.022
,,15040227,[],CHEMBL3369471,Inhibition of human BCL-2 overexpressed in mouse FDC-P1 cells assessed as cell viability after 24 hrs by Cell Titer Glo assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL3351631,Bioorg Med Chem Lett,2014,,CHEMBL443684,NAVITOCLAX,CHEMBL443684,,0,http://www.openphacts.org/units/Nanomolar,2254817,<,1,1,<,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.015
,,15667665,[],CHEMBL3603526,Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bak interaction by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2,,,CHEMBL3600357,J Med Chem,2015,,CHEMBL3601398,CGM-097,CHEMBL3601398,,0,http://www.openphacts.org/units/Nanomolar,2492871,>,1,1,>,,IC50,nM,,50000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50000.0
,,15667666,[],CHEMBL3603527,Inhibition of Bcl2 (unknown origin) assessed as inhibition of Bcl2-Bad interaction by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc2c(cc1OC(C)C)[C@H](c1ccc(Cl)cc1)N(c1ccc(N(C)C[C@H]3CC[C@H](N4CCN(C)C(=O)C4)CC3)cc1)C(=O)C2,,,CHEMBL3600357,J Med Chem,2015,,CHEMBL3601398,CGM-097,CHEMBL3601398,,0,http://www.openphacts.org/units/Nanomolar,2492871,>,1,1,>,,IC50,nM,,50000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50000.0
,278910,16259059,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '10.36', 'le': '0.19', 'lle': '1.21', 'sei': '3.63'}",CHEMBL1269072,,CHEMBL1269072,6.66,1,http://www.openphacts.org/units/Nanomolar,2576276,=,37,1,=,,IC50,nM,,220.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,220.0
,298892,16262410,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.69', 'le': '0.20', 'lle': '0.65', 'sei': '5.95'}",CHEMBL3703601,,CHEMBL3703601,9.30,0,http://www.openphacts.org/units/Nanomolar,2581053,=,37,1,=,,IC50,nM,,0.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.5
,298914,16265028,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)CC1CN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1,,,CHEMBL3638929,,2015,"{'bei': '9.01', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703622,,CHEMBL3703622,9.40,0,http://www.openphacts.org/units/Nanomolar,2581074,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298907,16276423,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '6.13', 'le': '0.12', 'lle': '-3.32', 'sei': '3.98'}",CHEMBL3703615,,CHEMBL3703615,5.92,0,http://www.openphacts.org/units/Nanomolar,2581067,=,37,1,=,,IC50,nM,,1195.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1195.0
,298910,16277114,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.34', 'le': '0.19', 'lle': '1.19', 'sei': '5.57'}",CHEMBL3703618,,CHEMBL3703618,9.22,0,http://www.openphacts.org/units/Nanomolar,2581070,=,37,1,=,,IC50,nM,,0.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.6
,298919,16278882,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CNCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.36', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703627,,CHEMBL3703627,7.57,0,http://www.openphacts.org/units/Nanomolar,2581079,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,298896,16279846,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.70', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703605,,CHEMBL3703605,9.05,0,http://www.openphacts.org/units/Nanomolar,2581057,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,278907,16280789,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.09', 'le': '0.17', 'lle': '-0.58', 'sei': '3.75'}",CHEMBL1269075,,CHEMBL1269075,5.59,1,http://www.openphacts.org/units/Nanomolar,2576280,=,37,1,=,,IC50,nM,,2570.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2570.0
,278906,16284136,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.25', 'le': '0.15', 'lle': '-2.46', 'sei': '3.47'}",CHEMBL1269074,,CHEMBL1269074,5.17,1,http://www.openphacts.org/units/Nanomolar,2576279,=,37,1,=,,IC50,nM,,6730.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6730.0
,298902,16284249,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '6.89', 'le': '0.14', 'lle': '-2.06', 'sei': '4.54'}",CHEMBL3703611,,CHEMBL3703611,6.60,0,http://www.openphacts.org/units/Nanomolar,2581063,=,37,1,=,,IC50,nM,,253.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,253.0
,298906,16284325,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '8.44', 'le': '0.17', 'lle': '-1.09', 'sei': '5.48'}",CHEMBL3703614,,CHEMBL3703614,8.15,0,http://www.openphacts.org/units/Nanomolar,2581066,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,278908,16284692,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.81', 'le': '0.16', 'lle': '-1.29', 'sei': '3.80'}",CHEMBL1269077,,CHEMBL1269077,5.66,1,http://www.openphacts.org/units/Nanomolar,2576282,=,37,1,=,,IC50,nM,,2170.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2170.0
,298915,16285710,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)(C)OP(=O)(O)OCO[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703623,,CHEMBL3703623,8.40,0,http://www.openphacts.org/units/Nanomolar,2581075,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,298903,16286037,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.90', 'le': '0.18', 'lle': '-0.14', 'sei': '5.86'}",CHEMBL3703612,,CHEMBL3703612,8.52,0,http://www.openphacts.org/units/Nanomolar,2581064,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,298912,16286830,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703620,,CHEMBL3703620,9.40,0,http://www.openphacts.org/units/Nanomolar,2581072,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298891,16290503,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,,CHEMBL3703600,,CHEMBL3703600,,0,http://www.openphacts.org/units/Nanomolar,2581052,<,37,1,<,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,278912,16290875,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1,,,CHEMBL3638406,,2015,"{'bei': '8.82', 'le': '0.16', 'lle': '1.01', 'sei': '3.22'}",CHEMBL1269012,,CHEMBL1269012,6.68,1,http://www.openphacts.org/units/Nanomolar,2576275,=,37,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,210.0
,298905,16292282,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '9.00', 'le': '0.18', 'lle': '-0.54', 'sei': '5.84'}",CHEMBL3703614,,CHEMBL3703614,8.70,0,http://www.openphacts.org/units/Nanomolar,2581066,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,298897,16294221,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.82', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703606,,CHEMBL3703606,9.05,0,http://www.openphacts.org/units/Nanomolar,2581058,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,298893,16296869,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.32', 'le': '0.19', 'lle': '1.48', 'sei': '5.15'}",CHEMBL3703602,,CHEMBL3703602,9.10,0,http://www.openphacts.org/units/Nanomolar,2581054,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,298904,16299404,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '10.45', 'le': '0.21', 'lle': '0.82', 'sei': '5.89'}",CHEMBL3703613,,CHEMBL3703613,9.10,0,http://www.openphacts.org/units/Nanomolar,2581065,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,278901,16301195,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '13.11', 'le': '0.24', 'lle': '1.58', 'sei': '4.31'}",CHEMBL1272170,,CHEMBL1272170,6.43,1,http://www.openphacts.org/units/Nanomolar,2576273,=,37,1,=,,IC50,nM,,370.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,370.0
,278903,16306561,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.57', 'le': '0.16', 'lle': '-1.28', 'sei': '3.69'}",CHEMBL1269076,,CHEMBL1269076,5.51,1,http://www.openphacts.org/units/Nanomolar,2576281,=,37,1,=,,IC50,nM,,3120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3120.0
,298920,16310657,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,NCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.32', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703628,,CHEMBL3703628,7.42,0,http://www.openphacts.org/units/Nanomolar,2581080,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,298894,16313109,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(C[C@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.72', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703603,,CHEMBL3703603,9.00,0,http://www.openphacts.org/units/Nanomolar,2581055,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,278904,16313968,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '11.14', 'le': '0.20', 'lle': '0.76', 'sei': '4.38'}",CHEMBL1269107,,CHEMBL1269107,6.54,1,http://www.openphacts.org/units/Nanomolar,2576283,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,298911,16314625,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.11', 'le': '0.19', 'lle': '0.97', 'sei': '5.44'}",CHEMBL3703619,,CHEMBL3703619,9.00,0,http://www.openphacts.org/units/Nanomolar,2581071,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298913,16316774,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703621,,CHEMBL3703621,9.40,0,http://www.openphacts.org/units/Nanomolar,2581073,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298901,16316942,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.80', 'le': '0.16', 'lle': '-0.11', 'sei': '4.71'}",CHEMBL3703610,,CHEMBL3703610,7.80,0,http://www.openphacts.org/units/Nanomolar,2581062,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,298889,16320563,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCO)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,,CHEMBL3703598,,CHEMBL3703598,,0,http://www.openphacts.org/units/Nanomolar,2581050,<,37,1,<,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298917,16326775,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,COP(=O)(O)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '8.56', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703625,,CHEMBL3703625,9.00,0,http://www.openphacts.org/units/Nanomolar,2581077,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,278909,16327665,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.87', 'le': '0.19', 'lle': '-0.62', 'sei': '4.34'}",CHEMBL1269110,,CHEMBL1269110,6.47,1,http://www.openphacts.org/units/Nanomolar,2576284,=,37,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,340.0
,298921,16329223,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.74', 'le': '0.16', 'lle': '-1.61', 'sei': '5.94'}",CHEMBL3703629,,CHEMBL3703629,7.62,0,http://www.openphacts.org/units/Nanomolar,2581081,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,298898,16329277,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703607,,CHEMBL3703607,9.15,0,http://www.openphacts.org/units/Nanomolar,2581059,=,37,1,=,,IC50,nM,,0.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.7
,298918,16334536,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.86', 'le': '0.16', 'lle': '-1.11', 'sei': '4.98'}",CHEMBL3703626,,CHEMBL3703626,7.52,0,http://www.openphacts.org/units/Nanomolar,2581078,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,298900,16338144,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.89', 'le': '0.18', 'lle': '-0.09', 'sei': '5.26'}",CHEMBL3703609,,CHEMBL3703609,8.52,0,http://www.openphacts.org/units/Nanomolar,2581061,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,278911,16339725,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.11', 'le': '0.17', 'lle': '0.97', 'sei': '3.20'}",CHEMBL1269070,,CHEMBL1269070,6.64,1,http://www.openphacts.org/units/Nanomolar,2576274,=,37,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,230.0
,298916,16342727,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCOP(=O)(OCC)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '6.88', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703624,,CHEMBL3703624,7.52,0,http://www.openphacts.org/units/Nanomolar,2581076,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,298909,16342866,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)C[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.13', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703617,,CHEMBL3703617,9.52,0,http://www.openphacts.org/units/Nanomolar,2581069,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298908,16344057,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.13', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703616,,CHEMBL3703616,9.52,0,http://www.openphacts.org/units/Nanomolar,2581068,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298895,16345632,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '7.66', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703604,,CHEMBL3703604,8.70,0,http://www.openphacts.org/units/Nanomolar,2581056,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,298890,16347770,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL3638929,,2015,"{'bei': '11.49', 'le': '0.23', 'lle': '1.01', 'sei': '6.56'}",CHEMBL3703599,,CHEMBL3703599,9.52,0,http://www.openphacts.org/units/Nanomolar,2581051,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,278902,16348091,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '12.73', 'le': '0.24', 'lle': '1.60', 'sei': '4.42'}",CHEMBL1272224,,CHEMBL1272224,6.60,1,http://www.openphacts.org/units/Nanomolar,2576277,=,37,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,250.0
,298899,16354033,[],CHEMBL3707482,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.89', 'le': '0.18', 'lle': '0.18', 'sei': '5.18'}",CHEMBL3703608,,CHEMBL3703608,8.40,0,http://www.openphacts.org/units/Nanomolar,2581060,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,278905,16355372,[],CHEMBL3707868,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.89', 'le': '0.18', 'lle': '-0.43', 'sei': '3.78'}",CHEMBL1269073,,CHEMBL1269073,5.64,1,http://www.openphacts.org/units/Nanomolar,2576278,=,37,1,=,,IC50,nM,,2270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2270.0
,,16560893,[],CHEMBL3801206,Inhibition of Bcl2 in human DMS53 cells assessed as growth inhibition,B,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)Oc1ccc(C(=O)Nc2c(C(=O)O)nn(-c3ccc(Oc4ccccc4)cc3)c2-c2ccc(OC(C)C)cc2)cc1,,,CHEMBL3797039,J Med Chem,2016,"{'bei': '8.96', 'le': '0.16', 'lle': '-2.56', 'sei': '4.74'}",CHEMBL3799447,,CHEMBL3799447,5.30,0,http://www.openphacts.org/units/Nanomolar,2775626,=,1,1,=,,IC50,nM,,5000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.0
,,16623378,[],CHEMBL3822337,Inhibition of FITC-labeled Bid BH3 peptide binding to human GST-tagged BCL2 lacking C-terminal transmembrane domain expressed in Escherichia coli XL-1 Blue cells preincubated for 10 mins followed by FITC-labeled Bid BH3 peptide addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,,,CHEMBL3817778,Medchemcomm,2016,"{'bei': '18.76', 'le': '0.34', 'lle': '1.46', 'sei': '11.20'}",CHEMBL408194,OBATOCLAX,CHEMBL408194,5.96,0,http://www.openphacts.org/units/Nanomolar,2783261,=,1,1,=,,IC50,nM,,1110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.11
,,16782277,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '10.80', 'le': '0.20', 'lle': '1.79', 'sei': '3.64'}",CHEMBL3929718,,CHEMBL3929718,6.99,0,http://www.openphacts.org/units/Nanomolar,2805749,=,1,1,=,,IC50,nM,,103.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.103
,,16782279,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '9.50', 'le': '0.18', 'lle': '1.16', 'sei': '3.41'}",CHEMBL3957283,,CHEMBL3957283,6.54,0,http://www.openphacts.org/units/Nanomolar,2805750,=,1,1,=,,IC50,nM,,286.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.286
,,16782281,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '8.49', 'le': '0.16', 'lle': '-0.08', 'sei': '3.17'}",CHEMBL3918448,,CHEMBL3918448,6.08,0,http://www.openphacts.org/units/Nanomolar,2805751,=,1,1,=,,IC50,nM,,825.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.825
,,16782283,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '8.48', 'le': '0.16', 'lle': '-0.62', 'sei': '3.29'}",CHEMBL3932954,,CHEMBL3932954,6.32,0,http://www.openphacts.org/units/Nanomolar,2805752,=,1,1,=,,IC50,nM,,483.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.483
,,16782285,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCCCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '7.86', 'le': '0.15', 'lle': '-1.65', 'sei': '3.17'}",CHEMBL3971530,,CHEMBL3971530,6.08,0,http://www.openphacts.org/units/Nanomolar,2805753,=,1,1,=,,IC50,nM,,840.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.84
,,16782287,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCC(=O)O)C(=O)C(O)=C2C(C)C,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '9.87', 'le': '0.19', 'lle': '1.81', 'sei': '2.92'}",CHEMBL1962390,,CHEMBL1962390,6.24,0,http://www.openphacts.org/units/Nanomolar,2805755,=,1,1,=,,IC50,nM,,573.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.573
,,16782289,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCC(=O)O)C(=O)C(O)=C2C(C)C,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '9.04', 'le': '0.17', 'lle': '0.23', 'sei': '2.91'}",CHEMBL3951720,,CHEMBL3951720,6.22,0,http://www.openphacts.org/units/Nanomolar,2805757,=,1,1,=,,IC50,nM,,596.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.596
,,16782291,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc2c(c(O)c1-c1c(C)cc3c(c1O)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C3C(C)C)/C(=C/NCCCCC(=O)O)C(=O)C(O)=C2C(C)C,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '8.84', 'le': '0.17', 'lle': '-0.43', 'sei': '2.97'}",CHEMBL1962393,,CHEMBL1962393,6.34,0,http://www.openphacts.org/units/Nanomolar,2805758,=,1,1,=,,IC50,nM,,458.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.458
,,16782293,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '8.96', 'le': '0.17', 'lle': '0.27', 'sei': '3.35'}",CHEMBL3918448,,CHEMBL3918448,6.43,0,http://www.openphacts.org/units/Nanomolar,2805769,=,1,1,=,,IC50,nM,,375.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.375
,,16782295,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)CCCN/C=C1\C(=O)C(O)=C(C(C)C)c2cc(C)c(-c3c(C)cc4c(c3O)/C(=C/NCCCC(=O)OC)C(=O)C(O)=C4C(C)C)c(O)c21,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '8.85', 'le': '0.17', 'lle': '0.18', 'sei': '3.31'}",CHEMBL3918448,,CHEMBL3918448,6.34,0,http://www.openphacts.org/units/Nanomolar,2805768,=,1,1,=,,IC50,nM,,452.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.452
,,16782297,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL3864191,ACS Med Chem Lett,2016,"{'bei': '11.42', 'le': '0.21', 'lle': '-0.46', 'sei': '3.81'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,5.92,0,http://www.openphacts.org/units/Nanomolar,2805764,=,1,1,=,,IC50,nM,,1191.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.191
,,16782299,[],CHEMBL3865725,Inhibition of FAM-Bid binding to human BCL2 expressed in Escherichia coli BL21 after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000019,assay format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL3864191,ACS Med Chem Lett,2016,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,0,http://www.openphacts.org/units/Nanomolar,2805767,<,1,1,<,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.001
,,16895009,[],CHEMBL3882095,Inhibition of recombinant human C-terminal minus Bcl-2 using 26-mer fluorescein labeled BH3 peptide as substrate after 3 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-])CC(=O)NO,,,CHEMBL3881527,,2008,,CHEMBL3943273,,CHEMBL3943273,,0,http://www.openphacts.org/units/Nanomolar,2829133,<=,38,1,<=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.1
,198897,17602398,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.43', 'le': '0.21', 'lle': '1.63', 'sei': '8.30'}",CHEMBL3704808,,CHEMBL3704808,8.43,0,http://www.openphacts.org/units/Nanomolar,2582327,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,198898,17602399,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.62', 'le': '0.21', 'lle': '1.64', 'sei': '8.23'}",CHEMBL3704809,,CHEMBL3704809,7.96,0,http://www.openphacts.org/units/Nanomolar,2582328,=,37,1,=,,IC50,nM,,11.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.1
,198899,17602400,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.26', 'le': '0.22', 'lle': '1.63', 'sei': '9.40'}",CHEMBL3704810,,CHEMBL3704810,8.22,0,http://www.openphacts.org/units/Nanomolar,2582329,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,198900,17602401,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.21', 'lle': '2.45', 'sei': '7.79'}",CHEMBL3704811,,CHEMBL3704811,8.07,0,http://www.openphacts.org/units/Nanomolar,2582330,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,198901,17602402,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)ncn3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.13', 'le': '0.21', 'lle': '0.99', 'sei': '8.45'}",CHEMBL3704812,,CHEMBL3704812,8.11,0,http://www.openphacts.org/units/Nanomolar,2582331,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,198902,17602403,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.81', 'le': '0.22', 'lle': '2.39', 'sei': '7.39'}",CHEMBL3704813,,CHEMBL3704813,8.10,0,http://www.openphacts.org/units/Nanomolar,2582332,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,198903,17602404,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)N4CCN(C)CC4)c(C(F)(F)F)n2C)OCO3)CC1,,,CHEMBL3638572,,2015,"{'bei': '9.40', 'le': '0.18', 'lle': '2.51', 'sei': '7.49'}",CHEMBL3704814,,CHEMBL3704814,7.28,0,http://www.openphacts.org/units/Nanomolar,2582333,=,37,1,=,,IC50,nM,,52.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,52.9
,201220,17602405,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3ccn(C)c3c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.96', 'le': '0.18', 'lle': '1.72', 'sei': '6.30'}",CHEMBL3704815,,CHEMBL3704815,7.80,0,http://www.openphacts.org/units/Nanomolar,2582334,=,37,1,=,,IC50,nM,,15.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.9
,201221,17602406,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C2=CC3C(C=CN3C)N=C2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.90', 'le': '0.22', 'lle': '2.63', 'sei': '9.27'}",CHEMBL3704816,,CHEMBL3704816,8.70,0,http://www.openphacts.org/units/Nanomolar,2582335,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,201222,17602407,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccc(F)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.58', 'le': '0.18', 'lle': '0.89', 'sei': '6.61'}",CHEMBL3704817,,CHEMBL3704817,6.35,0,http://www.openphacts.org/units/Nanomolar,2582336,=,37,1,=,,IC50,nM,,447.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,447.0
,304775,17685642,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.97', 'le': '0.26', 'lle': '1.64', 'sei': '9.93'}",CHEMBL3701291,,CHEMBL3701291,8.30,0,http://www.openphacts.org/units/Nanomolar,2578595,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,304776,17685643,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)cn2C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.67', 'le': '0.20', 'lle': '0.28', 'sei': '8.64'}",CHEMBL3701292,,CHEMBL3701292,7.61,0,http://www.openphacts.org/units/Nanomolar,2578596,=,37,1,=,,IC50,nM,,24.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.6
,304777,17685644,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.55', 'le': '0.20', 'lle': '0.33', 'sei': '9.94'}",CHEMBL3701293,,CHEMBL3701293,7.67,0,http://www.openphacts.org/units/Nanomolar,2578597,=,37,1,=,,IC50,nM,,21.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.2
,304778,17685645,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.22', 'sei': '9.84'}",CHEMBL3701294,,CHEMBL3701294,7.60,0,http://www.openphacts.org/units/Nanomolar,2578598,=,37,1,=,,IC50,nM,,25.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.2
,304779,17685646,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C2CC2)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.08', 'le': '0.19', 'lle': '-0.54', 'sei': '9.84'}",CHEMBL3701295,,CHEMBL3701295,7.59,0,http://www.openphacts.org/units/Nanomolar,2578599,=,37,1,=,,IC50,nM,,25.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.6
,304780,17685647,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)cn2C)OCO3)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.38', 'le': '0.19', 'lle': '1.24', 'sei': '8.00'}",CHEMBL3701296,,CHEMBL3701296,7.65,0,http://www.openphacts.org/units/Nanomolar,2578600,=,37,1,=,,IC50,nM,,22.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.4
,304781,17685648,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '1.07', 'sei': '9.96'}",CHEMBL3701297,,CHEMBL3701297,7.79,0,http://www.openphacts.org/units/Nanomolar,2578601,=,37,1,=,,IC50,nM,,16.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.2
,304782,17685649,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1CCCO,,,CHEMBL3638572,,2015,"{'bei': '11.17', 'le': '0.21', 'lle': '1.28', 'sei': '7.97'}",CHEMBL3701298,,CHEMBL3701298,7.85,0,http://www.openphacts.org/units/Nanomolar,2578602,=,37,1,=,,IC50,nM,,14.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.2
,304783,17685650,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.59', 'le': '0.21', 'lle': '1.65', 'sei': '8.60'}",CHEMBL3701299,,CHEMBL3701299,8.26,0,http://www.openphacts.org/units/Nanomolar,2578603,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304784,17685651,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '1.60', 'sei': '8.64'}",CHEMBL3701300,,CHEMBL3701300,8.36,0,http://www.openphacts.org/units/Nanomolar,2578604,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304785,17685652,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.24', 'le': '0.21', 'lle': '1.45', 'sei': '8.17'}",CHEMBL3701301,,CHEMBL3701301,7.90,0,http://www.openphacts.org/units/Nanomolar,2578605,=,37,1,=,,IC50,nM,,12.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.6
,304786,17685653,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.99', 'le': '0.23', 'lle': '0.86', 'sei': '10.35'}",CHEMBL3701302,,CHEMBL3701302,8.10,0,http://www.openphacts.org/units/Nanomolar,2578606,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,304787,17685654,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)OCO3)n1CCO,,,CHEMBL3638572,,2015,"{'bei': '11.54', 'le': '0.21', 'lle': '2.25', 'sei': '7.19'}",CHEMBL3701303,,CHEMBL3701303,8.41,0,http://www.openphacts.org/units/Nanomolar,2578607,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304788,17685655,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccncc3)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '14.16', 'le': '0.26', 'lle': '1.63', 'sei': '9.45'}",CHEMBL3701304,,CHEMBL3701304,8.31,0,http://www.openphacts.org/units/Nanomolar,2578608,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,304789,17685656,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.85', 'le': '0.22', 'lle': '3.24', 'sei': '7.27'}",CHEMBL3701305,,CHEMBL3701305,8.33,0,http://www.openphacts.org/units/Nanomolar,2578609,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,304790,17685657,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.71', 'le': '0.21', 'lle': '1.82', 'sei': '8.46'}",CHEMBL3701306,,CHEMBL3701306,8.18,0,http://www.openphacts.org/units/Nanomolar,2578610,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,304791,17685658,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCO,,,CHEMBL3638572,,2015,"{'bei': '13.32', 'le': '0.25', 'lle': '3.25', 'sei': '6.90'}",CHEMBL3701307,,CHEMBL3701307,8.44,0,http://www.openphacts.org/units/Nanomolar,2578611,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304792,17685659,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.16', 'le': '0.22', 'lle': '2.88', 'sei': '7.79'}",CHEMBL3701308,,CHEMBL3701308,8.21,0,http://www.openphacts.org/units/Nanomolar,2578612,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,304793,17685660,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.36', 'le': '0.23', 'lle': '2.43', 'sei': '8.74'}",CHEMBL3701309,,CHEMBL3701309,8.40,0,http://www.openphacts.org/units/Nanomolar,2578613,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,304794,17685661,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '12.97', 'le': '0.24', 'lle': '2.97', 'sei': '7.35'}",CHEMBL3701310,,CHEMBL3701310,8.39,0,http://www.openphacts.org/units/Nanomolar,2578614,=,37,1,=,,IC50,nM,,4.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.1
,304795,17685662,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,CHEMBL3638572,,2015,"{'bei': '12.54', 'le': '0.23', 'lle': '2.52', 'sei': '7.87'}",CHEMBL3701311,,CHEMBL3701311,8.28,0,http://www.openphacts.org/units/Nanomolar,2578615,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304796,17685663,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.75', 'le': '0.26', 'lle': '0.80', 'sei': '10.33'}",CHEMBL3701312,,CHEMBL3701312,8.12,0,http://www.openphacts.org/units/Nanomolar,2578616,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,304797,17685664,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C(=O)N(c2ccccc2)c2ccc(O)cc2)CC(c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2COCCN2CCOCC2)N1C,,,CHEMBL3638572,,2015,"{'bei': '11.34', 'le': '0.21', 'lle': '1.20', 'sei': '9.54'}",CHEMBL3701313,,CHEMBL3701313,8.18,0,http://www.openphacts.org/units/Nanomolar,2578617,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,304798,17685665,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN,,,CHEMBL3638572,,2015,"{'bei': '13.16', 'le': '0.24', 'lle': '3.17', 'sei': '6.50'}",CHEMBL3701314,,CHEMBL3701314,8.33,0,http://www.openphacts.org/units/Nanomolar,2578618,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,304799,17685666,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '13.81', 'le': '0.25', 'lle': '2.13', 'sei': '8.77'}",CHEMBL3701315,,CHEMBL3701315,8.14,0,http://www.openphacts.org/units/Nanomolar,2578619,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,304800,17685667,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)Oc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.25', 'le': '0.22', 'lle': '1.02', 'sei': '7.57'}",CHEMBL3701316,,CHEMBL3701316,7.88,0,http://www.openphacts.org/units/Nanomolar,2578620,=,37,1,=,,IC50,nM,,13.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.3
,304801,17685668,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.22', 'lle': '0.58', 'sei': '10.18'}",CHEMBL3701317,,CHEMBL3701317,7.96,0,http://www.openphacts.org/units/Nanomolar,2578621,=,37,1,=,,IC50,nM,,10.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.9
,304802,17685669,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '0.71', 'sei': '10.33'}",CHEMBL3701318,,CHEMBL3701318,8.09,0,http://www.openphacts.org/units/Nanomolar,2578622,=,37,1,=,,IC50,nM,,8.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.2
,304803,17685670,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.12', 'le': '0.20', 'lle': '1.04', 'sei': '7.01'}",CHEMBL3701319,,CHEMBL3701319,7.30,0,http://www.openphacts.org/units/Nanomolar,2578623,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,304804,17685671,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCNC(=O)NCc1ccc(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.04', 'le': '0.22', 'lle': '1.76', 'sei': '6.68'}",CHEMBL3701320,,CHEMBL3701320,7.15,0,http://www.openphacts.org/units/Nanomolar,2578624,=,37,1,=,,IC50,nM,,71.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,71.4
,304805,17685672,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)NCc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.01', 'le': '0.20', 'lle': '0.65', 'sei': '6.75'}",CHEMBL3701321,,CHEMBL3701321,7.22,0,http://www.openphacts.org/units/Nanomolar,2578625,=,37,1,=,,IC50,nM,,60.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.4
,304806,17685673,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.40', 'le': '0.25', 'lle': '1.22', 'sei': '9.45'}",CHEMBL3701322,,CHEMBL3701322,8.12,0,http://www.openphacts.org/units/Nanomolar,2578626,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,304807,17685674,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.49', 'le': '0.25', 'lle': '2.41', 'sei': '7.98'}",CHEMBL3701323,,CHEMBL3701323,8.14,0,http://www.openphacts.org/units/Nanomolar,2578627,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,304808,17685675,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)Oc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.20', 'lle': '0.33', 'sei': '6.91'}",CHEMBL3701324,,CHEMBL3701324,7.19,0,http://www.openphacts.org/units/Nanomolar,2578628,=,37,1,=,,IC50,nM,,64.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,64.4
,304809,17685676,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.95', 'le': '0.24', 'lle': '0.86', 'sei': '9.50'}",CHEMBL3701325,,CHEMBL3701325,8.00,0,http://www.openphacts.org/units/Nanomolar,2578629,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,304810,17685677,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.67', 'le': '0.23', 'lle': '1.39', 'sei': '8.12'}",CHEMBL3701326,,CHEMBL3701326,8.28,0,http://www.openphacts.org/units/Nanomolar,2578630,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304811,17685678,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.83', 'le': '0.25', 'lle': '1.29', 'sei': '9.84'}",CHEMBL3701327,,CHEMBL3701327,8.29,0,http://www.openphacts.org/units/Nanomolar,2578631,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304812,17685679,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.54', 'le': '0.21', 'lle': '2.32', 'sei': '7.44'}",CHEMBL3701328,,CHEMBL3701328,8.52,0,http://www.openphacts.org/units/Nanomolar,2578632,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304813,17685680,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCN(C(=O)O)c3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.28', 'le': '0.21', 'lle': '0.11', 'sei': '6.97'}",CHEMBL3701329,,CHEMBL3701329,7.41,0,http://www.openphacts.org/units/Nanomolar,2578633,=,37,1,=,,IC50,nM,,38.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.9
,304814,17685681,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.61', 'le': '0.19', 'lle': '0.81', 'sei': '6.83'}",CHEMBL3701330,,CHEMBL3701330,7.12,0,http://www.openphacts.org/units/Nanomolar,2578634,=,37,1,=,,IC50,nM,,76.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,76.6
,304815,17685682,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.95', 'le': '0.22', 'lle': '3.18', 'sei': '7.19'}",CHEMBL3701331,,CHEMBL3701331,8.23,0,http://www.openphacts.org/units/Nanomolar,2578635,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,304816,17685683,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3C)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '13.23', 'le': '0.24', 'lle': '2.56', 'sei': '7.01'}",CHEMBL3701332,,CHEMBL3701332,8.36,0,http://www.openphacts.org/units/Nanomolar,2578636,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304817,17685684,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.34', 'le': '0.21', 'lle': '2.70', 'sei': '7.44'}",CHEMBL3701333,,CHEMBL3701333,8.40,0,http://www.openphacts.org/units/Nanomolar,2578637,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,304818,17685685,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.21', 'lle': '3.12', 'sei': '6.25'}",CHEMBL3701334,,CHEMBL3701334,8.23,0,http://www.openphacts.org/units/Nanomolar,2578638,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,304819,17685686,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.21', 'lle': '1.00', 'sei': '7.08'}",CHEMBL3701335,,CHEMBL3701335,7.57,0,http://www.openphacts.org/units/Nanomolar,2578639,=,37,1,=,,IC50,nM,,26.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.7
,304820,17685687,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCNC(=O)NCc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.70', 'le': '0.23', 'lle': '2.15', 'sei': '7.05'}",CHEMBL3701336,,CHEMBL3701336,7.54,0,http://www.openphacts.org/units/Nanomolar,2578640,=,37,1,=,,IC50,nM,,28.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.9
,304821,17685688,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.21', 'le': '0.21', 'lle': '1.10', 'sei': '7.07'}",CHEMBL3701337,,CHEMBL3701337,7.36,0,http://www.openphacts.org/units/Nanomolar,2578641,=,37,1,=,,IC50,nM,,43.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.5
,304822,17685689,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.02', 'le': '0.18', 'lle': '-0.11', 'sei': '6.35'}",CHEMBL3701338,,CHEMBL3701338,7.75,0,http://www.openphacts.org/units/Nanomolar,2578642,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,304823,17685690,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNS(=O)(=O)CCc3ccc(F)cc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.24', 'le': '0.18', 'lle': '0.27', 'sei': '5.97'}",CHEMBL3701339,,CHEMBL3701339,6.68,0,http://www.openphacts.org/units/Nanomolar,2578643,=,37,1,=,,IC50,nM,,209.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,209.6
,304824,17685691,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.64', 'le': '0.19', 'lle': '0.51', 'sei': '6.66'}",CHEMBL3701340,,CHEMBL3701340,7.12,0,http://www.openphacts.org/units/Nanomolar,2578644,=,37,1,=,,IC50,nM,,75.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,75.0
,304825,17685692,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Cc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.84', 'le': '0.20', 'lle': '0.63', 'sei': '7.48'}",CHEMBL3701341,,CHEMBL3701341,7.10,0,http://www.openphacts.org/units/Nanomolar,2578645,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,304826,17685693,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.48', 'le': '0.19', 'lle': '-0.05', 'sei': '6.43'}",CHEMBL3701342,,CHEMBL3701342,6.88,0,http://www.openphacts.org/units/Nanomolar,2578646,=,37,1,=,,IC50,nM,,133.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,133.3
,304827,17685694,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNS(=O)(=O)CCc3ccc(F)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.70', 'le': '0.18', 'lle': '0.50', 'sei': '6.14'}",CHEMBL3701343,,CHEMBL3701343,6.87,0,http://www.openphacts.org/units/Nanomolar,2578647,=,37,1,=,,IC50,nM,,134.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,134.0
,304828,17685695,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.90', 'le': '0.25', 'lle': '1.95', 'sei': '8.59'}",CHEMBL3701344,,CHEMBL3701344,8.35,0,http://www.openphacts.org/units/Nanomolar,2578648,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,304829,17685696,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '12.91', 'le': '0.24', 'lle': '1.69', 'sei': '8.45'}",CHEMBL3701345,,CHEMBL3701345,7.84,0,http://www.openphacts.org/units/Nanomolar,2578649,=,37,1,=,,IC50,nM,,14.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.3
,304830,17685697,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.87', 'le': '0.24', 'lle': '0.48', 'sei': '9.92'}",CHEMBL3701346,,CHEMBL3701346,8.29,0,http://www.openphacts.org/units/Nanomolar,2578650,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304831,17685698,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.60', 'le': '0.19', 'lle': '1.17', 'sei': '8.12'}",CHEMBL3701347,,CHEMBL3701347,7.66,0,http://www.openphacts.org/units/Nanomolar,2578651,=,37,1,=,,IC50,nM,,21.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.9
,304832,17685699,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)NCc2ccc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)c(C(=O)N3Cc4ccccc4C[C@H]3C)c2)cc1,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '0.60', 'sei': '7.47'}",CHEMBL3701348,,CHEMBL3701348,7.77,0,http://www.openphacts.org/units/Nanomolar,2578652,=,37,1,=,,IC50,nM,,16.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.9
,304833,17685700,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.92', 'le': '0.22', 'lle': '2.44', 'sei': '8.23'}",CHEMBL3701349,,CHEMBL3701349,7.90,0,http://www.openphacts.org/units/Nanomolar,2578653,=,37,1,=,,IC50,nM,,12.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.5
,304834,17685701,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '14.62', 'le': '0.27', 'lle': '2.83', 'sei': '8.36'}",CHEMBL3701350,,CHEMBL3701350,8.68,0,http://www.openphacts.org/units/Nanomolar,2578654,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,304835,17685702,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.01', 'le': '0.20', 'lle': '2.17', 'sei': '7.62'}",CHEMBL3701351,,CHEMBL3701351,8.28,0,http://www.openphacts.org/units/Nanomolar,2578655,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,304836,17685703,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.26', 'le': '0.21', 'lle': '1.09', 'sei': '8.55'}",CHEMBL3701352,,CHEMBL3701352,8.21,0,http://www.openphacts.org/units/Nanomolar,2578656,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304840,17685707,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(CN3CCOCC3)n1C)OCO2,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.21', 'lle': '2.45', 'sei': '6.73'}",CHEMBL3701353,,CHEMBL3701353,7.71,0,http://www.openphacts.org/units/Nanomolar,2578657,=,37,1,=,,IC50,nM,,19.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.5
,304841,17685708,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.21', 'lle': '2.55', 'sei': '7.05'}",CHEMBL3701354,,CHEMBL3701354,8.08,0,http://www.openphacts.org/units/Nanomolar,2578658,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,304842,17685709,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '10.51', 'le': '0.19', 'lle': '2.55', 'sei': '6.23'}",CHEMBL3701355,,CHEMBL3701355,7.71,0,http://www.openphacts.org/units/Nanomolar,2578659,=,37,1,=,,IC50,nM,,19.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.7
,304843,17685710,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CCF,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.21', 'lle': '2.59', 'sei': '7.04'}",CHEMBL3701356,,CHEMBL3701356,8.07,0,http://www.openphacts.org/units/Nanomolar,2578660,=,37,1,=,,IC50,nM,,8.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.6
,304844,17685711,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CC(F)F,,,CHEMBL3638572,,2015,"{'bei': '11.04', 'le': '0.21', 'lle': '2.38', 'sei': '7.12'}",CHEMBL3701357,,CHEMBL3701357,8.15,0,http://www.openphacts.org/units/Nanomolar,2578661,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,304845,17685712,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.20', 'le': '0.21', 'lle': '2.34', 'sei': '6.87'}",CHEMBL3701358,,CHEMBL3701358,7.87,0,http://www.openphacts.org/units/Nanomolar,2578662,=,37,1,=,,IC50,nM,,13.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.5
,304846,17685713,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.05', 'le': '0.20', 'lle': '0.92', 'sei': '7.98'}",CHEMBL3701359,,CHEMBL3701359,7.72,0,http://www.openphacts.org/units/Nanomolar,2578663,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,304847,17685714,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,CHEMBL3638572,,2015,"{'bei': '12.36', 'le': '0.23', 'lle': '1.10', 'sei': '9.28'}",CHEMBL3701360,,CHEMBL3701360,8.12,0,http://www.openphacts.org/units/Nanomolar,2578664,=,37,1,=,,IC50,nM,,7.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.6
,304848,17685715,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCN(C)CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.63', 'le': '0.22', 'lle': '2.41', 'sei': '7.15'}",CHEMBL3701361,,CHEMBL3701361,8.19,0,http://www.openphacts.org/units/Nanomolar,2578665,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,304849,17685716,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2[nH]c(C)c(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.03', 'le': '0.20', 'lle': '1.88', 'sei': '6.58'}",CHEMBL3701362,,CHEMBL3701362,7.64,0,http://www.openphacts.org/units/Nanomolar,2578666,=,37,1,=,,IC50,nM,,22.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.9
,304850,17685717,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.08', 'le': '0.21', 'lle': '2.21', 'sei': '7.29'}",CHEMBL3701363,,CHEMBL3701363,7.68,0,http://www.openphacts.org/units/Nanomolar,2578667,=,37,1,=,,IC50,nM,,21.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.1
,304851,17685718,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.72', 'le': '0.22', 'lle': '1.66', 'sei': '9.66'}",CHEMBL3701364,,CHEMBL3701364,8.70,0,http://www.openphacts.org/units/Nanomolar,2578668,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,304852,17685719,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.23', 'lle': '1.96', 'sei': '7.86'}",CHEMBL3701365,,CHEMBL3701365,8.41,0,http://www.openphacts.org/units/Nanomolar,2578669,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304853,17685720,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '0.54', 'sei': '6.12'}",CHEMBL3701366,,CHEMBL3701366,7.04,0,http://www.openphacts.org/units/Nanomolar,2578670,=,37,1,=,,IC50,nM,,91.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,91.5
,304854,17685721,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)ccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.51', 'le': '0.22', 'lle': '1.57', 'sei': '7.02'}",CHEMBL3701367,,CHEMBL3701367,8.07,0,http://www.openphacts.org/units/Nanomolar,2578671,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,304855,17685722,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@@H]3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.50', 'le': '0.22', 'lle': '2.78', 'sei': '8.50'}",CHEMBL3701368,,CHEMBL3701368,8.44,0,http://www.openphacts.org/units/Nanomolar,2578672,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304856,17685723,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@H]3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.53', 'le': '0.22', 'lle': '2.81', 'sei': '8.53'}",CHEMBL3701369,,CHEMBL3701369,8.47,0,http://www.openphacts.org/units/Nanomolar,2578673,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304857,17685724,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.01', 'le': '0.23', 'lle': '1.70', 'sei': '8.81'}",CHEMBL3701370,,CHEMBL3701370,8.47,0,http://www.openphacts.org/units/Nanomolar,2578674,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304858,17685725,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.61', 'le': '0.22', 'lle': '2.37', 'sei': '7.96'}",CHEMBL3701371,,CHEMBL3701371,8.38,0,http://www.openphacts.org/units/Nanomolar,2578675,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304859,17685726,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.26', 'le': '0.21', 'lle': '1.88', 'sei': '7.86'}",CHEMBL3701372,,CHEMBL3701372,8.28,0,http://www.openphacts.org/units/Nanomolar,2578676,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,304860,17685727,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.82', 'le': '0.20', 'lle': '0.82', 'sei': '10.44'}",CHEMBL3701373,,CHEMBL3701373,7.74,0,http://www.openphacts.org/units/Nanomolar,2578677,=,37,1,=,,IC50,nM,,18.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.1
,304861,17685728,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CC3(CCO3)C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.23', 'lle': '2.23', 'sei': '8.68'}",CHEMBL3701374,,CHEMBL3701374,8.34,0,http://www.openphacts.org/units/Nanomolar,2578678,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,304862,17685729,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.95', 'le': '0.20', 'lle': '1.51', 'sei': '7.72'}",CHEMBL3701375,,CHEMBL3701375,8.13,0,http://www.openphacts.org/units/Nanomolar,2578679,=,37,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,304863,17685730,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(c3)CCN4C)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.81', 'le': '0.20', 'lle': '1.94', 'sei': '7.77'}",CHEMBL3701376,,CHEMBL3701376,8.06,0,http://www.openphacts.org/units/Nanomolar,2578680,=,37,1,=,,IC50,nM,,8.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.8
,304864,17685731,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.22', 'lle': '1.95', 'sei': '8.54'}",CHEMBL3701377,,CHEMBL3701377,8.20,0,http://www.openphacts.org/units/Nanomolar,2578681,=,37,1,=,,IC50,nM,,6.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.3
,304865,17685732,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.22', 'lle': '2.36', 'sei': '7.75'}",CHEMBL3701378,,CHEMBL3701378,8.29,0,http://www.openphacts.org/units/Nanomolar,2578682,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304866,17685733,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.98', 'le': '0.18', 'lle': '2.25', 'sei': '6.41'}",CHEMBL3701379,,CHEMBL3701379,7.83,0,http://www.openphacts.org/units/Nanomolar,2578683,=,37,1,=,,IC50,nM,,14.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.8
,304867,17685734,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.15', 'le': '0.22', 'lle': '1.89', 'sei': '8.79'}",CHEMBL3701380,,CHEMBL3701380,8.01,0,http://www.openphacts.org/units/Nanomolar,2578684,=,37,1,=,,IC50,nM,,9.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.7
,304868,17685735,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.57', 'le': '0.21', 'lle': '1.63', 'sei': '8.58'}",CHEMBL3701381,,CHEMBL3701381,8.24,0,http://www.openphacts.org/units/Nanomolar,2578685,=,37,1,=,,IC50,nM,,5.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.7
,304869,17685736,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '1.83', 'sei': '8.03'}",CHEMBL3701382,VOB-560,CHEMBL3701382,8.59,0,http://www.openphacts.org/units/Nanomolar,2578686,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304870,17685737,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(Nc1ncnc(N)c1C#N)c1cc(Cl)c2ccnnc2c1-c1cccc(F)c1,,,CHEMBL3638572,,2015,"{'bei': '18.31', 'le': '0.35', 'lle': '3.18', 'sei': '6.78'}",CHEMBL3701383,,CHEMBL3701383,7.69,0,http://www.openphacts.org/units/Nanomolar,2578687,=,37,1,=,,IC50,nM,,20.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.6
,304871,17685738,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.22', 'lle': '1.82', 'sei': '8.95'}",CHEMBL3701384,,CHEMBL3701384,8.44,0,http://www.openphacts.org/units/Nanomolar,2578688,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304872,17685739,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc3ccn(C)c3cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.74', 'le': '0.20', 'lle': '0.71', 'sei': '8.15'}",CHEMBL3701385,,CHEMBL3701385,7.83,0,http://www.openphacts.org/units/Nanomolar,2578689,=,37,1,=,,IC50,nM,,14.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.7
,304873,17685740,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.76', 'le': '0.20', 'lle': '0.25', 'sei': '10.12'}",CHEMBL3701386,,CHEMBL3701386,7.67,0,http://www.openphacts.org/units/Nanomolar,2578690,=,37,1,=,,IC50,nM,,21.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.2
,304874,17685741,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.31', 'le': '0.19', 'lle': '0.40', 'sei': '7.83'}",CHEMBL3640002,,CHEMBL3640002,7.52,0,http://www.openphacts.org/units/Nanomolar,2578691,=,37,1,=,,IC50,nM,,30.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.3
,304875,17685742,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '0.40', 'sei': '10.76'}",CHEMBL3701387,,CHEMBL3701387,8.42,0,http://www.openphacts.org/units/Nanomolar,2578692,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,304876,17685743,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.46', 'le': '0.22', 'lle': '0.78', 'sei': '9.03'}",CHEMBL3701388,,CHEMBL3701388,8.68,0,http://www.openphacts.org/units/Nanomolar,2578693,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,304877,17685744,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.33', 'le': '0.21', 'lle': '1.20', 'sei': '9.11'}",CHEMBL3701389,,CHEMBL3701389,8.60,0,http://www.openphacts.org/units/Nanomolar,2578694,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304878,17685745,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,CHEMBL3638572,,2015,"{'bei': '11.58', 'le': '0.22', 'lle': '1.34', 'sei': '7.60'}",CHEMBL3701390,,CHEMBL3701390,8.46,0,http://www.openphacts.org/units/Nanomolar,2578695,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304879,17685746,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.04', 'le': '0.20', 'lle': '2.61', 'sei': '6.81'}",CHEMBL3701391,,CHEMBL3701391,7.80,0,http://www.openphacts.org/units/Nanomolar,2578696,=,37,1,=,,IC50,nM,,15.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.7
,304880,17685747,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.80', 'le': '0.22', 'lle': '2.31', 'sei': '7.37'}",CHEMBL3701392,,CHEMBL3701392,8.35,0,http://www.openphacts.org/units/Nanomolar,2578697,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,304881,17685748,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.01', 'le': '0.23', 'lle': '1.30', 'sei': '8.24'}",CHEMBL3701393,,CHEMBL3701393,8.41,0,http://www.openphacts.org/units/Nanomolar,2578698,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304882,17685749,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.22', 'lle': '1.89', 'sei': '8.33'}",CHEMBL3701394,,CHEMBL3701394,8.00,0,http://www.openphacts.org/units/Nanomolar,2578699,=,37,1,=,,IC50,nM,,9.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.9
,304883,17685750,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,CHEMBL3638572,,2015,"{'bei': '9.96', 'le': '0.19', 'lle': '0.89', 'sei': '6.22'}",CHEMBL3701395,,CHEMBL3701395,7.31,0,http://www.openphacts.org/units/Nanomolar,2578700,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,304884,17685751,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.27', 'le': '0.21', 'lle': '0.85', 'sei': '7.94'}",CHEMBL3701396,,CHEMBL3701396,8.10,0,http://www.openphacts.org/units/Nanomolar,2578701,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,304885,17685752,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.55', 'le': '0.20', 'lle': '1.70', 'sei': '7.20'}",CHEMBL3701397,,CHEMBL3701397,7.58,0,http://www.openphacts.org/units/Nanomolar,2578702,=,37,1,=,,IC50,nM,,26.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.1
,304886,17685753,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.60', 'le': '0.20', 'lle': '1.74', 'sei': '7.23'}",CHEMBL3701397,,CHEMBL3701397,7.62,0,http://www.openphacts.org/units/Nanomolar,2578702,=,37,1,=,,IC50,nM,,24.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.2
,304887,17685754,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccnc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.84', 'le': '0.20', 'lle': '1.71', 'sei': '5.96'}",CHEMBL3701398,,CHEMBL3701398,7.61,0,http://www.openphacts.org/units/Nanomolar,2578703,=,37,1,=,,IC50,nM,,24.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.4
,304888,17685755,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.27', 'le': '0.22', 'lle': '2.28', 'sei': '7.83'}",CHEMBL3701399,,CHEMBL3701399,8.38,0,http://www.openphacts.org/units/Nanomolar,2578704,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304889,17685756,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)c(F)c3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '11.09', 'le': '0.21', 'lle': '2.22', 'sei': '7.30'}",CHEMBL3701400,,CHEMBL3701400,7.69,0,http://www.openphacts.org/units/Nanomolar,2578705,=,37,1,=,,IC50,nM,,20.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.6
,304890,17685757,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '11.60', 'le': '0.21', 'lle': '2.16', 'sei': '7.11'}",CHEMBL3701401,,CHEMBL3701401,8.27,0,http://www.openphacts.org/units/Nanomolar,2578706,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,304891,17685758,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.39', 'le': '0.21', 'lle': '1.44', 'sei': '8.24'}",CHEMBL3701402,,CHEMBL3701402,7.91,0,http://www.openphacts.org/units/Nanomolar,2578707,=,37,1,=,,IC50,nM,,12.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.2
,304892,17685759,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.21', 'lle': '2.03', 'sei': '8.48'}",CHEMBL3701403,,CHEMBL3701403,8.00,0,http://www.openphacts.org/units/Nanomolar,2578708,=,37,1,=,,IC50,nM,,9.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.9
,304893,17685760,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.23', 'lle': '1.81', 'sei': '8.60'}",CHEMBL3701404,,CHEMBL3701404,8.26,0,http://www.openphacts.org/units/Nanomolar,2578709,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304894,17685761,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.42', 'le': '0.22', 'lle': '0.97', 'sei': '7.95'}",CHEMBL3701405,,CHEMBL3701405,8.51,0,http://www.openphacts.org/units/Nanomolar,2578710,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304895,17685762,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCCO4)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.21', 'lle': '2.64', 'sei': '6.78'}",CHEMBL3701406,,CHEMBL3701406,8.51,0,http://www.openphacts.org/units/Nanomolar,2578711,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304896,17685763,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '1.97', 'sei': '7.87'}",CHEMBL3701407,,CHEMBL3701407,8.42,0,http://www.openphacts.org/units/Nanomolar,2578712,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,304897,17685764,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.57', 'le': '0.24', 'lle': '2.57', 'sei': '8.89'}",CHEMBL3701309,,CHEMBL3701309,8.54,0,http://www.openphacts.org/units/Nanomolar,2578613,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,304898,17685765,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.22', 'lle': '2.41', 'sei': '7.33'}",CHEMBL3701408,,CHEMBL3701408,8.52,0,http://www.openphacts.org/units/Nanomolar,2578713,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304899,17685766,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.85', 'le': '0.22', 'lle': '2.67', 'sei': '7.59'}",CHEMBL3701409,,CHEMBL3701409,8.00,0,http://www.openphacts.org/units/Nanomolar,2578714,=,37,1,=,,IC50,nM,,10.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.1
,304900,17685767,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.51', 'le': '0.23', 'lle': '1.96', 'sei': '8.38'}",CHEMBL3701410,,CHEMBL3701410,8.55,0,http://www.openphacts.org/units/Nanomolar,2578715,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,304901,17685768,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.39', 'le': '0.23', 'lle': '2.75', 'sei': '8.55'}",CHEMBL3701349,,CHEMBL3701349,8.21,0,http://www.openphacts.org/units/Nanomolar,2578653,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304902,17685769,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.27', 'le': '0.23', 'lle': '2.36', 'sei': '8.04'}",CHEMBL3701411,,CHEMBL3701411,8.60,0,http://www.openphacts.org/units/Nanomolar,2578716,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304903,17685770,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.46', 'le': '0.23', 'lle': '2.72', 'sei': '8.36'}",CHEMBL3701412,,CHEMBL3701412,8.04,0,http://www.openphacts.org/units/Nanomolar,2578717,=,37,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
,304904,17685771,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.25', 'le': '0.21', 'lle': '2.44', 'sei': '7.53'}",CHEMBL3701413,,CHEMBL3701413,7.93,0,http://www.openphacts.org/units/Nanomolar,2578718,=,37,1,=,,IC50,nM,,11.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.7
,304905,17685772,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.69', 'le': '0.21', 'lle': '2.49', 'sei': '6.95'}",CHEMBL3701414,,CHEMBL3701414,7.87,0,http://www.openphacts.org/units/Nanomolar,2578719,=,37,1,=,,IC50,nM,,13.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.6
,304906,17685773,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C#N)cc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.74', 'le': '0.22', 'lle': '1.78', 'sei': '7.53'}",CHEMBL3701415,,CHEMBL3701415,8.38,0,http://www.openphacts.org/units/Nanomolar,2578720,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304907,17685774,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.99', 'le': '0.22', 'lle': '2.76', 'sei': '7.31'}",CHEMBL3704775,,CHEMBL3704775,8.28,0,http://www.openphacts.org/units/Nanomolar,2582294,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304908,17685775,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,CHEMBL3638572,,2015,"{'bei': '12.13', 'le': '0.22', 'lle': '2.06', 'sei': '7.78'}",CHEMBL3704776,,CHEMBL3704776,8.66,0,http://www.openphacts.org/units/Nanomolar,2582295,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,304909,17685776,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3ccc(F)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.22', 'lle': '2.22', 'sei': '7.90'}",CHEMBL3704777,,CHEMBL3704777,8.46,0,http://www.openphacts.org/units/Nanomolar,2582296,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304910,17685777,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.64', 'le': '0.22', 'lle': '2.26', 'sei': '7.32'}",CHEMBL3704778,,CHEMBL3704778,8.51,0,http://www.openphacts.org/units/Nanomolar,2582297,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304911,17685778,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3CC2C(F)(F)F)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.03', 'le': '0.21', 'lle': '-0.65', 'sei': '9.21'}",CHEMBL3704779,,CHEMBL3704779,7.70,0,http://www.openphacts.org/units/Nanomolar,2582298,=,37,1,=,,IC50,nM,,19.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.9
,304912,17685779,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,CHEMBL3638572,,2015,"{'bei': '12.29', 'le': '0.23', 'lle': '2.24', 'sei': '8.87'}",CHEMBL3704780,,CHEMBL3704780,8.52,0,http://www.openphacts.org/units/Nanomolar,2582299,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304913,17685780,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,CHEMBL3638572,,2015,"{'bei': '12.22', 'le': '0.23', 'lle': '2.19', 'sei': '8.81'}",CHEMBL3704781,,CHEMBL3704781,8.47,0,http://www.openphacts.org/units/Nanomolar,2582300,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304914,17685781,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.84', 'le': '0.23', 'lle': '2.80', 'sei': '8.03'}",CHEMBL3704782,,CHEMBL3704782,8.59,0,http://www.openphacts.org/units/Nanomolar,2582301,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304915,17685782,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '2.35', 'sei': '8.96'}",CHEMBL3704783,,CHEMBL3704783,8.46,0,http://www.openphacts.org/units/Nanomolar,2582302,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304916,17685783,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)ccn3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.95', 'le': '0.20', 'lle': '1.83', 'sei': '6.30'}",CHEMBL3704784,,CHEMBL3704784,7.83,0,http://www.openphacts.org/units/Nanomolar,2582303,=,37,1,=,,IC50,nM,,14.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.9
,304917,17685784,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(C#N)s2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.35', 'le': '0.20', 'lle': '0.14', 'sei': '7.16'}",CHEMBL3704785,,CHEMBL3704785,7.31,0,http://www.openphacts.org/units/Nanomolar,2582304,=,37,1,=,,IC50,nM,,49.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.1
,304918,17685785,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.22', 'lle': '1.63', 'sei': '8.19'}",CHEMBL3704786,,CHEMBL3704786,8.36,0,http://www.openphacts.org/units/Nanomolar,2582305,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304919,17685786,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.73', 'le': '0.22', 'lle': '1.92', 'sei': '7.64'}",CHEMBL3704787,,CHEMBL3704787,7.95,0,http://www.openphacts.org/units/Nanomolar,2582306,=,37,1,=,,IC50,nM,,11.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.3
,304920,17685787,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(F)c(OC)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.40', 'le': '0.21', 'lle': '2.68', 'sei': '6.71'}",CHEMBL3704788,,CHEMBL3704788,8.21,0,http://www.openphacts.org/units/Nanomolar,2582307,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304921,17685788,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.75', 'le': '0.22', 'lle': '2.34', 'sei': '7.39'}",CHEMBL3704789,,CHEMBL3704789,8.59,0,http://www.openphacts.org/units/Nanomolar,2582308,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304922,17685789,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.23', 'lle': '1.41', 'sei': '9.75'}",CHEMBL3704790,,CHEMBL3704790,8.46,0,http://www.openphacts.org/units/Nanomolar,2582309,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304923,17685790,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2csc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.23', 'lle': '1.35', 'sei': '8.35'}",CHEMBL3704791,,CHEMBL3704791,8.52,0,http://www.openphacts.org/units/Nanomolar,2582310,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304924,17685791,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.68', 'le': '0.22', 'lle': '2.22', 'sei': '7.29'}",CHEMBL3704792,,CHEMBL3704792,8.26,0,http://www.openphacts.org/units/Nanomolar,2582311,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304925,17685792,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(F)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '1.94', 'sei': '7.79'}",CHEMBL3704793,,CHEMBL3704793,8.11,0,http://www.openphacts.org/units/Nanomolar,2582312,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,304926,17685793,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.26', 'le': '0.23', 'lle': '2.17', 'sei': '8.06'}",CHEMBL3701365,,CHEMBL3701365,8.62,0,http://www.openphacts.org/units/Nanomolar,2578669,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,304927,17685794,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.23', 'le': '0.23', 'lle': '2.01', 'sei': '8.20'}",CHEMBL3701382,VOB-560,CHEMBL3701382,8.77,0,http://www.openphacts.org/units/Nanomolar,2578686,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,304928,17685795,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)nn2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.17', 'le': '0.23', 'lle': '2.73', 'sei': '7.15'}",CHEMBL3704794,,CHEMBL3704794,8.57,0,http://www.openphacts.org/units/Nanomolar,2582313,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,304929,17685796,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.22', 'lle': '2.54', 'sei': '7.84'}",CHEMBL3704795,,CHEMBL3704795,8.54,0,http://www.openphacts.org/units/Nanomolar,2582314,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,304930,17685797,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,CHEMBL3638572,,2015,"{'bei': '11.94', 'le': '0.22', 'lle': '2.32', 'sei': '8.41'}",CHEMBL3704796,,CHEMBL3704796,8.08,0,http://www.openphacts.org/units/Nanomolar,2582315,=,37,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,304931,17685798,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.22', 'lle': '2.40', 'sei': '8.50'}",CHEMBL3704797,,CHEMBL3704797,8.16,0,http://www.openphacts.org/units/Nanomolar,2582316,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,304932,17685799,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4CC3C(F)(F)F)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.93', 'le': '0.23', 'lle': '0.20', 'sei': '8.66'}",CHEMBL3704798,,CHEMBL3704798,8.19,0,http://www.openphacts.org/units/Nanomolar,2582317,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,304933,17685800,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(CCN3CCOCC3)c2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.93', 'le': '0.22', 'lle': '1.48', 'sei': '8.15'}",CHEMBL3704799,,CHEMBL3704799,8.72,0,http://www.openphacts.org/units/Nanomolar,2582318,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,304934,17685801,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(OCCN3CCOCC3)nc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.88', 'le': '0.23', 'lle': '2.14', 'sei': '7.57'}",CHEMBL3704800,,CHEMBL3704800,8.57,0,http://www.openphacts.org/units/Nanomolar,2582319,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,304935,17685802,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn(C)c1C#N,,,CHEMBL3638572,,2015,"{'bei': '11.12', 'le': '0.21', 'lle': '1.22', 'sei': '7.46'}",CHEMBL3704801,,CHEMBL3704801,7.98,0,http://www.openphacts.org/units/Nanomolar,2582320,=,37,1,=,,IC50,nM,,10.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.5
,304936,17685803,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(C#N)cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.76', 'le': '0.22', 'lle': '1.36', 'sei': '8.04'}",CHEMBL3704802,,CHEMBL3704802,8.60,0,http://www.openphacts.org/units/Nanomolar,2582321,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304937,17685804,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.20', 'le': '0.21', 'lle': '1.37', 'sei': '8.12'}",CHEMBL3704803,,CHEMBL3704803,8.55,0,http://www.openphacts.org/units/Nanomolar,2582322,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,304938,17685805,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.67', 'le': '0.22', 'lle': '0.68', 'sei': '9.81'}",CHEMBL3704804,,CHEMBL3704804,8.51,0,http://www.openphacts.org/units/Nanomolar,2582323,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304939,17685806,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)no1,,,CHEMBL3638572,,2015,"{'bei': '11.58', 'le': '0.22', 'lle': '1.35', 'sei': '7.55'}",CHEMBL3704805,,CHEMBL3704805,7.88,0,http://www.openphacts.org/units/Nanomolar,2582324,=,37,1,=,,IC50,nM,,13.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.3
,304940,17685807,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2cnc3c(ccn3C)c2)c2ccc(O)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.18', 'le': '0.19', 'lle': '0.92', 'sei': '6.82'}",CHEMBL3704806,,CHEMBL3704806,7.44,0,http://www.openphacts.org/units/Nanomolar,2582325,=,37,1,=,,IC50,nM,,36.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.6
,304941,17685808,[],CHEMBL3705658,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2CCc3ccccc3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.39', 'le': '0.25', 'lle': '0.18', 'sei': '11.73'}",CHEMBL3704807,,CHEMBL3704807,7.72,0,http://www.openphacts.org/units/Nanomolar,2582326,=,37,1,=,,IC50,nM,,19.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.2
,326147,17704895,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.84', 'le': '0.19', 'lle': '0.91', 'sei': '5.51'}",CHEMBL3948552,,CHEMBL3948552,6.29,0,http://www.openphacts.org/units/Nanomolar,2838208,=,37,1,=,,IC50,nM,,511.89,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,511.89
,326148,17704896,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.16', 'le': '0.22', 'lle': '1.92', 'sei': '5.45'}",CHEMBL3920752,,CHEMBL3920752,6.82,0,http://www.openphacts.org/units/Nanomolar,2838209,=,37,1,=,,IC50,nM,,150.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,150.9
,326149,17704897,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.24', 'le': '0.18', 'lle': '-0.11', 'sei': '5.42'}",CHEMBL3929521,,CHEMBL3929521,6.34,0,http://www.openphacts.org/units/Nanomolar,2838210,=,37,1,=,,IC50,nM,,455.26,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,455.265
,326150,17704898,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '9.75', 'le': '0.18', 'lle': '1.18', 'sei': '5.16'}",CHEMBL3926219,,CHEMBL3926219,5.90,0,http://www.openphacts.org/units/Nanomolar,2838211,=,37,1,=,,IC50,nM,,1265.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1265.765
,326151,17704899,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.12', 'le': '0.23', 'lle': '2.74', 'sei': '5.58'}",CHEMBL3927241,,CHEMBL3927241,6.99,0,http://www.openphacts.org/units/Nanomolar,2838212,=,37,1,=,,IC50,nM,,102.02,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,102.02
,326152,17704900,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.71', 'le': '0.16', 'lle': '-0.12', 'sei': '4.85'}",CHEMBL3899211,,CHEMBL3899211,5.68,0,http://www.openphacts.org/units/Nanomolar,2838213,=,37,1,=,,IC50,nM,,2092.72,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2092.72
,326153,17704901,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.72', 'le': '0.16', 'lle': '-0.09', 'sei': '5.09'}",CHEMBL3908169,,CHEMBL3908169,5.81,0,http://www.openphacts.org/units/Nanomolar,2838214,=,37,1,=,,IC50,nM,,1539.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1539.27
,326154,17704902,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.26', 'le': '0.15', 'lle': '-0.41', 'sei': '4.73'}",CHEMBL3932621,,CHEMBL3932621,5.53,0,http://www.openphacts.org/units/Nanomolar,2838215,=,37,1,=,,IC50,nM,,2943.39,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2943.39
,326155,17704903,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.22', 'le': '0.22', 'lle': '1.07', 'sei': '6.27'}",CHEMBL3895678,,CHEMBL3895678,6.21,0,http://www.openphacts.org/units/Nanomolar,2838216,=,37,1,=,,IC50,nM,,623.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,623.56
,326156,17704904,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.25', 'le': '0.20', 'lle': '0.38', 'sei': '6.62'}",CHEMBL3923681,,CHEMBL3923681,5.82,0,http://www.openphacts.org/units/Nanomolar,2838217,=,37,1,=,,IC50,nM,,1529.09,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1529.09
,326157,17704905,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.64', 'le': '0.24', 'lle': '2.07', 'sei': '6.63'}",CHEMBL3914781,,CHEMBL3914781,6.55,0,http://www.openphacts.org/units/Nanomolar,2838218,=,37,1,=,,IC50,nM,,278.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,278.405
,326158,17704906,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '11.88', 'le': '0.22', 'lle': '1.54', 'sei': '7.20'}",CHEMBL3918229,,CHEMBL3918229,6.33,0,http://www.openphacts.org/units/Nanomolar,2838219,=,37,1,=,,IC50,nM,,470.04,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,470.04
,326159,17704907,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '1.04', 'sei': '5.62'}",CHEMBL3948552,,CHEMBL3948552,6.42,0,http://www.openphacts.org/units/Nanomolar,2838208,=,37,1,=,,IC50,nM,,384.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,384.11
,326160,17704908,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.24', 'le': '0.22', 'lle': '1.97', 'sei': '5.49'}",CHEMBL3920752,,CHEMBL3920752,6.87,0,http://www.openphacts.org/units/Nanomolar,2838209,=,37,1,=,,IC50,nM,,134.92,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,134.92
,326161,17704909,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.07', 'sei': '5.45'}",CHEMBL3929521,,CHEMBL3929521,6.38,0,http://www.openphacts.org/units/Nanomolar,2838210,=,37,1,=,,IC50,nM,,421.44,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,421.435
,326162,17704910,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '10.11', 'le': '0.19', 'lle': '1.39', 'sei': '5.35'}",CHEMBL3926219,,CHEMBL3926219,6.11,0,http://www.openphacts.org/units/Nanomolar,2838211,=,37,1,=,,IC50,nM,,773.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,773.35
,326163,17704911,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.26', 'le': '0.23', 'lle': '2.82', 'sei': '5.65'}",CHEMBL3927241,,CHEMBL3927241,7.07,0,http://www.openphacts.org/units/Nanomolar,2838212,=,37,1,=,,IC50,nM,,84.81,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.805
,326164,17704912,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '9.04', 'le': '0.17', 'lle': '0.09', 'sei': '5.03'}",CHEMBL3899211,,CHEMBL3899211,5.89,0,http://www.openphacts.org/units/Nanomolar,2838213,=,37,1,=,,IC50,nM,,1286.87,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1286.87
,326165,17704913,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.84', 'le': '0.16', 'lle': '-0.01', 'sei': '5.16'}",CHEMBL3908169,,CHEMBL3908169,5.89,0,http://www.openphacts.org/units/Nanomolar,2838214,=,37,1,=,,IC50,nM,,1282.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1282.77
,326166,17704914,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.61', 'le': '0.16', 'lle': '-0.17', 'sei': '4.93'}",CHEMBL3932621,,CHEMBL3932621,5.76,0,http://www.openphacts.org/units/Nanomolar,2838215,=,37,1,=,,IC50,nM,,1716.45,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1716.455
,326167,17704915,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.53', 'le': '0.22', 'lle': '1.23', 'sei': '6.45'}",CHEMBL3895678,,CHEMBL3895678,6.38,0,http://www.openphacts.org/units/Nanomolar,2838216,=,37,1,=,,IC50,nM,,421.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,421.875
,326168,17704916,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.67', 'le': '0.21', 'lle': '0.61', 'sei': '6.88'}",CHEMBL3923681,,CHEMBL3923681,6.05,0,http://www.openphacts.org/units/Nanomolar,2838217,=,37,1,=,,IC50,nM,,892.38,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,892.385
,326169,17704917,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.74', 'le': '0.24', 'lle': '2.12', 'sei': '6.68'}",CHEMBL3914781,,CHEMBL3914781,6.61,0,http://www.openphacts.org/units/Nanomolar,2838218,=,37,1,=,,IC50,nM,,246.94,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,246.945
,326170,17704918,[],CHEMBL3887237,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.29', 'le': '0.23', 'lle': '1.76', 'sei': '7.45'}",CHEMBL3918229,,CHEMBL3918229,6.55,0,http://www.openphacts.org/units/Nanomolar,2838219,=,37,1,=,,IC50,nM,,282.81,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,282.815
,326171,17704919,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.36', 'le': '0.18', 'lle': '0.58', 'sei': '4.93'}",CHEMBL3909422,,CHEMBL3909422,6.16,0,http://www.openphacts.org/units/Nanomolar,2838220,=,37,1,=,,IC50,nM,,692.43,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,692.435
,326172,17704920,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.78', 'le': '0.21', 'lle': '2.27', 'sei': '5.15'}",CHEMBL3937363,,CHEMBL3937363,6.42,0,http://www.openphacts.org/units/Nanomolar,2838221,=,37,1,=,,IC50,nM,,377.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,377.205
,326173,17704921,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '11.06', 'le': '0.21', 'lle': '1.97', 'sei': '5.53'}",CHEMBL3900418,,CHEMBL3900418,6.90,0,http://www.openphacts.org/units/Nanomolar,2838222,=,37,1,=,,IC50,nM,,126.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,126.56
,326174,17704922,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.90', 'le': '0.16', 'lle': '-1.05', 'sei': '4.46'}",CHEMBL3924890,,CHEMBL3924890,6.10,0,http://www.openphacts.org/units/Nanomolar,2838223,=,37,1,=,,IC50,nM,,799.39,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,799.39
,326175,17704923,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.09', 'le': '0.17', 'lle': '0.10', 'sei': '4.75'}",CHEMBL3927159,,CHEMBL3927159,6.21,0,http://www.openphacts.org/units/Nanomolar,2838224,=,37,1,=,,IC50,nM,,609.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,609.245
,326176,17704924,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.21', 'le': '0.18', 'lle': '-1.14', 'sei': '5.49'}",CHEMBL3902718,,CHEMBL3902718,6.25,0,http://www.openphacts.org/units/Nanomolar,2838225,=,37,1,=,,IC50,nM,,562.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,562.775
,326177,17704925,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.75', 'le': '0.18', 'lle': '-1.24', 'sei': '5.45'}",CHEMBL3890069,,CHEMBL3890069,6.20,0,http://www.openphacts.org/units/Nanomolar,2838226,=,37,1,=,,IC50,nM,,638.23,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,638.23
,326178,17704926,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.80', 'sei': '4.35'}",CHEMBL3959104,,CHEMBL3959104,6.08,0,http://www.openphacts.org/units/Nanomolar,2838227,=,37,1,=,,IC50,nM,,835.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,835.86
,326179,17704927,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3982550,,CHEMBL3982550,,0,http://www.openphacts.org/units/Nanomolar,2838228,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326180,17704928,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3950403,,CHEMBL3950403,,0,http://www.openphacts.org/units/Nanomolar,2838229,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326181,17704929,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.84', 'le': '0.17', 'lle': '1.38', 'sei': '4.32'}",CHEMBL3974550,,CHEMBL3974550,6.53,0,http://www.openphacts.org/units/Nanomolar,2838230,=,37,1,=,,IC50,nM,,296.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,296.105
,326182,17704930,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.92', 'le': '0.13', 'lle': '-2.84', 'sei': '4.21'}",CHEMBL3945127,,CHEMBL3945127,5.18,0,http://www.openphacts.org/units/Nanomolar,2838231,=,37,1,=,,IC50,nM,,6630.34,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6630.34
,326183,17704931,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.53', 'le': '0.13', 'lle': '-3.75', 'sei': '4.52'}",CHEMBL3962530,,CHEMBL3962530,5.14,0,http://www.openphacts.org/units/Nanomolar,2838232,=,37,1,=,,IC50,nM,,7278.41,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7278.41
,326184,17704932,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.09', 'le': '0.18', 'lle': '-0.42', 'sei': '5.40'}",CHEMBL3938600,,CHEMBL3938600,6.15,0,http://www.openphacts.org/units/Nanomolar,2838233,=,37,1,=,,IC50,nM,,714.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,714.5
,326185,17704933,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.56', 'le': '0.16', 'lle': '-1.58', 'sei': '4.98'}",CHEMBL3959636,,CHEMBL3959636,5.66,0,http://www.openphacts.org/units/Nanomolar,2838234,=,37,1,=,,IC50,nM,,2174.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2174.795
,326186,17704934,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.59', 'le': '0.18', 'lle': '1.54', 'sei': '4.71'}",CHEMBL3890556,,CHEMBL3890556,6.19,0,http://www.openphacts.org/units/Nanomolar,2838235,=,37,1,=,,IC50,nM,,639.96,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,639.955
,326187,17704935,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.67', 'le': '0.17', 'lle': '-0.69', 'sei': '5.29'}",CHEMBL3967288,,CHEMBL3967288,6.02,0,http://www.openphacts.org/units/Nanomolar,2838236,=,37,1,=,,IC50,nM,,957.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,957.155
,326188,17704936,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.04', 'le': '0.17', 'lle': '0.93', 'sei': '4.07'}",CHEMBL3899521,,CHEMBL3899521,6.23,0,http://www.openphacts.org/units/Nanomolar,2838237,=,37,1,=,,IC50,nM,,584.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,584.685
,326189,17704937,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.25', 'sei': '4.61'}",CHEMBL3904990,,CHEMBL3904990,6.07,0,http://www.openphacts.org/units/Nanomolar,2838238,=,37,1,=,,IC50,nM,,855.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,855.19
,326190,17704938,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.44', 'le': '0.16', 'lle': '-0.54', 'sei': '4.94'}",CHEMBL3917653,,CHEMBL3917653,5.87,0,http://www.openphacts.org/units/Nanomolar,2838239,=,37,1,=,,IC50,nM,,1356.79,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1356.79
,326191,17704939,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.98', 'le': '0.16', 'lle': '-1.59', 'sei': '5.08'}",CHEMBL3942106,,CHEMBL3942106,5.78,0,http://www.openphacts.org/units/Nanomolar,2838240,=,37,1,=,,IC50,nM,,1653.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1653.195
,326192,17704940,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.23', 'le': '0.18', 'lle': '1.29', 'sei': '4.81'}",CHEMBL3926618,,CHEMBL3926618,5.62,0,http://www.openphacts.org/units/Nanomolar,2838241,=,37,1,=,,IC50,nM,,2387.99,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2387.985
,326193,17704941,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.18', 'le': '0.18', 'lle': '0.92', 'sei': '4.70'}",CHEMBL3890050,,CHEMBL3890050,6.19,0,http://www.openphacts.org/units/Nanomolar,2838242,=,37,1,=,,IC50,nM,,651.76,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,651.765
,326194,17704942,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.69', 'le': '0.17', 'lle': '-0.16', 'sei': '4.46'}",CHEMBL3977288,,CHEMBL3977288,6.37,0,http://www.openphacts.org/units/Nanomolar,2838243,=,37,1,=,,IC50,nM,,427.08,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,427.085
,326195,17704943,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.87', 'le': '0.18', 'lle': '-0.91', 'sei': '5.54'}",CHEMBL3948036,,CHEMBL3948036,6.31,0,http://www.openphacts.org/units/Nanomolar,2838244,=,37,1,=,,IC50,nM,,493.55,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,493.545
,326196,17704944,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.61', 'le': '0.18', 'lle': '0.28', 'sei': '5.58'}",CHEMBL3985364,,CHEMBL3985364,6.34,0,http://www.openphacts.org/units/Nanomolar,2838245,=,37,1,=,,IC50,nM,,454.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,454.155
,326197,17704945,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.07', 'le': '0.17', 'lle': '0.65', 'sei': '4.53'}",CHEMBL3953351,,CHEMBL3953351,6.35,0,http://www.openphacts.org/units/Nanomolar,2838246,=,37,1,=,,IC50,nM,,447.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,447.69
,326198,17704946,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.54', 'le': '0.16', 'lle': '-1.10', 'sei': '5.41'}",CHEMBL3893085,,CHEMBL3893085,6.15,0,http://www.openphacts.org/units/Nanomolar,2838247,=,37,1,=,,IC50,nM,,709.36,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,709.36
,326199,17704947,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.84', 'le': '0.14', 'lle': '-1.98', 'sei': '3.91'}",CHEMBL3962105,,CHEMBL3962105,5.58,0,http://www.openphacts.org/units/Nanomolar,2838248,=,37,1,=,,IC50,nM,,2626.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2626.685
,326200,17704948,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.00', 'le': '0.13', 'lle': '-2.58', 'sei': '4.28'}",CHEMBL3902056,,CHEMBL3902056,5.27,0,http://www.openphacts.org/units/Nanomolar,2838249,=,37,1,=,,IC50,nM,,5412.52,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5412.515
,326201,17704949,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.86', 'le': '0.17', 'lle': '0.51', 'sei': '4.69'}",CHEMBL3976266,,CHEMBL3976266,6.20,0,http://www.openphacts.org/units/Nanomolar,2838250,=,37,1,=,,IC50,nM,,631.49,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,631.485
,326202,17704950,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.31', 'le': '0.14', 'lle': '-1.04', 'sei': '4.01'}",CHEMBL3912231,,CHEMBL3912231,5.28,0,http://www.openphacts.org/units/Nanomolar,2838251,=,37,1,=,,IC50,nM,,5299.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5299.7
,326203,17704951,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.39', 'le': '0.16', 'lle': '-0.21', 'sei': '3.98'}",CHEMBL3982160,,CHEMBL3982160,6.07,0,http://www.openphacts.org/units/Nanomolar,2838252,=,37,1,=,,IC50,nM,,843.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,843.135
,326204,17704952,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.60', 'le': '0.18', 'lle': '1.12', 'sei': '4.30'}",CHEMBL3948609,,CHEMBL3948609,6.57,0,http://www.openphacts.org/units/Nanomolar,2838253,=,37,1,=,,IC50,nM,,271.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,271.77
,326205,17704953,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.18', 'le': '0.16', 'lle': '-1.61', 'sei': '5.25'}",CHEMBL3932360,,CHEMBL3932360,5.97,0,http://www.openphacts.org/units/Nanomolar,2838254,=,37,1,=,,IC50,nM,,1076.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1076.21
,326206,17704954,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3943276,,CHEMBL3943276,,0,http://www.openphacts.org/units/Nanomolar,2838255,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326207,17704955,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.68', 'le': '0.18', 'lle': '-0.39', 'sei': '5.78'}",CHEMBL3972844,,CHEMBL3972844,6.57,0,http://www.openphacts.org/units/Nanomolar,2838256,=,37,1,=,,IC50,nM,,268.82,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,268.82
,326208,17704956,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.42', 'le': '0.17', 'lle': '0.43', 'sei': '4.15'}",CHEMBL3900742,,CHEMBL3900742,6.20,0,http://www.openphacts.org/units/Nanomolar,2838257,=,37,1,=,,IC50,nM,,632.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,632.205
,326209,17704957,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.26', 'le': '0.18', 'lle': '0.38', 'sei': '4.49'}",CHEMBL3897154,,CHEMBL3897154,6.17,0,http://www.openphacts.org/units/Nanomolar,2838258,=,37,1,=,,IC50,nM,,672.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,672.575
,326210,17704958,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.21', 'le': '0.18', 'lle': '0.37', 'sei': '4.42'}",CHEMBL3957281,,CHEMBL3957281,6.18,0,http://www.openphacts.org/units/Nanomolar,2838259,=,37,1,=,,IC50,nM,,660.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,660.495
,326211,17704959,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.00', 'le': '0.19', 'lle': '1.07', 'sei': '4.70'}",CHEMBL3985961,,CHEMBL3985961,6.57,0,http://www.openphacts.org/units/Nanomolar,2838260,=,37,1,=,,IC50,nM,,270.38,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,270.38
,326212,17704960,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.51', 'le': '0.16', 'lle': '-0.16', 'sei': '4.66'}",CHEMBL4111735,,CHEMBL4111735,6.09,0,http://www.openphacts.org/units/Nanomolar,2838261,=,37,1,=,,IC50,nM,,806.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,806.98
,326213,17704961,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.54', 'le': '0.16', 'lle': '-0.52', 'sei': '4.33'}",CHEMBL3916294,,CHEMBL3916294,6.05,0,http://www.openphacts.org/units/Nanomolar,2838262,=,37,1,=,,IC50,nM,,884.62,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,884.625
,326214,17704962,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.95', 'le': '0.18', 'lle': '0.55', 'sei': '4.51'}",CHEMBL3946968,,CHEMBL3946968,6.32,0,http://www.openphacts.org/units/Nanomolar,2838263,=,37,1,=,,IC50,nM,,479.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,479.98
,326215,17704963,[],CHEMBL3887238,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.42', 'le': '0.18', 'lle': '0.12', 'sei': '5.43'}",CHEMBL3950260,,CHEMBL3950260,6.18,0,http://www.openphacts.org/units/Nanomolar,2838264,=,37,1,=,,IC50,nM,,666.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,666.035
,326216,17704964,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.55', 'le': '0.18', 'lle': '0.70', 'sei': '5.03'}",CHEMBL3909422,,CHEMBL3909422,6.29,0,http://www.openphacts.org/units/Nanomolar,2838220,=,37,1,=,,IC50,nM,,518.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,518.875
,326217,17704965,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.96', 'le': '0.21', 'lle': '2.38', 'sei': '5.23'}",CHEMBL3937363,,CHEMBL3937363,6.53,0,http://www.openphacts.org/units/Nanomolar,2838221,=,37,1,=,,IC50,nM,,294.71,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,294.715
,326218,17704966,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '11.29', 'le': '0.22', 'lle': '2.11', 'sei': '5.64'}",CHEMBL3900418,,CHEMBL3900418,7.04,0,http://www.openphacts.org/units/Nanomolar,2838222,=,37,1,=,,IC50,nM,,90.44,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.435
,326219,17704967,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.99', 'le': '0.16', 'lle': '-0.98', 'sei': '4.51'}",CHEMBL3924890,,CHEMBL3924890,6.17,0,http://www.openphacts.org/units/Nanomolar,2838223,=,37,1,=,,IC50,nM,,675.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,675.4
,326220,17704968,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.34', 'le': '0.18', 'lle': '0.26', 'sei': '4.88'}",CHEMBL3927159,,CHEMBL3927159,6.38,0,http://www.openphacts.org/units/Nanomolar,2838224,=,37,1,=,,IC50,nM,,412.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,412.24
,326221,17704969,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.32', 'le': '0.18', 'lle': '-1.06', 'sei': '5.57'}",CHEMBL3902718,,CHEMBL3902718,6.33,0,http://www.openphacts.org/units/Nanomolar,2838225,=,37,1,=,,IC50,nM,,465.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,465.17
,326222,17704970,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.91', 'le': '0.18', 'lle': '-1.12', 'sei': '5.56'}",CHEMBL3890069,,CHEMBL3890069,6.33,0,http://www.openphacts.org/units/Nanomolar,2838226,=,37,1,=,,IC50,nM,,473.64,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,473.64
,326223,17704971,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.55', 'le': '0.16', 'lle': '-0.70', 'sei': '4.42'}",CHEMBL3959104,,CHEMBL3959104,6.18,0,http://www.openphacts.org/units/Nanomolar,2838227,=,37,1,=,,IC50,nM,,664.26,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,664.26
,326224,17704972,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.78', 'le': '0.13', 'lle': '-3.14', 'sei': '4.48'}",CHEMBL3982550,,CHEMBL3982550,5.10,0,http://www.openphacts.org/units/Nanomolar,2838228,=,37,1,=,,IC50,nM,,7935.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7935.67
,326225,17704973,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.32', 'le': '0.14', 'lle': '-2.55', 'sei': '4.45'}",CHEMBL3950403,,CHEMBL3950403,5.47,0,http://www.openphacts.org/units/Nanomolar,2838229,=,37,1,=,,IC50,nM,,3349.66,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3349.66
,326226,17704974,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.93', 'le': '0.17', 'lle': '1.45', 'sei': '4.36'}",CHEMBL3974550,,CHEMBL3974550,6.60,0,http://www.openphacts.org/units/Nanomolar,2838230,=,37,1,=,,IC50,nM,,253.16,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,253.155
,326227,17704975,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.10', 'le': '0.13', 'lle': '-2.71', 'sei': '4.32'}",CHEMBL3945127,,CHEMBL3945127,5.31,0,http://www.openphacts.org/units/Nanomolar,2838231,=,37,1,=,,IC50,nM,,4863.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4863.58
,326228,17704976,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.83', 'le': '0.14', 'lle': '-3.51', 'sei': '4.73'}",CHEMBL3962530,,CHEMBL3962530,5.38,0,http://www.openphacts.org/units/Nanomolar,2838232,=,37,1,=,,IC50,nM,,4210.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4210.985
,326229,17704977,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.25', 'le': '0.18', 'lle': '-0.32', 'sei': '5.50'}",CHEMBL3938600,,CHEMBL3938600,6.25,0,http://www.openphacts.org/units/Nanomolar,2838233,=,37,1,=,,IC50,nM,,558.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,558.67
,326230,17704978,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.66', 'le': '0.16', 'lle': '-1.50', 'sei': '5.04'}",CHEMBL3959636,,CHEMBL3959636,5.74,0,http://www.openphacts.org/units/Nanomolar,2838234,=,37,1,=,,IC50,nM,,1832.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1832.245
,326231,17704979,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.79', 'le': '0.19', 'lle': '1.67', 'sei': '4.81'}",CHEMBL3890556,,CHEMBL3890556,6.32,0,http://www.openphacts.org/units/Nanomolar,2838235,=,37,1,=,,IC50,nM,,475.07,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,475.075
,326232,17704980,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.74', 'le': '0.17', 'lle': '-0.64', 'sei': '5.34'}",CHEMBL3967288,,CHEMBL3967288,6.07,0,http://www.openphacts.org/units/Nanomolar,2838236,=,37,1,=,,IC50,nM,,849.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,849.56
,326233,17704981,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.19', 'le': '0.18', 'lle': '1.04', 'sei': '4.14'}",CHEMBL3899521,,CHEMBL3899521,6.34,0,http://www.openphacts.org/units/Nanomolar,2838237,=,37,1,=,,IC50,nM,,456.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,456.67
,326234,17704982,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.48', 'le': '0.16', 'lle': '-0.20', 'sei': '4.65'}",CHEMBL3904990,,CHEMBL3904990,6.12,0,http://www.openphacts.org/units/Nanomolar,2838238,=,37,1,=,,IC50,nM,,757.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,757.035
,326235,17704983,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.60', 'le': '0.16', 'lle': '-0.43', 'sei': '5.04'}",CHEMBL3917653,,CHEMBL3917653,5.98,0,http://www.openphacts.org/units/Nanomolar,2838239,=,37,1,=,,IC50,nM,,1053.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1053.175
,326236,17704984,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.87', 'le': '0.16', 'lle': '-1.67', 'sei': '5.01'}",CHEMBL3942106,,CHEMBL3942106,5.70,0,http://www.openphacts.org/units/Nanomolar,2838240,=,37,1,=,,IC50,nM,,1980.97,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1980.97
,326237,17704985,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.46', 'le': '0.18', 'lle': '1.43', 'sei': '4.92'}",CHEMBL3926618,,CHEMBL3926618,5.76,0,http://www.openphacts.org/units/Nanomolar,2838241,=,37,1,=,,IC50,nM,,1735.78,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1735.775
,326238,17704986,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.40', 'le': '0.18', 'lle': '1.06', 'sei': '4.81'}",CHEMBL3890050,,CHEMBL3890050,6.33,0,http://www.openphacts.org/units/Nanomolar,2838242,=,37,1,=,,IC50,nM,,466.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,466.345
,326239,17704987,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.99', 'le': '0.18', 'lle': '0.06', 'sei': '4.62'}",CHEMBL3977288,,CHEMBL3977288,6.59,0,http://www.openphacts.org/units/Nanomolar,2838243,=,37,1,=,,IC50,nM,,254.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,254.5
,326240,17704988,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.05', 'le': '0.18', 'lle': '-0.79', 'sei': '5.65'}",CHEMBL3948036,,CHEMBL3948036,6.43,0,http://www.openphacts.org/units/Nanomolar,2838244,=,37,1,=,,IC50,nM,,370.43,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,370.43
,326241,17704989,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.85', 'le': '0.19', 'lle': '0.44', 'sei': '5.72'}",CHEMBL3985364,,CHEMBL3985364,6.50,0,http://www.openphacts.org/units/Nanomolar,2838245,=,37,1,=,,IC50,nM,,314.95,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,314.95
,326242,17704990,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.30', 'le': '0.18', 'lle': '0.81', 'sei': '4.65'}",CHEMBL3953351,,CHEMBL3953351,6.51,0,http://www.openphacts.org/units/Nanomolar,2838246,=,37,1,=,,IC50,nM,,310.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,310.86
,326243,17704991,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.72', 'le': '0.16', 'lle': '-0.97', 'sei': '5.52'}",CHEMBL3893085,,CHEMBL3893085,6.28,0,http://www.openphacts.org/units/Nanomolar,2838247,=,37,1,=,,IC50,nM,,529.08,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,529.08
,326244,17704992,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.89', 'le': '0.14', 'lle': '-1.94', 'sei': '3.93'}",CHEMBL3962105,,CHEMBL3962105,5.62,0,http://www.openphacts.org/units/Nanomolar,2838248,=,37,1,=,,IC50,nM,,2392.61,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2392.61
,326245,17704993,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.25', 'le': '0.14', 'lle': '-2.40', 'sei': '4.43'}",CHEMBL3902056,,CHEMBL3902056,5.45,0,http://www.openphacts.org/units/Nanomolar,2838249,=,37,1,=,,IC50,nM,,3533.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3533.025
,326246,17704994,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.99', 'le': '0.17', 'lle': '0.60', 'sei': '4.76'}",CHEMBL3976266,,CHEMBL3976266,6.29,0,http://www.openphacts.org/units/Nanomolar,2838250,=,37,1,=,,IC50,nM,,511.57,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,511.57
,326247,17704995,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.55', 'le': '0.14', 'lle': '-0.87', 'sei': '4.14'}",CHEMBL3912231,,CHEMBL3912231,5.45,0,http://www.openphacts.org/units/Nanomolar,2838251,=,37,1,=,,IC50,nM,,3558.82,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3558.815
,326248,17704996,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.55', 'le': '0.16', 'lle': '-0.09', 'sei': '4.06'}",CHEMBL3982160,,CHEMBL3982160,6.19,0,http://www.openphacts.org/units/Nanomolar,2838252,=,37,1,=,,IC50,nM,,641.46,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,641.455
,326249,17704997,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.64', 'le': '0.18', 'lle': '1.14', 'sei': '4.32'}",CHEMBL3948609,,CHEMBL3948609,6.59,0,http://www.openphacts.org/units/Nanomolar,2838253,=,37,1,=,,IC50,nM,,257.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,257.155
,326250,17704998,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.33', 'le': '0.16', 'lle': '-1.50', 'sei': '5.34'}",CHEMBL3932360,,CHEMBL3932360,6.08,0,http://www.openphacts.org/units/Nanomolar,2838254,=,37,1,=,,IC50,nM,,834.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,834.155
,326251,17704999,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3943276,,CHEMBL3943276,,0,http://www.openphacts.org/units/Nanomolar,2838255,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326252,17705000,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.57', 'le': '0.18', 'lle': '-0.48', 'sei': '5.70'}",CHEMBL3972844,,CHEMBL3972844,6.48,0,http://www.openphacts.org/units/Nanomolar,2838256,=,37,1,=,,IC50,nM,,327.93,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,327.93
,326253,17705001,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.49', 'le': '0.17', 'lle': '0.48', 'sei': '4.18'}",CHEMBL3900742,,CHEMBL3900742,6.25,0,http://www.openphacts.org/units/Nanomolar,2838257,=,37,1,=,,IC50,nM,,565.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,565.685
,326254,17705002,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.37', 'le': '0.18', 'lle': '0.46', 'sei': '4.54'}",CHEMBL3897154,,CHEMBL3897154,6.25,0,http://www.openphacts.org/units/Nanomolar,2838258,=,37,1,=,,IC50,nM,,562.23,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,562.23
,326255,17705003,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.35', 'le': '0.18', 'lle': '0.47', 'sei': '4.49'}",CHEMBL3957281,,CHEMBL3957281,6.28,0,http://www.openphacts.org/units/Nanomolar,2838259,=,37,1,=,,IC50,nM,,530.64,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,530.645
,326256,17705004,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '1.09', 'sei': '4.72'}",CHEMBL3985961,,CHEMBL3985961,6.59,0,http://www.openphacts.org/units/Nanomolar,2838260,=,37,1,=,,IC50,nM,,254.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,254.695
,326257,17705005,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.57', 'le': '0.16', 'lle': '-0.11', 'sei': '4.69'}",CHEMBL4111735,,CHEMBL4111735,6.14,0,http://www.openphacts.org/units/Nanomolar,2838261,=,37,1,=,,IC50,nM,,726.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,726.275
,326258,17705006,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.86', 'le': '0.17', 'lle': '-0.29', 'sei': '4.49'}",CHEMBL3916294,,CHEMBL3916294,6.28,0,http://www.openphacts.org/units/Nanomolar,2838262,=,37,1,=,,IC50,nM,,522.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,522.095
,326259,17705007,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.26', 'le': '0.18', 'lle': '0.76', 'sei': '4.66'}",CHEMBL3946968,,CHEMBL3946968,6.53,0,http://www.openphacts.org/units/Nanomolar,2838263,=,37,1,=,,IC50,nM,,292.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,292.905
,326260,17705008,[],CHEMBL3887239,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.64', 'le': '0.18', 'lle': '0.26', 'sei': '5.56'}",CHEMBL3950260,,CHEMBL3950260,6.32,0,http://www.openphacts.org/units/Nanomolar,2838264,=,37,1,=,,IC50,nM,,474.73,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,474.73
,363127,17738502,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCO)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,,CHEMBL3703598,,CHEMBL3703598,,1,http://www.openphacts.org/units/Nanomolar,2860363,<,37,1,<,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,363128,17738503,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL3886500,,2016,"{'bei': '11.49', 'le': '0.23', 'lle': '1.01', 'sei': '6.56'}",CHEMBL3703599,,CHEMBL3703599,9.52,1,http://www.openphacts.org/units/Nanomolar,2860364,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,363129,17738504,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,,CHEMBL3703600,,CHEMBL3703600,,1,http://www.openphacts.org/units/Nanomolar,2860365,<,37,1,<,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,363130,17738505,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '9.69', 'le': '0.20', 'lle': '0.65', 'sei': '5.95'}",CHEMBL3703601,,CHEMBL3703601,9.30,1,http://www.openphacts.org/units/Nanomolar,2860366,=,37,1,=,,IC50,nM,,0.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.5
,363131,17738506,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '9.32', 'le': '0.19', 'lle': '1.48', 'sei': '5.15'}",CHEMBL3703602,,CHEMBL3703602,9.10,1,http://www.openphacts.org/units/Nanomolar,2860367,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,363132,17738507,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(C[C@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '8.72', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703603,,CHEMBL3703603,9.00,1,http://www.openphacts.org/units/Nanomolar,2860368,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,363133,17738508,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '7.66', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703604,,CHEMBL3703604,8.70,1,http://www.openphacts.org/units/Nanomolar,2860369,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,363134,17738509,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '8.70', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703605,,CHEMBL3703605,9.05,1,http://www.openphacts.org/units/Nanomolar,2860370,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,363135,17738510,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '8.82', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703606,,CHEMBL3703606,9.05,1,http://www.openphacts.org/units/Nanomolar,2860371,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,363136,17738511,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '8.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703607,,CHEMBL3703607,9.15,1,http://www.openphacts.org/units/Nanomolar,2860372,=,37,1,=,,IC50,nM,,0.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.7
,363137,17738512,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '8.89', 'le': '0.18', 'lle': '0.18', 'sei': '5.18'}",CHEMBL3703608,,CHEMBL3703608,8.40,1,http://www.openphacts.org/units/Nanomolar,2860373,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,363138,17738513,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '8.89', 'le': '0.18', 'lle': '-0.09', 'sei': '5.26'}",CHEMBL3703609,,CHEMBL3703609,8.52,1,http://www.openphacts.org/units/Nanomolar,2860374,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,363139,17738514,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.80', 'le': '0.16', 'lle': '-0.11', 'sei': '4.71'}",CHEMBL3703610,,CHEMBL3703610,7.80,1,http://www.openphacts.org/units/Nanomolar,2860375,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,363140,17738515,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '6.89', 'le': '0.14', 'lle': '-2.06', 'sei': '4.54'}",CHEMBL3703611,,CHEMBL3703611,6.60,1,http://www.openphacts.org/units/Nanomolar,2860376,=,37,1,=,,IC50,nM,,253.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,253.0
,363141,17738516,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '8.90', 'le': '0.18', 'lle': '-0.14', 'sei': '5.86'}",CHEMBL3703612,,CHEMBL3703612,8.52,1,http://www.openphacts.org/units/Nanomolar,2860377,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,363142,17738517,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '10.45', 'le': '0.21', 'lle': '0.82', 'sei': '5.89'}",CHEMBL3703613,,CHEMBL3703613,9.10,1,http://www.openphacts.org/units/Nanomolar,2860378,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,363143,17738518,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '9.00', 'le': '0.18', 'lle': '-0.54', 'sei': '5.84'}",CHEMBL3703614,,CHEMBL3703614,8.70,1,http://www.openphacts.org/units/Nanomolar,2860379,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,363144,17738519,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '8.44', 'le': '0.17', 'lle': '-1.09', 'sei': '5.48'}",CHEMBL3703614,,CHEMBL3703614,8.15,1,http://www.openphacts.org/units/Nanomolar,2860379,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,363145,17738520,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '6.13', 'le': '0.12', 'lle': '-3.32', 'sei': '3.98'}",CHEMBL3703615,,CHEMBL3703615,5.92,1,http://www.openphacts.org/units/Nanomolar,2860380,=,37,1,=,,IC50,nM,,1195.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1195.0
,363146,17738521,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '9.39', 'le': None, 'lle': None, 'sei': None}",CHEMBL4108604,,CHEMBL4108604,9.52,0,http://www.openphacts.org/units/Nanomolar,2860381,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,363147,17738522,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCNC[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3886500,,2016,"{'bei': '9.39', 'le': None, 'lle': None, 'sei': None}",CHEMBL4111781,,CHEMBL4111781,9.52,0,http://www.openphacts.org/units/Nanomolar,2860382,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,363148,17738523,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '9.34', 'le': '0.19', 'lle': '1.19', 'sei': '5.57'}",CHEMBL3703618,,CHEMBL3703618,9.22,1,http://www.openphacts.org/units/Nanomolar,2860383,=,37,1,=,,IC50,nM,,0.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.6
,363149,17738524,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '9.11', 'le': '0.19', 'lle': '0.97', 'sei': '5.44'}",CHEMBL3703619,,CHEMBL3703619,9.00,1,http://www.openphacts.org/units/Nanomolar,2860384,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,363150,17738525,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703620,,CHEMBL3703620,9.40,1,http://www.openphacts.org/units/Nanomolar,2860385,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,363151,17738526,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3886500,,2016,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703621,,CHEMBL3703621,9.40,1,http://www.openphacts.org/units/Nanomolar,2860386,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,363152,17738527,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)CC1CN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1,,,CHEMBL3886500,,2016,"{'bei': '9.01', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703622,,CHEMBL3703622,9.40,1,http://www.openphacts.org/units/Nanomolar,2860387,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,363153,17738528,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)(C)OP(=O)(O)OCO[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703623,,CHEMBL3703623,8.40,1,http://www.openphacts.org/units/Nanomolar,2860388,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,363154,17738529,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCOP(=O)(OCC)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '6.88', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703624,,CHEMBL3703624,7.52,1,http://www.openphacts.org/units/Nanomolar,2860389,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,363155,17738530,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,COP(=O)(O)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '8.56', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703625,,CHEMBL3703625,9.00,1,http://www.openphacts.org/units/Nanomolar,2860390,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,363156,17738531,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.86', 'le': '0.16', 'lle': '-1.11', 'sei': '4.98'}",CHEMBL3703626,,CHEMBL3703626,7.52,1,http://www.openphacts.org/units/Nanomolar,2860391,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,363157,17738532,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CNCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.36', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703627,,CHEMBL3703627,7.57,1,http://www.openphacts.org/units/Nanomolar,2860392,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,363158,17738533,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,NCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.32', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703628,,CHEMBL3703628,7.42,1,http://www.openphacts.org/units/Nanomolar,2860393,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,363159,17738534,[],CHEMBL3887911,"Fluorescence Polarization Assay: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-c) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502). Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"")assays may be developed using a c-terminal 6XHIS tagged Bcl-2 (aa 1-204) and a C-terminal 6XHIS tagged Bcl-XL (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluorescein isothiocyanate (FITC-DLRPEIRIAQELRRIGDEFNETYTRR). Dilutions of either Bcl-2 (1.3 nM) or Bcl-XL (0.8 nM) may be added to serial dilutions of antagonist and incubated for one hour prior to the addition of 2 nM of fluorescent peptide tracer (Anaspec, Fremont, Calif.) in the assay buffer. Final assay buffer conditions may be 20 mM HEPES, pH 7.5, 1 mM DTT, 0.005% Tween-20 and 50 mM NaCl. Samples may be read after 20-minute incubation. Fluorescence polarization values may be plotted as a function of the antagonist concentration.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3886500,,2016,"{'bei': '7.74', 'le': '0.16', 'lle': '-1.61', 'sei': '5.94'}",CHEMBL3703629,,CHEMBL3703629,7.62,1,http://www.openphacts.org/units/Nanomolar,2860394,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,405176,17771445,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.16', 'le': '0.20', 'lle': '0.17', 'sei': '6.18'}",CHEMBL2031012,,CHEMBL2031012,7.52,0,http://www.openphacts.org/units/Nanomolar,2882706,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405177,17771446,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)cccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.17', 'lle': '-1.30', 'sei': '5.51'}",CHEMBL3928986,,CHEMBL3928986,6.70,0,http://www.openphacts.org/units/Nanomolar,2882707,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405178,17771447,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.71', 'le': '0.19', 'lle': '-0.48', 'sei': '6.18'}",CHEMBL3901024,,CHEMBL3901024,7.52,0,http://www.openphacts.org/units/Nanomolar,2882708,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405179,17771448,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.54', 'le': '0.19', 'lle': '-0.55', 'sei': '6.08'}",CHEMBL2031017,,CHEMBL2031017,7.40,0,http://www.openphacts.org/units/Nanomolar,2882709,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405180,17771449,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(C#N)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.89', 'le': '0.15', 'lle': '-1.18', 'sei': '4.15'}",CHEMBL3923567,,CHEMBL3923567,6.04,0,http://www.openphacts.org/units/Nanomolar,2882710,=,37,1,=,,IC50,nM,,920.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,920.0
,405181,17771450,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(Cl)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.09', 'le': '0.18', 'lle': '-0.95', 'sei': '5.79'}",CHEMBL3892056,,CHEMBL3892056,7.05,0,http://www.openphacts.org/units/Nanomolar,2882711,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405182,17771451,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.54', 'le': '0.19', 'lle': '-0.55', 'sei': '6.08'}",CHEMBL2031018,,CHEMBL2031018,7.40,0,http://www.openphacts.org/units/Nanomolar,2882712,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405183,17771452,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCc5ccccc5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.45', 'le': '0.18', 'lle': '-0.93', 'sei': '6.11'}",CHEMBL3914542,,CHEMBL3914542,8.00,0,http://www.openphacts.org/units/Nanomolar,2882713,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405184,17771453,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.18', 'lle': '-0.83', 'sei': '5.58'}",CHEMBL3984367,,CHEMBL3984367,7.30,0,http://www.openphacts.org/units/Nanomolar,2882714,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405185,17771454,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.00', 'le': '0.16', 'lle': '-0.10', 'sei': '4.85'}",CHEMBL2031014,,CHEMBL2031014,6.96,1,http://www.openphacts.org/units/Nanomolar,2882715,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405186,17771455,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(N(C)C)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.72', 'le': '0.18', 'lle': '-0.66', 'sei': '6.02'}",CHEMBL3904423,,CHEMBL3904423,7.52,0,http://www.openphacts.org/units/Nanomolar,2882716,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405187,17771456,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.40', 'le': '0.14', 'lle': '-0.91', 'sei': '4.56'}",CHEMBL3978452,,CHEMBL3978452,6.54,0,http://www.openphacts.org/units/Nanomolar,2882717,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,405188,17771457,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.40', 'le': '0.14', 'lle': '-0.91', 'sei': '4.56'}",CHEMBL3952199,,CHEMBL3952199,6.54,0,http://www.openphacts.org/units/Nanomolar,2882718,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,405189,17771458,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.02', 'le': '0.14', 'lle': '-1.07', 'sei': '4.58'}",CHEMBL3981017,,CHEMBL3981017,6.29,0,http://www.openphacts.org/units/Nanomolar,2882719,=,37,1,=,,IC50,nM,,510.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,510.0
,405190,17771459,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)CN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.50', 'le': '0.15', 'lle': '-1.37', 'sei': '4.70'}",CHEMBL3957469,,CHEMBL3957469,6.31,0,http://www.openphacts.org/units/Nanomolar,2882720,=,37,1,=,,IC50,nM,,490.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,490.0
,405191,17771460,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(CNS(=O)(=O)c3ccc4ccc(OCCC5CCCN5C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.11', 'le': '0.14', 'lle': '-2.50', 'sei': '5.18'}",CHEMBL3891889,,CHEMBL3891889,6.07,0,http://www.openphacts.org/units/Nanomolar,2882721,=,37,1,=,,IC50,nM,,860.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,860.0
,405192,17771461,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.93', 'le': '0.14', 'lle': '-1.84', 'sei': '4.35'}",CHEMBL3968488,,CHEMBL3968488,5.84,0,http://www.openphacts.org/units/Nanomolar,2882722,=,37,1,=,,IC50,nM,,1460.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1460.0
,405193,17771462,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.25', 'le': '0.12', 'lle': '-2.79', 'sei': '4.04'}",CHEMBL3936837,,CHEMBL3936837,5.42,0,http://www.openphacts.org/units/Nanomolar,2882723,=,37,1,=,,IC50,nM,,3780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3780.0
,405194,17771463,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.85', 'le': '0.21', 'lle': '-0.35', 'sei': '6.91'}",CHEMBL3980078,,CHEMBL3980078,8.41,0,http://www.openphacts.org/units/Nanomolar,2882724,=,37,1,=,,IC50,nM,,3.93,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.93
,405195,17771464,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.06', 'le': '0.21', 'lle': '-0.51', 'sei': '6.69'}",CHEMBL3893121,,CHEMBL3893121,8.14,0,http://www.openphacts.org/units/Nanomolar,2882725,=,37,1,=,,IC50,nM,,7.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.25
,405196,17771465,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.13', 'le': '0.16', 'lle': '0.32', 'sei': '4.85'}",CHEMBL3890787,,CHEMBL3890787,7.05,0,http://www.openphacts.org/units/Nanomolar,2882726,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405197,17771466,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.23', 'sei': '4.81'}",CHEMBL3918855,,CHEMBL3918855,6.82,0,http://www.openphacts.org/units/Nanomolar,2882727,=,37,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,150.0
,405198,17771467,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.51', 'le': '0.19', 'lle': '0.64', 'sei': '5.78'}",CHEMBL2031021,,CHEMBL2031021,7.22,0,http://www.openphacts.org/units/Nanomolar,2882728,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405199,17771468,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)C3CCCCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.85', 'le': '0.15', 'lle': '-1.06', 'sei': '4.65'}",CHEMBL3927598,,CHEMBL3927598,6.60,0,http://www.openphacts.org/units/Nanomolar,2882729,=,37,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,250.0
,405200,17771469,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.18', 'lle': '-1.36', 'sei': '6.16'}",CHEMBL2031022,,CHEMBL2031022,7.70,0,http://www.openphacts.org/units/Nanomolar,2882730,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405201,17771470,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.29', 'le': '0.15', 'lle': '-1.93', 'sei': '4.72'}",CHEMBL3955216,,CHEMBL3955216,6.70,0,http://www.openphacts.org/units/Nanomolar,2882731,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405202,17771471,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CCSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.42', 'le': '0.17', 'lle': '-1.05', 'sei': '5.84'}",CHEMBL3948491,,CHEMBL3948491,7.30,0,http://www.openphacts.org/units/Nanomolar,2882732,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405203,17771472,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.22', 'le': '0.17', 'lle': '-2.20', 'sei': '5.77'}",CHEMBL3893154,,CHEMBL3893154,7.30,0,http://www.openphacts.org/units/Nanomolar,2882733,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405204,17771473,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)N3CCOCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.66', 'le': '0.15', 'lle': '0.46', 'sei': '4.19'}",CHEMBL3912236,,CHEMBL3912236,6.47,0,http://www.openphacts.org/units/Nanomolar,2882734,=,37,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,340.0
,405205,17771474,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4CCCN4CCOCC4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.48', 'le': '0.15', 'lle': '-0.46', 'sei': '4.61'}",CHEMBL3917408,,CHEMBL3917408,6.41,0,http://www.openphacts.org/units/Nanomolar,2882735,=,37,1,=,,IC50,nM,,390.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,390.0
,405206,17771475,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(Cl)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.72', 'le': '0.19', 'lle': '-0.12', 'sei': '6.08'}",CHEMBL3954188,,CHEMBL3954188,7.70,0,http://www.openphacts.org/units/Nanomolar,2882736,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405207,17771476,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(I)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.19', 'le': '0.21', 'lle': '0.34', 'sei': '6.41'}",CHEMBL3947141,,CHEMBL3947141,8.11,0,http://www.openphacts.org/units/Nanomolar,2882737,=,37,1,=,,IC50,nM,,7.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.69
,405208,17771477,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)c(Br)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.15', 'le': '0.21', 'lle': '-0.31', 'sei': '6.62'}",CHEMBL3962921,,CHEMBL3962921,8.38,0,http://www.openphacts.org/units/Nanomolar,2882738,=,37,1,=,,IC50,nM,,4.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.19
,405209,17771478,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.48', 'le': '0.18', 'lle': '0.59', 'sei': '5.14'}",CHEMBL2031024,,CHEMBL2031024,7.30,0,http://www.openphacts.org/units/Nanomolar,2882739,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405210,17771479,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.50', 'le': '0.20', 'lle': '1.41', 'sei': '5.47'}",CHEMBL2031027,,CHEMBL2031027,8.07,0,http://www.openphacts.org/units/Nanomolar,2882740,=,37,1,=,,IC50,nM,,8.41,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.41
,405211,17771480,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@@H]2C(=O)O)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.37', 'le': '0.14', 'lle': '-1.02', 'sei': '3.64'}",CHEMBL3893974,,CHEMBL3893974,5.78,0,http://www.openphacts.org/units/Nanomolar,2882741,=,37,1,=,,IC50,nM,,1650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1650.0
,405212,17771481,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.32', 'le': '0.18', 'lle': '-0.22', 'sei': '5.29'}",CHEMBL2031031,,CHEMBL2031031,6.92,1,http://www.openphacts.org/units/Nanomolar,2882742,=,37,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,405213,17771482,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccc(C(=O)O)cc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.79', 'le': '0.13', 'lle': '-1.72', 'sei': '3.35'}",CHEMBL3898017,,CHEMBL3898017,5.33,0,http://www.openphacts.org/units/Nanomolar,2882743,=,37,1,=,,IC50,nM,,4710.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4710.0
,405214,17771483,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3S(=O)(=O)C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.04', 'le': '0.16', 'lle': '-0.18', 'sei': '4.08'}",CHEMBL3963540,,CHEMBL3963540,6.36,0,http://www.openphacts.org/units/Nanomolar,2882744,=,37,1,=,,IC50,nM,,440.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,440.0
,405215,17771484,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.18', 'lle': '-0.07', 'sei': '5.49'}",CHEMBL2031025,,CHEMBL2031025,7.70,0,http://www.openphacts.org/units/Nanomolar,2882745,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405216,17771485,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CNC2CCN(C)CC2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.88', 'le': '0.17', 'lle': '0.30', 'sei': '5.62'}",CHEMBL3963300,,CHEMBL3963300,7.70,0,http://www.openphacts.org/units/Nanomolar,2882746,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405217,17771486,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(CCO)CC2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.98', 'le': '0.16', 'lle': '0.72', 'sei': '4.75'}",CHEMBL3964058,,CHEMBL3964058,7.05,0,http://www.openphacts.org/units/Nanomolar,2882747,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405218,17771487,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.51', 'le': '0.19', 'lle': '0.71', 'sei': '5.96'}",CHEMBL2031026,,CHEMBL2031026,8.00,0,http://www.openphacts.org/units/Nanomolar,2882748,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405219,17771488,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.96', 'le': '0.17', 'lle': '0.58', 'sei': '4.83'}",CHEMBL3975289,,CHEMBL3975289,7.30,0,http://www.openphacts.org/units/Nanomolar,2882749,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405220,17771489,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.78', 'le': '0.18', 'lle': '-1.58', 'sei': '6.18'}",CHEMBL3942482,,CHEMBL3942482,7.52,0,http://www.openphacts.org/units/Nanomolar,2882750,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405221,17771490,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC(F)(F)F)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.76', 'le': '0.17', 'lle': '-0.93', 'sei': '5.72'}",CHEMBL3960836,,CHEMBL3960836,6.96,0,http://www.openphacts.org/units/Nanomolar,2882751,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405222,17771491,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(CCC(F)(F)F)CCC(F)(F)F)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.17', 'lle': '-0.55', 'sei': '5.83'}",CHEMBL3986056,,CHEMBL3986056,7.10,0,http://www.openphacts.org/units/Nanomolar,2882752,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,405223,17771492,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc2c(c1)OCCO2,,,CHEMBL3886736,,2016,"{'bei': '8.74', 'le': '0.17', 'lle': '-0.37', 'sei': '5.11'}",CHEMBL3954559,,CHEMBL3954559,7.16,0,http://www.openphacts.org/units/Nanomolar,2882753,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405224,17771493,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,CHEMBL3886736,,2016,"{'bei': '8.38', 'le': '0.16', 'lle': '-2.77', 'sei': '6.00'}",CHEMBL3940231,,CHEMBL3940231,7.30,0,http://www.openphacts.org/units/Nanomolar,2882754,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405225,17771494,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc(C(=O)OC)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.61', 'le': '0.17', 'lle': '-0.49', 'sei': '4.76'}",CHEMBL3937806,,CHEMBL3937806,7.05,0,http://www.openphacts.org/units/Nanomolar,2882755,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405226,17771495,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.12', 'le': '0.16', 'lle': '1.85', 'sei': '4.55'}",CHEMBL3889549,,CHEMBL3889549,7.16,0,http://www.openphacts.org/units/Nanomolar,2882756,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405227,17771496,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)cc1C,,,CHEMBL3886736,,2016,"{'bei': '9.40', 'le': '0.18', 'lle': '-0.05', 'sei': '5.46'}",CHEMBL3917569,,CHEMBL3917569,6.64,0,http://www.openphacts.org/units/Nanomolar,2882757,=,37,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,230.0
,405228,17771497,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.94', 'le': '0.18', 'lle': '-1.96', 'sei': '6.33'}",CHEMBL3945459,,CHEMBL3945459,7.70,0,http://www.openphacts.org/units/Nanomolar,2882758,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405229,17771498,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.89', 'le': '0.18', 'lle': '-1.00', 'sei': '5.69'}",CHEMBL3906577,,CHEMBL3906577,8.07,0,http://www.openphacts.org/units/Nanomolar,2882759,=,37,1,=,,IC50,nM,,8.49,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.49
,405230,17771499,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.69', 'le': '0.18', 'lle': '-0.42', 'sei': '5.51'}",CHEMBL3938217,,CHEMBL3938217,8.00,0,http://www.openphacts.org/units/Nanomolar,2882760,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405231,17771500,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.24', 'le': '0.18', 'lle': '-1.12', 'sei': '6.29'}",CHEMBL3964186,,CHEMBL3964186,6.58,0,http://www.openphacts.org/units/Nanomolar,2882761,=,37,1,=,,IC50,nM,,260.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,260.0
,405232,17771501,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.11', 'le': '0.20', 'lle': '0.93', 'sei': '5.78'}",CHEMBL3931099,,CHEMBL3931099,7.22,0,http://www.openphacts.org/units/Nanomolar,2882762,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405233,17771502,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C(F)(F)F)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.37', 'le': '0.19', 'lle': '-0.14', 'sei': '6.03'}",CHEMBL3894163,,CHEMBL3894163,7.52,0,http://www.openphacts.org/units/Nanomolar,2882763,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405234,17771503,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(F)(F)F)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.57', 'le': '0.19', 'lle': '-0.89', 'sei': '7.07'}",CHEMBL3968982,,CHEMBL3968982,7.40,0,http://www.openphacts.org/units/Nanomolar,2882764,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405235,17771504,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.77', 'le': '0.18', 'lle': '-0.81', 'sei': '5.48'}",CHEMBL3936947,,CHEMBL3936947,8.05,0,http://www.openphacts.org/units/Nanomolar,2882765,=,37,1,=,,IC50,nM,,8.85,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.85
,405236,17771505,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '5.81', 'le': None, 'lle': None, 'sei': None}",CHEMBL3927011,,CHEMBL3927011,6.00,0,http://www.openphacts.org/units/Nanomolar,2882766,=,37,1,=,,IC50,nM,,1010.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1010.0
,405237,17771506,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.95', 'le': '0.20', 'lle': '0.67', 'sei': '5.42'}",CHEMBL3901575,,CHEMBL3901575,8.00,0,http://www.openphacts.org/units/Nanomolar,2882767,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405238,17771507,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)CCN4CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.26', 'le': '0.20', 'lle': '1.34', 'sei': '5.54'}",CHEMBL3931548,,CHEMBL3931548,8.04,0,http://www.openphacts.org/units/Nanomolar,2882768,=,37,1,=,,IC50,nM,,9.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.15
,405239,17771508,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.79', 'le': '0.21', 'lle': '0.40', 'sei': '6.49'}",CHEMBL3927392,,CHEMBL3927392,8.11,0,http://www.openphacts.org/units/Nanomolar,2882769,=,37,1,=,,IC50,nM,,7.84,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.84
,405240,17771509,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(ccn4CC)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.75', 'le': '0.21', 'lle': '1.15', 'sei': '5.75'}",CHEMBL3912610,,CHEMBL3912610,8.45,0,http://www.openphacts.org/units/Nanomolar,2882770,=,37,1,=,,IC50,nM,,3.59,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.59
,405241,17771510,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(-c2ccc(CC(=O)O)cc2)cc1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.56', 'le': None, 'lle': None, 'sei': None}",CHEMBL3963735,,CHEMBL3963735,8.00,0,http://www.openphacts.org/units/Nanomolar,2882771,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405242,17771511,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)NCc2ccc(-c3ccc(CC(=O)O)cc3)cc2)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3c(c2)CCN3Cc2ccc(Cl)c(Cl)c2)cc1C(=O)N1CCc2ccccc2C1,,,CHEMBL3886736,,2016,"{'bei': '7.28', 'le': None, 'lle': None, 'sei': None}",CHEMBL3918064,,CHEMBL3918064,7.30,0,http://www.openphacts.org/units/Nanomolar,2882772,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405243,17771512,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,CHEMBL3886736,,2016,"{'bei': '8.13', 'le': '0.17', 'lle': '-3.49', 'sei': '6.57'}",CHEMBL3890955,,CHEMBL3890955,8.00,0,http://www.openphacts.org/units/Nanomolar,2882773,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405244,17771513,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,CHEMBL3886736,,2016,"{'bei': '7.87', 'le': '0.16', 'lle': '-3.98', 'sei': '6.08'}",CHEMBL3960038,,CHEMBL3960038,7.40,0,http://www.openphacts.org/units/Nanomolar,2882774,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405245,17771514,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,CHEMBL3886736,,2016,"{'bei': '7.61', 'le': '0.16', 'lle': '-4.23', 'sei': '5.88'}",CHEMBL3899265,,CHEMBL3899265,7.16,0,http://www.openphacts.org/units/Nanomolar,2882775,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405246,17771515,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.40', 'le': '0.16', 'lle': '-2.32', 'sei': '5.11'}",CHEMBL2030850,,CHEMBL2030850,7.00,1,http://www.openphacts.org/units/Nanomolar,2882776,=,37,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,405247,17771516,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.88', 'le': '0.17', 'lle': '-2.27', 'sei': '5.62'}",CHEMBL3927294,,CHEMBL3927294,7.70,0,http://www.openphacts.org/units/Nanomolar,2882777,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405248,17771517,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1,,,CHEMBL3886736,,2016,"{'bei': '8.72', 'le': None, 'lle': None, 'sei': None}",CHEMBL3939961,,CHEMBL3939961,6.24,0,http://www.openphacts.org/units/Nanomolar,2882778,=,37,1,=,,IC50,nM,,580.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,580.0
,405249,17771518,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.71', 'le': '0.16', 'lle': '-1.75', 'sei': '5.26'}",CHEMBL2030851,,CHEMBL2030851,6.89,1,http://www.openphacts.org/units/Nanomolar,2882779,=,37,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,130.0
,405250,17771519,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.33', 'le': '0.18', 'lle': '-1.59', 'sei': '5.88'}",CHEMBL2030852,,CHEMBL2030852,7.70,0,http://www.openphacts.org/units/Nanomolar,2882780,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405251,17771520,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.82', 'le': '0.19', 'lle': '-1.18', 'sei': '6.20'}",CHEMBL2030853,,CHEMBL2030853,8.11,1,http://www.openphacts.org/units/Nanomolar,2882781,=,37,1,=,,IC50,nM,,7.83,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.83
,405252,17771521,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1,,,CHEMBL3886736,,2016,"{'bei': '10.36', 'le': '0.19', 'lle': '1.32', 'sei': '5.43'}",CHEMBL2030856,,CHEMBL2030856,7.70,1,http://www.openphacts.org/units/Nanomolar,2882782,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405253,17771522,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '7.85', 'le': '0.16', 'lle': '-3.69', 'sei': '5.62'}",CHEMBL3966210,,CHEMBL3966210,7.70,0,http://www.openphacts.org/units/Nanomolar,2882783,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405254,17771523,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.53', 'le': '0.19', 'lle': '-1.74', 'sei': '6.26'}",CHEMBL2030864,,CHEMBL2030864,8.20,0,http://www.openphacts.org/units/Nanomolar,2882784,=,37,1,=,,IC50,nM,,6.37,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.37
,405255,17771524,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(OCC(O)CO)cc1,,,CHEMBL3886736,,2016,"{'bei': '10.25', 'le': '0.19', 'lle': '2.51', 'sei': '4.72'}",CHEMBL3982792,,CHEMBL3982792,8.09,0,http://www.openphacts.org/units/Nanomolar,2882785,=,37,1,=,,IC50,nM,,8.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.13
,405256,17771525,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1,,,CHEMBL3886736,,2016,"{'bei': '10.98', 'le': '0.21', 'lle': '1.79', 'sei': '5.64'}",CHEMBL2030859,,CHEMBL2030859,8.00,0,http://www.openphacts.org/units/Nanomolar,2882786,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405257,17771526,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.86', 'le': '0.19', 'lle': '0.36', 'sei': '5.72'}",CHEMBL3912906,,CHEMBL3912906,6.96,0,http://www.openphacts.org/units/Nanomolar,2882787,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405258,17771527,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CC(=O)NC)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.34', 'le': '0.16', 'lle': '0.56', 'sei': '4.22'}",CHEMBL3890311,,CHEMBL3890311,6.37,0,http://www.openphacts.org/units/Nanomolar,2882788,=,37,1,=,,IC50,nM,,430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,430.0
,405259,17771528,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CCCN(C)C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.62', 'le': '0.16', 'lle': '-0.31', 'sei': '5.36'}",CHEMBL3921891,,CHEMBL3921891,6.70,0,http://www.openphacts.org/units/Nanomolar,2882789,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405260,17771529,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CC(=O)O)c(-c2ccc(C(=O)NS(=O)(=O)c3cccc4ccccc34)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.17', 'lle': '0.70', 'sei': '4.31'}",CHEMBL3962772,,CHEMBL3962772,6.85,0,http://www.openphacts.org/units/Nanomolar,2882790,=,37,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,405261,17771530,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CCN2CCOCC2)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '8.29', 'le': '0.16', 'lle': '1.16', 'sei': '4.48'}",CHEMBL3893805,,CHEMBL3893805,6.92,0,http://www.openphacts.org/units/Nanomolar,2882791,=,37,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,405262,17771531,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL3886736,,2016,"{'bei': '9.48', 'le': '0.21', 'lle': '1.63', 'sei': '5.52'}",CHEMBL3897725,,CHEMBL3897725,8.16,0,http://www.openphacts.org/units/Nanomolar,2882792,=,37,1,=,,IC50,nM,,6.97,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.97
,405263,17771532,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.85', 'le': '0.17', 'lle': '-1.04', 'sei': '5.33'}",CHEMBL3965698,,CHEMBL3965698,6.22,0,http://www.openphacts.org/units/Nanomolar,2882793,=,37,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,600.0
,405264,17771533,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ccc(Br)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '10.15', 'le': '0.21', 'lle': '-1.04', 'sei': '8.03'}",CHEMBL3986556,,CHEMBL3986556,8.00,0,http://www.openphacts.org/units/Nanomolar,2882794,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405265,17771534,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '9.75', 'le': '0.19', 'lle': '0.19', 'sei': '5.44'}",CHEMBL3957861,,CHEMBL3957861,7.22,0,http://www.openphacts.org/units/Nanomolar,2882795,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405266,17771535,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.44', 'le': '0.20', 'lle': '-2.03', 'sei': '7.11'}",CHEMBL3912240,,CHEMBL3912240,8.00,0,http://www.openphacts.org/units/Nanomolar,2882796,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405267,17771536,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '10.79', 'le': '0.22', 'lle': '1.15', 'sei': '6.07'}",CHEMBL2031009,,CHEMBL2031009,8.06,1,http://www.openphacts.org/units/Nanomolar,2882797,=,37,1,=,,IC50,nM,,8.78,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.78
,405268,17771537,[],CHEMBL3888503,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL3886736,,2016,"{'bei': '11.12', 'le': '0.22', 'lle': '1.42', 'sei': '5.98'}",CHEMBL2031008,,CHEMBL2031008,8.29,0,http://www.openphacts.org/units/Nanomolar,2882798,=,37,1,=,,IC50,nM,,5.09,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.09
,,17999571,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '12.00', 'le': '0.22', 'lle': '-0.16', 'sei': '4.00'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,6.22,0,http://www.openphacts.org/units/Nanomolar,2982465,=,1,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.6
,,17999572,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '14.81', 'le': '0.27', 'lle': '0.57', 'sei': '5.97'}",CHEMBL4091074,,CHEMBL4091074,4.54,0,http://www.openphacts.org/units/Nanomolar,2982468,=,1,1,=,,IC50,nM,,29050.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,29.05
,,17999573,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '16.10', 'le': '0.29', 'lle': '0.41', 'sei': '7.01'}",CHEMBL4063192,,CHEMBL4063192,4.67,0,http://www.openphacts.org/units/Nanomolar,2982467,=,1,1,=,,IC50,nM,,21120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,21.12
,,17999574,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,Clc1cccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)c1,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '19.89', 'le': '0.38', 'lle': '1.57', 'sei': '9.26'}",CHEMBL4075044,,CHEMBL4075044,6.18,0,http://www.openphacts.org/units/Nanomolar,2982474,=,1,1,=,,IC50,nM,,660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.66
,,17999575,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=[N+]([O-])c1ccc(Nc2nnc(-c3c[nH]c4ccccc34)o2)cc1,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '16.86', 'le': '0.31', 'lle': '1.55', 'sei': '4.93'}",CHEMBL4066452,,CHEMBL4066452,5.42,0,http://www.openphacts.org/units/Nanomolar,2982472,=,1,1,=,,IC50,nM,,3830.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.83
,,17999576,[],CHEMBL4001923,Inhibition of biotinylated Bim peptide binding to His-tagged Bcl-2 (unknown origin) preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000357,single protein format,O=[N+]([O-])c1ccccc1Nc1nnc(-c2c[nH]c3ccccc23)o1,,,CHEMBL4000233,Bioorg Med Chem Lett,2017,"{'bei': '18.38', 'le': '0.34', 'lle': '2.04', 'sei': '5.38'}",CHEMBL4102399,,CHEMBL4102399,5.91,0,http://www.openphacts.org/units/Nanomolar,2982470,=,1,1,=,,IC50,nM,,1240.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.24
,,18243583,[],CHEMBL4052842,Inhibition of FITC-labeled Bim BH3 binding to GST-tagged Bcl-2 (unknown origin) preincubated for 2 mins followed by FITC-Bim-BH3 addition measured after 10 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL4052581,J Med Chem,2017,"{'bei': '12.80', 'le': '0.23', 'lle': '1.73', 'sei': '5.03'}",CHEMBL1269107,,CHEMBL1269107,7.51,0,http://www.openphacts.org/units/Nanomolar,3027336,=,1,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,,18390898,[],CHEMBL4147762,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COC1=CC(c2cc3ccccc3[nH]2)=N/C1=C\c1[nH]c(C)cc1C,,,CHEMBL4145520,Eur J Med Chem,2018,"{'bei': '18.76', 'le': '0.34', 'lle': '1.46', 'sei': '11.20'}",CHEMBL408194,OBATOCLAX,CHEMBL408194,5.96,1,http://www.openphacts.org/units/Nanomolar,3052596,=,1,1,=,,IC50,nM,,1110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.11
,,18472115,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '7.00', 'le': '0.14', 'lle': '-2.40', 'sei': '5.37'}",CHEMBL4215940,,CHEMBL4215940,6.71,0,http://www.openphacts.org/units/Nanomolar,3066011,=,1,1,=,,IC50,nM,,193.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,193.0
,,18472116,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)n1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '12.32', 'le': '0.24', 'lle': '2.19', 'sei': '8.19'}",CHEMBL4218253,,CHEMBL4218253,7.17,0,http://www.openphacts.org/units/Nanomolar,3066021,=,1,1,=,,IC50,nM,,67.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,67.4
,,18472117,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)CC1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '11.29', 'le': '0.23', 'lle': '2.42', 'sei': '8.89'}",CHEMBL4213316,,CHEMBL4213316,6.78,0,http://www.openphacts.org/units/Nanomolar,3066020,=,1,1,=,,IC50,nM,,168.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,168.0
,,18472118,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(C)(=O)=O)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '12.22', 'le': '0.25', 'lle': '1.49', 'sei': '9.04'}",CHEMBL4204650,,CHEMBL4204650,6.30,0,http://www.openphacts.org/units/Nanomolar,3066019,=,1,1,=,,IC50,nM,,495.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,495.0
,,18472119,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '9.36', 'le': '0.18', 'lle': '-0.53', 'sei': '4.73'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,8.13,0,http://www.openphacts.org/units/Nanomolar,3066018,=,1,1,=,,IC50,nM,,7.39,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.39
,,18472120,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.20', 'le': '0.17', 'lle': '-0.84', 'sei': '6.22'}",CHEMBL443684,NAVITOCLAX,CHEMBL443684,7.99,0,http://www.openphacts.org/units/Nanomolar,3066017,=,1,1,=,,IC50,nM,,10.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.3
,,18472121,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CNC2(Cn3cnc4ccc(C(=O)NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)cc43)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,,CHEMBL4204583,,CHEMBL4204583,,0,http://www.openphacts.org/units/Nanomolar,3066016,>,1,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,,18472122,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CNC2(Cn3cnc4cc(C(=O)NS(=O)(=O)c5ccc(N[C@H](CCN6CCOCC6)CSc6ccccc6)c(S(=O)(=O)C(F)(F)F)c5)ccc43)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '6.97', 'le': '0.14', 'lle': '-2.21', 'sei': '4.59'}",CHEMBL4218405,,CHEMBL4218405,6.97,0,http://www.openphacts.org/units/Nanomolar,3066015,=,1,1,=,,IC50,nM,,108.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,108.0
,,18472123,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3nc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)sc3C2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '7.79', 'le': '0.16', 'lle': '-1.11', 'sei': '5.38'}",CHEMBL4216380,,CHEMBL4216380,7.42,0,http://www.openphacts.org/units/Nanomolar,3066014,=,1,1,=,,IC50,nM,,38.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.1
,,18472124,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3sc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3C2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '7.61', 'le': '0.16', 'lle': '-1.89', 'sei': '5.78'}",CHEMBL4211496,,CHEMBL4211496,7.24,0,http://www.openphacts.org/units/Nanomolar,3066013,=,1,1,=,,IC50,nM,,57.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.9
,,18472125,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCc3cc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)ccc3C2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.35', 'le': '0.17', 'lle': '-1.17', 'sei': '6.31'}",CHEMBL4216466,,CHEMBL4216466,7.90,0,http://www.openphacts.org/units/Nanomolar,3066012,=,1,1,=,,IC50,nM,,12.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.6
,,18472135,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(CN6CC(F)(F)C6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.62', 'le': '0.18', 'lle': '0.84', 'sei': '6.05'}",CHEMBL4211198,,CHEMBL4211198,7.76,0,http://www.openphacts.org/units/Nanomolar,3066030,=,1,1,=,,IC50,nM,,17.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.3
,,18472136,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(CN6CCOCC6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.75', 'le': '0.18', 'lle': '1.57', 'sei': '5.82'}",CHEMBL4207006,,CHEMBL4207006,7.84,0,http://www.openphacts.org/units/Nanomolar,3066029,=,1,1,=,,IC50,nM,,14.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.5
,,18472137,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)CN5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.61', 'le': '0.17', 'lle': '0.23', 'sei': '5.99'}",CHEMBL4206829,,CHEMBL4206829,7.68,0,http://www.openphacts.org/units/Nanomolar,3066028,=,1,1,=,,IC50,nM,,20.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.7
,,18472138,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CC5CC5)C(=O)N5CCOCC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '7.91', 'le': '0.16', 'lle': '0.19', 'sei': '4.93'}",CHEMBL4208633,,CHEMBL4208633,7.17,0,http://www.openphacts.org/units/Nanomolar,3066027,=,1,1,=,,IC50,nM,,68.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,68.2
,,18472139,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CC(F)(F)C6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.57', 'le': '0.18', 'lle': '0.03', 'sei': '6.26'}",CHEMBL4202464,,CHEMBL4202464,7.46,0,http://www.openphacts.org/units/Nanomolar,3066026,=,1,1,=,,IC50,nM,,34.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.8
,,18472140,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5(CN6CCOCC6)CC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '8.55', 'le': '0.17', 'lle': '0.58', 'sei': '5.76'}",CHEMBL4209752,,CHEMBL4209752,7.39,0,http://www.openphacts.org/units/Nanomolar,3066025,=,1,1,=,,IC50,nM,,40.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.7
,,18472141,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCO)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '9.37', 'le': '0.19', 'lle': '1.37', 'sei': '5.76'}",CHEMBL4209621,,CHEMBL4209621,7.34,0,http://www.openphacts.org/units/Nanomolar,3066024,=,1,1,=,,IC50,nM,,46.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,46.0
,,18472142,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N5CC(F)(F)C5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '9.15', 'le': '0.19', 'lle': '0.34', 'sei': '6.85'}",CHEMBL4206007,,CHEMBL4206007,7.33,0,http://www.openphacts.org/units/Nanomolar,3066023,=,1,1,=,,IC50,nM,,46.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,46.6
,,18472143,[],CHEMBL4182824,Displacement of Bax-derived peptide from Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CCC(C)(C)C4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL4177735,Bioorg Med Chem,2018,"{'bei': '9.54', 'le': '0.20', 'lle': '0.59', 'sei': '6.71'}",CHEMBL4210809,,CHEMBL4210809,7.19,0,http://www.openphacts.org/units/Nanomolar,3066022,=,1,1,=,,IC50,nM,,65.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,65.1
,,18752589,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCNC3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.08', 'le': '0.18', 'lle': '1.72', 'sei': '3.84'}",CHEMBL4284025,,CHEMBL4284025,8.72,0,http://www.openphacts.org/units/Nanomolar,3115802,=,1,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,,18752590,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.73', 'le': '0.15', 'lle': '1.61', 'sei': '3.16'}",CHEMBL4294620,,CHEMBL4294620,7.54,0,http://www.openphacts.org/units/Nanomolar,3115801,=,1,1,=,,IC50,nM,,28.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.7
,,18752591,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2[C@@H](C)C(OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)C[C@H]3CO)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.35', 'le': '0.14', 'lle': '1.24', 'sei': '3.01'}",CHEMBL4287383,,CHEMBL4287383,7.17,0,http://www.openphacts.org/units/Nanomolar,3115800,=,1,1,=,,IC50,nM,,67.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,67.1
,,18752592,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.73', 'le': '0.15', 'lle': '1.75', 'sei': '3.08'}",CHEMBL4279468,,CHEMBL4279468,7.30,0,http://www.openphacts.org/units/Nanomolar,3115799,=,1,1,=,,IC50,nM,,50.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.1
,,18752593,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@]3(C)O[C@]24[C@H]1CC[C@@H](C)[C@@H]4C[C@H]3O,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.92', 'le': '0.15', 'lle': '1.89', 'sei': '3.27'}",CHEMBL4290795,,CHEMBL4290795,7.50,0,http://www.openphacts.org/units/Nanomolar,3115798,=,1,1,=,,IC50,nM,,31.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.9
,,18752594,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.11', 'le': '0.17', 'lle': '1.88', 'sei': '3.90'}",CHEMBL4282932,,CHEMBL4282932,8.46,0,http://www.openphacts.org/units/Nanomolar,3115797,=,1,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,,18752595,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.31', 'le': '0.18', 'lle': '2.02', 'sei': '4.14'}",CHEMBL4294191,,CHEMBL4294191,8.66,0,http://www.openphacts.org/units/Nanomolar,3115796,=,1,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,,18752596,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24O3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.57', 'le': '0.18', 'lle': '1.69', 'sei': '4.38'}",CHEMBL4286311,,CHEMBL4286311,8.74,0,http://www.openphacts.org/units/Nanomolar,3115795,=,1,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,,18752597,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32O4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.98', 'le': '0.17', 'lle': '1.08', 'sei': '4.28'}",CHEMBL4279038,,CHEMBL4279038,8.55,0,http://www.openphacts.org/units/Nanomolar,3115794,=,1,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,,18752598,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.36', 'le': '0.18', 'lle': '-0.53', 'sei': '4.73'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,8.13,1,http://www.openphacts.org/units/Nanomolar,3115793,=,1,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,,18752599,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@H]1OC2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]([C@]1(C)CC(=O)N1CCN(c5ccc(C(=O)NS(=O)(=O)c6ccc(NCC7CCOCC7)c([N+](=O)[O-])c6)c(Oc6cnc7[nH]ccc7c6)c5)CC1)[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.66', 'le': '0.15', 'lle': '0.98', 'sei': '3.17'}",CHEMBL4278774,,CHEMBL4278774,7.46,0,http://www.openphacts.org/units/Nanomolar,3115792,=,1,1,=,,IC50,nM,,34.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.7
,,18752600,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@@H]2[C@]34OO[C@](C)(CC[C@@H]13)O[C@H]4O[C@]2(C)C(=O)N1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.61', 'le': '0.17', 'lle': '2.02', 'sei': '3.49'}",CHEMBL4286682,,CHEMBL4286682,7.89,0,http://www.openphacts.org/units/Nanomolar,3115791,=,1,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,,18752601,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CC(=O)N2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.39', 'le': '0.16', 'lle': '1.41', 'sei': '3.51'}",CHEMBL4277317,,CHEMBL4277317,7.92,0,http://www.openphacts.org/units/Nanomolar,3115790,=,1,1,=,,IC50,nM,,11.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.9
,,18752602,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@H](N(C)CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.11', 'le': '0.16', 'lle': '1.30', 'sei': '3.67'}",CHEMBL4285268,,CHEMBL4285268,7.78,0,http://www.openphacts.org/units/Nanomolar,3115789,=,1,1,=,,IC50,nM,,16.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.7
,,18752603,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2[C@@](C)(O)[C@@H](OCCN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '7.34', 'le': '0.14', 'lle': '1.38', 'sei': '2.96'}",CHEMBL4280705,,CHEMBL4280705,7.06,0,http://www.openphacts.org/units/Nanomolar,3115788,=,1,1,=,,IC50,nM,,86.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,86.5
,,18752604,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](OCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.77', 'le': '0.17', 'lle': '1.73', 'sei': '3.80'}",CHEMBL4288614,,CHEMBL4288614,8.30,0,http://www.openphacts.org/units/Nanomolar,3115787,=,1,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,,18752605,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CCCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '9.45', 'le': '0.18', 'lle': '1.55', 'sei': '4.27'}",CHEMBL4295247,,CHEMBL4295247,8.92,0,http://www.openphacts.org/units/Nanomolar,3115786,=,1,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,,18752606,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1[C@@H](CCN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)O[C@@H]2O[C@@]3(C)CC[C@H]4[C@H](C)CC[C@@H]1[C@@]24OO3,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.62', 'le': '0.17', 'lle': '1.03', 'sei': '3.83'}",CHEMBL4278369,,CHEMBL4278369,8.01,0,http://www.openphacts.org/units/Nanomolar,3115785,=,1,1,=,,IC50,nM,,9.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.7
,,18752607,[],CHEMBL4264659,Inhibition of FAM-labelled Bax binding to Bcl2 (unknown origin) after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CC[C@H]2C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)=C(C(F)(F)F)O[C@@H]3O[C@@]4(C)CC[C@@H]1[C@]32OO4,,,CHEMBL4261603,Eur J Med Chem,2018,"{'bei': '8.48', 'le': '0.16', 'lle': '0.81', 'sei': '3.93'}",CHEMBL4292460,,CHEMBL4292460,8.21,0,http://www.openphacts.org/units/Nanomolar,3115784,=,1,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,,18916446,[],CHEMBL4322141,Inhibition of Bcl2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(c2ccccc2)c2ccccc2)nn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL4321790,J Med Chem,2019,"{'bei': '13.06', 'le': '0.24', 'lle': '1.18', 'sei': '8.91'}",CHEMBL503454,,CHEMBL503454,7.52,1,http://www.openphacts.org/units/Nanomolar,3155623,=,1,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,,18917097,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(C#N)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '13.51', 'le': '0.30', 'lle': '-0.11', 'sei': '8.72'}",CHEMBL4470807,,CHEMBL4470807,5.64,0,http://www.openphacts.org/units/Nanomolar,3155798,=,1,1,=,,IC50,nM,,2310.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.31
,,18917098,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)(C)c1ccc(C(=O)NCCN2C(=O)c3cccc4c(Sc5ccc(Br)cc5)ccc(c34)C2=O)cc1,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '9.36', 'le': '0.20', 'lle': '-1.58', 'sei': '8.27'}",CHEMBL4530348,,CHEMBL4530348,5.50,0,http://www.openphacts.org/units/Nanomolar,3155799,=,1,1,=,,IC50,nM,,3180.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.18
,,18917099,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,COC(=O)CCNC1=C(C#N)C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc1c23,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '10.83', 'le': '0.24', 'lle': '0.00', 'sei': '6.75'}",CHEMBL4552126,,CHEMBL4552126,5.34,0,http://www.openphacts.org/units/Nanomolar,3155800,=,1,1,=,,IC50,nM,,4520.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.52
,,18917100,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,COC(=O)CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '9.34', 'le': '0.20', 'lle': '0.12', 'sei': '5.73'}",CHEMBL4591149,,CHEMBL4591149,5.32,0,http://www.openphacts.org/units/Nanomolar,3155801,=,1,1,=,,IC50,nM,,4780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.78
,,18917101,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '5.64', 'le': '0.12', 'lle': '0.16', 'sei': '2.52'}",CHEMBL4455274,,CHEMBL4455274,4.82,0,http://www.openphacts.org/units/Nanomolar,3155802,=,1,1,=,,IC50,nM,,15210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,15.21
,,18917102,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '5.67', 'le': '0.12', 'lle': '-0.44', 'sei': '2.62'}",CHEMBL4568556,,CHEMBL4568556,5.00,0,http://www.openphacts.org/units/Nanomolar,3155803,=,1,1,=,,IC50,nM,,10020.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.02
,,18917103,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '6.89', 'le': '0.14', 'lle': '0.05', 'sei': '3.28'}",CHEMBL4460727,,CHEMBL4460727,6.27,0,http://www.openphacts.org/units/Nanomolar,3155797,=,1,1,=,,IC50,nM,,540.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.54
,,18917104,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O)NCCCCCCNC(=O)CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '4.76', 'le': None, 'lle': None, 'sei': None}",CHEMBL4476628,,CHEMBL4476628,4.87,0,http://www.openphacts.org/units/Nanomolar,3155804,=,1,1,=,,IC50,nM,,13470.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,13.47
,,18917105,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCOCCOCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '5.63', 'le': '0.12', 'lle': '0.62', 'sei': '2.53'}",CHEMBL4565306,,CHEMBL4565306,5.31,0,http://www.openphacts.org/units/Nanomolar,3155805,=,1,1,=,,IC50,nM,,4940.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.94
,,18917106,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(CCCCC(=O)NCCN1C(=O)c2cccc3c(Sc4ccc(Br)cc4)ccc(c23)C1=O)NCCCCCCCCNc1cccc2c1C(=O)N(C1CCC(=O)NC1=O)C2=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '5.45', 'le': '0.11', 'lle': '-1.88', 'sei': '2.68'}",CHEMBL4560793,,CHEMBL4560793,5.12,0,http://www.openphacts.org/units/Nanomolar,3155806,=,1,1,=,,IC50,nM,,7660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.66
,,18917107,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(NCCC(=O)NCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '6.40', 'le': '0.13', 'lle': '0.19', 'sei': '2.80'}",CHEMBL4454922,,CHEMBL4454922,4.98,0,http://www.openphacts.org/units/Nanomolar,3155807,=,1,1,=,,IC50,nM,,10480.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.48
,,18917108,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(NCCC(=O)NCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '6.22', 'le': '0.13', 'lle': '-0.56', 'sei': '2.82'}",CHEMBL4572365,,CHEMBL4572365,5.01,0,http://www.openphacts.org/units/Nanomolar,3155808,=,1,1,=,,IC50,nM,,9710.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.71
,,18917109,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(NCCC(=O)NCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '6.85', 'le': '0.14', 'lle': '-0.64', 'sei': '3.22'}",CHEMBL4533471,,CHEMBL4533471,5.71,0,http://www.openphacts.org/units/Nanomolar,3155809,=,1,1,=,,IC50,nM,,1940.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.94
,,18917110,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(NCCC(=O)NCCCCCC(=O)NCCCCCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '5.21', 'le': '0.11', 'lle': '-2.10', 'sei': '2.39'}",CHEMBL4436367,,CHEMBL4436367,4.93,0,http://www.openphacts.org/units/Nanomolar,3155810,=,1,1,=,,IC50,nM,,11650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,11.65
,,18917111,[],CHEMBL4322321,Inhibition of biotinylated Bim peptide (81 to 106 residues) binding to His-tagged human Bcl-2 expressed in Escherichia coli BL21 (DE3) cells preincubated for 1 hr followed by biotinylated Bim peptide addition measured after 2 hrs by ELISA,B,,,BAO_0000190,BAO_0000219,cell-based format,N#CC1=C(NCCC(=O)NCCOCCOCCNc2cccc3c2C(=O)N(C2CCC(=O)NC2=O)C3=O)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4321796,J Med Chem,2019,"{'bei': '6.53', 'le': '0.13', 'lle': '0.82', 'sei': '2.88'}",CHEMBL4579464,,CHEMBL4579464,5.65,0,http://www.openphacts.org/units/Nanomolar,3155811,=,1,1,=,,IC50,nM,,2240.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.24
,,18954871,[],CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4330103,Bioorg Med Chem Lett,2019,"{'bei': '7.38', 'le': '0.14', 'lle': '-1.66', 'sei': '3.13'}",CHEMBL4579774,,CHEMBL4579774,6.64,0,http://www.openphacts.org/units/Nanomolar,3162111,=,1,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.23
,,18954872,[],CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4330103,Bioorg Med Chem Lett,2019,"{'bei': '7.25', 'le': '0.14', 'lle': '-2.07', 'sei': '3.12'}",CHEMBL4469267,,CHEMBL4469267,6.62,0,http://www.openphacts.org/units/Nanomolar,3162112,=,1,1,=,,IC50,nM,,240.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.24
,,18954873,[],CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCCCCCC(=O)NO)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4330103,Bioorg Med Chem Lett,2019,"{'bei': '7.12', 'le': '0.14', 'lle': '-2.48', 'sei': '3.11'}",CHEMBL4592343,,CHEMBL4592343,6.60,0,http://www.openphacts.org/units/Nanomolar,3162113,=,1,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.25
,,18954874,[],CHEMBL4332203,Inhibition of FAM-Bid peptide binding to Bcl2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4330103,Bioorg Med Chem Lett,2019,"{'bei': '7.64', 'le': '0.15', 'lle': '-2.02', 'sei': '3.86'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,6.64,0,http://www.openphacts.org/units/Nanomolar,3162114,=,1,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.23
,,19055854,[],CHEMBL4356645,Inhibition of recombinant C-terminal His10x-tagged human Bcl-2 (2 to 211 residues) expressed in Escherichia coli cells interaction with biotinylated human Bim (51 to 76 residues) incubated for 60 mins by HTRF assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CO[C@H]1/C=C/C[C@H](C)[C@@H](C)S(=O)(=O)NC(=O)c2ccc3c(c2)N(C[C@@H]2CC[C@H]21)C[C@@]1(CCCc2cc(Cl)ccc21)CO3,,,CHEMBL4354823,J Med Chem,2019,"{'bei': '9.32', 'le': '0.19', 'lle': '-0.19', 'sei': '6.73'}",CHEMBL4446378,TAPOTOCLAX,CHEMBL4446378,5.71,0,http://www.openphacts.org/units/Nanomolar,3179404,=,1,1,=,,IC50,nM,,1930.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1930.0
,,19132494,[],CHEMBL4375085,Displacement of N-terminal fluorescein labelled Puma-BH3 peptide from human N-terminal thrombin cleavage site-fused/His6-tagged Bcl-2 expressed in Escherichia coliBL21(DE3) pLysS cells by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CCc1sc2ncnc(N[C@@H](C)C(=O)O)c2c1CC,Outside typical range,"Values for this activity type are unusually large/small, so may not be accurate",CHEMBL4373699,J Med Chem,2019,,CHEMBL4572199,,CHEMBL4572199,,0,http://www.openphacts.org/units/Nanomolar,3193205,=,1,1,=,,IC50,nM,,164000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,164.0
,,19146009,[],CHEMBL4378480,Inhibition of human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells by surface plasmon resonance assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CC[C@H](C)[C@H](NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCCNC(=N)N)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@@H](N)CCC(=O)O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCNC(=N)N)C(=O)O,,,CHEMBL4376822,J Med Chem,2020,"{'bei': '2.78', 'le': None, 'lle': None, 'sei': None}",CHEMBL2442251,,CHEMBL2442251,8.48,0,http://www.openphacts.org/units/Nanomolar,3195366,=,1,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,,19146013,[],CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,COc1cc2c(cc1C(CN1CCCC1)c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(C[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)cc1)OCO2,,,CHEMBL4376822,J Med Chem,2020,"{'bei': '7.85', 'le': '0.16', 'lle': '-0.70', 'sei': '5.47'}",CHEMBL4519659,,CHEMBL4519659,7.70,0,http://www.openphacts.org/units/Nanomolar,3195382,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.02
,,19146014,[],CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,C[N+](C)(CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-])CC(=O)O,,,CHEMBL4376822,J Med Chem,2020,"{'bei': '7.22', 'le': '0.14', 'lle': '-1.18', 'sei': '3.88'}",CHEMBL4453237,,CHEMBL4453237,6.30,0,http://www.openphacts.org/units/Nanomolar,3195380,=,1,1,=,,IC50,nM,,500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.5
,,19146015,[],CHEMBL4378481,Displacement of fluorescein labelled Puma-BH3 peptide from human BCl2 expressed in Escherichia coli BL21 (DE3) pLysS cells incubated for 2 hrs by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL4376822,J Med Chem,2020,"{'bei': '11.73', 'le': '0.22', 'lle': '1.14', 'sei': '6.97'}",CHEMBL4438456,,CHEMBL4438456,5.89,0,http://www.openphacts.org/units/Nanomolar,3195383,=,1,1,=,,IC50,nM,,1300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.3
,Not Determined,19282961,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(O)c1ccc(-c2ccc(F)cc2)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,,CHEMBL106708,,CHEMBL106708,,0,,3220108,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,Not Determined,19282962,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(O)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)F)c1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,,CHEMBL4524407,,CHEMBL4524407,,0,,3220109,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,Not Determined,19282963,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(O)c1ccc(-c2ccc(F)cc2S(=O)(=O)F)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,,CHEMBL4464321,,CHEMBL4464321,,0,,3220110,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,Not Determined,19282964,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(O)c1ccc(-c2ccc(F)c(S(=O)(=O)F)c2)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,,CHEMBL4437855,,CHEMBL4437855,,0,,3220111,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,,19282965,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)F)c1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '7.63', 'le': '0.16', 'lle': '0.23', 'sei': '3.45'}",CHEMBL4529727,,CHEMBL4529727,5.70,0,http://www.openphacts.org/units/Nanomolar,3220112,=,1,1,=,,IC50,nM,,2000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.0
,,19282966,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2S(=O)(=O)F)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '6.10', 'le': '0.12', 'lle': '-0.91', 'sei': '2.76'}",CHEMBL4473013,,CHEMBL4473013,4.56,0,http://www.openphacts.org/units/Nanomolar,3220113,=,1,1,=,,IC50,nM,,27600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,27.6
,,19282967,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)c(S(=O)(=O)F)c2)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '6.71', 'le': '0.14', 'lle': '-0.46', 'sei': '3.04'}",CHEMBL4584015,,CHEMBL4584015,5.01,0,http://www.openphacts.org/units/Nanomolar,3220114,=,1,1,=,,IC50,nM,,9700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.7
,,19282968,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '7.82', 'le': '0.15', 'lle': '-0.61', 'sei': '3.97'}",CHEMBL4592905,,CHEMBL4592905,5.20,0,http://www.openphacts.org/units/Nanomolar,3220115,=,1,1,=,,IC50,nM,,6300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.3
,,19282969,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)c1cc(C(=O)NS(=O)(=O)c2ccc(N[C@H](CCN3CCOCC3)CSc3ccccc3)c([N+](=O)[O-])c2)ccc1-c1ccc(F)cc1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,,CHEMBL4446373,,CHEMBL4446373,,0,http://www.openphacts.org/units/Nanomolar,3220116,>,1,1,>,,IC50,nM,,99000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,99.0
,,19282970,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(F)cc2)c(S(=O)(=O)O)c1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '5.71', 'le': '0.12', 'lle': '-0.81', 'sei': '2.30'}",CHEMBL4560892,,CHEMBL4560892,4.25,0,http://www.openphacts.org/units/Nanomolar,3220117,=,1,1,=,,IC50,nM,,55900.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,55.9
,,19282971,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,C#CCN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(-c3ccc(F)cc3)c(S(=O)(=O)F)c2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '7.21', 'le': '0.15', 'lle': '-0.20', 'sei': '4.01'}",CHEMBL4474764,,CHEMBL4474764,5.89,0,http://www.openphacts.org/units/Nanomolar,3220118,=,1,1,=,,IC50,nM,,1300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.3
,,19282972,[],CHEMBL4409525,Inhibition of recombinant human C-terminal 6xHis-tagged Bcl-2 (M1 to F212 residues) expressed in Escherichia coli using HyLite Fluor 647-labeled BIM peptide as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL4406861,Bioorg Med Chem Lett,2019,"{'bei': '8.93', 'le': '0.18', 'lle': '-0.13', 'sei': '6.78'}",CHEMBL443684,NAVITOCLAX,CHEMBL443684,8.70,0,http://www.openphacts.org/units/Nanomolar,3220119,=,1,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.002
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237697,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2C(F)(F)F)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.68', 'le': '0.19', 'lle': '-0.61', 'sei': '5.27'}",CHEMBL4863897,,CHEMBL4863897,9.07,0,http://www.openphacts.org/units/Nanomolar,3614857,=,1,1,=,,IC50,nM,,0.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.86
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237698,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.78', 'le': '0.19', 'lle': '-0.21', 'sei': '5.13'}",CHEMBL4868427,,CHEMBL4868427,8.82,0,http://www.openphacts.org/units/Nanomolar,3614858,=,1,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237699,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C2=C(CN3CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)CCC(C)(C)C2)cc1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.75', 'le': '0.19', 'lle': '0.40', 'sei': '4.65'}",CHEMBL4873467,,CHEMBL4873467,8.42,0,http://www.openphacts.org/units/Nanomolar,3614859,=,1,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237700,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccccc2C(F)(F)F)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.72', 'le': '0.19', 'lle': '-0.26', 'sei': '5.10'}",CHEMBL4861424,,CHEMBL4861424,8.77,0,http://www.openphacts.org/units/Nanomolar,3614861,=,1,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237701,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)c(Cl)c2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.71', 'le': '0.19', 'lle': '-0.58', 'sei': '5.29'}",CHEMBL4867128,,CHEMBL4867128,9.10,0,http://www.openphacts.org/units/Nanomolar,3614862,=,1,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237702,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '10.18', 'le': '0.20', 'lle': '0.50', 'sei': '5.45'}",CHEMBL4860213,,CHEMBL4860213,9.05,0,http://www.openphacts.org/units/Nanomolar,3614863,=,1,1,=,,IC50,nM,,0.89,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.89
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237703,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CC)CCCNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '10.38', 'le': '0.20', 'lle': '0.19', 'sei': '5.74'}",CHEMBL4852442,,CHEMBL4852442,9.52,0,http://www.openphacts.org/units/Nanomolar,3614864,=,1,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237704,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.57', 'le': '0.18', 'lle': '0.07', 'sei': '5.19'}",CHEMBL4858569,,CHEMBL4858569,8.62,0,http://www.openphacts.org/units/Nanomolar,3614865,=,1,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237705,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)C(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '8.88', 'le': '0.17', 'lle': '-0.87', 'sei': '4.71'}",CHEMBL4847514,,CHEMBL4847514,8.62,0,http://www.openphacts.org/units/Nanomolar,3614866,=,1,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237706,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.38', 'le': '0.18', 'lle': '-0.31', 'sei': '4.84'}",CHEMBL4862150,,CHEMBL4862150,8.33,0,http://www.openphacts.org/units/Nanomolar,3614867,=,1,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237707,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.98', 'le': '0.19', 'lle': '0.33', 'sei': '5.07'}",CHEMBL4860155,,CHEMBL4860155,8.72,0,http://www.openphacts.org/units/Nanomolar,3614868,=,1,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237708,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.97', 'le': '0.19', 'lle': '0.01', 'sei': '5.32'}",CHEMBL4878326,,CHEMBL4878326,9.00,0,http://www.openphacts.org/units/Nanomolar,3614869,=,1,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237709,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.08', 'le': '0.18', 'lle': '-0.66', 'sei': '4.77'}",CHEMBL4878411,,CHEMBL4878411,8.08,0,http://www.openphacts.org/units/Nanomolar,3614870,=,1,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237710,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.40', 'le': '0.18', 'lle': '-0.24', 'sei': '4.94'}",CHEMBL4855086,,CHEMBL4855086,8.36,0,http://www.openphacts.org/units/Nanomolar,3614871,=,1,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237711,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCCOC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.44', 'le': '0.18', 'lle': '-0.47', 'sei': '5.04'}",CHEMBL4855736,,CHEMBL4855736,8.52,0,http://www.openphacts.org/units/Nanomolar,3614872,=,1,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237712,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCSCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(C(F)(F)F)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '9.56', 'le': '0.19', 'lle': '-0.93', 'sei': '5.49'}",CHEMBL4858527,,CHEMBL4858527,8.78,0,http://www.openphacts.org/units/Nanomolar,3614873,=,1,1,=,,IC50,nM,,1.65,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.65
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237713,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(Oc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(C(F)(F)F)cc5)CC(C)(C)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-])C1CCOCC1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '8.76', 'le': '0.17', 'lle': '-1.34', 'sei': '4.75'}",CHEMBL4866646,,CHEMBL4866646,8.04,0,http://www.openphacts.org/units/Nanomolar,3614874,=,1,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237714,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '10.12', 'le': '0.19', 'lle': '0.60', 'sei': '5.59'}",CHEMBL4851700,,CHEMBL4851700,9.12,0,http://www.openphacts.org/units/Nanomolar,3614875,=,1,1,=,,IC50,nM,,0.75,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.75
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237715,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(C(F)(F)F)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '10.00', 'le': '0.19', 'lle': '0.00', 'sei': '5.70'}",CHEMBL4851332,,CHEMBL4851332,9.30,0,http://www.openphacts.org/units/Nanomolar,3614876,=,1,1,=,,IC50,nM,,0.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23237716,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.25', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '15.0'}]",CHEMBL4828452,Displacement of Bak derived peptide from Bcl-2 (unknown origin) measured after 15 mins by microplate reader assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4825763,Bioorg Med Chem,2021,"{'bei': '10.36', 'le': '0.20', 'lle': '0.34', 'sei': '5.23'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,9.00,0,http://www.openphacts.org/units/Nanomolar,3614877,=,1,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283859,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(N3CCSCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '18.40', 'le': '0.35', 'lle': '2.71', 'sei': '8.98'}",CHEMBL4848284,,CHEMBL4848284,6.10,0,http://www.openphacts.org/units/Nanomolar,3622900,=,1,1,=,,IC50,nM,,800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283860,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(Sc3ccccc3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '16.98', 'le': '0.31', 'lle': '0.75', 'sei': '8.89'}",CHEMBL4855924,,CHEMBL4855924,5.75,0,http://www.openphacts.org/units/Nanomolar,3622901,=,1,1,=,,IC50,nM,,1800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283861,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(Sc3ccc(Br)cc3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '14.75', 'le': '0.32', 'lle': '0.40', 'sei': '9.52'}",CHEMBL4470807,,CHEMBL4470807,6.16,0,http://www.openphacts.org/units/Nanomolar,3622902,=,1,1,=,,IC50,nM,,700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283862,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '14.59', 'le': '0.27', 'lle': '-0.56', 'sei': '8.59'}",CHEMBL4851461,,CHEMBL4851461,5.55,0,http://www.openphacts.org/units/Nanomolar,3622903,=,1,1,=,,IC50,nM,,2800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283863,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(Sc2ccc3c4c(cccc24)C(=O)C(C#N)=C3C#N)cc1,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '14.15', 'le': '0.26', 'lle': '0.21', 'sei': '7.06'}",CHEMBL4854644,,CHEMBL4854644,5.21,0,http://www.openphacts.org/units/Nanomolar,3622904,=,1,1,=,,IC50,nM,,6100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.1
,,23283864,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(NCCO)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,,CHEMBL4861266,,CHEMBL4861266,,0,http://www.openphacts.org/units/Nanomolar,3622905,>,1,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283865,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(SC3CCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '15.36', 'le': '0.29', 'lle': '0.21', 'sei': '7.85'}",CHEMBL4862718,,CHEMBL4862718,5.08,0,http://www.openphacts.org/units/Nanomolar,3622906,=,1,1,=,,IC50,nM,,8400.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,8.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283866,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '14.71', 'le': '0.28', 'lle': '-0.19', 'sei': '7.84'}",CHEMBL4849170,,CHEMBL4849170,5.07,0,http://www.openphacts.org/units/Nanomolar,3622907,=,1,1,=,,IC50,nM,,8600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,8.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283867,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(NCc3ccccc3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '14.40', 'le': '0.25', 'lle': '0.38', 'sei': '6.30'}",CHEMBL4862583,,CHEMBL4862583,4.83,0,http://www.openphacts.org/units/Nanomolar,3622908,=,1,1,=,,IC50,nM,,14800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,14.8
,,23283868,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(C#N)c2ccc(NC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,,CHEMBL4849303,,CHEMBL4849303,,0,http://www.openphacts.org/units/Nanomolar,3622909,>,1,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283869,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(NCc2ccccc2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '12.45', 'le': '0.23', 'lle': '-1.21', 'sei': '9.99'}",CHEMBL4852221,,CHEMBL4852221,5.28,0,http://www.openphacts.org/units/Nanomolar,3622910,=,1,1,=,,IC50,nM,,5200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283870,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(NCC2CCCCC2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '12.35', 'le': '0.23', 'lle': '-1.55', 'sei': '10.06'}",CHEMBL4858808,,CHEMBL4858808,5.32,0,http://www.openphacts.org/units/Nanomolar,3622911,=,1,1,=,,IC50,nM,,4800.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283871,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCCCNC1=C(C#N)C(=O)c2cccc3c(SC4CCCCC4)ccc1c23,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '12.28', 'le': '0.23', 'lle': '-1.29', 'sei': '9.07'}",CHEMBL4877337,,CHEMBL4877337,4.80,0,http://www.openphacts.org/units/Nanomolar,3622912,=,1,1,=,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,16.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283872,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(NCCO)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '13.26', 'le': '0.25', 'lle': '0.74', 'sei': '6.86'}",CHEMBL4862537,,CHEMBL4862537,5.02,0,http://www.openphacts.org/units/Nanomolar,3622913,=,1,1,=,,IC50,nM,,9600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283873,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(NCCC(N)=O)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '12.01', 'le': '0.23', 'lle': '0.71', 'sei': '5.07'}",CHEMBL4852727,,CHEMBL4852727,4.87,0,http://www.openphacts.org/units/Nanomolar,3622914,=,1,1,=,,IC50,nM,,13500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,13.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,23283874,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1=C(NCCN2CCOCC2)c2ccc(SC3CCCCC3)c3cccc(c23)C1=O,,,CHEMBL4837197,Eur J Med Chem,2021,"{'bei': '10.56', 'le': '0.20', 'lle': '0.11', 'sei': '7.23'}",CHEMBL4872862,,CHEMBL4872862,4.73,0,http://www.openphacts.org/units/Nanomolar,3622915,=,1,1,=,,IC50,nM,,18700.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,18.7
,,23283875,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL4837197,Eur J Med Chem,2021,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,0,http://www.openphacts.org/units/Nanomolar,3622916,>,1,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.1
,,23283876,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,O[C@@H]1[C@H](O)[C@@H](COCc2ccc(Cl)cc2)O[C@H]1n1c(NCc2ccc(Cl)c(Cl)c2)nc2cncnc21,,,CHEMBL4837197,Eur J Med Chem,2021,,CHEMBL4861551,,CHEMBL4861551,,0,http://www.openphacts.org/units/Nanomolar,3622917,>,1,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,20.0
,,23283877,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '30.0'}]",CHEMBL4837884,Inhibition of FAM-Bim peptide binding to human Bcl-2 (2 to 206) measured after 30 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC[n+]1ccccc1/C=c1\s/c(=C2/Sc3ccccc3N2C)c(=O)n1C.[Cl-],,,CHEMBL4837197,Eur J Med Chem,2021,,CHEMBL4853795,,CHEMBL5028432,,0,http://www.openphacts.org/units/Nanomolar,3622918,>,1,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,20.0
,Active,23364076,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'Num of experiments', 'standard_units': None, 'standard_value': '3.0', 'text_value': None, 'type': 'Num of experiments', 'units': None, 'value': '3.0'}]",CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL4507310,,2021,"{'bei': '9.88', 'le': '0.19', 'lle': '-0.59', 'sei': '5.15'}",CHEMBL4228713,A-1211212,CHEMBL4228713,8.85,0,http://www.openphacts.org/units/Nanomolar,3359749,=,54,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,Not Active,23364167,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'Num of experiments', 'standard_units': None, 'standard_value': '3.0', 'text_value': None, 'type': 'Num of experiments', 'units': None, 'value': '3.0'}]",CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL4507310,,2021,"{'bei': '7.22', 'le': '0.14', 'lle': '-2.35', 'sei': '3.80'}",CHEMBL4551344,A-1210227,CHEMBL4551344,6.53,0,http://www.openphacts.org/units/Nanomolar,3359750,=,54,1,=,,IC50,nM,,296.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,296.0
,Not Active,23365290,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'Num of experiments', 'standard_units': None, 'standard_value': '3.0', 'text_value': None, 'type': 'Num of experiments', 'units': None, 'value': '3.0'}]",CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1,,,CHEMBL4507311,,2021,"{'bei': '9.58', 'le': '0.19', 'lle': '0.09', 'sei': '5.95'}",CHEMBL3342332,A-1155463,CHEMBL3342332,6.42,0,http://www.openphacts.org/units/Nanomolar,3359751,=,54,1,=,,IC50,nM,,382.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,382.0
,Not Active,23365381,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': None, 'standard_type': 'Num of experiments', 'standard_units': None, 'standard_value': '3.0', 'text_value': None, 'type': 'Num of experiments', 'units': None, 'value': '3.0'}]",CHEMBL4883619,Time-resolved fluorescence energy transfer (TR-FRET) with BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(Nc1nc2ccccc2s1)c1cccc2c1CN(c1nc(C(=O)O)c(CCOc3ccc(-n4ncc5cncnc54)cc3)s1)CC2,,,CHEMBL4507311,,2021,"{'bei': '8.04', 'le': '0.15', 'lle': '-0.60', 'sei': '3.66'}",CHEMBL3342191,A-1107969,CHEMBL3342191,5.42,0,http://www.openphacts.org/units/Nanomolar,3359752,=,54,1,=,,IC50,nM,,3780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.78
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24363649,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'Time_Lower', 'standard_units': 'min', 'standard_value': '120.0', 'text_value': None, 'type': 'Time_Lower', 'units': 'min', 'value': '120.0'}, {'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'Time_Upper', 'standard_units': 'min', 'standard_value': '180.0', 'text_value': None, 'type': 'Time_Upper', 'units': 'min', 'value': '180.0'}]",CHEMBL5035037,Inhibition of Fluor 647-labeled Bim peptide C binding to human C-Terminal 6His-tagged Bcl-2 expressed in Escherichia coli incubated for 120 to 180 mins by lanthascreen TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13,,,CHEMBL5034015,J Med Chem,2021,"{'bei': '6.99', 'le': '0.14', 'lle': '-3.48', 'sei': '5.39'}",CHEMBL4297482,AZD-5991,CHEMBL4297482,4.70,0,http://www.openphacts.org/units/Nanomolar,3775182,=,1,1,=,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24661215,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'Time_Lower', 'standard_units': 'min', 'standard_value': '120.0', 'text_value': None, 'type': 'Time_Lower', 'units': 'min', 'value': '120.0'}, {'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'Time_Upper', 'standard_units': 'min', 'standard_value': '180.0', 'text_value': None, 'type': 'Time_Upper', 'units': 'min', 'value': '180.0'}]",CHEMBL5096358,Inhibition of C-terminal His6-tagged Bcl-2 (1 to 212 residues) (unknown origin) expressed in Escherichia coli using biotin-labeled Bim peptide GGMRPEIWIANELRRIGDEFNA as substrate incubated for 120 to 180 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1c2c(nn1C)CSCc1cc(n(C)n1)CSc1cc(c3ccccc3c1)OCCCc1c(C(=O)O)n(C)c3c-2c(Cl)ccc13,Potential transcription error,"Values appear to be an order of magnitude different from previously reported, so units may be incorrect",CHEMBL5096144,Bioorg Med Chem Lett,2021,,CHEMBL4297482,AZD-5991,CHEMBL4297482,,1,http://www.openphacts.org/units/Nanomolar,3842267,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24662005,[],CHEMBL5096798,Inhibition of BCL-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5096156,J Med Chem,2021,"{'bei': '8.80', 'le': '0.17', 'lle': '-1.02', 'sei': '4.44'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,7.64,0,http://www.openphacts.org/units/Nanomolar,3842533,=,1,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24706377,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.333', 'text_value': None, 'type': 'Time', 'units': 'min', 'value': '80.0'}]",CHEMBL5108715,Displacement of synthetic peptide tracer conjugated to fluorescein isothiocyanate from C-terminal 6xHis-tagged Bcl-2 (1 to 204 residues) (unknown origin) preincubated for 1 hr followed by tracer addition measured after 20 mins by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5107957,Eur J Med Chem,2022,"{'bei': '8.89', 'le': '0.18', 'lle': '0.15', 'sei': '5.38'}",CHEMBL3703600,,CHEMBL3703600,8.41,0,http://www.openphacts.org/units/Nanomolar,3852664,=,1,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861001,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.87', 'le': '0.25', 'lle': '0.06', 'sei': '8.00'}",CHEMBL5202782,,CHEMBL5202782,5.68,0,http://www.openphacts.org/units/Nanomolar,3883969,=,1,1,=,,IC50,nM,,2100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.1
,NA,24861002,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(=O)c1ccc(C(=O)N2N=C(c3ccc(NC(=O)OC(C)(C)C)cc3)CC2c2ccccc2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5184262,,CHEMBL5184262,,0,,3883963,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861003,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(S(C)(=O)=O)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5201439,,CHEMBL5201439,,0,,3883962,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861004,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '13.07', 'le': '0.24', 'lle': '0.43', 'sei': '5.57'}",CHEMBL5179160,,CHEMBL5179160,6.36,0,http://www.openphacts.org/units/Nanomolar,3883961,=,1,1,=,,IC50,nM,,439.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.439
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861005,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.65', 'le': '0.26', 'lle': '-0.21', 'sei': '9.27'}",CHEMBL5188416,,CHEMBL5188416,6.58,0,http://www.openphacts.org/units/Nanomolar,3883960,=,1,1,=,,IC50,nM,,262.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.262
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861006,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccncc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.66', 'le': '0.22', 'lle': '-0.62', 'sei': '6.62'}",CHEMBL5201820,,CHEMBL5201820,5.56,0,http://www.openphacts.org/units/Nanomolar,3883959,=,1,1,=,,IC50,nM,,2780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.78
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861007,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cccnc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.10', 'le': '0.23', 'lle': '-0.39', 'sei': '6.90'}",CHEMBL5190824,,CHEMBL5190824,5.79,0,http://www.openphacts.org/units/Nanomolar,3883958,=,1,1,=,,IC50,nM,,1630.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.63
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861008,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccn3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.87', 'le': '0.25', 'lle': '0.01', 'sei': '7.38'}",CHEMBL5196601,,CHEMBL5196601,6.19,0,http://www.openphacts.org/units/Nanomolar,3883957,=,1,1,=,,IC50,nM,,650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.65
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861009,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3cncs3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.16', 'le': '0.22', 'lle': '-0.88', 'sei': '6.39'}",CHEMBL5170050,,CHEMBL5170050,5.36,0,http://www.openphacts.org/units/Nanomolar,3883956,=,1,1,=,,IC50,nM,,4360.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.36
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861010,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3nccs3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.98', 'le': '0.24', 'lle': '-0.45', 'sei': '6.91'}",CHEMBL5203025,,CHEMBL5203025,5.79,0,http://www.openphacts.org/units/Nanomolar,3883955,=,1,1,=,,IC50,nM,,1610.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.61
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861011,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccoc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.62', 'le': '0.22', 'lle': '-0.96', 'sei': '6.44'}",CHEMBL5185435,,CHEMBL5185435,5.42,0,http://www.openphacts.org/units/Nanomolar,3883954,=,1,1,=,,IC50,nM,,3820.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.82
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861012,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.56', 'le': '0.24', 'lle': '-0.48', 'sei': '7.01'}",CHEMBL5184993,,CHEMBL5184993,5.90,0,http://www.openphacts.org/units/Nanomolar,3883953,=,1,1,=,,IC50,nM,,1260.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.26
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861013,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1ccc(C(=O)N2N=C(c3ccc(NC(=O)OC(C)(C)C)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.31', 'le': '0.23', 'lle': '-0.45', 'sei': '6.52'}",CHEMBL5201389,,CHEMBL5201389,5.48,0,http://www.openphacts.org/units/Nanomolar,3883952,=,1,1,=,,IC50,nM,,3290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,3.29
,NA,24861014,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1ccc(C(=O)N2N=C(c3ccc(N)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5179170,,CHEMBL5179170,,0,,3883951,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861015,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5176013,,CHEMBL5176013,,0,,3883950,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861016,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1ccc(C(=O)N2N=C(c3ccc(NS(=O)(=O)C(F)(F)F)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5181735,,CHEMBL5181735,,0,,3883949,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861017,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccco3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL392723,,CHEMBL392723,,0,,3883948,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861018,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3cccc(F)c3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5170553,,CHEMBL5170553,,0,,3883947,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861019,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1cccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)c1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5205908,,CHEMBL5205908,,0,,3883946,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861020,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccccc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5203092,,CHEMBL5203092,,0,,3883945,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861021,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,COc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.37', 'le': '0.22', 'lle': '1.35', 'sei': '4.94'}",CHEMBL5171960,,CHEMBL5171960,5.00,0,http://www.openphacts.org/units/Nanomolar,3883944,=,1,1,=,,IC50,nM,,10110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.11
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861022,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C#N)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.80', 'le': '0.23', 'lle': '1.62', 'sei': '4.43'}",CHEMBL5183128,,CHEMBL5183128,5.13,0,http://www.openphacts.org/units/Nanomolar,3883943,=,1,1,=,,IC50,nM,,7440.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,7.44
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861023,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc([N+](=O)[O-])cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.55', 'le': '0.24', 'lle': '2.16', 'sei': '4.22'}",CHEMBL5204089,,CHEMBL5204089,5.71,0,http://www.openphacts.org/units/Nanomolar,3883942,=,1,1,=,,IC50,nM,,1970.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.97
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861024,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(F)(F)F)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.60', 'le': '0.23', 'lle': '0.88', 'sei': '6.02'}",CHEMBL5204882,,CHEMBL5204882,5.54,0,http://www.openphacts.org/units/Nanomolar,3883941,=,1,1,=,,IC50,nM,,2880.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.88
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861025,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.48', 'le': '0.26', 'lle': '1.20', 'sei': '6.10'}",CHEMBL5183356,,CHEMBL5183356,5.61,0,http://www.openphacts.org/units/Nanomolar,3883940,=,1,1,=,,IC50,nM,,2470.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.47
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861026,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Cl)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.54', 'le': '0.25', 'lle': '1.27', 'sei': '6.05'}",CHEMBL5198074,,CHEMBL5198074,5.57,0,http://www.openphacts.org/units/Nanomolar,3883939,=,1,1,=,,IC50,nM,,2720.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.72
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861027,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CS(=O)(=O)Nc1ccc(C2=NN(C(=O)c3ccc(F)cc3)C(c3ccco3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.46', 'le': '0.22', 'lle': '1.12', 'sei': '5.32'}",CHEMBL5189940,,CHEMBL5189940,4.90,0,http://www.openphacts.org/units/Nanomolar,3883938,=,1,1,=,,IC50,nM,,12660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,12.66
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861028,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,Cc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.33', 'le': '0.22', 'lle': '0.85', 'sei': '5.22'}",CHEMBL5201208,,CHEMBL5201208,4.80,0,http://www.openphacts.org/units/Nanomolar,3883937,=,1,1,=,,IC50,nM,,15900.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,15.9
,NA,24861029,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccncc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5181504,,CHEMBL5181504,,0,,3883968,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861030,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3cccnc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.93', 'le': '0.20', 'lle': '-0.58', 'sei': '5.77'}",CHEMBL5180902,,CHEMBL5180902,4.84,0,http://www.openphacts.org/units/Nanomolar,3883967,=,1,1,=,,IC50,nM,,14500.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,14.5
,NA,24861031,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccccn3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5199110,,CHEMBL5199110,,0,,3883966,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861032,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(=O)C(F)(F)F)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5197825,,CHEMBL5197825,,0,,3883965,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
,NA,24861033,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(C(C)(C)C)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5193361,,CHEMBL5193361,,0,,3883964,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861034,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '15.20', 'le': '0.32', 'lle': '1.47', 'sei': '10.54'}",CHEMBL5182854,,CHEMBL5182854,7.48,0,http://www.openphacts.org/units/Nanomolar,3883970,=,1,1,=,,IC50,nM,,32.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0328
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861035,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '16.50', 'le': '0.35', 'lle': '1.96', 'sei': '11.77'}",CHEMBL5202594,,CHEMBL5202594,8.36,0,http://www.openphacts.org/units/Nanomolar,3883971,=,1,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0044
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861036,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)OC1CC1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '14.58', 'le': '0.30', 'lle': '1.21', 'sei': '10.36'}",CHEMBL5202671,,CHEMBL5202671,7.36,0,http://www.openphacts.org/units/Nanomolar,3883972,=,1,1,=,,IC50,nM,,44.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0441
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861037,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)COC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '13.04', 'le': '0.27', 'lle': '0.14', 'sei': '9.56'}",CHEMBL5201326,,CHEMBL5201326,6.79,0,http://www.openphacts.org/units/Nanomolar,3883973,=,1,1,=,,IC50,nM,,164.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16399999999999998
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861038,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,C=CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '14.86', 'le': '0.31', 'lle': '1.32', 'sei': '10.56'}",CHEMBL5187331,,CHEMBL5187331,7.50,0,http://www.openphacts.org/units/Nanomolar,3883974,=,1,1,=,,IC50,nM,,31.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0318
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861039,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,C#CCCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '13.92', 'le': '0.29', 'lle': '1.18', 'sei': '10.12'}",CHEMBL5182395,,CHEMBL5182395,7.19,0,http://www.openphacts.org/units/Nanomolar,3883975,=,1,1,=,,IC50,nM,,65.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.065
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861040,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CNC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.01', 'le': '0.23', 'lle': '0.07', 'sei': '7.12'}",CHEMBL5174166,,CHEMBL5174166,5.26,0,http://www.openphacts.org/units/Nanomolar,3883976,=,1,1,=,,IC50,nM,,5530.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.53
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861041,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CN(C)C(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.43', 'le': '0.24', 'lle': '0.09', 'sei': '8.64'}",CHEMBL5201193,,CHEMBL5201193,5.62,0,http://www.openphacts.org/units/Nanomolar,3883977,=,1,1,=,,IC50,nM,,2410.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.41
,NA,24861042,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)N1CCCC1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5176388,,CHEMBL5176388,,0,,3883978,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861043,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)NC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.77', 'le': '0.27', 'lle': '0.49', 'sei': '8.75'}",CHEMBL5203263,,CHEMBL5203263,6.46,0,http://www.openphacts.org/units/Nanomolar,3883979,=,1,1,=,,IC50,nM,,350.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.35
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861044,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)NC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '9.69', 'le': '0.20', 'lle': '-1.32', 'sei': '6.82'}",CHEMBL5209197,,CHEMBL5209197,5.04,0,http://www.openphacts.org/units/Nanomolar,3883980,=,1,1,=,,IC50,nM,,9220.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.22
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861045,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1cccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)c1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '9.52', 'le': '0.20', 'lle': '-1.83', 'sei': '6.98'}",CHEMBL5188723,,CHEMBL5188723,4.96,0,http://www.openphacts.org/units/Nanomolar,3883981,=,1,1,=,,IC50,nM,,11060.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,11.06
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861046,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cn1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.49', 'le': '0.26', 'lle': '0.33', 'sei': '7.76'}",CHEMBL5170955,,CHEMBL5170955,6.51,0,http://www.openphacts.org/units/Nanomolar,3883982,=,1,1,=,,IC50,nM,,309.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.309
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861047,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)nc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.33', 'le': '0.26', 'lle': '0.25', 'sei': '7.66'}",CHEMBL5205655,,CHEMBL5205655,6.43,0,http://www.openphacts.org/units/Nanomolar,3883983,=,1,1,=,,IC50,nM,,372.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.37200000000000005
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861048,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC1C(c2ccc(NC(=O)OC(C)(C)C)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '14.15', 'le': '0.30', 'lle': '0.53', 'sei': '10.65'}",CHEMBL5196944,,CHEMBL5196944,7.56,0,http://www.openphacts.org/units/Nanomolar,3883984,=,1,1,=,,IC50,nM,,27.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0274
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861049,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2c2ccccc2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '11.34', 'le': '0.23', 'lle': '-1.42', 'sei': '9.53'}",CHEMBL5193713,,CHEMBL5193713,6.76,0,http://www.openphacts.org/units/Nanomolar,3883985,=,1,1,=,,IC50,nM,,172.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.172
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861050,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2C)cn1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '16.68', 'le': '0.35', 'lle': '2.66', 'sei': '10.37'}",CHEMBL5183315,,CHEMBL5183315,8.70,0,http://www.openphacts.org/units/Nanomolar,3883986,=,1,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.002
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861051,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC1C(c2ccc(N3CCOC3=O)cc2)=NN(C(=O)c2ccc(Br)cc2)C1c1ccccc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.48', 'le': '0.22', 'lle': '-0.35', 'sei': '8.50'}",CHEMBL5195576,,CHEMBL5195576,5.29,0,http://www.openphacts.org/units/Nanomolar,3883987,=,1,1,=,,IC50,nM,,5160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.16
,NA,24861052,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,O=C(O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5187447,,CHEMBL5187447,,0,,3883988,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861053,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,COC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '12.49', 'le': '0.26', 'lle': '0.56', 'sei': '9.81'}",CHEMBL5176214,,CHEMBL5176214,5.79,0,http://www.openphacts.org/units/Nanomolar,3883989,=,1,1,=,,IC50,nM,,1640.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.64
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861054,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '14.16', 'le': '0.30', 'lle': '0.95', 'sei': '11.80'}",CHEMBL5197785,,CHEMBL5197785,6.96,0,http://www.openphacts.org/units/Nanomolar,3883990,=,1,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.11
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861055,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)C(=O)Oc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.71', 'le': '0.22', 'lle': '-0.74', 'sei': '8.93'}",CHEMBL5200411,,CHEMBL5200411,5.26,0,http://www.openphacts.org/units/Nanomolar,3883991,=,1,1,=,,IC50,nM,,5450.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.45
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861056,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CN(C)C(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.98', 'le': '0.23', 'lle': '0.09', 'sei': '9.87'}",CHEMBL5174227,,CHEMBL5174227,5.23,0,http://www.openphacts.org/units/Nanomolar,3883992,=,1,1,=,,IC50,nM,,5910.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,5.91
,NA,24861057,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CC(C)(C)NC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5201043,,CHEMBL5201043,,0,,3883993,,1,0,,,IC50,,,,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,,,,
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861058,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149881,Inhibition of biotin-linker-Beclin 1 BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,B,,,BAO_0000190,BAO_0000019,assay format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5143754,ACS Med Chem Lett,2022,"{'bei': '10.38', 'le': '0.21', 'lle': '0.56', 'sei': '6.59'}",CHEMBL376408,ABT 737,CHEMBL376408,8.44,0,http://www.openphacts.org/units/Nanomolar,3883994,=,1,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.0036
,,24861059,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,Cc1ccc(C(=O)N2N=C(c3ccc(NS(C)(=O)=O)cc3)CC2c2ccco2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5201208,,CHEMBL5201208,,0,http://www.openphacts.org/units/Nanomolar,3883937,>,1,1,>,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,10.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861060,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5182854,,CHEMBL5182854,5.18,0,http://www.openphacts.org/units/Nanomolar,3883970,=,1,1,=,,IC50,nM,,6620.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,6.62
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861061,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5202594,,CHEMBL5202594,6.05,0,http://www.openphacts.org/units/Nanomolar,3883971,=,1,1,=,,IC50,nM,,881.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.8809999999999999
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861062,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,O=C(Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1)OC1CC1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5202671,,CHEMBL5202671,4.82,0,http://www.openphacts.org/units/Nanomolar,3883972,=,1,1,=,,IC50,nM,,15100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,15.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861063,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,C=CCOC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5187331,,CHEMBL5187331,5.05,0,http://www.openphacts.org/units/Nanomolar,3883974,=,1,1,=,,IC50,nM,,8830.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,8.83
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861064,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)Nc1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2C)cn1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5183315,,CHEMBL5183315,6.80,0,http://www.openphacts.org/units/Nanomolar,3883986,=,1,1,=,,IC50,nM,,157.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.157
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861065,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,CC(C)OC(=O)c1ccc(C2=NN(C(=O)c3ccc(Br)cc3)C(c3ccccc3)C2)cc1,,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL5197785,,CHEMBL5197785,5.36,0,http://www.openphacts.org/units/Nanomolar,3883990,=,1,1,=,,IC50,nM,,4360.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.36
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24861066,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '3.0', 'text_value': None, 'type': 'Time', 'units': 'hrs', 'value': '3.0'}]",CHEMBL5149882,Inhibition of biotin-linker-Bax BH3 peptide binding to human C-terminal 6His-tagged Bcl-2 (1 to 218 residues) expressed in Escherichia coli BL21 Star (DE3) pLysS measured after 3 hrs by AlphaLISA assay,T,,,BAO_0000190,BAO_0000019,assay format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5143754,ACS Med Chem Lett,2022,,CHEMBL376408,ABT 737,CHEMBL376408,7.14,0,http://www.openphacts.org/units/Nanomolar,3883994,=,1,1,=,,IC50,nM,,72.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.07200000000000001
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24863014,[],CHEMBL5150894,Inhibition of BCL2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,CCCn1cc(/C=N/N=C2\C(=O)Nc3ccc(C)cc32)c2ccccc21,,,CHEMBL5149978,Eur J Med Chem,2021,"{'bei': '18.40', 'le': '0.33', 'lle': '2.20', 'sei': '10.79'}",CHEMBL5196783,,CHEMBL5196783,6.34,1,http://www.openphacts.org/units/Nanomolar,3884760,=,1,1,=,,IC50,nM,,460.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.46
,,24954370,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': 'https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212', 'standard_type': 'Affinity Biochemical Source Knowledge', 'standard_units': None, 'standard_value': None, 'text_value': 'https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212', 'type': 'Affinity Biochemical Source Knowledge', 'units': None, 'value': None}]",CHEMBL5210488,Affinity Biochemical interaction (TR-FRET assay) EUB0000263b BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@H]1CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5210307,,2023,"{'bei': '9.88', 'le': '0.19', 'lle': '-0.59', 'sei': '5.15'}",CHEMBL4228713,A-1211212,CHEMBL4228713,8.85,0,http://www.openphacts.org/units/Nanomolar,3898051,=,65,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,,24954385,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': 'https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212', 'standard_type': 'Affinity Biochemical Source Knowledge', 'standard_units': None, 'standard_value': None, 'text_value': 'https://doi.org/10.1126/scitranslmed.aaa4642, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1211212', 'type': 'Affinity Biochemical Source Knowledge', 'units': None, 'value': None}]",CHEMBL5210503,Affinity Biochemical interaction (TR-FRET assay) EUB0000746a BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(Cc3ccc(C(F)(F)F)cc3-c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5210307,,2023,"{'bei': '7.22', 'le': '0.14', 'lle': '-2.35', 'sei': '3.80'}",CHEMBL4551344,A-1210227,CHEMBL4551344,6.53,0,http://www.openphacts.org/units/Nanomolar,3898066,=,65,1,=,,IC50,nM,,296.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,296.0
,,24956547,"[{'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': 'CellTiter-Glo Luminescent Cell Viability Assay (BCL-XL dependent cell line MOLT-4): EC50 = 214 nM, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463;', 'standard_type': 'Selectivity Comments', 'standard_units': None, 'standard_value': None, 'text_value': 'CellTiter-Glo Luminescent Cell Viability Assay (BCL-XL dependent cell line MOLT-4): EC50 = 214 nM, https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463;', 'type': 'Selectivity Comments', 'units': None, 'value': None}, {'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': 'In-vitro potency', 'standard_type': 'Selectivity Remarks', 'standard_units': None, 'standard_value': None, 'text_value': 'In-vitro potency', 'type': 'Selectivity Remarks', 'units': None, 'value': None}, {'comments': None, 'relation': None, 'result_flag': 0, 'standard_relation': None, 'standard_text_value': 'https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463', 'standard_type': 'Selectivity Source Knowledge', 'standard_units': None, 'standard_value': None, 'text_value': 'https://www.sgc-ffm.uni-frankfurt.de/#!specificprobeoverview/A-1155463', 'type': 'Selectivity Source Knowledge', 'units': None, 'value': None}]",CHEMBL5213794,Selectivity interaction (TR-FRET assay) EUB0000262b BCL2,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC#Cc1ccc(OCCCc2sc(N3CCc4cccc(C(=O)Nc5nc6ccccc6s5)c4C3)nc2C(=O)O)c(F)c1,,,CHEMBL5212743,,2023,"{'bei': '9.58', 'le': '0.19', 'lle': '0.09', 'sei': '5.95'}",CHEMBL3342332,A-1155463,CHEMBL3342332,6.42,0,http://www.openphacts.org/units/Nanomolar,3898310,=,65,1,=,,IC50,nM,,382.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,382.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,24987654,[],CHEMBL5228637,Inhibition of Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,CCCn1cc(/C=N/N=C2\C(=O)Nc3ccc(C)cc32)c2ccccc21,,,CHEMBL5226338,Eur J Med Chem,2021,"{'bei': '18.40', 'le': '0.33', 'lle': '2.20', 'sei': '10.79'}",CHEMBL5196783,,CHEMBL5196783,6.34,0,http://www.openphacts.org/units/Nanomolar,3906898,=,1,1,=,,IC50,nM,,460.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.46
"{'action_type': 'BINDING AGENT', 'description': 'Binds to a substance such as a cell surface antigen, targeting a drug to that location, but not necessarily affecting the functioning of the substance itself', 'parent_type': 'OTHER'}",,24999395,[],CHEMBL5232571,Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(Nc2nnc(-c3cc(-c4ccc(Br)cc4)nc4ccccc34)o2)cc1,,,CHEMBL5230155,Eur J Med Chem,2021,"{'bei': '12.50', 'le': '0.26', 'lle': '-1.06', 'sei': '8.95'}",CHEMBL5276080,,CHEMBL5276080,5.71,0,http://www.openphacts.org/units/Nanomolar,3910589,=,1,1,=,,IC50,nM,,1930.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.93
"{'action_type': 'BINDING AGENT', 'description': 'Binds to a substance such as a cell surface antigen, targeting a drug to that location, but not necessarily affecting the functioning of the substance itself', 'parent_type': 'OTHER'}",,24999396,[],CHEMBL5232571,Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc2nc(-c3ccc(Br)cc3)cc(-c3nnc(Nc4ccc([N+](=O)[O-])cc4)o3)c2c1,,,CHEMBL5230155,Eur J Med Chem,2021,"{'bei': '13.17', 'le': '0.27', 'lle': '0.45', 'sei': '5.87'}",CHEMBL5291477,,CHEMBL5291477,6.82,0,http://www.openphacts.org/units/Nanomolar,3910590,=,1,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.15
"{'action_type': 'BINDING AGENT', 'description': 'Binds to a substance such as a cell surface antigen, targeting a drug to that location, but not necessarily affecting the functioning of the substance itself', 'parent_type': 'OTHER'}",,24999397,[],CHEMBL5232571,Displacement of biotinylated Bim peptide from Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(C)C)c(O)c(O)c(C=O)c2c(O)c1-c1c(C)cc2c(C(C)C)c(O)c(O)c(C=O)c2c1O,,,CHEMBL5230155,Eur J Med Chem,2021,"{'bei': '12.00', 'le': '0.22', 'lle': '-0.16', 'sei': '4.00'}",CHEMBL51483,GOSSYPOL,CHEMBL51483,6.22,1,http://www.openphacts.org/units/Nanomolar,3910643,=,1,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25006077,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5234917,Inhibition of Flu-BakBH3 binding to recombinant GST-tagged Bcl-2 (unknown origin) incubated for 30 mins by competitive fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)C1=C(N)Oc2ccc(Br)cc2C1C(C#N)C(=O)OCC,,,CHEMBL5233252,Eur J Med Chem,2020,"{'bei': '12.33', 'le': '0.28', 'lle': '2.69', 'sei': '4.52'}",CHEMBL288542,,CHEMBL288542,5.05,0,http://www.openphacts.org/units/Nanomolar,3912957,=,1,1,=,,IC50,nM,,9000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,9.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25006079,[],CHEMBL5234919,Inhibition of BH3 peptide binding to Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NC[C@H](C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL5233252,Eur J Med Chem,2020,"{'bei': '9.27', 'le': '0.17', 'lle': '-1.09', 'sei': '3.62'}",CHEMBL1094250,"1,1',6,6',7,7'-HEXAHYDROXY-3,3'-DIMETHYL-N5-((R)-2-PHENYLPROPYL)-N5'-((R)-2-PHENYLPROPYL)-2,2'-BINAPHTHYL-5,5'-DICARBOXAMIDE (ATROPISOMERIC MIX)",CHEMBL1094250,6.50,1,http://www.openphacts.org/units/Nanomolar,3912958,=,1,1,=,,IC50,nM,,320.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.32
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25006099,[],CHEMBL5234938,Binding affinity to Bcl-2 (unknown origin) by ELISA analysis,B,,,BAO_0000190,BAO_0000357,single protein format,O=[N+]([O-])c1ccccc1Nc1nnc(-c2c[nH]c3ccccc23)o1,,,CHEMBL5233252,Eur J Med Chem,2020,"{'bei': '16.71', 'le': '0.31', 'lle': '1.50', 'sei': '4.89'}",CHEMBL4102399,,CHEMBL4102399,5.37,0,http://www.openphacts.org/units/Nanomolar,3912965,=,1,1,=,,IC50,nM,,4270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,4.27
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25006102,[],CHEMBL5234941,Inhibition of Bcl-2 (unknown origin) by ELISA analysis,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)c1ccc(C(=O)NCCN2C(=O)c3cccc4c(Sc5ccc(Br)cc5)ccc(c34)C2=O)cc1,,,CHEMBL5233252,Eur J Med Chem,2020,"{'bei': '9.66', 'le': '0.20', 'lle': '-1.40', 'sei': '8.54'}",CHEMBL4530348,,CHEMBL4530348,5.68,0,http://www.openphacts.org/units/Nanomolar,3912966,=,1,1,=,,IC50,nM,,2110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,2.11
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25031361,[],CHEMBL5241833,Inhibition of Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c(O)c1-c1c(C)cc2c(C(=O)NCC(C)c3ccccc3)c(O)c(O)cc2c1O,,,CHEMBL5241079,Eur J Med Chem,2021,"{'bei': '9.27', 'le': '0.17', 'lle': '-1.09', 'sei': '3.62'}",CHEMBL538616,,CHEMBL538616,6.50,1,http://www.openphacts.org/units/Nanomolar,3919308,=,1,1,=,,IC50,nM,,320.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.32
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25031362,[],CHEMBL5241833,Inhibition of Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL5241079,Eur J Med Chem,2021,"{'bei': '12.80', 'le': '0.23', 'lle': '1.73', 'sei': '5.03'}",CHEMBL1269107,,CHEMBL1269107,7.51,1,http://www.openphacts.org/units/Nanomolar,3919309,=,1,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25031371,[],CHEMBL5241841,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL5241079,Eur J Med Chem,2021,"{'bei': '10.03', 'le': '0.18', 'lle': '0.11', 'sei': '3.95'}",CHEMBL1269107,,CHEMBL1269107,5.89,0,http://www.openphacts.org/units/Nanomolar,3919309,=,1,1,=,,IC50,nM,,1300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,1.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25031372,[],CHEMBL5241841,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O,,,CHEMBL5241079,Eur J Med Chem,2021,"{'bei': '11.00', 'le': '0.21', 'lle': '-0.33', 'sei': '5.79'}",CHEMBL555017,GAMBOGIC ACID,CHEMBL555017,6.91,0,http://www.openphacts.org/units/Nanomolar,3919310,=,1,1,=,,IC50,nM,,122.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.122
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25097973,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '4.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '4.0'}]",CHEMBL5260438,Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)NCCNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,,,CHEMBL5257141,ACS Med Chem Lett,2023,,CHEMBL5268884,,CHEMBL5268884,,0,http://www.openphacts.org/units/Nanomolar,3935633,<,1,1,<,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25097974,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '4.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '4.0'}]",CHEMBL5260438,Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCOCCOCCNC(=O)CCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5257141,ACS Med Chem Lett,2023,,CHEMBL5276934,,CHEMBL5276934,,0,http://www.openphacts.org/units/Nanomolar,3935634,<,1,1,<,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25097975,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '4.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '4.0'}]",CHEMBL5260438,Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5257141,ACS Med Chem Lett,2023,,CHEMBL5270107,,CHEMBL5270107,,0,http://www.openphacts.org/units/Nanomolar,3935635,<,1,1,<,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25097976,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '4.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '4.0'}]",CHEMBL5260438,Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCOCCOCCNC(=O)COc5cccc6c5C(=O)N(C5CCC(=O)NC5=O)C6=O)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5257141,ACS Med Chem Lett,2023,,CHEMBL5279723,,CHEMBL5279723,,0,http://www.openphacts.org/units/Nanomolar,3935636,<,1,1,<,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25097977,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '4.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '4.0'}]",CHEMBL5260438,Inhibition of BCL-2 (unknown origin) using FITC-Ahx-GQVGRQLAIIGDDINR-CONH2 as substrate incubated for 4 hrs by fluorescence polarization competition assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)NCCOCCOCCNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])ccc1NC(=O)[C@@H]1N[C@@H](CC(C)(C)C)[C@](C#N)(c2ccc(Cl)cc2F)[C@H]1c1cccc(Cl)c1F,,,CHEMBL5257141,ACS Med Chem Lett,2023,,CHEMBL5283597,,CHEMBL5283597,,0,http://www.openphacts.org/units/Nanomolar,3935637,<,1,1,<,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,,25521733,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.08333', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '5.0'}]",CHEMBL5337577,Inhibition of GST fused Bcl-2 (unknown origin) incubated for 5 min by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOC(=O)CS(=O)(=O)c1nc(-c2ccc(F)cc2)cc(C(F)(F)F)n1,,,CHEMBL5335817,Bioorg Med Chem Lett,2024,,CHEMBL1417970,,CHEMBL1417970,,0,http://www.openphacts.org/units/Nanomolar,3971427,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860821,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.36', 'le': '0.18', 'lle': '-1.33', 'sei': '4.47'}",CHEMBL5560407,,CHEMBL5560407,7.55,0,http://www.openphacts.org/units/Nanomolar,4059570,=,1,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860822,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.03', 'le': '0.17', 'lle': '-1.59', 'sei': '4.32'}",CHEMBL5560077,,CHEMBL5560077,7.29,0,http://www.openphacts.org/units/Nanomolar,4059571,=,1,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860823,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.23', 'le': '0.20', 'lle': '-0.62', 'sei': '4.89'}",CHEMBL5542608,,CHEMBL5542608,8.26,0,http://www.openphacts.org/units/Nanomolar,4059572,=,1,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860824,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3c(F)cccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.64', 'le': '0.19', 'lle': '-1.06', 'sei': '4.72'}",CHEMBL5557529,,CHEMBL5557529,7.96,0,http://www.openphacts.org/units/Nanomolar,4059573,=,1,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860825,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.39', 'le': '0.20', 'lle': '-0.20', 'sei': '4.76'}",CHEMBL5559481,,CHEMBL5559481,8.03,0,http://www.openphacts.org/units/Nanomolar,4059574,=,1,1,=,,IC50,nM,,9.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860826,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.78', 'le': '0.20', 'lle': '0.08', 'sei': '5.02'}",CHEMBL5560980,,CHEMBL5560980,8.48,0,http://www.openphacts.org/units/Nanomolar,4059575,=,1,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860827,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.70', 'le': '0.16', 'lle': '-1.24', 'sei': '3.91'}",CHEMBL5557096,,CHEMBL5557096,6.60,0,http://www.openphacts.org/units/Nanomolar,4059576,=,1,1,=,,IC50,nM,,249.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,249.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860828,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.71', 'le': '0.18', 'lle': '-0.98', 'sei': '4.53'}",CHEMBL5567852,,CHEMBL5567852,7.64,0,http://www.openphacts.org/units/Nanomolar,4059577,=,1,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860829,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC(c4ccccc4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.54', 'sei': '4.35'}",CHEMBL5563244,,CHEMBL5563244,7.34,0,http://www.openphacts.org/units/Nanomolar,4059578,=,1,1,=,,IC50,nM,,46.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,46.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860830,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.66', 'le': '0.18', 'lle': '-0.76', 'sei': '4.42'}",CHEMBL5568324,,CHEMBL5568324,7.47,0,http://www.openphacts.org/units/Nanomolar,4059579,=,1,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860831,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccnc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.52', 'le': '0.20', 'lle': '0.52', 'sei': '4.48'}",CHEMBL5532222,,CHEMBL5532222,8.14,0,http://www.openphacts.org/units/Nanomolar,4059580,=,1,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860832,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.48', 'le': '0.18', 'lle': '-1.05', 'sei': '4.38'}",CHEMBL5527871,,CHEMBL5527871,7.39,0,http://www.openphacts.org/units/Nanomolar,4059581,=,1,1,=,,IC50,nM,,41.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860833,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3F)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.89', 'le': '0.19', 'lle': '-0.55', 'sei': '4.64'}",CHEMBL5518078,,CHEMBL5518078,7.82,0,http://www.openphacts.org/units/Nanomolar,4059604,=,1,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860834,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3-c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.22', 'le': '0.17', 'lle': '-2.08', 'sei': '4.64'}",CHEMBL5561570,,CHEMBL5561570,7.82,0,http://www.openphacts.org/units/Nanomolar,4059605,=,1,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860835,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.83', 'le': '0.20', 'lle': '-0.02', 'sei': '5.05'}",CHEMBL5566790,,CHEMBL5566790,8.52,0,http://www.openphacts.org/units/Nanomolar,4059606,=,1,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860836,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.47', 'le': '0.20', 'lle': '-0.40', 'sei': '4.97'}",CHEMBL5562291,,CHEMBL5562291,8.39,0,http://www.openphacts.org/units/Nanomolar,4059607,=,1,1,=,,IC50,nM,,4.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860837,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.46', 'le': '0.20', 'lle': '-0.83', 'sei': '5.05'}",CHEMBL5557735,,CHEMBL5557735,8.52,0,http://www.openphacts.org/units/Nanomolar,4059608,=,1,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860838,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.71', 'le': '0.18', 'lle': '-1.48', 'sei': '4.77'}",CHEMBL5517916,,CHEMBL5517916,8.05,0,http://www.openphacts.org/units/Nanomolar,4059609,=,1,1,=,,IC50,nM,,8.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860839,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.67', 'le': '0.20', 'lle': '-0.43', 'sei': '5.14'}",CHEMBL5542692,,CHEMBL5542692,8.68,0,http://www.openphacts.org/units/Nanomolar,4059610,=,1,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860840,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.33', 'le': '0.21', 'lle': '0.10', 'sei': '5.46'}",CHEMBL5557016,,CHEMBL5557016,9.21,0,http://www.openphacts.org/units/Nanomolar,4059611,=,1,1,=,,IC50,nM,,0.62,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.62
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860841,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.74', 'le': '0.18', 'lle': '-1.19', 'sei': '4.69'}",CHEMBL5543056,,CHEMBL5543056,7.92,0,http://www.openphacts.org/units/Nanomolar,4059612,=,1,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860842,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.88', 'le': '0.19', 'lle': '-1.33', 'sei': '4.84'}",CHEMBL5532439,,CHEMBL5532439,8.17,0,http://www.openphacts.org/units/Nanomolar,4059613,=,1,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860843,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.52', 'le': '0.18', 'lle': '-1.88', 'sei': '4.74'}",CHEMBL5562934,,CHEMBL5562934,8.01,0,http://www.openphacts.org/units/Nanomolar,4059614,=,1,1,=,,IC50,nM,,9.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860844,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.65', 'le': '0.16', 'lle': '-2.88', 'sei': '4.38'}",CHEMBL5558697,,CHEMBL5558697,7.40,1,http://www.openphacts.org/units/Nanomolar,4059615,=,1,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860845,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3Cc3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.56', 'le': '0.16', 'lle': '-1.90', 'sei': '4.19'}",CHEMBL5563903,,CHEMBL5563903,7.08,0,http://www.openphacts.org/units/Nanomolar,4059616,=,1,1,=,,IC50,nM,,84.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860846,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)c(F)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.78', 'le': '0.18', 'lle': '-1.13', 'sei': '4.81'}",CHEMBL5557944,,CHEMBL5557944,8.12,0,http://www.openphacts.org/units/Nanomolar,4059617,=,1,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860847,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2F)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.24', 'le': '0.19', 'lle': '-0.74', 'sei': '5.04'}",CHEMBL5567807,,CHEMBL5567807,8.51,0,http://www.openphacts.org/units/Nanomolar,4059618,=,1,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,,25860848,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2Cl)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,,CHEMBL5568064,,CHEMBL5568064,,1,http://www.openphacts.org/units/Nanomolar,4059619,>,1,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860849,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cn2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.88', 'le': '0.20', 'lle': '0.35', 'sei': '4.87'}",CHEMBL5532350,,CHEMBL5532350,8.85,0,http://www.openphacts.org/units/Nanomolar,4059620,=,1,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860850,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.24', 'le': '0.17', 'lle': '-1.46', 'sei': '4.53'}",CHEMBL5523489,,CHEMBL5523489,7.64,0,http://www.openphacts.org/units/Nanomolar,4059592,=,1,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,,25860851,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)o2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,,CHEMBL5566112,,CHEMBL5566112,,1,http://www.openphacts.org/units/Nanomolar,4059593,>,1,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,,25860852,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cccc(CN3CCCC3c3ccccc3C3CC3)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,,CHEMBL5542383,,CHEMBL5542383,,1,http://www.openphacts.org/units/Nanomolar,4059594,>,1,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860853,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.62', 'le': '0.18', 'lle': '-1.05', 'sei': '4.79'}",CHEMBL5568336,,CHEMBL5568336,8.09,0,http://www.openphacts.org/units/Nanomolar,4059595,=,1,1,=,,IC50,nM,,8.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860854,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.71', 'le': '0.16', 'lle': '-1.70', 'sei': '4.34'}",CHEMBL5561459,,CHEMBL5561459,7.33,1,http://www.openphacts.org/units/Nanomolar,4059596,=,1,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860855,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.62', 'le': '0.18', 'lle': '-1.07', 'sei': '4.72'}",CHEMBL5559280,,CHEMBL5559280,7.96,0,http://www.openphacts.org/units/Nanomolar,4059597,=,1,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860856,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(N4CCCC4c4ccccc4C4CC4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.78', 'le': '0.17', 'lle': '-1.17', 'sei': '4.43'}",CHEMBL5565358,,CHEMBL5565358,7.62,1,http://www.openphacts.org/units/Nanomolar,4059598,=,1,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860857,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.06', 'le': '0.21', 'lle': '0.10', 'sei': '5.36'}",CHEMBL5531998,,CHEMBL5531998,9.06,0,http://www.openphacts.org/units/Nanomolar,4059599,=,1,1,=,,IC50,nM,,0.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.88
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860858,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.97', 'le': '0.21', 'lle': '0.09', 'sei': '5.31'}",CHEMBL5564159,,CHEMBL5564159,8.96,0,http://www.openphacts.org/units/Nanomolar,4059600,=,1,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860859,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.98', 'le': '0.21', 'lle': '1.10', 'sei': '5.23'}",CHEMBL5566724,,CHEMBL5566724,9.00,0,http://www.openphacts.org/units/Nanomolar,4059601,=,1,1,=,,IC50,nM,,0.99,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.99
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860860,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(CN3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.69', 'le': '0.20', 'lle': '-0.23', 'sei': '5.26'}",CHEMBL5559354,,CHEMBL5559354,8.89,0,http://www.openphacts.org/units/Nanomolar,4059602,=,1,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860861,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(CN3CCCC3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.70', 'le': '0.20', 'lle': '1.25', 'sei': '5.01'}",CHEMBL5568386,,CHEMBL5568386,8.62,0,http://www.openphacts.org/units/Nanomolar,4059603,=,1,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860862,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(CN3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.47', 'le': '0.22', 'lle': '1.42', 'sei': '5.56'}",CHEMBL5564702,,CHEMBL5564702,9.57,0,http://www.openphacts.org/units/Nanomolar,4059582,=,1,1,=,,IC50,nM,,0.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.27
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860863,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.99', 'le': '0.23', 'lle': '1.63', 'sei': '5.99'}",CHEMBL5557867,,CHEMBL5557867,10.31,0,http://www.openphacts.org/units/Nanomolar,4059583,=,1,1,=,,IC50,nM,,0.049,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.049
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860864,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.10', 'le': '0.23', 'lle': '1.73', 'sei': '6.05'}",CHEMBL5555281,,CHEMBL5555281,10.41,1,http://www.openphacts.org/units/Nanomolar,4059584,=,1,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860865,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.37', 'le': '0.20', 'lle': '0.24', 'sei': '5.19'}",CHEMBL5564343,,CHEMBL5564343,8.92,1,http://www.openphacts.org/units/Nanomolar,4059585,=,1,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860866,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.92', 'le': '0.23', 'lle': '2.02', 'sei': '5.77'}",CHEMBL5560955,,CHEMBL5560955,9.92,0,http://www.openphacts.org/units/Nanomolar,4059586,=,1,1,=,,IC50,nM,,0.12,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.12
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860867,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(CN4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.70', 'le': '0.18', 'lle': '0.06', 'sei': '4.77'}",CHEMBL5565924,,CHEMBL5565924,8.21,0,http://www.openphacts.org/units/Nanomolar,4059587,=,1,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860868,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(CN2CCCC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.37', 'le': '0.18', 'lle': '-0.74', 'sei': '4.76'}",CHEMBL5562147,,CHEMBL5562147,8.19,0,http://www.openphacts.org/units/Nanomolar,4059588,=,1,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860869,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(C3CC(N4CCCC4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.21', 'le': '0.17', 'lle': '-0.88', 'sei': '4.68'}",CHEMBL5562740,,CHEMBL5562740,8.05,0,http://www.openphacts.org/units/Nanomolar,4059589,=,1,1,=,,IC50,nM,,8.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860870,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(N3CC(N4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.50', 'le': '0.18', 'lle': '1.24', 'sei': '4.59'}",CHEMBL5559198,,CHEMBL5559198,8.05,1,http://www.openphacts.org/units/Nanomolar,4059590,=,1,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860871,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3CC(N4CCC[C@H]4c4ccccc4C4CC4)CC3C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.97', 'le': '0.17', 'lle': '-0.56', 'sei': '4.41'}",CHEMBL5561898,,CHEMBL5561898,7.58,0,http://www.openphacts.org/units/Nanomolar,4059591,=,1,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860872,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.05', 'le': '0.21', 'lle': '0.98', 'sei': '5.49'}",CHEMBL5565335,,CHEMBL5565335,9.44,0,http://www.openphacts.org/units/Nanomolar,4059621,=,1,1,=,,IC50,nM,,0.36,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.36
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860873,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.29', 'le': '0.20', 'lle': '0.34', 'sei': '5.11'}",CHEMBL5557109,,CHEMBL5557109,8.80,0,http://www.openphacts.org/units/Nanomolar,4059622,=,1,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860874,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccc(Cl)cc2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.01', 'le': '0.19', 'lle': '0.09', 'sei': '4.97'}",CHEMBL5554998,,CHEMBL5554998,8.55,0,http://www.openphacts.org/units/Nanomolar,4059623,=,1,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860875,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Br)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.90', 'le': '0.22', 'lle': '1.23', 'sei': '5.69'}",CHEMBL5562355,,CHEMBL5562355,9.80,0,http://www.openphacts.org/units/Nanomolar,4059624,=,1,1,=,,IC50,nM,,0.16,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.16
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860876,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.34', 'le': '0.23', 'lle': '2.17', 'sei': '5.98'}",CHEMBL5564290,,CHEMBL5564290,10.29,0,http://www.openphacts.org/units/Nanomolar,4059625,=,1,1,=,,IC50,nM,,0.051,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.051
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860877,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.29', 'le': '0.23', 'lle': '2.05', 'sei': '6.06'}",CHEMBL5542719,,CHEMBL5542719,10.42,0,http://www.openphacts.org/units/Nanomolar,4059626,=,1,1,=,,IC50,nM,,0.038,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.038
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860878,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.32', 'le': '0.23', 'lle': '1.69', 'sei': '6.17'}",CHEMBL5560614,,CHEMBL5560614,10.62,0,http://www.openphacts.org/units/Nanomolar,4059627,=,1,1,=,,IC50,nM,,0.024,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.024
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860879,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.57', 'le': '0.20', 'lle': '0.25', 'sei': '5.38'}",CHEMBL5568440,,CHEMBL5568440,9.26,0,http://www.openphacts.org/units/Nanomolar,4059628,=,1,1,=,,IC50,nM,,0.55,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.55
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860880,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.57', 'le': '0.20', 'lle': '0.17', 'sei': '5.37'}",CHEMBL5555045,,CHEMBL5555045,9.24,0,http://www.openphacts.org/units/Nanomolar,4059629,=,1,1,=,,IC50,nM,,0.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.58
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860881,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.02', 'le': '0.23', 'lle': '2.39', 'sei': '5.64'}",CHEMBL5567413,,CHEMBL5567413,10.21,0,http://www.openphacts.org/units/Nanomolar,4059630,=,1,1,=,,IC50,nM,,0.061,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.061
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860882,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CCOc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.60', 'le': '0.22', 'lle': '1.81', 'sei': '5.53'}",CHEMBL5556265,,CHEMBL5556265,10.02,0,http://www.openphacts.org/units/Nanomolar,4059631,=,1,1,=,,IC50,nM,,0.095,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.095
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860883,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Oc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.52', 'le': '0.22', 'lle': '1.53', 'sei': '5.58'}",CHEMBL5562626,,CHEMBL5562626,10.12,1,http://www.openphacts.org/units/Nanomolar,4059632,=,1,1,=,,IC50,nM,,0.076,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.076
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860884,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,COCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.31', 'le': '0.22', 'lle': '1.82', 'sei': '5.39'}",CHEMBL5561534,,CHEMBL5561534,9.77,0,http://www.openphacts.org/units/Nanomolar,4059633,=,1,1,=,,IC50,nM,,0.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.17
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860885,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.33', 'le': '0.23', 'lle': '2.77', 'sei': '6.07'}",CHEMBL5560718,,CHEMBL5560718,10.64,1,http://www.openphacts.org/units/Nanomolar,4059634,=,1,1,=,,IC50,nM,,0.023,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.023
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860886,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2N2CCCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.96', 'le': '0.21', 'lle': '1.33', 'sei': '5.56'}",CHEMBL5523480,,CHEMBL5523480,9.74,0,http://www.openphacts.org/units/Nanomolar,4059635,=,1,1,=,,IC50,nM,,0.18,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.18
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860887,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.08', 'le': '0.22', 'lle': '0.96', 'sei': '5.59'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,9.62,0,http://www.openphacts.org/units/Nanomolar,4059649,=,1,1,=,,IC50,nM,,0.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.24
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860888,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5C6COCC56)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.35', 'le': '0.23', 'lle': '2.22', 'sei': '6.17'}",CHEMBL5523428,,CHEMBL5523428,10.62,1,http://www.openphacts.org/units/Nanomolar,4059636,=,1,1,=,,IC50,nM,,0.024,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.024
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860889,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CC6COCC6C5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.68', 'le': '0.22', 'lle': '1.20', 'sei': '6.03'}",CHEMBL5562694,,CHEMBL5562694,10.38,0,http://www.openphacts.org/units/Nanomolar,4059637,=,1,1,=,,IC50,nM,,0.042,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.042
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860890,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCN(C)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.88', 'le': '0.23', 'lle': '1.55', 'sei': '6.26'}",CHEMBL5567889,,CHEMBL5567889,10.40,0,http://www.openphacts.org/units/Nanomolar,4059638,=,1,1,=,,IC50,nM,,0.04,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.04
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860891,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCC(F)(F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.03', 'le': '0.21', 'lle': '-0.44', 'sei': '6.07'}",CHEMBL5559861,,CHEMBL5559861,9.89,0,http://www.openphacts.org/units/Nanomolar,4059639,=,1,1,=,,IC50,nM,,0.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.13
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860892,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.04', 'le': '0.23', 'lle': '1.28', 'sei': '5.86'}",CHEMBL5314951,SONROTOCLAX,CHEMBL5314951,10.72,0,http://www.openphacts.org/units/Nanomolar,4059640,=,1,1,=,,IC50,nM,,0.019,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.019
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860893,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.10', 'le': '0.23', 'lle': '1.33', 'sei': '5.88'}",CHEMBL5560668,,CHEMBL5560668,10.77,0,http://www.openphacts.org/units/Nanomolar,4059641,=,1,1,=,,IC50,nM,,0.017,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.017
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860894,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@]1(C)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.13', 'le': '0.21', 'lle': '-0.04', 'sei': '5.85'}",CHEMBL5561680,,CHEMBL5561680,10.06,1,http://www.openphacts.org/units/Nanomolar,4059642,=,1,1,=,,IC50,nM,,0.087,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.087
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860895,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.21', 'le': '0.23', 'lle': '2.63', 'sei': '5.82'}",CHEMBL5567138,,CHEMBL5567138,10.55,0,http://www.openphacts.org/units/Nanomolar,4059643,=,1,1,=,,IC50,nM,,0.028,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.028
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860896,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '12.06', 'le': '0.23', 'lle': '2.50', 'sei': '5.75'}",CHEMBL5556406,,CHEMBL5556406,10.42,1,http://www.openphacts.org/units/Nanomolar,4059644,=,1,1,=,,IC50,nM,,0.038,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.038
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860897,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(CN4CCOCC4)C5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.85', 'le': '0.22', 'lle': '2.78', 'sei': '6.01'}",CHEMBL5558905,,CHEMBL5558905,10.54,0,http://www.openphacts.org/units/Nanomolar,4059645,=,1,1,=,,IC50,nM,,0.029,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.029
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860898,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(C4CCOCC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.93', 'le': '0.23', 'lle': '1.93', 'sei': '5.86'}",CHEMBL5568435,,CHEMBL5568435,10.62,0,http://www.openphacts.org/units/Nanomolar,4059646,=,1,1,=,,IC50,nM,,0.024,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.024
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860899,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)N[C@H](C4CCC(C)(O)CC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.79', 'le': '0.22', 'lle': '1.61', 'sei': '5.63'}",CHEMBL5532549,,CHEMBL5532549,10.82,0,http://www.openphacts.org/units/Nanomolar,4059647,=,1,1,=,,IC50,nM,,0.015,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.015
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860900,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)N[C@H](C4CCC(C)(O)CC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.76', 'le': '0.22', 'lle': '1.59', 'sei': '5.62'}",CHEMBL5532549,,CHEMBL5532549,10.80,0,http://www.openphacts.org/units/Nanomolar,4059648,=,1,1,=,,IC50,nM,,0.016,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.016
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860901,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '13.78', 'le': '0.26', 'lle': '3.13', 'sei': '9.24'}",CHEMBL3701382,VOB-560,CHEMBL3701382,9.89,0,http://www.openphacts.org/units/Nanomolar,4059650,=,1,1,=,,IC50,nM,,0.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.13
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860902,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.72', 'le': '0.21', 'lle': '1.67', 'sei': '5.22'}",CHEMBL5567397,,CHEMBL5567397,9.46,0,http://www.openphacts.org/units/Nanomolar,4059651,=,1,1,=,,IC50,nM,,0.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.35
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860903,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CN(c2cc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c2cc3cc[nH]c3nc2O1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.66', 'le': '0.19', 'lle': '0.13', 'sei': '5.09'}",CHEMBL5314523,LACUTOCLAX,CHEMBL5314523,8.92,0,http://www.openphacts.org/units/Nanomolar,4059652,=,1,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860904,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCCn3nc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc32)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.11', 'le': '0.16', 'lle': '-2.26', 'sei': '3.94'}",CHEMBL5560115,,CHEMBL5560115,7.35,0,http://www.openphacts.org/units/Nanomolar,4059653,=,1,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,45.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25860905,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510211,Inhibition of Bcl-2 (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3n(n2)C(c2ccc(Cl)cc2)CCN3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.54', 'le': '0.17', 'lle': '-0.45', 'sei': '3.42'}",CHEMBL5558230,,CHEMBL5558230,6.69,0,http://www.openphacts.org/units/Nanomolar,4059654,=,1,1,=,,IC50,nM,,205.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,205.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861149,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.33', 'le': '0.20', 'lle': '0.21', 'sei': '5.17'}",CHEMBL5555281,,CHEMBL5555281,8.89,0,http://www.openphacts.org/units/Nanomolar,4059584,=,1,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861150,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.92', 'le': '0.17', 'lle': '-0.84', 'sei': '4.43'}",CHEMBL5565335,,CHEMBL5565335,7.62,0,http://www.openphacts.org/units/Nanomolar,4059621,=,1,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861151,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.48', 'le': '0.16', 'lle': '-1.22', 'sei': '4.21'}",CHEMBL5557109,,CHEMBL5557109,7.24,0,http://www.openphacts.org/units/Nanomolar,4059622,=,1,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861152,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccc(Cl)cc2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.10', 'le': '0.16', 'lle': '-1.54', 'sei': '4.02'}",CHEMBL5554998,,CHEMBL5554998,6.92,0,http://www.openphacts.org/units/Nanomolar,4059623,=,1,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861153,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Br)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.77', 'le': '0.18', 'lle': '-0.68', 'sei': '4.58'}",CHEMBL5562355,,CHEMBL5562355,7.89,0,http://www.openphacts.org/units/Nanomolar,4059624,=,1,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861154,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.08', 'le': '0.19', 'lle': '0.29', 'sei': '4.89'}",CHEMBL5564290,,CHEMBL5564290,8.41,0,http://www.openphacts.org/units/Nanomolar,4059625,=,1,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861155,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.03', 'le': '0.19', 'lle': '0.14', 'sei': '4.95'}",CHEMBL5542719,,CHEMBL5542719,8.51,0,http://www.openphacts.org/units/Nanomolar,4059626,=,1,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861156,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.14', 'le': '0.19', 'lle': '-0.19', 'sei': '5.08'}",CHEMBL5560614,,CHEMBL5560614,8.74,0,http://www.openphacts.org/units/Nanomolar,4059627,=,1,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861157,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.90', 'le': '0.17', 'lle': '-1.21', 'sei': '4.53'}",CHEMBL5568440,,CHEMBL5568440,7.80,0,http://www.openphacts.org/units/Nanomolar,4059628,=,1,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861158,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.89', 'le': '0.17', 'lle': '-1.30', 'sei': '4.52'}",CHEMBL5555045,,CHEMBL5555045,7.77,0,http://www.openphacts.org/units/Nanomolar,4059629,=,1,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861159,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.95', 'le': '0.19', 'lle': '0.64', 'sei': '4.67'}",CHEMBL5567413,,CHEMBL5567413,8.46,0,http://www.openphacts.org/units/Nanomolar,4059630,=,1,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861160,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CCOc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.69', 'le': '0.18', 'lle': '0.17', 'sei': '4.62'}",CHEMBL5556265,,CHEMBL5556265,8.38,0,http://www.openphacts.org/units/Nanomolar,4059631,=,1,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861161,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)Oc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.67', 'le': '0.18', 'lle': '-0.10', 'sei': '4.69'}",CHEMBL5562626,,CHEMBL5562626,8.49,0,http://www.openphacts.org/units/Nanomolar,4059632,=,1,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861162,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,COCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.26', 'le': '0.18', 'lle': '0.05', 'sei': '4.41'}",CHEMBL5561534,,CHEMBL5561534,8.00,0,http://www.openphacts.org/units/Nanomolar,4059633,=,1,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861163,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.44', 'le': '0.20', 'lle': '1.14', 'sei': '5.14'}",CHEMBL5560718,,CHEMBL5560718,9.01,0,http://www.openphacts.org/units/Nanomolar,4059634,=,1,1,=,,IC50,nM,,0.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.98
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861164,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2N2CCCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.42', 'le': '0.18', 'lle': '-0.03', 'sei': '4.78'}",CHEMBL5523480,,CHEMBL5523480,8.38,0,http://www.openphacts.org/units/Nanomolar,4059635,=,1,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861165,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.75', 'le': '0.17', 'lle': '-1.06', 'sei': '4.42'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,7.60,0,http://www.openphacts.org/units/Nanomolar,4059649,=,1,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861166,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5C6COCC56)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.00', 'le': '0.19', 'lle': '0.20', 'sei': '5.00'}",CHEMBL5523428,,CHEMBL5523428,8.60,1,http://www.openphacts.org/units/Nanomolar,4059636,=,1,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861167,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CC6COCC6C5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.75', 'sei': '4.90'}",CHEMBL5562694,,CHEMBL5562694,8.43,0,http://www.openphacts.org/units/Nanomolar,4059637,=,1,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861168,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCN(C)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.05', 'le': '0.19', 'lle': '-0.05', 'sei': '5.30'}",CHEMBL5567889,,CHEMBL5567889,8.80,0,http://www.openphacts.org/units/Nanomolar,4059638,=,1,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861169,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCC(F)(F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.60', 'le': '0.18', 'lle': '-1.73', 'sei': '5.28'}",CHEMBL5559861,,CHEMBL5559861,8.60,0,http://www.openphacts.org/units/Nanomolar,4059639,=,1,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861170,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.64', 'le': '0.20', 'lle': '0.03', 'sei': '5.17'}",CHEMBL5314951,SONROTOCLAX,CHEMBL5314951,9.47,0,http://www.openphacts.org/units/Nanomolar,4059640,=,1,1,=,,IC50,nM,,0.34,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.34
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861171,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.82', 'le': '0.19', 'lle': '-0.70', 'sei': '4.78'}",CHEMBL5560668,,CHEMBL5560668,8.74,0,http://www.openphacts.org/units/Nanomolar,4059641,=,1,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861172,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CO[C@]1(C)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.72', 'le': '0.17', 'lle': '-2.21', 'sei': '4.58'}",CHEMBL5561680,,CHEMBL5561680,7.89,0,http://www.openphacts.org/units/Nanomolar,4059642,=,1,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861173,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.25', 'le': '0.20', 'lle': '0.93', 'sei': '4.88'}",CHEMBL5567138,,CHEMBL5567138,8.85,0,http://www.openphacts.org/units/Nanomolar,4059643,=,1,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861174,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '10.53', 'le': '0.20', 'lle': '1.18', 'sei': '5.02'}",CHEMBL5556406,,CHEMBL5556406,9.10,0,http://www.openphacts.org/units/Nanomolar,4059644,=,1,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861175,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(CN4CCOCC4)C5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.70', 'le': '0.18', 'lle': '0.86', 'sei': '4.92'}",CHEMBL5558905,,CHEMBL5558905,8.62,0,http://www.openphacts.org/units/Nanomolar,4059645,=,1,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861176,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)NC(C4CCOCC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.85', 'le': '0.19', 'lle': '0.08', 'sei': '4.84'}",CHEMBL5568435,,CHEMBL5568435,8.77,0,http://www.openphacts.org/units/Nanomolar,4059646,=,1,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861177,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)N[C@H](C4CCC(C)(O)CC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.98', 'le': '0.19', 'lle': '-0.05', 'sei': '4.76'}",CHEMBL5532549,,CHEMBL5532549,9.16,0,http://www.openphacts.org/units/Nanomolar,4059647,=,1,1,=,,IC50,nM,,0.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.69
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861178,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4cc5c(c([N+](=O)[O-])c4)N[C@H](C4CCC(C)(O)CC4)CO5)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '9.84', 'le': '0.19', 'lle': '-0.17', 'sei': '4.70'}",CHEMBL5532549,,CHEMBL5532549,9.04,0,http://www.openphacts.org/units/Nanomolar,4059648,=,1,1,=,,IC50,nM,,0.92,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.92
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861179,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '11.54', 'le': '0.22', 'lle': '1.52', 'sei': '7.74'}",CHEMBL3701382,VOB-560,CHEMBL3701382,8.28,0,http://www.openphacts.org/units/Nanomolar,4059650,=,1,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861180,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.21', 'le': '0.16', 'lle': '-0.55', 'sei': '4.00'}",CHEMBL5567397,,CHEMBL5567397,7.24,0,http://www.openphacts.org/units/Nanomolar,4059651,=,1,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,25861181,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '1.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '90.0'}]",CHEMBL5510215,Inhibition of Bcl-2 G101V mutant (unknown origin) using (Ac-GQVGRQLAIIGDK (FITC) INR-amide) as substrate preincubated for 30 mins followed by substrate addition and measured after 60 mins by TR-FRET assay,B,P10415,G101V,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1CN(c2cc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC(C)(C)CC4)CC3)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c2cc3cc[nH]c3nc2O1,,,CHEMBL5506028,J Med Chem,2024,"{'bei': '8.34', 'le': '0.16', 'lle': '-1.09', 'sei': '4.39'}",CHEMBL5314523,LACUTOCLAX,CHEMBL5314523,7.70,0,http://www.openphacts.org/units/Nanomolar,4059652,=,1,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,,25948842,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '2.0', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '120.0'}]",CHEMBL5536176,Inhibition of Bcl-2 (unknown origin) incubated for 120 mins by TR-FRET assay,B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C(=O)[C@H](Cc1ccc(C(F)(F)F)cc1)NC(=O)/C(C#N)=C/c1ccccc1P(C)(C)=O,,,CHEMBL5532718,ACS Med Chem Lett,2024,,CHEMBL5572242,,CHEMBL5572242,,0,http://www.openphacts.org/units/Nanomolar,4076979,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044971,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n(CCN3CCOCC3)c3c(-c4ccccc4Cn4cc(CCNC(=O)c5ccc(F)cc5)c5ccccc54)cccc23)cc(C)c1Cl,,,CHEMBL5584309,J Med Chem,2024,,CHEMBL5598253,,CHEMBL5598253,,0,http://www.openphacts.org/units/Nanomolar,4096009,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044972,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n(CCN3CCOCC3)c3c(-c4ccccc4Cn4cc(CCNC(=O)c5ccc(Cl)cc5)c5ccccc54)cccc23)cc(C)c1Cl,,,CHEMBL5584309,J Med Chem,2024,,CHEMBL5598470,,CHEMBL5598470,,0,http://www.openphacts.org/units/Nanomolar,4096010,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044973,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n(CCN3CCOCC3)c3c(-c4ccccc4Cn4cc(CCNC(=O)c5ccc(OC(F)(F)F)cc5)c5ccccc54)cccc23)cc(C)c1Cl,,,CHEMBL5584309,J Med Chem,2024,,CHEMBL5597184,,CHEMBL5597184,,0,http://www.openphacts.org/units/Nanomolar,4096014,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044974,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n(CCN3CCOCC3)c3c(-c4ccccc4Cn4cc(CCN(CCN5CCOCC5)S(=O)(=O)c5ccc(F)cc5)c5ccccc54)cccc23)cc(C)c1Cl,,,CHEMBL5584309,J Med Chem,2024,,CHEMBL5596340,,CHEMBL5596340,,0,http://www.openphacts.org/units/Nanomolar,4096023,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044975,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c(COc2ccc(N3CCN(S(=O)(=O)N(C)C)CC3)cc2)c1-c1cccc2c(CCCOc3cccc4ccccc34)c(C(=O)O)n(CCN3CCOCC3)c12,,,CHEMBL5584309,J Med Chem,2024,,CHEMBL3417704,,CHEMBL3417704,,0,http://www.openphacts.org/units/Nanomolar,4096024,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
,,26044976,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,Potential transcription error,"Values appear to be an order of magnitude different from previously reported, so units may be incorrect",CHEMBL5584309,J Med Chem,2024,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,1,http://www.openphacts.org/units/Nanomolar,4096026,>,1,1,>,,IC50,nM,,100000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,100.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26044977,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '0.5', 'text_value': None, 'type': 'TIME', 'units': 'min', 'value': '30.0'}]",CHEMBL5586931,Binding affinity to Bcl-2 (unknown origin) pre-incubated for 30 mins followed by addition FAM-peptide further incubated for 20 mins by fluorescence polarization-based binding assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)=CCC[C@]1(C)C=Cc2c(O)c3c(c(CC=C(C)C)c2O1)O[C@]12C(=C[C@@H]4C[C@H]1C(C)(C)O[C@@]2(C/C=C(/C)C(=O)O)C4=O)C3=O,,,CHEMBL5584309,J Med Chem,2024,"{'bei': '10.81', 'le': '0.20', 'lle': '-0.44', 'sei': '5.69'}",CHEMBL555017,GAMBOGIC ACID,CHEMBL555017,6.80,0,http://www.openphacts.org/units/Nanomolar,4096027,=,1,1,=,,IC50,nM,,160.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,0.16
,,26117925,[],CHEMBL5611695,Inhibition of Bcl-2 (unknown origin),B,,,BAO_0000190,BAO_0000357,single protein format,C=CC(=O)N(c1ccc(O[C@@H]2CC[C@@H](N)C2)cc1)[C@@H](C)c1ccc(C(F)(F)F)c(C#N)c1,,,CHEMBL5608257,J Med Chem,2024,,CHEMBL5613766,,CHEMBL5613766,,0,http://www.openphacts.org/units/Nanomolar,4123581,>,1,1,>,,IC50,nM,,30000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,uM,UO_0000065,,30.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26187997,[],CHEMBL5635886,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5634110,Eur J Med Chem,2023,"{'bei': '8.20', 'le': '0.17', 'lle': '-0.84', 'sei': '6.22'}",CHEMBL443684,NAVITOCLAX,CHEMBL443684,7.99,1,http://www.openphacts.org/units/Nanomolar,4133922,=,1,1,=,,IC50,nM,,10.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26187998,[],CHEMBL5635886,Inhibition of Bcl-2 (unknown origin) by fluorescence polarization assay,B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(CN6CC(F)(F)C6)COC5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5634110,Eur J Med Chem,2023,"{'bei': '8.61', 'le': '0.18', 'lle': '0.88', 'sei': '6.18'}",CHEMBL5647478,,CHEMBL5647478,7.76,0,http://www.openphacts.org/units/Nanomolar,4133923,=,1,1,=,,IC50,nM,,17.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.3
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26329340,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719140,Inhibition of Bcl-2 in human RPMI-8226 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '6.97', 'le': '0.14', 'lle': '-2.21', 'sei': '4.43'}",CHEMBL376408,ABT 737,CHEMBL376408,5.67,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,2139.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2139.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26329476,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719224,Inhibition of Bcl-2 in bortezomib Resistant human RPMI-8226 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '6.38', 'le': '0.13', 'lle': '-2.69', 'sei': '4.05'}",CHEMBL376408,ABT 737,CHEMBL376408,5.19,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,6457.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6457.5
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26329630,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719318,Inhibition of Bcl-2 in Melphalan Resistant human RPMI-8226 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '7.13', 'le': '0.14', 'lle': '-2.08', 'sei': '4.53'}",CHEMBL376408,ABT 737,CHEMBL376408,5.80,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,1585.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1585.9
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26329789,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719412,Inhibition of Bcl-2 in human ANBL-6 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '6.15', 'le': '0.12', 'lle': '-2.88', 'sei': '3.90'}",CHEMBL376408,ABT 737,CHEMBL376408,5.00,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10000.0
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26329946,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719505,Inhibition of Bcl-2 in human bortezomib-resistant ANBL6 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '6.55', 'le': '0.13', 'lle': '-2.55', 'sei': '4.16'}",CHEMBL376408,ABT 737,CHEMBL376408,5.33,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,4678.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4678.4
"{'action_type': 'INHIBITOR', 'description': 'Negatively effects (inhibits) the normal functioning of the protein e.g., prevention of enzymatic reaction or activation of downstream pathway', 'parent_type': 'NEGATIVE MODULATOR'}",,26330103,"[{'comments': None, 'relation': '=', 'result_flag': 0, 'standard_relation': '=', 'standard_text_value': None, 'standard_type': 'TIME', 'standard_units': 'hr', 'standard_value': '72.0', 'text_value': None, 'type': 'TIME', 'units': 'hrs', 'value': '72.0'}]",CHEMBL5719598,Inhibition of Bcl-2 in human U-266 cells assessed as reduction of cell growth incubated for 72 hrs by CellTiter 96 aqueous one solution cell proliferation assay,B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(Cc4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL5715952,Oncotarget,2015,"{'bei': '6.15', 'le': '0.12', 'lle': '-2.88', 'sei': '3.90'}",CHEMBL376408,ABT 737,CHEMBL376408,5.00,0,http://www.openphacts.org/units/Nanomolar,4140637,=,72,1,=,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10000.0
,198897,26576035,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.43', 'le': '0.21', 'lle': '1.63', 'sei': '8.30'}",CHEMBL3704808,,CHEMBL3704808,8.43,0,http://www.openphacts.org/units/Nanomolar,2582327,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,198898,26576038,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.62', 'le': '0.21', 'lle': '1.64', 'sei': '8.23'}",CHEMBL3704809,,CHEMBL3704809,7.96,0,http://www.openphacts.org/units/Nanomolar,2582328,=,37,1,=,,IC50,nM,,11.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.1
,198899,26576041,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.26', 'le': '0.22', 'lle': '1.63', 'sei': '9.40'}",CHEMBL3704810,,CHEMBL3704810,8.22,0,http://www.openphacts.org/units/Nanomolar,2582329,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,198900,26576044,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.21', 'lle': '2.45', 'sei': '7.79'}",CHEMBL3704811,,CHEMBL3704811,8.07,0,http://www.openphacts.org/units/Nanomolar,2582330,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,198901,26576047,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)ncn3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.13', 'le': '0.21', 'lle': '0.99', 'sei': '8.45'}",CHEMBL3704812,,CHEMBL3704812,8.11,0,http://www.openphacts.org/units/Nanomolar,2582331,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,198902,26576050,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.81', 'le': '0.22', 'lle': '2.39', 'sei': '7.39'}",CHEMBL3704813,,CHEMBL3704813,8.10,0,http://www.openphacts.org/units/Nanomolar,2582332,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,198903,26576053,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)N4CCN(C)CC4)c(C(F)(F)F)n2C)OCO3)CC1,,,CHEMBL3638572,,2015,"{'bei': '9.40', 'le': '0.18', 'lle': '2.51', 'sei': '7.49'}",CHEMBL3704814,,CHEMBL3704814,7.28,0,http://www.openphacts.org/units/Nanomolar,2582333,=,37,1,=,,IC50,nM,,52.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,52.9
,201220,26576056,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3ccn(C)c3c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.96', 'le': '0.18', 'lle': '1.72', 'sei': '6.30'}",CHEMBL3704815,,CHEMBL3704815,7.80,0,http://www.openphacts.org/units/Nanomolar,2582334,=,37,1,=,,IC50,nM,,15.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.9
,201221,26576059,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C2=CC3C(C=CN3C)N=C2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.90', 'le': '0.22', 'lle': '2.63', 'sei': '9.27'}",CHEMBL3704816,,CHEMBL3704816,8.70,0,http://www.openphacts.org/units/Nanomolar,2582335,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,201222,26576062,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccc(F)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.58', 'le': '0.18', 'lle': '0.89', 'sei': '6.61'}",CHEMBL3704817,,CHEMBL3704817,6.35,0,http://www.openphacts.org/units/Nanomolar,2582336,=,37,1,=,,IC50,nM,,447.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,447.0
,278901,26589857,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(C)C)C2=O)C(=O)c2cc(O)c(O)c(C(C)C)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '13.11', 'le': '0.24', 'lle': '1.58', 'sei': '4.31'}",CHEMBL1272170,,CHEMBL1272170,6.43,1,http://www.openphacts.org/units/Nanomolar,2576273,=,37,1,=,,IC50,nM,,370.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,370.0
,278902,26589860,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC(C)C)C2=O)C(=O)c2cc(O)c(O)c(CC(C)C)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '12.73', 'le': '0.24', 'lle': '1.60', 'sei': '4.42'}",CHEMBL1272224,,CHEMBL1272224,6.60,1,http://www.openphacts.org/units/Nanomolar,2576277,=,37,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,250.0
,278903,26589863,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccc(C)cc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccc(C)cc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.57', 'le': '0.16', 'lle': '-1.28', 'sei': '3.69'}",CHEMBL1269076,,CHEMBL1269076,5.51,1,http://www.openphacts.org/units/Nanomolar,2576281,=,37,1,=,,IC50,nM,,3120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3120.0
,278904,26589866,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '11.14', 'le': '0.20', 'lle': '0.76', 'sei': '4.38'}",CHEMBL1269107,,CHEMBL1269107,6.54,1,http://www.openphacts.org/units/Nanomolar,2576283,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,278905,26589869,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CC3CCCC3)C2=O)C(=O)c2cc(O)c(O)c(CC3CCCC3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.89', 'le': '0.18', 'lle': '-0.43', 'sei': '3.78'}",CHEMBL1269073,,CHEMBL1269073,5.64,1,http://www.openphacts.org/units/Nanomolar,2576278,=,37,1,=,,IC50,nM,,2270.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2270.0
,278906,26589872,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCC3CCCCC3)C2=O)C(=O)c2cc(O)c(O)c(CCC3CCCCC3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.25', 'le': '0.15', 'lle': '-2.46', 'sei': '3.47'}",CHEMBL1269074,,CHEMBL1269074,5.17,1,http://www.openphacts.org/units/Nanomolar,2576279,=,37,1,=,,IC50,nM,,6730.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6730.0
,278907,26589875,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.09', 'le': '0.17', 'lle': '-0.58', 'sei': '3.75'}",CHEMBL1269075,,CHEMBL1269075,5.59,1,http://www.openphacts.org/units/Nanomolar,2576280,=,37,1,=,,IC50,nM,,2570.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2570.0
,278908,26589878,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3CCCc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(CCCc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '8.81', 'le': '0.16', 'lle': '-1.29', 'sei': '3.80'}",CHEMBL1269077,,CHEMBL1269077,5.66,1,http://www.openphacts.org/units/Nanomolar,2576282,=,37,1,=,,IC50,nM,,2170.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2170.0
,278909,26589881,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3Cc3ccc(Cl)cc3)C2=O)C(=O)c2cc(O)c(O)c(Cc3ccc(Cl)cc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.87', 'le': '0.19', 'lle': '-0.62', 'sei': '4.34'}",CHEMBL1269110,,CHEMBL1269110,6.47,1,http://www.openphacts.org/units/Nanomolar,2576284,=,37,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,340.0
,278910,26589884,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)Cc3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)Cc3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '10.36', 'le': '0.19', 'lle': '1.21', 'sei': '3.63'}",CHEMBL1269072,,CHEMBL1269072,6.66,1,http://www.openphacts.org/units/Nanomolar,2576276,=,37,1,=,,IC50,nM,,220.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,220.0
,278911,26589887,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C2=C(C)C(=O)c3c(cc(O)c(O)c3C(=O)NCC(C)c3ccccc3)C2=O)C(=O)c2cc(O)c(O)c(C(=O)NCC(C)c3ccccc3)c2C1=O,,,CHEMBL3638406,,2015,"{'bei': '9.11', 'le': '0.17', 'lle': '0.97', 'sei': '3.20'}",CHEMBL1269070,,CHEMBL1269070,6.64,1,http://www.openphacts.org/units/Nanomolar,2576274,=,37,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,230.0
,278912,26589890,[],CHEMBL5729944,"Fluorescence Polarization Assay: A Bak BH3 peptide (F-BakBH3) (GQVGRQLAIIGDDINR (SEQ ID NO:1)) was labeled at the N-terminus with fluorescein isothiocyanate (FITC) (Molecular Probes) and purified by HPLC. For competitive binding assays, 100 nM GST-BCL-XL DTM protein was preincubated with the tested compound at varying concentrations in 47.5 uL PBS (pH=7.4) in 96-well black plates at room temperature for 10 min, then 2.5 uL of 100 nM FITC-labeled Bak BH3 peptide was added to produce a final volume of 50 uL. The wild-type and mutant Bak BH3 peptides were included in each assay plate as positive and negative controls, respectively. After 30 min incubation at room temperature, the polarization values in millipolarization units were measured at excitation/emission wavelengths of 480/535 nm with a multilabel plate reader (PerkinElmer). IC50 was determined by fitting the experimental data to a sigmoidal dose-response nonlinear regression model.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccc(CCNC(=O)c2c(O)c(O)cc3c2C(=O)C(C)=C(C2=C(C)C(=O)c4c(cc(O)c(O)c4C(=O)NCCc4ccc(CC)cc4)C2=O)C3=O)cc1,,,CHEMBL3638406,,2015,"{'bei': '8.82', 'le': '0.16', 'lle': '1.01', 'sei': '3.22'}",CHEMBL1269012,,CHEMBL1269012,6.68,1,http://www.openphacts.org/units/Nanomolar,2576275,=,37,1,=,,IC50,nM,,210.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,210.0
,298889,26595683,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCO)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,,CHEMBL3703598,,CHEMBL3703598,,0,http://www.openphacts.org/units/Nanomolar,2581050,<,37,1,<,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298890,26595686,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1[N+](=O)[O-],,,CHEMBL3638929,,2015,"{'bei': '11.49', 'le': '0.23', 'lle': '1.01', 'sei': '6.56'}",CHEMBL3703599,,CHEMBL3703599,9.52,0,http://www.openphacts.org/units/Nanomolar,2581051,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298891,26595689,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,,CHEMBL3703600,,CHEMBL3703600,,0,http://www.openphacts.org/units/Nanomolar,2581052,<,37,1,<,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298892,26595692,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.69', 'le': '0.20', 'lle': '0.65', 'sei': '5.95'}",CHEMBL3703601,,CHEMBL3703601,9.30,0,http://www.openphacts.org/units/Nanomolar,2581053,=,37,1,=,,IC50,nM,,0.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.5
,298893,26595695,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCO)CCO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.32', 'le': '0.19', 'lle': '1.48', 'sei': '5.15'}",CHEMBL3703602,,CHEMBL3703602,9.10,0,http://www.openphacts.org/units/Nanomolar,2581054,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,298894,26595698,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(C[C@H](O)CF)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.72', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703603,,CHEMBL3703603,9.00,0,http://www.openphacts.org/units/Nanomolar,2581055,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298895,26595701,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN(CCOP(=O)(O)O)CCOP(=O)(O)O)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '7.66', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703604,,CHEMBL3703604,8.70,0,http://www.openphacts.org/units/Nanomolar,2581056,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,298896,26595704,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.70', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703605,,CHEMBL3703605,9.05,0,http://www.openphacts.org/units/Nanomolar,2581057,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,298897,26595707,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCOP(=O)(O)O)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.82', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703606,,CHEMBL3703606,9.05,0,http://www.openphacts.org/units/Nanomolar,2581058,=,37,1,=,,IC50,nM,,0.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.9
,298898,26595710,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCN(CCOP(=O)(O)O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703607,,CHEMBL3703607,9.15,0,http://www.openphacts.org/units/Nanomolar,2581059,=,37,1,=,,IC50,nM,,0.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.7
,298899,26595713,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.89', 'le': '0.18', 'lle': '0.18', 'sei': '5.18'}",CHEMBL3703608,,CHEMBL3703608,8.40,0,http://www.openphacts.org/units/Nanomolar,2581060,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,298900,26595716,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](N)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '8.89', 'le': '0.18', 'lle': '-0.09', 'sei': '5.26'}",CHEMBL3703609,,CHEMBL3703609,8.52,0,http://www.openphacts.org/units/Nanomolar,2581061,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,298901,26595719,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCN(CCO)CC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.80', 'le': '0.16', 'lle': '-0.11', 'sei': '4.71'}",CHEMBL3703610,,CHEMBL3703610,7.80,0,http://www.openphacts.org/units/Nanomolar,2581062,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,298902,26595722,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '6.89', 'le': '0.14', 'lle': '-2.06', 'sei': '4.54'}",CHEMBL3703611,,CHEMBL3703611,6.60,0,http://www.openphacts.org/units/Nanomolar,2581063,=,37,1,=,,IC50,nM,,253.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,253.0
,298903,26595725,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '8.90', 'le': '0.18', 'lle': '-0.14', 'sei': '5.86'}",CHEMBL3703612,,CHEMBL3703612,8.52,0,http://www.openphacts.org/units/Nanomolar,2581064,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,298904,26595728,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '10.45', 'le': '0.21', 'lle': '0.82', 'sei': '5.89'}",CHEMBL3703613,,CHEMBL3703613,9.10,0,http://www.openphacts.org/units/Nanomolar,2581065,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,298905,26595731,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '9.00', 'le': '0.18', 'lle': '-0.54', 'sei': '5.84'}",CHEMBL3703614,,CHEMBL3703614,8.70,0,http://www.openphacts.org/units/Nanomolar,2581066,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,298906,26595734,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '8.44', 'le': '0.17', 'lle': '-1.09', 'sei': '5.48'}",CHEMBL3703614,,CHEMBL3703614,8.15,0,http://www.openphacts.org/units/Nanomolar,2581066,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,298907,26595737,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N#C[C@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '6.13', 'le': '0.12', 'lle': '-3.32', 'sei': '3.98'}",CHEMBL3703615,,CHEMBL3703615,5.92,0,http://www.openphacts.org/units/Nanomolar,2581067,=,37,1,=,,IC50,nM,,1195.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1195.0
,298908,26595740,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)C[C@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.13', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703616,,CHEMBL3703616,9.52,0,http://www.openphacts.org/units/Nanomolar,2581068,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298909,26595743,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)C[C@@H]1COCCN1CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC([C@@H](O)c4ccccc4-c4ccc(Cl)cc4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL3638929,,2015,"{'bei': '9.13', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703617,,CHEMBL3703617,9.52,0,http://www.openphacts.org/units/Nanomolar,2581069,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,298910,26595746,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.34', 'le': '0.19', 'lle': '1.19', 'sei': '5.57'}",CHEMBL3703618,,CHEMBL3703618,9.22,0,http://www.openphacts.org/units/Nanomolar,2581070,=,37,1,=,,IC50,nM,,0.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.6
,298911,26595749,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCO[C@H](CO)C2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.11', 'le': '0.19', 'lle': '0.97', 'sei': '5.44'}",CHEMBL3703619,,CHEMBL3703619,9.00,0,http://www.openphacts.org/units/Nanomolar,2581071,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298912,26595752,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703620,,CHEMBL3703620,9.40,0,http://www.openphacts.org/units/Nanomolar,2581072,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298913,26595755,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCOC[C@@H]2CO)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCC([C@@H](O)c3ccccc3-c3ccc(Cl)cc3)CC2)cc1,,,CHEMBL3638929,,2015,"{'bei': '9.52', 'le': '0.19', 'lle': '1.37', 'sei': '5.68'}",CHEMBL3703621,,CHEMBL3703621,9.40,0,http://www.openphacts.org/units/Nanomolar,2581073,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298914,26595758,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCN(CC)CC1CN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC([C@@H](O)c5ccccc5-c5ccc(Cl)cc5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CCO1,,,CHEMBL3638929,,2015,"{'bei': '9.01', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703622,,CHEMBL3703622,9.40,0,http://www.openphacts.org/units/Nanomolar,2581074,=,37,1,=,,IC50,nM,,0.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.4
,298915,26595761,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CC(C)(C)OP(=O)(O)OCO[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.47', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703623,,CHEMBL3703623,8.40,0,http://www.openphacts.org/units/Nanomolar,2581075,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,298916,26595764,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CCOP(=O)(OCC)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '6.88', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703624,,CHEMBL3703624,7.52,0,http://www.openphacts.org/units/Nanomolar,2581076,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,298917,26595767,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,COP(=O)(O)O[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '8.56', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703625,,CHEMBL3703625,9.00,0,http://www.openphacts.org/units/Nanomolar,2581077,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,298918,26595770,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.86', 'le': '0.16', 'lle': '-1.11', 'sei': '4.98'}",CHEMBL3703626,,CHEMBL3703626,7.52,0,http://www.openphacts.org/units/Nanomolar,2581078,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,298919,26595773,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CNCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.36', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703627,,CHEMBL3703627,7.57,0,http://www.openphacts.org/units/Nanomolar,2581079,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,298920,26595776,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,NCC(=O)N[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.32', 'le': None, 'lle': None, 'sei': None}",CHEMBL3703628,,CHEMBL3703628,7.42,0,http://www.openphacts.org/units/Nanomolar,2581080,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,298921,26595779,[],CHEMBL5729981,"Fluorescence Polarization: Bcl-xL and Bcl-2 FP binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) may be determined using a variety of known methods. One such assay is a sensitive and quantitative in vitro binding assay using fluorescence polarization (""FP"") described by Wang, J.-L.; Zhang, Z-J.; Choksi, S.; Sjam. S.; Lu, Z.; Croce, C. M.; Alnemri, E. S.; Komgold, R.; Huang, Z. Cell permeable Bcl-2 binding peptides: a chemical approach to apoptosis induction in tumor cells. Cancer Res. 2000, 60, 1498-1502).Additionally, the binding affinity of compound(s) of Formulae (I), (I-a), (I-b), (I-c), (I-d) and/or (I-e) to Bcl-2 protein in vitro was determined by a competitive binding assay based on fluorescence polarization. For example, fluorescence polarization (""FP"") assays may be developed using a c-terminal 6.times.HIS tagged Bcl-2 (aa 1-204) and a C-terminal 6.times.HIS tagged Bcl-X.sub.L (aa 1-209). The tracer may be a synthetic peptide BH-3 peptide Bim conjugated to Fluores.",B,,,BAO_0000190,BAO_0000219,cell-based format,CN(C)[C@@H](c1ccccc1-c1ccc(Cl)cc1)C1CCN(c2ccc(C(=O)NS(=O)(=O)c3ccc(N[C@H](CCN4CCOCC4)CSc4ccccc4)c(S(=O)(=O)C(F)(F)F)c3)cc2)CC1,,,CHEMBL3638929,,2015,"{'bei': '7.74', 'le': '0.16', 'lle': '-1.61', 'sei': '5.94'}",CHEMBL3703629,,CHEMBL3703629,7.62,0,http://www.openphacts.org/units/Nanomolar,2581081,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,304775,26596547,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.97', 'le': '0.26', 'lle': '1.64', 'sei': '9.93'}",CHEMBL3701291,,CHEMBL3701291,8.30,0,http://www.openphacts.org/units/Nanomolar,2578595,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,304776,26596550,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)cn2C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.67', 'le': '0.20', 'lle': '0.28', 'sei': '8.64'}",CHEMBL3701292,,CHEMBL3701292,7.61,0,http://www.openphacts.org/units/Nanomolar,2578596,=,37,1,=,,IC50,nM,,24.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.6
,304777,26596553,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.55', 'le': '0.20', 'lle': '0.33', 'sei': '9.94'}",CHEMBL3701293,,CHEMBL3701293,7.67,0,http://www.openphacts.org/units/Nanomolar,2578597,=,37,1,=,,IC50,nM,,21.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.2
,304778,26596556,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cc1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.22', 'sei': '9.84'}",CHEMBL3701294,,CHEMBL3701294,7.60,0,http://www.openphacts.org/units/Nanomolar,2578598,=,37,1,=,,IC50,nM,,25.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.2
,304779,26596559,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)cn2C2CC2)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.08', 'le': '0.19', 'lle': '-0.54', 'sei': '9.84'}",CHEMBL3701295,,CHEMBL3701295,7.59,0,http://www.openphacts.org/units/Nanomolar,2578599,=,37,1,=,,IC50,nM,,25.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.6
,304780,26596562,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)cn2C)OCO3)CC1,,,CHEMBL3638572,,2015,"{'bei': '10.38', 'le': '0.19', 'lle': '1.24', 'sei': '8.00'}",CHEMBL3701296,,CHEMBL3701296,7.65,0,http://www.openphacts.org/units/Nanomolar,2578600,=,37,1,=,,IC50,nM,,22.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.4
,304781,26596565,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '1.07', 'sei': '9.96'}",CHEMBL3701297,,CHEMBL3701297,7.79,0,http://www.openphacts.org/units/Nanomolar,2578601,=,37,1,=,,IC50,nM,,16.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.2
,304782,26596568,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1CCCO,,,CHEMBL3638572,,2015,"{'bei': '11.17', 'le': '0.21', 'lle': '1.28', 'sei': '7.97'}",CHEMBL3701298,,CHEMBL3701298,7.85,0,http://www.openphacts.org/units/Nanomolar,2578602,=,37,1,=,,IC50,nM,,14.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.2
,304783,26596571,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.59', 'le': '0.21', 'lle': '1.65', 'sei': '8.60'}",CHEMBL3701299,,CHEMBL3701299,8.26,0,http://www.openphacts.org/units/Nanomolar,2578603,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304784,26596574,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '1.60', 'sei': '8.64'}",CHEMBL3701300,,CHEMBL3701300,8.36,0,http://www.openphacts.org/units/Nanomolar,2578604,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304785,26596577,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.24', 'le': '0.21', 'lle': '1.45', 'sei': '8.17'}",CHEMBL3701301,,CHEMBL3701301,7.90,0,http://www.openphacts.org/units/Nanomolar,2578605,=,37,1,=,,IC50,nM,,12.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.6
,304786,26596580,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.99', 'le': '0.23', 'lle': '0.86', 'sei': '10.35'}",CHEMBL3701302,,CHEMBL3701302,8.10,0,http://www.openphacts.org/units/Nanomolar,2578606,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,304787,26596583,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)OCO3)n1CCO,,,CHEMBL3638572,,2015,"{'bei': '11.54', 'le': '0.21', 'lle': '2.25', 'sei': '7.19'}",CHEMBL3701303,,CHEMBL3701303,8.41,0,http://www.openphacts.org/units/Nanomolar,2578607,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304788,26596586,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccncc3)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '14.16', 'le': '0.26', 'lle': '1.63', 'sei': '9.45'}",CHEMBL3701304,,CHEMBL3701304,8.31,0,http://www.openphacts.org/units/Nanomolar,2578608,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,304789,26596589,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.85', 'le': '0.22', 'lle': '3.24', 'sei': '7.27'}",CHEMBL3701305,,CHEMBL3701305,8.33,0,http://www.openphacts.org/units/Nanomolar,2578609,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,304790,26596592,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.71', 'le': '0.21', 'lle': '1.82', 'sei': '8.46'}",CHEMBL3701306,,CHEMBL3701306,8.18,0,http://www.openphacts.org/units/Nanomolar,2578610,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,304791,26596595,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCO,,,CHEMBL3638572,,2015,"{'bei': '13.32', 'le': '0.25', 'lle': '3.25', 'sei': '6.90'}",CHEMBL3701307,,CHEMBL3701307,8.44,0,http://www.openphacts.org/units/Nanomolar,2578611,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304792,26596598,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.16', 'le': '0.22', 'lle': '2.88', 'sei': '7.79'}",CHEMBL3701308,,CHEMBL3701308,8.21,0,http://www.openphacts.org/units/Nanomolar,2578612,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,304793,26596601,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.36', 'le': '0.23', 'lle': '2.43', 'sei': '8.74'}",CHEMBL3701309,,CHEMBL3701309,8.40,0,http://www.openphacts.org/units/Nanomolar,2578613,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,304794,26596604,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '12.97', 'le': '0.24', 'lle': '2.97', 'sei': '7.35'}",CHEMBL3701310,,CHEMBL3701310,8.39,0,http://www.openphacts.org/units/Nanomolar,2578614,=,37,1,=,,IC50,nM,,4.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.1
,304795,26596607,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,CHEMBL3638572,,2015,"{'bei': '12.54', 'le': '0.23', 'lle': '2.52', 'sei': '7.87'}",CHEMBL3701311,,CHEMBL3701311,8.28,0,http://www.openphacts.org/units/Nanomolar,2578615,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304796,26596610,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.75', 'le': '0.26', 'lle': '0.80', 'sei': '10.33'}",CHEMBL3701312,,CHEMBL3701312,8.12,0,http://www.openphacts.org/units/Nanomolar,2578616,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,304797,26596613,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=C(C(=O)N(c2ccccc2)c2ccc(O)cc2)CC(c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2COCCN2CCOCC2)N1C,,,CHEMBL3638572,,2015,"{'bei': '11.34', 'le': '0.21', 'lle': '1.20', 'sei': '9.54'}",CHEMBL3701313,,CHEMBL3701313,8.18,0,http://www.openphacts.org/units/Nanomolar,2578617,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,304798,26596616,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN,,,CHEMBL3638572,,2015,"{'bei': '13.16', 'le': '0.24', 'lle': '3.17', 'sei': '6.50'}",CHEMBL3701314,,CHEMBL3701314,8.33,0,http://www.openphacts.org/units/Nanomolar,2578618,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,304799,26596619,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '13.81', 'le': '0.25', 'lle': '2.13', 'sei': '8.77'}",CHEMBL3701315,,CHEMBL3701315,8.14,0,http://www.openphacts.org/units/Nanomolar,2578619,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,304800,26596622,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)Oc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.25', 'le': '0.22', 'lle': '1.02', 'sei': '7.57'}",CHEMBL3701316,,CHEMBL3701316,7.88,0,http://www.openphacts.org/units/Nanomolar,2578620,=,37,1,=,,IC50,nM,,13.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.3
,304801,26596625,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.22', 'lle': '0.58', 'sei': '10.18'}",CHEMBL3701317,,CHEMBL3701317,7.96,0,http://www.openphacts.org/units/Nanomolar,2578621,=,37,1,=,,IC50,nM,,10.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.9
,304802,26596628,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '0.71', 'sei': '10.33'}",CHEMBL3701318,,CHEMBL3701318,8.09,0,http://www.openphacts.org/units/Nanomolar,2578622,=,37,1,=,,IC50,nM,,8.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.2
,304803,26596631,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.12', 'le': '0.20', 'lle': '1.04', 'sei': '7.01'}",CHEMBL3701319,,CHEMBL3701319,7.30,0,http://www.openphacts.org/units/Nanomolar,2578623,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,304804,26596634,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCNC(=O)NCc1ccc(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.04', 'le': '0.22', 'lle': '1.76', 'sei': '6.68'}",CHEMBL3701320,,CHEMBL3701320,7.15,0,http://www.openphacts.org/units/Nanomolar,2578624,=,37,1,=,,IC50,nM,,71.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,71.4
,304805,26596637,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNC(=O)NCc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.01', 'le': '0.20', 'lle': '0.65', 'sei': '6.75'}",CHEMBL3701321,,CHEMBL3701321,7.22,0,http://www.openphacts.org/units/Nanomolar,2578625,=,37,1,=,,IC50,nM,,60.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.4
,304806,26596640,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.40', 'le': '0.25', 'lle': '1.22', 'sei': '9.45'}",CHEMBL3701322,,CHEMBL3701322,8.12,0,http://www.openphacts.org/units/Nanomolar,2578626,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,304807,26596643,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.49', 'le': '0.25', 'lle': '2.41', 'sei': '7.98'}",CHEMBL3701323,,CHEMBL3701323,8.14,0,http://www.openphacts.org/units/Nanomolar,2578627,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,304808,26596646,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)Oc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.20', 'lle': '0.33', 'sei': '6.91'}",CHEMBL3701324,,CHEMBL3701324,7.19,0,http://www.openphacts.org/units/Nanomolar,2578628,=,37,1,=,,IC50,nM,,64.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,64.4
,304809,26596649,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(F)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.95', 'le': '0.24', 'lle': '0.86', 'sei': '9.50'}",CHEMBL3701325,,CHEMBL3701325,8.00,0,http://www.openphacts.org/units/Nanomolar,2578629,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,304810,26596652,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.67', 'le': '0.23', 'lle': '1.39', 'sei': '8.12'}",CHEMBL3701326,,CHEMBL3701326,8.28,0,http://www.openphacts.org/units/Nanomolar,2578630,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304811,26596655,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.83', 'le': '0.25', 'lle': '1.29', 'sei': '9.84'}",CHEMBL3701327,,CHEMBL3701327,8.29,0,http://www.openphacts.org/units/Nanomolar,2578631,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304812,26596658,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.54', 'le': '0.21', 'lle': '2.32', 'sei': '7.44'}",CHEMBL3701328,,CHEMBL3701328,8.52,0,http://www.openphacts.org/units/Nanomolar,2578632,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304813,26596661,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCN(C(=O)O)c3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.28', 'le': '0.21', 'lle': '0.11', 'sei': '6.97'}",CHEMBL3701329,,CHEMBL3701329,7.41,0,http://www.openphacts.org/units/Nanomolar,2578633,=,37,1,=,,IC50,nM,,38.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.9
,304814,26596664,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.61', 'le': '0.19', 'lle': '0.81', 'sei': '6.83'}",CHEMBL3701330,,CHEMBL3701330,7.12,0,http://www.openphacts.org/units/Nanomolar,2578634,=,37,1,=,,IC50,nM,,76.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,76.6
,304815,26596667,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.95', 'le': '0.22', 'lle': '3.18', 'sei': '7.19'}",CHEMBL3701331,,CHEMBL3701331,8.23,0,http://www.openphacts.org/units/Nanomolar,2578635,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,304816,26596670,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3C)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '13.23', 'le': '0.24', 'lle': '2.56', 'sei': '7.01'}",CHEMBL3701332,,CHEMBL3701332,8.36,0,http://www.openphacts.org/units/Nanomolar,2578636,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304817,26596673,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.34', 'le': '0.21', 'lle': '2.70', 'sei': '7.44'}",CHEMBL3701333,,CHEMBL3701333,8.40,0,http://www.openphacts.org/units/Nanomolar,2578637,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,304818,26596676,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.21', 'lle': '3.12', 'sei': '6.25'}",CHEMBL3701334,,CHEMBL3701334,8.23,0,http://www.openphacts.org/units/Nanomolar,2578638,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,304819,26596679,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.21', 'lle': '1.00', 'sei': '7.08'}",CHEMBL3701335,,CHEMBL3701335,7.57,0,http://www.openphacts.org/units/Nanomolar,2578639,=,37,1,=,,IC50,nM,,26.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.7
,304820,26596682,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCNC(=O)NCc1ccc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(C)c3ccc(O)cc3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '12.70', 'le': '0.23', 'lle': '2.15', 'sei': '7.05'}",CHEMBL3701336,,CHEMBL3701336,7.54,0,http://www.openphacts.org/units/Nanomolar,2578640,=,37,1,=,,IC50,nM,,28.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.9
,304821,26596685,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.21', 'le': '0.21', 'lle': '1.10', 'sei': '7.07'}",CHEMBL3701337,,CHEMBL3701337,7.36,0,http://www.openphacts.org/units/Nanomolar,2578641,=,37,1,=,,IC50,nM,,43.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.5
,304822,26596688,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(CNC(=O)COc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.02', 'le': '0.18', 'lle': '-0.11', 'sei': '6.35'}",CHEMBL3701338,,CHEMBL3701338,7.75,0,http://www.openphacts.org/units/Nanomolar,2578642,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,304823,26596691,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNS(=O)(=O)CCc3ccc(F)cc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.24', 'le': '0.18', 'lle': '0.27', 'sei': '5.97'}",CHEMBL3701339,,CHEMBL3701339,6.68,0,http://www.openphacts.org/units/Nanomolar,2578643,=,37,1,=,,IC50,nM,,209.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,209.6
,304824,26596694,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)NCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.64', 'le': '0.19', 'lle': '0.51', 'sei': '6.66'}",CHEMBL3701340,,CHEMBL3701340,7.12,0,http://www.openphacts.org/units/Nanomolar,2578644,=,37,1,=,,IC50,nM,,75.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,75.0
,304825,26596697,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Cc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.84', 'le': '0.20', 'lle': '0.63', 'sei': '7.48'}",CHEMBL3701341,,CHEMBL3701341,7.10,0,http://www.openphacts.org/units/Nanomolar,2578645,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,304826,26596700,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc(CCNC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.48', 'le': '0.19', 'lle': '-0.05', 'sei': '6.43'}",CHEMBL3701342,,CHEMBL3701342,6.88,0,http://www.openphacts.org/units/Nanomolar,2578646,=,37,1,=,,IC50,nM,,133.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,133.3
,304827,26596703,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2ccc(CNS(=O)(=O)CCc3ccc(F)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.70', 'le': '0.18', 'lle': '0.50', 'sei': '6.14'}",CHEMBL3701343,,CHEMBL3701343,6.87,0,http://www.openphacts.org/units/Nanomolar,2578647,=,37,1,=,,IC50,nM,,134.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,134.0
,304828,26596706,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.90', 'le': '0.25', 'lle': '1.95', 'sei': '8.59'}",CHEMBL3701344,,CHEMBL3701344,8.35,0,http://www.openphacts.org/units/Nanomolar,2578648,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,304829,26596709,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2C)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '12.91', 'le': '0.24', 'lle': '1.69', 'sei': '8.45'}",CHEMBL3701345,,CHEMBL3701345,7.84,0,http://www.openphacts.org/units/Nanomolar,2578649,=,37,1,=,,IC50,nM,,14.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.3
,304830,26596712,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.87', 'le': '0.24', 'lle': '0.48', 'sei': '9.92'}",CHEMBL3701346,,CHEMBL3701346,8.29,0,http://www.openphacts.org/units/Nanomolar,2578650,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304831,26596715,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.60', 'le': '0.19', 'lle': '1.17', 'sei': '8.12'}",CHEMBL3701347,,CHEMBL3701347,7.66,0,http://www.openphacts.org/units/Nanomolar,2578651,=,37,1,=,,IC50,nM,,21.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.9
,304832,26596718,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)NCc2ccc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)c(C(=O)N3Cc4ccccc4C[C@H]3C)c2)cc1,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '0.60', 'sei': '7.47'}",CHEMBL3701348,,CHEMBL3701348,7.77,0,http://www.openphacts.org/units/Nanomolar,2578652,=,37,1,=,,IC50,nM,,16.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.9
,304833,26596721,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.92', 'le': '0.22', 'lle': '2.44', 'sei': '8.23'}",CHEMBL3701349,,CHEMBL3701349,7.90,0,http://www.openphacts.org/units/Nanomolar,2578653,=,37,1,=,,IC50,nM,,12.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.5
,304834,26596724,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '14.62', 'le': '0.27', 'lle': '2.83', 'sei': '8.36'}",CHEMBL3701350,,CHEMBL3701350,8.68,0,http://www.openphacts.org/units/Nanomolar,2578654,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,304835,26596727,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.01', 'le': '0.20', 'lle': '2.17', 'sei': '7.62'}",CHEMBL3701351,,CHEMBL3701351,8.28,0,http://www.openphacts.org/units/Nanomolar,2578655,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,304836,26596730,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.26', 'le': '0.21', 'lle': '1.09', 'sei': '8.55'}",CHEMBL3701352,,CHEMBL3701352,8.21,0,http://www.openphacts.org/units/Nanomolar,2578656,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304840,26596733,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(CN3CCOCC3)n1C)OCO2,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.21', 'lle': '2.45', 'sei': '6.73'}",CHEMBL3701353,,CHEMBL3701353,7.71,0,http://www.openphacts.org/units/Nanomolar,2578657,=,37,1,=,,IC50,nM,,19.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.5
,304841,26596736,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.21', 'lle': '2.55', 'sei': '7.05'}",CHEMBL3701354,,CHEMBL3701354,8.08,0,http://www.openphacts.org/units/Nanomolar,2578658,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,304842,26596739,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '10.51', 'le': '0.19', 'lle': '2.55', 'sei': '6.23'}",CHEMBL3701355,,CHEMBL3701355,7.71,0,http://www.openphacts.org/units/Nanomolar,2578659,=,37,1,=,,IC50,nM,,19.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.7
,304843,26596742,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CCF,,,CHEMBL3638572,,2015,"{'bei': '11.19', 'le': '0.21', 'lle': '2.59', 'sei': '7.04'}",CHEMBL3701356,,CHEMBL3701356,8.07,0,http://www.openphacts.org/units/Nanomolar,2578660,=,37,1,=,,IC50,nM,,8.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.6
,304844,26596745,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1CC(F)F,,,CHEMBL3638572,,2015,"{'bei': '11.04', 'le': '0.21', 'lle': '2.38', 'sei': '7.12'}",CHEMBL3701357,,CHEMBL3701357,8.15,0,http://www.openphacts.org/units/Nanomolar,2578661,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,304845,26596748,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.20', 'le': '0.21', 'lle': '2.34', 'sei': '6.87'}",CHEMBL3701358,,CHEMBL3701358,7.87,0,http://www.openphacts.org/units/Nanomolar,2578662,=,37,1,=,,IC50,nM,,13.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.5
,304846,26596751,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.05', 'le': '0.20', 'lle': '0.92', 'sei': '7.98'}",CHEMBL3701359,,CHEMBL3701359,7.72,0,http://www.openphacts.org/units/Nanomolar,2578663,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,304847,26596754,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)n1CCN(C)C,,,CHEMBL3638572,,2015,"{'bei': '12.36', 'le': '0.23', 'lle': '1.10', 'sei': '9.28'}",CHEMBL3701360,,CHEMBL3701360,8.12,0,http://www.openphacts.org/units/Nanomolar,2578664,=,37,1,=,,IC50,nM,,7.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.6
,304848,26596757,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCN(C)CCn1c(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)OCO3)cc(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.63', 'le': '0.22', 'lle': '2.41', 'sei': '7.15'}",CHEMBL3701361,,CHEMBL3701361,8.19,0,http://www.openphacts.org/units/Nanomolar,2578665,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,304849,26596760,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2[nH]c(C)c(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.03', 'le': '0.20', 'lle': '1.88', 'sei': '6.58'}",CHEMBL3701362,,CHEMBL3701362,7.64,0,http://www.openphacts.org/units/Nanomolar,2578666,=,37,1,=,,IC50,nM,,22.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.9
,304850,26596763,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.08', 'le': '0.21', 'lle': '2.21', 'sei': '7.29'}",CHEMBL3701363,,CHEMBL3701363,7.68,0,http://www.openphacts.org/units/Nanomolar,2578667,=,37,1,=,,IC50,nM,,21.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.1
,304851,26596766,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.72', 'le': '0.22', 'lle': '1.66', 'sei': '9.66'}",CHEMBL3701364,,CHEMBL3701364,8.70,0,http://www.openphacts.org/units/Nanomolar,2578668,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,304852,26596769,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.23', 'lle': '1.96', 'sei': '7.86'}",CHEMBL3701365,,CHEMBL3701365,8.41,0,http://www.openphacts.org/units/Nanomolar,2578669,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304853,26596772,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '0.54', 'sei': '6.12'}",CHEMBL3701366,,CHEMBL3701366,7.04,0,http://www.openphacts.org/units/Nanomolar,2578670,=,37,1,=,,IC50,nM,,91.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,91.5
,304854,26596775,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)ccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.51', 'le': '0.22', 'lle': '1.57', 'sei': '7.02'}",CHEMBL3701367,,CHEMBL3701367,8.07,0,http://www.openphacts.org/units/Nanomolar,2578671,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,304855,26596778,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@@H]3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.50', 'le': '0.22', 'lle': '2.78', 'sei': '8.50'}",CHEMBL3701368,,CHEMBL3701368,8.44,0,http://www.openphacts.org/units/Nanomolar,2578672,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304856,26596781,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN3CCOC[C@H]3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.53', 'le': '0.22', 'lle': '2.81', 'sei': '8.53'}",CHEMBL3701369,,CHEMBL3701369,8.47,0,http://www.openphacts.org/units/Nanomolar,2578673,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304857,26596784,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.01', 'le': '0.23', 'lle': '1.70', 'sei': '8.81'}",CHEMBL3701370,,CHEMBL3701370,8.47,0,http://www.openphacts.org/units/Nanomolar,2578674,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304858,26596787,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.61', 'le': '0.22', 'lle': '2.37', 'sei': '7.96'}",CHEMBL3701371,,CHEMBL3701371,8.38,0,http://www.openphacts.org/units/Nanomolar,2578675,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304859,26596790,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.26', 'le': '0.21', 'lle': '1.88', 'sei': '7.86'}",CHEMBL3701372,,CHEMBL3701372,8.28,0,http://www.openphacts.org/units/Nanomolar,2578676,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,304860,26596793,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.82', 'le': '0.20', 'lle': '0.82', 'sei': '10.44'}",CHEMBL3701373,,CHEMBL3701373,7.74,0,http://www.openphacts.org/units/Nanomolar,2578677,=,37,1,=,,IC50,nM,,18.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.1
,304861,26596796,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CC3(CCO3)C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.23', 'lle': '2.23', 'sei': '8.68'}",CHEMBL3701374,,CHEMBL3701374,8.34,0,http://www.openphacts.org/units/Nanomolar,2578678,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,304862,26596799,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.95', 'le': '0.20', 'lle': '1.51', 'sei': '7.72'}",CHEMBL3701375,,CHEMBL3701375,8.13,0,http://www.openphacts.org/units/Nanomolar,2578679,=,37,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,304863,26596802,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(c3)CCN4C)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.81', 'le': '0.20', 'lle': '1.94', 'sei': '7.77'}",CHEMBL3701376,,CHEMBL3701376,8.06,0,http://www.openphacts.org/units/Nanomolar,2578680,=,37,1,=,,IC50,nM,,8.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.8
,304864,26596805,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.22', 'lle': '1.95', 'sei': '8.54'}",CHEMBL3701377,,CHEMBL3701377,8.20,0,http://www.openphacts.org/units/Nanomolar,2578681,=,37,1,=,,IC50,nM,,6.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.3
,304865,26596808,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.22', 'lle': '2.36', 'sei': '7.75'}",CHEMBL3701378,,CHEMBL3701378,8.29,0,http://www.openphacts.org/units/Nanomolar,2578682,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,304866,26596811,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '9.98', 'le': '0.18', 'lle': '2.25', 'sei': '6.41'}",CHEMBL3701379,,CHEMBL3701379,7.83,0,http://www.openphacts.org/units/Nanomolar,2578683,=,37,1,=,,IC50,nM,,14.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.8
,304867,26596814,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccncc2)c2ccc(O)cc2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.15', 'le': '0.22', 'lle': '1.89', 'sei': '8.79'}",CHEMBL3701380,,CHEMBL3701380,8.01,0,http://www.openphacts.org/units/Nanomolar,2578684,=,37,1,=,,IC50,nM,,9.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.7
,304868,26596817,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.57', 'le': '0.21', 'lle': '1.63', 'sei': '8.58'}",CHEMBL3701381,,CHEMBL3701381,8.24,0,http://www.openphacts.org/units/Nanomolar,2578685,=,37,1,=,,IC50,nM,,5.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.7
,304869,26596820,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '1.83', 'sei': '8.03'}",CHEMBL3701382,VOB-560,CHEMBL3701382,8.59,0,http://www.openphacts.org/units/Nanomolar,2578686,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304870,26596823,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(Nc1ncnc(N)c1C#N)c1cc(Cl)c2ccnnc2c1-c1cccc(F)c1,,,CHEMBL3638572,,2015,"{'bei': '18.31', 'le': '0.35', 'lle': '3.18', 'sei': '6.78'}",CHEMBL3701383,,CHEMBL3701383,7.69,0,http://www.openphacts.org/units/Nanomolar,2578687,=,37,1,=,,IC50,nM,,20.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.6
,304871,26596826,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.55', 'le': '0.22', 'lle': '1.82', 'sei': '8.95'}",CHEMBL3701384,,CHEMBL3701384,8.44,0,http://www.openphacts.org/units/Nanomolar,2578688,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,304872,26596829,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc3ccn(C)c3cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.74', 'le': '0.20', 'lle': '0.71', 'sei': '8.15'}",CHEMBL3701385,,CHEMBL3701385,7.83,0,http://www.openphacts.org/units/Nanomolar,2578689,=,37,1,=,,IC50,nM,,14.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.7
,304873,26596832,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.76', 'le': '0.20', 'lle': '0.25', 'sei': '10.12'}",CHEMBL3701386,,CHEMBL3701386,7.67,0,http://www.openphacts.org/units/Nanomolar,2578690,=,37,1,=,,IC50,nM,,21.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.2
,304874,26596835,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.31', 'le': '0.19', 'lle': '0.40', 'sei': '7.83'}",CHEMBL3640002,,CHEMBL3640002,7.52,0,http://www.openphacts.org/units/Nanomolar,2578691,=,37,1,=,,IC50,nM,,30.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.3
,304875,26596838,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '0.40', 'sei': '10.76'}",CHEMBL3701387,,CHEMBL3701387,8.42,0,http://www.openphacts.org/units/Nanomolar,2578692,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,304876,26596841,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.46', 'le': '0.22', 'lle': '0.78', 'sei': '9.03'}",CHEMBL3701388,,CHEMBL3701388,8.68,0,http://www.openphacts.org/units/Nanomolar,2578693,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,304877,26596844,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.33', 'le': '0.21', 'lle': '1.20', 'sei': '9.11'}",CHEMBL3701389,,CHEMBL3701389,8.60,0,http://www.openphacts.org/units/Nanomolar,2578694,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304878,26596847,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,CHEMBL3638572,,2015,"{'bei': '11.58', 'le': '0.22', 'lle': '1.34', 'sei': '7.60'}",CHEMBL3701390,,CHEMBL3701390,8.46,0,http://www.openphacts.org/units/Nanomolar,2578695,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304879,26596850,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.04', 'le': '0.20', 'lle': '2.61', 'sei': '6.81'}",CHEMBL3701391,,CHEMBL3701391,7.80,0,http://www.openphacts.org/units/Nanomolar,2578696,=,37,1,=,,IC50,nM,,15.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.7
,304880,26596853,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.80', 'le': '0.22', 'lle': '2.31', 'sei': '7.37'}",CHEMBL3701392,,CHEMBL3701392,8.35,0,http://www.openphacts.org/units/Nanomolar,2578697,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,304881,26596856,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.01', 'le': '0.23', 'lle': '1.30', 'sei': '8.24'}",CHEMBL3701393,,CHEMBL3701393,8.41,0,http://www.openphacts.org/units/Nanomolar,2578698,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,304882,26596859,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)c(F)c2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.22', 'lle': '1.89', 'sei': '8.33'}",CHEMBL3701394,,CHEMBL3701394,8.00,0,http://www.openphacts.org/units/Nanomolar,2578699,=,37,1,=,,IC50,nM,,9.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.9
,304883,26596862,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,CHEMBL3638572,,2015,"{'bei': '9.96', 'le': '0.19', 'lle': '0.89', 'sei': '6.22'}",CHEMBL3701395,,CHEMBL3701395,7.31,0,http://www.openphacts.org/units/Nanomolar,2578700,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,304884,26596865,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.27', 'le': '0.21', 'lle': '0.85', 'sei': '7.94'}",CHEMBL3701396,,CHEMBL3701396,8.10,0,http://www.openphacts.org/units/Nanomolar,2578701,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,304885,26596868,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.55', 'le': '0.20', 'lle': '1.70', 'sei': '7.20'}",CHEMBL3701397,,CHEMBL3701397,7.58,0,http://www.openphacts.org/units/Nanomolar,2578702,=,37,1,=,,IC50,nM,,26.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.1
,304886,26596871,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn([C@H]3CCOC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.60', 'le': '0.20', 'lle': '1.74', 'sei': '7.23'}",CHEMBL3701397,,CHEMBL3701397,7.62,0,http://www.openphacts.org/units/Nanomolar,2578702,=,37,1,=,,IC50,nM,,24.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.2
,304887,26596874,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccnc(C#N)n2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.84', 'le': '0.20', 'lle': '1.71', 'sei': '5.96'}",CHEMBL3701398,,CHEMBL3701398,7.61,0,http://www.openphacts.org/units/Nanomolar,2578703,=,37,1,=,,IC50,nM,,24.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.4
,304888,26596877,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.27', 'le': '0.22', 'lle': '2.28', 'sei': '7.83'}",CHEMBL3701399,,CHEMBL3701399,8.38,0,http://www.openphacts.org/units/Nanomolar,2578704,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304889,26596880,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)c(F)c3)c3cnn(C)c3)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '11.09', 'le': '0.21', 'lle': '2.22', 'sei': '7.30'}",CHEMBL3701400,,CHEMBL3701400,7.69,0,http://www.openphacts.org/units/Nanomolar,2578705,=,37,1,=,,IC50,nM,,20.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.6
,304890,26596883,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c1,,,CHEMBL3638572,,2015,"{'bei': '11.60', 'le': '0.21', 'lle': '2.16', 'sei': '7.11'}",CHEMBL3701401,,CHEMBL3701401,8.27,0,http://www.openphacts.org/units/Nanomolar,2578706,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,304891,26596886,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.39', 'le': '0.21', 'lle': '1.44', 'sei': '8.24'}",CHEMBL3701402,,CHEMBL3701402,7.91,0,http://www.openphacts.org/units/Nanomolar,2578707,=,37,1,=,,IC50,nM,,12.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.2
,304892,26596889,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.49', 'le': '0.21', 'lle': '2.03', 'sei': '8.48'}",CHEMBL3701403,,CHEMBL3701403,8.00,0,http://www.openphacts.org/units/Nanomolar,2578708,=,37,1,=,,IC50,nM,,9.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.9
,304893,26596892,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1CCN1CCOCC1,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.23', 'lle': '1.81', 'sei': '8.60'}",CHEMBL3701404,,CHEMBL3701404,8.26,0,http://www.openphacts.org/units/Nanomolar,2578709,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304894,26596895,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.42', 'le': '0.22', 'lle': '0.97', 'sei': '7.95'}",CHEMBL3701405,,CHEMBL3701405,8.51,0,http://www.openphacts.org/units/Nanomolar,2578710,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304895,26596898,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCCO4)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.48', 'le': '0.21', 'lle': '2.64', 'sei': '6.78'}",CHEMBL3701406,,CHEMBL3701406,8.51,0,http://www.openphacts.org/units/Nanomolar,2578711,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304896,26596901,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.97', 'le': '0.23', 'lle': '1.97', 'sei': '7.87'}",CHEMBL3701407,,CHEMBL3701407,8.42,0,http://www.openphacts.org/units/Nanomolar,2578712,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,304897,26596904,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.57', 'le': '0.24', 'lle': '2.57', 'sei': '8.89'}",CHEMBL3701309,,CHEMBL3701309,8.54,0,http://www.openphacts.org/units/Nanomolar,2578613,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,304898,26596907,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.22', 'lle': '2.41', 'sei': '7.33'}",CHEMBL3701408,,CHEMBL3701408,8.52,0,http://www.openphacts.org/units/Nanomolar,2578713,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304899,26596910,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cnn(C)c3)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.85', 'le': '0.22', 'lle': '2.67', 'sei': '7.59'}",CHEMBL3701409,,CHEMBL3701409,8.00,0,http://www.openphacts.org/units/Nanomolar,2578714,=,37,1,=,,IC50,nM,,10.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.1
,304900,26596913,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cccc(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.51', 'le': '0.23', 'lle': '1.96', 'sei': '8.38'}",CHEMBL3701410,,CHEMBL3701410,8.55,0,http://www.openphacts.org/units/Nanomolar,2578715,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,304901,26596916,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.39', 'le': '0.23', 'lle': '2.75', 'sei': '8.55'}",CHEMBL3701349,,CHEMBL3701349,8.21,0,http://www.openphacts.org/units/Nanomolar,2578653,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304902,26596919,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.27', 'le': '0.23', 'lle': '2.36', 'sei': '8.04'}",CHEMBL3701411,,CHEMBL3701411,8.60,0,http://www.openphacts.org/units/Nanomolar,2578716,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304903,26596922,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.46', 'le': '0.23', 'lle': '2.72', 'sei': '8.36'}",CHEMBL3701412,,CHEMBL3701412,8.04,0,http://www.openphacts.org/units/Nanomolar,2578717,=,37,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
,304904,26596925,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3COC3)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.25', 'le': '0.21', 'lle': '2.44', 'sei': '7.53'}",CHEMBL3701413,,CHEMBL3701413,7.93,0,http://www.openphacts.org/units/Nanomolar,2578718,=,37,1,=,,IC50,nM,,11.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.7
,304905,26596928,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3ccccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.69', 'le': '0.21', 'lle': '2.49', 'sei': '6.95'}",CHEMBL3701414,,CHEMBL3701414,7.87,0,http://www.openphacts.org/units/Nanomolar,2578719,=,37,1,=,,IC50,nM,,13.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.6
,304906,26596931,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C#N)cc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1,,,CHEMBL3638572,,2015,"{'bei': '11.74', 'le': '0.22', 'lle': '1.78', 'sei': '7.53'}",CHEMBL3701415,,CHEMBL3701415,8.38,0,http://www.openphacts.org/units/Nanomolar,2578720,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,304907,26596934,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.99', 'le': '0.22', 'lle': '2.76', 'sei': '7.31'}",CHEMBL3704775,,CHEMBL3704775,8.28,0,http://www.openphacts.org/units/Nanomolar,2582294,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,304908,26596937,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc1C#N,,,CHEMBL3638572,,2015,"{'bei': '12.13', 'le': '0.22', 'lle': '2.06', 'sei': '7.78'}",CHEMBL3704776,,CHEMBL3704776,8.66,0,http://www.openphacts.org/units/Nanomolar,2582295,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,304909,26596940,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3ccc(F)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.22', 'lle': '2.22', 'sei': '7.90'}",CHEMBL3704777,,CHEMBL3704777,8.46,0,http://www.openphacts.org/units/Nanomolar,2582296,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304910,26596943,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.64', 'le': '0.22', 'lle': '2.26', 'sei': '7.32'}",CHEMBL3704778,,CHEMBL3704778,8.51,0,http://www.openphacts.org/units/Nanomolar,2582297,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304911,26596946,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(ccn3C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3CC2C(F)(F)F)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.03', 'le': '0.21', 'lle': '-0.65', 'sei': '9.21'}",CHEMBL3704779,,CHEMBL3704779,7.70,0,http://www.openphacts.org/units/Nanomolar,2582298,=,37,1,=,,IC50,nM,,19.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.9
,304912,26596949,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,CHEMBL3638572,,2015,"{'bei': '12.29', 'le': '0.23', 'lle': '2.24', 'sei': '8.87'}",CHEMBL3704780,,CHEMBL3704780,8.52,0,http://www.openphacts.org/units/Nanomolar,2582299,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304913,26596952,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,CHEMBL3638572,,2015,"{'bei': '12.22', 'le': '0.23', 'lle': '2.19', 'sei': '8.81'}",CHEMBL3704781,,CHEMBL3704781,8.47,0,http://www.openphacts.org/units/Nanomolar,2582300,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,304914,26596955,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.84', 'le': '0.23', 'lle': '2.80', 'sei': '8.03'}",CHEMBL3704782,,CHEMBL3704782,8.59,0,http://www.openphacts.org/units/Nanomolar,2582301,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304915,26596958,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(c2)CCN3C)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.83', 'le': '0.22', 'lle': '2.35', 'sei': '8.96'}",CHEMBL3704783,,CHEMBL3704783,8.46,0,http://www.openphacts.org/units/Nanomolar,2582302,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304916,26596961,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)ccn3)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '10.95', 'le': '0.20', 'lle': '1.83', 'sei': '6.30'}",CHEMBL3704784,,CHEMBL3704784,7.83,0,http://www.openphacts.org/units/Nanomolar,2582303,=,37,1,=,,IC50,nM,,14.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.9
,304917,26596964,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(C#N)s2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.35', 'le': '0.20', 'lle': '0.14', 'sei': '7.16'}",CHEMBL3704785,,CHEMBL3704785,7.31,0,http://www.openphacts.org/units/Nanomolar,2582304,=,37,1,=,,IC50,nM,,49.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.1
,304918,26596967,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2ccc(F)c(C#N)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.91', 'le': '0.22', 'lle': '1.63', 'sei': '8.19'}",CHEMBL3704786,,CHEMBL3704786,8.36,0,http://www.openphacts.org/units/Nanomolar,2582305,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,304919,26596970,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnccn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.73', 'le': '0.22', 'lle': '1.92', 'sei': '7.64'}",CHEMBL3704787,,CHEMBL3704787,7.95,0,http://www.openphacts.org/units/Nanomolar,2582306,=,37,1,=,,IC50,nM,,11.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.3
,304920,26596973,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ncc(N(C(=O)c2cc(-c3cc(F)c(OC)cc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.40', 'le': '0.21', 'lle': '2.68', 'sei': '6.71'}",CHEMBL3704788,,CHEMBL3704788,8.21,0,http://www.openphacts.org/units/Nanomolar,2582307,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,304921,26596976,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3cc(C#N)n(C)c3C)c(C)n2C)cc1F,,,CHEMBL3638572,,2015,"{'bei': '11.75', 'le': '0.22', 'lle': '2.34', 'sei': '7.39'}",CHEMBL3704789,,CHEMBL3704789,8.59,0,http://www.openphacts.org/units/Nanomolar,2582308,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,304922,26596979,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.23', 'lle': '1.41', 'sei': '9.75'}",CHEMBL3704790,,CHEMBL3704790,8.46,0,http://www.openphacts.org/units/Nanomolar,2582309,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,304923,26596982,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2csc(C#N)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.07', 'le': '0.23', 'lle': '1.35', 'sei': '8.35'}",CHEMBL3704791,,CHEMBL3704791,8.52,0,http://www.openphacts.org/units/Nanomolar,2582310,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,304924,26596985,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cnc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn1,,,CHEMBL3638572,,2015,"{'bei': '11.68', 'le': '0.22', 'lle': '2.22', 'sei': '7.29'}",CHEMBL3704792,,CHEMBL3704792,8.26,0,http://www.openphacts.org/units/Nanomolar,2582311,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,304925,26596988,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(F)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.66', 'le': '0.22', 'lle': '1.94', 'sei': '7.79'}",CHEMBL3704793,,CHEMBL3704793,8.11,0,http://www.openphacts.org/units/Nanomolar,2582312,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,304926,26596991,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(C)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.26', 'le': '0.23', 'lle': '2.17', 'sei': '8.06'}",CHEMBL3701365,,CHEMBL3701365,8.62,0,http://www.openphacts.org/units/Nanomolar,2578669,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,304927,26596994,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.23', 'le': '0.23', 'lle': '2.01', 'sei': '8.20'}",CHEMBL3701382,VOB-560,CHEMBL3701382,8.77,0,http://www.openphacts.org/units/Nanomolar,2578686,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,304928,26596997,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)nn2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '12.17', 'le': '0.23', 'lle': '2.73', 'sei': '7.15'}",CHEMBL3704794,,CHEMBL3704794,8.57,0,http://www.openphacts.org/units/Nanomolar,2582313,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,304929,26597000,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc3c(cnn3C)c2)cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.96', 'le': '0.22', 'lle': '2.54', 'sei': '7.84'}",CHEMBL3704795,,CHEMBL3704795,8.54,0,http://www.openphacts.org/units/Nanomolar,2582314,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,304930,26597003,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)cc1N(C(=O)c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n(C)c1C)c1ccc(O)cc1,,,CHEMBL3638572,,2015,"{'bei': '11.94', 'le': '0.22', 'lle': '2.32', 'sei': '8.41'}",CHEMBL3704796,,CHEMBL3704796,8.08,0,http://www.openphacts.org/units/Nanomolar,2582315,=,37,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,304931,26597006,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cnn1C,,,CHEMBL3638572,,2015,"{'bei': '12.06', 'le': '0.22', 'lle': '2.40', 'sei': '8.50'}",CHEMBL3704797,,CHEMBL3704797,8.16,0,http://www.openphacts.org/units/Nanomolar,2582316,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,304932,26597009,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4CC3C(F)(F)F)n(C)c2C)c2ccc(O)cc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.93', 'le': '0.23', 'lle': '0.20', 'sei': '8.66'}",CHEMBL3704798,,CHEMBL3704798,8.19,0,http://www.openphacts.org/units/Nanomolar,2582317,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,304933,26597012,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cc(C#N)n(CCN3CCOCC3)c2C)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.93', 'le': '0.22', 'lle': '1.48', 'sei': '8.15'}",CHEMBL3704799,,CHEMBL3704799,8.72,0,http://www.openphacts.org/units/Nanomolar,2582318,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,304934,26597015,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnc(OCCN3CCOCC3)nc2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2C)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.88', 'le': '0.23', 'lle': '2.14', 'sei': '7.57'}",CHEMBL3704800,,CHEMBL3704800,8.57,0,http://www.openphacts.org/units/Nanomolar,2582319,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,304935,26597018,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)cn(C)c1C#N,,,CHEMBL3638572,,2015,"{'bei': '11.12', 'le': '0.21', 'lle': '1.22', 'sei': '7.46'}",CHEMBL3704801,,CHEMBL3704801,7.98,0,http://www.openphacts.org/units/Nanomolar,2582320,=,37,1,=,,IC50,nM,,10.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.5
,304936,26597021,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1c(C#N)cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)c1C,,,CHEMBL3638572,,2015,"{'bei': '11.76', 'le': '0.22', 'lle': '1.36', 'sei': '8.04'}",CHEMBL3704802,,CHEMBL3704802,8.60,0,http://www.openphacts.org/units/Nanomolar,2582321,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,304937,26597024,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccc(O)cc2)c2cnn(C3CCOC3)c2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CCCN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.20', 'le': '0.21', 'lle': '1.37', 'sei': '8.12'}",CHEMBL3704803,,CHEMBL3704803,8.55,0,http://www.openphacts.org/units/Nanomolar,2582322,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,304938,26597027,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CCCN3CCOCC3)n(C)c2C)c2ccccc2)cc(C#N)n1C,,,CHEMBL3638572,,2015,"{'bei': '11.67', 'le': '0.22', 'lle': '0.68', 'sei': '9.81'}",CHEMBL3704804,,CHEMBL3704804,8.51,0,http://www.openphacts.org/units/Nanomolar,2582323,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,304939,26597030,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n(C)c2C)c2ccc(O)cc2)no1,,,CHEMBL3638572,,2015,"{'bei': '11.58', 'le': '0.22', 'lle': '1.35', 'sei': '7.55'}",CHEMBL3704805,,CHEMBL3704805,7.88,0,http://www.openphacts.org/units/Nanomolar,2582324,=,37,1,=,,IC50,nM,,13.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.3
,304940,26597033,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2cnc3c(ccn3C)c2)c2ccc(O)cn2)cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n1C,,,CHEMBL3638572,,2015,"{'bei': '10.18', 'le': '0.19', 'lle': '0.92', 'sei': '6.82'}",CHEMBL3704806,,CHEMBL3704806,7.44,0,http://www.openphacts.org/units/Nanomolar,2582325,=,37,1,=,,IC50,nM,,36.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.6
,304941,26597036,[],CHEMBL5729828,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(c2ccccc2)c2ccc(O)cc2)cc(-c2cc(Cl)ccc2C(=O)N2CCc3ccccc3C2)n1C,,,CHEMBL3638572,,2015,"{'bei': '13.39', 'le': '0.25', 'lle': '0.18', 'sei': '11.73'}",CHEMBL3704807,,CHEMBL3704807,7.72,0,http://www.openphacts.org/units/Nanomolar,2582326,=,37,1,=,,IC50,nM,,19.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.2
,326147,26603263,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.84', 'le': '0.19', 'lle': '0.91', 'sei': '5.51'}",CHEMBL3948552,,CHEMBL3948552,6.29,0,http://www.openphacts.org/units/Nanomolar,2838208,=,37,1,=,,IC50,nM,,511.89,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,511.89
,326148,26603266,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.16', 'le': '0.22', 'lle': '1.92', 'sei': '5.45'}",CHEMBL3920752,,CHEMBL3920752,6.82,0,http://www.openphacts.org/units/Nanomolar,2838209,=,37,1,=,,IC50,nM,,150.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,150.9
,326149,26603269,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.24', 'le': '0.18', 'lle': '-0.11', 'sei': '5.42'}",CHEMBL3929521,,CHEMBL3929521,6.34,0,http://www.openphacts.org/units/Nanomolar,2838210,=,37,1,=,,IC50,nM,,455.26,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,455.265
,326150,26603272,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '9.75', 'le': '0.18', 'lle': '1.18', 'sei': '5.16'}",CHEMBL3926219,,CHEMBL3926219,5.90,0,http://www.openphacts.org/units/Nanomolar,2838211,=,37,1,=,,IC50,nM,,1265.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1265.765
,326151,26603275,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.12', 'le': '0.23', 'lle': '2.74', 'sei': '5.58'}",CHEMBL3927241,,CHEMBL3927241,6.99,0,http://www.openphacts.org/units/Nanomolar,2838212,=,37,1,=,,IC50,nM,,102.02,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,102.02
,326152,26603278,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.71', 'le': '0.16', 'lle': '-0.12', 'sei': '4.85'}",CHEMBL3899211,,CHEMBL3899211,5.68,0,http://www.openphacts.org/units/Nanomolar,2838213,=,37,1,=,,IC50,nM,,2092.72,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2092.72
,326153,26603281,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.72', 'le': '0.16', 'lle': '-0.09', 'sei': '5.09'}",CHEMBL3908169,,CHEMBL3908169,5.81,0,http://www.openphacts.org/units/Nanomolar,2838214,=,37,1,=,,IC50,nM,,1539.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1539.27
,326154,26603284,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.26', 'le': '0.15', 'lle': '-0.41', 'sei': '4.73'}",CHEMBL3932621,,CHEMBL3932621,5.53,0,http://www.openphacts.org/units/Nanomolar,2838215,=,37,1,=,,IC50,nM,,2943.39,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2943.39
,326155,26603287,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.22', 'le': '0.22', 'lle': '1.07', 'sei': '6.27'}",CHEMBL3895678,,CHEMBL3895678,6.21,0,http://www.openphacts.org/units/Nanomolar,2838216,=,37,1,=,,IC50,nM,,623.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,623.56
,326156,26603290,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.25', 'le': '0.20', 'lle': '0.38', 'sei': '6.62'}",CHEMBL3923681,,CHEMBL3923681,5.82,0,http://www.openphacts.org/units/Nanomolar,2838217,=,37,1,=,,IC50,nM,,1529.09,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1529.09
,326157,26603293,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.64', 'le': '0.24', 'lle': '2.07', 'sei': '6.63'}",CHEMBL3914781,,CHEMBL3914781,6.55,0,http://www.openphacts.org/units/Nanomolar,2838218,=,37,1,=,,IC50,nM,,278.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,278.405
,326158,26603296,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '11.88', 'le': '0.22', 'lle': '1.54', 'sei': '7.20'}",CHEMBL3918229,,CHEMBL3918229,6.33,0,http://www.openphacts.org/units/Nanomolar,2838219,=,37,1,=,,IC50,nM,,470.04,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,470.04
,326159,26603299,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)OCC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '1.04', 'sei': '5.62'}",CHEMBL3948552,,CHEMBL3948552,6.42,0,http://www.openphacts.org/units/Nanomolar,2838208,=,37,1,=,,IC50,nM,,384.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,384.11
,326160,26603302,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.24', 'le': '0.22', 'lle': '1.97', 'sei': '5.49'}",CHEMBL3920752,,CHEMBL3920752,6.87,0,http://www.openphacts.org/units/Nanomolar,2838209,=,37,1,=,,IC50,nM,,134.92,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,134.92
,326161,26603305,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OCC(=O)Nc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.07', 'sei': '5.45'}",CHEMBL3929521,,CHEMBL3929521,6.38,0,http://www.openphacts.org/units/Nanomolar,2838210,=,37,1,=,,IC50,nM,,421.44,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,421.435
,326162,26603308,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '10.11', 'le': '0.19', 'lle': '1.39', 'sei': '5.35'}",CHEMBL3926219,,CHEMBL3926219,6.11,0,http://www.openphacts.org/units/Nanomolar,2838211,=,37,1,=,,IC50,nM,,773.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,773.35
,326163,26603311,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.26', 'le': '0.23', 'lle': '2.82', 'sei': '5.65'}",CHEMBL3927241,,CHEMBL3927241,7.07,0,http://www.openphacts.org/units/Nanomolar,2838212,=,37,1,=,,IC50,nM,,84.81,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.805
,326164,26603314,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '9.04', 'le': '0.17', 'lle': '0.09', 'sei': '5.03'}",CHEMBL3899211,,CHEMBL3899211,5.89,0,http://www.openphacts.org/units/Nanomolar,2838213,=,37,1,=,,IC50,nM,,1286.87,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1286.87
,326165,26603317,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)OCc3ccccc3)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.84', 'le': '0.16', 'lle': '-0.01', 'sei': '5.16'}",CHEMBL3908169,,CHEMBL3908169,5.89,0,http://www.openphacts.org/units/Nanomolar,2838214,=,37,1,=,,IC50,nM,,1282.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1282.77
,326166,26603320,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OCC(=O)Nc3ccccc3F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '8.61', 'le': '0.16', 'lle': '-0.17', 'sei': '4.93'}",CHEMBL3932621,,CHEMBL3932621,5.76,0,http://www.openphacts.org/units/Nanomolar,2838215,=,37,1,=,,IC50,nM,,1716.45,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1716.455
,326167,26603323,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '11.53', 'le': '0.22', 'lle': '1.23', 'sei': '6.45'}",CHEMBL3895678,,CHEMBL3895678,6.38,0,http://www.openphacts.org/units/Nanomolar,2838216,=,37,1,=,,IC50,nM,,421.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,421.875
,326168,26603326,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886230,,2015,"{'bei': '10.67', 'le': '0.21', 'lle': '0.61', 'sei': '6.88'}",CHEMBL3923681,,CHEMBL3923681,6.05,0,http://www.openphacts.org/units/Nanomolar,2838217,=,37,1,=,,IC50,nM,,892.38,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,892.385
,326169,26603329,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(O)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.74', 'le': '0.24', 'lle': '2.12', 'sei': '6.68'}",CHEMBL3914781,,CHEMBL3914781,6.61,0,http://www.openphacts.org/units/Nanomolar,2838218,=,37,1,=,,IC50,nM,,246.94,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,246.945
,326170,26603332,[],CHEMBL5730026,"Surface plasmon resonance (SPR): The SPR assay is configured to examine solution inhibition of BCL-2 binding to peptide derivatized sensor surfaces to generate IC50 values as a measure of inhibitor potency. Solution Inhibition Assay Format: Biacore TM A100 (GE Healthcare, Uppsala, Sweden) was used to conduct all experiments reported herein. Sensor surface preparation and all interaction analyses experiments were performed at 25 C. Reagents were purchased from GE Healthcare. Running buffer containing 10 mM Hepes, pH7.4, 150 mM sodium chloride, 1.25 mM Dithiothreitol, 3% Dimethyl sulfoxide and 0.05% polysorbate 20 were utilized throughout all analyses. Biotinylated BAK, BAD and NOXA peptides were diluted to 10 nM in running buffer and captured onto a sensor surface pre-derivatized with streptavidin (sensor chip SA) to peptide surface densities in the range 50-100 R.U. Peptide captured surfaces were blocked with 50004 PEO2Biotin. A blank detection spot in each flowcell was similarly blocked with PEO2-biotin and served as a reference spot in the competition assay.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2cc(OC)ccc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886230,,2015,"{'bei': '12.29', 'le': '0.23', 'lle': '1.76', 'sei': '7.45'}",CHEMBL3918229,,CHEMBL3918229,6.55,0,http://www.openphacts.org/units/Nanomolar,2838219,=,37,1,=,,IC50,nM,,282.81,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,282.815
,326171,26603335,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.36', 'le': '0.18', 'lle': '0.58', 'sei': '4.93'}",CHEMBL3909422,,CHEMBL3909422,6.16,0,http://www.openphacts.org/units/Nanomolar,2838220,=,37,1,=,,IC50,nM,,692.43,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,692.435
,326172,26603338,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.78', 'le': '0.21', 'lle': '2.27', 'sei': '5.15'}",CHEMBL3937363,,CHEMBL3937363,6.42,0,http://www.openphacts.org/units/Nanomolar,2838221,=,37,1,=,,IC50,nM,,377.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,377.205
,326173,26603341,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '11.06', 'le': '0.21', 'lle': '1.97', 'sei': '5.53'}",CHEMBL3900418,,CHEMBL3900418,6.90,0,http://www.openphacts.org/units/Nanomolar,2838222,=,37,1,=,,IC50,nM,,126.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,126.56
,326174,26603344,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.90', 'le': '0.16', 'lle': '-1.05', 'sei': '4.46'}",CHEMBL3924890,,CHEMBL3924890,6.10,0,http://www.openphacts.org/units/Nanomolar,2838223,=,37,1,=,,IC50,nM,,799.39,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,799.39
,326175,26603347,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.09', 'le': '0.17', 'lle': '0.10', 'sei': '4.75'}",CHEMBL3927159,,CHEMBL3927159,6.21,0,http://www.openphacts.org/units/Nanomolar,2838224,=,37,1,=,,IC50,nM,,609.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,609.245
,326176,26603350,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.21', 'le': '0.18', 'lle': '-1.14', 'sei': '5.49'}",CHEMBL3902718,,CHEMBL3902718,6.25,0,http://www.openphacts.org/units/Nanomolar,2838225,=,37,1,=,,IC50,nM,,562.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,562.775
,326177,26603353,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.75', 'le': '0.18', 'lle': '-1.24', 'sei': '5.45'}",CHEMBL3890069,,CHEMBL3890069,6.20,0,http://www.openphacts.org/units/Nanomolar,2838226,=,37,1,=,,IC50,nM,,638.23,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,638.23
,326178,26603356,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.80', 'sei': '4.35'}",CHEMBL3959104,,CHEMBL3959104,6.08,0,http://www.openphacts.org/units/Nanomolar,2838227,=,37,1,=,,IC50,nM,,835.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,835.86
,326179,26603359,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3982550,,CHEMBL3982550,,0,http://www.openphacts.org/units/Nanomolar,2838228,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326180,26603362,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3950403,,CHEMBL3950403,,0,http://www.openphacts.org/units/Nanomolar,2838229,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326181,26603365,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.84', 'le': '0.17', 'lle': '1.38', 'sei': '4.32'}",CHEMBL3974550,,CHEMBL3974550,6.53,0,http://www.openphacts.org/units/Nanomolar,2838230,=,37,1,=,,IC50,nM,,296.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,296.105
,326182,26603368,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.92', 'le': '0.13', 'lle': '-2.84', 'sei': '4.21'}",CHEMBL3945127,,CHEMBL3945127,5.18,0,http://www.openphacts.org/units/Nanomolar,2838231,=,37,1,=,,IC50,nM,,6630.34,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6630.34
,326183,26603371,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.53', 'le': '0.13', 'lle': '-3.75', 'sei': '4.52'}",CHEMBL3962530,,CHEMBL3962530,5.14,0,http://www.openphacts.org/units/Nanomolar,2838232,=,37,1,=,,IC50,nM,,7278.41,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7278.41
,326184,26603374,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.09', 'le': '0.18', 'lle': '-0.42', 'sei': '5.40'}",CHEMBL3938600,,CHEMBL3938600,6.15,0,http://www.openphacts.org/units/Nanomolar,2838233,=,37,1,=,,IC50,nM,,714.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,714.5
,326185,26603377,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.56', 'le': '0.16', 'lle': '-1.58', 'sei': '4.98'}",CHEMBL3959636,,CHEMBL3959636,5.66,0,http://www.openphacts.org/units/Nanomolar,2838234,=,37,1,=,,IC50,nM,,2174.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2174.795
,326186,26603380,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.59', 'le': '0.18', 'lle': '1.54', 'sei': '4.71'}",CHEMBL3890556,,CHEMBL3890556,6.19,0,http://www.openphacts.org/units/Nanomolar,2838235,=,37,1,=,,IC50,nM,,639.96,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,639.955
,326187,26603383,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.67', 'le': '0.17', 'lle': '-0.69', 'sei': '5.29'}",CHEMBL3967288,,CHEMBL3967288,6.02,0,http://www.openphacts.org/units/Nanomolar,2838236,=,37,1,=,,IC50,nM,,957.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,957.155
,326188,26603386,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.04', 'le': '0.17', 'lle': '0.93', 'sei': '4.07'}",CHEMBL3899521,,CHEMBL3899521,6.23,0,http://www.openphacts.org/units/Nanomolar,2838237,=,37,1,=,,IC50,nM,,584.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,584.685
,326189,26603389,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.25', 'sei': '4.61'}",CHEMBL3904990,,CHEMBL3904990,6.07,0,http://www.openphacts.org/units/Nanomolar,2838238,=,37,1,=,,IC50,nM,,855.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,855.19
,326190,26603392,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.44', 'le': '0.16', 'lle': '-0.54', 'sei': '4.94'}",CHEMBL3917653,,CHEMBL3917653,5.87,0,http://www.openphacts.org/units/Nanomolar,2838239,=,37,1,=,,IC50,nM,,1356.79,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1356.79
,326191,26603395,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.98', 'le': '0.16', 'lle': '-1.59', 'sei': '5.08'}",CHEMBL3942106,,CHEMBL3942106,5.78,0,http://www.openphacts.org/units/Nanomolar,2838240,=,37,1,=,,IC50,nM,,1653.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1653.195
,326192,26603398,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.23', 'le': '0.18', 'lle': '1.29', 'sei': '4.81'}",CHEMBL3926618,,CHEMBL3926618,5.62,0,http://www.openphacts.org/units/Nanomolar,2838241,=,37,1,=,,IC50,nM,,2387.99,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2387.985
,326193,26603401,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.18', 'le': '0.18', 'lle': '0.92', 'sei': '4.70'}",CHEMBL3890050,,CHEMBL3890050,6.19,0,http://www.openphacts.org/units/Nanomolar,2838242,=,37,1,=,,IC50,nM,,651.76,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,651.765
,326194,26603404,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.69', 'le': '0.17', 'lle': '-0.16', 'sei': '4.46'}",CHEMBL3977288,,CHEMBL3977288,6.37,0,http://www.openphacts.org/units/Nanomolar,2838243,=,37,1,=,,IC50,nM,,427.08,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,427.085
,326195,26603407,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.87', 'le': '0.18', 'lle': '-0.91', 'sei': '5.54'}",CHEMBL3948036,,CHEMBL3948036,6.31,0,http://www.openphacts.org/units/Nanomolar,2838244,=,37,1,=,,IC50,nM,,493.55,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,493.545
,326196,26603410,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.61', 'le': '0.18', 'lle': '0.28', 'sei': '5.58'}",CHEMBL3985364,,CHEMBL3985364,6.34,0,http://www.openphacts.org/units/Nanomolar,2838245,=,37,1,=,,IC50,nM,,454.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,454.155
,326197,26603413,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.07', 'le': '0.17', 'lle': '0.65', 'sei': '4.53'}",CHEMBL3953351,,CHEMBL3953351,6.35,0,http://www.openphacts.org/units/Nanomolar,2838246,=,37,1,=,,IC50,nM,,447.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,447.69
,326198,26603416,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.54', 'le': '0.16', 'lle': '-1.10', 'sei': '5.41'}",CHEMBL3893085,,CHEMBL3893085,6.15,0,http://www.openphacts.org/units/Nanomolar,2838247,=,37,1,=,,IC50,nM,,709.36,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,709.36
,326199,26603419,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.84', 'le': '0.14', 'lle': '-1.98', 'sei': '3.91'}",CHEMBL3962105,,CHEMBL3962105,5.58,0,http://www.openphacts.org/units/Nanomolar,2838248,=,37,1,=,,IC50,nM,,2626.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2626.685
,326200,26603422,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.00', 'le': '0.13', 'lle': '-2.58', 'sei': '4.28'}",CHEMBL3902056,,CHEMBL3902056,5.27,0,http://www.openphacts.org/units/Nanomolar,2838249,=,37,1,=,,IC50,nM,,5412.52,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5412.515
,326201,26603425,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.86', 'le': '0.17', 'lle': '0.51', 'sei': '4.69'}",CHEMBL3976266,,CHEMBL3976266,6.20,0,http://www.openphacts.org/units/Nanomolar,2838250,=,37,1,=,,IC50,nM,,631.49,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,631.485
,326202,26603428,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.31', 'le': '0.14', 'lle': '-1.04', 'sei': '4.01'}",CHEMBL3912231,,CHEMBL3912231,5.28,0,http://www.openphacts.org/units/Nanomolar,2838251,=,37,1,=,,IC50,nM,,5299.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5299.7
,326203,26603431,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.39', 'le': '0.16', 'lle': '-0.21', 'sei': '3.98'}",CHEMBL3982160,,CHEMBL3982160,6.07,0,http://www.openphacts.org/units/Nanomolar,2838252,=,37,1,=,,IC50,nM,,843.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,843.135
,326204,26603434,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.60', 'le': '0.18', 'lle': '1.12', 'sei': '4.30'}",CHEMBL3948609,,CHEMBL3948609,6.57,0,http://www.openphacts.org/units/Nanomolar,2838253,=,37,1,=,,IC50,nM,,271.77,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,271.77
,326205,26603437,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.18', 'le': '0.16', 'lle': '-1.61', 'sei': '5.25'}",CHEMBL3932360,,CHEMBL3932360,5.97,0,http://www.openphacts.org/units/Nanomolar,2838254,=,37,1,=,,IC50,nM,,1076.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1076.21
,326206,26603440,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3943276,,CHEMBL3943276,,0,http://www.openphacts.org/units/Nanomolar,2838255,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326207,26603443,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.68', 'le': '0.18', 'lle': '-0.39', 'sei': '5.78'}",CHEMBL3972844,,CHEMBL3972844,6.57,0,http://www.openphacts.org/units/Nanomolar,2838256,=,37,1,=,,IC50,nM,,268.82,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,268.82
,326208,26603446,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.42', 'le': '0.17', 'lle': '0.43', 'sei': '4.15'}",CHEMBL3900742,,CHEMBL3900742,6.20,0,http://www.openphacts.org/units/Nanomolar,2838257,=,37,1,=,,IC50,nM,,632.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,632.205
,326209,26603449,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.26', 'le': '0.18', 'lle': '0.38', 'sei': '4.49'}",CHEMBL3897154,,CHEMBL3897154,6.17,0,http://www.openphacts.org/units/Nanomolar,2838258,=,37,1,=,,IC50,nM,,672.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,672.575
,326210,26603452,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.21', 'le': '0.18', 'lle': '0.37', 'sei': '4.42'}",CHEMBL3957281,,CHEMBL3957281,6.18,0,http://www.openphacts.org/units/Nanomolar,2838259,=,37,1,=,,IC50,nM,,660.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,660.495
,326211,26603455,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.00', 'le': '0.19', 'lle': '1.07', 'sei': '4.70'}",CHEMBL3985961,,CHEMBL3985961,6.57,0,http://www.openphacts.org/units/Nanomolar,2838260,=,37,1,=,,IC50,nM,,270.38,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,270.38
,326212,26603458,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.51', 'le': '0.16', 'lle': '-0.16', 'sei': '4.66'}",CHEMBL4111735,,CHEMBL4111735,6.09,0,http://www.openphacts.org/units/Nanomolar,2838261,=,37,1,=,,IC50,nM,,806.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,806.98
,326213,26603461,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.54', 'le': '0.16', 'lle': '-0.52', 'sei': '4.33'}",CHEMBL3916294,,CHEMBL3916294,6.05,0,http://www.openphacts.org/units/Nanomolar,2838262,=,37,1,=,,IC50,nM,,884.62,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,884.625
,326214,26603464,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.95', 'le': '0.18', 'lle': '0.55', 'sei': '4.51'}",CHEMBL3946968,,CHEMBL3946968,6.32,0,http://www.openphacts.org/units/Nanomolar,2838263,=,37,1,=,,IC50,nM,,479.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,479.98
,326215,26603467,[],CHEMBL5730027,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.42', 'le': '0.18', 'lle': '0.12', 'sei': '5.43'}",CHEMBL3950260,,CHEMBL3950260,6.18,0,http://www.openphacts.org/units/Nanomolar,2838264,=,37,1,=,,IC50,nM,,666.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,666.035
,326216,26603470,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)c3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.55', 'le': '0.18', 'lle': '0.70', 'sei': '5.03'}",CHEMBL3909422,,CHEMBL3909422,6.29,0,http://www.openphacts.org/units/Nanomolar,2838220,=,37,1,=,,IC50,nM,,518.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,518.875
,326217,26603473,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(C)(=O)=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.96', 'le': '0.21', 'lle': '2.38', 'sei': '5.23'}",CHEMBL3937363,,CHEMBL3937363,6.53,0,http://www.openphacts.org/units/Nanomolar,2838221,=,37,1,=,,IC50,nM,,294.71,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,294.715
,326218,26603476,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(NS(=O)(=O)C(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '11.29', 'le': '0.22', 'lle': '2.11', 'sei': '5.64'}",CHEMBL3900418,,CHEMBL3900418,7.04,0,http://www.openphacts.org/units/Nanomolar,2838222,=,37,1,=,,IC50,nM,,90.44,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.435
,326219,26603479,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc([S+]([O-])c4ccccc4)cs3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.99', 'le': '0.16', 'lle': '-0.98', 'sei': '4.51'}",CHEMBL3924890,,CHEMBL3924890,6.17,0,http://www.openphacts.org/units/Nanomolar,2838223,=,37,1,=,,IC50,nM,,675.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,675.4
,326220,26603482,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(C)=O)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.34', 'le': '0.18', 'lle': '0.26', 'sei': '4.88'}",CHEMBL3927159,,CHEMBL3927159,6.38,0,http://www.openphacts.org/units/Nanomolar,2838224,=,37,1,=,,IC50,nM,,412.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,412.24
,326221,26603485,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc(Cl)cc3Br)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.32', 'le': '0.18', 'lle': '-1.06', 'sei': '5.57'}",CHEMBL3902718,,CHEMBL3902718,6.33,0,http://www.openphacts.org/units/Nanomolar,2838225,=,37,1,=,,IC50,nM,,465.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,465.17
,326222,26603488,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)c(Br)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.91', 'le': '0.18', 'lle': '-1.12', 'sei': '5.56'}",CHEMBL3890069,,CHEMBL3890069,6.33,0,http://www.openphacts.org/units/Nanomolar,2838226,=,37,1,=,,IC50,nM,,473.64,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,473.64
,326223,26603491,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(-c4ccccc4)noc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.55', 'le': '0.16', 'lle': '-0.70', 'sei': '4.42'}",CHEMBL3959104,,CHEMBL3959104,6.18,0,http://www.openphacts.org/units/Nanomolar,2838227,=,37,1,=,,IC50,nM,,664.26,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,664.26
,326224,26603494,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccc(Cl)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.78', 'le': '0.13', 'lle': '-3.14', 'sei': '4.48'}",CHEMBL3982550,,CHEMBL3982550,5.10,0,http://www.openphacts.org/units/Nanomolar,2838228,=,37,1,=,,IC50,nM,,7935.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7935.67
,326225,26603497,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccccc4C)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.32', 'le': '0.14', 'lle': '-2.55', 'sei': '4.45'}",CHEMBL3950403,,CHEMBL3950403,5.47,0,http://www.openphacts.org/units/Nanomolar,2838229,=,37,1,=,,IC50,nM,,3349.66,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3349.66
,326226,26603500,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCN3C(=O)c4ccccc4C3=O)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.93', 'le': '0.17', 'lle': '1.45', 'sei': '4.36'}",CHEMBL3974550,,CHEMBL3974550,6.60,0,http://www.openphacts.org/units/Nanomolar,2838230,=,37,1,=,,IC50,nM,,253.16,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,253.155
,326227,26603503,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Oc4ccc(C)cc4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.10', 'le': '0.13', 'lle': '-2.71', 'sei': '4.32'}",CHEMBL3945127,,CHEMBL3945127,5.31,0,http://www.openphacts.org/units/Nanomolar,2838231,=,37,1,=,,IC50,nM,,4863.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4863.58
,326228,26603506,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cc(Cl)cc(Cl)c4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.83', 'le': '0.14', 'lle': '-3.51', 'sei': '4.73'}",CHEMBL3962530,,CHEMBL3962530,5.38,0,http://www.openphacts.org/units/Nanomolar,2838232,=,37,1,=,,IC50,nM,,4210.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4210.985
,326229,26603509,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.25', 'le': '0.18', 'lle': '-0.32', 'sei': '5.50'}",CHEMBL3938600,,CHEMBL3938600,6.25,0,http://www.openphacts.org/units/Nanomolar,2838233,=,37,1,=,,IC50,nM,,558.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,558.67
,326230,26603512,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Br)cc3CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.66', 'le': '0.16', 'lle': '-1.50', 'sei': '5.04'}",CHEMBL3959636,,CHEMBL3959636,5.74,0,http://www.openphacts.org/units/Nanomolar,2838234,=,37,1,=,,IC50,nM,,1832.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1832.245
,326231,26603515,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cn(C)cn3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.79', 'le': '0.19', 'lle': '1.67', 'sei': '4.81'}",CHEMBL3890556,,CHEMBL3890556,6.32,0,http://www.openphacts.org/units/Nanomolar,2838235,=,37,1,=,,IC50,nM,,475.07,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,475.075
,326232,26603518,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(Cl)ccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.74', 'le': '0.17', 'lle': '-0.64', 'sei': '5.34'}",CHEMBL3967288,,CHEMBL3967288,6.07,0,http://www.openphacts.org/units/Nanomolar,2838236,=,37,1,=,,IC50,nM,,849.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,849.56
,326233,26603521,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(C(=O)OC)o3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.19', 'le': '0.18', 'lle': '1.04', 'sei': '4.14'}",CHEMBL3899521,,CHEMBL3899521,6.34,0,http://www.openphacts.org/units/Nanomolar,2838237,=,37,1,=,,IC50,nM,,456.67,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,456.67
,326234,26603524,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4ccn(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.48', 'le': '0.16', 'lle': '-0.20', 'sei': '4.65'}",CHEMBL3904990,,CHEMBL3904990,6.12,0,http://www.openphacts.org/units/Nanomolar,2838238,=,37,1,=,,IC50,nM,,757.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,757.035
,326235,26603527,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4ccn(C)c34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.60', 'le': '0.16', 'lle': '-0.43', 'sei': '5.04'}",CHEMBL3917653,,CHEMBL3917653,5.98,0,http://www.openphacts.org/units/Nanomolar,2838239,=,37,1,=,,IC50,nM,,1053.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1053.175
,326236,26603530,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.87', 'le': '0.16', 'lle': '-1.67', 'sei': '5.01'}",CHEMBL3942106,,CHEMBL3942106,5.70,0,http://www.openphacts.org/units/Nanomolar,2838240,=,37,1,=,,IC50,nM,,1980.97,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1980.97
,326237,26603533,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])N(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.46', 'le': '0.18', 'lle': '1.43', 'sei': '4.92'}",CHEMBL3926618,,CHEMBL3926618,5.76,0,http://www.openphacts.org/units/Nanomolar,2838241,=,37,1,=,,IC50,nM,,1735.78,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1735.775
,326238,26603536,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3c(C)nn(C)c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.40', 'le': '0.18', 'lle': '1.06', 'sei': '4.81'}",CHEMBL3890050,,CHEMBL3890050,6.33,0,http://www.openphacts.org/units/Nanomolar,2838242,=,37,1,=,,IC50,nM,,466.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,466.345
,326239,26603539,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(NC(C)=O)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.99', 'le': '0.18', 'lle': '0.06', 'sei': '4.62'}",CHEMBL3977288,,CHEMBL3977288,6.59,0,http://www.openphacts.org/units/Nanomolar,2838243,=,37,1,=,,IC50,nM,,254.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,254.5
,326240,26603542,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(Cl)c3Cl)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.05', 'le': '0.18', 'lle': '-0.79', 'sei': '5.65'}",CHEMBL3948036,,CHEMBL3948036,6.43,0,http://www.openphacts.org/units/Nanomolar,2838244,=,37,1,=,,IC50,nM,,370.43,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,370.43
,326241,26603545,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.85', 'le': '0.19', 'lle': '0.44', 'sei': '5.72'}",CHEMBL3985364,,CHEMBL3985364,6.50,0,http://www.openphacts.org/units/Nanomolar,2838245,=,37,1,=,,IC50,nM,,314.95,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,314.95
,326242,26603548,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.30', 'le': '0.18', 'lle': '0.81', 'sei': '4.65'}",CHEMBL3953351,,CHEMBL3953351,6.51,0,http://www.openphacts.org/units/Nanomolar,2838246,=,37,1,=,,IC50,nM,,310.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,310.86
,326243,26603551,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])CCc3cccc4ccccc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.72', 'le': '0.16', 'lle': '-0.97', 'sei': '5.52'}",CHEMBL3893085,,CHEMBL3893085,6.28,0,http://www.openphacts.org/units/Nanomolar,2838247,=,37,1,=,,IC50,nM,,529.08,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,529.08
,326244,26603554,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '6.89', 'le': '0.14', 'lle': '-1.94', 'sei': '3.93'}",CHEMBL3962105,,CHEMBL3962105,5.62,0,http://www.openphacts.org/units/Nanomolar,2838248,=,37,1,=,,IC50,nM,,2392.61,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2392.61
,326245,26603557,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(F)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.25', 'le': '0.14', 'lle': '-2.40', 'sei': '4.43'}",CHEMBL3902056,,CHEMBL3902056,5.45,0,http://www.openphacts.org/units/Nanomolar,2838249,=,37,1,=,,IC50,nM,,3533.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3533.025
,326246,26603560,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc4c(c3)OCCO4)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.99', 'le': '0.17', 'lle': '0.60', 'sei': '4.76'}",CHEMBL3976266,,CHEMBL3976266,6.29,0,http://www.openphacts.org/units/Nanomolar,2838250,=,37,1,=,,IC50,nM,,511.57,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,511.57
,326247,26603563,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(-c4ccn(C)n4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '7.55', 'le': '0.14', 'lle': '-0.87', 'sei': '4.14'}",CHEMBL3912231,,CHEMBL3912231,5.45,0,http://www.openphacts.org/units/Nanomolar,2838251,=,37,1,=,,IC50,nM,,3558.82,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3558.815
,326248,26603566,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4noc(C)n4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.55', 'le': '0.16', 'lle': '-0.09', 'sei': '4.06'}",CHEMBL3982160,,CHEMBL3982160,6.19,0,http://www.openphacts.org/units/Nanomolar,2838252,=,37,1,=,,IC50,nM,,641.46,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,641.455
,326249,26603569,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc4nonc34)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.64', 'le': '0.18', 'lle': '1.14', 'sei': '4.32'}",CHEMBL3948609,,CHEMBL3948609,6.59,0,http://www.openphacts.org/units/Nanomolar,2838253,=,37,1,=,,IC50,nM,,257.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,257.155
,326250,26603572,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3sc4ccc(F)cc4c3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.33', 'le': '0.16', 'lle': '-1.50', 'sei': '5.34'}",CHEMBL3932360,,CHEMBL3932360,6.08,0,http://www.openphacts.org/units/Nanomolar,2838254,=,37,1,=,,IC50,nM,,834.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,834.155
,326251,26603575,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(Oc4ccc(C)cc4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,,CHEMBL3943276,,CHEMBL3943276,,0,http://www.openphacts.org/units/Nanomolar,2838255,>,37,1,>,,IC50,nM,,16000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16000.0
,326252,26603578,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(F)c(Br)cc3F)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.57', 'le': '0.18', 'lle': '-0.48', 'sei': '5.70'}",CHEMBL3972844,,CHEMBL3972844,6.48,0,http://www.openphacts.org/units/Nanomolar,2838256,=,37,1,=,,IC50,nM,,327.93,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,327.93
,326253,26603581,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3scc(C(=O)OC)c3OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.49', 'le': '0.17', 'lle': '0.48', 'sei': '4.18'}",CHEMBL3900742,,CHEMBL3900742,6.25,0,http://www.openphacts.org/units/Nanomolar,2838257,=,37,1,=,,IC50,nM,,565.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,565.685
,326254,26603584,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cccc(C#N)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.37', 'le': '0.18', 'lle': '0.46', 'sei': '4.54'}",CHEMBL3897154,,CHEMBL3897154,6.25,0,http://www.openphacts.org/units/Nanomolar,2838258,=,37,1,=,,IC50,nM,,562.23,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,562.23
,326255,26603587,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3cc(N)ccc3C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.35', 'le': '0.18', 'lle': '0.47', 'sei': '4.49'}",CHEMBL3957281,,CHEMBL3957281,6.28,0,http://www.openphacts.org/units/Nanomolar,2838259,=,37,1,=,,IC50,nM,,530.64,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,530.645
,326256,26603590,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccccc3N)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '10.04', 'le': '0.19', 'lle': '1.09', 'sei': '4.72'}",CHEMBL3985961,,CHEMBL3985961,6.59,0,http://www.openphacts.org/units/Nanomolar,2838260,=,37,1,=,,IC50,nM,,254.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,254.695
,326257,26603593,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])C[C@]34CC[C@H](CC3=O)C4(C)C)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.57', 'le': '0.16', 'lle': '-0.11', 'sei': '4.69'}",CHEMBL4111735,,CHEMBL4111735,6.14,0,http://www.openphacts.org/units/Nanomolar,2838261,=,37,1,=,,IC50,nM,,726.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,726.275
,326258,26603596,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccc(-c4cnco4)cc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '8.86', 'le': '0.17', 'lle': '-0.29', 'sei': '4.49'}",CHEMBL3916294,,CHEMBL3916294,6.28,0,http://www.openphacts.org/units/Nanomolar,2838262,=,37,1,=,,IC50,nM,,522.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,522.095
,326259,26603599,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])c3ccsc3C(=O)OC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.26', 'le': '0.18', 'lle': '0.76', 'sei': '4.66'}",CHEMBL3946968,,CHEMBL3946968,6.53,0,http://www.openphacts.org/units/Nanomolar,2838263,=,37,1,=,,IC50,nM,,292.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,292.905
,326260,26603602,[],CHEMBL5730028,"Surface plasmon resonance (SPR): Methods for Determining IC50s.The present method includes utility of a Surface plasmon resonance (SPR)- based biosensor (Biacore GE Healthcare, Uppsala, Sweden) to characterize BCL-2 inhibitors.Biacore utilizes the phenomenon of surface plasmon resonance (SPR) to detect and measure binding interactions. In a typical Biacore experiment, one of the interacting molecules (ligand) is immobilized on a flexible dextran matrix while the interacting partner (analyte) is allowed to flow across that surface. A binding interaction results in an increase in mass on the sensor surface and a corresponding direct change in the refractive index of the medium in the vicinity of the sensor surface. Changes in refractive index or signal are recorded in resonance units (R.U.) Signal changes due to association and dissociation of complexes are monitored in a non-invasive manner, continuously and in real-time, the results of which are reported in the form of a sensorgram.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(C)n(-c2ccc(N[S+]([O-])Cc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886231,,2015,"{'bei': '9.64', 'le': '0.18', 'lle': '0.26', 'sei': '5.56'}",CHEMBL3950260,,CHEMBL3950260,6.32,0,http://www.openphacts.org/units/Nanomolar,2838264,=,37,1,=,,IC50,nM,,474.73,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,474.73
,405176,26633818,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.16', 'le': '0.20', 'lle': '0.17', 'sei': '6.18'}",CHEMBL2031012,,CHEMBL2031012,7.52,0,http://www.openphacts.org/units/Nanomolar,2882706,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405177,26633821,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)cccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.17', 'lle': '-1.30', 'sei': '5.51'}",CHEMBL3928986,,CHEMBL3928986,6.70,0,http://www.openphacts.org/units/Nanomolar,2882707,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405178,26633824,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.71', 'le': '0.19', 'lle': '-0.48', 'sei': '6.18'}",CHEMBL3901024,,CHEMBL3901024,7.52,0,http://www.openphacts.org/units/Nanomolar,2882708,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405179,26633827,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.54', 'le': '0.19', 'lle': '-0.55', 'sei': '6.08'}",CHEMBL2031017,,CHEMBL2031017,7.40,0,http://www.openphacts.org/units/Nanomolar,2882709,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405180,26633830,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(C#N)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.89', 'le': '0.15', 'lle': '-1.18', 'sei': '4.15'}",CHEMBL3923567,,CHEMBL3923567,6.04,0,http://www.openphacts.org/units/Nanomolar,2882710,=,37,1,=,,IC50,nM,,920.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,920.0
,405181,26633833,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(Cl)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.09', 'le': '0.18', 'lle': '-0.95', 'sei': '5.79'}",CHEMBL3892056,,CHEMBL3892056,7.05,0,http://www.openphacts.org/units/Nanomolar,2882711,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405182,26633836,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.54', 'le': '0.19', 'lle': '-0.55', 'sei': '6.08'}",CHEMBL2031018,,CHEMBL2031018,7.40,0,http://www.openphacts.org/units/Nanomolar,2882712,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405183,26633839,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCc5ccccc5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.45', 'le': '0.18', 'lle': '-0.93', 'sei': '6.11'}",CHEMBL3914542,,CHEMBL3914542,8.00,0,http://www.openphacts.org/units/Nanomolar,2882713,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405184,26633842,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.18', 'lle': '-0.83', 'sei': '5.58'}",CHEMBL3984367,,CHEMBL3984367,7.30,0,http://www.openphacts.org/units/Nanomolar,2882714,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405185,26633845,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.00', 'le': '0.16', 'lle': '-0.10', 'sei': '4.85'}",CHEMBL2031014,,CHEMBL2031014,6.96,1,http://www.openphacts.org/units/Nanomolar,2882715,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405186,26633848,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(N(C)C)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.72', 'le': '0.18', 'lle': '-0.66', 'sei': '6.02'}",CHEMBL3904423,,CHEMBL3904423,7.52,0,http://www.openphacts.org/units/Nanomolar,2882716,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405187,26633851,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(OCCCN5CCOCC5)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.40', 'le': '0.14', 'lle': '-0.91', 'sei': '4.56'}",CHEMBL3978452,,CHEMBL3978452,6.54,0,http://www.openphacts.org/units/Nanomolar,2882717,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,405188,26633854,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCOCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.40', 'le': '0.14', 'lle': '-0.91', 'sei': '4.56'}",CHEMBL3952199,,CHEMBL3952199,6.54,0,http://www.openphacts.org/units/Nanomolar,2882718,=,37,1,=,,IC50,nM,,290.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,290.0
,405189,26633857,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.02', 'le': '0.14', 'lle': '-1.07', 'sei': '4.58'}",CHEMBL3981017,,CHEMBL3981017,6.29,0,http://www.openphacts.org/units/Nanomolar,2882719,=,37,1,=,,IC50,nM,,510.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,510.0
,405190,26633860,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OC(C)CN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.50', 'le': '0.15', 'lle': '-1.37', 'sei': '4.70'}",CHEMBL3957469,,CHEMBL3957469,6.31,0,http://www.openphacts.org/units/Nanomolar,2882720,=,37,1,=,,IC50,nM,,490.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,490.0
,405191,26633863,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(CNS(=O)(=O)c3ccc4ccc(OCCC5CCCN5C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.11', 'le': '0.14', 'lle': '-2.50', 'sei': '5.18'}",CHEMBL3891889,,CHEMBL3891889,6.07,0,http://www.openphacts.org/units/Nanomolar,2882721,=,37,1,=,,IC50,nM,,860.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,860.0
,405192,26633866,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.93', 'le': '0.14', 'lle': '-1.84', 'sei': '4.35'}",CHEMBL3968488,,CHEMBL3968488,5.84,0,http://www.openphacts.org/units/Nanomolar,2882722,=,37,1,=,,IC50,nM,,1460.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1460.0
,405193,26633869,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(OCCCN5CCCC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.25', 'le': '0.12', 'lle': '-2.79', 'sei': '4.04'}",CHEMBL3936837,,CHEMBL3936837,5.42,0,http://www.openphacts.org/units/Nanomolar,2882723,=,37,1,=,,IC50,nM,,3780.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3780.0
,405194,26633872,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.85', 'le': '0.21', 'lle': '-0.35', 'sei': '6.91'}",CHEMBL3980078,,CHEMBL3980078,8.41,0,http://www.openphacts.org/units/Nanomolar,2882724,=,37,1,=,,IC50,nM,,3.93,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.93
,405195,26633875,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.06', 'le': '0.21', 'lle': '-0.51', 'sei': '6.69'}",CHEMBL3893121,,CHEMBL3893121,8.14,0,http://www.openphacts.org/units/Nanomolar,2882725,=,37,1,=,,IC50,nM,,7.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.25
,405196,26633878,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N5CCN(C)CC5)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.13', 'le': '0.16', 'lle': '0.32', 'sei': '4.85'}",CHEMBL3890787,,CHEMBL3890787,7.05,0,http://www.openphacts.org/units/Nanomolar,2882726,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405197,26633881,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(C(=O)N(C)C)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.41', 'le': '0.16', 'lle': '-0.23', 'sei': '4.81'}",CHEMBL3918855,,CHEMBL3918855,6.82,0,http://www.openphacts.org/units/Nanomolar,2882727,=,37,1,=,,IC50,nM,,150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,150.0
,405198,26633884,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.51', 'le': '0.19', 'lle': '0.64', 'sei': '5.78'}",CHEMBL2031021,,CHEMBL2031021,7.22,0,http://www.openphacts.org/units/Nanomolar,2882728,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405199,26633887,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)C3CCCCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.85', 'le': '0.15', 'lle': '-1.06', 'sei': '4.65'}",CHEMBL3927598,,CHEMBL3927598,6.60,0,http://www.openphacts.org/units/Nanomolar,2882729,=,37,1,=,,IC50,nM,,250.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,250.0
,405200,26633890,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.18', 'lle': '-1.36', 'sei': '6.16'}",CHEMBL2031022,,CHEMBL2031022,7.70,0,http://www.openphacts.org/units/Nanomolar,2882730,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405201,26633893,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.29', 'le': '0.15', 'lle': '-1.93', 'sei': '4.72'}",CHEMBL3955216,,CHEMBL3955216,6.70,0,http://www.openphacts.org/units/Nanomolar,2882731,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405202,26633896,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4CCSc3ccccc3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.42', 'le': '0.17', 'lle': '-1.05', 'sei': '5.84'}",CHEMBL3948491,,CHEMBL3948491,7.30,0,http://www.openphacts.org/units/Nanomolar,2882732,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405203,26633899,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.22', 'le': '0.17', 'lle': '-2.20', 'sei': '5.77'}",CHEMBL3893154,,CHEMBL3893154,7.30,0,http://www.openphacts.org/units/Nanomolar,2882733,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405204,26633902,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4C(=O)N3CCOCC3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.66', 'le': '0.15', 'lle': '0.46', 'sei': '4.19'}",CHEMBL3912236,,CHEMBL3912236,6.47,0,http://www.openphacts.org/units/Nanomolar,2882734,=,37,1,=,,IC50,nM,,340.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,340.0
,405205,26633905,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4CCCN4CCOCC4)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.48', 'le': '0.15', 'lle': '-0.46', 'sei': '4.61'}",CHEMBL3917408,,CHEMBL3917408,6.41,0,http://www.openphacts.org/units/Nanomolar,2882735,=,37,1,=,,IC50,nM,,390.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,390.0
,405206,26633908,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(Cl)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.72', 'le': '0.19', 'lle': '-0.12', 'sei': '6.08'}",CHEMBL3954188,,CHEMBL3954188,7.70,0,http://www.openphacts.org/units/Nanomolar,2882736,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405207,26633911,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)c(I)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.19', 'le': '0.21', 'lle': '0.34', 'sei': '6.41'}",CHEMBL3947141,,CHEMBL3947141,8.11,0,http://www.openphacts.org/units/Nanomolar,2882737,=,37,1,=,,IC50,nM,,7.69,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.69
,405208,26633914,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)c(Br)cn4CC)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.15', 'le': '0.21', 'lle': '-0.31', 'sei': '6.62'}",CHEMBL3962921,,CHEMBL3962921,8.38,0,http://www.openphacts.org/units/Nanomolar,2882738,=,37,1,=,,IC50,nM,,4.19,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.19
,405209,26633917,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.48', 'le': '0.18', 'lle': '0.59', 'sei': '5.14'}",CHEMBL2031024,,CHEMBL2031024,7.30,0,http://www.openphacts.org/units/Nanomolar,2882739,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405210,26633920,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.50', 'le': '0.20', 'lle': '1.41', 'sei': '5.47'}",CHEMBL2031027,,CHEMBL2031027,8.07,0,http://www.openphacts.org/units/Nanomolar,2882740,=,37,1,=,,IC50,nM,,8.41,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.41
,405211,26633923,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@@H]2C(=O)O)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.37', 'le': '0.14', 'lle': '-1.02', 'sei': '3.64'}",CHEMBL3893974,,CHEMBL3893974,5.78,0,http://www.openphacts.org/units/Nanomolar,2882741,=,37,1,=,,IC50,nM,,1650.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1650.0
,405212,26633926,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2COc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.32', 'le': '0.18', 'lle': '-0.22', 'sei': '5.29'}",CHEMBL2031031,,CHEMBL2031031,6.92,1,http://www.openphacts.org/units/Nanomolar,2882742,=,37,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,405213,26633929,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccc(C(=O)O)cc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '6.79', 'le': '0.13', 'lle': '-1.72', 'sei': '3.35'}",CHEMBL3898017,,CHEMBL3898017,5.33,0,http://www.openphacts.org/units/Nanomolar,2882743,=,37,1,=,,IC50,nM,,4710.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4710.0
,405214,26633932,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3S(=O)(=O)C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.04', 'le': '0.16', 'lle': '-0.18', 'sei': '4.08'}",CHEMBL3963540,,CHEMBL3963540,6.36,0,http://www.openphacts.org/units/Nanomolar,2882744,=,37,1,=,,IC50,nM,,440.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,440.0
,405215,26633935,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCCOC)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.18', 'lle': '-0.07', 'sei': '5.49'}",CHEMBL2031025,,CHEMBL2031025,7.70,0,http://www.openphacts.org/units/Nanomolar,2882745,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405216,26633938,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CNC2CCN(C)CC2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.88', 'le': '0.17', 'lle': '0.30', 'sei': '5.62'}",CHEMBL3963300,,CHEMBL3963300,7.70,0,http://www.openphacts.org/units/Nanomolar,2882746,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405217,26633941,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(CCO)CC2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.98', 'le': '0.16', 'lle': '0.72', 'sei': '4.75'}",CHEMBL3964058,,CHEMBL3964058,7.05,0,http://www.openphacts.org/units/Nanomolar,2882747,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405218,26633944,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCN(C)C)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.51', 'le': '0.19', 'lle': '0.71', 'sei': '5.96'}",CHEMBL2031026,,CHEMBL2031026,8.00,0,http://www.openphacts.org/units/Nanomolar,2882748,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405219,26633947,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2COCCO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.96', 'le': '0.17', 'lle': '0.58', 'sei': '4.83'}",CHEMBL3975289,,CHEMBL3975289,7.30,0,http://www.openphacts.org/units/Nanomolar,2882749,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405220,26633950,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.78', 'le': '0.18', 'lle': '-1.58', 'sei': '6.18'}",CHEMBL3942482,,CHEMBL3942482,7.52,0,http://www.openphacts.org/units/Nanomolar,2882750,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405221,26633953,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC(F)(F)F)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.76', 'le': '0.17', 'lle': '-0.93', 'sei': '5.72'}",CHEMBL3960836,,CHEMBL3960836,6.96,0,http://www.openphacts.org/units/Nanomolar,2882751,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405222,26633956,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)N(CCC(F)(F)F)CCC(F)(F)F)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3ccccc3c2)cc1C(=O)N1CCc2ccccc2C1,,,CHEMBL3886736,,2016,"{'bei': '8.65', 'le': '0.17', 'lle': '-0.55', 'sei': '5.83'}",CHEMBL3986056,,CHEMBL3986056,7.10,0,http://www.openphacts.org/units/Nanomolar,2882752,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,405223,26633959,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc2c(c1)OCCO2,,,CHEMBL3886736,,2016,"{'bei': '8.74', 'le': '0.17', 'lle': '-0.37', 'sei': '5.11'}",CHEMBL3954559,,CHEMBL3954559,7.16,0,http://www.openphacts.org/units/Nanomolar,2882753,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405224,26633962,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,CHEMBL3886736,,2016,"{'bei': '8.38', 'le': '0.16', 'lle': '-2.77', 'sei': '6.00'}",CHEMBL3940231,,CHEMBL3940231,7.30,0,http://www.openphacts.org/units/Nanomolar,2882754,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405225,26633965,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1ccc(C(=O)OC)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.61', 'le': '0.17', 'lle': '-0.49', 'sei': '4.76'}",CHEMBL3937806,,CHEMBL3937806,7.05,0,http://www.openphacts.org/units/Nanomolar,2882755,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,405226,26633968,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.12', 'le': '0.16', 'lle': '1.85', 'sei': '4.55'}",CHEMBL3889549,,CHEMBL3889549,7.16,0,http://www.openphacts.org/units/Nanomolar,2882756,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405227,26633971,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)cc1C,,,CHEMBL3886736,,2016,"{'bei': '9.40', 'le': '0.18', 'lle': '-0.05', 'sei': '5.46'}",CHEMBL3917569,,CHEMBL3917569,6.64,0,http://www.openphacts.org/units/Nanomolar,2882757,=,37,1,=,,IC50,nM,,230.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,230.0
,405228,26633974,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccc(I)cc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.94', 'le': '0.18', 'lle': '-1.96', 'sei': '6.33'}",CHEMBL3945459,,CHEMBL3945459,7.70,0,http://www.openphacts.org/units/Nanomolar,2882758,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405229,26633977,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.89', 'le': '0.18', 'lle': '-1.00', 'sei': '5.69'}",CHEMBL3906577,,CHEMBL3906577,8.07,0,http://www.openphacts.org/units/Nanomolar,2882759,=,37,1,=,,IC50,nM,,8.49,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.49
,405230,26633980,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.69', 'le': '0.18', 'lle': '-0.42', 'sei': '5.51'}",CHEMBL3938217,,CHEMBL3938217,8.00,0,http://www.openphacts.org/units/Nanomolar,2882760,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405231,26633983,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.24', 'le': '0.18', 'lle': '-1.12', 'sei': '6.29'}",CHEMBL3964186,,CHEMBL3964186,6.58,0,http://www.openphacts.org/units/Nanomolar,2882761,=,37,1,=,,IC50,nM,,260.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,260.0
,405232,26633986,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '10.11', 'le': '0.20', 'lle': '0.93', 'sei': '5.78'}",CHEMBL3931099,,CHEMBL3931099,7.22,0,http://www.openphacts.org/units/Nanomolar,2882762,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405233,26633989,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C(F)(F)F)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.37', 'le': '0.19', 'lle': '-0.14', 'sei': '6.03'}",CHEMBL3894163,,CHEMBL3894163,7.52,0,http://www.openphacts.org/units/Nanomolar,2882763,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,405234,26633992,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(F)(F)F)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.57', 'le': '0.19', 'lle': '-0.89', 'sei': '7.07'}",CHEMBL3968982,,CHEMBL3968982,7.40,0,http://www.openphacts.org/units/Nanomolar,2882764,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405235,26633995,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(ccn4Cc4ccc(Cl)c(Cl)c4)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '8.77', 'le': '0.18', 'lle': '-0.81', 'sei': '5.48'}",CHEMBL3936947,,CHEMBL3936947,8.05,0,http://www.openphacts.org/units/Nanomolar,2882765,=,37,1,=,,IC50,nM,,8.85,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.85
,405236,26633998,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCC(=O)NCCN1CCN(C)CC1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '5.81', 'le': None, 'lle': None, 'sei': None}",CHEMBL3927011,,CHEMBL3927011,6.00,0,http://www.openphacts.org/units/Nanomolar,2882766,=,37,1,=,,IC50,nM,,1010.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1010.0
,405237,26634001,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.95', 'le': '0.20', 'lle': '0.67', 'sei': '5.42'}",CHEMBL3901575,,CHEMBL3901575,8.00,0,http://www.openphacts.org/units/Nanomolar,2882767,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405238,26634004,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(c3)CCN4CC)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.26', 'le': '0.20', 'lle': '1.34', 'sei': '5.54'}",CHEMBL3931548,,CHEMBL3931548,8.04,0,http://www.openphacts.org/units/Nanomolar,2882768,=,37,1,=,,IC50,nM,,9.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.15
,405239,26634007,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.79', 'le': '0.21', 'lle': '0.40', 'sei': '6.49'}",CHEMBL3927392,,CHEMBL3927392,8.11,0,http://www.openphacts.org/units/Nanomolar,2882769,=,37,1,=,,IC50,nM,,7.84,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.84
,405240,26634010,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3cc(Br)c4c(ccn4CC)c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '9.75', 'le': '0.21', 'lle': '1.15', 'sei': '5.75'}",CHEMBL3912610,,CHEMBL3912610,8.45,0,http://www.openphacts.org/units/Nanomolar,2882770,=,37,1,=,,IC50,nM,,3.59,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.59
,405241,26634013,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(-c2ccc(CC(=O)O)cc2)cc1)C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(c3)CCN4Cc3ccc(Cl)c(Cl)c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl,,,CHEMBL3886736,,2016,"{'bei': '7.56', 'le': None, 'lle': None, 'sei': None}",CHEMBL3963735,,CHEMBL3963735,8.00,0,http://www.openphacts.org/units/Nanomolar,2882771,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405242,26634016,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)c(C(=O)NCc2ccc(-c3ccc(CC(=O)O)cc3)cc2)nn1-c1ccc(C(=O)NS(=O)(=O)c2ccc3c(c2)CCN3Cc2ccc(Cl)c(Cl)c2)cc1C(=O)N1CCc2ccccc2C1,,,CHEMBL3886736,,2016,"{'bei': '7.28', 'le': None, 'lle': None, 'sei': None}",CHEMBL3918064,,CHEMBL3918064,7.30,0,http://www.openphacts.org/units/Nanomolar,2882772,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,405243,26634019,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,CHEMBL3886736,,2016,"{'bei': '8.13', 'le': '0.17', 'lle': '-3.49', 'sei': '6.57'}",CHEMBL3890955,,CHEMBL3890955,8.00,0,http://www.openphacts.org/units/Nanomolar,2882773,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405244,26634022,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2ccc(Cl)cc2)c1,,,CHEMBL3886736,,2016,"{'bei': '7.87', 'le': '0.16', 'lle': '-3.98', 'sei': '6.08'}",CHEMBL3960038,,CHEMBL3960038,7.40,0,http://www.openphacts.org/units/Nanomolar,2882774,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,405245,26634025,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1nn(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C)c1Cl)c1cccc(-c2cccc(Cl)c2)c1,,,CHEMBL3886736,,2016,"{'bei': '7.61', 'le': '0.16', 'lle': '-4.23', 'sei': '5.88'}",CHEMBL3899265,,CHEMBL3899265,7.16,0,http://www.openphacts.org/units/Nanomolar,2882775,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,405246,26634028,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.40', 'le': '0.16', 'lle': '-2.32', 'sei': '5.11'}",CHEMBL2030850,,CHEMBL2030850,7.00,1,http://www.openphacts.org/units/Nanomolar,2882776,=,37,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,405247,26634031,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.88', 'le': '0.17', 'lle': '-2.27', 'sei': '5.62'}",CHEMBL3927294,,CHEMBL3927294,7.70,0,http://www.openphacts.org/units/Nanomolar,2882777,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405248,26634034,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)CC[Si](C)(C)C)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccccc1,,,CHEMBL3886736,,2016,"{'bei': '8.72', 'le': None, 'lle': None, 'sei': None}",CHEMBL3939961,,CHEMBL3939961,6.24,0,http://www.openphacts.org/units/Nanomolar,2882778,=,37,1,=,,IC50,nM,,580.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,580.0
,405249,26634037,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccccc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '8.71', 'le': '0.16', 'lle': '-1.75', 'sei': '5.26'}",CHEMBL2030851,,CHEMBL2030851,6.89,1,http://www.openphacts.org/units/Nanomolar,2882779,=,37,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,130.0
,405250,26634040,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2ccc(Cl)cc2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.33', 'le': '0.18', 'lle': '-1.59', 'sei': '5.88'}",CHEMBL2030852,,CHEMBL2030852,7.70,0,http://www.openphacts.org/units/Nanomolar,2882780,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405251,26634043,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.82', 'le': '0.19', 'lle': '-1.18', 'sei': '6.20'}",CHEMBL2030853,,CHEMBL2030853,8.11,1,http://www.openphacts.org/units/Nanomolar,2882781,=,37,1,=,,IC50,nM,,7.83,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.83
,405252,26634046,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(CCO)cc1,,,CHEMBL3886736,,2016,"{'bei': '10.36', 'le': '0.19', 'lle': '1.32', 'sei': '5.43'}",CHEMBL2030856,,CHEMBL2030856,7.70,1,http://www.openphacts.org/units/Nanomolar,2882782,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405253,26634049,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4c(Cl)ccc(Br)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(C(=O)OCC)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '7.85', 'le': '0.16', 'lle': '-3.69', 'sei': '5.62'}",CHEMBL3966210,,CHEMBL3966210,7.70,0,http://www.openphacts.org/units/Nanomolar,2882783,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,405254,26634052,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(Oc2cccc(Cl)c2)cc1,,,CHEMBL3886736,,2016,"{'bei': '9.53', 'le': '0.19', 'lle': '-1.74', 'sei': '6.26'}",CHEMBL2030864,,CHEMBL2030864,8.20,0,http://www.openphacts.org/units/Nanomolar,2882784,=,37,1,=,,IC50,nM,,6.37,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.37
,405255,26634055,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)c(CO)nn1-c1ccc(OCC(O)CO)cc1,,,CHEMBL3886736,,2016,"{'bei': '10.25', 'le': '0.19', 'lle': '2.51', 'sei': '4.72'}",CHEMBL3982792,,CHEMBL3982792,8.09,0,http://www.openphacts.org/units/Nanomolar,2882785,=,37,1,=,,IC50,nM,,8.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.13
,405256,26634058,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)c(CO)nn1-c1ccccc1,,,CHEMBL3886736,,2016,"{'bei': '10.98', 'le': '0.21', 'lle': '1.79', 'sei': '5.64'}",CHEMBL2030859,,CHEMBL2030859,8.00,0,http://www.openphacts.org/units/Nanomolar,2882786,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405257,26634061,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.86', 'le': '0.19', 'lle': '0.36', 'sei': '5.72'}",CHEMBL3912906,,CHEMBL3912906,6.96,0,http://www.openphacts.org/units/Nanomolar,2882787,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,405258,26634064,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CC(=O)NC)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.34', 'le': '0.16', 'lle': '0.56', 'sei': '4.22'}",CHEMBL3890311,,CHEMBL3890311,6.37,0,http://www.openphacts.org/units/Nanomolar,2882788,=,37,1,=,,IC50,nM,,430.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,430.0
,405259,26634067,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CCCN(C)C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.62', 'le': '0.16', 'lle': '-0.31', 'sei': '5.36'}",CHEMBL3921891,,CHEMBL3921891,6.70,0,http://www.openphacts.org/units/Nanomolar,2882789,=,37,1,=,,IC50,nM,,200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,200.0
,405260,26634070,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CC(=O)O)c(-c2ccc(C(=O)NS(=O)(=O)c3cccc4ccccc34)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.14', 'le': '0.17', 'lle': '0.70', 'sei': '4.31'}",CHEMBL3962772,,CHEMBL3962772,6.85,0,http://www.openphacts.org/units/Nanomolar,2882790,=,37,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,405261,26634073,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(CCN2CCOCC2)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '8.29', 'le': '0.16', 'lle': '1.16', 'sei': '4.48'}",CHEMBL3893805,,CHEMBL3893805,6.92,0,http://www.openphacts.org/units/Nanomolar,2882791,=,37,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,405262,26634076,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(C)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(I)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL3886736,,2016,"{'bei': '9.48', 'le': '0.21', 'lle': '1.63', 'sei': '5.52'}",CHEMBL3897725,,CHEMBL3897725,8.16,0,http://www.openphacts.org/units/Nanomolar,2882792,=,37,1,=,,IC50,nM,,6.97,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.97
,405263,26634079,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '8.85', 'le': '0.17', 'lle': '-1.04', 'sei': '5.33'}",CHEMBL3965698,,CHEMBL3965698,6.22,0,http://www.openphacts.org/units/Nanomolar,2882793,=,37,1,=,,IC50,nM,,600.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,600.0
,405264,26634082,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ccc(Br)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '10.15', 'le': '0.21', 'lle': '-1.04', 'sei': '8.03'}",CHEMBL3986556,,CHEMBL3986556,8.00,0,http://www.openphacts.org/units/Nanomolar,2882794,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405265,26634085,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4ccccc4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '9.75', 'le': '0.19', 'lle': '0.19', 'sei': '5.44'}",CHEMBL3957861,,CHEMBL3957861,7.22,0,http://www.openphacts.org/units/Nanomolar,2882795,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,405266,26634088,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(Cc1ccc(Cl)c(Cl)c1)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2CCc3ccccc3C2)n1,,,CHEMBL3886736,,2016,"{'bei': '9.44', 'le': '0.20', 'lle': '-2.03', 'sei': '7.11'}",CHEMBL3912240,,CHEMBL3912240,8.00,0,http://www.openphacts.org/units/Nanomolar,2882796,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,405267,26634091,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CO)n1,,,CHEMBL3886736,,2016,"{'bei': '10.79', 'le': '0.22', 'lle': '1.15', 'sei': '6.07'}",CHEMBL2031009,,CHEMBL2031009,8.06,1,http://www.openphacts.org/units/Nanomolar,2882797,=,37,1,=,,IC50,nM,,8.78,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.78
,405268,26634094,[],CHEMBL5730228,"Fluorescence Polarization Assay (FPA): The assays were performed in black flat-bottom 384-well plates. The final assay volume was 50 l prepared from additions of Gst-Bcl-2 (Bcl-2: GENBANK Accession No. P10415), fluoresceinated 18-mer BIM peptide (NH2-YYANFEDGIRRLEQAIWI-[FAM]) (SEQ ID NO: 1), and test compounds in assay buffer consisting of 20 mM Sodium Phosphate, 1 mM EDTA, 50 mM NaCl, and 0.05% Pluronic Acid. The reaction was incubated at room temperature for 60 minutes and fluorescence polarization of the reaction was detected on the LJL Plate Reader. Inhibition data were calculated from mP values generated by the no protein control reactions for 100% inhibition and vehicle-only reactions for 0% inhibition. The final concentrations of reagents in the assay were 4.9 nM BCL-2, 5 nM fluoresceinated 18-mer BIM peptide and 1% DMSO.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(CCC)c1ncc(Cl)c(-c2ccc(C(=O)NS(=O)(=O)c3ccc4cccc(Cl)c4c3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN)n1,,,CHEMBL3886736,,2016,"{'bei': '11.12', 'le': '0.22', 'lle': '1.42', 'sei': '5.98'}",CHEMBL2031008,,CHEMBL2031008,8.29,0,http://www.openphacts.org/units/Nanomolar,2882798,=,37,1,=,,IC50,nM,,5.09,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.09
,599893,27087050,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.90', 'le': '0.20', 'lle': '0.94', 'sei': '8.01'}",CHEMBL3958369,,CHEMBL3958369,7.75,0,http://www.openphacts.org/units/Nanomolar,4232599,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599894,27087053,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.62', 'le': '0.19', 'lle': '0.59', 'sei': '7.96'}",CHEMBL3983424,,CHEMBL3983424,7.70,0,http://www.openphacts.org/units/Nanomolar,4232600,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,599895,27087056,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(Cl)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.33', 'le': '0.19', 'lle': '0.24', 'sei': '7.96'}",CHEMBL3927695,,CHEMBL3927695,7.70,0,http://www.openphacts.org/units/Nanomolar,4232601,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,599896,27087059,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '10.39', 'le': '0.19', 'lle': '0.47', 'sei': '7.98'}",CHEMBL3899673,,CHEMBL3899673,7.72,0,http://www.openphacts.org/units/Nanomolar,4232602,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,599897,27087062,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(OC(F)(F)F)cc1,,,CHEMBL5726033,,2017,"{'bei': '9.17', 'le': '0.17', 'lle': '-0.41', 'sei': '6.88'}",CHEMBL3940396,,CHEMBL3940396,7.29,0,http://www.openphacts.org/units/Nanomolar,4232603,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,599898,27087065,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.76', 'le': '0.20', 'lle': '1.31', 'sei': '6.69'}",CHEMBL3943706,,CHEMBL3943706,7.82,0,http://www.openphacts.org/units/Nanomolar,4232604,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599899,27087068,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,CHEMBL5726033,,2017,"{'bei': '10.41', 'le': '0.19', 'lle': '1.05', 'sei': '7.20'}",CHEMBL3934859,,CHEMBL3934859,7.82,0,http://www.openphacts.org/units/Nanomolar,4232605,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599900,27087071,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.30', 'le': '0.19', 'lle': '1.09', 'sei': '7.89'}",CHEMBL3939864,,CHEMBL3939864,7.89,0,http://www.openphacts.org/units/Nanomolar,4232606,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,599901,27087074,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.14', 'le': '0.19', 'lle': '0.44', 'sei': '7.62'}",CHEMBL3959149,,CHEMBL3959149,7.75,0,http://www.openphacts.org/units/Nanomolar,4232607,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599902,27087077,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4n2CCCC4)OCO3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.38', 'le': '0.19', 'lle': '0.72', 'sei': '7.44'}",CHEMBL5780777,,CHEMBL5780777,7.92,0,http://www.openphacts.org/units/Nanomolar,4232608,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,599903,27087080,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.02', 'le': '0.18', 'lle': '0.11', 'sei': '7.67'}",CHEMBL3921211,,CHEMBL3921211,7.80,0,http://www.openphacts.org/units/Nanomolar,4232609,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,599904,27087083,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1COCCN1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,CHEMBL5726033,,2017,"{'bei': '9.99', 'le': '0.18', 'lle': '0.09', 'sei': '7.64'}",CHEMBL3949045,,CHEMBL3949045,7.77,0,http://www.openphacts.org/units/Nanomolar,4232610,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,599905,27087086,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1COCCN1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,CHEMBL5726033,,2017,"{'bei': '9.96', 'le': '0.18', 'lle': '0.06', 'sei': '7.62'}",CHEMBL3904445,,CHEMBL3904445,7.75,0,http://www.openphacts.org/units/Nanomolar,4232611,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599906,27087089,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H]1COC[C@H](C)N1C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n1CCCC3)OCO2,,,CHEMBL5726033,,2017,"{'bei': '8.95', 'le': '0.16', 'lle': '-0.98', 'sei': '6.98'}",CHEMBL3935948,,CHEMBL3935948,7.09,0,http://www.openphacts.org/units/Nanomolar,4232612,=,37,1,=,,IC50,nM,,81.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,81.0
,599907,27087092,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Br)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.38', 'le': '0.19', 'lle': '-0.84', 'sei': '9.01'}",CHEMBL3918235,,CHEMBL3918235,7.50,0,http://www.openphacts.org/units/Nanomolar,4232613,=,37,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,599908,27087095,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Br)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.45', 'le': '0.19', 'lle': '-0.26', 'sei': '9.29'}",CHEMBL3916185,,CHEMBL3916185,7.57,0,http://www.openphacts.org/units/Nanomolar,4232614,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,599909,27087098,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.63', 'le': '0.20', 'lle': '-0.27', 'sei': '9.53'}",CHEMBL3933816,,CHEMBL3933816,7.46,0,http://www.openphacts.org/units/Nanomolar,4232615,=,37,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,599910,27087101,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,CHEMBL5726033,,2017,"{'bei': '10.32', 'le': '0.19', 'lle': '-0.04', 'sei': '8.48'}",CHEMBL3961292,,CHEMBL3961292,7.66,0,http://www.openphacts.org/units/Nanomolar,4232616,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599911,27087104,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.03', 'le': '0.19', 'lle': '-0.65', 'sei': '9.10'}",CHEMBL3924899,,CHEMBL3924899,7.57,0,http://www.openphacts.org/units/Nanomolar,4232617,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,599912,27087107,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.38', 'le': '0.20', 'lle': '0.13', 'sei': '9.64'}",CHEMBL3955979,,CHEMBL3955979,7.85,0,http://www.openphacts.org/units/Nanomolar,4232618,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,599913,27087110,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.53', 'le': '0.19', 'lle': '0.06', 'sei': '9.34'}",CHEMBL3919460,,CHEMBL3919460,7.77,0,http://www.openphacts.org/units/Nanomolar,4232619,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,599914,27087113,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '11.01', 'le': '0.20', 'lle': '0.33', 'sei': '9.63'}",CHEMBL3944500,,CHEMBL3944500,7.54,0,http://www.openphacts.org/units/Nanomolar,4232620,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,599915,27087116,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.09', 'le': '0.19', 'lle': '-0.34', 'sei': '9.53'}",CHEMBL3953784,,CHEMBL3953784,7.77,0,http://www.openphacts.org/units/Nanomolar,4232621,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,599916,27087119,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCOc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.06', 'le': '0.19', 'lle': '0.21', 'sei': '8.56'}",CHEMBL3979356,,CHEMBL3979356,7.77,0,http://www.openphacts.org/units/Nanomolar,4232622,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,599917,27087122,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CC)c1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5726033,,2017,"{'bei': '9.84', 'le': '0.19', 'lle': '-0.97', 'sei': '9.33'}",CHEMBL3962005,,CHEMBL3962005,7.60,0,http://www.openphacts.org/units/Nanomolar,4232623,=,37,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,599918,27087125,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCC2,,,CHEMBL5726033,,2017,"{'bei': '10.06', 'le': '0.19', 'lle': '-0.76', 'sei': '9.53'}",CHEMBL3934509,,CHEMBL3934509,7.46,0,http://www.openphacts.org/units/Nanomolar,4232624,=,37,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,599919,27087128,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '-0.25', 'sei': '10.22'}",CHEMBL3923492,,CHEMBL3923492,7.89,0,http://www.openphacts.org/units/Nanomolar,4232625,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,599920,27087131,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.13', 'le': '0.19', 'lle': '0.24', 'sei': '7.74'}",CHEMBL3918945,,CHEMBL3918945,7.48,0,http://www.openphacts.org/units/Nanomolar,4232626,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,599921,27087134,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.43', 'le': '0.17', 'lle': '-0.26', 'sei': '7.35'}",CHEMBL3947942,,CHEMBL3947942,7.47,0,http://www.openphacts.org/units/Nanomolar,4232627,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,599922,27087137,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '10.19', 'le': '0.19', 'lle': '0.06', 'sei': '8.27'}",CHEMBL3920154,,CHEMBL3920154,7.64,0,http://www.openphacts.org/units/Nanomolar,4232628,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,599923,27087140,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.44', 'le': '0.19', 'lle': '0.72', 'sei': '7.83'}",CHEMBL3904944,,CHEMBL3904944,7.57,0,http://www.openphacts.org/units/Nanomolar,4232629,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,599924,27087143,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.06', 'le': '0.18', 'lle': '0.48', 'sei': '7.70'}",CHEMBL3911061,,CHEMBL3911061,7.82,0,http://www.openphacts.org/units/Nanomolar,4232630,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599925,27087146,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCOc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '9.64', 'le': '0.18', 'lle': '-0.60', 'sei': '7.97'}",CHEMBL3962412,,CHEMBL3962412,7.37,0,http://www.openphacts.org/units/Nanomolar,4232631,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,599926,27087149,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.11', 'le': '0.19', 'lle': '0.42', 'sei': '7.60'}",CHEMBL3959149,,CHEMBL3959149,7.72,0,http://www.openphacts.org/units/Nanomolar,4232607,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,599927,27087152,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.80', 'le': '0.20', 'lle': '0.88', 'sei': '7.94'}",CHEMBL3958369,,CHEMBL3958369,7.68,0,http://www.openphacts.org/units/Nanomolar,4232599,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,599928,27087155,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.01', 'le': '0.18', 'lle': '1.07', 'sei': '6.81'}",CHEMBL3983908,,CHEMBL3983908,7.80,0,http://www.openphacts.org/units/Nanomolar,4232632,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,599929,27087158,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.85', 'le': '0.18', 'lle': '0.59', 'sei': '7.83'}",CHEMBL3956101,,CHEMBL3956101,7.82,0,http://www.openphacts.org/units/Nanomolar,4232633,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599930,27087161,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCOc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.53', 'le': '0.18', 'lle': '0.92', 'sei': '6.95'}",CHEMBL3976773,,CHEMBL3976773,7.58,0,http://www.openphacts.org/units/Nanomolar,4232634,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,599931,27087164,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.44', 'le': '0.20', 'lle': '0.28', 'sei': '8.21'}",CHEMBL3909703,,CHEMBL3909703,7.89,0,http://www.openphacts.org/units/Nanomolar,4232635,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,599932,27087167,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)c4n3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.20', 'le': '0.17', 'lle': '-0.76', 'sei': '8.54'}",CHEMBL3963693,,CHEMBL3963693,6.96,0,http://www.openphacts.org/units/Nanomolar,4232636,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,599933,27087170,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.63', 'le': '0.20', 'lle': '0.75', 'sei': '8.18'}",CHEMBL3915037,,CHEMBL3915037,7.85,0,http://www.openphacts.org/units/Nanomolar,4232637,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,599934,27087173,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC2(CC2)c2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.37', 'le': '0.18', 'lle': '-0.88', 'sei': '8.99'}",CHEMBL3899534,,CHEMBL3899534,7.33,0,http://www.openphacts.org/units/Nanomolar,4232638,=,37,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
,599935,27087176,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.99', 'le': '0.19', 'lle': '-0.93', 'sei': '9.23'}",CHEMBL3901829,,CHEMBL3901829,7.68,0,http://www.openphacts.org/units/Nanomolar,4232639,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,599936,27087179,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(C(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.18', 'le': '0.17', 'lle': '-1.35', 'sei': '8.70'}",CHEMBL3961905,,CHEMBL3961905,7.24,0,http://www.openphacts.org/units/Nanomolar,4232640,=,37,1,=,,IC50,nM,,58.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,58.0
,599937,27087182,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(OC(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '8.57', 'le': '0.16', 'lle': '-1.58', 'sei': '7.45'}",CHEMBL3892886,,CHEMBL3892886,6.89,0,http://www.openphacts.org/units/Nanomolar,4232641,=,37,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,130.0
,599938,27087185,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(OC(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.14', 'le': '0.17', 'lle': '-1.12', 'sei': '7.95'}",CHEMBL3892886,,CHEMBL3892886,7.35,0,http://www.openphacts.org/units/Nanomolar,4232641,=,37,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,45.0
,599939,27087188,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(OC(F)(F)F)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.81', 'le': '0.18', 'lle': '-0.58', 'sei': '8.53'}",CHEMBL3892886,,CHEMBL3892886,7.89,0,http://www.openphacts.org/units/Nanomolar,4232641,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,599940,27087191,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '10.09', 'le': '0.19', 'lle': '0.24', 'sei': '7.75'}",CHEMBL3899673,,CHEMBL3899673,7.50,0,http://www.openphacts.org/units/Nanomolar,4232602,=,37,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,599941,27087194,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,CHEMBL5726033,,2017,"{'bei': '10.94', 'le': '0.20', 'lle': '-0.65', 'sei': '10.54'}",CHEMBL3896532,,CHEMBL3896532,7.80,0,http://www.openphacts.org/units/Nanomolar,4232642,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,599942,27087197,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1C(F)(F)F,,,CHEMBL5726033,,2017,"{'bei': '8.44', 'le': '0.16', 'lle': '-2.02', 'sei': '7.71'}",CHEMBL3919115,,CHEMBL3919115,6.75,0,http://www.openphacts.org/units/Nanomolar,4232643,=,37,1,=,,IC50,nM,,180.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,180.0
,599943,27087200,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CSc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1C(F)(F)F,,,CHEMBL5726033,,2017,"{'bei': '8.27', 'le': '0.16', 'lle': '-2.73', 'sei': '8.62'}",CHEMBL3951630,,CHEMBL3951630,6.75,0,http://www.openphacts.org/units/Nanomolar,4232644,=,37,1,=,,IC50,nM,,180.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,180.0
,599944,27087203,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)c(F)c3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.67', 'le': '0.18', 'lle': '-0.89', 'sei': '8.98'}",CHEMBL3910202,,CHEMBL3910202,7.47,0,http://www.openphacts.org/units/Nanomolar,4232645,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,599945,27087206,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4ccccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.76', 'le': '0.19', 'lle': '0.02', 'sei': '9.31'}",CHEMBL3980328,,CHEMBL3980328,7.70,0,http://www.openphacts.org/units/Nanomolar,4232646,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,599946,27087209,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4ccccn24)OCO3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.25', 'le': '0.19', 'lle': '0.59', 'sei': '8.33'}",CHEMBL5895579,,CHEMBL5895579,7.92,0,http://www.openphacts.org/units/Nanomolar,4232647,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,599947,27087212,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.83', 'le': '0.20', 'lle': '0.74', 'sei': '7.96'}",CHEMBL3986763,,CHEMBL3986763,7.66,0,http://www.openphacts.org/units/Nanomolar,4232648,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599948,27087215,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.38', 'le': '0.19', 'lle': '0.48', 'sei': '7.80'}",CHEMBL3959528,,CHEMBL3959528,7.89,0,http://www.openphacts.org/units/Nanomolar,4232649,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,599949,27087218,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.98', 'le': '0.18', 'lle': '-0.17', 'sei': '7.64'}",CHEMBL3922165,,CHEMBL3922165,7.72,0,http://www.openphacts.org/units/Nanomolar,4232650,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,599950,27087221,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.05', 'le': '0.18', 'lle': '0.75', 'sei': '7.70'}",CHEMBL3954237,,CHEMBL3954237,7.66,0,http://www.openphacts.org/units/Nanomolar,4232651,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599951,27087224,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)n1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.72', 'le': '0.18', 'lle': '-0.79', 'sei': '7.57'}",CHEMBL3982905,,CHEMBL3982905,7.66,0,http://www.openphacts.org/units/Nanomolar,4232652,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599952,27087227,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.90', 'le': '0.18', 'lle': '0.38', 'sei': '7.72'}",CHEMBL3912115,,CHEMBL3912115,7.68,0,http://www.openphacts.org/units/Nanomolar,4232653,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,599953,27087230,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)N1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.51', 'le': '0.17', 'lle': '-0.18', 'sei': '7.55'}",CHEMBL3936554,,CHEMBL3936554,7.51,0,http://www.openphacts.org/units/Nanomolar,4232654,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,599954,27087233,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccn23)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.29', 'le': '0.19', 'lle': '-0.40', 'sei': '10.24'}",CHEMBL3899558,,CHEMBL3899558,7.85,0,http://www.openphacts.org/units/Nanomolar,4232655,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,599955,27087236,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.36', 'le': '0.19', 'lle': '-0.04', 'sei': '9.63'}",CHEMBL3927581,,CHEMBL3927581,7.80,0,http://www.openphacts.org/units/Nanomolar,4232656,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,599956,27087239,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.16', 'le': '0.19', 'lle': '-0.71', 'sei': '9.22'}",CHEMBL3924162,,CHEMBL3924162,7.62,0,http://www.openphacts.org/units/Nanomolar,4232657,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,599957,27087242,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.60', 'le': '0.18', 'lle': '0.25', 'sei': '7.63'}",CHEMBL3896415,,CHEMBL3896415,7.58,0,http://www.openphacts.org/units/Nanomolar,4232658,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,599958,27087245,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCCO5)n4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.98', 'le': '0.18', 'lle': '0.27', 'sei': '7.64'}",CHEMBL3894500,,CHEMBL3894500,7.72,0,http://www.openphacts.org/units/Nanomolar,4232659,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,599959,27087248,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccn23)c1,,,CHEMBL5726033,,2017,"{'bei': '10.29', 'le': '0.19', 'lle': '-0.01', 'sei': '8.36'}",CHEMBL3965900,,CHEMBL3965900,7.68,0,http://www.openphacts.org/units/Nanomolar,4232660,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,599960,27087251,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CN(C(=O)OC(C)(C)C)CC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '7.70', 'le': '0.14', 'lle': '-1.05', 'sei': '5.08'}",CHEMBL3946893,,CHEMBL3946893,6.66,0,http://www.openphacts.org/units/Nanomolar,4232661,=,37,1,=,,IC50,nM,,220.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,220.0
,599961,27087254,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CNCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.96', 'le': '0.18', 'lle': '1.56', 'sei': '6.70'}",CHEMBL3971090,,CHEMBL3971090,7.62,0,http://www.openphacts.org/units/Nanomolar,4232662,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,599962,27087257,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4n2CCC4)OCO3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.18', 'le': '0.19', 'lle': '0.95', 'sei': '8.12'}",CHEMBL3937031,,CHEMBL3937031,7.77,0,http://www.openphacts.org/units/Nanomolar,4232663,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,599963,27087260,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCC3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.14', 'le': '0.19', 'lle': '-0.11', 'sei': '9.90'}",CHEMBL3909105,,CHEMBL3909105,7.64,0,http://www.openphacts.org/units/Nanomolar,4232664,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,599964,27087263,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.68', 'le': '0.20', 'lle': '0.59', 'sei': '8.58'}",CHEMBL3945926,,CHEMBL3945926,7.51,0,http://www.openphacts.org/units/Nanomolar,4232665,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,599965,27087266,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccc(O)cc1)c1ccc2c(c1)CCN2,,,CHEMBL5726033,,2017,"{'bei': '10.09', 'le': '0.19', 'lle': '0.62', 'sei': '7.55'}",CHEMBL3921561,,CHEMBL3921561,7.51,0,http://www.openphacts.org/units/Nanomolar,4232666,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,599966,27087269,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3COCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.11', 'le': '0.19', 'lle': '1.25', 'sei': '6.99'}",CHEMBL3955751,,CHEMBL3955751,7.75,0,http://www.openphacts.org/units/Nanomolar,4232667,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599967,27087272,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3COCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '9.84', 'le': '0.18', 'lle': '1.56', 'sei': '6.92'}",CHEMBL3928123,,CHEMBL3928123,7.55,0,http://www.openphacts.org/units/Nanomolar,4232668,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,599968,27087275,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2COCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '10.18', 'le': '0.19', 'lle': '0.11', 'sei': '8.55'}",CHEMBL3952674,,CHEMBL3952674,7.48,0,http://www.openphacts.org/units/Nanomolar,4232669,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,599969,27087278,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2ccc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCCC4)c3ccc(O)cc3)cc21,,,CHEMBL5726033,,2017,"{'bei': '10.08', 'le': '0.19', 'lle': '-0.87', 'sei': '9.31'}",CHEMBL3925867,,CHEMBL3925867,7.75,0,http://www.openphacts.org/units/Nanomolar,4232670,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599970,27087281,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2ccc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCCC4)c3ccc(O)cc3)cc21,,,CHEMBL5726033,,2017,"{'bei': '9.96', 'le': '0.18', 'lle': '0.05', 'sei': '7.62'}",CHEMBL3928763,,CHEMBL3928763,7.75,0,http://www.openphacts.org/units/Nanomolar,4232671,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,599971,27087284,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccsc1,,,CHEMBL5726033,,2017,"{'bei': '10.44', 'le': '0.20', 'lle': '-0.40', 'sei': '9.44'}",CHEMBL3964632,,CHEMBL3964632,7.39,0,http://www.openphacts.org/units/Nanomolar,4232672,=,37,1,=,,IC50,nM,,41.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.0
,599972,27087287,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3COCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.13', 'le': '0.19', 'lle': '0.25', 'sei': '8.29'}",CHEMBL3972831,,CHEMBL3972831,7.66,0,http://www.openphacts.org/units/Nanomolar,4232673,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599973,27087290,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.96', 'le': '0.20', 'lle': '1.30', 'sei': '7.83'}",CHEMBL3901752,,CHEMBL3901752,7.57,0,http://www.openphacts.org/units/Nanomolar,4232674,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,599974,27087293,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '11.30', 'le': '0.21', 'lle': '0.44', 'sei': '10.35'}",CHEMBL3977790,,CHEMBL3977790,8.10,0,http://www.openphacts.org/units/Nanomolar,4232675,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,599975,27087296,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2COCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '11.15', 'le': '0.21', 'lle': '1.86', 'sei': '7.84'}",CHEMBL3938853,,CHEMBL3938853,8.30,0,http://www.openphacts.org/units/Nanomolar,4232676,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,599976,27087299,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '11.14', 'le': '0.20', 'lle': '1.83', 'sei': '7.44'}",CHEMBL3909288,,CHEMBL3909288,8.52,0,http://www.openphacts.org/units/Nanomolar,4232677,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,599977,27087302,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '11.20', 'le': '0.20', 'lle': '0.35', 'sei': '9.88'}",CHEMBL3931918,,CHEMBL3931918,8.22,0,http://www.openphacts.org/units/Nanomolar,4232678,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,599978,27087305,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.61', 'le': '0.19', 'lle': '1.05', 'sei': '7.83'}",CHEMBL3948972,,CHEMBL3948972,7.96,0,http://www.openphacts.org/units/Nanomolar,4232679,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,599979,27087308,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1Cl,,,CHEMBL5726033,,2017,"{'bei': '10.27', 'le': '0.20', 'lle': '-0.99', 'sei': '9.84'}",CHEMBL3917644,,CHEMBL3917644,7.70,0,http://www.openphacts.org/units/Nanomolar,4232680,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,599980,27087311,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(-c3cc(F)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2COCC3)c2ccc(O)cc2)cc1F,,,CHEMBL5726033,,2017,"{'bei': '11.02', 'le': '0.20', 'lle': '1.06', 'sei': '9.05'}",CHEMBL3940211,,CHEMBL3940211,7.92,0,http://www.openphacts.org/units/Nanomolar,4232681,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,599981,27087314,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccc(O)cc1)c1ccc(F)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.79', 'le': '0.20', 'lle': '1.05', 'sei': '8.69'}",CHEMBL3912209,,CHEMBL3912209,7.60,0,http://www.openphacts.org/units/Nanomolar,4232682,=,37,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,599982,27087317,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(F)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1COCC2)N(c1ccc(O)cc1)c1ccc(F)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.87', 'le': '0.20', 'lle': '1.11', 'sei': '8.75'}",CHEMBL3912209,,CHEMBL3912209,7.66,0,http://www.openphacts.org/units/Nanomolar,4232682,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,599983,27087320,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ncc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3COCC4)c3ccc(O)cc3)ccc21,,,CHEMBL5726033,,2017,"{'bei': '10.96', 'le': '0.21', 'lle': '1.49', 'sei': '7.88'}",CHEMBL3911010,,CHEMBL3911010,8.30,0,http://www.openphacts.org/units/Nanomolar,4232683,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,599984,27087323,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1ccc2cc(N(C(=O)c3cc(-c4cc(Cl)ccc4C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)n4c3CCCC4)c3ccc(O)cc3)cnc21,,,CHEMBL5726033,,2017,"{'bei': '10.89', 'le': '0.20', 'lle': '0.61', 'sei': '8.56'}",CHEMBL3889970,,CHEMBL3889970,8.22,0,http://www.openphacts.org/units/Nanomolar,4232684,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,599985,27087326,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(cnn4C)c3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '10.86', 'le': '0.20', 'lle': '1.18', 'sei': '7.74'}",CHEMBL3917121,,CHEMBL3917121,8.15,0,http://www.openphacts.org/units/Nanomolar,4232685,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,599986,27087329,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1,,,CHEMBL5726033,,2017,"{'bei': '10.42', 'le': '0.19', 'lle': '1.26', 'sei': '8.00'}",CHEMBL3956422,,CHEMBL3956422,8.00,0,http://www.openphacts.org/units/Nanomolar,4232686,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,599987,27087332,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3n2CCCC3)CC1=O,,,CHEMBL5726033,,2017,"{'bei': '10.44', 'le': '0.20', 'lle': '0.49', 'sei': '8.65'}",CHEMBL3909919,,CHEMBL3909919,8.15,0,http://www.openphacts.org/units/Nanomolar,4232687,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,599988,27087335,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,CHEMBL5726033,,2017,"{'bei': '10.64', 'le': '0.20', 'lle': '-0.42', 'sei': '9.67'}",CHEMBL3976786,,CHEMBL3976786,8.05,0,http://www.openphacts.org/units/Nanomolar,4232688,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,599989,27087338,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C[N+]2([O-])CCOCC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.35', 'le': '0.19', 'lle': '0.70', 'sei': '6.46'}",CHEMBL5930470,,CHEMBL5930470,7.52,0,http://www.openphacts.org/units/Nanomolar,4232689,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,599990,27087341,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CCOC)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-c1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)c2n1CCCC2,,,CHEMBL5726033,,2017,"{'bei': '9.78', 'le': '0.18', 'lle': '-1.32', 'sei': '9.06'}",CHEMBL3902613,,CHEMBL3902613,7.54,0,http://www.openphacts.org/units/Nanomolar,4232690,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,599991,27087344,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.88', 'le': '0.21', 'lle': '-0.05', 'sei': '10.00'}",CHEMBL3962639,,CHEMBL3962639,7.82,0,http://www.openphacts.org/units/Nanomolar,4232691,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599992,27087347,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '11.55', 'le': '0.21', 'lle': '0.97', 'sei': '9.20'}",CHEMBL3914379,,CHEMBL3914379,8.05,0,http://www.openphacts.org/units/Nanomolar,4232692,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,599993,27087350,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CC(O)CC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '2.03', 'sei': '6.67'}",CHEMBL3953887,,CHEMBL3953887,7.80,0,http://www.openphacts.org/units/Nanomolar,4232693,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,599994,27087353,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c(-c2cc(C(=O)N(c3ccc(O)cc3)c3ccc(C)c(F)c3)c3n2CCCC3)c1,,,CHEMBL5726033,,2017,"{'bei': '11.04', 'le': '0.20', 'lle': '0.52', 'sei': '9.20'}",CHEMBL3985932,,CHEMBL3985932,8.05,0,http://www.openphacts.org/units/Nanomolar,4232694,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,599995,27087356,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccccc1F,,,CHEMBL5726033,,2017,"{'bei': '11.26', 'le': '0.21', 'lle': '0.23', 'sei': '10.35'}",CHEMBL3948585,,CHEMBL3948585,8.10,0,http://www.openphacts.org/units/Nanomolar,4232695,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,599996,27087359,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(F)c1,,,CHEMBL5726033,,2017,"{'bei': '11.12', 'le': '0.21', 'lle': '0.13', 'sei': '10.22'}",CHEMBL3977784,,CHEMBL3977784,8.00,0,http://www.openphacts.org/units/Nanomolar,4232696,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,599997,27087362,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)cc1F,,,CHEMBL5726033,,2017,"{'bei': '10.61', 'le': '0.20', 'lle': '-0.19', 'sei': '10.00'}",CHEMBL3939826,,CHEMBL3939826,7.82,0,http://www.openphacts.org/units/Nanomolar,4232697,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599998,27087365,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1ccc(F)c(F)c1,,,CHEMBL5726033,,2017,"{'bei': '10.61', 'le': '0.20', 'lle': '-0.19', 'sei': '10.00'}",CHEMBL3966070,,CHEMBL3966070,7.82,0,http://www.openphacts.org/units/Nanomolar,4232698,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,599999,27087368,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5726033,,2017,"{'bei': '11.08', 'le': '0.21', 'lle': '0.45', 'sei': '7.88'}",CHEMBL3894316,,CHEMBL3894316,8.05,0,http://www.openphacts.org/units/Nanomolar,4232699,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,600000,27087371,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2ccncc12)N(c1ccc(O)cc1)c1cccc(F)c1,,,CHEMBL5726033,,2017,"{'bei': '10.29', 'le': '0.19', 'lle': '1.02', 'sei': '6.85'}",CHEMBL3965758,,CHEMBL3965758,7.47,0,http://www.openphacts.org/units/Nanomolar,4232700,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,600001,27087374,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(F)c1,,,CHEMBL5726033,,2017,"{'bei': '10.70', 'le': '0.20', 'lle': '0.86', 'sei': '8.06'}",CHEMBL3903292,,CHEMBL3903292,7.80,0,http://www.openphacts.org/units/Nanomolar,4232701,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,600002,27087377,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)N1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1,,,CHEMBL5726033,,2017,"{'bei': '9.72', 'le': '0.18', 'lle': '1.61', 'sei': '6.13'}",CHEMBL3977431,,CHEMBL3977431,7.66,0,http://www.openphacts.org/units/Nanomolar,4232702,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,600003,27087380,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5726033,,2017,"{'bei': '10.33', 'le': '0.19', 'lle': '-0.19', 'sei': '8.63'}",CHEMBL3929493,,CHEMBL3929493,7.55,0,http://www.openphacts.org/units/Nanomolar,4232703,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,600004,27087383,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cc(F)cc(F)c1,,,CHEMBL5726033,,2017,"{'bei': '10.06', 'le': '0.19', 'lle': '-0.59', 'sei': '9.48'}",CHEMBL3949282,,CHEMBL3949282,7.42,0,http://www.openphacts.org/units/Nanomolar,4232704,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,600005,27087386,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5726033,,2017,"{'bei': '10.60', 'le': '0.20', 'lle': '-0.45', 'sei': '9.69'}",CHEMBL3983630,,CHEMBL3983630,7.58,0,http://www.openphacts.org/units/Nanomolar,4232705,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,600006,27087389,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(CC(F)(F)F)CC2)OCO3)n2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.06', 'sei': '8.36'}",CHEMBL3954544,,CHEMBL3954544,7.58,0,http://www.openphacts.org/units/Nanomolar,4232706,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,600007,27087392,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-c2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4n2CCCC4)OCO3)CC1=O,,,CHEMBL5726033,,2017,"{'bei': '10.84', 'le': '0.20', 'lle': '1.75', 'sei': '7.42'}",CHEMBL3927836,,CHEMBL3927836,8.00,0,http://www.openphacts.org/units/Nanomolar,4232707,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,600008,27087395,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1ccc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5726033,,2017,"{'bei': '11.08', 'le': '0.21', 'lle': '0.45', 'sei': '7.88'}",CHEMBL3899834,,CHEMBL3899834,8.05,0,http://www.openphacts.org/units/Nanomolar,4232708,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,600009,27087398,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)N(c1ccc(O)cc1)c1cccc(Cl)c1,,,CHEMBL5726033,,2017,"{'bei': '10.23', 'le': '0.20', 'lle': '-0.86', 'sei': '9.61'}",CHEMBL3964991,,CHEMBL3964991,7.52,0,http://www.openphacts.org/units/Nanomolar,4232709,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,600010,27087401,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1ccccc1N(C(=O)c1cc(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726033,,2017,"{'bei': '10.23', 'le': '0.19', 'lle': '-0.17', 'sei': '7.28'}",CHEMBL3937283,,CHEMBL3937283,7.43,0,http://www.openphacts.org/units/Nanomolar,4232710,=,37,1,=,,IC50,nM,,37.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,37.0
,600011,27087404,[],CHEMBL5731902,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1cc(N(C(=O)c2cc(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)n3c2CCCC3)c2ccc(O)cc2)cn1,,,CHEMBL5726033,,2017,"{'bei': '11.66', 'le': '0.22', 'lle': '1.76', 'sei': '8.56'}",CHEMBL3896666,,CHEMBL3896666,8.22,0,http://www.openphacts.org/units/Nanomolar,4232711,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,673538,27301625,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL5726419,,2017,"{'bei': '12.34', 'le': '0.22', 'lle': '0.38', 'sei': '9.32'}",CHEMBL5763892,,CHEMBL5763892,6.67,0,http://www.openphacts.org/units/Nanomolar,4274817,=,37,1,=,,IC50,nM,,213.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,213.0
,673539,27301628,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccccc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN,,,CHEMBL5726419,,2017,"{'bei': '13.11', 'le': '0.24', 'lle': '1.30', 'sei': '7.95'}",CHEMBL6008213,,CHEMBL6008213,7.30,0,http://www.openphacts.org/units/Nanomolar,4274818,=,37,1,=,,IC50,nM,,50.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.5
,673540,27301631,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc3[nH]ccc3c2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '11.25', 'le': '0.20', 'lle': '-0.53', 'sei': '10.58'}",CHEMBL5960474,,CHEMBL5960474,6.84,0,http://www.openphacts.org/units/Nanomolar,4274819,=,37,1,=,,IC50,nM,,146.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,146.0
,673541,27301634,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(C(F)(F)F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '10.60', 'le': '0.20', 'lle': '-0.70', 'sei': '10.03'}",CHEMBL5965013,,CHEMBL5965013,6.92,0,http://www.openphacts.org/units/Nanomolar,4274820,=,37,1,=,,IC50,nM,,120.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,120.0
,673542,27301637,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '12.58', 'le': '0.24', 'lle': '0.54', 'sei': '11.29'}",CHEMBL6057025,,CHEMBL6057025,7.79,0,http://www.openphacts.org/units/Nanomolar,4274821,=,37,1,=,,IC50,nM,,16.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.2
,673543,27301640,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '12.62', 'le': '0.23', 'lle': '0.87', 'sei': '11.02'}",CHEMBL5781944,,CHEMBL5781944,7.61,0,http://www.openphacts.org/units/Nanomolar,4274822,=,37,1,=,,IC50,nM,,24.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.8
,673544,27301643,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,CHEMBL5726419,,2017,"{'bei': '11.91', 'le': '0.22', 'lle': '1.59', 'sei': '7.77'}",CHEMBL5991810,,CHEMBL5991810,7.66,0,http://www.openphacts.org/units/Nanomolar,4274823,=,37,1,=,,IC50,nM,,22.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.1
,673545,27301646,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)c(Br)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.44', 'le': '0.21', 'lle': '-0.28', 'sei': '10.42'}",CHEMBL5966587,,CHEMBL5966587,7.53,0,http://www.openphacts.org/units/Nanomolar,4274824,=,37,1,=,,IC50,nM,,29.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.6
,673546,27301649,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(O)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '12.11', 'le': '0.22', 'lle': '1.95', 'sei': '8.59'}",CHEMBL5865515,,CHEMBL5865515,7.94,0,http://www.openphacts.org/units/Nanomolar,4274825,=,37,1,=,,IC50,nM,,11.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.4
,673547,27301652,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cccc(Cl)c1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '11.87', 'le': '0.22', 'lle': '0.10', 'sei': '10.65'}",CHEMBL6019016,,CHEMBL6019016,7.35,0,http://www.openphacts.org/units/Nanomolar,4274826,=,37,1,=,,IC50,nM,,44.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,44.6
,673548,27301655,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(OC(F)(F)F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.13', 'le': '0.17', 'lle': '-0.57', 'sei': '8.11'}",CHEMBL6016116,,CHEMBL6016116,6.61,0,http://www.openphacts.org/units/Nanomolar,4274827,=,37,1,=,,IC50,nM,,245.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,245.0
,673549,27301658,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.55', 'le': '0.19', 'lle': '0.57', 'sei': '9.87'}",CHEMBL6033601,,CHEMBL6033601,7.13,0,http://www.openphacts.org/units/Nanomolar,4274828,=,37,1,=,,IC50,nM,,74.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,74.3
,673550,27301661,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(F)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.57', 'le': '0.21', 'lle': '1.19', 'sei': '10.53'}",CHEMBL5896937,,CHEMBL5896937,7.61,0,http://www.openphacts.org/units/Nanomolar,4274829,=,37,1,=,,IC50,nM,,24.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.6
,673551,27301664,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.09', 'le': '0.22', 'lle': '0.92', 'sei': '11.03'}",CHEMBL5918227,,CHEMBL5918227,7.97,0,http://www.openphacts.org/units/Nanomolar,4274830,=,37,1,=,,IC50,nM,,10.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.7
,673552,27301667,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1ccccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '12.16', 'le': '0.22', 'lle': '0.50', 'sei': '8.94'}",CHEMBL5763414,,CHEMBL5763414,7.58,0,http://www.openphacts.org/units/Nanomolar,4274831,=,37,1,=,,IC50,nM,,26.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.1
,673553,27301670,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.42', 'le': '0.21', 'lle': '1.80', 'sei': '8.61'}",CHEMBL5898529,,CHEMBL5898529,7.81,0,http://www.openphacts.org/units/Nanomolar,4274832,=,37,1,=,,IC50,nM,,15.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.6
,673554,27301673,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(Cl)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.47', 'le': '0.20', 'lle': '0.12', 'sei': '9.77'}",CHEMBL5983669,,CHEMBL5983669,7.06,0,http://www.openphacts.org/units/Nanomolar,4274833,=,37,1,=,,IC50,nM,,87.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,87.6
,673555,27301676,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '12.05', 'le': '0.23', 'lle': '1.18', 'sei': '11.24'}",CHEMBL6054106,,CHEMBL6054106,8.12,0,http://www.openphacts.org/units/Nanomolar,4274834,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,673556,27301679,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)c(Cl)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.85', 'le': '0.21', 'lle': '0.10', 'sei': '10.64'}",CHEMBL6029111,,CHEMBL6029111,7.69,0,http://www.openphacts.org/units/Nanomolar,4274835,=,37,1,=,,IC50,nM,,20.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.5
,673557,27301682,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Cl)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.70', 'le': '0.22', 'lle': '1.02', 'sei': '11.21'}",CHEMBL5985247,,CHEMBL5985247,8.10,0,http://www.openphacts.org/units/Nanomolar,4274836,=,37,1,=,,IC50,nM,,8.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.0
,673558,27301685,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1ccc(Br)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.23', 'le': '0.20', 'lle': '0.30', 'sei': '10.17'}",CHEMBL5953508,,CHEMBL5953508,7.35,0,http://www.openphacts.org/units/Nanomolar,4274837,=,37,1,=,,IC50,nM,,44.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,44.6
,673559,27301688,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(Cl)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.95', 'le': '0.21', 'lle': '0.75', 'sei': '9.10'}",CHEMBL5922530,,CHEMBL5922530,8.26,0,http://www.openphacts.org/units/Nanomolar,4274838,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,673560,27301691,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.52', 'le': '0.21', 'lle': '1.29', 'sei': '9.32'}",CHEMBL5875901,,CHEMBL5875901,8.46,0,http://www.openphacts.org/units/Nanomolar,4274839,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,673561,27301694,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)OCO3)c2ccccc12)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.94', 'le': '0.22', 'lle': '2.03', 'sei': '9.21'}",CHEMBL6034767,,CHEMBL6034767,8.36,0,http://www.openphacts.org/units/Nanomolar,4274840,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,673562,27301697,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)c(F)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.11', 'sei': '8.94'}",CHEMBL5906111,,CHEMBL5906111,8.11,0,http://www.openphacts.org/units/Nanomolar,4274841,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,673563,27301700,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.46', 'le': '0.21', 'lle': '1.46', 'sei': '9.32'}",CHEMBL5929135,,CHEMBL5929135,8.46,0,http://www.openphacts.org/units/Nanomolar,4274842,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,673564,27301703,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(CCc4ccccc4)c4ccc(Cl)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '7.77', 'le': '0.15', 'lle': '-1.77', 'sei': '8.45'}",CHEMBL6047973,,CHEMBL6047973,5.96,0,http://www.openphacts.org/units/Nanomolar,4274843,=,37,1,=,,IC50,nM,,1110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1110.0
,673565,27301706,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.10', 'le': '0.20', 'lle': '1.08', 'sei': '7.91'}",CHEMBL5967333,,CHEMBL5967333,8.42,0,http://www.openphacts.org/units/Nanomolar,4274844,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,673566,27301709,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1C[C@H]2CCC[C@H]2C1,,,CHEMBL5726419,,2017,"{'bei': '9.08', 'le': '0.18', 'lle': '-1.91', 'sei': '9.60'}",CHEMBL5977962,,CHEMBL5977962,6.62,0,http://www.openphacts.org/units/Nanomolar,4274845,=,37,1,=,,IC50,nM,,238.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,238.0
,673567,27301712,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4cccc(Oc5ccccc5)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.73', 'le': '0.18', 'lle': '-0.75', 'sei': '7.91'}",CHEMBL5893493,,CHEMBL5893493,7.90,0,http://www.openphacts.org/units/Nanomolar,4274846,=,37,1,=,,IC50,nM,,12.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.5
,673568,27301715,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(CCc4ccccc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.84', 'le': '0.20', 'lle': '1.34', 'sei': '8.94'}",CHEMBL5984895,,CHEMBL5984895,8.11,0,http://www.openphacts.org/units/Nanomolar,4274847,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,673569,27301718,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.46', 'le': '0.21', 'lle': '1.87', 'sei': '7.60'}",CHEMBL5753121,,CHEMBL5753121,8.43,0,http://www.openphacts.org/units/Nanomolar,4274848,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,673570,27301721,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,CHEMBL5726419,,2017,"{'bei': '10.82', 'le': '0.22', 'lle': '0.51', 'sei': '9.76'}",CHEMBL5991444,,CHEMBL5991444,7.64,0,http://www.openphacts.org/units/Nanomolar,4274849,=,37,1,=,,IC50,nM,,23.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.1
,673571,27301724,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5sccc5c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.49', 'le': '0.20', 'lle': '0.07', 'sei': '8.98'}",CHEMBL5858896,,CHEMBL5858896,8.14,0,http://www.openphacts.org/units/Nanomolar,4274850,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,673572,27301727,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5occc5c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.75', 'le': '0.20', 'lle': '0.57', 'sei': '7.86'}",CHEMBL6017811,,CHEMBL6017811,8.17,0,http://www.openphacts.org/units/Nanomolar,4274851,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,673573,27301730,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.58', 'le': '0.19', 'lle': '0.82', 'sei': '8.55'}",CHEMBL5814743,,CHEMBL5814743,8.17,0,http://www.openphacts.org/units/Nanomolar,4274852,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,673574,27301733,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.66', 'le': '0.21', 'lle': '0.55', 'sei': '9.17'}",CHEMBL5954869,,CHEMBL5954869,8.08,0,http://www.openphacts.org/units/Nanomolar,4274853,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,673575,27301736,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5c(c4)CCN5)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.56', 'le': '0.19', 'lle': '1.21', 'sei': '7.82'}",CHEMBL6030452,,CHEMBL6030452,8.04,0,http://www.openphacts.org/units/Nanomolar,4274854,=,37,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
,673576,27301739,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.05', 'le': '0.20', 'lle': '-0.39', 'sei': '9.06'}",CHEMBL5894463,,CHEMBL5894463,7.98,0,http://www.openphacts.org/units/Nanomolar,4274855,=,37,1,=,,IC50,nM,,10.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.5
,673577,27301742,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.51', 'le': '0.19', 'lle': '1.01', 'sei': '7.89'}",CHEMBL5916895,,CHEMBL5916895,7.88,0,http://www.openphacts.org/units/Nanomolar,4274856,=,37,1,=,,IC50,nM,,13.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.1
,673578,27301745,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.04', 'le': '0.22', 'lle': '0.94', 'sei': '11.25'}",CHEMBL5855276,,CHEMBL5855276,8.13,0,http://www.openphacts.org/units/Nanomolar,4274857,=,37,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,673579,27301748,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(OC(F)(F)F)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.15', 'le': '0.19', 'lle': '0.40', 'sei': '8.17'}",CHEMBL5806110,,CHEMBL5806110,8.16,0,http://www.openphacts.org/units/Nanomolar,4274858,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,673580,27301751,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)cc2)cc1F,,,CHEMBL5726419,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '0.96', 'sei': '9.11'}",CHEMBL6038995,,CHEMBL6038995,8.27,0,http://www.openphacts.org/units/Nanomolar,4274859,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,673581,27301754,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc(Br)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c2)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.98', 'le': '0.22', 'lle': '0.69', 'sei': '11.13'}",CHEMBL5834896,,CHEMBL5834896,8.05,0,http://www.openphacts.org/units/Nanomolar,4274860,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,673582,27301757,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc3[nH]ccc3c2)cc1,,,CHEMBL5726419,,2017,"{'bei': '9.57', 'le': '0.17', 'lle': '-0.70', 'sei': '8.39'}",CHEMBL5830921,,CHEMBL5830921,7.24,0,http://www.openphacts.org/units/Nanomolar,4274861,=,37,1,=,,IC50,nM,,57.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.2
,673583,27301760,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)c(F)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '1.16', 'sei': '9.15'}",CHEMBL5828104,,CHEMBL5828104,8.30,0,http://www.openphacts.org/units/Nanomolar,4274862,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,673584,27301763,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc(Br)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c3ccccc23)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.24', 'le': '0.20', 'lle': '-0.33', 'sei': '10.90'}",CHEMBL5745145,,CHEMBL5745145,7.87,0,http://www.openphacts.org/units/Nanomolar,4274863,=,37,1,=,,IC50,nM,,13.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.4
,673585,27301766,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc(F)c(Cl)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.96', 'le': '0.19', 'lle': '0.04', 'sei': '8.47'}",CHEMBL5925400,,CHEMBL5925400,7.69,0,http://www.openphacts.org/units/Nanomolar,4274864,=,37,1,=,,IC50,nM,,20.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.5
,673586,27301769,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(Cl)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.78', 'le': '0.20', 'lle': '-0.83', 'sei': '10.68'}",CHEMBL5761128,,CHEMBL5761128,7.72,0,http://www.openphacts.org/units/Nanomolar,4274865,=,37,1,=,,IC50,nM,,19.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.2
,673587,27301772,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)Oc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(C)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '8.62', 'le': '0.16', 'lle': '-0.70', 'sei': '6.91'}",CHEMBL5753100,,CHEMBL5753100,6.69,0,http://www.openphacts.org/units/Nanomolar,4274866,=,37,1,=,,IC50,nM,,206.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,206.0
,673588,27301775,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.04', 'le': '0.22', 'lle': '1.36', 'sei': '8.77'}",CHEMBL5908404,,CHEMBL5908404,8.11,0,http://www.openphacts.org/units/Nanomolar,4274867,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,673589,27301778,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.79', 'le': '0.22', 'lle': '0.42', 'sei': '11.24'}",CHEMBL5792411,,CHEMBL5792411,8.12,0,http://www.openphacts.org/units/Nanomolar,4274868,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,673590,27301781,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)c(Cl)c2)cc1,,,CHEMBL5726419,,2017,"{'bei': '8.82', 'le': '0.17', 'lle': '-1.05', 'sei': '7.47'}",CHEMBL5880144,,CHEMBL5880144,6.78,0,http://www.openphacts.org/units/Nanomolar,4274869,=,37,1,=,,IC50,nM,,168.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,168.0
,673591,27301784,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc(O)c(Cl)c2)cc1,,,CHEMBL5726419,,2017,"{'bei': '8.20', 'le': '0.15', 'lle': '-2.10', 'sei': '7.20'}",CHEMBL5826882,,CHEMBL5826882,6.53,0,http://www.openphacts.org/units/Nanomolar,4274870,=,37,1,=,,IC50,nM,,296.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,296.0
,673592,27301787,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.70', 'le': '0.23', 'lle': '0.70', 'sei': '11.48'}",CHEMBL5792914,,CHEMBL5792914,8.29,0,http://www.openphacts.org/units/Nanomolar,4274871,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,673593,27301790,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.82', 'le': '0.22', 'lle': '1.10', 'sei': '11.32'}",CHEMBL5931438,,CHEMBL5931438,8.18,0,http://www.openphacts.org/units/Nanomolar,4274872,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,673594,27301793,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.92', 'le': '0.22', 'lle': '1.59', 'sei': '8.90'}",CHEMBL5889255,,CHEMBL5889255,8.23,0,http://www.openphacts.org/units/Nanomolar,4274873,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,673595,27301796,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)c2ccc3[nH]ncc3c2)cc1,,,CHEMBL5726419,,2017,"{'bei': '9.37', 'le': '0.17', 'lle': '-0.24', 'sei': '7.16'}",CHEMBL6014963,,CHEMBL6014963,7.10,0,http://www.openphacts.org/units/Nanomolar,4274874,=,37,1,=,,IC50,nM,,79.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,79.7
,673596,27301799,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.96', 'le': '0.20', 'lle': '-0.33', 'sei': '10.42'}",CHEMBL5985126,,CHEMBL5985126,8.05,0,http://www.openphacts.org/units/Nanomolar,4274875,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,673597,27301802,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.06', 'le': '0.22', 'lle': '1.00', 'sei': '11.06'}",CHEMBL6021221,,CHEMBL6021221,8.54,0,http://www.openphacts.org/units/Nanomolar,4274876,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,673598,27301805,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Br)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.46', 'le': '0.21', 'lle': '0.05', 'sei': '11.18'}",CHEMBL5867960,,CHEMBL5867960,8.08,0,http://www.openphacts.org/units/Nanomolar,4274877,=,37,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,673599,27301808,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.14', 'le': '0.21', 'lle': '0.09', 'sei': '9.48'}",CHEMBL5805210,,CHEMBL5805210,8.35,0,http://www.openphacts.org/units/Nanomolar,4274878,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,673600,27301811,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(O)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.58', 'le': '0.22', 'lle': '0.92', 'sei': '9.09'}",CHEMBL5834331,,CHEMBL5834331,8.41,0,http://www.openphacts.org/units/Nanomolar,4274879,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,673601,27301814,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c3ccccc23)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.57', 'le': '0.22', 'lle': '0.29', 'sei': '11.59'}",CHEMBL5939713,,CHEMBL5939713,8.38,0,http://www.openphacts.org/units/Nanomolar,4274880,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,673602,27301817,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.19', 'le': '0.21', 'lle': '0.23', 'sei': '11.28'}",CHEMBL5970047,,CHEMBL5970047,8.15,0,http://www.openphacts.org/units/Nanomolar,4274881,=,37,1,=,,IC50,nM,,7.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.1
,673603,27301820,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(Cl)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.82', 'le': '0.21', 'lle': '-0.38', 'sei': '11.15'}",CHEMBL6061883,,CHEMBL6061883,8.06,0,http://www.openphacts.org/units/Nanomolar,4274882,=,37,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,673604,27301823,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)c(F)cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.15', 'le': '0.21', 'lle': '0.74', 'sei': '10.77'}",CHEMBL6033384,,CHEMBL6033384,8.31,0,http://www.openphacts.org/units/Nanomolar,4274883,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,673605,27301826,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(F)c(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.79', 'le': '0.20', 'lle': '0.02', 'sei': '10.92'}",CHEMBL5932092,,CHEMBL5932092,8.43,0,http://www.openphacts.org/units/Nanomolar,4274884,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,673606,27301829,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCC(F)(F)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.08', 'le': '0.18', 'lle': '-1.94', 'sei': '8.33'}",CHEMBL5964702,,CHEMBL5964702,7.07,0,http://www.openphacts.org/units/Nanomolar,4274885,=,37,1,=,,IC50,nM,,85.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,85.5
,673607,27301832,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C2CCCC2)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.06', 'le': '0.20', 'lle': '-0.67', 'sei': '9.28'}",CHEMBL5841406,,CHEMBL5841406,8.17,0,http://www.openphacts.org/units/Nanomolar,4274886,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,673608,27301835,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(Cl)c4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '8.77', 'le': '0.16', 'lle': '-0.92', 'sei': '7.40'}",CHEMBL5840578,,CHEMBL5840578,7.08,0,http://www.openphacts.org/units/Nanomolar,4274887,=,37,1,=,,IC50,nM,,83.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,83.8
,673609,27301838,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(Cl)c4)c4ccc5[nH]ccc5c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.77', 'le': '0.18', 'lle': '-0.24', 'sei': '7.28'}",CHEMBL6059439,,CHEMBL6059439,7.75,0,http://www.openphacts.org/units/Nanomolar,4274888,=,37,1,=,,IC50,nM,,17.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.6
,673610,27301841,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '12.05', 'le': '0.22', 'lle': '2.71', 'sei': '7.60'}",CHEMBL6012410,,CHEMBL6012410,8.43,0,http://www.openphacts.org/units/Nanomolar,4274889,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,673611,27301844,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(F)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.65', 'le': '0.21', 'lle': '2.02', 'sei': '9.01'}",CHEMBL5813720,,CHEMBL5813720,8.17,0,http://www.openphacts.org/units/Nanomolar,4274890,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,673612,27301847,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc(Cl)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.74', 'le': '0.22', 'lle': '1.76', 'sei': '9.29'}",CHEMBL5767663,,CHEMBL5767663,8.43,0,http://www.openphacts.org/units/Nanomolar,4274891,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,673613,27301850,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.59', 'le': '0.22', 'lle': '0.85', 'sei': '9.39'}",CHEMBL6029737,,CHEMBL6029737,8.27,0,http://www.openphacts.org/units/Nanomolar,4274892,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,673614,27301853,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.56', 'le': '0.21', 'lle': '1.87', 'sei': '7.85'}",CHEMBL5990681,,CHEMBL5990681,8.36,0,http://www.openphacts.org/units/Nanomolar,4274893,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,673615,27301856,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)cc4)c4ccc5[nH]ccc5c4)c4cc(Cl)ccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.72', 'le': '0.18', 'lle': '-0.28', 'sei': '7.24'}",CHEMBL5934690,,CHEMBL5934690,7.71,0,http://www.openphacts.org/units/Nanomolar,4274894,=,37,1,=,,IC50,nM,,19.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.6
,673616,27301859,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.52', 'le': '0.22', 'lle': '0.95', 'sei': '10.85'}",CHEMBL5899243,,CHEMBL5899243,8.38,0,http://www.openphacts.org/units/Nanomolar,4274895,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,673617,27301862,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.46', 'le': '0.21', 'lle': '1.94', 'sei': '8.83'}",CHEMBL5994527,,CHEMBL5994527,8.44,0,http://www.openphacts.org/units/Nanomolar,4274896,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,673618,27301865,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc(Cl)ccc3C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)c2)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '12.02', 'le': '0.23', 'lle': '1.03', 'sei': '11.45'}",CHEMBL5863109,,CHEMBL5863109,8.28,0,http://www.openphacts.org/units/Nanomolar,4274897,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,673619,27301868,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Cl)cc(Cl)c1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.72', 'le': '0.21', 'lle': '-0.05', 'sei': '9.11'}",CHEMBL5811940,,CHEMBL5811940,8.02,0,http://www.openphacts.org/units/Nanomolar,4274898,=,37,1,=,,IC50,nM,,9.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.6
,673620,27301871,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.11', 'le': '0.21', 'lle': '0.21', 'sei': '10.99'}",CHEMBL5825530,,CHEMBL5825530,8.48,0,http://www.openphacts.org/units/Nanomolar,4274899,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,673621,27301874,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN(C)C)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.88', 'le': '0.22', 'lle': '1.28', 'sei': '8.77'}",CHEMBL5939034,,CHEMBL5939034,8.10,0,http://www.openphacts.org/units/Nanomolar,4274900,=,37,1,=,,IC50,nM,,7.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.9
,673622,27301877,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc(Cl)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN(C)C,,,CHEMBL5726419,,2017,"{'bei': '12.19', 'le': '0.23', 'lle': '0.45', 'sei': '11.08'}",CHEMBL5914561,,CHEMBL5914561,8.19,0,http://www.openphacts.org/units/Nanomolar,4274901,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,673623,27301880,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c2)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '12.05', 'le': '0.22', 'lle': '2.09', 'sei': '9.27'}",CHEMBL6016149,,CHEMBL6016149,8.41,0,http://www.openphacts.org/units/Nanomolar,4274902,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,673624,27301883,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccc(O)c(F)c4)c4ccc5c(ccn5C)c4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.39', 'le': '0.19', 'lle': '0.72', 'sei': '8.59'}",CHEMBL6002454,,CHEMBL6002454,8.21,0,http://www.openphacts.org/units/Nanomolar,4274903,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,673625,27301886,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cn(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCN(C)CC3)OCO4)c3ccccc23)C2CCNCC2)cc1,,,CHEMBL5726419,,2017,"{'bei': '6.90', 'le': '0.13', 'lle': '-0.88', 'sei': '6.06'}",CHEMBL5950606,,CHEMBL5950606,5.00,0,http://www.openphacts.org/units/Nanomolar,4274904,=,37,1,=,,IC50,nM,,10000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10000.0
,673626,27301889,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCn1ccc2cc(N(C(=O)c3cn(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCN(C)CC4)OCO5)c4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726419,,2017,"{'bei': '10.57', 'le': '0.19', 'lle': '0.49', 'sei': '8.70'}",CHEMBL5988003,,CHEMBL5988003,8.32,0,http://www.openphacts.org/units/Nanomolar,4274905,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,673627,27301892,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)n1ccc2cc(N(C(=O)c3cn(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCN(C)CC4)OCO5)c4ccccc34)c3ccc(O)cc3)ccc21,,,CHEMBL5726419,,2017,"{'bei': '10.19', 'le': '0.19', 'lle': '-0.23', 'sei': '8.53'}",CHEMBL5895531,,CHEMBL5895531,8.16,0,http://www.openphacts.org/units/Nanomolar,4274906,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,673628,27301895,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1C(=O)N1CCN(C)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.08', 'le': '0.18', 'lle': '-0.05', 'sei': '6.66'}",CHEMBL5836806,,CHEMBL5836806,7.00,0,http://www.openphacts.org/units/Nanomolar,4274907,=,37,1,=,,IC50,nM,,99.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,99.1
,673629,27301898,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCN(C2CCC2)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.12', 'le': '0.20', 'lle': '-0.37', 'sei': '9.17'}",CHEMBL5897415,,CHEMBL5897415,8.08,0,http://www.openphacts.org/units/Nanomolar,4274908,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,673630,27301901,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCN(C)CC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '10.70', 'le': '0.20', 'lle': '1.78', 'sei': '7.55'}",CHEMBL5864999,,CHEMBL5864999,7.76,0,http://www.openphacts.org/units/Nanomolar,4274909,=,37,1,=,,IC50,nM,,17.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.4
,673631,27301904,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3[nH]ccc3c2)cn1-c1cc(Br)ccc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCCC1,,,CHEMBL5726419,,2017,"{'bei': '10.60', 'le': '0.21', 'lle': '-0.65', 'sei': '9.11'}",CHEMBL5900815,,CHEMBL5900815,7.73,0,http://www.openphacts.org/units/Nanomolar,4274910,=,37,1,=,,IC50,nM,,18.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.8
,673632,27301907,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCCC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '0.52', 'sei': '8.51'}",CHEMBL5821166,,CHEMBL5821166,7.87,0,http://www.openphacts.org/units/Nanomolar,4274911,=,37,1,=,,IC50,nM,,13.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.6
,673633,27301910,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(N(C(=O)c2cc(C)n(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)c2)c2ccc(O)cc2)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.26', 'le': '0.21', 'lle': '1.30', 'sei': '7.97'}",CHEMBL5861827,,CHEMBL5861827,7.71,0,http://www.openphacts.org/units/Nanomolar,4274912,=,37,1,=,,IC50,nM,,19.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.6
,673634,27301913,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,CHEMBL5726419,,2017,"{'bei': '11.03', 'le': '0.20', 'lle': '0.50', 'sei': '9.40'}",CHEMBL5954156,,CHEMBL5954156,7.36,0,http://www.openphacts.org/units/Nanomolar,4274913,=,37,1,=,,IC50,nM,,44.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,44.0
,673635,27301916,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '1.35', 'sei': '7.70'}",CHEMBL5767875,,CHEMBL5767875,7.45,0,http://www.openphacts.org/units/Nanomolar,4274914,=,37,1,=,,IC50,nM,,35.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.5
,673636,27301919,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.54', 'le': '0.21', 'lle': '1.77', 'sei': '8.22'}",CHEMBL5907541,,CHEMBL5907541,8.36,0,http://www.openphacts.org/units/Nanomolar,4274915,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,673637,27301922,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,CHEMBL5726419,,2017,"{'bei': '11.43', 'le': '0.21', 'lle': '1.26', 'sei': '8.96'}",CHEMBL6015715,,CHEMBL6015715,8.09,0,http://www.openphacts.org/units/Nanomolar,4274916,=,37,1,=,,IC50,nM,,8.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.1
,673638,27301925,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2cccc(N3CCN(C)CC3)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.59', 'le': '0.21', 'lle': '1.39', 'sei': '8.74'}",CHEMBL6036904,,CHEMBL6036904,7.93,0,http://www.openphacts.org/units/Nanomolar,4274917,=,37,1,=,,IC50,nM,,11.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.8
,673639,27301928,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)c2c1CCCC2)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.86', 'le': '0.20', 'lle': '1.05', 'sei': '7.98'}",CHEMBL5929262,,CHEMBL5929262,7.72,0,http://www.openphacts.org/units/Nanomolar,4274918,=,37,1,=,,IC50,nM,,19.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.2
,673640,27301931,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CN(C)C3)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.90', 'le': '0.22', 'lle': '0.90', 'sei': '8.72'}",CHEMBL6035212,,CHEMBL6035212,7.62,0,http://www.openphacts.org/units/Nanomolar,4274919,=,37,1,=,,IC50,nM,,23.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.7
,673641,27301934,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(c2)CCN3C)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,CHEMBL5726419,,2017,"{'bei': '12.23', 'le': '0.22', 'lle': '1.06', 'sei': '8.96'}",CHEMBL6060497,,CHEMBL6060497,7.84,0,http://www.openphacts.org/units/Nanomolar,4274920,=,37,1,=,,IC50,nM,,14.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.5
,673642,27301937,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3CCN3CCOCC3)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1C)OCO2,,,CHEMBL5726419,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '0.85', 'sei': '7.79'}",CHEMBL5901675,,CHEMBL5901675,7.92,0,http://www.openphacts.org/units/Nanomolar,4274921,=,37,1,=,,IC50,nM,,12.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.1
,673643,27301940,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCC2,,,CHEMBL5726419,,2017,"{'bei': '11.28', 'le': '0.21', 'lle': '0.77', 'sei': '9.76'}",CHEMBL5966539,,CHEMBL5966539,8.12,0,http://www.openphacts.org/units/Nanomolar,4274922,=,37,1,=,,IC50,nM,,7.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.6
,673644,27301943,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2c(cc1C(=O)N1Cc3ccccc3C[C@H]1CN1CCOCC1)CCO2,,,CHEMBL5726419,,2017,"{'bei': '11.40', 'le': '0.21', 'lle': '1.43', 'sei': '8.91'}",CHEMBL6013088,,CHEMBL6013088,8.23,0,http://www.openphacts.org/units/Nanomolar,4274923,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,673645,27301946,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(=O)N(c2ccc(O)cc2)c2ccc3c(ccn3C)c2)cn1-c1cc2occc2cc1C(=O)N1Cc2ccccc2C[C@H]1CN1CCOCC1,,,CHEMBL5726419,,2017,"{'bei': '10.48', 'le': '0.19', 'lle': '-0.06', 'sei': '7.84'}",CHEMBL5739898,,CHEMBL5739898,7.55,0,http://www.openphacts.org/units/Nanomolar,4274924,=,37,1,=,,IC50,nM,,28.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.4
,673646,27301949,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1nn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN)c2ccccc12,,,CHEMBL5726419,,2017,"{'bei': '11.81', 'le': '0.22', 'lle': '0.76', 'sei': '7.52'}",CHEMBL5746825,,CHEMBL5746825,6.35,0,http://www.openphacts.org/units/Nanomolar,4274925,=,37,1,=,,IC50,nM,,448.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,448.0
,673647,27301952,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '12.59', 'le': '0.23', 'lle': '0.74', 'sei': '8.61'}",CHEMBL5882975,,CHEMBL5882975,7.27,0,http://www.openphacts.org/units/Nanomolar,4274926,=,37,1,=,,IC50,nM,,53.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,53.3
,673648,27301955,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '12.22', 'le': '0.22', 'lle': '-0.08', 'sei': '9.84'}",CHEMBL6030240,,CHEMBL6030240,7.05,0,http://www.openphacts.org/units/Nanomolar,4274927,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,673649,27301958,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '13.03', 'le': '0.23', 'lle': '0.88', 'sei': '8.41'}",CHEMBL5756948,,CHEMBL5756948,7.72,0,http://www.openphacts.org/units/Nanomolar,4274928,=,37,1,=,,IC50,nM,,18.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.9
,673650,27301961,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc31)OCO2,,,CHEMBL5726419,,2017,"{'bei': '12.06', 'le': '0.22', 'lle': '1.24', 'sei': '7.29'}",CHEMBL5817613,,CHEMBL5817613,7.50,0,http://www.openphacts.org/units/Nanomolar,4274929,=,37,1,=,,IC50,nM,,31.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.7
,673651,27301964,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccc(C(=O)O)cc21,,,CHEMBL5726419,,2017,"{'bei': '9.77', 'le': '0.18', 'lle': '-0.15', 'sei': '4.99'}",CHEMBL6025146,,CHEMBL6025146,6.08,0,http://www.openphacts.org/units/Nanomolar,4274930,=,37,1,=,,IC50,nM,,841.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,841.0
,673652,27301967,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1OCc1ccccc1,,,CHEMBL5726419,,2017,"{'bei': '6.52', 'le': '0.12', 'lle': '-3.47', 'sei': '4.52'}",CHEMBL5752243,,CHEMBL5752243,4.65,0,http://www.openphacts.org/units/Nanomolar,4274931,=,37,1,=,,IC50,nM,,22200.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22200.0
,673653,27301970,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1O,,,CHEMBL5726419,,2017,"{'bei': '12.80', 'le': '0.23', 'lle': '1.74', 'sei': '7.01'}",CHEMBL5745266,,CHEMBL5745266,7.98,0,http://www.openphacts.org/units/Nanomolar,4274932,=,37,1,=,,IC50,nM,,10.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.4
,673654,27301973,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(N)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '12.29', 'le': '0.22', 'lle': '1.17', 'sei': '6.59'}",CHEMBL5924981,,CHEMBL5924981,7.28,0,http://www.openphacts.org/units/Nanomolar,4274933,=,37,1,=,,IC50,nM,,52.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,52.2
,673655,27301976,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNc1ccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)c1,,,CHEMBL5726419,,2017,"{'bei': '12.53', 'le': '0.23', 'lle': '1.03', 'sei': '7.88'}",CHEMBL5884492,,CHEMBL5884492,7.60,0,http://www.openphacts.org/units/Nanomolar,4274934,=,37,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,673656,27301979,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)c1,,,CHEMBL5726419,,2017,"{'bei': '11.67', 'le': '0.21', 'lle': '0.65', 'sei': '8.26'}",CHEMBL5831476,,CHEMBL5831476,7.25,0,http://www.openphacts.org/units/Nanomolar,4274935,=,37,1,=,,IC50,nM,,56.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,56.7
,673657,27301982,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NCc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '10.47', 'le': '0.19', 'lle': '-0.99', 'sei': '7.41'}",CHEMBL5760477,,CHEMBL5760477,7.15,0,http://www.openphacts.org/units/Nanomolar,4274936,=,37,1,=,,IC50,nM,,70.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.6
,673658,27301985,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '11.51', 'le': '0.21', 'lle': '-0.29', 'sei': '10.35'}",CHEMBL5870146,,CHEMBL5870146,7.15,0,http://www.openphacts.org/units/Nanomolar,4274937,=,37,1,=,,IC50,nM,,71.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,71.5
,673659,27301988,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)COc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '10.26', 'le': '0.19', 'lle': '-0.09', 'sei': '6.07'}",CHEMBL5831745,,CHEMBL5831745,7.46,0,http://www.openphacts.org/units/Nanomolar,4274938,=,37,1,=,,IC50,nM,,35.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,35.0
,673660,27301991,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1O,,,CHEMBL5726419,,2017,"{'bei': '12.39', 'le': '0.23', 'lle': '1.36', 'sei': '6.53'}",CHEMBL5760905,,CHEMBL5760905,7.91,0,http://www.openphacts.org/units/Nanomolar,4274939,=,37,1,=,,IC50,nM,,12.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.2
,673661,27301994,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '12.47', 'le': '0.23', 'lle': '0.91', 'sei': '7.69'}",CHEMBL5978117,,CHEMBL5978117,7.76,0,http://www.openphacts.org/units/Nanomolar,4274940,=,37,1,=,,IC50,nM,,17.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.2
,673662,27301997,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '12.60', 'le': '0.23', 'lle': '0.51', 'sei': '9.47'}",CHEMBL5984436,,CHEMBL5984436,7.65,0,http://www.openphacts.org/units/Nanomolar,4274941,=,37,1,=,,IC50,nM,,22.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.5
,673663,27302000,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccccc1-n1nc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '12.71', 'le': '0.23', 'lle': '1.31', 'sei': '7.21'}",CHEMBL5928975,,CHEMBL5928975,7.55,0,http://www.openphacts.org/units/Nanomolar,4274942,=,37,1,=,,IC50,nM,,28.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.3
,673664,27302003,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)CSc2ccccc2)ccc1-n1nc(C(=O)N(c2ccccc2)c2ccccc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '10.32', 'le': '0.19', 'lle': '-0.59', 'sei': '6.75'}",CHEMBL6042065,,CHEMBL6042065,7.67,0,http://www.openphacts.org/units/Nanomolar,4274943,=,37,1,=,,IC50,nM,,21.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.6
,673665,27302006,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN)c(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '12.00', 'le': '0.22', 'lle': '0.75', 'sei': '7.78'}",CHEMBL5917599,,CHEMBL5917599,7.29,0,http://www.openphacts.org/units/Nanomolar,4274944,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,673666,27302009,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2nc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN)cc1N,,,CHEMBL5726419,,2017,"{'bei': '10.70', 'le': '0.19', 'lle': '0.54', 'sei': '5.56'}",CHEMBL5858824,,CHEMBL5858824,6.66,0,http://www.openphacts.org/units/Nanomolar,4274945,=,37,1,=,,IC50,nM,,218.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,218.0
,673667,27302012,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc31)OCO2,,,CHEMBL5726419,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '-0.03', 'sei': '5.93'}",CHEMBL5863038,,CHEMBL5863038,6.54,0,http://www.openphacts.org/units/Nanomolar,4274946,=,37,1,=,,IC50,nM,,286.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,286.0
,673668,27302015,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccccc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.66', 'le': '0.21', 'lle': '0.75', 'sei': '10.90'}",CHEMBL5968365,,CHEMBL5968365,7.88,0,http://www.openphacts.org/units/Nanomolar,4274947,=,37,1,=,,IC50,nM,,13.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.2
,673669,27302018,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '12.65', 'le': '0.24', 'lle': '0.44', 'sei': '8.64'}",CHEMBL5788955,,CHEMBL5788955,7.93,0,http://www.openphacts.org/units/Nanomolar,4274948,=,37,1,=,,IC50,nM,,11.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.7
,673670,27302021,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,NC[C@@H]1Cc2ccccc2CN1C(=O)c1cc(NC(=O)CSc2ccccc2)ccc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '-0.78', 'sei': '6.45'}",CHEMBL5819768,,CHEMBL5819768,7.79,0,http://www.openphacts.org/units/Nanomolar,4274949,=,37,1,=,,IC50,nM,,16.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.1
,673671,27302024,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)CC1Oc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN)c(-n3cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc43)cc2O1,,,CHEMBL5726419,,2017,"{'bei': '10.49', 'le': '0.19', 'lle': '-0.71', 'sei': '6.59'}",CHEMBL5906194,,CHEMBL5906194,7.27,0,http://www.openphacts.org/units/Nanomolar,4274950,=,37,1,=,,IC50,nM,,54.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,54.1
,673672,27302027,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.25', 'le': '0.21', 'lle': '0.21', 'sei': '11.06'}",CHEMBL5750459,,CHEMBL5750459,7.99,0,http://www.openphacts.org/units/Nanomolar,4274951,=,37,1,=,,IC50,nM,,10.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.2
,673673,27302030,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(NC(=O)CSc3ccccc3)ccc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.09', 'le': '0.17', 'lle': '-1.22', 'sei': '7.54'}",CHEMBL5991985,,CHEMBL5991985,7.64,0,http://www.openphacts.org/units/Nanomolar,4274952,=,37,1,=,,IC50,nM,,22.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.8
,673674,27302033,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.26', 'le': '0.21', 'lle': '1.25', 'sei': '8.94'}",CHEMBL6048662,,CHEMBL6048662,8.11,0,http://www.openphacts.org/units/Nanomolar,4274953,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,673675,27302036,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.77', 'le': '0.21', 'lle': '1.65', 'sei': '8.35'}",CHEMBL5994962,,CHEMBL5994962,8.49,0,http://www.openphacts.org/units/Nanomolar,4274954,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,673676,27302039,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)cc1Cl,,,CHEMBL5726419,,2017,"{'bei': '10.03', 'le': '0.19', 'lle': '-0.36', 'sei': '9.11'}",CHEMBL5830905,,CHEMBL5830905,7.43,0,http://www.openphacts.org/units/Nanomolar,4274955,=,37,1,=,,IC50,nM,,37.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,37.4
,673677,27302042,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '11.25', 'le': '0.20', 'lle': '0.80', 'sei': '9.75'}",CHEMBL5757762,,CHEMBL5757762,7.94,0,http://www.openphacts.org/units/Nanomolar,4274956,=,37,1,=,,IC50,nM,,11.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.4
,673678,27302045,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '10.08', 'le': '0.18', 'lle': '-1.41', 'sei': '8.90'}",CHEMBL5799114,,CHEMBL5799114,6.97,0,http://www.openphacts.org/units/Nanomolar,4274957,=,37,1,=,,IC50,nM,,108.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,108.0
,673679,27302048,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OCCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.59', 'le': '0.19', 'lle': '0.87', 'sei': '8.57'}",CHEMBL5832526,,CHEMBL5832526,7.78,0,http://www.openphacts.org/units/Nanomolar,4274958,=,37,1,=,,IC50,nM,,16.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.8
,673680,27302051,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '-1.88', 'sei': '10.35'}",CHEMBL5809792,,CHEMBL5809792,7.14,0,http://www.openphacts.org/units/Nanomolar,4274959,=,37,1,=,,IC50,nM,,71.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,71.8
,673681,27302054,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CO)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '14.11', 'le': '0.25', 'lle': '1.51', 'sei': '9.74'}",CHEMBL5978367,,CHEMBL5978367,8.38,0,http://www.openphacts.org/units/Nanomolar,4274960,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,673682,27302057,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2ccccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.25', 'le': '0.19', 'lle': '-1.60', 'sei': '9.82'}",CHEMBL6062105,,CHEMBL6062105,6.78,0,http://www.openphacts.org/units/Nanomolar,4274961,=,37,1,=,,IC50,nM,,168.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,168.0
,673683,27302060,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCCCC2)OCO3)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.48', 'le': '0.19', 'lle': '-0.71', 'sei': '8.44'}",CHEMBL5908915,,CHEMBL5908915,7.38,0,http://www.openphacts.org/units/Nanomolar,4274962,=,37,1,=,,IC50,nM,,41.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.2
,673684,27302063,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN(C)C)c(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '11.68', 'le': '0.21', 'lle': '0.15', 'sei': '9.71'}",CHEMBL5864277,,CHEMBL5864277,7.60,0,http://www.openphacts.org/units/Nanomolar,4274963,=,37,1,=,,IC50,nM,,25.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.1
,673685,27302066,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCCCC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.61', 'le': '0.21', 'lle': '0.13', 'sei': '8.33'}",CHEMBL5935254,,CHEMBL5935254,8.21,0,http://www.openphacts.org/units/Nanomolar,4274964,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,673686,27302069,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccccc4)c4ccccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '0.58', 'sei': '10.96'}",CHEMBL5902614,,CHEMBL5902614,7.73,0,http://www.openphacts.org/units/Nanomolar,4274965,=,37,1,=,,IC50,nM,,18.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.8
,673687,27302072,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2ccc(Cl)cc2-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.17', 'le': '0.21', 'lle': '-0.32', 'sei': '14.91'}",CHEMBL6063727,,CHEMBL6063727,7.76,0,http://www.openphacts.org/units/Nanomolar,4274966,=,37,1,=,,IC50,nM,,17.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.5
,673688,27302075,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1ccc(Cl)cc1-n1cc(C(=O)N(c2ccccc2)c2ccc(O)cc2)c2ccccc21,,,CHEMBL5726419,,2017,"{'bei': '11.82', 'le': '0.22', 'lle': '-0.36', 'sei': '11.22'}",CHEMBL5910525,,CHEMBL5910525,7.74,0,http://www.openphacts.org/units/Nanomolar,4274967,=,37,1,=,,IC50,nM,,18.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.1
,673689,27302078,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-n1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc31)OCO2,,,CHEMBL5726419,,2017,"{'bei': '11.97', 'le': '0.22', 'lle': '0.79', 'sei': '9.10'}",CHEMBL5997609,,CHEMBL5997609,7.96,0,http://www.openphacts.org/units/Nanomolar,4274968,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,673690,27302081,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccccc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.56', 'le': '0.21', 'lle': '1.02', 'sei': '10.01'}",CHEMBL5886009,,CHEMBL5886009,8.16,0,http://www.openphacts.org/units/Nanomolar,4274969,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,673691,27302084,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OC(F)(F)O3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.20', 'le': '0.17', 'lle': '-0.50', 'sei': '7.67'}",CHEMBL5857187,,CHEMBL5857187,6.96,0,http://www.openphacts.org/units/Nanomolar,4274970,=,37,1,=,,IC50,nM,,111.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,111.0
,673692,27302087,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc(O)c(O)cc2-n2cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3ccccc32)CC1,,,CHEMBL5726419,,2017,"{'bei': '11.42', 'le': '0.21', 'lle': '1.54', 'sei': '7.17'}",CHEMBL5750655,,CHEMBL5750655,8.08,0,http://www.openphacts.org/units/Nanomolar,4274971,=,37,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,673693,27302090,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '0.91', 'sei': '8.12'}",CHEMBL6046174,,CHEMBL6046174,7.85,0,http://www.openphacts.org/units/Nanomolar,4274972,=,37,1,=,,IC50,nM,,14.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.1
,673694,27302093,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC1COc2cc(-n3cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc43)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCN(C)CC3)cc2O1,,,CHEMBL5726419,,2017,"{'bei': '10.19', 'le': '0.19', 'lle': '0.08', 'sei': '8.56'}",CHEMBL5987041,,CHEMBL5987041,7.76,0,http://www.openphacts.org/units/Nanomolar,4274973,=,37,1,=,,IC50,nM,,17.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.3
,673695,27302096,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cn(-c2cc(Cl)ccc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCOCC2)c2ccccc12)N(c1ccccc1)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '10.94', 'le': '0.20', 'lle': '-0.24', 'sei': '9.75'}",CHEMBL5745694,,CHEMBL5745694,7.63,0,http://www.openphacts.org/units/Nanomolar,4274974,=,37,1,=,,IC50,nM,,23.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.5
,673696,27302099,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)C3CCCCC3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '10.77', 'le': '0.20', 'lle': '0.53', 'sei': '9.41'}",CHEMBL5775349,,CHEMBL5775349,7.67,0,http://www.openphacts.org/units/Nanomolar,4274975,=,37,1,=,,IC50,nM,,21.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.6
,673697,27302102,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccccc42)OC[C@H](COCc2ccccc2)O3)CC1,,,CHEMBL5726419,,2017,"{'bei': '9.10', 'le': '0.17', 'lle': '-0.72', 'sei': '7.78'}",CHEMBL5985491,,CHEMBL5985491,7.78,0,http://www.openphacts.org/units/Nanomolar,4274976,=,37,1,=,,IC50,nM,,16.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.8
,673698,27302105,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(F)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '10.87', 'le': '0.20', 'lle': '0.59', 'sei': '9.65'}",CHEMBL5798028,,CHEMBL5798028,7.87,0,http://www.openphacts.org/units/Nanomolar,4274977,=,37,1,=,,IC50,nM,,13.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.6
,673699,27302108,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc(C)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.46', 'le': '0.21', 'lle': '0.80', 'sei': '10.13'}",CHEMBL5822872,,CHEMBL5822872,8.25,0,http://www.openphacts.org/units/Nanomolar,4274978,=,37,1,=,,IC50,nM,,5.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.6
,673700,27302111,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cn(-c2cc(OC)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12)c1ccccc1,,,CHEMBL5726419,,2017,"{'bei': '11.92', 'le': '0.22', 'lle': '1.56', 'sei': '10.03'}",CHEMBL5757201,,CHEMBL5757201,8.17,0,http://www.openphacts.org/units/Nanomolar,4274979,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,673701,27302114,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4cc(F)ccc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.17', 'le': '0.19', 'lle': '0.51', 'sei': '8.28'}",CHEMBL5972946,,CHEMBL5972946,7.51,0,http://www.openphacts.org/units/Nanomolar,4274980,=,37,1,=,,IC50,nM,,31.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.1
,673702,27302117,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C[C@@H]2Cc3ccccc3CN2C(=O)c2cc3c(cc2-n2cc(C(=O)N(c4ccccc4)c4ccc(O)cc4)c4ccc(F)cc42)OCO3)CC1,,,CHEMBL5726419,,2017,"{'bei': '10.85', 'le': '0.20', 'lle': '1.01', 'sei': '8.83'}",CHEMBL6022916,,CHEMBL6022916,8.01,0,http://www.openphacts.org/units/Nanomolar,4274981,=,37,1,=,,IC50,nM,,9.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.8
,673703,27302120,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccccc3)c3ccc4[nH]ccc4c3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.37', 'le': '0.21', 'lle': '0.85', 'sei': '8.71'}",CHEMBL5987519,,CHEMBL5987519,8.47,0,http://www.openphacts.org/units/Nanomolar,4274982,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,673704,27302123,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(-c2ccc(NC(=O)CSc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12,,,CHEMBL5726419,,2017,"{'bei': '9.22', 'le': '0.17', 'lle': '-0.98', 'sei': '8.92'}",CHEMBL6043187,,CHEMBL6043187,7.24,0,http://www.openphacts.org/units/Nanomolar,4274983,=,37,1,=,,IC50,nM,,57.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.7
,673705,27302126,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cn(-c2ccc(NC(=O)COc3ccccc3)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12,,,CHEMBL5726419,,2017,"{'bei': '8.86', 'le': '0.16', 'lle': '-0.69', 'sei': '7.54'}",CHEMBL6055064,,CHEMBL6055064,6.81,0,http://www.openphacts.org/units/Nanomolar,4274984,=,37,1,=,,IC50,nM,,155.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,155.0
,673706,27302129,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc(F)cc3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.50', 'le': '0.21', 'lle': '1.53', 'sei': '8.36'}",CHEMBL6020153,,CHEMBL6020153,8.51,0,http://www.openphacts.org/units/Nanomolar,4274985,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,673707,27302132,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4[nH]ccc4c3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '1.04', 'sei': '7.11'}",CHEMBL5990271,,CHEMBL5990271,8.36,0,http://www.openphacts.org/units/Nanomolar,4274986,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,673708,27302135,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cn(-c2cc(OC)c(O)cc2C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c2ccccc12)c1ccc(O)cc1,,,CHEMBL5726419,,2017,"{'bei': '11.40', 'le': '0.21', 'lle': '1.69', 'sei': '7.86'}",CHEMBL5800065,,CHEMBL5800065,8.00,0,http://www.openphacts.org/units/Nanomolar,4274987,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,673709,27302138,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(-n2cc(C(=O)N(c3ccc(O)cc3)C3CCCCC3)c3ccccc32)c(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)cc1O,,,CHEMBL5726419,,2017,"{'bei': '11.44', 'le': '0.21', 'lle': '1.49', 'sei': '8.19'}",CHEMBL5961933,,CHEMBL5961933,8.33,0,http://www.openphacts.org/units/Nanomolar,4274988,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,673710,27302141,[],CHEMBL5732641,"Fluorescence Polarisation Assay: Method A:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.50108M in a buffer solution (NaPO4 20 mM, NaCl 50 mM, EDTA 1 mM, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.Method B:The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C(=O)N2Cc3ccccc3C[C@H]2CN2CCN(C)CC2)c(-n2cc(C(=O)N(c3ccc(O)cc3)c3ccc4c(ccn4C)c3)c3ccccc32)c1,,,CHEMBL5726419,,2017,"{'bei': '11.02', 'le': '0.20', 'lle': '0.74', 'sei': '9.68'}",CHEMBL5908462,,CHEMBL5908462,8.37,0,http://www.openphacts.org/units/Nanomolar,4274989,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,701490,27383852,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC(C)(C)C)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.38', 'le': '0.19', 'lle': '1.22', 'sei': '7.32'}",CHEMBL5866497,,CHEMBL5866497,7.89,0,http://www.openphacts.org/units/Nanomolar,4292498,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,701491,27383855,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CNCC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.70', 'le': '0.18', 'lle': '1.38', 'sei': '7.09'}",CHEMBL5982560,,CHEMBL5982560,6.40,0,http://www.openphacts.org/units/Nanomolar,4292499,=,37,1,=,,IC50,nM,,397.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,397.0
,701492,27383858,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.68', 'le': '0.18', 'lle': '1.62', 'sei': '6.70'}",CHEMBL5798521,,CHEMBL5798521,7.75,0,http://www.openphacts.org/units/Nanomolar,4292500,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,701493,27383861,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)Cc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.87', 'le': '0.19', 'lle': '1.78', 'sei': '6.95'}",CHEMBL5943881,,CHEMBL5943881,8.04,0,http://www.openphacts.org/units/Nanomolar,4292501,=,37,1,=,,IC50,nM,,9.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.2
,701494,27383864,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccc4ccccc4c2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '8.67', 'le': '0.16', 'lle': '0.10', 'sei': '6.37'}",CHEMBL5847053,,CHEMBL5847053,7.37,0,http://www.openphacts.org/units/Nanomolar,4292502,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,701495,27383867,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC(C)(C)C)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.41', 'le': '0.17', 'lle': '0.40', 'sei': '6.51'}",CHEMBL6061142,,CHEMBL6061142,7.02,0,http://www.openphacts.org/units/Nanomolar,4292503,=,37,1,=,,IC50,nM,,95.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,95.0
,701496,27383870,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CNC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '8.49', 'le': '0.16', 'lle': '0.50', 'sei': '6.07'}",CHEMBL5883522,,CHEMBL5883522,5.48,0,http://www.openphacts.org/units/Nanomolar,4292504,=,37,1,=,,IC50,nM,,3300.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3300.0
,701497,27383873,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.65', 'le': '0.19', 'lle': '1.68', 'sei': '8.26'}",CHEMBL6002401,,CHEMBL6002401,8.14,0,http://www.openphacts.org/units/Nanomolar,4292505,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,701498,27383876,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.34', 'le': '0.19', 'lle': '1.20', 'sei': '8.16'}",CHEMBL5887132,,CHEMBL5887132,8.05,0,http://www.openphacts.org/units/Nanomolar,4292506,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,701499,27383879,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CNC2,,,CHEMBL5726583,,2017,"{'bei': '12.30', 'le': '0.22', 'lle': '1.24', 'sei': '8.86'}",CHEMBL5977746,,CHEMBL5977746,6.90,0,http://www.openphacts.org/units/Nanomolar,4292507,=,37,1,=,,IC50,nM,,127.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,127.0
,701500,27383882,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.91', 'le': '0.20', 'lle': '2.03', 'sei': '7.77'}",CHEMBL5925901,,CHEMBL5925901,7.66,0,http://www.openphacts.org/units/Nanomolar,4292508,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,701501,27383885,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)c2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.82', 'le': '0.18', 'lle': '0.84', 'sei': '7.47'}",CHEMBL5930893,,CHEMBL5930893,7.37,0,http://www.openphacts.org/units/Nanomolar,4292509,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,701502,27383888,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OC(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '10.54', 'le': '0.19', 'lle': '-0.34', 'sei': '7.31'}",CHEMBL5996625,,CHEMBL5996625,6.97,0,http://www.openphacts.org/units/Nanomolar,4292510,=,37,1,=,,IC50,nM,,108.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,108.0
,701503,27383891,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.94', 'le': '0.22', 'lle': '0.95', 'sei': '9.41'}",CHEMBL5783636,,CHEMBL5783636,8.10,0,http://www.openphacts.org/units/Nanomolar,4292511,=,37,1,=,,IC50,nM,,7.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.9
,701504,27383894,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.14', 'le': '0.20', 'lle': '0.18', 'sei': '8.97'}",CHEMBL5911445,,CHEMBL5911445,7.72,0,http://www.openphacts.org/units/Nanomolar,4292512,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,701505,27383897,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '1.33', 'sei': '7.63'}",CHEMBL5889756,,CHEMBL5889756,8.22,0,http://www.openphacts.org/units/Nanomolar,4292513,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,701506,27383900,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NC(C)(C)C)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.45', 'le': '0.17', 'lle': '0.84', 'sei': '6.37'}",CHEMBL5879405,,CHEMBL5879405,7.04,0,http://www.openphacts.org/units/Nanomolar,4292514,=,37,1,=,,IC50,nM,,91.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,91.0
,701507,27383903,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCS(=O)(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.06', 'le': '0.19', 'lle': '2.38', 'sei': '6.42'}",CHEMBL5789940,,CHEMBL5789940,7.42,0,http://www.openphacts.org/units/Nanomolar,4292515,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,701508,27383906,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.32', 'le': '0.18', 'lle': '1.25', 'sei': '6.34'}",CHEMBL5755708,,CHEMBL5755708,7.33,0,http://www.openphacts.org/units/Nanomolar,4292516,=,37,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
,701509,27383909,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)C1CC1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.24', 'le': '0.22', 'lle': '1.39', 'sei': '8.94'}",CHEMBL6015543,,CHEMBL6015543,7.70,0,http://www.openphacts.org/units/Nanomolar,4292517,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,701510,27383912,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)CCc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.65', 'le': '0.18', 'lle': '1.59', 'sei': '6.79'}",CHEMBL5906827,,CHEMBL5906827,7.85,0,http://www.openphacts.org/units/Nanomolar,4292518,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,701511,27383915,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)c2cccnc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.09', 'le': '0.17', 'lle': '1.68', 'sei': '5.57'}",CHEMBL5987615,,CHEMBL5987615,7.16,0,http://www.openphacts.org/units/Nanomolar,4292519,=,37,1,=,,IC50,nM,,70.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,70.0
,701512,27383918,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(Cc1ccccc1)C(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '11.16', 'le': '0.20', 'lle': '0.11', 'sei': '9.16'}",CHEMBL5806867,,CHEMBL5806867,7.89,0,http://www.openphacts.org/units/Nanomolar,4292520,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,701513,27383921,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(Cc1ccc(Cl)cc1)C(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.42', 'le': '0.20', 'lle': '-0.72', 'sei': '8.97'}",CHEMBL5954684,,CHEMBL5954684,7.72,0,http://www.openphacts.org/units/Nanomolar,4292521,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,701514,27383924,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(CC(C)C(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.46', 'le': '0.19', 'lle': '-0.55', 'sei': '8.76'}",CHEMBL6052420,,CHEMBL6052420,7.54,0,http://www.openphacts.org/units/Nanomolar,4292522,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,701515,27383927,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1ccc(OC(F)(F)F)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '9.86', 'le': '0.18', 'lle': '-0.52', 'sei': '7.89'}",CHEMBL5990443,,CHEMBL5990443,7.52,0,http://www.openphacts.org/units/Nanomolar,4292523,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,701516,27383930,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCNC2,,,CHEMBL5726583,,2017,"{'bei': '12.32', 'le': '0.22', 'lle': '1.37', 'sei': '9.10'}",CHEMBL6001407,,CHEMBL6001407,7.08,0,http://www.openphacts.org/units/Nanomolar,4292524,=,37,1,=,,IC50,nM,,83.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,83.0
,701517,27383933,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(Cc1ccccn1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.72', 'le': '0.21', 'lle': '0.67', 'sei': '9.33'}",CHEMBL5842152,,CHEMBL5842152,7.64,0,http://www.openphacts.org/units/Nanomolar,4292525,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,701518,27383936,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCC1CCCCC1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.26', 'le': '0.21', 'lle': '-0.80', 'sei': '10.94'}",CHEMBL5987623,,CHEMBL5987623,7.55,0,http://www.openphacts.org/units/Nanomolar,4292526,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,701519,27383939,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.48', 'le': '0.21', 'lle': '-0.21', 'sei': '11.30'}",CHEMBL5890570,,CHEMBL5890570,7.80,0,http://www.openphacts.org/units/Nanomolar,4292527,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,701520,27383942,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Cc1csc(-c3cnccn3)n1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.64', 'le': '0.20', 'lle': '1.07', 'sei': '6.52'}",CHEMBL5742098,,CHEMBL5742098,8.13,0,http://www.openphacts.org/units/Nanomolar,4292528,=,37,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,701521,27383945,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CCC1CCCCC1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.48', 'le': '0.19', 'lle': '-0.93', 'sei': '8.51'}",CHEMBL5859886,,CHEMBL5859886,7.33,0,http://www.openphacts.org/units/Nanomolar,4292529,=,37,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
,701522,27383948,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.50', 'le': '0.21', 'lle': '-0.10', 'sei': '10.84'}",CHEMBL5851747,,CHEMBL5851747,7.48,0,http://www.openphacts.org/units/Nanomolar,4292530,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,701523,27383951,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '13.17', 'le': '0.24', 'lle': '1.95', 'sei': '9.65'}",CHEMBL5754652,,CHEMBL5754652,8.31,0,http://www.openphacts.org/units/Nanomolar,4292531,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,701524,27383954,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)c1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.27', 'le': '0.22', 'lle': '1.07', 'sei': '9.67'}",CHEMBL5935434,,CHEMBL5935434,8.33,0,http://www.openphacts.org/units/Nanomolar,4292532,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,701525,27383957,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.01', 'le': '0.22', 'lle': '1.13', 'sei': '9.66'}",CHEMBL5959510,,CHEMBL5959510,8.32,0,http://www.openphacts.org/units/Nanomolar,4292533,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,701526,27383960,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)CCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.76', 'le': '0.21', 'lle': '0.73', 'sei': '9.65'}",CHEMBL5824869,,CHEMBL5824869,8.31,0,http://www.openphacts.org/units/Nanomolar,4292534,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,701527,27383963,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(S(=O)(=O)Cc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.55', 'le': '0.18', 'lle': '1.42', 'sei': '6.61'}",CHEMBL5832240,,CHEMBL5832240,7.64,0,http://www.openphacts.org/units/Nanomolar,4292535,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,701528,27383966,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)c1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.99', 'le': '0.21', 'lle': '1.04', 'sei': '7.61'}",CHEMBL5807850,,CHEMBL5807850,7.85,0,http://www.openphacts.org/units/Nanomolar,4292536,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,701529,27383969,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.58', 'le': '0.22', 'lle': '1.49', 'sei': '8.19'}",CHEMBL5873539,,CHEMBL5873539,8.44,0,http://www.openphacts.org/units/Nanomolar,4292537,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,701530,27383972,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(S(=O)(=O)c1ccc3ccccc3c1)C2,,,CHEMBL5726583,,2017,"{'bei': '9.92', 'le': '0.18', 'lle': '-0.37', 'sei': '7.35'}",CHEMBL6027901,,CHEMBL6027901,7.58,0,http://www.openphacts.org/units/Nanomolar,4292538,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,701531,27383975,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2cccnc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.70', 'le': '0.18', 'lle': '1.57', 'sei': '6.66'}",CHEMBL5988387,,CHEMBL5988387,7.42,0,http://www.openphacts.org/units/Nanomolar,4292539,=,37,1,=,,IC50,nM,,38.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,38.0
,701532,27383978,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OC(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '9.84', 'le': '0.18', 'lle': '-1.90', 'sei': '7.46'}",CHEMBL5991327,,CHEMBL5991327,7.11,0,http://www.openphacts.org/units/Nanomolar,4292540,=,37,1,=,,IC50,nM,,77.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,77.0
,701533,27383981,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CNC2,,,CHEMBL5726583,,2017,"{'bei': '12.66', 'le': '0.23', 'lle': '0.52', 'sei': '10.14'}",CHEMBL5942386,,CHEMBL5942386,7.89,0,http://www.openphacts.org/units/Nanomolar,4292541,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,701534,27383984,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Oc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.49', 'le': '0.21', 'lle': '0.24', 'sei': '8.21'}",CHEMBL5876253,,CHEMBL5876253,7.82,0,http://www.openphacts.org/units/Nanomolar,4292542,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,701535,27383987,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.14', 'le': '0.22', 'lle': '0.81', 'sei': '8.85'}",CHEMBL5802285,,CHEMBL5802285,8.43,0,http://www.openphacts.org/units/Nanomolar,4292543,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,701536,27383990,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)OC(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '11.74', 'le': '0.22', 'lle': '0.57', 'sei': '8.31'}",CHEMBL5774912,,CHEMBL5774912,7.92,0,http://www.openphacts.org/units/Nanomolar,4292544,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,701537,27383993,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)NC(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '11.96', 'le': '0.22', 'lle': '1.13', 'sei': '8.21'}",CHEMBL5885945,,CHEMBL5885945,8.06,0,http://www.openphacts.org/units/Nanomolar,4292545,=,37,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,701538,27383996,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccc(Cl)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.47', 'le': '0.20', 'lle': '0.00', 'sei': '8.01'}",CHEMBL6034173,,CHEMBL6034173,7.64,0,http://www.openphacts.org/units/Nanomolar,4292546,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,701539,27383999,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1cccc(Cl)c1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.62', 'le': '0.20', 'lle': '0.10', 'sei': '8.12'}",CHEMBL5989389,,CHEMBL5989389,7.75,0,http://www.openphacts.org/units/Nanomolar,4292547,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,701540,27384002,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(CC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.65', 'le': '0.21', 'lle': '1.11', 'sei': '8.67'}",CHEMBL5772057,,CHEMBL5772057,8.26,0,http://www.openphacts.org/units/Nanomolar,4292548,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701541,27384005,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.12', 'le': '0.22', 'lle': '1.44', 'sei': '8.83'}",CHEMBL6050685,,CHEMBL6050685,8.42,0,http://www.openphacts.org/units/Nanomolar,4292549,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,701542,27384008,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(C#N)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.01', 'le': '0.22', 'lle': '1.56', 'sei': '7.84'}",CHEMBL5747376,,CHEMBL5747376,8.62,0,http://www.openphacts.org/units/Nanomolar,4292550,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,701543,27384011,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(CC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.88', 'le': '0.22', 'lle': '0.90', 'sei': '9.75'}",CHEMBL5808360,,CHEMBL5808360,8.40,0,http://www.openphacts.org/units/Nanomolar,4292551,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701544,27384014,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '12.62', 'le': '0.23', 'lle': '2.08', 'sei': '7.95'}",CHEMBL5830631,,CHEMBL5830631,7.80,0,http://www.openphacts.org/units/Nanomolar,4292552,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,701545,27384017,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCS(=O)(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '12.63', 'le': '0.24', 'lle': '2.65', 'sei': '8.16'}",CHEMBL5862634,,CHEMBL5862634,8.42,0,http://www.openphacts.org/units/Nanomolar,4292553,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,701546,27384020,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '11.92', 'le': '0.22', 'lle': '0.75', 'sei': '10.41'}",CHEMBL5923406,,CHEMBL5923406,7.19,0,http://www.openphacts.org/units/Nanomolar,4292554,=,37,1,=,,IC50,nM,,65.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,65.0
,701547,27384023,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(N)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.80', 'le': '0.22', 'lle': '1.18', 'sei': '6.90'}",CHEMBL5945004,,CHEMBL5945004,8.38,0,http://www.openphacts.org/units/Nanomolar,4292555,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,701548,27384026,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)Nc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.30', 'le': '0.21', 'lle': '0.91', 'sei': '6.83'}",CHEMBL5758769,,CHEMBL5758769,8.49,0,http://www.openphacts.org/units/Nanomolar,4292556,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,701549,27384029,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Nc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.10', 'le': '0.22', 'lle': '0.62', 'sei': '8.39'}",CHEMBL5745898,,CHEMBL5745898,8.23,0,http://www.openphacts.org/units/Nanomolar,4292557,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,701550,27384032,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)NCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.04', 'le': '0.22', 'lle': '1.07', 'sei': '8.52'}",CHEMBL5975714,,CHEMBL5975714,8.36,0,http://www.openphacts.org/units/Nanomolar,4292558,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701551,27384035,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.08', 'le': '0.20', 'lle': '-0.01', 'sei': '8.08'}",CHEMBL5765320,,CHEMBL5765320,7.70,0,http://www.openphacts.org/units/Nanomolar,4292559,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,701552,27384038,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.76', 'le': '0.23', 'lle': '1.28', 'sei': '8.77'}",CHEMBL6057321,,CHEMBL6057321,8.36,0,http://www.openphacts.org/units/Nanomolar,4292560,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701553,27384041,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)OCc1cnc3[nH]ccc3c1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.30', 'le': '0.19', 'lle': '-0.02', 'sei': '6.10'}",CHEMBL6061074,,CHEMBL6061074,7.57,0,http://www.openphacts.org/units/Nanomolar,4292561,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,701554,27384044,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Nc1ccc(N3CCN(C)CC3)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.52', 'le': '0.19', 'lle': '0.83', 'sei': '7.83'}",CHEMBL6061404,,CHEMBL6061404,8.19,0,http://www.openphacts.org/units/Nanomolar,4292562,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,701555,27384047,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N1CCC(c3ccccc3)C1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.62', 'le': '0.19', 'lle': '-0.19', 'sei': '8.73'}",CHEMBL5832336,,CHEMBL5832336,7.80,0,http://www.openphacts.org/units/Nanomolar,4292563,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,701556,27384050,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N1CCC(c3ccccc3)C1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '0.00', 'sei': '8.99'}",CHEMBL5830561,,CHEMBL5830561,8.03,0,http://www.openphacts.org/units/Nanomolar,4292564,=,37,1,=,,IC50,nM,,9.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.4
,701557,27384053,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.77', 'le': '0.23', 'lle': '1.41', 'sei': '8.96'}",CHEMBL5780970,,CHEMBL5780970,8.54,0,http://www.openphacts.org/units/Nanomolar,4292565,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,701558,27384056,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.91', 'le': '0.20', 'lle': '1.58', 'sei': '7.89'}",CHEMBL5966110,,CHEMBL5966110,8.51,0,http://www.openphacts.org/units/Nanomolar,4292566,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,701559,27384059,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.66', 'le': '0.20', 'lle': '1.79', 'sei': '8.41'}",CHEMBL6052590,,CHEMBL6052590,8.29,0,http://www.openphacts.org/units/Nanomolar,4292567,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701560,27384062,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Nc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '12.15', 'le': '0.22', 'lle': '0.78', 'sei': '8.59'}",CHEMBL5980019,,CHEMBL5980019,8.43,0,http://www.openphacts.org/units/Nanomolar,4292568,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,701561,27384065,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.55', 'le': '0.21', 'lle': '0.06', 'sei': '11.12'}",CHEMBL5744802,,CHEMBL5744802,7.68,0,http://www.openphacts.org/units/Nanomolar,4292569,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,701562,27384068,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)NCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.82', 'le': '0.22', 'lle': '1.04', 'sei': '8.53'}",CHEMBL5767350,,CHEMBL5767350,8.37,0,http://www.openphacts.org/units/Nanomolar,4292570,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,701563,27384071,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N(C)c1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.60', 'le': '0.21', 'lle': '0.53', 'sei': '9.20'}",CHEMBL5924068,,CHEMBL5924068,8.21,0,http://www.openphacts.org/units/Nanomolar,4292571,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,701564,27384074,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.59', 'le': '0.23', 'lle': '1.70', 'sei': '9.75'}",CHEMBL5921277,,CHEMBL5921277,8.40,0,http://www.openphacts.org/units/Nanomolar,4292572,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701565,27384077,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)NC(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '11.55', 'le': '0.21', 'lle': '0.74', 'sei': '7.77'}",CHEMBL6032199,,CHEMBL6032199,7.62,0,http://www.openphacts.org/units/Nanomolar,4292573,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,701566,27384080,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Nc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.78', 'le': '0.20', 'lle': '1.44', 'sei': '7.59'}",CHEMBL6008881,,CHEMBL6008881,8.40,0,http://www.openphacts.org/units/Nanomolar,4292574,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701567,27384083,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NCc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.54', 'le': '0.19', 'lle': '1.72', 'sei': '7.56'}",CHEMBL5910678,,CHEMBL5910678,8.36,0,http://www.openphacts.org/units/Nanomolar,4292575,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701568,27384086,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '13.06', 'le': '0.24', 'lle': '2.49', 'sei': '8.41'}",CHEMBL5988103,,CHEMBL5988103,8.25,0,http://www.openphacts.org/units/Nanomolar,4292576,=,37,1,=,,IC50,nM,,5.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.6
,701569,27384089,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.65', 'le': '0.23', 'lle': '1.61', 'sei': '9.59'}",CHEMBL5836984,,CHEMBL5836984,8.26,0,http://www.openphacts.org/units/Nanomolar,4292577,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701570,27384092,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)C(C)(C)C)C2,,,CHEMBL5726583,,2017,"{'bei': '11.39', 'le': '0.21', 'lle': '0.45', 'sei': '8.59'}",CHEMBL5758353,,CHEMBL5758353,7.68,0,http://www.openphacts.org/units/Nanomolar,4292578,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,701571,27384095,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)c1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.20', 'le': '0.20', 'lle': '0.14', 'sei': '8.70'}",CHEMBL5966512,,CHEMBL5966512,7.77,0,http://www.openphacts.org/units/Nanomolar,4292579,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,701572,27384098,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N1CC(c3ccccc3)C1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.87', 'le': '0.20', 'lle': '0.22', 'sei': '8.76'}",CHEMBL5951994,,CHEMBL5951994,7.82,0,http://www.openphacts.org/units/Nanomolar,4292580,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,701573,27384101,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)N1CC(c3ccccc3)C1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.32', 'le': '0.21', 'lle': '0.67', 'sei': '9.30'}",CHEMBL5786581,,CHEMBL5786581,8.31,0,http://www.openphacts.org/units/Nanomolar,4292581,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,701574,27384104,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)N(C)Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.60', 'le': '0.21', 'lle': '0.58', 'sei': '9.20'}",CHEMBL5978766,,CHEMBL5978766,8.21,0,http://www.openphacts.org/units/Nanomolar,4292582,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,701575,27384107,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)COc1ccccc1Cl)C2,,,CHEMBL5726583,,2017,"{'bei': '11.33', 'le': '0.21', 'lle': '0.62', 'sei': '8.67'}",CHEMBL5818630,,CHEMBL5818630,8.26,0,http://www.openphacts.org/units/Nanomolar,4292583,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701576,27384110,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CNc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.95', 'le': '0.22', 'lle': '1.28', 'sei': '8.45'}",CHEMBL5746270,,CHEMBL5746270,8.29,0,http://www.openphacts.org/units/Nanomolar,4292584,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701577,27384113,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.22', 'le': '0.21', 'lle': '2.02', 'sei': '7.84'}",CHEMBL6023571,,CHEMBL6023571,8.46,0,http://www.openphacts.org/units/Nanomolar,4292585,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,701578,27384116,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.25', 'le': '0.21', 'lle': '2.45', 'sei': '8.58'}",CHEMBL6020028,,CHEMBL6020028,8.46,0,http://www.openphacts.org/units/Nanomolar,4292586,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,701579,27384119,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H](C(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1)c1ccccc1,,,CHEMBL5726583,,2017,"{'bei': '11.61', 'le': '0.21', 'lle': '0.46', 'sei': '9.53'}",CHEMBL5937563,,CHEMBL5937563,8.21,0,http://www.openphacts.org/units/Nanomolar,4292587,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,701580,27384122,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)[C@H](C)c1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.54', 'le': '0.21', 'lle': '0.40', 'sei': '9.47'}",CHEMBL5910246,,CHEMBL5910246,8.15,0,http://www.openphacts.org/units/Nanomolar,4292588,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,701581,27384125,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(CC(=O)Nc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.10', 'le': '0.20', 'lle': '0.69', 'sei': '7.85'}",CHEMBL5794438,,CHEMBL5794438,7.70,0,http://www.openphacts.org/units/Nanomolar,4292589,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,701582,27384128,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)OCc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.70', 'le': '0.21', 'lle': '0.53', 'sei': '8.70'}",CHEMBL5880025,,CHEMBL5880025,8.29,0,http://www.openphacts.org/units/Nanomolar,4292590,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701583,27384131,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OCc2ccccc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.39', 'le': '0.19', 'lle': '1.18', 'sei': '7.66'}",CHEMBL5859126,,CHEMBL5859126,8.25,0,http://www.openphacts.org/units/Nanomolar,4292591,=,37,1,=,,IC50,nM,,5.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.6
,701584,27384134,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC(C(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3C)cc2C1)c1ccccc1,,,CHEMBL5726583,,2017,"{'bei': '10.89', 'le': '0.20', 'lle': '-0.29', 'sei': '9.12'}",CHEMBL5768211,,CHEMBL5768211,7.85,0,http://www.openphacts.org/units/Nanomolar,4292592,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,701585,27384137,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(NCCN3CCOCC3)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.24', 'le': '0.19', 'lle': '1.48', 'sei': '7.60'}",CHEMBL5743666,,CHEMBL5743666,8.41,0,http://www.openphacts.org/units/Nanomolar,4292593,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,701586,27384140,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(N3CCN(C)CC3)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.51', 'le': '0.19', 'lle': '1.37', 'sei': '8.98'}",CHEMBL5913609,,CHEMBL5913609,8.31,0,http://www.openphacts.org/units/Nanomolar,4292594,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,701587,27384143,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.61', 'le': '0.19', 'lle': '1.18', 'sei': '7.81'}",CHEMBL6017111,,CHEMBL6017111,8.42,0,http://www.openphacts.org/units/Nanomolar,4292595,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,701588,27384146,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,CHEMBL5726583,,2017,"{'bei': '10.40', 'le': '0.19', 'lle': '1.02', 'sei': '7.66'}",CHEMBL5991247,,CHEMBL5991247,8.26,0,http://www.openphacts.org/units/Nanomolar,4292596,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701589,27384149,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.59', 'le': '0.19', 'lle': '1.17', 'sei': '7.80'}",CHEMBL5911983,,CHEMBL5911983,8.41,0,http://www.openphacts.org/units/Nanomolar,4292597,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,701590,27384152,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(CC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '12.57', 'le': '0.23', 'lle': '1.93', 'sei': '9.01'}",CHEMBL6036174,,CHEMBL6036174,8.59,0,http://www.openphacts.org/units/Nanomolar,4292598,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,701591,27384155,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(F)cc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.38', 'le': '0.23', 'lle': '1.51', 'sei': '9.64'}",CHEMBL6040541,,CHEMBL6040541,8.30,0,http://www.openphacts.org/units/Nanomolar,4292599,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,701592,27384158,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)COc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.63', 'le': '0.23', 'lle': '1.95', 'sei': '8.86'}",CHEMBL6009488,,CHEMBL6009488,8.44,0,http://www.openphacts.org/units/Nanomolar,4292600,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,701593,27384161,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)C(C)Oc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.97', 'le': '0.22', 'lle': '1.29', 'sei': '8.58'}",CHEMBL5788493,,CHEMBL5788493,8.17,0,http://www.openphacts.org/units/Nanomolar,4292601,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,701594,27384164,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(Cl)cc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.81', 'le': '0.22', 'lle': '0.40', 'sei': '8.54'}",CHEMBL5906047,,CHEMBL5906047,8.14,0,http://www.openphacts.org/units/Nanomolar,4292602,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,701595,27384167,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(F)cc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.30', 'le': '0.23', 'lle': '1.06', 'sei': '8.68'}",CHEMBL6054224,,CHEMBL6054224,8.28,0,http://www.openphacts.org/units/Nanomolar,4292603,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,701596,27384170,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '12.64', 'le': '0.23', 'lle': '1.07', 'sei': '8.87'}",CHEMBL5961751,,CHEMBL5961751,8.46,0,http://www.openphacts.org/units/Nanomolar,4292604,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,701597,27384173,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(NCCN(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.41', 'sei': '8.45'}",CHEMBL5771935,,CHEMBL5771935,8.57,0,http://www.openphacts.org/units/Nanomolar,4292605,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,701598,27384176,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)C1(c3ccccc3)CC1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.22', 'le': '0.20', 'lle': '0.39', 'sei': '9.37'}",CHEMBL5886123,,CHEMBL5886123,8.07,0,http://www.openphacts.org/units/Nanomolar,4292606,=,37,1,=,,IC50,nM,,8.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.6
,701599,27384179,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '12.75', 'le': '0.23', 'lle': '2.11', 'sei': '7.87'}",CHEMBL5824288,,CHEMBL5824288,7.72,0,http://www.openphacts.org/units/Nanomolar,4292607,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,701600,27384182,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)NCc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.09', 'le': '0.22', 'lle': '1.28', 'sei': '8.23'}",CHEMBL5767189,,CHEMBL5767189,8.08,0,http://www.openphacts.org/units/Nanomolar,4292608,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,701601,27384185,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '12.79', 'le': '0.23', 'lle': '1.95', 'sei': '8.57'}",CHEMBL5970546,,CHEMBL5970546,7.38,0,http://www.openphacts.org/units/Nanomolar,4292609,=,37,1,=,,IC50,nM,,42.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,42.0
,701602,27384188,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN3CCN(C)CC3)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.49', 'le': '0.19', 'lle': '1.50', 'sei': '9.12'}",CHEMBL6059840,,CHEMBL6059840,8.44,0,http://www.openphacts.org/units/Nanomolar,4292610,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,701603,27384191,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.90', 'le': '0.23', 'lle': '1.00', 'sei': '11.21'}",CHEMBL5994212,,CHEMBL5994212,8.42,0,http://www.openphacts.org/units/Nanomolar,4292611,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,701604,27384194,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.48', 'le': '0.21', 'lle': '1.74', 'sei': '9.67'}",CHEMBL5864714,,CHEMBL5864714,8.47,0,http://www.openphacts.org/units/Nanomolar,4292612,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,701605,27384197,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(CCCN2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.24', 'le': '0.21', 'lle': '0.15', 'sei': '9.81'}",CHEMBL6056802,,CHEMBL6056802,7.68,0,http://www.openphacts.org/units/Nanomolar,4292613,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,701606,27384200,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.69', 'le': '0.21', 'lle': '2.30', 'sei': '10.98'}",CHEMBL5872522,,CHEMBL5872522,8.60,0,http://www.openphacts.org/units/Nanomolar,4292614,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,701607,27384203,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '13.01', 'le': '0.24', 'lle': '1.48', 'sei': '12.86'}",CHEMBL6037009,,CHEMBL6037009,8.47,0,http://www.openphacts.org/units/Nanomolar,4292615,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,701608,27384206,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CNCC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.65', 'le': '0.21', 'lle': '0.70', 'sei': '10.78'}",CHEMBL5906342,,CHEMBL5906342,6.21,0,http://www.openphacts.org/units/Nanomolar,4292616,=,37,1,=,,IC50,nM,,622.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,622.0
,701609,27384209,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.78', 'le': '0.20', 'lle': '1.53', 'sei': '7.98'}",CHEMBL5929538,,CHEMBL5929538,8.60,0,http://www.openphacts.org/units/Nanomolar,4292617,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,701610,27384212,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.54', 'le': '0.19', 'lle': '1.60', 'sei': '7.30'}",CHEMBL5885093,,CHEMBL5885093,8.54,0,http://www.openphacts.org/units/Nanomolar,4292618,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,701611,27384215,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.54', 'le': '0.20', 'lle': '1.01', 'sei': '7.96'}",CHEMBL5903986,,CHEMBL5903986,8.59,0,http://www.openphacts.org/units/Nanomolar,4292619,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,701612,27384218,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1cccc(NCCN(C)C)c1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.62', 'le': '0.19', 'lle': '1.12', 'sei': '8.16'}",CHEMBL5894635,,CHEMBL5894635,8.28,0,http://www.openphacts.org/units/Nanomolar,4292620,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,701613,27384221,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(F)(F)F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.34', 'le': '0.17', 'lle': '-0.03', 'sei': '7.35'}",CHEMBL5773807,,CHEMBL5773807,7.92,0,http://www.openphacts.org/units/Nanomolar,4292621,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,701614,27384224,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(OC(F)(F)F)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.33', 'le': '0.17', 'lle': '0.23', 'sei': '6.89'}",CHEMBL5878109,,CHEMBL5878109,8.06,0,http://www.openphacts.org/units/Nanomolar,4292622,=,37,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,701615,27384227,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.18', 'le': '0.19', 'lle': '0.74', 'sei': '7.63'}",CHEMBL5772453,,CHEMBL5772453,8.23,0,http://www.openphacts.org/units/Nanomolar,4292623,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,701616,27384230,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.54', 'le': '0.19', 'lle': '1.68', 'sei': '6.45'}",CHEMBL5824401,,CHEMBL5824401,8.48,0,http://www.openphacts.org/units/Nanomolar,4292624,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,701617,27384233,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.44', 'le': '0.19', 'lle': '1.52', 'sei': '7.23'}",CHEMBL5814241,,CHEMBL5814241,8.46,0,http://www.openphacts.org/units/Nanomolar,4292625,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,701618,27384236,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN3CCOCC3)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.71', 'le': '0.20', 'lle': '1.46', 'sei': '8.61'}",CHEMBL6009560,,CHEMBL6009560,8.48,0,http://www.openphacts.org/units/Nanomolar,4292626,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,701619,27384239,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '2.11', 'sei': '8.63'}",CHEMBL5777249,,CHEMBL5777249,8.51,0,http://www.openphacts.org/units/Nanomolar,4292627,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,701620,27384242,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)/C=C/c2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.99', 'le': '0.20', 'lle': '1.92', 'sei': '8.52'}",CHEMBL5976126,,CHEMBL5976126,8.40,0,http://www.openphacts.org/units/Nanomolar,4292628,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701621,27384245,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CCC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.80', 'le': '0.20', 'lle': '1.21', 'sei': '8.46'}",CHEMBL6050995,,CHEMBL6050995,8.34,0,http://www.openphacts.org/units/Nanomolar,4292629,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,701622,27384248,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)Oc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '-1.13', 'sei': '8.56'}",CHEMBL5855472,,CHEMBL5855472,8.15,0,http://www.openphacts.org/units/Nanomolar,4292630,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,701623,27384251,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccccc3)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.08', 'le': '0.20', 'lle': '-0.52', 'sei': '9.72'}",CHEMBL5915933,,CHEMBL5915933,8.37,0,http://www.openphacts.org/units/Nanomolar,4292631,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,701624,27384254,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(CCC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,CHEMBL5726583,,2017,"{'bei': '10.15', 'le': '0.19', 'lle': '1.67', 'sei': '7.49'}",CHEMBL5854152,,CHEMBL5854152,8.08,0,http://www.openphacts.org/units/Nanomolar,4292632,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,701625,27384257,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(/C=C/C(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)c1,,,CHEMBL5726583,,2017,"{'bei': '10.30', 'le': '0.19', 'lle': '1.68', 'sei': '7.58'}",CHEMBL5821621,,CHEMBL5821621,8.17,0,http://www.openphacts.org/units/Nanomolar,4292633,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,701626,27384260,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)/C=C/c2ccc(Cl)c(Cl)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.64', 'le': '0.19', 'lle': '0.24', 'sei': '8.14'}",CHEMBL5975661,,CHEMBL5975661,8.03,0,http://www.openphacts.org/units/Nanomolar,4292634,=,37,1,=,,IC50,nM,,9.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.4
,701627,27384263,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)CCc1ccc(NCCN(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '9.99', 'le': '0.18', 'lle': '0.37', 'sei': '7.81'}",CHEMBL5967193,,CHEMBL5967193,7.92,0,http://www.openphacts.org/units/Nanomolar,4292635,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,701628,27384266,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.80', 'le': '0.20', 'lle': '1.54', 'sei': '7.69'}",CHEMBL5927352,,CHEMBL5927352,8.29,0,http://www.openphacts.org/units/Nanomolar,4292636,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701629,27384269,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.38', 'le': '0.20', 'lle': '1.09', 'sei': '7.59'}",CHEMBL5839241,,CHEMBL5839241,8.18,0,http://www.openphacts.org/units/Nanomolar,4292637,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,701630,27384272,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(N)=O)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.00', 'le': '0.18', 'lle': '2.20', 'sei': '5.45'}",CHEMBL5878919,,CHEMBL5878919,8.23,0,http://www.openphacts.org/units/Nanomolar,4292638,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,701631,27384275,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C(=O)c1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.71', 'le': '0.18', 'lle': '1.63', 'sei': '6.45'}",CHEMBL5914311,,CHEMBL5914311,8.26,0,http://www.openphacts.org/units/Nanomolar,4292639,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701632,27384278,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(-n4ccnc4)cc2)CC3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.76', 'le': '0.18', 'lle': '1.14', 'sei': '6.58'}",CHEMBL5918037,,CHEMBL5918037,8.26,0,http://www.openphacts.org/units/Nanomolar,4292640,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,701633,27384281,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(CN(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.09', 'le': '0.20', 'lle': '1.07', 'sei': '9.31'}",CHEMBL5900526,,CHEMBL5900526,8.32,0,http://www.openphacts.org/units/Nanomolar,4292641,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,701634,27384284,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.11', 'le': '0.22', 'lle': '1.81', 'sei': '7.62'}",CHEMBL5937444,,CHEMBL5937444,8.38,0,http://www.openphacts.org/units/Nanomolar,4292642,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,701635,27384287,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '2.24', 'sei': '6.50'}",CHEMBL5884005,,CHEMBL5884005,8.55,0,http://www.openphacts.org/units/Nanomolar,4292643,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,701636,27384290,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.24', 'le': '0.22', 'lle': '1.49', 'sei': '7.13'}",CHEMBL5982104,,CHEMBL5982104,8.49,0,http://www.openphacts.org/units/Nanomolar,4292644,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,701637,27384293,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cc(C#N)ccc1OC(=O)N1CCc2cc(-c3cc(C(=O)N(C)c4ccc(O)cc4)c4n3CCCC4)c(C(=O)N3Cc4ccccc4C[C@H]3CN3CCOCC3)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '10.21', 'le': '0.19', 'lle': '1.71', 'sei': '6.05'}",CHEMBL5871668,,CHEMBL5871668,8.52,0,http://www.openphacts.org/units/Nanomolar,4292645,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,701638,27384296,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(NCCN(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.80', 'le': '0.20', 'lle': '0.99', 'sei': '9.81'}",CHEMBL5914943,,CHEMBL5914943,7.96,0,http://www.openphacts.org/units/Nanomolar,4292646,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,701639,27384299,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.38', 'le': '0.22', 'lle': '1.51', 'sei': '9.33'}",CHEMBL5889287,,CHEMBL5889287,8.37,0,http://www.openphacts.org/units/Nanomolar,4292647,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,701640,27384302,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.88', 'le': '0.20', 'lle': '2.10', 'sei': '8.10'}",CHEMBL5751596,,CHEMBL5751596,8.28,0,http://www.openphacts.org/units/Nanomolar,4292648,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,701641,27384305,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '1.58', 'sei': '7.35'}",CHEMBL5978810,,CHEMBL5978810,8.19,0,http://www.openphacts.org/units/Nanomolar,4292649,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,701642,27384308,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(NCCN(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '0.79', 'sei': '7.57'}",CHEMBL5818397,,CHEMBL5818397,8.38,0,http://www.openphacts.org/units/Nanomolar,4292650,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,701643,27384311,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1ccc(OCCN(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.78', 'le': '0.20', 'lle': '1.28', 'sei': '8.53'}",CHEMBL5795689,,CHEMBL5795689,8.41,0,http://www.openphacts.org/units/Nanomolar,4292651,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,701644,27384314,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Oc1ccc(CCC(=O)N(C)C)cc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.70', 'le': '0.20', 'lle': '0.85', 'sei': '7.35'}",CHEMBL5881894,,CHEMBL5881894,8.49,0,http://www.openphacts.org/units/Nanomolar,4292652,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,701645,27384317,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.47', 'le': '0.19', 'lle': '1.88', 'sei': '7.58'}",CHEMBL5792612,,CHEMBL5792612,8.17,0,http://www.openphacts.org/units/Nanomolar,4292653,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,701646,27384320,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)OC2CCS(=O)(=O)C2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.02', 'le': '0.21', 'lle': '2.47', 'sei': '5.93'}",CHEMBL5741708,,CHEMBL5741708,7.68,0,http://www.openphacts.org/units/Nanomolar,4292654,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,701647,27384323,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(c3ccc(O)cc3)c3cnc4c(ccn4C)c3)c3n1CCCC3)CN(C(=O)COc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '-0.23', 'sei': '7.37'}",CHEMBL6007251,,CHEMBL6007251,8.34,0,http://www.openphacts.org/units/Nanomolar,4292655,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,701648,27384326,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.71', 'le': '0.20', 'lle': '2.27', 'sei': '7.49'}",CHEMBL5747498,,CHEMBL5747498,8.07,0,http://www.openphacts.org/units/Nanomolar,4292656,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,701649,27384329,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)COCc2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.95', 'le': '0.22', 'lle': '1.53', 'sei': '8.56'}",CHEMBL5751670,,CHEMBL5751670,8.16,0,http://www.openphacts.org/units/Nanomolar,4292657,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,701650,27384332,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2CCc4ccccc4C2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '10.85', 'le': '0.20', 'lle': '-0.63', 'sei': '9.55'}",CHEMBL5880339,,CHEMBL5880339,7.17,0,http://www.openphacts.org/units/Nanomolar,4292658,=,37,1,=,,IC50,nM,,68.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,68.0
,701651,27384335,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2CCc4ccccc4C2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '11.35', 'le': '0.21', 'lle': '0.11', 'sei': '11.36'}",CHEMBL6000962,,CHEMBL6000962,7.48,0,http://www.openphacts.org/units/Nanomolar,4292659,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,701652,27384338,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '11.21', 'le': '0.21', 'lle': '-0.62', 'sei': '10.08'}",CHEMBL5996803,,CHEMBL5996803,7.57,0,http://www.openphacts.org/units/Nanomolar,4292660,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,701653,27384341,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '11.67', 'le': '0.21', 'lle': '0.09', 'sei': '11.93'}",CHEMBL6054886,,CHEMBL6054886,7.85,0,http://www.openphacts.org/units/Nanomolar,4292661,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,701654,27384344,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '10.22', 'le': '0.19', 'lle': '0.67', 'sei': '9.89'}",CHEMBL5762647,,CHEMBL5762647,7.75,0,http://www.openphacts.org/units/Nanomolar,4292662,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,701655,27384347,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)COc2ccccc2)C3)n2ccccc12)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.56', 'le': '0.19', 'lle': '1.78', 'sei': '7.64'}",CHEMBL5784186,,CHEMBL5784186,8.19,0,http://www.openphacts.org/units/Nanomolar,4292663,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,701656,27384350,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3ccccn13)CN(C(=O)COc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.85', 'le': '0.22', 'lle': '1.09', 'sei': '8.64'}",CHEMBL5941752,,CHEMBL5941752,8.19,0,http://www.openphacts.org/units/Nanomolar,4292664,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,701657,27384353,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2Cc3cc(C(=O)N4Cc5ccccc5C[C@H]4C)c(-c4cc(C(=O)N(C)c5ccc(O)cc5)c5n4CCCC5)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.86', 'le': '0.22', 'lle': '0.36', 'sei': '8.65'}",CHEMBL5905897,,CHEMBL5905897,8.24,0,http://www.openphacts.org/units/Nanomolar,4292665,=,37,1,=,,IC50,nM,,5.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.7
,701658,27384356,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CCN(C(=O)Cc1cccc(N3CCN(C)CC3)c1)C2,,,CHEMBL5726583,,2017,"{'bei': '10.72', 'le': '0.20', 'lle': '1.54', 'sei': '9.16'}",CHEMBL5831694,,CHEMBL5831694,8.48,0,http://www.openphacts.org/units/Nanomolar,4292666,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,701659,27384359,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CNC(=O)N1Cc2cc(C(=O)N3Cc4ccccc4C[C@H]3C)c(-c3cc(C(=O)N(C)c4ccc(O)cc4)c(C)n3C)cc2C1,,,CHEMBL5726583,,2017,"{'bei': '13.39', 'le': '0.25', 'lle': '2.70', 'sei': '8.07'}",CHEMBL6001766,,CHEMBL6001766,7.92,0,http://www.openphacts.org/units/Nanomolar,4292667,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,701660,27384362,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@@H]1Cc2ccccc2CN1C(=O)c1cc2c(cc1-c1cc(C(=O)N(C)c3ccc(O)cc3)c3n1CCCC3)CN(C(=O)CSc1ccccc1)C2,,,CHEMBL5726583,,2017,"{'bei': '11.66', 'le': '0.22', 'lle': '0.59', 'sei': '9.63'}",CHEMBL6055416,,CHEMBL6055416,8.29,0,http://www.openphacts.org/units/Nanomolar,4292668,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701661,27384365,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Cc2ccc4c(c2)OCO4)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.15', 'le': '0.22', 'lle': '2.09', 'sei': '8.10'}",CHEMBL5767592,,CHEMBL5767592,8.47,0,http://www.openphacts.org/units/Nanomolar,4292669,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,701662,27384368,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@@H](N)c2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.87', 'le': '0.20', 'lle': '1.15', 'sei': '6.48'}",CHEMBL5763378,,CHEMBL5763378,7.26,0,http://www.openphacts.org/units/Nanomolar,4292670,=,37,1,=,,IC50,nM,,55.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,55.0
,701663,27384371,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@H](N)c2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.32', 'le': '0.22', 'lle': '2.12', 'sei': '7.34'}",CHEMBL5922941,,CHEMBL5922941,8.23,0,http://www.openphacts.org/units/Nanomolar,4292671,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,701664,27384374,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@H](O)c2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.53', 'le': '0.23', 'lle': '2.23', 'sei': '7.88'}",CHEMBL5908546,,CHEMBL5908546,8.38,0,http://www.openphacts.org/units/Nanomolar,4292672,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,701665,27384377,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CN2CCCCC2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.77', 'le': '0.20', 'lle': '1.21', 'sei': '7.96'}",CHEMBL5769779,,CHEMBL5769779,7.11,0,http://www.openphacts.org/units/Nanomolar,4292673,=,37,1,=,,IC50,nM,,78.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,78.0
,701666,27384380,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.98', 'le': '0.20', 'lle': '1.60', 'sei': '7.82'}",CHEMBL5749911,,CHEMBL5749911,8.43,0,http://www.openphacts.org/units/Nanomolar,4292674,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,701667,27384383,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.38', 'sei': '7.98'}",CHEMBL5914383,,CHEMBL5914383,8.60,0,http://www.openphacts.org/units/Nanomolar,4292675,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,701668,27384386,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.71', 'le': '0.20', 'lle': '0.91', 'sei': '7.91'}",CHEMBL5963628,,CHEMBL5963628,8.52,0,http://www.openphacts.org/units/Nanomolar,4292676,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,701669,27384389,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(CCCC)C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n(C)c1C,,,CHEMBL5726583,,2017,"{'bei': '9.98', 'le': '0.18', 'lle': '0.09', 'sei': '8.66'}",CHEMBL6021363,,CHEMBL6021363,7.58,0,http://www.openphacts.org/units/Nanomolar,4292677,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,701670,27384392,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.90', 'le': '0.22', 'lle': '1.80', 'sei': '8.59'}",CHEMBL5863505,,CHEMBL5863505,8.47,0,http://www.openphacts.org/units/Nanomolar,4292678,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,701671,27384395,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.17', 'le': '0.21', 'lle': '2.22', 'sei': '8.42'}",CHEMBL5978602,,CHEMBL5978602,8.57,0,http://www.openphacts.org/units/Nanomolar,4292679,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,701672,27384398,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.22', 'le': '0.21', 'lle': '1.79', 'sei': '8.00'}",CHEMBL5741565,,CHEMBL5741565,8.62,0,http://www.openphacts.org/units/Nanomolar,4292680,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,701673,27384401,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.75', 'le': '0.20', 'lle': '1.36', 'sei': '8.66'}",CHEMBL5772479,,CHEMBL5772479,8.54,0,http://www.openphacts.org/units/Nanomolar,4292681,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,701674,27384404,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Nc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.13', 'le': '0.20', 'lle': '1.91', 'sei': '7.57'}",CHEMBL5813223,,CHEMBL5813223,8.38,0,http://www.openphacts.org/units/Nanomolar,4292682,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,701675,27384407,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Nc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.40', 'le': '0.23', 'lle': '1.12', 'sei': '8.44'}",CHEMBL5903712,,CHEMBL5903712,8.28,0,http://www.openphacts.org/units/Nanomolar,4292683,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,701676,27384410,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2OCCN(C)C)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.51', 'le': '0.21', 'lle': '1.63', 'sei': '8.07'}",CHEMBL5879788,,CHEMBL5879788,8.70,0,http://www.openphacts.org/units/Nanomolar,4292684,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,701677,27384413,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(OCCN(C)C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.29', 'le': '0.21', 'lle': '1.47', 'sei': '7.92'}",CHEMBL5760108,,CHEMBL5760108,8.54,0,http://www.openphacts.org/units/Nanomolar,4292685,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,701678,27384416,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(N(C)CCN(C)C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '0.95', 'sei': '10.26'}",CHEMBL5993417,,CHEMBL5993417,8.37,0,http://www.openphacts.org/units/Nanomolar,4292686,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,701679,27384419,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(OCCN(C)C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.35', 'le': '0.21', 'lle': '1.04', 'sei': '9.59'}",CHEMBL5838298,,CHEMBL5838298,8.40,0,http://www.openphacts.org/units/Nanomolar,4292687,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701680,27384422,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(N(C)CCN(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.85', 'le': '0.20', 'lle': '1.23', 'sei': '8.20'}",CHEMBL5805677,,CHEMBL5805677,8.35,0,http://www.openphacts.org/units/Nanomolar,4292688,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,701681,27384425,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(OCCN(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.57', 'le': '0.21', 'lle': '1.67', 'sei': '8.11'}",CHEMBL5955038,,CHEMBL5955038,8.74,0,http://www.openphacts.org/units/Nanomolar,4292689,=,37,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,701682,27384428,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(N(C)CCN(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.99', 'le': '0.20', 'lle': '0.86', 'sei': '10.15'}",CHEMBL5877503,,CHEMBL5877503,8.28,0,http://www.openphacts.org/units/Nanomolar,4292690,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,701683,27384431,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(NCCN(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.50', 'le': '0.21', 'lle': '1.10', 'sei': '9.40'}",CHEMBL5869795,,CHEMBL5869795,8.49,0,http://www.openphacts.org/units/Nanomolar,4292691,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,701684,27384434,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cccc(C#N)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.34', 'le': '0.19', 'lle': '1.75', 'sei': '6.12'}",CHEMBL6025190,,CHEMBL6025190,8.06,0,http://www.openphacts.org/units/Nanomolar,4292692,=,37,1,=,,IC50,nM,,8.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.8
,701685,27384437,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,C#Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.73', 'le': '0.20', 'lle': '1.93', 'sei': '7.74'}",CHEMBL5820135,,CHEMBL5820135,8.35,0,http://www.openphacts.org/units/Nanomolar,4292693,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,701686,27384440,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Cl)c(Cl)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.41', 'le': '0.18', 'lle': '-0.01', 'sei': '7.19'}",CHEMBL5981194,,CHEMBL5981194,7.75,0,http://www.openphacts.org/units/Nanomolar,4292694,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,701687,27384443,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4ccccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.02', 'le': '0.18', 'lle': '0.47', 'sei': '7.47'}",CHEMBL5859076,,CHEMBL5859076,8.06,0,http://www.openphacts.org/units/Nanomolar,4292695,=,37,1,=,,IC50,nM,,8.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.8
,701688,27384446,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4cc[nH]c4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.34', 'le': '0.19', 'lle': '1.28', 'sei': '6.64'}",CHEMBL5914305,,CHEMBL5914305,8.20,0,http://www.openphacts.org/units/Nanomolar,4292696,=,37,1,=,,IC50,nM,,6.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.3
,701689,27384449,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.38', 'le': '0.19', 'lle': '1.31', 'sei': '6.66'}",CHEMBL5742039,,CHEMBL5742039,8.23,0,http://www.openphacts.org/units/Nanomolar,4292697,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,701690,27384452,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)NCc2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.53', 'le': '0.19', 'lle': '2.39', 'sei': '5.75'}",CHEMBL5861332,,CHEMBL5861332,8.36,0,http://www.openphacts.org/units/Nanomolar,4292698,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701691,27384455,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccccc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.44', 'le': '0.21', 'lle': '1.56', 'sei': '9.82'}",CHEMBL6020264,,CHEMBL6020264,8.60,0,http://www.openphacts.org/units/Nanomolar,4292699,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,701692,27384458,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4cc[nH]c4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.48', 'le': '0.19', 'lle': '0.93', 'sei': '7.88'}",CHEMBL5928745,,CHEMBL5928745,8.14,0,http://www.openphacts.org/units/Nanomolar,4292700,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,701693,27384461,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.66', 'le': '0.20', 'lle': '1.07', 'sei': '8.02'}",CHEMBL5740858,,CHEMBL5740858,8.28,0,http://www.openphacts.org/units/Nanomolar,4292701,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,701694,27384464,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.56', 'le': '0.19', 'lle': '1.60', 'sei': '7.07'}",CHEMBL5818506,,CHEMBL5818506,8.21,0,http://www.openphacts.org/units/Nanomolar,4292702,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,701695,27384467,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cnc4c(ccn4C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.31', 'le': '0.19', 'lle': '1.54', 'sei': '7.74'}",CHEMBL6007828,,CHEMBL6007828,8.16,0,http://www.openphacts.org/units/Nanomolar,4292703,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,701696,27384470,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cnc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.49', 'le': '0.21', 'lle': '0.66', 'sei': '7.67'}",CHEMBL6063634,,CHEMBL6063634,7.96,0,http://www.openphacts.org/units/Nanomolar,4292704,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,701697,27384473,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.43', 'le': '0.19', 'lle': '2.18', 'sei': '5.73'}",CHEMBL5920610,,CHEMBL5920610,8.32,0,http://www.openphacts.org/units/Nanomolar,4292705,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,701698,27384476,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.15', 'le': '0.22', 'lle': '1.83', 'sei': '6.53'}",CHEMBL5914402,,CHEMBL5914402,8.66,0,http://www.openphacts.org/units/Nanomolar,4292706,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,701699,27384479,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(C(=O)O)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.41', 'le': '0.19', 'lle': '2.17', 'sei': '5.73'}",CHEMBL5901939,,CHEMBL5901939,8.31,0,http://www.openphacts.org/units/Nanomolar,4292707,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,701700,27384482,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.88', 'le': '0.20', 'lle': '2.77', 'sei': '6.34'}",CHEMBL5959165,,CHEMBL5959165,8.82,0,http://www.openphacts.org/units/Nanomolar,4292708,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,701701,27384485,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Oc2cccc(C(=O)O)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.96', 'le': '0.18', 'lle': '1.57', 'sei': '6.66'}",CHEMBL5979822,,CHEMBL5979822,7.92,0,http://www.openphacts.org/units/Nanomolar,4292709,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,701702,27384488,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccccc2CCC(=O)N(C)C)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.22', 'le': '0.21', 'lle': '1.47', 'sei': '7.45'}",CHEMBL5947068,,CHEMBL5947068,8.62,0,http://www.openphacts.org/units/Nanomolar,4292710,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,701703,27384491,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(CCC(=O)N(C)C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.27', 'le': '0.21', 'lle': '1.51', 'sei': '7.49'}",CHEMBL5957233,,CHEMBL5957233,8.66,0,http://www.openphacts.org/units/Nanomolar,4292711,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,701704,27384494,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.81', 'le': '0.22', 'lle': '2.15', 'sei': '9.39'}",CHEMBL6018795,,CHEMBL6018795,8.39,0,http://www.openphacts.org/units/Nanomolar,4292712,=,37,1,=,,IC50,nM,,4.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.1
,701705,27384497,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.12', 'le': '0.20', 'lle': '2.59', 'sei': '9.19'}",CHEMBL5814775,,CHEMBL5814775,8.51,0,http://www.openphacts.org/units/Nanomolar,4292713,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,701706,27384500,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.15', 'le': '0.20', 'lle': '2.14', 'sei': '8.66'}",CHEMBL5957217,,CHEMBL5957217,8.54,0,http://www.openphacts.org/units/Nanomolar,4292714,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,701707,27384503,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.04', 'le': '0.20', 'lle': '2.06', 'sei': '8.58'}",CHEMBL5911510,,CHEMBL5911510,8.46,0,http://www.openphacts.org/units/Nanomolar,4292715,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,701708,27384506,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Cc2ccccc2)CC3)n(C)c1C)c1ccc(O)cc1,,,CHEMBL5726583,,2017,"{'bei': '11.01', 'le': '0.20', 'lle': '1.80', 'sei': '8.71'}",CHEMBL5747447,,CHEMBL5747447,8.59,0,http://www.openphacts.org/units/Nanomolar,4292716,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,701709,27384509,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN(C)C)CN(C(=O)C(F)(F)F)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.60', 'le': '0.20', 'lle': '1.73', 'sei': '8.16'}",CHEMBL5862127,,CHEMBL5862127,7.29,0,http://www.openphacts.org/units/Nanomolar,4292717,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,701710,27384512,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCN(C)CC2)CN(C(=O)C(F)(F)F)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.28', 'le': '0.19', 'lle': '2.40', 'sei': '8.25'}",CHEMBL5787910,,CHEMBL5787910,7.64,0,http://www.openphacts.org/units/Nanomolar,4292718,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,701711,27384515,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)Oc2ccc(Br)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.96', 'le': '0.20', 'lle': '1.09', 'sei': '7.69'}",CHEMBL6010857,,CHEMBL6010857,8.29,0,http://www.openphacts.org/units/Nanomolar,4292719,=,37,1,=,,IC50,nM,,5.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.1
,701712,27384518,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccccc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4C)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '12.72', 'le': '0.23', 'lle': '0.75', 'sei': '11.30'}",CHEMBL5874228,,CHEMBL5874228,8.48,0,http://www.openphacts.org/units/Nanomolar,4292720,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,701713,27384521,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(C#N)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.91', 'le': '0.22', 'lle': '0.79', 'sei': '8.17'}",CHEMBL5872583,,CHEMBL5872583,8.08,0,http://www.openphacts.org/units/Nanomolar,4292721,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,701714,27384524,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2cccc(CCC(=O)N(C)C)c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.04', 'le': '0.20', 'lle': '0.86', 'sei': '8.70'}",CHEMBL5917372,,CHEMBL5917372,8.30,0,http://www.openphacts.org/units/Nanomolar,4292722,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,701715,27384527,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(CCC(=O)N(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.11', 'le': '0.20', 'lle': '0.92', 'sei': '8.76'}",CHEMBL5949935,,CHEMBL5949935,8.36,0,http://www.openphacts.org/units/Nanomolar,4292723,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701716,27384530,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc4[nH]ccc4c2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.64', 'le': '0.21', 'lle': '0.15', 'sei': '8.86'}",CHEMBL5979212,,CHEMBL5979212,8.05,0,http://www.openphacts.org/units/Nanomolar,4292724,=,37,1,=,,IC50,nM,,8.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.9
,701717,27384533,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)OC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.55', 'le': '0.23', 'lle': '1.07', 'sei': '8.88'}",CHEMBL5992723,,CHEMBL5992723,8.47,0,http://www.openphacts.org/units/Nanomolar,4292725,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,701718,27384536,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.25', 'le': '0.21', 'lle': '1.84', 'sei': '7.93'}",CHEMBL5967330,,CHEMBL5967330,8.55,0,http://www.openphacts.org/units/Nanomolar,4292726,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,701719,27384539,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)NC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.37', 'le': '0.23', 'lle': '1.37', 'sei': '8.50'}",CHEMBL6010750,,CHEMBL6010750,8.34,0,http://www.openphacts.org/units/Nanomolar,4292727,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,701720,27384542,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)NC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.01', 'le': '0.20', 'lle': '2.08', 'sei': '7.56'}",CHEMBL6042482,,CHEMBL6042482,8.36,0,http://www.openphacts.org/units/Nanomolar,4292728,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,701721,27384545,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.60', 'sei': '8.46'}",CHEMBL5910501,,CHEMBL5910501,8.34,0,http://www.openphacts.org/units/Nanomolar,4292729,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,701722,27384548,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.30', 'le': '0.23', 'lle': '0.86', 'sei': '9.61'}",CHEMBL5926064,,CHEMBL5926064,8.28,0,http://www.openphacts.org/units/Nanomolar,4292730,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,701723,27384551,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)OC2CCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.89', 'sei': '7.61'}",CHEMBL5779078,,CHEMBL5779078,8.21,0,http://www.openphacts.org/units/Nanomolar,4292731,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,701724,27384554,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)O[C@@H]2C[C@H](C)CC[C@H]2C(C)C)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.41', 'le': '0.17', 'lle': '-0.16', 'sei': '7.12'}",CHEMBL5748092,,CHEMBL5748092,7.68,0,http://www.openphacts.org/units/Nanomolar,4292732,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,701725,27384557,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)CN(C(=O)CC24CC5CC(CC(C5)C2)C4)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '9.93', 'le': '0.18', 'lle': '0.67', 'sei': '8.16'}",CHEMBL5902574,,CHEMBL5902574,8.04,0,http://www.openphacts.org/units/Nanomolar,4292733,=,37,1,=,,IC50,nM,,9.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.1
,701726,27384560,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)CN2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.61', 'le': '0.21', 'lle': '1.88', 'sei': '8.76'}",CHEMBL5878085,,CHEMBL5878085,7.82,0,http://www.openphacts.org/units/Nanomolar,4292734,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,701727,27384563,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](NC(=O)OC(C)(C)C)CC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.01', 'le': '0.20', 'lle': '0.80', 'sei': '6.51'}",CHEMBL5782918,,CHEMBL5782918,8.70,0,http://www.openphacts.org/units/Nanomolar,4292735,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,701728,27384566,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](N)CC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '12.42', 'le': '0.23', 'lle': '2.24', 'sei': '7.06'}",CHEMBL5924588,,CHEMBL5924588,8.57,0,http://www.openphacts.org/units/Nanomolar,4292736,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,701729,27384569,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)O[C@H]2CC[C@H](N(C)C)CC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.70', 'le': '0.22', 'lle': '1.46', 'sei': '8.52'}",CHEMBL5802833,,CHEMBL5802833,8.40,0,http://www.openphacts.org/units/Nanomolar,4292737,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,701730,27384572,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N(C)c1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(C)c5ccc(O)cc5)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '10.11', 'le': '0.19', 'lle': '1.92', 'sei': '6.51'}",CHEMBL5775598,,CHEMBL5775598,8.34,0,http://www.openphacts.org/units/Nanomolar,4292738,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,701731,27384575,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)Oc2ccc(CCC(=O)N(C)C)cc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.00', 'le': '0.20', 'lle': '1.29', 'sei': '7.30'}",CHEMBL5871630,,CHEMBL5871630,8.44,0,http://www.openphacts.org/units/Nanomolar,4292739,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,701732,27384578,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(OC(=O)N2CCc3cc(-c4cc(C(=O)N(c5ccc(O)cc5)c5cc(C#N)n(C)c5C)c(C)n4C)c(C(=O)N4Cc5ccccc5C[C@H]4CN4CCOCC4)cc3C2)cc1,,,CHEMBL5726583,,2017,"{'bei': '9.76', 'le': '0.18', 'lle': '0.54', 'sei': '6.23'}",CHEMBL5740273,,CHEMBL5740273,8.51,0,http://www.openphacts.org/units/Nanomolar,4292740,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,701733,27384581,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2C)CN(C(=O)[C@@H](O)c2ccccc2)C3)n1C,,,CHEMBL5726583,,2017,"{'bei': '11.19', 'le': '0.20', 'lle': '1.33', 'sei': '7.04'}",CHEMBL5902233,,CHEMBL5902233,7.48,0,http://www.openphacts.org/units/Nanomolar,4292741,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,701734,27384584,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.86', 'le': '0.20', 'lle': '1.31', 'sei': '7.80'}",CHEMBL6016389,,CHEMBL6016389,8.41,0,http://www.openphacts.org/units/Nanomolar,4292742,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,701735,27384587,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)Oc2ccccc2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.96', 'le': '0.20', 'lle': '1.35', 'sei': '7.95'}",CHEMBL6056476,,CHEMBL6056476,8.57,0,http://www.openphacts.org/units/Nanomolar,4292743,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,701736,27384590,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccc(O)cc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.80', 'le': '0.20', 'lle': '1.02', 'sei': '7.89'}",CHEMBL5828406,,CHEMBL5828406,8.51,0,http://www.openphacts.org/units/Nanomolar,4292744,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,701737,27384593,[],CHEMBL5732950,"Fluorescence Polarisation Assay: The fluorescence polarisation tests were carried out on microplates (384 wells). The Bcl-2 protein, labelled (histag-Bcl-2 such that Bcl-2 corresponds to the UniProtKB primary accession number: P10415), at a final concentration of 2.50108 M, is mixed with a fluorescent peptide (Fluorescein-REIGAQLRRMADDLNAQY), at a final concentration of 1.00108 M in a buffer solution (Hepes 10 mM, NaCl 150 mM, Tween20 0.05%, pH 7.4), in the presence or in the absence of increasing concentrations of test compounds. After incubation for 2 hours, the fluorescence polarisation is measured.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(C(=O)N(C)c2ccccc2)cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CCCN2CCOCC2)CN(C(=O)OC2CCCCC2)CC3)n1C,,,CHEMBL5726583,,2017,"{'bei': '10.91', 'le': '0.20', 'lle': '0.64', 'sei': '9.62'}",CHEMBL5979408,,CHEMBL5979408,8.42,0,http://www.openphacts.org/units/Nanomolar,4292745,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,714910,27423455,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '10.07', 'le': '0.20', 'lle': '0.09', 'sei': '4.97'}",CHEMBL5872170,,CHEMBL5872170,8.85,0,http://www.openphacts.org/units/Nanomolar,4301272,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,714912,27423458,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '10.33', 'le': '0.20', 'lle': '1.47', 'sei': '5.03'}",CHEMBL5915070,,CHEMBL5915070,9.12,0,http://www.openphacts.org/units/Nanomolar,4301273,=,37,1,=,,IC50,nM,,0.76,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.76
,714914,27423461,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '10.13', 'le': '0.20', 'lle': '0.12', 'sei': '5.19'}",CHEMBL5862961,,CHEMBL5862961,8.92,0,http://www.openphacts.org/units/Nanomolar,4301274,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,714916,27423464,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cccc([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '11.09', 'le': '0.22', 'lle': '0.54', 'sei': '5.64'}",CHEMBL5846384,,CHEMBL5846384,8.51,0,http://www.openphacts.org/units/Nanomolar,4301275,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,714918,27423467,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.85', 'le': '0.19', 'lle': '1.07', 'sei': '4.63'}",CHEMBL5995747,,CHEMBL5995747,8.68,0,http://www.openphacts.org/units/Nanomolar,4301276,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,714920,27423470,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.86', 'le': '0.19', 'lle': '0.91', 'sei': '4.80'}",CHEMBL5567397,,CHEMBL5567397,8.70,0,http://www.openphacts.org/units/Nanomolar,4301277,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,714923,27423473,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.82', 'le': '0.19', 'lle': '-1.15', 'sei': '5.11'}",CHEMBL5925473,,CHEMBL5925473,8.62,0,http://www.openphacts.org/units/Nanomolar,4301278,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,714925,27423476,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.75', 'le': '0.19', 'lle': '1.98', 'sei': '4.53'}",CHEMBL5753919,,CHEMBL5753919,8.62,0,http://www.openphacts.org/units/Nanomolar,4301279,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,714928,27423479,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3=C(c4ccc(Cl)cc4)CC4(CC3)COC4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.92', 'le': '0.19', 'lle': '0.10', 'sei': '4.90'}",CHEMBL6018977,,CHEMBL6018977,8.72,0,http://www.openphacts.org/units/Nanomolar,4301280,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,714930,27423482,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,CNc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC5(CCC5)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,CHEMBL5726656,,2019,"{'bei': '10.65', 'le': '0.21', 'lle': '0.47', 'sei': '5.21'}",CHEMBL6064691,,CHEMBL6064691,8.48,0,http://www.openphacts.org/units/Nanomolar,4301281,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,714932,27423485,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(c5ccc(Cl)cc5)CC5(CCC5)CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,CHEMBL5726656,,2019,"{'bei': '9.78', 'le': '0.19', 'lle': '-0.11', 'sei': '5.15'}",CHEMBL5857346,,CHEMBL5857346,7.92,0,http://www.openphacts.org/units/Nanomolar,4301282,=,37,1,=,,IC50,nM,,11.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.9
,714934,27423488,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.50', 'le': '0.18', 'lle': '-1.50', 'sei': '4.95'}",CHEMBL6022853,,CHEMBL6022853,8.36,0,http://www.openphacts.org/units/Nanomolar,4301283,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,714936,27423491,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '10.07', 'le': '0.20', 'lle': '1.10', 'sei': '4.90'}",CHEMBL5896213,,CHEMBL5896213,8.89,0,http://www.openphacts.org/units/Nanomolar,4301284,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,714938,27423494,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1nc2cc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC6(CCC6)CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc([N+](=O)[O-])c2[nH]1,,,CHEMBL5726656,,2019,"{'bei': '9.91', 'le': '0.19', 'lle': '-0.55', 'sei': '4.69'}",CHEMBL5888847,,CHEMBL5888847,8.42,0,http://www.openphacts.org/units/Nanomolar,4301285,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,714940,27423497,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2[nH]c(C3CC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.80', 'le': '0.19', 'lle': '-0.42', 'sei': '4.63'}",CHEMBL6055136,,CHEMBL6055136,8.30,0,http://www.openphacts.org/units/Nanomolar,4301286,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,714942,27423500,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2c(cnn2CC2CCOCC2)c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.58', 'le': '0.19', 'lle': '-0.06', 'sei': '4.88'}",CHEMBL5815622,,CHEMBL5815622,8.68,0,http://www.openphacts.org/units/Nanomolar,4301287,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,714944,27423503,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2nn(CC3CCOCC3)cc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.58', 'le': '0.19', 'lle': '-0.06', 'sei': '4.88'}",CHEMBL5958618,,CHEMBL5958618,8.68,0,http://www.openphacts.org/units/Nanomolar,4301288,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,714946,27423506,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cnn(CC3CCOCC3)c2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.71', 'le': '0.19', 'lle': '0.06', 'sei': '4.95'}",CHEMBL5923329,,CHEMBL5923329,8.80,0,http://www.openphacts.org/units/Nanomolar,4301289,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,714948,27423509,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cn(CC3CCOCC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.81', 'le': '0.19', 'lle': '0.15', 'sei': '5.00'}",CHEMBL5953504,,CHEMBL5953504,8.89,0,http://www.openphacts.org/units/Nanomolar,4301290,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,714950,27423512,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cnn(C3CCOCC3)c2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.67', 'le': '0.19', 'lle': '-0.05', 'sei': '4.85'}",CHEMBL5776346,,CHEMBL5776346,8.62,0,http://www.openphacts.org/units/Nanomolar,4301291,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,714952,27423515,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2cn(C3CCOCC3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.93', 'le': '0.19', 'lle': '0.18', 'sei': '4.98'}",CHEMBL5821856,,CHEMBL5821856,8.85,0,http://www.openphacts.org/units/Nanomolar,4301292,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,714954,27423518,[],CHEMBL5733102,"Bcl-2 and Bcl-xL Inhibition: Fluorescein labeled BIM (81-106), BAK (72-87), and BID (79-99) peptides, named as Flu-BIM, Flu-BAK, and Flu-BID, respectively, were used as the fluorescent probes in FP assays for Bcl-2, Bcl-xL, and Mcl-1, respectively. By monitoring the total fluorescence polarization values of mixtures composed of fluorescent probes at fixed concentrations and proteins with increasing concentrations up to the full saturation, the Kd values of Flu-BIM to Bcl-2, Flu-BAK to Bcl-xL and Flu-BID to Mcl-1 were determined to be 0.550.15, 4.40.8 and 6.90.9 nM, respectively. Fluorescence polarization values were measured using the Infinite M-1000 plate reader (Tecan U.S., Research Triangle Park, N.C.) in Microfluor 1 96-well, black, round-bottom plates (Thermo Scientific). To each well, 1 nM of Flu-BIM, or 2 nM of Flu-BAK or 2 nM of Flu-BID and increasing concentrations of Bcl-2, or Bcl-xL, or Mcl-1 were added to a final volume of 125 l in the assay buffer (100 mM potassium phosphate, pH 7.5, 100 g/ml bovine -globulin, 0.02% sodium azide, Invitrogen, with 0.01% Triton X-100 and 4% DMSO). Plates were mixed and incubated at room temperature for 1 hour with gentle shaking to assure equilibrium. The polarization values in millipolarization units (mP) were measured at an excitation wavelength of 485 nm and an emission wavelength of 530 nm. Equilibrium dissociation constants (Kd) were then calculated by fitting the sigmoidal dose-dependent FP increases as a function of protein concentrations using Graphpad Prism 5.0 software (Graphpad Software, San Diego, Calif.). Ki values of representative Compounds of the Disclosure to Bcl-2, Bcl-xL, and Mcl-1 were determined from competitive binding experiments in which serial dilutions of inhibitors were added into 96-well plates containing fixed concentration of the fluorescent probes and proteins in each well. Mixtures of 5 l of the tested inhibitors in DMSO and 120 l of pre-incubated protein/probe complexes in the assay buffer were added into assay plates and incubated at room temperature for 2 hours with gentle shaking. Final concentrations of the protein and probe are 1.5 nM and 1 nM for the Bcl-2 assay, 10 nM and 2 nM for the Bcl-xL assay, and 20 nM and 2 nM for Mcl-1 assay, respectively. Negative controls containing protein/probe complex only (equivalent to 0% inhibition), and positive controls containing free probe only (equivalent to 100% inhibition), were included in each assay plate. FP values were measured as described above. IC50 values were determined by nonlinear regression fitting of the competition curves. The Ki values of competitive inhibitors were calculated using an equation described in Nikolovska-Coleska et al., Analytical Biochemistry 332: 261-73 (2004), based upon the measured IC50 values, the Kd values of the probes to the proteins, and the concentrations of the proteins and probes in the competitive assays. Ki values were also calculated using the equation of Huang, Journal of Biomolecular Screening 8:34-38 (2003).",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1cc([N+](=O)[O-])c2[nH]c(-c3ccncc3)nc2c1)c1ccc(N2CCN(CC3=C(c4ccc(Cl)cc4)CC4(CCC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5726656,,2019,"{'bei': '9.69', 'le': '0.19', 'lle': '-0.33', 'sei': '4.45'}",CHEMBL5827545,,CHEMBL5827545,8.57,0,http://www.openphacts.org/units/Nanomolar,4301293,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,836021,27775178,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,0,http://www.openphacts.org/units/Nanomolar,4376156,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836022,27775181,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5727360,,2019,,CHEMBL6026786,,CHEMBL6026786,,0,http://www.openphacts.org/units/Nanomolar,4376157,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836023,27775184,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5995608,,CHEMBL5995608,,0,http://www.openphacts.org/units/Nanomolar,4376158,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836024,27775187,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC5CCN(C6CCOCC6)CC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5821697,,CHEMBL5821697,,0,http://www.openphacts.org/units/Nanomolar,4376159,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836025,27775190,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCCCN5CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL6023840,,CHEMBL6023840,,0,http://www.openphacts.org/units/Nanomolar,4376160,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836026,27775193,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N5CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5803887,,CHEMBL5803887,,0,http://www.openphacts.org/units/Nanomolar,4376161,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836027,27775196,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5771552,,CHEMBL5771552,,0,http://www.openphacts.org/units/Nanomolar,4376162,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836028,27775199,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3-n3ncc4nc5[nH]ccc5cc43)cc2[N+](=O)[O-])CC1,,,CHEMBL5727360,,2019,,CHEMBL5775106,,CHEMBL5775106,,0,http://www.openphacts.org/units/Nanomolar,4376163,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836029,27775202,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(F)(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3-n3ncc4nc5[nH]ccc5cc43)cc2[N+](=O)[O-])CC1,,,CHEMBL5727360,,2019,,CHEMBL5797373,,CHEMBL5797373,,0,http://www.openphacts.org/units/Nanomolar,4376164,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836030,27775205,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(SCC5CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5930645,,CHEMBL5930645,,0,http://www.openphacts.org/units/Nanomolar,4376165,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836031,27775208,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCN(C6COC6)CC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5998648,,CHEMBL5998648,,0,http://www.openphacts.org/units/Nanomolar,4376166,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836032,27775211,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5(F)CCN(C6COC6)CC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5814490,,CHEMBL5814490,,0,http://www.openphacts.org/units/Nanomolar,4376167,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836033,27775214,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5CN(C6COC6)CCO5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL5742900,,CHEMBL5742900,,0,http://www.openphacts.org/units/Nanomolar,4376168,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836034,27775217,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(F)(COc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(c6ccc(Cl)cc6)CC(C)(C)CC5)CC4)cc3-n3ncc4nc5[nH]ccc5cc43)cc2[N+](=O)[O-])CC1,,,CHEMBL5727360,,2019,,CHEMBL5954403,,CHEMBL5954403,,0,http://www.openphacts.org/units/Nanomolar,4376169,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,836035,27775220,[],CHEMBL5734495,"Bcl-2 Competition Binding (Fluorescence Polarization) Assay: The fluorescence-labeled 23 amino acid peptide BH3 was purchased from CalBiochem (NLWAAQRYGRELRRMSDKFVD, SEQ ID NO: 1). An unbound Fluorescein labeled BH3 peptide emits random light with respect to the plane of polarization plane of excited light, resulting in a lower polarization degree (mP) value. When the peptide is bound to Bcl-2, the complex tumble slower and the emitted light can have a higher level of polarization, resulting in a higher mP value. This binding assay was performed in 96-well plate and with each assay contained 15 and 30 nM of labeled peptide and purified Bcl-2 protein (purchased from R&D Systems, Inc). The assay buffer contained 20 mM Hepes (pH 7.0), 50 mM KCl, 5 mM MgCl2, 20 mM Na2MoO4, 0.1 mg/ml Bovine Gamma Globulin and 0.01% NP40. Compounds were diluted in DMSO and added to the final assay with concentration range from 20 uM to 2 nM. The polarization degree (mP) value was determined by BioTek Synergy II with background subtraction after 3 hours of incubation at room temperature. IC50 was calculated using Prism software with sigmoidal dose-response curve fitting. ABT-737 was used as reference compound. Such assays, carried out with a range of doses of test compounds, allow the determination of an approximate IC50 value. Although the inhibitory properties of the compounds of the present invention vary with structural change as expected, the activity generally exhibited by these agents is in the range of IC50=0.1-1000 nM.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(OCC5CCOCC5)c([N+](=O)[O-])c4)c(-n4ncc5nc6[nH]ccc6cc54)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5727360,,2019,,CHEMBL6023306,,CHEMBL6023306,,0,http://www.openphacts.org/units/Nanomolar,4376170,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1153243,28655771,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COC/C=C\Cn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5842007,,CHEMBL5842007,,0,http://www.openphacts.org/units/Nanomolar,4562613,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153247,28655783,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL6010648,,CHEMBL6010648,,0,http://www.openphacts.org/units/Nanomolar,4562614,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153251,28655795,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COC/C=C\Cn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5954440,,CHEMBL5954440,,0,http://www.openphacts.org/units/Nanomolar,4562615,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153255,28655807,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5871078,,CHEMBL5871078,,0,http://www.openphacts.org/units/Nanomolar,4562616,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153259,28655819,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5ccccc45)c(C(=O)O)n(c13)C/C=C\COC2,,,CHEMBL5729039,,2022,,CHEMBL5927519,,CHEMBL5927519,,0,http://www.openphacts.org/units/Nanomolar,4562617,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153262,28655828,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5ccccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5902873,,CHEMBL5902873,,0,http://www.openphacts.org/units/Nanomolar,4562618,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153265,28655837,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5ccccc45)c(C(=O)O)n(c13)C/C=C\COC2,,,CHEMBL5729039,,2022,,CHEMBL5868411,,CHEMBL5868411,,0,http://www.openphacts.org/units/Nanomolar,4562619,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153269,28655849,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5907640,,CHEMBL5907640,,0,http://www.openphacts.org/units/Nanomolar,4562620,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153273,28655861,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3ccc(F)c4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5919933,,CHEMBL5919933,,0,http://www.openphacts.org/units/Nanomolar,4562621,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153276,28655870,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3ccc(F)c4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5919933,,CHEMBL5919933,,0,http://www.openphacts.org/units/Nanomolar,4562621,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153280,28655882,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5783977,,CHEMBL5783977,,0,http://www.openphacts.org/units/Nanomolar,4562622,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153283,28655891,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL6013614,,CHEMBL6013614,,0,http://www.openphacts.org/units/Nanomolar,4562623,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153286,28655900,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n3c4c(c(F)ccc24)-c2c(nn(C)c2C)COCCCC3)cc(C)c1Cl,,,CHEMBL5729039,,2022,,CHEMBL5891217,,CHEMBL5891217,,0,http://www.openphacts.org/units/Nanomolar,4562624,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153290,28655912,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5843991,,CHEMBL5843991,,0,http://www.openphacts.org/units/Nanomolar,4562625,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153294,28655924,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5843991,,CHEMBL5843991,,0,http://www.openphacts.org/units/Nanomolar,4562625,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153299,28655939,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3ccc(F)c4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5988202,,CHEMBL5988202,,0,http://www.openphacts.org/units/Nanomolar,4562626,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153303,28655951,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5940127,,CHEMBL5940127,,0,http://www.openphacts.org/units/Nanomolar,4562627,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153306,28655960,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5940127,,CHEMBL5940127,,0,http://www.openphacts.org/units/Nanomolar,4562627,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153309,28655969,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)COCCCCn1c(C(=O)O)c(CCCOc3cc(C)c(Cl)c(C)c3)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5952326,,CHEMBL5952326,,0,http://www.openphacts.org/units/Nanomolar,4562628,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153312,28655978,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5cc(F)ccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL6053159,,CHEMBL6053159,,0,http://www.openphacts.org/units/Nanomolar,4562629,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153315,28655987,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4ccc(F)c5ccccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5866210,,CHEMBL5866210,,0,http://www.openphacts.org/units/Nanomolar,4562630,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153318,28655996,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5c4CCCC5)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5872984,,CHEMBL5872984,,0,http://www.openphacts.org/units/Nanomolar,4562631,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153321,28656005,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5c4CCC5)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5912404,,CHEMBL5912404,,0,http://www.openphacts.org/units/Nanomolar,4562632,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153324,28656014,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(OCCCc2c(C(=O)O)n3c4c(c(F)ccc24)-c2c(C)nn(C)c2COCCCC3)cc(C)c1Cl,,,CHEMBL5729039,,2022,,CHEMBL5740999,,CHEMBL5740999,,0,http://www.openphacts.org/units/Nanomolar,4562633,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153327,28656023,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5ccccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5842261,,CHEMBL5842261,,0,http://www.openphacts.org/units/Nanomolar,4562634,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153331,28656035,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5cc(F)ccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5980683,,CHEMBL5980683,,0,http://www.openphacts.org/units/Nanomolar,4562635,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153336,28656050,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4ccc(F)c5ccccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5922756,,CHEMBL5922756,,0,http://www.openphacts.org/units/Nanomolar,4562636,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153340,28656062,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5c4CCCC5)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5801045,,CHEMBL5801045,,0,http://www.openphacts.org/units/Nanomolar,4562637,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153343,28656071,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cccc5c4CCC5)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5790764,,CHEMBL5790764,,0,http://www.openphacts.org/units/Nanomolar,4562638,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153346,28656080,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4cc(C)c(Cl)c(C)c4)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5742367,,CHEMBL5742367,,0,http://www.openphacts.org/units/Nanomolar,4562639,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153350,28656092,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1nn(C)c2c1-c1c(F)ccc3c(CCCOc4ccc(F)c5ccccc45)c(C(=O)O)n(c13)CCCCOC2,,,CHEMBL5729039,,2022,,CHEMBL5922756,,CHEMBL5922756,,0,http://www.openphacts.org/units/Nanomolar,4562636,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153354,28656104,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c2c(nn1C)C[N+](C)(C)CCCCn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5879235,,CHEMBL5879235,,0,http://www.openphacts.org/units/Nanomolar,4562641,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153357,28656113,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)CN(C)CCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5885001,,CHEMBL5885001,,0,http://www.openphacts.org/units/Nanomolar,4562642,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153360,28656122,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)CN(C)CCCCn1c(C(=O)O)c(CCCOc3cccc4c3CCCC4)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL6058728,,CHEMBL6058728,,0,http://www.openphacts.org/units/Nanomolar,4562643,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153363,28656131,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)CN(C)CCCCn1c(C(=O)O)c(CCCOc3cccc4cc(F)ccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5924328,,CHEMBL5924328,,0,http://www.openphacts.org/units/Nanomolar,4562644,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1153366,28656140,[],CHEMBL5737955,"Biological Assay 2: BCL-2 Assay: In the assay 11 different concentrations of each compound (0.1 nM, 0.33 nM, 1.1 nM, 3.8 nM, 13 nM, 44 nM, 0.15 M, 0.51 M, 1.7 M, 5.9 M and 20 M) were typically measured as duplicates in the same microtiter plate. For that, 100-fold concentrated DMSO solutions were prepared by serial dilutions (1:3.4) of a 2 mM stock solution in a clear, 384-well microtiter plate (Greiner Bio-One, Frickenhausen, Germany). From there, 50 nl were transferred in a dark test plate (Greiner Bio-One, Frickenhausen, Germany). The assay was initiated by addition of 2 l of a 2,5-fold concentrated His-BCL-2 solution (usually for a 1 nM end concentration in 5 l reaction volume) in aqueous assay buffer [50 mM Tris/HCl pH 7, 100 mM sodium chloride (NaCl), 50 mM potassium fluoride (KF), 0.005% Tween-20, 2 mM DTT, 0.1% bovine gamma globulin (BGG)] to the compounds in the assay plate. This was followed by a 10-minute incubation step at 22 C. for pre-equilibration of the putative complex between His-BCL-2 and the compounds. After that, 3 l of a 1.67-fold concentrated solution (in assay buffer) consisting of Bad BH3-derived peptide (1 nM end concentration) and TR-FRET detection reagents [1.67 nM anti-His-Eu cryptate and 1.67 nM streptavidin-XL665 (both from Cisbio Bioassays, Codolet, France)], were added.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c2c(nn1C)CN(C)CCCCn1c(C(=O)O)c(CCCOc3cccc4ccccc34)c3ccc(F)c-2c31,,,CHEMBL5729039,,2022,,CHEMBL5757443,,CHEMBL5757443,,0,http://www.openphacts.org/units/Nanomolar,4562645,>,37,1,>,,IC50,nM,,20000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20000.0
,1166480,28689209,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL6014501,,CHEMBL6014501,,0,http://www.openphacts.org/units/Nanomolar,4570104,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166482,28689215,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL5848802,,CHEMBL5848802,,0,http://www.openphacts.org/units/Nanomolar,4570107,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166484,28689221,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL5754780,ASARETOCLAX,CHEMBL5754780,,1,http://www.openphacts.org/units/Nanomolar,4570117,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166486,28689227,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(C23CC(Cl)(C2)C3)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCC(O)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729090,,2022,,CHEMBL6057868,,CHEMBL6057868,,1,http://www.openphacts.org/units/Nanomolar,4570127,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166488,28689233,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(C23CC(C)(C2)C3)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCC(O)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729090,,2022,,CHEMBL5805527,,CHEMBL5805527,,1,http://www.openphacts.org/units/Nanomolar,4570124,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166490,28689239,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729090,,2022,,CHEMBL5910247,,CHEMBL5910247,,1,http://www.openphacts.org/units/Nanomolar,4570128,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166492,28689245,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC12CC(C3=C(CN4CCN(c5ccc(C(=O)NS(=O)(=O)c6ccc(N[C@H](CCN(C)CCO)CSc7ccccc7)c(S(=O)(=O)C(F)(F)F)c6)cc5)CC4)CCC(C)(C)C3)(C1)C2,,,CHEMBL5729090,,2022,,CHEMBL5991770,,CHEMBL5991770,,1,http://www.openphacts.org/units/Nanomolar,4570129,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166494,28689251,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL5873088,,CHEMBL5873088,,0,http://www.openphacts.org/units/Nanomolar,4570130,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166496,28689257,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c([N+](=O)[O-])c4)cc3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL5886834,,CHEMBL5886834,,0,http://www.openphacts.org/units/Nanomolar,4570131,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166498,28689263,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729090,,2022,,CHEMBL5983851,,CHEMBL5983851,,1,http://www.openphacts.org/units/Nanomolar,4570132,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166500,28689269,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C(F)F)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729090,,2022,,CHEMBL5910058,,CHEMBL5910058,,0,http://www.openphacts.org/units/Nanomolar,4570133,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166502,28689275,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCC(O)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL6046089,,CHEMBL6046089,,0,http://www.openphacts.org/units/Nanomolar,4570134,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166504,28689281,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CCN(CC[C@H](CSc2ccccc2)Nc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCN(CC5=C(C67CC(C(F)F)(C6)C7)CC(C)(C)CC5)CC4)cc3)cc2S(=O)(=O)C(F)(F)F)CC1,,,CHEMBL5729090,,2022,,CHEMBL5960241,,CHEMBL5960241,,0,http://www.openphacts.org/units/Nanomolar,4570135,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166506,28689287,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C(F)F)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729090,,2022,,CHEMBL5860956,,CHEMBL5860956,,0,http://www.openphacts.org/units/Nanomolar,4570136,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166508,28689293,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCNCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL6041335,,CHEMBL6041335,,0,http://www.openphacts.org/units/Nanomolar,4570137,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166510,28689299,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCC(O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(CC3=C(C45CC(C(F)F)(C4)C5)CC4(CCC4)CC3)CC2)cc1,,,CHEMBL5729090,,2022,,CHEMBL6034449,,CHEMBL6034449,,0,http://www.openphacts.org/units/Nanomolar,4570138,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166512,28689305,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCN(CCO)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729090,,2022,,CHEMBL6017409,,CHEMBL6017409,,0,http://www.openphacts.org/units/Nanomolar,4570139,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166514,28689311,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C(F)F)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729090,,2022,,CHEMBL5971739,,CHEMBL5971739,,0,http://www.openphacts.org/units/Nanomolar,4570140,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166516,28689317,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729090,,2022,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,1,http://www.openphacts.org/units/Nanomolar,4570125,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1166518,28689323,[],CHEMBL5738049,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology. The compounds were then incubated with protein for 10 min at room temperature. The respective FAM labeled peptide was added and incubated for another 10 min and then anti-GST-Tb was added. After 60 min at rt, the HTRF fluorescence signal ratio was measured.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729090,,2022,,CHEMBL443684,NAVITOCLAX,CHEMBL443684,,1,http://www.openphacts.org/units/Nanomolar,4570126,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171510,28703510,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C)(C2)C3)C1,,,CHEMBL5729125,,2022,,CHEMBL6014501,,CHEMBL6014501,,1,http://www.openphacts.org/units/Nanomolar,4573739,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171512,28703516,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C)(C2)C3)C1,,,CHEMBL5729125,,2022,,CHEMBL5848802,,CHEMBL5848802,,1,http://www.openphacts.org/units/Nanomolar,4573742,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171514,28703522,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(C23CC(C(F)F)(C2)C3)C1,,,CHEMBL5729125,,2022,,CHEMBL5754780,ASARETOCLAX,CHEMBL5754780,,0,http://www.openphacts.org/units/Nanomolar,4573752,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171516,28703528,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(C23CC(Cl)(C2)C3)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCC(O)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729125,,2022,,CHEMBL6057868,,CHEMBL6057868,,0,http://www.openphacts.org/units/Nanomolar,4573762,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171518,28703534,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(C23CC(C)(C2)C3)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCC(O)CC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729125,,2022,,CHEMBL5805527,,CHEMBL5805527,,0,http://www.openphacts.org/units/Nanomolar,4573759,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171520,28703540,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(CCO)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729125,,2022,,CHEMBL5910247,,CHEMBL5910247,,0,http://www.openphacts.org/units/Nanomolar,4573763,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171522,28703546,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC12CC(C3=C(CN4CCN(c5ccc(C(=O)NS(=O)(=O)c6ccc(N[C@H](CCN(C)CCO)CSc7ccccc7)c(S(=O)(=O)C(F)(F)F)c6)cc5)CC4)CCC(C)(C)C3)(C1)C2,,,CHEMBL5729125,,2022,,CHEMBL5991770,,CHEMBL5991770,,0,http://www.openphacts.org/units/Nanomolar,4573764,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171524,28703552,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL6045482,,CHEMBL6045482,,0,http://www.openphacts.org/units/Nanomolar,4573765,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171526,28703558,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL6015456,,CHEMBL6015456,,0,http://www.openphacts.org/units/Nanomolar,4573766,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171528,28703564,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC[C@H](CSc1ccccc1)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCN(CC4=C(C56CC(C)(C5)C6)CC(C)(C)CC4)CC3)cc2)cc1S(=O)(=O)C(F)(F)F,,,CHEMBL5729125,,2022,,CHEMBL5983851,,CHEMBL5983851,,0,http://www.openphacts.org/units/Nanomolar,4573767,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171530,28703570,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5925530,,CHEMBL5925530,,0,http://www.openphacts.org/units/Nanomolar,4573768,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171532,28703576,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5961051,,CHEMBL5961051,,0,http://www.openphacts.org/units/Nanomolar,4573769,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171534,28703582,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5879652,,CHEMBL5879652,,0,http://www.openphacts.org/units/Nanomolar,4573770,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171536,28703588,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5787940,,CHEMBL5787940,,0,http://www.openphacts.org/units/Nanomolar,4573771,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171538,28703594,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5969739,,CHEMBL5969739,,0,http://www.openphacts.org/units/Nanomolar,4573772,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171540,28703600,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H](CCN2CCC(O)CC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(N2CCN(CC3=C(C45CC(C(F)F)(C4)C5)CC4(CCC4)CC3)CC2)cc1,,,CHEMBL5729125,,2022,,CHEMBL6034449,,CHEMBL6034449,,1,http://www.openphacts.org/units/Nanomolar,4573773,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171542,28703606,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL5964166,,CHEMBL5964166,,0,http://www.openphacts.org/units/Nanomolar,4573774,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171544,28703612,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,,,,CHEMBL5729125,,2022,,CHEMBL6029466,,CHEMBL6029466,,0,http://www.openphacts.org/units/Nanomolar,4573775,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171546,28703618,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729125,,2022,,CHEMBL3137309,VENETOCLAX,CHEMBL3137309,,1,http://www.openphacts.org/units/Nanomolar,4573760,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1171548,28703624,[],CHEMBL5738117,"Homogeneous Time Resolved Fluorescence (HTRF) Assay: Table 2: Binding to Bcl-2 proteins Bcl-2, and Bcl-XL was also assessed using an HTRF assay. Background: FAM-Bak/Bad binds to surface pocket of the Bcl-2 protein family. This binding can be monitored by HTRF signals between anti-GST-Tb and FAM-peptide using GST-tagged Bcl proteins. Assay conditions: Bcl-2: 4 nM Bcl-2, 100 nM FAM-Bak peptide, Bcl-XL: 3 nM Bcl-XL, 40 nM FAM-Bad peptide in 20 mM K Phosphate, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.005% Triton X-100 and 1% DMSO (final). Assay procedure: Compounds were tested in 10-dose IC50 mode, in singlicate, with 3-fold serial dilution starting at 10 M or 1 M. Compound stock solutions were added to protein solution using Acoustic technology.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(c2ccc(Cl)cc2)=C(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(N[C@H](CCN5CCOCC5)CSc5ccccc5)c(S(=O)(=O)C(F)(F)F)c4)cc3)CC2)C1,,,CHEMBL5729125,,2022,,CHEMBL443684,NAVITOCLAX,CHEMBL443684,,0,http://www.openphacts.org/units/Nanomolar,4573761,<,37,1,<,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1196965,28773980,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)OC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '13.86', 'le': '0.25', 'lle': '-0.95', 'sei': '10.92'}",CHEMBL5859755,,CHEMBL5859755,7.37,0,http://www.openphacts.org/units/Nanomolar,4590559,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,1196967,28773986,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.49', 'le': '0.16', 'lle': '-2.03', 'sei': '4.06'}",CHEMBL5560407,,CHEMBL5560407,6.85,0,http://www.openphacts.org/units/Nanomolar,4590560,=,37,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,1196969,28773992,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.56', 'le': '0.17', 'lle': '-1.97', 'sei': '4.10'}",CHEMBL5560077,,CHEMBL5560077,6.91,0,http://www.openphacts.org/units/Nanomolar,4590561,=,37,1,=,,IC50,nM,,122.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,122.0
,1196970,28773995,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.66', 'le': '0.19', 'lle': '-1.08', 'sei': '4.62'}",CHEMBL5542608,,CHEMBL5542608,7.80,0,http://www.openphacts.org/units/Nanomolar,4590562,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1196972,28774001,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.43', 'le': '0.20', 'lle': '-0.46', 'sei': '4.99'}",CHEMBL6009922,,CHEMBL6009922,8.42,0,http://www.openphacts.org/units/Nanomolar,4590563,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,1196974,28774007,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.18', 'lle': '-1.44', 'sei': '4.41'}",CHEMBL5822566,,CHEMBL5822566,7.44,0,http://www.openphacts.org/units/Nanomolar,4590564,=,37,1,=,,IC50,nM,,36.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.0
,1196976,28774013,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)c(Cl)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.54', 'le': '0.15', 'lle': '-3.19', 'sei': '3.76'}",CHEMBL6016027,,CHEMBL6016027,6.35,0,http://www.openphacts.org/units/Nanomolar,4590565,=,37,1,=,,IC50,nM,,449.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,449.0
,1196977,28774016,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)c(C(F)(F)F)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.46', 'le': '0.12', 'lle': '-3.82', 'sei': '3.22'}",CHEMBL5933296,,CHEMBL5933296,5.43,0,http://www.openphacts.org/units/Nanomolar,4590566,=,37,1,=,,IC50,nM,,3689.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3689.0
,1196978,28774019,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(C(F)(F)F)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.59', 'le': '0.15', 'lle': '-2.87', 'sei': '3.78'}",CHEMBL5751353,,CHEMBL5751353,6.38,0,http://www.openphacts.org/units/Nanomolar,4590567,=,37,1,=,,IC50,nM,,417.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,417.0
,1196979,28774022,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '-0.97', 'sei': '4.82'}",CHEMBL5542692,,CHEMBL5542692,8.14,0,http://www.openphacts.org/units/Nanomolar,4590568,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,1196981,28774028,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.73', 'le': '0.20', 'lle': '-0.39', 'sei': '5.17'}",CHEMBL5543056,,CHEMBL5543056,8.72,0,http://www.openphacts.org/units/Nanomolar,4590569,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,1196983,28774034,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.20', 'le': '0.17', 'lle': '-1.63', 'sei': '4.43'}",CHEMBL5557016,,CHEMBL5557016,7.48,0,http://www.openphacts.org/units/Nanomolar,4590570,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,1196985,28774040,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(C(F)(F)F)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.81', 'le': '0.13', 'lle': '-3.53', 'sei': '3.39'}",CHEMBL5954413,,CHEMBL5954413,5.72,0,http://www.openphacts.org/units/Nanomolar,4590571,=,37,1,=,,IC50,nM,,1884.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1884.0
,1196986,28774043,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.34', 'le': '0.14', 'lle': '-3.14', 'sei': '3.54'}",CHEMBL6046208,,CHEMBL6046208,5.97,0,http://www.openphacts.org/units/Nanomolar,4590572,=,37,1,=,,IC50,nM,,1075.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1075.0
,1196987,28774046,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.98', 'le': '0.19', 'lle': '-0.69', 'sei': '4.65'}",CHEMBL5566790,,CHEMBL5566790,7.85,0,http://www.openphacts.org/units/Nanomolar,4590573,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1196989,28774052,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.04', 'le': '0.19', 'lle': '-1.17', 'sei': '4.85'}",CHEMBL5557735,,CHEMBL5557735,8.18,0,http://www.openphacts.org/units/Nanomolar,4590574,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,1196991,28774058,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3-c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.68', 'le': '0.16', 'lle': '-2.53', 'sei': '4.36'}",CHEMBL5561570,,CHEMBL5561570,7.37,0,http://www.openphacts.org/units/Nanomolar,4590575,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,1196992,28774061,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(C4CC4)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.46', 'le': '0.16', 'lle': '-2.23', 'sei': '4.07'}",CHEMBL5878519,,CHEMBL5878519,6.88,0,http://www.openphacts.org/units/Nanomolar,4590576,=,37,1,=,,IC50,nM,,133.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,133.0
,1196993,28774064,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-1.50', 'sei': '4.45'}",CHEMBL5849462,,CHEMBL5849462,7.51,0,http://www.openphacts.org/units/Nanomolar,4590577,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,1196995,28774070,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.02', 'le': '0.17', 'lle': '-1.52', 'sei': '4.20'}",CHEMBL5567852,,CHEMBL5567852,7.10,0,http://www.openphacts.org/units/Nanomolar,4590578,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,1196997,28774076,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)c(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.07', 'le': '0.14', 'lle': '-3.59', 'sei': '3.53'}",CHEMBL5946898,,CHEMBL5946898,5.95,0,http://www.openphacts.org/units/Nanomolar,4590579,=,37,1,=,,IC50,nM,,1122.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1122.0
,1196998,28774079,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.78', 'le': '0.18', 'lle': '-0.39', 'sei': '4.41'}",CHEMBL5972023,,CHEMBL5972023,7.85,0,http://www.openphacts.org/units/Nanomolar,4590580,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197000,28774085,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.37', 'le': '0.16', 'lle': '-1.52', 'sei': '3.77'}",CHEMBL5806787,,CHEMBL5806787,6.72,0,http://www.openphacts.org/units/Nanomolar,4590581,=,37,1,=,,IC50,nM,,191.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,191.0
,1197001,28774088,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CC(c2ccccc2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1=O,,,CHEMBL5729271,,2022,"{'bei': '8.77', 'le': '0.17', 'lle': '-1.24', 'sei': '3.85'}",CHEMBL6045461,,CHEMBL6045461,7.15,0,http://www.openphacts.org/units/Nanomolar,4590582,=,37,1,=,,IC50,nM,,71.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,71.0
,1197002,28774091,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C(=O)CC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.56', 'le': '0.18', 'lle': '0.02', 'sei': '3.97'}",CHEMBL5884281,,CHEMBL5884281,7.39,0,http://www.openphacts.org/units/Nanomolar,4590583,=,37,1,=,,IC50,nM,,41.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.0
,1197004,28774097,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.21', 'le': '0.17', 'lle': '-1.11', 'sei': '4.22'}",CHEMBL5568324,,CHEMBL5568324,7.12,0,http://www.openphacts.org/units/Nanomolar,4590584,=,37,1,=,,IC50,nM,,76.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,76.0
,1197006,28774103,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3Cc3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.41', 'le': '0.16', 'lle': '-1.60', 'sei': '3.92'}",CHEMBL5754545,,CHEMBL5754545,6.62,0,http://www.openphacts.org/units/Nanomolar,4590585,=,37,1,=,,IC50,nM,,241.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,241.0
,1197007,28774106,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1cccc(CC2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.68', 'le': '0.18', 'lle': '-0.77', 'sei': '4.67'}",CHEMBL5910360,,CHEMBL5910360,7.89,0,http://www.openphacts.org/units/Nanomolar,4590586,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197009,28774112,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3Cc3cccc(C4CCCC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.73', 'le': '0.16', 'lle': '-2.29', 'sei': '4.42'}",CHEMBL6059224,,CHEMBL6059224,7.47,0,http://www.openphacts.org/units/Nanomolar,4590587,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,1197011,28774118,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.24', 'le': '0.17', 'lle': '-1.13', 'sei': '4.31'}",CHEMBL5560980,,CHEMBL5560980,7.27,0,http://www.openphacts.org/units/Nanomolar,4590588,=,37,1,=,,IC50,nM,,54.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,54.0
,1197013,28774124,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.17', 'le': '0.19', 'lle': '-0.40', 'sei': '4.74'}",CHEMBL5560980,,CHEMBL5560980,8.00,0,http://www.openphacts.org/units/Nanomolar,4590588,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1197015,28774130,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC(c4ccccc4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.48', 'le': '0.16', 'lle': '-1.33', 'sei': '3.88'}",CHEMBL5563244,,CHEMBL5563244,6.55,0,http://www.openphacts.org/units/Nanomolar,4590589,=,37,1,=,,IC50,nM,,281.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,281.0
,1197016,28774133,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccnc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.80', 'le': '0.18', 'lle': '-0.03', 'sei': '4.17'}",CHEMBL5532222,,CHEMBL5532222,7.58,0,http://www.openphacts.org/units/Nanomolar,4590590,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,1197017,28774136,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.54', 'le': '0.16', 'lle': '-1.78', 'sei': '3.94'}",CHEMBL5527871,,CHEMBL5527871,6.66,0,http://www.openphacts.org/units/Nanomolar,4590591,=,37,1,=,,IC50,nM,,221.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,221.0
,1197018,28774139,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1N1CCCC1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.78', 'le': '0.18', 'lle': '-0.84', 'sei': '4.56'}",CHEMBL5742232,,CHEMBL5742232,7.70,0,http://www.openphacts.org/units/Nanomolar,4590592,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197020,28774145,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3c(F)cccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.19', 'le': '0.18', 'lle': '-1.43', 'sei': '4.49'}",CHEMBL5557529,,CHEMBL5557529,7.58,0,http://www.openphacts.org/units/Nanomolar,4590593,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,1197022,28774151,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3)c(F)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.93', 'le': '0.17', 'lle': '-1.31', 'sei': '4.18'}",CHEMBL5858004,,CHEMBL5858004,7.06,0,http://www.openphacts.org/units/Nanomolar,4590594,=,37,1,=,,IC50,nM,,87.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,87.0
,1197023,28774154,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.54', 'le': '0.18', 'lle': '-1.61', 'sei': '4.67'}",CHEMBL5532439,,CHEMBL5532439,7.89,0,http://www.openphacts.org/units/Nanomolar,4590595,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197025,28774160,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.05', 'le': '0.15', 'lle': '-3.39', 'sei': '4.08'}",CHEMBL5558697,,CHEMBL5558697,6.89,0,http://www.openphacts.org/units/Nanomolar,4590596,=,37,1,=,,IC50,nM,,130.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,130.0
,1197026,28774163,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.92', 'le': '0.15', 'lle': '-1.83', 'sei': '3.56'}",CHEMBL5557096,,CHEMBL5557096,6.01,0,http://www.openphacts.org/units/Nanomolar,4590597,=,37,1,=,,IC50,nM,,977.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,977.0
,1197027,28774166,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3(c3ccccc3)C(F)(F)F)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.57', 'le': '0.18', 'lle': '-0.90', 'sei': '4.77'}",CHEMBL5785783,,CHEMBL5785783,8.05,0,http://www.openphacts.org/units/Nanomolar,4590598,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,1197029,28774172,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC1(c2ccccc2)CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.29', 'le': '0.18', 'lle': '-1.35', 'sei': '4.41'}",CHEMBL5978045,,CHEMBL5978045,7.44,0,http://www.openphacts.org/units/Nanomolar,4590599,=,37,1,=,,IC50,nM,,36.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.0
,1197030,28774175,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C(c2ccccc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.79', 'le': '0.18', 'lle': '0.47', 'sei': '4.57'}",CHEMBL5784373,,CHEMBL5784373,7.85,0,http://www.openphacts.org/units/Nanomolar,4590600,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197031,28774178,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.13', 'le': '0.17', 'lle': '-2.17', 'sei': '4.48'}",CHEMBL6040153,,CHEMBL6040153,7.57,0,http://www.openphacts.org/units/Nanomolar,4590601,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197033,28774184,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCC(=O)N3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5780829,,CHEMBL5780829,,0,http://www.openphacts.org/units/Nanomolar,4590602,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197034,28774187,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.89', 'le': '0.17', 'lle': '-1.88', 'sei': '4.28'}",CHEMBL5876808,,CHEMBL5876808,7.23,0,http://www.openphacts.org/units/Nanomolar,4590603,=,37,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,59.0
,1197035,28774190,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(C3CCCN3c3ccccc3[N+](=O)[O-])cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.17', 'lle': '-0.60', 'sei': '3.56'}",CHEMBL5900945,,CHEMBL5900945,7.54,0,http://www.openphacts.org/units/Nanomolar,4590604,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197037,28774196,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.06', 'le': '0.17', 'lle': '-2.02', 'sei': '4.45'}",CHEMBL5517916,,CHEMBL5517916,7.51,0,http://www.openphacts.org/units/Nanomolar,4590605,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,1197038,28774199,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.89', 'le': '0.19', 'lle': '-0.23', 'sei': '4.69'}",CHEMBL5836637,,CHEMBL5836637,8.07,0,http://www.openphacts.org/units/Nanomolar,4590606,=,37,1,=,,IC50,nM,,8.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.5
,1197040,28774205,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)Nc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.94', 'le': '0.17', 'lle': '0.14', 'sei': '3.60'}",CHEMBL5938561,,CHEMBL5938561,7.75,0,http://www.openphacts.org/units/Nanomolar,4590607,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197042,28774211,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.69', 'le': '0.18', 'lle': '-0.54', 'sei': '4.89'}",CHEMBL5804195,,CHEMBL5804195,8.41,0,http://www.openphacts.org/units/Nanomolar,4590608,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,1197044,28774217,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)c(F)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.90', 'le': '0.17', 'lle': '-1.85', 'sei': '4.38'}",CHEMBL5557944,,CHEMBL5557944,7.40,0,http://www.openphacts.org/units/Nanomolar,4590609,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,1197045,28774220,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2F)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.49', 'le': '0.18', 'lle': '-1.36', 'sei': '4.67'}",CHEMBL5567807,,CHEMBL5567807,7.89,0,http://www.openphacts.org/units/Nanomolar,4590610,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197047,28774226,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.27', 'le': '0.19', 'lle': '-0.51', 'sei': '5.06'}",CHEMBL5889012,,CHEMBL5889012,8.54,0,http://www.openphacts.org/units/Nanomolar,4590611,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,1197049,28774232,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(Cl)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.77', 'le': '0.19', 'lle': '-1.04', 'sei': '4.90'}",CHEMBL5834695,,CHEMBL5834695,8.28,0,http://www.openphacts.org/units/Nanomolar,4590612,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197051,28774238,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.17', 'lle': '-0.96', 'sei': '4.36'}",CHEMBL5899122,,CHEMBL5899122,7.77,0,http://www.openphacts.org/units/Nanomolar,4590613,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197053,28774244,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '-1.07', 'sei': '4.91'}",CHEMBL5967713,,CHEMBL5967713,8.28,0,http://www.openphacts.org/units/Nanomolar,4590614,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,1197055,28774250,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.08', 'le': '0.17', 'lle': '-2.10', 'sei': '4.53'}",CHEMBL5982840,,CHEMBL5982840,7.64,0,http://www.openphacts.org/units/Nanomolar,4590615,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197057,28774256,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.84', 'le': '0.19', 'lle': '-0.02', 'sei': '4.30'}",CHEMBL6006767,,CHEMBL6006767,7.25,0,http://www.openphacts.org/units/Nanomolar,4590616,=,37,1,=,,IC50,nM,,56.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,56.0
,1197058,28774259,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC1CCCCC1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.34', 'le': '0.16', 'lle': '-2.34', 'sei': '3.99'}",CHEMBL5848564,,CHEMBL5848564,6.73,0,http://www.openphacts.org/units/Nanomolar,4590617,=,37,1,=,,IC50,nM,,186.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,186.0
,1197059,28774262,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3Cc3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.29', 'le': '0.14', 'lle': '-2.95', 'sei': '3.57'}",CHEMBL5563903,,CHEMBL5563903,6.03,0,http://www.openphacts.org/units/Nanomolar,4590618,=,37,1,=,,IC50,nM,,942.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,942.0
,1197060,28774265,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cnccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.61', 'le': '0.18', 'lle': '-0.68', 'sei': '4.31'}",CHEMBL6022796,,CHEMBL6022796,7.82,0,http://www.openphacts.org/units/Nanomolar,4590619,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197062,28774271,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccnn3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.17', 'le': '0.17', 'lle': '-0.39', 'sei': '3.95'}",CHEMBL5938623,,CHEMBL5938623,7.37,0,http://www.openphacts.org/units/Nanomolar,4590620,=,37,1,=,,IC50,nM,,43.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,43.0
,1197063,28774274,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.73', 'le': '0.15', 'lle': '-3.21', 'sei': '3.88'}",CHEMBL5858367,,CHEMBL5858367,6.55,0,http://www.openphacts.org/units/Nanomolar,4590621,=,37,1,=,,IC50,nM,,283.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,283.0
,1197064,28774277,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(C2CC2)c(C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)c1,,,CHEMBL5729271,,2022,"{'bei': '8.35', 'le': '0.16', 'lle': '-2.51', 'sei': '4.09'}",CHEMBL6024224,,CHEMBL6024224,6.90,0,http://www.openphacts.org/units/Nanomolar,4590622,=,37,1,=,,IC50,nM,,125.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,125.0
,1197065,28774280,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.91', 'sei': '4.33'}",CHEMBL5828646,,CHEMBL5828646,7.31,0,http://www.openphacts.org/units/Nanomolar,4590623,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1197067,28774286,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.62', 'le': '0.17', 'lle': '-1.80', 'sei': '4.20'}",CHEMBL6057930,,CHEMBL6057930,7.08,0,http://www.openphacts.org/units/Nanomolar,4590624,=,37,1,=,,IC50,nM,,83.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,83.0
,1197068,28774289,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.55', 'le': '0.16', 'lle': '-2.03', 'sei': '4.19'}",CHEMBL5523489,,CHEMBL5523489,7.07,0,http://www.openphacts.org/units/Nanomolar,4590625,=,37,1,=,,IC50,nM,,85.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,85.0
,1197069,28774292,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3CCCN3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.87', 'le': '0.17', 'lle': '0.04', 'sei': '4.08'}",CHEMBL5919993,,CHEMBL5919993,7.02,0,http://www.openphacts.org/units/Nanomolar,4590626,=,37,1,=,,IC50,nM,,95.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,95.0
,1197070,28774295,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.34', 'le': '0.16', 'lle': '-2.03', 'sei': '4.06'}",CHEMBL5793276,,CHEMBL5793276,6.85,0,http://www.openphacts.org/units/Nanomolar,4590627,=,37,1,=,,IC50,nM,,141.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,141.0
,1197071,28774298,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(Cc2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.03', 'le': '0.17', 'lle': '-2.98', 'sei': '4.69'}",CHEMBL5839944,,CHEMBL5839944,7.77,0,http://www.openphacts.org/units/Nanomolar,4590628,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197073,28774304,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(C(=O)C3CCCN3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.93', 'le': '0.17', 'lle': '0.68', 'sei': '3.80'}",CHEMBL5783061,,CHEMBL5783061,7.19,0,http://www.openphacts.org/units/Nanomolar,4590629,=,37,1,=,,IC50,nM,,64.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,64.0
,1197074,28774307,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(CN3CCCC3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '0.43', 'sei': '4.53'}",CHEMBL5568386,,CHEMBL5568386,7.80,0,http://www.openphacts.org/units/Nanomolar,4590630,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197076,28774313,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(CN3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.92', 'le': '0.19', 'lle': '0.13', 'sei': '4.81'}",CHEMBL5564702,,CHEMBL5564702,8.28,0,http://www.openphacts.org/units/Nanomolar,4590631,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197078,28774319,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(CN3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.38', 'le': '0.20', 'lle': '0.51', 'sei': '5.03'}",CHEMBL5893602,,CHEMBL5893602,8.66,0,http://www.openphacts.org/units/Nanomolar,4590632,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,1197080,28774325,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCC[C@H]3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.53', 'le': '0.16', 'lle': '-2.05', 'sei': '4.18'}",CHEMBL5845601,,CHEMBL5845601,7.05,0,http://www.openphacts.org/units/Nanomolar,4590633,=,37,1,=,,IC50,nM,,89.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,89.0
,1197081,28774328,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '16.67', 'le': '0.30', 'lle': '1.32', 'sei': '12.20'}",CHEMBL5868833,,CHEMBL5868833,8.23,0,http://www.openphacts.org/units/Nanomolar,4590634,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197083,28774334,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.18', 'le': '0.19', 'lle': '-0.91', 'sei': '4.65'}",CHEMBL5905439,,CHEMBL5905439,7.85,0,http://www.openphacts.org/units/Nanomolar,4590635,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197085,28774340,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '15.25', 'le': '0.28', 'lle': '0.35', 'sei': '12.06'}",CHEMBL5953429,,CHEMBL5953429,8.14,0,http://www.openphacts.org/units/Nanomolar,4590636,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,1197087,28774346,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.92', 'le': '0.19', 'lle': '-0.77', 'sei': '4.80'}",CHEMBL5841782,,CHEMBL5841782,8.10,0,http://www.openphacts.org/units/Nanomolar,4590637,=,37,1,=,,IC50,nM,,7.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.9
,1197089,28774352,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccnc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.35', 'le': '0.18', 'lle': '-0.11', 'sei': '4.00'}",CHEMBL5997904,,CHEMBL5997904,7.28,0,http://www.openphacts.org/units/Nanomolar,4590638,=,37,1,=,,IC50,nM,,53.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,53.0
,1197090,28774355,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.63', 'le': '0.18', 'lle': '-0.24', 'sei': '4.51'}",CHEMBL5908012,,CHEMBL5908012,7.62,0,http://www.openphacts.org/units/Nanomolar,4590639,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,1197091,28774358,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccn3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '0.13', 'sei': '4.14'}",CHEMBL5976895,,CHEMBL5976895,7.52,0,http://www.openphacts.org/units/Nanomolar,4590640,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1197092,28774361,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3-c3ccoc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.58', 'le': '0.16', 'lle': '-2.01', 'sei': '3.98'}",CHEMBL5932525,,CHEMBL5932525,7.24,0,http://www.openphacts.org/units/Nanomolar,4590641,=,37,1,=,,IC50,nM,,58.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,58.0
,1197093,28774364,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.35', 'le': '0.18', 'lle': '-1.06', 'sei': '4.49'}",CHEMBL5936446,,CHEMBL5936446,7.58,0,http://www.openphacts.org/units/Nanomolar,4590642,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,1197095,28774370,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.89', 'le': '0.17', 'lle': '-1.50', 'sei': '4.45'}",CHEMBL5920168,,CHEMBL5920168,7.51,0,http://www.openphacts.org/units/Nanomolar,4590643,=,37,1,=,,IC50,nM,,31.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,31.0
,1197097,28774376,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4ccccc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.53', 'le': '0.16', 'lle': '-2.10', 'sei': '4.18'}",CHEMBL5815573,,CHEMBL5815573,7.05,0,http://www.openphacts.org/units/Nanomolar,4590644,=,37,1,=,,IC50,nM,,89.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,89.0
,1197098,28774379,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CC(c2ccccc2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '8.26', 'le': '0.16', 'lle': '-1.98', 'sei': '3.94'}",CHEMBL5910978,,CHEMBL5910978,6.65,0,http://www.openphacts.org/units/Nanomolar,4590645,=,37,1,=,,IC50,nM,,226.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,226.0
,1197099,28774382,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.40', 'le': '0.17', 'lle': '-2.19', 'sei': '4.21'}",CHEMBL5791810,,CHEMBL5791810,7.11,0,http://www.openphacts.org/units/Nanomolar,4590646,=,37,1,=,,IC50,nM,,78.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,78.0
,1197100,28774385,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.46', 'le': '0.18', 'lle': '-1.21', 'sei': '4.59'}",CHEMBL5756431,,CHEMBL5756431,7.75,0,http://www.openphacts.org/units/Nanomolar,4590647,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197102,28774391,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3-c3cccs3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.39', 'le': '0.16', 'lle': '-2.51', 'sei': '4.27'}",CHEMBL5741586,,CHEMBL5741586,7.21,0,http://www.openphacts.org/units/Nanomolar,4590648,=,37,1,=,,IC50,nM,,62.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,62.0
,1197103,28774394,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.36', 'le': '0.16', 'lle': '-2.34', 'sei': '4.29'}",CHEMBL5954289,,CHEMBL5954289,7.24,0,http://www.openphacts.org/units/Nanomolar,4590649,=,37,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
,1197105,28774400,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccncc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.88', 'le': '0.17', 'lle': '-0.48', 'sei': '3.80'}",CHEMBL5998503,,CHEMBL5998503,6.91,0,http://www.openphacts.org/units/Nanomolar,4590650,=,37,1,=,,IC50,nM,,124.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,124.0
,1197106,28774403,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-1.44', 'sei': '4.55'}",CHEMBL6016863,,CHEMBL6016863,7.68,0,http://www.openphacts.org/units/Nanomolar,4590651,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,1197108,28774409,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.24', 'le': '0.17', 'lle': '-1.48', 'sei': '4.47'}",CHEMBL5875766,,CHEMBL5875766,7.55,0,http://www.openphacts.org/units/Nanomolar,4590652,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,1197110,28774415,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.78', 'le': '0.17', 'lle': '-1.88', 'sei': '4.33'}",CHEMBL5857178,,CHEMBL5857178,7.31,0,http://www.openphacts.org/units/Nanomolar,4590653,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1197111,28774418,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3CC3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.69', 'le': '0.16', 'lle': '-1.73', 'sei': '4.28'}",CHEMBL5748708,,CHEMBL5748708,7.22,0,http://www.openphacts.org/units/Nanomolar,4590654,=,37,1,=,,IC50,nM,,60.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,60.0
,1197112,28774421,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,N#C[C@H]1C[C@H]1c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.12', 'le': '0.19', 'lle': '-0.10', 'sei': '4.43'}",CHEMBL5982871,,CHEMBL5982871,8.52,0,http://www.openphacts.org/units/Nanomolar,4590655,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,1197114,28774427,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,N#C[C@H]1C[C@@H]1c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.14', 'le': '0.17', 'lle': '-0.92', 'sei': '4.00'}",CHEMBL5826225,,CHEMBL5826225,7.70,0,http://www.openphacts.org/units/Nanomolar,4590656,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197116,28774433,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3[C@H]3CC3(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.79', 'le': '0.17', 'lle': '-1.63', 'sei': '4.44'}",CHEMBL5869282,,CHEMBL5869282,7.50,0,http://www.openphacts.org/units/Nanomolar,4590657,=,37,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,1197118,28774439,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3[C@@H]3CC3(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.45', 'le': '0.16', 'lle': '-1.91', 'sei': '4.27'}",CHEMBL5890286,,CHEMBL5890286,7.21,0,http://www.openphacts.org/units/Nanomolar,4590658,=,37,1,=,,IC50,nM,,62.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,62.0
,1197119,28774442,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.07', 'le': '0.17', 'lle': '-1.72', 'sei': '4.47'}",CHEMBL5834233,,CHEMBL5834233,7.54,0,http://www.openphacts.org/units/Nanomolar,4590659,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197121,28774448,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.34', 'le': '0.20', 'lle': '0.42', 'sei': '4.93'}",CHEMBL6006213,,CHEMBL6006213,8.48,0,http://www.openphacts.org/units/Nanomolar,4590660,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197123,28774454,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.76', 'le': '0.17', 'lle': '-1.21', 'sei': '4.15'}",CHEMBL5957647,,CHEMBL5957647,7.39,0,http://www.openphacts.org/units/Nanomolar,4590661,=,37,1,=,,IC50,nM,,41.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.0
,1197125,28774460,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.47', 'le': '0.16', 'lle': '-1.60', 'sei': '4.10'}",CHEMBL5874645,,CHEMBL5874645,7.29,0,http://www.openphacts.org/units/Nanomolar,4590662,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,1197126,28774463,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCOc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.25', 'le': '0.18', 'lle': '-1.06', 'sei': '4.34'}",CHEMBL6063832,,CHEMBL6063832,7.72,0,http://www.openphacts.org/units/Nanomolar,4590663,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197128,28774469,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCOc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.23', 'le': '0.18', 'lle': '-0.17', 'sei': '4.19'}",CHEMBL5780526,,CHEMBL5780526,7.85,0,http://www.openphacts.org/units/Nanomolar,4590664,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197130,28774475,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Oc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.86', 'sei': '4.45'}",CHEMBL6059936,,CHEMBL6059936,7.92,0,http://www.openphacts.org/units/Nanomolar,4590665,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197132,28774481,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3OC3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.30', 'le': '0.18', 'lle': '-0.79', 'sei': '4.35'}",CHEMBL5971182,,CHEMBL5971182,7.75,0,http://www.openphacts.org/units/Nanomolar,4590666,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197134,28774487,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.60', 'le': '0.17', 'lle': '-2.20', 'sei': '4.34'}",CHEMBL5983625,,CHEMBL5983625,7.32,0,http://www.openphacts.org/units/Nanomolar,4590667,=,37,1,=,,IC50,nM,,48.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,48.0
,1197135,28774490,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(C)c1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.35', 'le': '0.18', 'lle': '-1.09', 'sei': '4.46'}",CHEMBL5955049,,CHEMBL5955049,7.52,0,http://www.openphacts.org/units/Nanomolar,4590668,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1197137,28774496,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(F)c3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.02', 'le': '0.16', 'lle': '-2.14', 'sei': '3.94'}",CHEMBL5862498,,CHEMBL5862498,6.65,0,http://www.openphacts.org/units/Nanomolar,4590669,=,37,1,=,,IC50,nM,,222.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,222.0
,1197138,28774499,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.20', 'le': '0.16', 'lle': '-2.37', 'sei': '4.11'}",CHEMBL6018319,,CHEMBL6018319,6.93,0,http://www.openphacts.org/units/Nanomolar,4590670,=,37,1,=,,IC50,nM,,117.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,117.0
,1197139,28774502,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.18', 'lle': '-1.67', 'sei': '4.65'}",CHEMBL5833010,,CHEMBL5833010,7.85,0,http://www.openphacts.org/units/Nanomolar,4590671,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197141,28774508,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(F)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.43', 'le': '0.16', 'lle': '-1.97', 'sei': '4.17'}",CHEMBL5835008,,CHEMBL5835008,7.04,0,http://www.openphacts.org/units/Nanomolar,4590672,=,37,1,=,,IC50,nM,,92.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,92.0
,1197143,28774514,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(F)cc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.15', 'le': '0.17', 'lle': '-1.37', 'sei': '4.53'}",CHEMBL5969360,,CHEMBL5969360,7.64,0,http://www.openphacts.org/units/Nanomolar,4590673,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197144,28774517,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(F)ccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.85', 'le': '0.17', 'lle': '-1.62', 'sei': '4.38'}",CHEMBL5862976,,CHEMBL5862976,7.39,0,http://www.openphacts.org/units/Nanomolar,4590674,=,37,1,=,,IC50,nM,,41.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,41.0
,1197146,28774523,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(F)cccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.49', 'le': '0.18', 'lle': '-1.09', 'sei': '4.69'}",CHEMBL5932341,,CHEMBL5932341,7.92,0,http://www.openphacts.org/units/Nanomolar,4590675,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197148,28774529,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3sccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.14', 'le': '0.18', 'lle': '-1.41', 'sei': '4.46'}",CHEMBL6063626,,CHEMBL6063626,7.52,0,http://www.openphacts.org/units/Nanomolar,4590676,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1197150,28774535,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C3CCCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.39', 'le': '0.20', 'lle': '-0.06', 'sei': '4.82'}",CHEMBL5901849,,CHEMBL5901849,8.14,0,http://www.openphacts.org/units/Nanomolar,4590677,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,1197152,28774541,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4ccsc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.20', 'le': '0.16', 'lle': '-2.38', 'sei': '4.05'}",CHEMBL5928106,,CHEMBL5928106,6.83,0,http://www.openphacts.org/units/Nanomolar,4590678,=,37,1,=,,IC50,nM,,147.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,147.0
,1197153,28774544,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C#Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.94', 'le': '0.17', 'lle': '-0.51', 'sei': '4.24'}",CHEMBL6057270,,CHEMBL6057270,7.16,0,http://www.openphacts.org/units/Nanomolar,4590679,=,37,1,=,,IC50,nM,,69.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,69.0
,1197154,28774547,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCNCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.13', 'le': '0.17', 'lle': '-0.61', 'sei': '4.34'}",CHEMBL5940828,,CHEMBL5940828,7.85,0,http://www.openphacts.org/units/Nanomolar,4590680,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197156,28774553,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3Oc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.01', 'le': '0.15', 'lle': '-2.83', 'sei': '3.91'}",CHEMBL5968888,,CHEMBL5968888,6.96,0,http://www.openphacts.org/units/Nanomolar,4590681,=,37,1,=,,IC50,nM,,110.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,110.0
,1197157,28774556,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '8.92', 'le': '0.17', 'lle': '-1.33', 'sei': '4.24'}",CHEMBL5740413,,CHEMBL5740413,7.55,0,http://www.openphacts.org/units/Nanomolar,4590682,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,1197159,28774562,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC=CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '-0.91', 'sei': '4.59'}",CHEMBL5854884,,CHEMBL5854884,7.75,0,http://www.openphacts.org/units/Nanomolar,4590683,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197161,28774568,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3Cc4ccccc4C3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.11', 'le': '0.15', 'lle': '-2.62', 'sei': '4.16'}",CHEMBL5967423,,CHEMBL5967423,7.02,0,http://www.openphacts.org/units/Nanomolar,4590684,=,37,1,=,,IC50,nM,,96.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,96.0
,1197163,28774574,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(O)CC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.04', 'le': '0.19', 'lle': '1.00', 'sei': '4.21'}",CHEMBL5935001,,CHEMBL5935001,7.96,0,http://www.openphacts.org/units/Nanomolar,4590685,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,1197165,28774580,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@@H]1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.09', 'le': '0.17', 'lle': '-0.80', 'sei': '4.32'}",CHEMBL6007118,,CHEMBL6007118,7.70,0,http://www.openphacts.org/units/Nanomolar,4590686,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197167,28774586,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@H]1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '8.96', 'le': '0.17', 'lle': '-0.91', 'sei': '4.26'}",CHEMBL5992113,,CHEMBL5992113,7.58,0,http://www.openphacts.org/units/Nanomolar,4590687,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,1197169,28774592,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(F)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-1.00', 'sei': '4.64'}",CHEMBL5795683,,CHEMBL5795683,7.82,0,http://www.openphacts.org/units/Nanomolar,4590688,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197171,28774598,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(F)(F)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.44', 'le': '0.16', 'lle': '-1.92', 'sei': '4.27'}",CHEMBL5947397,,CHEMBL5947397,7.20,0,http://www.openphacts.org/units/Nanomolar,4590689,=,37,1,=,,IC50,nM,,63.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,63.0
,1197173,28774604,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.26', 'le': '0.19', 'lle': '0.22', 'sei': '4.64'}",CHEMBL5999290,,CHEMBL5999290,7.82,0,http://www.openphacts.org/units/Nanomolar,4590690,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197175,28774610,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3Cc3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.78', 'sei': '4.72'}",CHEMBL5775752,,CHEMBL5775752,7.96,0,http://www.openphacts.org/units/Nanomolar,4590691,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,1197177,28774616,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.97', 'le': '0.19', 'lle': '-0.41', 'sei': '4.67'}",CHEMBL5791517,,CHEMBL5791517,7.89,0,http://www.openphacts.org/units/Nanomolar,4590692,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197179,28774622,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.47', 'le': '0.20', 'lle': '-0.13', 'sei': '5.00'}",CHEMBL6010468,,CHEMBL6010468,8.43,0,http://www.openphacts.org/units/Nanomolar,4590693,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,1197181,28774628,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C=Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.86', 'le': '0.19', 'lle': '-0.72', 'sei': '4.69'}",CHEMBL5830005,,CHEMBL5830005,7.92,0,http://www.openphacts.org/units/Nanomolar,4590694,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197183,28774634,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(F)cc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.73', 'le': '0.17', 'lle': '-1.55', 'sei': '4.29'}",CHEMBL5819835,,CHEMBL5819835,7.24,0,http://www.openphacts.org/units/Nanomolar,4590695,=,37,1,=,,IC50,nM,,58.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,58.0
,1197184,28774637,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3c(Cl)cccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.90', 'le': '0.17', 'lle': '-2.37', 'sei': '4.17'}",CHEMBL5820024,,CHEMBL5820024,7.04,0,http://www.openphacts.org/units/Nanomolar,4590696,=,37,1,=,,IC50,nM,,92.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,92.0
,1197185,28774640,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3C3CCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.04', 'le': '0.19', 'lle': '-0.09', 'sei': '4.57'}",CHEMBL5848464,,CHEMBL5848464,7.72,0,http://www.openphacts.org/units/Nanomolar,4590697,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197187,28774646,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.76', 'le': '0.17', 'lle': '-2.04', 'sei': '4.33'}",CHEMBL5898424,,CHEMBL5898424,7.30,0,http://www.openphacts.org/units/Nanomolar,4590698,=,37,1,=,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1197189,28774652,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Oc1ccc(Br)cc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '6.70', 'le': '0.14', 'lle': '-3.42', 'sei': '3.44'}",CHEMBL6007921,,CHEMBL6007921,6.12,0,http://www.openphacts.org/units/Nanomolar,4590699,=,37,1,=,,IC50,nM,,756.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,756.0
,1197190,28774655,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '10.19', 'le': '0.19', 'lle': '-0.24', 'sei': '4.78'}",CHEMBL6020371,,CHEMBL6020371,8.06,0,http://www.openphacts.org/units/Nanomolar,4590700,=,37,1,=,,IC50,nM,,8.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.7
,1197192,28774661,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.72', 'le': '0.18', 'lle': '-1.16', 'sei': '4.72'}",CHEMBL6011371,,CHEMBL6011371,7.96,0,http://www.openphacts.org/units/Nanomolar,4590701,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,1197194,28774667,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.66', 'le': '0.18', 'lle': '-0.20', 'sei': '4.38'}",CHEMBL5794713,,CHEMBL5794713,7.80,0,http://www.openphacts.org/units/Nanomolar,4590702,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197196,28774673,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '8.43', 'le': '0.16', 'lle': '-1.11', 'sei': '3.51'}",CHEMBL6034421,,CHEMBL6034421,6.76,0,http://www.openphacts.org/units/Nanomolar,4590703,=,37,1,=,,IC50,nM,,174.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,174.0
,1197197,28774676,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C=Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.41', 'le': '0.18', 'lle': '-1.09', 'sei': '4.47'}",CHEMBL5876206,,CHEMBL5876206,7.55,0,http://www.openphacts.org/units/Nanomolar,4590704,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,1197199,28774682,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4c3OCO4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.18', 'lle': '-0.15', 'sei': '4.04'}",CHEMBL5787141,,CHEMBL5787141,7.57,0,http://www.openphacts.org/units/Nanomolar,4590705,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197201,28774688,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc4c3OC(F)(F)O4)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.02', 'le': '0.15', 'lle': '-1.45', 'sei': '3.67'}",CHEMBL5879749,,CHEMBL5879749,6.87,0,http://www.openphacts.org/units/Nanomolar,4590706,=,37,1,=,,IC50,nM,,135.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,135.0
,1197202,28774691,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.45', 'le': '0.18', 'lle': '-1.27', 'sei': '4.65'}",CHEMBL5861984,,CHEMBL5861984,7.85,0,http://www.openphacts.org/units/Nanomolar,4590707,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197204,28774697,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '8.84', 'le': '0.17', 'lle': '-2.04', 'sei': '4.42'}",CHEMBL5980151,,CHEMBL5980151,7.47,0,http://www.openphacts.org/units/Nanomolar,4590708,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,1197206,28774703,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(Cl)cc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.49', 'le': '0.16', 'lle': '-2.29', 'sei': '4.28'}",CHEMBL5892515,,CHEMBL5892515,7.23,0,http://www.openphacts.org/units/Nanomolar,4590709,=,37,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,59.0
,1197207,28774706,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(Cl)ccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.34', 'le': '0.16', 'lle': '-2.42', 'sei': '4.20'}",CHEMBL6021718,,CHEMBL6021718,7.10,0,http://www.openphacts.org/units/Nanomolar,4590710,=,37,1,=,,IC50,nM,,80.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,80.0
,1197208,28774709,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(F)(F)c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.74', 'le': '0.17', 'lle': '-1.76', 'sei': '4.35'}",CHEMBL5748367,,CHEMBL5748367,7.35,0,http://www.openphacts.org/units/Nanomolar,4590711,=,37,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,45.0
,1197209,28774712,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3CC(F)(F)F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.27', 'le': '0.16', 'lle': '-2.00', 'sei': '4.21'}",CHEMBL5814085,,CHEMBL5814085,7.10,0,http://www.openphacts.org/units/Nanomolar,4590712,=,37,1,=,,IC50,nM,,79.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,79.0
,1197210,28774715,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CCCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.32', 'le': '0.16', 'lle': '-2.62', 'sei': '4.17'}",CHEMBL5912154,,CHEMBL5912154,7.03,0,http://www.openphacts.org/units/Nanomolar,4590713,=,37,1,=,,IC50,nM,,93.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,93.0
,1197211,28774718,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)Oc2cccc(C3CCCN3C3CC=C(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)c2O1,,,CHEMBL5729271,,2022,"{'bei': '8.59', 'le': '0.16', 'lle': '-1.21', 'sei': '3.89'}",CHEMBL5967521,,CHEMBL5967521,7.29,0,http://www.openphacts.org/units/Nanomolar,4590714,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,1197212,28774721,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C#Cc1cccc(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '8.80', 'le': '0.17', 'lle': '-0.92', 'sei': '4.17'}",CHEMBL5843645,,CHEMBL5843645,7.05,0,http://www.openphacts.org/units/Nanomolar,4590715,=,37,1,=,,IC50,nM,,90.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,90.0
,1197213,28774724,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,N#CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.26', 'le': '0.17', 'lle': '-0.82', 'sei': '4.05'}",CHEMBL5823455,,CHEMBL5823455,7.80,0,http://www.openphacts.org/units/Nanomolar,4590716,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197215,28774730,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C#CC1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.13', 'le': '0.17', 'lle': '-1.05', 'sei': '4.55'}",CHEMBL6063904,,CHEMBL6063904,7.68,0,http://www.openphacts.org/units/Nanomolar,4590717,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,1197217,28774736,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.13', 'le': '0.19', 'lle': '0.17', 'sei': '4.59'}",CHEMBL6037680,,CHEMBL6037680,8.17,0,http://www.openphacts.org/units/Nanomolar,4590718,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,1197219,28774742,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3csc4ccccc34)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.57', 'le': '0.17', 'lle': '-2.07', 'sei': '4.23'}",CHEMBL6058162,,CHEMBL6058162,7.14,0,http://www.openphacts.org/units/Nanomolar,4590719,=,37,1,=,,IC50,nM,,72.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,72.0
,1197220,28774745,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC(c4ccccc4Cl)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.67', 'le': '0.17', 'lle': '-1.26', 'sei': '4.17'}",CHEMBL5758771,,CHEMBL5758771,7.04,0,http://www.openphacts.org/units/Nanomolar,4590720,=,37,1,=,,IC50,nM,,92.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,92.0
,1197221,28774748,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)ccc3F)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.31', 'le': '0.18', 'lle': '-1.24', 'sei': '4.60'}",CHEMBL5747296,,CHEMBL5747296,7.77,0,http://www.openphacts.org/units/Nanomolar,4590721,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197223,28774754,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)ccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.56', 'le': '0.17', 'lle': '-2.24', 'sei': '4.32'}",CHEMBL5770314,,CHEMBL5770314,7.28,0,http://www.openphacts.org/units/Nanomolar,4590722,=,37,1,=,,IC50,nM,,52.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,52.0
,1197224,28774757,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.86', 'le': '0.19', 'lle': '-0.99', 'sei': '4.85'}",CHEMBL6033879,,CHEMBL6033879,8.19,0,http://www.openphacts.org/units/Nanomolar,4590723,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,1197226,28774763,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCN(C)c1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '8.53', 'le': '0.16', 'lle': '-1.05', 'sei': '4.46'}",CHEMBL5743310,,CHEMBL5743310,7.82,0,http://www.openphacts.org/units/Nanomolar,4590724,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197228,28774769,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCNc1ccc(C2CC2)c(C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)c1,,,CHEMBL5729271,,2022,"{'bei': '9.17', 'le': '0.17', 'lle': '-0.56', 'sei': '4.50'}",CHEMBL5934655,,CHEMBL5934655,8.28,0,http://www.openphacts.org/units/Nanomolar,4590725,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,1197230,28774775,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC/C=C/c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.32', 'le': '0.16', 'lle': '-2.50', 'sei': '4.10'}",CHEMBL5805896,,CHEMBL5805896,6.92,0,http://www.openphacts.org/units/Nanomolar,4590726,=,37,1,=,,IC50,nM,,121.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,121.0
,1197231,28774778,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(c1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1)C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.03', 'le': '0.17', 'lle': '-0.95', 'sei': '4.44'}",CHEMBL5965178,,CHEMBL5965178,7.64,0,http://www.openphacts.org/units/Nanomolar,4590727,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197233,28774784,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.83', 'le': '0.17', 'lle': '-1.01', 'sei': '4.48'}",CHEMBL5781330,,CHEMBL5781330,7.70,0,http://www.openphacts.org/units/Nanomolar,4590728,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197235,28774790,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CC=C(c2ccccc2C2CCCN2C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.23', 'le': '0.16', 'lle': '-1.22', 'sei': '3.92'}",CHEMBL6064593,,CHEMBL6064593,7.41,0,http://www.openphacts.org/units/Nanomolar,4590729,=,37,1,=,,IC50,nM,,39.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,39.0
,1197236,28774793,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc(C4CC4)cs3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.20', 'le': '0.18', 'lle': '-1.36', 'sei': '4.48'}",CHEMBL6049964,,CHEMBL6049964,7.57,0,http://www.openphacts.org/units/Nanomolar,4590730,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197238,28774799,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccn(C4CC4)n3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.69', 'le': '0.17', 'lle': '-0.52', 'sei': '3.76'}",CHEMBL5881143,,CHEMBL5881143,7.01,0,http://www.openphacts.org/units/Nanomolar,4590731,=,37,1,=,,IC50,nM,,97.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,97.0
,1197239,28774802,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC(Cl)CC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.74', 'le': '0.17', 'lle': '-1.65', 'sei': '4.41'}",CHEMBL5766474,,CHEMBL5766474,7.44,0,http://www.openphacts.org/units/Nanomolar,4590732,=,37,1,=,,IC50,nM,,36.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.0
,1197241,28774808,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C1CC(c2ccccc2C2CC2)N(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.21', 'le': '0.17', 'lle': '-1.40', 'sei': '4.53'}",CHEMBL6026974,,CHEMBL6026974,7.64,0,http://www.openphacts.org/units/Nanomolar,4590733,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197243,28774814,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CC4CCCC4C3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.57', 'le': '0.16', 'lle': '-2.16', 'sei': '4.35'}",CHEMBL5816689,,CHEMBL5816689,7.35,0,http://www.openphacts.org/units/Nanomolar,4590734,=,37,1,=,,IC50,nM,,45.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,45.0
,1197244,28774817,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3Cc4ccccc4C3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.06', 'le': '0.15', 'lle': '-2.11', 'sei': '3.94'}",CHEMBL5947024,,CHEMBL5947024,6.65,0,http://www.openphacts.org/units/Nanomolar,4590735,=,37,1,=,,IC50,nM,,226.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,226.0
,1197245,28774820,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(c1ccccc1C1CC1)C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '-0.56', 'sei': '4.68'}",CHEMBL5874403,,CHEMBL5874403,8.33,0,http://www.openphacts.org/units/Nanomolar,4590736,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,1197247,28774826,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1CC1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.39', 'le': '0.18', 'lle': '-1.17', 'sei': '4.64'}",CHEMBL6031098,,CHEMBL6031098,7.82,0,http://www.openphacts.org/units/Nanomolar,4590737,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197249,28774832,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC(c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.52', 'le': '0.16', 'lle': '-1.56', 'sei': '4.12'}",CHEMBL5809113,,CHEMBL5809113,6.96,0,http://www.openphacts.org/units/Nanomolar,4590738,=,37,1,=,,IC50,nM,,109.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,109.0
,1197250,28774835,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '8.56', 'le': '0.16', 'lle': '-1.76', 'sei': '4.15'}",CHEMBL6056722,,CHEMBL6056722,7.01,0,http://www.openphacts.org/units/Nanomolar,4590739,=,37,1,=,,IC50,nM,,98.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,98.0
,1197251,28774838,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCN(C2CC=C(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '8.81', 'le': '0.17', 'lle': '-1.56', 'sei': '4.27'}",CHEMBL5796449,,CHEMBL5796449,7.21,0,http://www.openphacts.org/units/Nanomolar,4590740,=,37,1,=,,IC50,nM,,61.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,61.0
,1197252,28774841,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(F)cccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.32', 'le': '0.18', 'lle': '-0.90', 'sei': '4.47'}",CHEMBL5910758,,CHEMBL5910758,7.54,0,http://www.openphacts.org/units/Nanomolar,4590741,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197253,28774844,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)=Cc1ccccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.72', 'le': '0.16', 'lle': '-2.18', 'sei': '4.29'}",CHEMBL5779029,,CHEMBL5779029,7.24,0,http://www.openphacts.org/units/Nanomolar,4590742,=,37,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
,1197254,28774847,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cc4ccccc4s3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.44', 'le': '0.16', 'lle': '-2.18', 'sei': '4.17'}",CHEMBL5896435,,CHEMBL5896435,7.03,0,http://www.openphacts.org/units/Nanomolar,4590743,=,37,1,=,,IC50,nM,,93.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,93.0
,1197255,28774850,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.40', 'le': '0.18', 'lle': '-1.19', 'sei': '4.55'}",CHEMBL6058975,,CHEMBL6058975,7.68,0,http://www.openphacts.org/units/Nanomolar,4590744,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,1197257,28774856,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCCC1C2CCCC2CN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.69', 'le': '0.19', 'lle': '-0.73', 'sei': '4.57'}",CHEMBL5854462,,CHEMBL5854462,7.72,0,http://www.openphacts.org/units/Nanomolar,4590745,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197259,28774862,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(Cl)cccc1C1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.74', 'le': '0.17', 'lle': '-1.75', 'sei': '4.27'}",CHEMBL5874610,,CHEMBL5874610,7.21,0,http://www.openphacts.org/units/Nanomolar,4590746,=,37,1,=,,IC50,nM,,61.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,61.0
,1197260,28774865,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3=CCNCC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.00', 'le': '0.17', 'lle': '-0.65', 'sei': '4.27'}",CHEMBL6007862,,CHEMBL6007862,7.72,0,http://www.openphacts.org/units/Nanomolar,4590747,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197261,28774868,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.78', 'le': '0.13', 'lle': '-3.23', 'sei': '3.27'}",CHEMBL5766318,,CHEMBL5766318,5.51,0,http://www.openphacts.org/units/Nanomolar,4590748,=,37,1,=,,IC50,nM,,3080.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3080.0
,1197262,28774871,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.31', 'le': '0.18', 'lle': '-1.17', 'sei': '4.48'}",CHEMBL5766318,,CHEMBL5766318,7.57,0,http://www.openphacts.org/units/Nanomolar,4590749,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197264,28774877,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.40', 'le': '0.14', 'lle': '-2.90', 'sei': '3.59'}",CHEMBL6043986,,CHEMBL6043986,6.06,0,http://www.openphacts.org/units/Nanomolar,4590750,=,37,1,=,,IC50,nM,,862.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,862.0
,1197265,28774880,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.00', 'le': '0.19', 'lle': '-0.77', 'sei': '4.85'}",CHEMBL6009632,,CHEMBL6009632,8.19,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,1197267,28774886,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.67', 'le': '0.15', 'lle': '-2.68', 'sei': '3.72'}",CHEMBL6009632,,CHEMBL6009632,6.28,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,520.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,520.0
,1197268,28774889,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.56', 'sei': '4.98'}",CHEMBL6009632,,CHEMBL6009632,8.40,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,1197270,28774895,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.32', 'le': '0.14', 'lle': '-2.97', 'sei': '3.55'}",CHEMBL6043986,,CHEMBL6043986,5.99,0,http://www.openphacts.org/units/Nanomolar,4590750,=,37,1,=,,IC50,nM,,1016.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1016.0
,1197271,28774898,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '-1.04', 'sei': '4.69'}",CHEMBL6009632,,CHEMBL6009632,7.92,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197273,28774904,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.40', 'le': '0.14', 'lle': '-2.90', 'sei': '3.59'}",CHEMBL5869985,,CHEMBL5869985,6.06,0,http://www.openphacts.org/units/Nanomolar,4590752,=,37,1,=,,IC50,nM,,865.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,865.0
,1197274,28774907,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.56', 'sei': '4.98'}",CHEMBL6059159,,CHEMBL6059159,8.40,0,http://www.openphacts.org/units/Nanomolar,4590753,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,1197276,28774913,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.86', 'le': '0.13', 'lle': '-3.34', 'sei': '3.33'}",CHEMBL5830611,,CHEMBL5830611,5.62,0,http://www.openphacts.org/units/Nanomolar,4590754,=,37,1,=,,IC50,nM,,2418.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2418.0
,1197277,28774916,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.55', 'le': '0.18', 'lle': '-1.14', 'sei': '4.64'}",CHEMBL5924557,,CHEMBL5924557,7.82,0,http://www.openphacts.org/units/Nanomolar,4590755,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197279,28774922,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.65', 'le': '0.18', 'lle': '-1.29', 'sei': '4.69'}",CHEMBL5881653,,CHEMBL5881653,7.92,0,http://www.openphacts.org/units/Nanomolar,4590756,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197280,28774925,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C(C)c1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.43', 'le': '0.18', 'lle': '-1.40', 'sei': '4.57'}",CHEMBL5995096,,CHEMBL5995096,7.72,0,http://www.openphacts.org/units/Nanomolar,4590757,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197282,28774931,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.66', 'le': '0.13', 'lle': '-3.33', 'sei': '3.21'}",CHEMBL5776977,,CHEMBL5776977,5.42,0,http://www.openphacts.org/units/Nanomolar,4590758,=,37,1,=,,IC50,nM,,3846.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3846.0
,1197283,28774934,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.41', 'le': '0.18', 'lle': '-1.08', 'sei': '4.54'}",CHEMBL5867556,,CHEMBL5867556,7.66,0,http://www.openphacts.org/units/Nanomolar,4590759,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,1197284,28774937,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '6.96', 'le': '0.14', 'lle': '-3.08', 'sei': '3.35'}",CHEMBL5788044,,CHEMBL5788044,5.66,0,http://www.openphacts.org/units/Nanomolar,4590760,=,37,1,=,,IC50,nM,,2181.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2181.0
,1197285,28774940,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.39', 'le': '0.18', 'lle': '-1.10', 'sei': '4.53'}",CHEMBL5976482,,CHEMBL5976482,7.64,0,http://www.openphacts.org/units/Nanomolar,4590761,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197287,28774946,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@@H]3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.31', 'le': '0.14', 'lle': '-2.39', 'sei': '3.37'}",CHEMBL5774475,,CHEMBL5774475,5.70,0,http://www.openphacts.org/units/Nanomolar,4590762,=,37,1,=,,IC50,nM,,2020.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2020.0
,1197288,28774949,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.17', 'le': '0.19', 'lle': '-0.16', 'sei': '4.69'}",CHEMBL5818476,,CHEMBL5818476,7.92,0,http://www.openphacts.org/units/Nanomolar,4590763,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197290,28774955,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.38', 'le': '0.20', 'lle': '-0.16', 'sei': '4.88'}",CHEMBL5902426,,CHEMBL5902426,8.23,0,http://www.openphacts.org/units/Nanomolar,4590764,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197292,28774961,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@H]1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '7.68', 'le': '0.15', 'lle': '-2.45', 'sei': '3.67'}",CHEMBL5801811,,CHEMBL5801811,6.20,0,http://www.openphacts.org/units/Nanomolar,4590765,=,37,1,=,,IC50,nM,,631.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,631.0
,1197293,28774964,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.41', 'le': '0.20', 'lle': '-0.25', 'sei': '4.98'}",CHEMBL5996455,,CHEMBL5996455,8.40,0,http://www.openphacts.org/units/Nanomolar,4590766,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,1197295,28774970,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC(c4cccc(Cl)c4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5819969,,CHEMBL5819969,,0,http://www.openphacts.org/units/Nanomolar,4590767,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197296,28774973,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Oc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.00', 'le': '0.15', 'lle': '-2.91', 'sei': '3.92'}",CHEMBL5765475,,CHEMBL5765475,6.97,0,http://www.openphacts.org/units/Nanomolar,4590768,=,37,1,=,,IC50,nM,,107.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,107.0
,1197297,28774976,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3/C=C/c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.50', 'le': '0.16', 'lle': '-2.12', 'sei': '4.25'}",CHEMBL5977830,,CHEMBL5977830,7.18,0,http://www.openphacts.org/units/Nanomolar,4590769,=,37,1,=,,IC50,nM,,66.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,66.0
,1197298,28774979,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3/C=C/c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.25', 'le': '0.18', 'lle': '-0.98', 'sei': '4.41'}",CHEMBL5975953,,CHEMBL5975953,7.44,0,http://www.openphacts.org/units/Nanomolar,4590770,=,37,1,=,,IC50,nM,,36.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.0
,1197300,28774985,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1C1CCCN1C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.10', 'le': '0.19', 'lle': '0.08', 'sei': '4.59'}",CHEMBL5767470,,CHEMBL5767470,8.17,0,http://www.openphacts.org/units/Nanomolar,4590771,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,1197302,28774991,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N(Cc3ccccc3)Cc3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.16', 'le': '0.14', 'lle': '-3.01', 'sei': '3.52'}",CHEMBL6024819,,CHEMBL6024819,5.94,0,http://www.openphacts.org/units/Nanomolar,4590772,=,37,1,=,,IC50,nM,,1150.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1150.0
,1197303,28774994,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(NC(c3ccccc3)c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5906171,,CHEMBL5906171,,0,http://www.openphacts.org/units/Nanomolar,4590773,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197304,28774997,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@H](c1ccccc1)N(C)C1CCC(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,,CHEMBL5765082,,CHEMBL5765082,,0,http://www.openphacts.org/units/Nanomolar,4590774,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197305,28775000,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)OC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3)nc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '13.64', 'le': '0.25', 'lle': '-0.44', 'sei': '9.05'}",CHEMBL6025905,,CHEMBL6025905,7.27,0,http://www.openphacts.org/units/Nanomolar,4590775,=,37,1,=,,IC50,nM,,54.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,54.0
,1197306,28775003,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.87', 'le': '0.19', 'lle': '0.67', 'sei': '4.48'}",CHEMBL5943875,,CHEMBL5943875,7.70,0,http://www.openphacts.org/units/Nanomolar,4590776,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197308,28775009,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.57', 'le': '0.19', 'lle': '0.12', 'sei': '4.53'}",CHEMBL6048355,,CHEMBL6048355,7.80,0,http://www.openphacts.org/units/Nanomolar,4590777,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197310,28775015,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.61', 'le': '0.19', 'lle': '0.14', 'sei': '4.55'}",CHEMBL5984992,,CHEMBL5984992,7.82,0,http://www.openphacts.org/units/Nanomolar,4590778,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197311,28775018,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.93', 'le': '0.19', 'lle': '0.24', 'sei': '4.73'}",CHEMBL5566724,,CHEMBL5566724,8.14,0,http://www.openphacts.org/units/Nanomolar,4590779,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,1197313,28775024,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cn2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.03', 'le': '0.19', 'lle': '-0.33', 'sei': '4.50'}",CHEMBL5532350,,CHEMBL5532350,8.17,0,http://www.openphacts.org/units/Nanomolar,4590780,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,1197315,28775030,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3nc(N4CCCC4c4ccccc4)ccn3n2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.98', 'le': '0.17', 'lle': '0.04', 'sei': '3.67'}",CHEMBL5919132,,CHEMBL5919132,7.31,0,http://www.openphacts.org/units/Nanomolar,4590781,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1197316,28775033,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3cc(N4CCCC4c4ccccc4)ccc3s2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.39', 'le': '0.14', 'lle': '-3.32', 'sei': '3.63'}",CHEMBL6060414,,CHEMBL6060414,6.12,0,http://www.openphacts.org/units/Nanomolar,4590782,=,37,1,=,,IC50,nM,,755.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,755.0
,1197317,28775036,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3cc(N4CCC[C@@H]4c4ccccc4)ccc3s2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.32', 'le': '0.20', 'lle': '-0.89', 'sei': '5.07'}",CHEMBL5742800,,CHEMBL5742800,8.55,0,http://www.openphacts.org/units/Nanomolar,4590783,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,1197319,28775042,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(OC2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.43', 'le': '0.16', 'lle': '-1.59', 'sei': '3.96'}",CHEMBL5893176,,CHEMBL5893176,7.04,0,http://www.openphacts.org/units/Nanomolar,4590784,=,37,1,=,,IC50,nM,,91.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,91.0
,1197320,28775045,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(c1ccc(C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)c(Oc2cnc3[nH]ccc3c2)c1)C1CCC(N2CCCC2c2ccccc2C2CC2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.76', 'le': '0.17', 'lle': '-1.25', 'sei': '4.32'}",CHEMBL5817128,,CHEMBL5817128,7.43,0,http://www.openphacts.org/units/Nanomolar,4590785,=,37,1,=,,IC50,nM,,37.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,37.0
,1197322,28775051,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CCC(N4CCC[C@H]4c4ccccc4C4CC4)CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.68', 'le': '0.16', 'lle': '-1.21', 'sei': '4.34'}",CHEMBL5881285,,CHEMBL5881285,7.47,0,http://www.openphacts.org/units/Nanomolar,4590786,=,37,1,=,,IC50,nM,,34.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,34.0
,1197324,28775057,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CCC(N4CCC[C@@H]4c4ccccc4C4CC4)CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.10', 'le': '0.15', 'lle': '-1.71', 'sei': '4.05'}",CHEMBL5926296,,CHEMBL5926296,6.97,0,http://www.openphacts.org/units/Nanomolar,4590787,=,37,1,=,,IC50,nM,,107.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,107.0
,1197325,28775060,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCC(N4CCC[C@H]4c4ccccc4C4CC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.88', 'le': '0.17', 'lle': '-1.57', 'sei': '4.58'}",CHEMBL5891780,,CHEMBL5891780,7.89,0,http://www.openphacts.org/units/Nanomolar,4590788,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197327,28775066,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCC(N4CCC[C@@H]4c4ccccc4C4CC4)CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.69', 'le': '0.15', 'lle': '-2.63', 'sei': '3.97'}",CHEMBL5978292,,CHEMBL5978292,6.83,0,http://www.openphacts.org/units/Nanomolar,4590789,=,37,1,=,,IC50,nM,,149.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,149.0
,1197328,28775069,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1c(Cl)cccc1C1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.19', 'sei': '4.76'}",CHEMBL5828065,,CHEMBL5828065,8.34,0,http://www.openphacts.org/units/Nanomolar,4590790,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,1197330,28775075,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.59', 'le': '0.19', 'lle': '-1.02', 'sei': '4.77'}",CHEMBL6050481,,CHEMBL6050481,7.92,0,http://www.openphacts.org/units/Nanomolar,4590791,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197332,28775081,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.76', 'le': '0.19', 'lle': '-0.77', 'sei': '4.92'}",CHEMBL6037348,,CHEMBL6037348,8.16,0,http://www.openphacts.org/units/Nanomolar,4590792,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,1197334,28775087,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCCC5c5ccccc5Cl)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '-1.00', 'sei': '4.79'}",CHEMBL6049523,,CHEMBL6049523,7.80,0,http://www.openphacts.org/units/Nanomolar,4590793,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197336,28775093,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.46', 'le': '0.18', 'lle': '-0.94', 'sei': '4.82'}",CHEMBL5882786,,CHEMBL5882786,7.85,0,http://www.openphacts.org/units/Nanomolar,4590794,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197338,28775099,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC2CN(C3CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.82', 'le': '0.17', 'lle': '-0.84', 'sei': '4.35'}",CHEMBL5926155,,CHEMBL5926155,7.48,0,http://www.openphacts.org/units/Nanomolar,4590795,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,1197340,28775105,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.98', 'le': '0.17', 'lle': '-0.70', 'sei': '4.43'}",CHEMBL5760818,,CHEMBL5760818,7.62,0,http://www.openphacts.org/units/Nanomolar,4590796,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,1197342,28775111,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(O)COC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.71', 'le': '0.19', 'lle': '0.50', 'sei': '4.08'}",CHEMBL5869539,,CHEMBL5869539,7.72,0,http://www.openphacts.org/units/Nanomolar,4590797,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197344,28775117,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.59', 'le': '0.19', 'lle': '-1.08', 'sei': '4.46'}",CHEMBL5781678,,CHEMBL5781678,7.89,0,http://www.openphacts.org/units/Nanomolar,4590798,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197346,28775123,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N2CC3(CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.43', 'le': '0.16', 'lle': '-1.76', 'sei': '4.31'}",CHEMBL6010999,,CHEMBL6010999,6.90,0,http://www.openphacts.org/units/Nanomolar,4590799,=,37,1,=,,IC50,nM,,125.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,125.0
,1197347,28775126,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.01', 'le': '0.19', 'lle': '0.33', 'sei': '4.60'}",CHEMBL5906030,,CHEMBL5906030,8.19,0,http://www.openphacts.org/units/Nanomolar,4590800,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,1197349,28775132,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.16', 'le': '0.19', 'lle': '0.46', 'sei': '4.67'}",CHEMBL5975530,,CHEMBL5975530,8.32,0,http://www.openphacts.org/units/Nanomolar,4590801,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,1197351,28775138,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.11', 'le': '0.19', 'lle': '0.42', 'sei': '4.65'}",CHEMBL5916255,,CHEMBL5916255,8.28,0,http://www.openphacts.org/units/Nanomolar,4590802,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197353,28775144,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.22', 'le': '0.19', 'lle': '0.51', 'sei': '4.70'}",CHEMBL5841596,,CHEMBL5841596,8.37,0,http://www.openphacts.org/units/Nanomolar,4590803,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,1197355,28775150,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '0.35', 'sei': '4.61'}",CHEMBL5756316,,CHEMBL5756316,8.21,0,http://www.openphacts.org/units/Nanomolar,4590804,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,1197357,28775156,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '0.29', 'sei': '4.58'}",CHEMBL5916255,,CHEMBL5916255,8.15,0,http://www.openphacts.org/units/Nanomolar,4590802,=,37,1,=,,IC50,nM,,7.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.1
,1197359,28775162,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.05', 'le': '0.19', 'lle': '0.37', 'sei': '4.62'}",CHEMBL5841596,,CHEMBL5841596,8.23,0,http://www.openphacts.org/units/Nanomolar,4590803,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197361,28775168,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.23', 'le': '0.19', 'lle': '0.52', 'sei': '4.71'}",CHEMBL5975530,,CHEMBL5975530,8.38,0,http://www.openphacts.org/units/Nanomolar,4590801,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,1197363,28775174,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.76', 'le': '0.18', 'lle': '-1.09', 'sei': '4.67'}",CHEMBL5856073,,CHEMBL5856073,8.26,0,http://www.openphacts.org/units/Nanomolar,4590805,=,37,1,=,,IC50,nM,,5.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.5
,1197365,28775180,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.18', 'le': '0.17', 'lle': '-1.58', 'sei': '4.39'}",CHEMBL5799821,,CHEMBL5799821,7.77,0,http://www.openphacts.org/units/Nanomolar,4590806,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197367,28775186,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.77', 'le': '0.19', 'lle': '-1.08', 'sei': '4.67'}",CHEMBL5799821,,CHEMBL5799821,8.27,0,http://www.openphacts.org/units/Nanomolar,4590807,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,1197369,28775192,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.85', 'le': '0.19', 'lle': '-1.01', 'sei': '4.71'}",CHEMBL5799821,,CHEMBL5799821,8.34,0,http://www.openphacts.org/units/Nanomolar,4590808,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,1197371,28775198,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.07', 'le': '0.19', 'lle': '-0.83', 'sei': '4.82'}",CHEMBL5799821,,CHEMBL5799821,8.52,0,http://www.openphacts.org/units/Nanomolar,4590809,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,1197373,28775204,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.55', 'le': '0.18', 'lle': '0.81', 'sei': '4.60'}",CHEMBL5975083,,CHEMBL5975083,8.35,0,http://www.openphacts.org/units/Nanomolar,4590810,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,1197375,28775210,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC3(CC2)COC3)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.03', 'le': '0.17', 'lle': '-1.88', 'sei': '4.67'}",CHEMBL5858076,,CHEMBL5858076,7.75,0,http://www.openphacts.org/units/Nanomolar,4590811,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197377,28775216,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(N[C@H]2CC[C@H](N(CC3CC3)CC3CC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.98', 'le': '0.17', 'lle': '-2.58', 'sei': '5.10'}",CHEMBL5957356,,CHEMBL5957356,8.30,0,http://www.openphacts.org/units/Nanomolar,4590812,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1197379,28775222,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3CC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.82', 'le': '0.17', 'lle': '-0.74', 'sei': '4.40'}",CHEMBL5842246,,CHEMBL5842246,7.57,0,http://www.openphacts.org/units/Nanomolar,4590813,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197381,28775228,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL5729271,,2022,"{'bei': '9.38', 'le': '0.18', 'lle': '1.24', 'sei': '4.40'}",CHEMBL5826691,,CHEMBL5826691,8.47,0,http://www.openphacts.org/units/Nanomolar,4590814,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,1197383,28775234,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.57', 'le': '0.18', 'lle': '-1.02', 'sei': '4.71'}",CHEMBL5810057,,CHEMBL5810057,7.82,0,http://www.openphacts.org/units/Nanomolar,4590815,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197385,28775240,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '-1.22', 'sei': '4.55'}",CHEMBL6016691,,CHEMBL6016691,8.17,0,http://www.openphacts.org/units/Nanomolar,4590816,=,37,1,=,,IC50,nM,,6.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.7
,1197387,28775246,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.27', 'le': '0.19', 'lle': '-0.71', 'sei': '4.83'}",CHEMBL5956618,,CHEMBL5956618,8.68,0,http://www.openphacts.org/units/Nanomolar,4590817,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,1197389,28775252,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.99', 'le': '0.19', 'lle': '-0.95', 'sei': '4.70'}",CHEMBL5956618,,CHEMBL5956618,8.44,0,http://www.openphacts.org/units/Nanomolar,4590818,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,1197391,28775258,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.16', 'le': '0.19', 'lle': '-0.80', 'sei': '4.78'}",CHEMBL5956618,,CHEMBL5956618,8.59,0,http://www.openphacts.org/units/Nanomolar,4590819,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1197393,28775264,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.65', 'le': '0.18', 'lle': '-1.24', 'sei': '4.54'}",CHEMBL5922058,,CHEMBL5922058,8.15,0,http://www.openphacts.org/units/Nanomolar,4590820,=,37,1,=,,IC50,nM,,7.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.0
,1197395,28775270,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CNCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.81', 'le': '0.19', 'lle': '0.59', 'sei': '4.44'}",CHEMBL5818747,,CHEMBL5818747,8.02,0,http://www.openphacts.org/units/Nanomolar,4590821,=,37,1,=,,IC50,nM,,9.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.5
,1197397,28775276,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '-0.65', 'sei': '4.92'}",CHEMBL5971190,,CHEMBL5971190,8.31,0,http://www.openphacts.org/units/Nanomolar,4590822,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,1197399,28775282,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.13', 'le': '0.19', 'lle': '-0.50', 'sei': '5.01'}",CHEMBL5856844,,CHEMBL5856844,8.46,0,http://www.openphacts.org/units/Nanomolar,4590823,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,1197401,28775288,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.00', 'le': '0.19', 'lle': '-0.61', 'sei': '4.95'}",CHEMBL5972666,,CHEMBL5972666,8.35,0,http://www.openphacts.org/units/Nanomolar,4590824,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,1197403,28775294,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.14', 'le': '0.19', 'lle': '-0.49', 'sei': '5.02'}",CHEMBL5856844,,CHEMBL5856844,8.47,0,http://www.openphacts.org/units/Nanomolar,4590823,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,1197405,28775300,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.70', 'le': '0.18', 'lle': '-0.86', 'sei': '4.80'}",CHEMBL5972666,,CHEMBL5972666,8.10,0,http://www.openphacts.org/units/Nanomolar,4590824,=,37,1,=,,IC50,nM,,7.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.9
,1197407,28775306,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL5729271,,2022,"{'bei': '9.88', 'le': '0.19', 'lle': '0.44', 'sei': '4.78'}",CHEMBL5867513,,CHEMBL5867513,8.22,0,http://www.openphacts.org/units/Nanomolar,4590825,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,1197409,28775312,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL5729271,,2022,"{'bei': '9.30', 'le': '0.18', 'lle': '0.31', 'sei': '4.23'}",CHEMBL6016585,,CHEMBL6016585,8.00,0,http://www.openphacts.org/units/Nanomolar,4590826,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1197411,28775318,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '0.01', 'sei': '5.09'}",CHEMBL6019072,,CHEMBL6019072,8.62,0,http://www.openphacts.org/units/Nanomolar,4590827,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,1197413,28775324,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.79', 'le': '0.19', 'lle': '0.11', 'sei': '5.15'}",CHEMBL5861196,,CHEMBL5861196,8.72,0,http://www.openphacts.org/units/Nanomolar,4590828,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,1197415,28775330,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CC[C@H](N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.72', 'le': '0.18', 'lle': '0.05', 'sei': '5.12'}",CHEMBL5899109,,CHEMBL5899109,8.66,0,http://www.openphacts.org/units/Nanomolar,4590829,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,1197417,28775336,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3CCOCC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.95', 'le': '0.17', 'lle': '-1.16', 'sei': '4.86'}",CHEMBL5802937,,CHEMBL5802937,8.23,0,http://www.openphacts.org/units/Nanomolar,4590830,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197419,28775342,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CCN(C3COC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.75', 'le': '0.18', 'lle': '0.20', 'sei': '4.86'}",CHEMBL5982940,,CHEMBL5982940,8.37,0,http://www.openphacts.org/units/Nanomolar,4590831,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,1197421,28775348,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CCN(C3COC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.06', 'le': '0.17', 'lle': '-0.40', 'sei': '4.52'}",CHEMBL5828543,,CHEMBL5828543,7.77,0,http://www.openphacts.org/units/Nanomolar,4590832,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197423,28775354,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3CC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.80', 'le': '0.17', 'lle': '-1.68', 'sei': '4.81'}",CHEMBL5782018,,CHEMBL5782018,7.70,0,http://www.openphacts.org/units/Nanomolar,4590833,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197425,28775360,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC2CCN(C(CF)CF)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.30', 'le': '0.18', 'lle': '-0.78', 'sei': '4.95'}",CHEMBL5962842,,CHEMBL5962842,8.05,0,http://www.openphacts.org/units/Nanomolar,4590834,=,37,1,=,,IC50,nM,,8.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.9
,1197427,28775366,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c(Cl)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.00', 'le': '0.15', 'lle': '-3.17', 'sei': '5.14'}",CHEMBL6020098,,CHEMBL6020098,6.45,0,http://www.openphacts.org/units/Nanomolar,4590835,=,37,1,=,,IC50,nM,,353.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,353.0
,1197428,28775369,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1cc(S(=O)(=O)NC(=O)c2ccc(C3=CCC(N4CCCC4c4ccccc4C4CC4)CC3)cc2Oc2cnc3[nH]ccc3c2)ccc1NCC1CCOCC1,,,CHEMBL5729271,,2022,"{'bei': '7.99', 'le': '0.15', 'lle': '-2.46', 'sei': '4.26'}",CHEMBL5843415,,CHEMBL5843415,6.37,0,http://www.openphacts.org/units/Nanomolar,4590836,=,37,1,=,,IC50,nM,,431.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,431.0
,1197429,28775372,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.30', 'le': '0.14', 'lle': '-2.66', 'sei': '4.13'}",CHEMBL5775373,,CHEMBL5775373,6.60,0,http://www.openphacts.org/units/Nanomolar,4590837,=,37,1,=,,IC50,nM,,252.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,252.0
,1197430,28775375,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.56', 'le': '0.18', 'lle': '-0.22', 'sei': '4.85'}",CHEMBL6032884,,CHEMBL6032884,8.34,0,http://www.openphacts.org/units/Nanomolar,4590838,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,1197432,28775381,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.68', 'le': '0.18', 'lle': '-0.12', 'sei': '4.91'}",CHEMBL5940140,,CHEMBL5940140,8.44,0,http://www.openphacts.org/units/Nanomolar,4590839,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,1197434,28775387,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '-0.28', 'sei': '4.82'}",CHEMBL5933907,,CHEMBL5933907,8.28,0,http://www.openphacts.org/units/Nanomolar,4590840,=,37,1,=,,IC50,nM,,5.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.2
,1197436,28775393,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.08', 'le': '0.19', 'lle': '0.33', 'sei': '4.65'}",CHEMBL5805930,,CHEMBL5805930,8.28,0,http://www.openphacts.org/units/Nanomolar,4590841,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197438,28775399,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.19', 'lle': '0.43', 'sei': '4.71'}",CHEMBL5995925,,CHEMBL5995925,8.38,0,http://www.openphacts.org/units/Nanomolar,4590842,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,1197440,28775405,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.11', 'le': '0.19', 'lle': '0.35', 'sei': '4.66'}",CHEMBL5860139,,CHEMBL5860139,8.30,0,http://www.openphacts.org/units/Nanomolar,4590843,=,37,1,=,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1197442,28775411,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.36', 'le': '0.20', 'lle': '0.56', 'sei': '4.78'}",CHEMBL5966228,,CHEMBL5966228,8.51,0,http://www.openphacts.org/units/Nanomolar,4590844,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,1197444,28775417,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)[Si](C)(C)OC1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,,CHEMBL5960804,,CHEMBL5960804,,0,http://www.openphacts.org/units/Nanomolar,4590845,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197445,28775420,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)[Si](C)(C)OC1CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '6.42', 'le': None, 'lle': None, 'sei': None}",CHEMBL5753141,,CHEMBL5753141,6.07,0,http://www.openphacts.org/units/Nanomolar,4590846,=,37,1,=,,IC50,nM,,849.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,849.0
,1197446,28775423,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-1.16', 'sei': '4.40'}",CHEMBL5929872,,CHEMBL5929872,7.80,0,http://www.openphacts.org/units/Nanomolar,4590847,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197448,28775429,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '-0.68', 'sei': '4.68'}",CHEMBL5812387,,CHEMBL5812387,8.28,0,http://www.openphacts.org/units/Nanomolar,4590848,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197450,28775435,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC(=O)N2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.52', 'le': '0.18', 'lle': '0.02', 'sei': '4.19'}",CHEMBL6063527,,CHEMBL6063527,7.92,0,http://www.openphacts.org/units/Nanomolar,4590849,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197452,28775441,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.68', 'le': '0.16', 'lle': '-2.21', 'sei': '4.28'}",CHEMBL6055951,,CHEMBL6055951,7.23,0,http://www.openphacts.org/units/Nanomolar,4590850,=,37,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,59.0
,1197454,28775447,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.90', 'sei': '5.06'}",CHEMBL5912155,,CHEMBL5912155,8.54,0,http://www.openphacts.org/units/Nanomolar,4590851,=,37,1,=,,IC50,nM,,2.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.9
,1197456,28775453,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COCC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.02', 'le': '0.17', 'lle': '-2.16', 'sei': '4.59'}",CHEMBL6018441,,CHEMBL6018441,7.75,0,http://www.openphacts.org/units/Nanomolar,4590852,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197457,28775456,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CCN(C3CCOCC3)C2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.74', 'le': '0.17', 'lle': '-1.21', 'sei': '4.50'}",CHEMBL5782710,,CHEMBL5782710,7.75,0,http://www.openphacts.org/units/Nanomolar,4590853,=,37,1,=,,IC50,nM,,18.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,18.0
,1197459,28775462,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.85', 'le': '0.17', 'lle': '-0.89', 'sei': '4.05'}",CHEMBL6006690,,CHEMBL6006690,7.21,0,http://www.openphacts.org/units/Nanomolar,4590854,=,37,1,=,,IC50,nM,,61.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,61.0
,1197460,28775465,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.87', 'le': '0.17', 'lle': '-0.87', 'sei': '4.06'}",CHEMBL5762148,,CHEMBL5762148,7.23,0,http://www.openphacts.org/units/Nanomolar,4590855,=,37,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,59.0
,1197461,28775468,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.39', 'le': '0.20', 'lle': '-0.10', 'sei': '5.07'}",CHEMBL5979382,,CHEMBL5979382,8.55,0,http://www.openphacts.org/units/Nanomolar,4590856,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,1197463,28775474,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.31', 'le': '0.20', 'lle': '-0.17', 'sei': '5.02'}",CHEMBL5979382,,CHEMBL5979382,8.48,0,http://www.openphacts.org/units/Nanomolar,4590856,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197465,28775480,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.50', 'le': '0.20', 'lle': '-0.01', 'sei': '5.12'}",CHEMBL5917184,,CHEMBL5917184,8.64,0,http://www.openphacts.org/units/Nanomolar,4590857,=,37,1,=,,IC50,nM,,2.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.3
,1197467,28775486,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.22', 'le': '0.19', 'lle': '-1.25', 'sei': '4.79'}",CHEMBL5765058,,CHEMBL5765058,8.62,0,http://www.openphacts.org/units/Nanomolar,4590858,=,37,1,=,,IC50,nM,,2.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.4
,1197469,28775492,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.40', 'le': '0.20', 'lle': '-0.88', 'sei': '4.86'}",CHEMBL5901355,,CHEMBL5901355,8.74,0,http://www.openphacts.org/units/Nanomolar,4590859,=,37,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,1197471,28775498,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.51', 'le': '0.18', 'lle': '-1.62', 'sei': '4.45'}",CHEMBL5747331,,CHEMBL5747331,8.00,0,http://www.openphacts.org/units/Nanomolar,4590860,=,37,1,=,,IC50,nM,,10.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,10.0
,1197473,28775504,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.04', 'le': '0.19', 'lle': '-1.18', 'sei': '4.70'}",CHEMBL5818419,,CHEMBL5818419,8.44,0,http://www.openphacts.org/units/Nanomolar,4590861,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,1197475,28775510,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '8.96', 'le': '0.17', 'lle': '-2.08', 'sei': '4.19'}",CHEMBL5954667,,CHEMBL5954667,7.54,0,http://www.openphacts.org/units/Nanomolar,4590862,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197477,28775516,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.31', 'le': '0.20', 'lle': '-0.63', 'sei': '5.08'}",CHEMBL5928484,,CHEMBL5928484,8.57,0,http://www.openphacts.org/units/Nanomolar,4590863,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,1197479,28775522,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.53', 'le': '0.18', 'lle': '-1.28', 'sei': '4.69'}",CHEMBL5945870,,CHEMBL5945870,7.92,0,http://www.openphacts.org/units/Nanomolar,4590864,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197481,28775528,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.38', 'le': '0.20', 'lle': '0.36', 'sei': '4.75'}",CHEMBL5787701,,CHEMBL5787701,8.46,0,http://www.openphacts.org/units/Nanomolar,4590865,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,1197483,28775534,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.72', 'le': '0.18', 'lle': '-0.18', 'sei': '4.45'}",CHEMBL6006690,,CHEMBL6006690,7.92,0,http://www.openphacts.org/units/Nanomolar,4590854,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197485,28775540,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.19', 'lle': '0.21', 'sei': '4.67'}",CHEMBL5828583,,CHEMBL5828583,8.31,0,http://www.openphacts.org/units/Nanomolar,4590866,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,1197487,28775546,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.47', 'le': '0.18', 'lle': '-0.38', 'sei': '4.34'}",CHEMBL5762148,,CHEMBL5762148,7.72,0,http://www.openphacts.org/units/Nanomolar,4590855,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197489,28775552,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.76', 'le': '0.18', 'lle': '-0.19', 'sei': '5.12'}",CHEMBL6039862,,CHEMBL6039862,8.66,0,http://www.openphacts.org/units/Nanomolar,4590867,=,37,1,=,,IC50,nM,,2.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.2
,1197491,28775558,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.11', 'le': '0.17', 'lle': '-0.77', 'sei': '4.78'}",CHEMBL5985785,,CHEMBL5985785,8.08,0,http://www.openphacts.org/units/Nanomolar,4590868,=,37,1,=,,IC50,nM,,8.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.3
,1197493,28775564,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.96', 'le': '0.19', 'lle': '-0.06', 'sei': '5.13'}",CHEMBL5794896,,CHEMBL5794896,8.82,0,http://www.openphacts.org/units/Nanomolar,4590869,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1197495,28775570,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(F)(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.96', 'le': '0.19', 'lle': '-1.16', 'sei': '4.76'}",CHEMBL5846135,,CHEMBL5846135,8.55,0,http://www.openphacts.org/units/Nanomolar,4590870,=,37,1,=,,IC50,nM,,2.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.8
,1197497,28775576,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(F)(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.87', 'le': '0.19', 'lle': '-1.23', 'sei': '4.72'}",CHEMBL5982143,,CHEMBL5982143,8.48,0,http://www.openphacts.org/units/Nanomolar,4590871,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197499,28775582,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.51', 'le': '0.18', 'lle': '-1.42', 'sei': '4.39'}",CHEMBL6019566,,CHEMBL6019566,7.89,0,http://www.openphacts.org/units/Nanomolar,4590872,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197501,28775588,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(OCC4(F)CCN(C5COC5)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.36', 'le': '0.18', 'lle': '-0.34', 'sei': '4.84'}",CHEMBL6008607,,CHEMBL6008607,8.19,0,http://www.openphacts.org/units/Nanomolar,4590873,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,1197503,28775594,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(OCC4(F)CCN(C5COC5)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.20', 'le': '0.16', 'lle': '-1.81', 'sei': '4.31'}",CHEMBL5924691,,CHEMBL5924691,7.29,0,http://www.openphacts.org/units/Nanomolar,4590874,=,37,1,=,,IC50,nM,,51.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,51.0
,1197505,28775600,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5cccc(Cl)c5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.35', 'le': '0.18', 'lle': '-1.82', 'sei': '4.57'}",CHEMBL6055850,,CHEMBL6055850,8.22,0,http://www.openphacts.org/units/Nanomolar,4590875,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,1197507,28775606,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.56', 'le': '0.20', 'lle': '-0.27', 'sei': '4.89'}",CHEMBL5740186,,CHEMBL5740186,8.80,0,http://www.openphacts.org/units/Nanomolar,4590876,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1197509,28775612,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.71', 'le': '0.20', 'lle': '-0.15', 'sei': '4.96'}",CHEMBL5762696,,CHEMBL5762696,8.92,0,http://www.openphacts.org/units/Nanomolar,4590877,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197511,28775618,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.41', 'le': '0.18', 'lle': '-1.69', 'sei': '4.50'}",CHEMBL5910719,,CHEMBL5910719,8.09,0,http://www.openphacts.org/units/Nanomolar,4590878,=,37,1,=,,IC50,nM,,8.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.2
,1197513,28775624,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.82', 'le': '0.19', 'lle': '-1.35', 'sei': '4.69'}",CHEMBL6065902,,CHEMBL6065902,8.43,0,http://www.openphacts.org/units/Nanomolar,4590879,=,37,1,=,,IC50,nM,,3.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.7
,1197515,28775630,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.01', 'le': '0.19', 'lle': '-0.60', 'sei': '4.72'}",CHEMBL5842983,,CHEMBL5842983,8.49,0,http://www.openphacts.org/units/Nanomolar,4590880,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,1197517,28775636,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.71', 'le': '0.18', 'lle': '-0.85', 'sei': '4.59'}",CHEMBL6041868,,CHEMBL6041868,8.24,0,http://www.openphacts.org/units/Nanomolar,4590881,=,37,1,=,,IC50,nM,,5.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.7
,1197519,28775642,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.75', 'le': '0.19', 'lle': '-0.81', 'sei': '4.60'}",CHEMBL5842983,,CHEMBL5842983,8.28,0,http://www.openphacts.org/units/Nanomolar,4590882,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1197521,28775648,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.21', 'le': '0.19', 'lle': '-0.52', 'sei': '4.72'}",CHEMBL5976824,,CHEMBL5976824,8.48,0,http://www.openphacts.org/units/Nanomolar,4590883,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197523,28775654,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.83', 'le': '0.19', 'lle': '-0.83', 'sei': '4.54'}",CHEMBL5824698,,CHEMBL5824698,8.17,0,http://www.openphacts.org/units/Nanomolar,4590884,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,1197525,28775660,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CC[C@H](O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.90', 'le': '0.19', 'lle': '-0.77', 'sei': '4.58'}",CHEMBL5854104,,CHEMBL5854104,8.23,0,http://www.openphacts.org/units/Nanomolar,4590885,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197527,28775666,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CC[C@@H](O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.06', 'le': '0.19', 'lle': '-0.64', 'sei': '4.65'}",CHEMBL5948076,,CHEMBL5948076,8.36,0,http://www.openphacts.org/units/Nanomolar,4590886,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,1197529,28775672,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.39', 'le': '0.18', 'lle': '0.67', 'sei': '4.53'}",CHEMBL5932713,,CHEMBL5932713,8.21,0,http://www.openphacts.org/units/Nanomolar,4590887,=,37,1,=,,IC50,nM,,6.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.2
,1197531,28775678,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.84', 'le': '0.19', 'lle': '1.06', 'sei': '4.75'}",CHEMBL5858258,,CHEMBL5858258,8.60,0,http://www.openphacts.org/units/Nanomolar,4590888,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,1197533,28775684,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)N1CCOC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])C1,,,CHEMBL5729271,,2022,"{'bei': '9.07', 'le': '0.18', 'lle': '1.03', 'sei': '3.94'}",CHEMBL6023144,,CHEMBL6023144,8.13,0,http://www.openphacts.org/units/Nanomolar,4590889,=,37,1,=,,IC50,nM,,7.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.4
,1197535,28775690,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCN(C3COC3)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.54', 'le': '0.18', 'lle': '-0.16', 'sei': '4.94'}",CHEMBL5825277,,CHEMBL5825277,8.49,0,http://www.openphacts.org/units/Nanomolar,4590890,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,1197537,28775696,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC(=O)N1CCC(F)(COc2ncc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCCC5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2Cl)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.84', 'le': '0.17', 'lle': '-0.39', 'sei': '5.36'}",CHEMBL5917107,,CHEMBL5917107,8.05,0,http://www.openphacts.org/units/Nanomolar,4590891,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,1197539,28775702,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC(O)CC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(Cl)c3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.14', 'le': '0.18', 'lle': '-1.70', 'sei': '4.48'}",CHEMBL5769886,,CHEMBL5769886,7.92,0,http://www.openphacts.org/units/Nanomolar,4590892,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197541,28775708,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CN(C3COC3)CCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.49', 'le': '0.18', 'lle': '0.68', 'sei': '4.58'}",CHEMBL5929201,,CHEMBL5929201,8.31,0,http://www.openphacts.org/units/Nanomolar,4590893,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,1197543,28775714,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1-n1ncc2nc3[nH]ccc3cc21,,,CHEMBL5729271,,2022,"{'bei': '7.74', 'le': '0.15', 'lle': '-1.91', 'sei': '3.67'}",CHEMBL5774230,,CHEMBL5774230,6.51,0,http://www.openphacts.org/units/Nanomolar,4590894,=,37,1,=,,IC50,nM,,310.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,310.0
,1197544,28775717,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1-n1ncc2nc3[nH]ccc3cc21,,,CHEMBL5729271,,2022,"{'bei': '9.00', 'le': '0.17', 'lle': '-0.85', 'sei': '4.27'}",CHEMBL5774230,,CHEMBL5774230,7.57,0,http://www.openphacts.org/units/Nanomolar,4590894,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197546,28775723,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.10', 'le': '0.14', 'lle': '-3.46', 'sei': '4.00'}",CHEMBL5988601,,CHEMBL5988601,6.87,0,http://www.openphacts.org/units/Nanomolar,4590895,=,37,1,=,,IC50,nM,,134.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,134.0
,1197547,28775726,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1,,,CHEMBL5729271,,2022,"{'bei': '7.24', 'le': '0.14', 'lle': '-2.61', 'sei': '4.51'}",CHEMBL5802150,,CHEMBL5802150,6.05,0,http://www.openphacts.org/units/Nanomolar,4590896,=,37,1,=,,IC50,nM,,882.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,882.0
,1197548,28775729,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5978974,,CHEMBL5978974,,0,http://www.openphacts.org/units/Nanomolar,4590897,>,37,1,>,,IC50,nM,,1000.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1000.0
,1197549,28775732,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC(CCN2CCOCC2)CSc2ccccc2)c(S(=O)(=O)C(F)(F)F)c1)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1,,,CHEMBL5729271,,2022,"{'bei': '6.77', 'le': '0.14', 'lle': '-2.79', 'sei': '5.00'}",CHEMBL5890440,,CHEMBL5890440,6.25,0,http://www.openphacts.org/units/Nanomolar,4590898,=,37,1,=,,IC50,nM,,559.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,559.0
,1197550,28775735,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.65', 'le': '0.16', 'lle': '-2.88', 'sei': '4.38'}",CHEMBL5558697,,CHEMBL5558697,7.40,0,http://www.openphacts.org/units/Nanomolar,4590596,=,37,1,=,,IC50,nM,,40.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,40.0
,1197551,28775738,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.59', 'le': '0.20', 'lle': '0.33', 'sei': '5.10'}",CHEMBL5994332,,CHEMBL5994332,8.77,0,http://www.openphacts.org/units/Nanomolar,4590899,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,1197553,28775744,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.05', 'le': '0.17', 'lle': '-2.02', 'sei': '4.43'}",CHEMBL5823408,,CHEMBL5823408,7.48,0,http://www.openphacts.org/units/Nanomolar,4590900,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,1197555,28775750,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC4CCCC4C3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.05', 'le': '0.17', 'lle': '-2.02', 'sei': '4.57'}",CHEMBL5757008,,CHEMBL5757008,7.72,0,http://www.openphacts.org/units/Nanomolar,4590901,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197557,28775756,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc4c3OCC4)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.05', 'le': '0.17', 'lle': '-0.78', 'sei': '4.14'}",CHEMBL5959671,,CHEMBL5959671,7.38,0,http://www.openphacts.org/units/Nanomolar,4590902,=,37,1,=,,IC50,nM,,42.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,42.0
,1197558,28775759,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC4CCCC4C3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.25', 'le': '0.17', 'lle': '-1.35', 'sei': '4.46'}",CHEMBL5822503,,CHEMBL5822503,7.52,0,http://www.openphacts.org/units/Nanomolar,4590903,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1197559,28775762,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.63', 'sei': '4.84'}",CHEMBL5920092,,CHEMBL5920092,8.32,0,http://www.openphacts.org/units/Nanomolar,4590904,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,1197561,28775768,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.01', 'le': '0.21', 'lle': '0.60', 'sei': '5.55'}",CHEMBL6048606,,CHEMBL6048606,9.55,0,http://www.openphacts.org/units/Nanomolar,4590905,=,37,1,=,,IC50,nM,,0.28,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.28
,1197563,28775774,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cccc(N3CCCC3c3ccccc3C3CC3)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.22', 'le': '0.17', 'lle': '-1.62', 'sei': '4.44'}",CHEMBL5841259,,CHEMBL5841259,7.50,0,http://www.openphacts.org/units/Nanomolar,4590906,=,37,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,1197564,28775777,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Oc3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5808483,,CHEMBL5808483,,0,http://www.openphacts.org/units/Nanomolar,4590907,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197565,28775780,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCOCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.83', 'le': '0.19', 'lle': '-0.70', 'sei': '4.73'}",CHEMBL6021289,,CHEMBL6021289,8.42,0,http://www.openphacts.org/units/Nanomolar,4590908,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,1197567,28775786,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3C3=C(C4CC4)CCCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5805898,,CHEMBL5805898,,0,http://www.openphacts.org/units/Nanomolar,4590909,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197568,28775789,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=NC(=O)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1,,,CHEMBL5729271,,2022,"{'bei': '8.84', 'le': '0.17', 'lle': '-3.11', 'sei': '4.71'}",CHEMBL5892562,,CHEMBL5892562,7.17,0,http://www.openphacts.org/units/Nanomolar,4590910,=,37,1,=,,IC50,nM,,68.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,68.0
,1197569,28775792,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3CC3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.28', 'le': '0.17', 'lle': '-1.50', 'sei': '4.55'}",CHEMBL6039686,,CHEMBL6039686,7.68,0,http://www.openphacts.org/units/Nanomolar,4590911,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,1197570,28775795,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2Cl)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5568064,,CHEMBL5568064,,0,http://www.openphacts.org/units/Nanomolar,4590912,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197571,28775798,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCC(F)(F)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.48', 'le': '0.16', 'lle': '-2.97', 'sei': '4.47'}",CHEMBL5821827,,CHEMBL5821827,7.55,0,http://www.openphacts.org/units/Nanomolar,4590913,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,1197572,28775801,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CC1c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '11.09', 'le': '0.21', 'lle': '0.84', 'sei': '5.52'}",CHEMBL5981833,,CHEMBL5981833,9.49,0,http://www.openphacts.org/units/Nanomolar,4590914,=,37,1,=,,IC50,nM,,0.32,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.32
,1197574,28775807,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)OC(=O)N1CCC(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,,CHEMBL5965696,,CHEMBL5965696,,0,http://www.openphacts.org/units/Nanomolar,4590915,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197575,28775810,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CCNCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.81', 'le': '0.20', 'lle': '0.55', 'sei': '5.12'}",CHEMBL5909819,,CHEMBL5909819,9.25,0,http://www.openphacts.org/units/Nanomolar,4590916,=,37,1,=,,IC50,nM,,0.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.56
,1197577,28775816,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.12', 'le': '0.21', 'lle': '0.64', 'sei': '5.63'}",CHEMBL6053673,,CHEMBL6053673,9.68,0,http://www.openphacts.org/units/Nanomolar,4590917,=,37,1,=,,IC50,nM,,0.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.21
,1197579,28775822,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1=O,,,CHEMBL5729271,,2022,"{'bei': '11.61', 'le': '0.22', 'lle': '1.70', 'sei': '5.43'}",CHEMBL6021542,,CHEMBL6021542,10.26,0,http://www.openphacts.org/units/Nanomolar,4590918,=,37,1,=,,IC50,nM,,0.055,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.055
,1197581,28775828,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCN(CCC(F)(F)F)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.11', 'le': '0.16', 'lle': '-2.64', 'sei': '4.49'}",CHEMBL5740818,,CHEMBL5740818,7.72,0,http://www.openphacts.org/units/Nanomolar,4590919,=,37,1,=,,IC50,nM,,19.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,19.0
,1197582,28775831,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCN(CCO)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.28', 'le': '0.19', 'lle': '0.85', 'sei': '4.81'}",CHEMBL6017993,,CHEMBL6017993,9.25,0,http://www.openphacts.org/units/Nanomolar,4590920,=,37,1,=,,IC50,nM,,0.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.56
,1197584,28775837,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C(=O)CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.48', 'le': '0.18', 'lle': '0.42', 'sei': '4.64'}",CHEMBL5963587,,CHEMBL5963587,8.92,0,http://www.openphacts.org/units/Nanomolar,4590921,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197586,28775843,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N(C)CCN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.30', 'le': '0.18', 'lle': '0.00', 'sei': '4.62'}",CHEMBL5937625,,CHEMBL5937625,8.89,0,http://www.openphacts.org/units/Nanomolar,4590922,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,1197588,28775849,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CNCCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.12', 'le': '0.19', 'lle': '0.98', 'sei': '4.73'}",CHEMBL5741823,,CHEMBL5741823,9.52,0,http://www.openphacts.org/units/Nanomolar,4590923,=,37,1,=,,IC50,nM,,0.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.3
,1197590,28775855,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3=CCN(C4CC4)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.46', 'le': '0.18', 'lle': '-1.02', 'sei': '4.92'}",CHEMBL5980660,,CHEMBL5980660,8.46,0,http://www.openphacts.org/units/Nanomolar,4590924,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,1197592,28775861,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3=CCN(Cc4ccccc4)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.66', 'le': '0.16', 'lle': '-2.34', 'sei': '4.76'}",CHEMBL5742365,,CHEMBL5742365,8.18,0,http://www.openphacts.org/units/Nanomolar,4590925,=,37,1,=,,IC50,nM,,6.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.6
,1197593,28775864,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.23', 'le': '0.19', 'lle': '0.31', 'sei': '4.85'}",CHEMBL5878897,,CHEMBL5878897,9.17,0,http://www.openphacts.org/units/Nanomolar,4590926,=,37,1,=,,IC50,nM,,0.68,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.68
,1197595,28775870,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.44', 'sei': '4.51'}",CHEMBL5873270,,CHEMBL5873270,8.52,0,http://www.openphacts.org/units/Nanomolar,4590927,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,1197597,28775876,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)N1CC=C(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '8.54', 'le': '0.16', 'lle': '-0.32', 'sei': '3.86'}",CHEMBL5836762,,CHEMBL5836762,7.96,0,http://www.openphacts.org/units/Nanomolar,4590928,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,1197598,28775879,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(Cc2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.26', 'le': '0.21', 'lle': '0.85', 'sei': '5.79'}",CHEMBL5811985,,CHEMBL5811985,9.96,0,http://www.openphacts.org/units/Nanomolar,4590929,=,37,1,=,,IC50,nM,,0.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.11
,1197600,28775885,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(Oc2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.86', 'le': '0.21', 'lle': '0.92', 'sei': '5.31'}",CHEMBL6059979,,CHEMBL6059979,9.62,0,http://www.openphacts.org/units/Nanomolar,4590930,=,37,1,=,,IC50,nM,,0.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.24
,1197602,28775891,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(Cc2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.36', 'le': '0.21', 'lle': '2.07', 'sei': '5.73'}",CHEMBL5779937,,CHEMBL5779937,10.05,0,http://www.openphacts.org/units/Nanomolar,4590931,=,37,1,=,,IC50,nM,,0.089,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.089
,1197604,28775897,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,NC(=O)C1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.13', 'le': '0.19', 'lle': '0.11', 'sei': '4.29'}",CHEMBL6064098,,CHEMBL6064098,9.10,0,http://www.openphacts.org/units/Nanomolar,4590932,=,37,1,=,,IC50,nM,,0.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.8
,1197606,28775903,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3-c3ccncc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.16', 'le': '0.19', 'lle': '-0.65', 'sei': '4.75'}",CHEMBL5960930,,CHEMBL5960930,8.64,0,http://www.openphacts.org/units/Nanomolar,4590933,=,37,1,=,,IC50,nM,,2.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.3
,1197608,28775909,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC[C@@H](c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.69', 'le': '0.20', 'lle': '0.26', 'sei': '5.41'}",CHEMBL6024503,,CHEMBL6024503,9.30,0,http://www.openphacts.org/units/Nanomolar,4590934,=,37,1,=,,IC50,nM,,0.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.5
,1197610,28775915,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC[C@H](c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.89', 'le': '0.19', 'lle': '-0.44', 'sei': '5.00'}",CHEMBL5861804,,CHEMBL5861804,8.60,0,http://www.openphacts.org/units/Nanomolar,4590935,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,1197612,28775921,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CCCN(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.27', 'le': '0.19', 'lle': '0.48', 'sei': '5.27'}",CHEMBL6051337,,CHEMBL6051337,9.24,0,http://www.openphacts.org/units/Nanomolar,4590936,=,37,1,=,,IC50,nM,,0.58,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.58
,1197614,28775927,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CCCN(c2ccccc2[C@@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.93', 'le': '0.21', 'lle': '1.06', 'sei': '5.61'}",CHEMBL5802211,,CHEMBL5802211,9.82,0,http://www.openphacts.org/units/Nanomolar,4590937,=,37,1,=,,IC50,nM,,0.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.15
,1197616,28775933,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1C2CCC1CN(c1ccccc1[C@H]1CCCN1c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc1)C2,,,CHEMBL5729271,,2022,"{'bei': '10.05', 'le': '0.19', 'lle': '0.51', 'sei': '5.15'}",CHEMBL5906987,,CHEMBL5906987,9.02,0,http://www.openphacts.org/units/Nanomolar,4590938,=,37,1,=,,IC50,nM,,0.96,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.96
,1197618,28775939,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCNCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.88', 'le': '0.21', 'lle': '1.69', 'sei': '5.07'}",CHEMBL5982217,,CHEMBL5982217,9.33,0,http://www.openphacts.org/units/Nanomolar,4590939,=,37,1,=,,IC50,nM,,0.47,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.47
,1197620,28775945,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.40', 'le': '0.20', 'lle': '1.08', 'sei': '5.17'}",CHEMBL5811460,,CHEMBL5811460,9.06,0,http://www.openphacts.org/units/Nanomolar,4590940,=,37,1,=,,IC50,nM,,0.88,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.88
,1197622,28775951,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCOCC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.81', 'le': '0.19', 'lle': '0.35', 'sei': '4.65'}",CHEMBL5806788,,CHEMBL5806788,8.42,0,http://www.openphacts.org/units/Nanomolar,4590941,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,1197623,28775954,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CCS(=O)(=O)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.29', 'le': '0.20', 'lle': '0.79', 'sei': '4.59'}",CHEMBL5997261,,CHEMBL5997261,9.31,0,http://www.openphacts.org/units/Nanomolar,4590942,=,37,1,=,,IC50,nM,,0.49,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.49
,1197625,28775960,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3N3CCC(O)CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '0.17', 'sei': '4.35'}",CHEMBL5907442,,CHEMBL5907442,8.36,0,http://www.openphacts.org/units/Nanomolar,4590943,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,1197627,28775966,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CCN(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.72', 'le': '0.20', 'lle': '0.88', 'sei': '5.50'}",CHEMBL5962024,,CHEMBL5962024,9.64,0,http://www.openphacts.org/units/Nanomolar,4590944,=,37,1,=,,IC50,nM,,0.23,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.23
,1197629,28775972,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.63', 'le': '0.20', 'lle': '0.45', 'sei': '5.29'}",CHEMBL5840340,,CHEMBL5840340,9.10,0,http://www.openphacts.org/units/Nanomolar,4590945,=,37,1,=,,IC50,nM,,0.79,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.79
,1197631,28775978,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCOc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.30', 'le': '0.20', 'lle': '0.68', 'sei': '4.88'}",CHEMBL5820634,,CHEMBL5820634,8.85,0,http://www.openphacts.org/units/Nanomolar,4590946,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,1197633,28775984,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.23', 'le': '0.19', 'lle': '-0.02', 'sei': '4.69'}",CHEMBL5908484,,CHEMBL5908484,8.36,0,http://www.openphacts.org/units/Nanomolar,4590947,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,1197635,28775990,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)Cc1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '9.96', 'le': '0.19', 'lle': '-0.02', 'sei': '4.81'}",CHEMBL5934464,,CHEMBL5934464,8.27,0,http://www.openphacts.org/units/Nanomolar,4590948,=,37,1,=,,IC50,nM,,5.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.4
,1197636,28775993,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.57', 'le': '0.20', 'lle': '0.59', 'sei': '5.19'}",CHEMBL5943281,,CHEMBL5943281,8.92,0,http://www.openphacts.org/units/Nanomolar,4590949,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197637,28775996,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCCc1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '11.48', 'le': '0.22', 'lle': '1.13', 'sei': '5.73'}",CHEMBL5877756,,CHEMBL5877756,9.85,0,http://www.openphacts.org/units/Nanomolar,4590950,=,37,1,=,,IC50,nM,,0.14,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.14
,1197639,28776002,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(Oc2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.55', 'le': '0.20', 'lle': '0.89', 'sei': '5.08'}",CHEMBL5873197,,CHEMBL5873197,9.20,0,http://www.openphacts.org/units/Nanomolar,4590951,=,37,1,=,,IC50,nM,,0.63,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.63
,1197641,28776008,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(N(C)c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.64', 'le': '0.20', 'lle': '1.05', 'sei': '5.37'}",CHEMBL6036388,,CHEMBL6036388,9.42,0,http://www.openphacts.org/units/Nanomolar,4590952,=,37,1,=,,IC50,nM,,0.38,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.38
,1197643,28776014,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCCC(N(C)c2ccccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.52', 'le': '0.20', 'lle': '0.70', 'sei': '5.40'}",CHEMBL5937698,,CHEMBL5937698,9.46,0,http://www.openphacts.org/units/Nanomolar,4590953,=,37,1,=,,IC50,nM,,0.35,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.35
,1197645,28776020,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(CC1CCCN1C)c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.68', 'le': '0.20', 'lle': '0.84', 'sei': '5.48'}",CHEMBL5770993,,CHEMBL5770993,9.60,0,http://www.openphacts.org/units/Nanomolar,4590954,=,37,1,=,,IC50,nM,,0.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.25
,1197647,28776026,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC2(CC1)CN(c1ccccc1[C@H]1CCCN1c1ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc1)C2,,,CHEMBL5729271,,2022,"{'bei': '10.48', 'le': '0.20', 'lle': '0.79', 'sei': '5.45'}",CHEMBL6039338,,CHEMBL6039338,9.55,0,http://www.openphacts.org/units/Nanomolar,4590955,=,37,1,=,,IC50,nM,,0.28,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.28
,1197649,28776032,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC1CCCN1c1ccccc1C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.16', 'le': '0.19', 'lle': '0.37', 'sei': '5.21'}",CHEMBL5886990,,CHEMBL5886990,9.13,0,http://www.openphacts.org/units/Nanomolar,4590956,=,37,1,=,,IC50,nM,,0.74,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.74
,1197651,28776038,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1cc(-c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)cn1,,,CHEMBL5729271,,2022,"{'bei': '9.82', 'le': '0.18', 'lle': '-0.25', 'sei': '4.49'}",CHEMBL6034329,,CHEMBL6034329,8.38,0,http://www.openphacts.org/units/Nanomolar,4590957,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,1197653,28776044,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(n2nccc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '0.48', 'sei': '4.30'}",CHEMBL6049502,,CHEMBL6049502,8.17,0,http://www.openphacts.org/units/Nanomolar,4590958,=,37,1,=,,IC50,nM,,6.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.8
,1197654,28776047,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccc(Cl)cc2C2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.69', 'le': '0.19', 'lle': '-0.86', 'sei': '5.08'}",CHEMBL5835085,,CHEMBL5835085,8.74,0,http://www.openphacts.org/units/Nanomolar,4590959,=,37,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,1197656,28776053,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc4ccncc34)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.87', 'le': '0.17', 'lle': '-1.47', 'sei': '4.02'}",CHEMBL5815551,,CHEMBL5815551,7.31,0,http://www.openphacts.org/units/Nanomolar,4590960,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1197657,28776056,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1cc2cccc(C3CCCN3c3ccc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc3)c2n1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.20', 'sei': '4.24'}",CHEMBL6014680,,CHEMBL6014680,7.92,0,http://www.openphacts.org/units/Nanomolar,4590961,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197659,28776062,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCc2cccc(C3CCCN3c3ccc(-c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)cc3)c2C1,,,CHEMBL5729271,,2022,"{'bei': '9.26', 'le': '0.17', 'lle': '-0.42', 'sei': '4.53'}",CHEMBL5768126,,CHEMBL5768126,7.80,0,http://www.openphacts.org/units/Nanomolar,4590962,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1197660,28776065,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(c1ccccc1C1CC1)C1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '8.71', 'le': '0.16', 'lle': '-2.27', 'sei': '4.41'}",CHEMBL6006703,,CHEMBL6006703,7.44,0,http://www.openphacts.org/units/Nanomolar,4590963,=,37,1,=,,IC50,nM,,36.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,36.0
,1197662,28776071,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@H](F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.72', 'le': '0.18', 'lle': '-0.97', 'sei': '4.78'}",CHEMBL5756700,,CHEMBL5756700,8.08,0,http://www.openphacts.org/units/Nanomolar,4590964,=,37,1,=,,IC50,nM,,8.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.4
,1197664,28776077,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@H](F)C[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.91', 'le': '0.19', 'lle': '-0.81', 'sei': '4.88'}",CHEMBL6017527,,CHEMBL6017527,8.24,0,http://www.openphacts.org/units/Nanomolar,4590965,=,37,1,=,,IC50,nM,,5.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.8
,1197666,28776083,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@@H](F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.26', 'le': '0.21', 'lle': '0.31', 'sei': '5.54'}",CHEMBL5795254,,CHEMBL5795254,9.36,0,http://www.openphacts.org/units/Nanomolar,4590966,=,37,1,=,,IC50,nM,,0.44,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.44
,1197668,28776089,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C[C@@H](F)C[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.07', 'le': '0.17', 'lle': '-1.51', 'sei': '4.47'}",CHEMBL5882599,,CHEMBL5882599,7.54,0,http://www.openphacts.org/units/Nanomolar,4590967,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197669,28776092,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)=CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.51', 'le': '0.18', 'lle': '-1.29', 'sei': '4.67'}",CHEMBL5781680,,CHEMBL5781680,7.89,0,http://www.openphacts.org/units/Nanomolar,4590968,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1197671,28776098,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)(F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.07', 'le': '0.17', 'lle': '-1.65', 'sei': '4.56'}",CHEMBL6002785,,CHEMBL6002785,7.70,0,http://www.openphacts.org/units/Nanomolar,4590969,=,37,1,=,,IC50,nM,,20.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,20.0
,1197673,28776104,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(F)(F)C[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.30', 'le': '0.20', 'lle': '-0.61', 'sei': '5.18'}",CHEMBL6002785,,CHEMBL6002785,8.74,0,http://www.openphacts.org/units/Nanomolar,4590969,=,37,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,1197675,28776110,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(C4CC4)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.45', 'le': '0.16', 'lle': '-2.53', 'sei': '4.27'}",CHEMBL5752551,,CHEMBL5752551,7.21,0,http://www.openphacts.org/units/Nanomolar,4590970,=,37,1,=,,IC50,nM,,62.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,62.0
,1197676,28776113,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(c4ccccc4)CC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5850888,,CHEMBL5850888,,0,http://www.openphacts.org/units/Nanomolar,4590971,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197677,28776116,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.28', 'le': '0.19', 'lle': '-0.79', 'sei': '5.02'}",CHEMBL5831285,,CHEMBL5831285,8.48,0,http://www.openphacts.org/units/Nanomolar,4590972,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197679,28776122,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CC(c2ccccc2C2CC2)N(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.01', 'le': '0.19', 'lle': '-0.08', 'sei': '4.98'}",CHEMBL5866105,,CHEMBL5866105,8.57,0,http://www.openphacts.org/units/Nanomolar,4590973,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,1197680,28776125,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.05', 'le': '0.17', 'lle': '-2.02', 'sei': '4.43'}",CHEMBL5823408,,CHEMBL5823408,7.48,0,http://www.openphacts.org/units/Nanomolar,4590900,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,1197682,28776131,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3C(=O)COCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.76', 'le': '0.18', 'lle': '0.36', 'sei': '4.22'}",CHEMBL5804914,,CHEMBL5804914,8.23,0,http://www.openphacts.org/units/Nanomolar,4590974,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1197683,28776134,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCOCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.24', 'le': '0.17', 'lle': '-0.68', 'sei': '4.30'}",CHEMBL5860255,,CHEMBL5860255,7.66,0,http://www.openphacts.org/units/Nanomolar,4590975,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,1197684,28776137,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.76', 'le': '0.18', 'lle': '-0.04', 'sei': '4.78'}",CHEMBL5980488,,CHEMBL5980488,8.22,0,http://www.openphacts.org/units/Nanomolar,4590976,=,37,1,=,,IC50,nM,,6.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.0
,1197686,28776143,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCN3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.55', 'le': '0.18', 'lle': '-0.63', 'sei': '4.52'}",CHEMBL5908080,,CHEMBL5908080,7.77,0,http://www.openphacts.org/units/Nanomolar,4590977,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197687,28776146,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCN3c3ccccc3C3CC3)cc2)cc1Oc1cccc(Nc2ncccn2)c1,,,CHEMBL5729271,,2022,,CHEMBL5881366,,CHEMBL5881366,,0,http://www.openphacts.org/units/Nanomolar,4590978,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197688,28776149,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CNC(=O)c1ccc(Oc2cc(-c3ccc(N4CCC[C@@H]4c4ccccc4C4CC4)cc3)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)cn1,,,CHEMBL5729271,,2022,,CHEMBL5925151,,CHEMBL5925151,,0,http://www.openphacts.org/units/Nanomolar,4590979,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197689,28776152,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cccc(CN3CCCC3c3ccccc3C3CC3)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5542383,,CHEMBL5542383,,0,http://www.openphacts.org/units/Nanomolar,4590980,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197690,28776155,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.04', 'le': '0.17', 'lle': '-1.54', 'sei': '4.50'}",CHEMBL5752506,,CHEMBL5752506,7.60,0,http://www.openphacts.org/units/Nanomolar,4590981,=,37,1,=,,IC50,nM,,25.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,25.0
,1197692,28776161,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CCN3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.62', 'le': '0.18', 'lle': '-1.05', 'sei': '4.79'}",CHEMBL6037553,,CHEMBL6037553,8.09,0,http://www.openphacts.org/units/Nanomolar,4590982,=,37,1,=,,IC50,nM,,8.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.1
,1197694,28776167,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(CN3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.12', 'le': '0.19', 'lle': '-0.71', 'sei': '4.98'}",CHEMBL5805324,,CHEMBL5805324,8.41,0,http://www.openphacts.org/units/Nanomolar,4590983,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,1197696,28776173,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC[C@@H](CN3CCC[C@@H]3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5987502,,CHEMBL5987502,,0,http://www.openphacts.org/units/Nanomolar,4590984,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197697,28776176,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC[C@@H](CN3CCC[C@H]3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5828187,,CHEMBL5828187,,0,http://www.openphacts.org/units/Nanomolar,4590985,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197698,28776179,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC[C@H](CN3CCC[C@@H]3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5992308,,CHEMBL5992308,,0,http://www.openphacts.org/units/Nanomolar,4590986,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197699,28776182,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC[C@H](CN3CCC[C@H]3c3ccccc3C3CC3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5752307,,CHEMBL5752307,,0,http://www.openphacts.org/units/Nanomolar,4590987,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197700,28776185,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCC[C@H]3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.46', 'le': '0.16', 'lle': '-2.10', 'sei': '4.15'}",CHEMBL5845601,,CHEMBL5845601,7.00,0,http://www.openphacts.org/units/Nanomolar,4590633,=,37,1,=,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197701,28776188,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCC[C@@H]3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5923137,,CHEMBL5923137,,0,http://www.openphacts.org/units/Nanomolar,4590988,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197702,28776191,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1)N1CCCC1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,,CHEMBL6034288,,CHEMBL6034288,,0,http://www.openphacts.org/units/Nanomolar,4590989,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197703,28776194,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)o2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5566112,,CHEMBL5566112,,0,http://www.openphacts.org/units/Nanomolar,4590990,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197704,28776197,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CC(N4CCCC4c4ccccc4C4CC4)C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.78', 'le': '0.17', 'lle': '-1.17', 'sei': '4.43'}",CHEMBL5565358,,CHEMBL5565358,7.62,0,http://www.openphacts.org/units/Nanomolar,4590991,=,37,1,=,,IC50,nM,,24.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,24.0
,1197705,28776200,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC(N3CC(N4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '1.24', 'sei': '4.59'}",CHEMBL5559198,,CHEMBL5559198,8.05,0,http://www.openphacts.org/units/Nanomolar,4590992,=,37,1,=,,IC50,nM,,9.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.0
,1197706,28776203,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC(C3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.21', 'le': '0.17', 'lle': '-0.88', 'sei': '4.68'}",CHEMBL5871667,,CHEMBL5871667,8.05,0,http://www.openphacts.org/units/Nanomolar,4590993,=,37,1,=,,IC50,nM,,8.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,8.9
,1197708,28776209,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.62', 'le': '0.18', 'lle': '-1.07', 'sei': '4.72'}",CHEMBL5780703,,CHEMBL5780703,7.96,0,http://www.openphacts.org/units/Nanomolar,4590994,=,37,1,=,,IC50,nM,,11.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,11.0
,1197709,28776212,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(CC2CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.11', 'le': '0.17', 'lle': '-1.45', 'sei': '4.49'}",CHEMBL5946813,,CHEMBL5946813,7.58,0,http://www.openphacts.org/units/Nanomolar,4590995,=,37,1,=,,IC50,nM,,26.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,26.0
,1197710,28776215,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Cc2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.71', 'le': '0.16', 'lle': '-1.70', 'sei': '4.34'}",CHEMBL5561459,,CHEMBL5561459,7.33,0,http://www.openphacts.org/units/Nanomolar,4590996,=,37,1,=,,IC50,nM,,47.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,47.0
,1197711,28776218,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(Nc2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.46', 'le': '0.14', 'lle': '-3.00', 'sei': '3.42'}",CHEMBL5903784,,CHEMBL5903784,6.18,0,http://www.openphacts.org/units/Nanomolar,4590997,=,37,1,=,,IC50,nM,,660.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,660.0
,1197712,28776221,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.97', 'le': '0.17', 'lle': '-0.51', 'sei': '4.20'}",CHEMBL5758712,,CHEMBL5758712,7.23,0,http://www.openphacts.org/units/Nanomolar,4590998,=,37,1,=,,IC50,nM,,59.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,59.0
,1197713,28776224,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC6(CCCN6c6ccccc6C6CC6)CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,,CHEMBL5789244,,CHEMBL5789244,,0,http://www.openphacts.org/units/Nanomolar,4590999,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197714,28776227,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN3c3ccccc3Br)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.86', 'le': '0.18', 'lle': '-0.14', 'sei': '4.35'}",CHEMBL6013081,,CHEMBL6013081,7.48,0,http://www.openphacts.org/units/Nanomolar,4591000,=,37,1,=,,IC50,nM,,33.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,33.0
,1197715,28776230,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc5c(c4)CCC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '8.68', 'le': '0.16', 'lle': '-2.20', 'sei': '4.32'}",CHEMBL5932011,,CHEMBL5932011,7.77,0,http://www.openphacts.org/units/Nanomolar,4591001,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1197716,28776233,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc3[nH]c(N4CCCC4c4ccccc4C4CC4)nc3c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.28', 'le': '0.16', 'lle': '-1.92', 'sei': '3.58'}",CHEMBL5831887,,CHEMBL5831887,7.06,0,http://www.openphacts.org/units/Nanomolar,4591002,=,37,1,=,,IC50,nM,,87.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,87.0
,1197717,28776236,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1)N1CCCC1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,,CHEMBL5769676,,CHEMBL5769676,,0,http://www.openphacts.org/units/Nanomolar,4591003,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197718,28776239,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cnn(C3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)c2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.08', 'le': '0.19', 'lle': '0.14', 'sei': '4.63'}",CHEMBL5759943,,CHEMBL5759943,8.64,0,http://www.openphacts.org/units/Nanomolar,4591004,=,37,1,=,,IC50,nM,,2.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.3
,1197720,28776245,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCc4scc(-c5ccccc5)c4C3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,,CHEMBL5907451,,CHEMBL5907451,,0,http://www.openphacts.org/units/Nanomolar,4591005,>,37,1,>,,IC50,nM,,100.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,100.0
,1197721,28776248,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CCCN(c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.73', 'le': '0.17', 'lle': '-0.83', 'sei': '4.16'}",CHEMBL5799858,,CHEMBL5799858,7.16,0,http://www.openphacts.org/units/Nanomolar,4591006,=,37,1,=,,IC50,nM,,69.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,69.0
,1197722,28776251,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc([C@H]2CC[C@@H](N3CC(N4CCC[C@@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.62', 'le': '0.16', 'lle': '-1.11', 'sei': '4.38'}",CHEMBL6059089,,CHEMBL6059089,7.54,0,http://www.openphacts.org/units/Nanomolar,4591007,=,37,1,=,,IC50,nM,,29.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,29.0
,1197723,28776254,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc([C@H]2CC[C@@H](N3CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.03', 'le': '0.19', 'lle': '0.12', 'sei': '5.10'}",CHEMBL5856671,,CHEMBL5856671,8.77,0,http://www.openphacts.org/units/Nanomolar,4591008,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,1197724,28776257,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3cc(N4CCC[C@@H]4c4ccccc4)ccc3s2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.48', 'le': '0.24', 'lle': '0.91', 'sei': '6.13'}",CHEMBL5742800,,CHEMBL5742800,10.35,0,http://www.openphacts.org/units/Nanomolar,4590783,=,37,1,=,,IC50,nM,,0.045,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.045
,1197726,28776263,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.10', 'le': '0.23', 'lle': '1.73', 'sei': '6.05'}",CHEMBL5555281,,CHEMBL5555281,10.41,0,http://www.openphacts.org/units/Nanomolar,4591009,=,37,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
,1197728,28776269,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.95', 'le': '0.23', 'lle': '1.71', 'sei': '6.10'}",CHEMBL5972266,,CHEMBL5972266,10.49,0,http://www.openphacts.org/units/Nanomolar,4591010,=,37,1,=,,IC50,nM,,0.032,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.032
,1197730,28776275,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '12.00', 'le': '0.23', 'lle': '1.46', 'sei': '5.82'}",CHEMBL5854463,,CHEMBL5854463,10.66,0,http://www.openphacts.org/units/Nanomolar,4591011,=,37,1,=,,IC50,nM,,0.022,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.022
,1197732,28776281,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.92', 'le': '0.23', 'lle': '1.74', 'sei': '5.88'}",CHEMBL5542719,,CHEMBL5542719,10.11,0,http://www.openphacts.org/units/Nanomolar,4591012,=,37,1,=,,IC50,nM,,0.078,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.078
,1197734,28776287,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.98', 'le': '0.23', 'lle': '1.92', 'sei': '6.03'}",CHEMBL5807781,,CHEMBL5807781,10.38,0,http://www.openphacts.org/units/Nanomolar,4591013,=,37,1,=,,IC50,nM,,0.042,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.042
,1197736,28776293,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.95', 'le': '0.23', 'lle': '1.59', 'sei': '5.72'}",CHEMBL5941957,,CHEMBL5941957,10.47,0,http://www.openphacts.org/units/Nanomolar,4591014,=,37,1,=,,IC50,nM,,0.034,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.034
,1197738,28776299,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.37', 'le': '0.20', 'lle': '0.24', 'sei': '5.19'}",CHEMBL5564343,,CHEMBL5564343,8.92,0,http://www.openphacts.org/units/Nanomolar,4591015,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197740,28776305,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.26', 'le': '0.20', 'lle': '0.23', 'sei': '5.24'}",CHEMBL5896999,,CHEMBL5896999,9.01,0,http://www.openphacts.org/units/Nanomolar,4591016,=,37,1,=,,IC50,nM,,0.98,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.98
,1197742,28776311,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.36', 'le': '0.20', 'lle': '0.00', 'sei': '5.03'}",CHEMBL5792023,,CHEMBL5792023,9.20,0,http://www.openphacts.org/units/Nanomolar,4591017,=,37,1,=,,IC50,nM,,0.63,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.63
,1197744,28776317,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.06', 'le': '0.23', 'lle': '2.14', 'sei': '5.83'}",CHEMBL5836554,,CHEMBL5836554,10.04,0,http://www.openphacts.org/units/Nanomolar,4591018,=,37,1,=,,IC50,nM,,0.092,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.092
,1197746,28776323,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.64', 'le': '0.20', 'lle': '0.95', 'sei': '5.15'}",CHEMBL6017239,,CHEMBL6017239,8.85,0,http://www.openphacts.org/units/Nanomolar,4591019,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,1197748,28776329,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1c(Cl)cccc1C1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.19', 'sei': '4.76'}",CHEMBL5828065,,CHEMBL5828065,8.34,0,http://www.openphacts.org/units/Nanomolar,4590790,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,1197750,28776335,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.05', 'le': '0.23', 'lle': '2.72', 'sei': '5.73'}",CHEMBL5980890,,CHEMBL5980890,10.39,0,http://www.openphacts.org/units/Nanomolar,4591020,=,37,1,=,,IC50,nM,,0.041,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.041
,1197752,28776341,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.78', 'le': '0.22', 'lle': '2.48', 'sei': '5.60'}",CHEMBL5965443,,CHEMBL5965443,10.15,0,http://www.openphacts.org/units/Nanomolar,4591021,=,37,1,=,,IC50,nM,,0.07,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.07
,1197754,28776347,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC[C@@H](N4CCC[C@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.07', 'le': '0.21', 'lle': '0.61', 'sei': '5.63'}",CHEMBL5854815,,CHEMBL5854815,9.68,0,http://www.openphacts.org/units/Nanomolar,4591022,=,37,1,=,,IC50,nM,,0.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.21
,1197756,28776353,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC[C@@H](N4CCC[C@@H]4c4ccccc4C4CC4)C3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.62', 'le': '0.18', 'lle': '-0.66', 'sei': '4.89'}",CHEMBL5812634,,CHEMBL5812634,8.41,0,http://www.openphacts.org/units/Nanomolar,4591023,=,37,1,=,,IC50,nM,,3.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.9
,1197758,28776359,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.17', 'le': '0.23', 'lle': '2.99', 'sei': '5.71'}",CHEMBL5877687,,CHEMBL5877687,10.35,0,http://www.openphacts.org/units/Nanomolar,4591024,=,37,1,=,,IC50,nM,,0.045,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.045
,1197760,28776365,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.03', 'le': '0.23', 'lle': '2.87', 'sei': '5.64'}",CHEMBL5903988,,CHEMBL5903988,10.23,0,http://www.openphacts.org/units/Nanomolar,4591025,=,37,1,=,,IC50,nM,,0.059,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.059
,1197762,28776371,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(Cn3cnc4c(N)ncnc43)c(N3CCC[C@@H](N)C3)cn2)cc1F,,,CHEMBL5729271,,2022,"{'bei': '16.40', 'le': '0.30', 'lle': '4.77', 'sei': '6.08'}",CHEMBL6020918,,CHEMBL6020918,7.36,0,http://www.openphacts.org/units/Nanomolar,4591026,=,37,1,=,,IC50,nM,,44.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,44.0
,1197763,28776374,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccc(-c2cc(Cn3cnc4c(N)ncnc43)c(N3CCC[C@@H](N)C3)cn2)cc1F,,,CHEMBL5729271,,2022,"{'bei': '24.13', 'le': '0.45', 'lle': '8.23', 'sei': '8.95'}",CHEMBL6020918,,CHEMBL6020918,10.82,0,http://www.openphacts.org/units/Nanomolar,4591026,=,37,1,=,,IC50,nM,,0.015,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.015
,1197765,28776380,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.94', 'le': '0.23', 'lle': '2.40', 'sei': '5.69'}",CHEMBL5567138,,CHEMBL5567138,10.32,0,http://www.openphacts.org/units/Nanomolar,4591027,=,37,1,=,,IC50,nM,,0.048,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.048
,1197767,28776386,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.11', 'le': '0.23', 'lle': '1.51', 'sei': '6.07'}",CHEMBL5560614,,CHEMBL5560614,10.44,0,http://www.openphacts.org/units/Nanomolar,4591028,=,37,1,=,,IC50,nM,,0.036,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.036
,1197769,28776392,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.69', 'le': '0.22', 'lle': '1.26', 'sei': '5.98'}",CHEMBL5775285,,CHEMBL5775285,10.28,0,http://www.openphacts.org/units/Nanomolar,4591029,=,37,1,=,,IC50,nM,,0.052,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.052
,1197771,28776398,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.06', 'le': '0.23', 'lle': '2.50', 'sei': '5.75'}",CHEMBL5556406,,CHEMBL5556406,10.42,0,http://www.openphacts.org/units/Nanomolar,4591030,=,37,1,=,,IC50,nM,,0.038,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.038
,1197773,28776404,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.38', 'le': '0.22', 'lle': '0.69', 'sei': '5.54'}",CHEMBL5560668,,CHEMBL5560668,10.13,0,http://www.openphacts.org/units/Nanomolar,4591031,=,37,1,=,,IC50,nM,,0.074,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.074
,1197775,28776410,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.26', 'le': '0.19', 'lle': '-0.31', 'sei': '4.99'}",CHEMBL5943655,,CHEMBL5943655,9.13,0,http://www.openphacts.org/units/Nanomolar,4591032,=,37,1,=,,IC50,nM,,0.74,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.74
,1197777,28776416,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.75', 'le': '0.19', 'lle': '-0.76', 'sei': '4.74'}",CHEMBL5868656,,CHEMBL5868656,8.68,0,http://www.openphacts.org/units/Nanomolar,4591033,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,1197779,28776422,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2C2CCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.11', 'sei': '5.21'}",CHEMBL5970525,,CHEMBL5970525,8.96,0,http://www.openphacts.org/units/Nanomolar,4591034,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1197781,28776428,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.04', 'le': '0.19', 'lle': '-0.21', 'sei': '5.11'}",CHEMBL5568440,,CHEMBL5568440,8.80,0,http://www.openphacts.org/units/Nanomolar,4591035,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1197783,28776434,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cccc(C4CC4)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.46', 'le': '0.20', 'lle': '0.32', 'sei': '5.23'}",CHEMBL5766570,,CHEMBL5766570,9.00,0,http://www.openphacts.org/units/Nanomolar,4591036,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,1197785,28776440,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.94', 'le': '0.23', 'lle': '1.84', 'sei': '5.79'}",CHEMBL5564290,,CHEMBL5564290,9.96,0,http://www.openphacts.org/units/Nanomolar,4591037,=,37,1,=,,IC50,nM,,0.11,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.11
,1197787,28776446,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.13', 'le': '0.22', 'lle': '1.05', 'sei': '5.53'}",CHEMBL5565335,,CHEMBL5565335,9.51,0,http://www.openphacts.org/units/Nanomolar,4591038,=,37,1,=,,IC50,nM,,0.31,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.31
,1197789,28776452,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Br)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.42', 'le': '0.21', 'lle': '0.80', 'sei': '5.44'}",CHEMBL5562355,,CHEMBL5562355,9.37,0,http://www.openphacts.org/units/Nanomolar,4591039,=,37,1,=,,IC50,nM,,0.43,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.43
,1197791,28776458,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.78', 'le': '0.19', 'lle': '-0.10', 'sei': '4.86'}",CHEMBL6045065,,CHEMBL6045065,8.36,0,http://www.openphacts.org/units/Nanomolar,4591040,=,37,1,=,,IC50,nM,,4.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.4
,1197793,28776464,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.74', 'le': '0.19', 'lle': '-0.14', 'sei': '4.84'}",CHEMBL5557109,,CHEMBL5557109,8.32,0,http://www.openphacts.org/units/Nanomolar,4591041,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,1197795,28776470,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.75', 'le': '0.19', 'lle': '-0.13', 'sei': '4.84'}",CHEMBL6062678,,CHEMBL6062678,8.33,0,http://www.openphacts.org/units/Nanomolar,4591042,=,37,1,=,,IC50,nM,,4.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.7
,1197796,28776473,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccc(Cl)cc2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '-0.35', 'sei': '4.72'}",CHEMBL5554998,,CHEMBL5554998,8.11,0,http://www.openphacts.org/units/Nanomolar,4591043,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,1197798,28776479,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCOc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.68', 'le': '0.22', 'lle': '1.88', 'sei': '5.57'}",CHEMBL5556265,,CHEMBL5556265,10.09,0,http://www.openphacts.org/units/Nanomolar,4591044,=,37,1,=,,IC50,nM,,0.081,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.081
,1197800,28776485,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.33', 'le': '0.23', 'lle': '2.77', 'sei': '6.07'}",CHEMBL5560718,,CHEMBL5560718,10.64,0,http://www.openphacts.org/units/Nanomolar,4591045,=,37,1,=,,IC50,nM,,0.023,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.023
,1197802,28776491,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.98', 'le': '0.23', 'lle': '2.29', 'sei': '5.73'}",CHEMBL5806214,,CHEMBL5806214,10.68,0,http://www.openphacts.org/units/Nanomolar,4591046,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1197804,28776497,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.01', 'le': '0.23', 'lle': '2.31', 'sei': '5.74'}",CHEMBL5806214,,CHEMBL5806214,10.70,0,http://www.openphacts.org/units/Nanomolar,4591047,=,37,1,=,,IC50,nM,,0.02,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.02
,1197806,28776503,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2N2CCCC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.68', 'le': '0.20', 'lle': '1.08', 'sei': '5.42'}",CHEMBL5875749,,CHEMBL5875749,9.49,0,http://www.openphacts.org/units/Nanomolar,4591048,=,37,1,=,,IC50,nM,,0.32,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.32
,1197808,28776509,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@@H]2CCCN2C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)CC1,,,CHEMBL5729271,,2022,"{'bei': '7.92', 'le': '0.15', 'lle': '-1.29', 'sei': '4.13'}",CHEMBL6051188,,CHEMBL6051188,7.24,0,http://www.openphacts.org/units/Nanomolar,4591049,=,37,1,=,,IC50,nM,,57.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,57.0
,1197809,28776512,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@@H]2CCCN2C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)CC1,,,CHEMBL5729271,,2022,"{'bei': '7.75', 'le': '0.15', 'lle': '-1.51', 'sei': '4.06'}",CHEMBL5894601,,CHEMBL5894601,7.11,0,http://www.openphacts.org/units/Nanomolar,4591050,=,37,1,=,,IC50,nM,,78.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,78.0
,1197810,28776515,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.67', 'le': '0.22', 'lle': '2.10', 'sei': '5.47'}",CHEMBL5567413,,CHEMBL5567413,9.92,0,http://www.openphacts.org/units/Nanomolar,4591051,=,37,1,=,,IC50,nM,,0.12,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.12
,1197812,28776521,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)Oc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.52', 'le': '0.22', 'lle': '1.53', 'sei': '5.58'}",CHEMBL5562626,,CHEMBL5562626,10.12,0,http://www.openphacts.org/units/Nanomolar,4591052,=,37,1,=,,IC50,nM,,0.076,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.076
,1197814,28776527,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COCc1ccccc1C1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.13', 'le': '0.21', 'lle': '1.67', 'sei': '5.31'}",CHEMBL5739744,,CHEMBL5739744,9.62,0,http://www.openphacts.org/units/Nanomolar,4591053,=,37,1,=,,IC50,nM,,0.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.24
,1197816,28776533,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccccc2CO)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.21', 'le': '0.19', 'lle': '1.38', 'sei': '4.51'}",CHEMBL5928650,,CHEMBL5928650,8.68,0,http://www.openphacts.org/units/Nanomolar,4591054,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,1197818,28776539,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.93', 'le': '0.19', 'lle': '-0.45', 'sei': '5.17'}",CHEMBL5880669,,CHEMBL5880669,8.89,0,http://www.openphacts.org/units/Nanomolar,4591055,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,1197820,28776545,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@@H]2c2cccc(Cl)c2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.73', 'le': '0.19', 'lle': '-0.64', 'sei': '5.06'}",CHEMBL5880669,,CHEMBL5880669,8.70,0,http://www.openphacts.org/units/Nanomolar,4591055,=,37,1,=,,IC50,nM,,2.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.0
,1197822,28776551,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cc(Cl)ccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '-0.38', 'sei': '5.21'}",CHEMBL5780722,,CHEMBL5780722,8.96,0,http://www.openphacts.org/units/Nanomolar,4591056,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1197824,28776557,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c(Cl)cccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.88', 'le': '0.19', 'lle': '-0.30', 'sei': '5.07'}",CHEMBL5812498,,CHEMBL5812498,8.72,0,http://www.openphacts.org/units/Nanomolar,4591057,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,1197826,28776563,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1c(Cl)cccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.03', 'le': '0.20', 'lle': '-0.17', 'sei': '5.15'}",CHEMBL5925442,,CHEMBL5925442,8.85,0,http://www.openphacts.org/units/Nanomolar,4591058,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,1197828,28776569,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2ccc(C4CC4)cc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.80', 'le': '0.19', 'lle': '-0.74', 'sei': '5.13'}",CHEMBL5754014,,CHEMBL5754014,8.82,0,http://www.openphacts.org/units/Nanomolar,4591059,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1197830,28776575,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cc(C4CC4)ccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.80', 'le': '0.17', 'lle': '-1.64', 'sei': '4.60'}",CHEMBL5841055,,CHEMBL5841055,7.92,0,http://www.openphacts.org/units/Nanomolar,4591060,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1197832,28776581,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2sccc2-c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.16', 'le': '0.16', 'lle': '-2.55', 'sei': '4.44'}",CHEMBL5861737,,CHEMBL5861737,7.64,0,http://www.openphacts.org/units/Nanomolar,4591061,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197833,28776584,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.07', 'le': '0.21', 'lle': '0.75', 'sei': '5.63'}",CHEMBL5941985,,CHEMBL5941985,9.68,0,http://www.openphacts.org/units/Nanomolar,4591062,=,37,1,=,,IC50,nM,,0.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.21
,1197835,28776590,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(C4CC4)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '-0.36', 'sei': '5.21'}",CHEMBL5865162,,CHEMBL5865162,8.96,0,http://www.openphacts.org/units/Nanomolar,4591063,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1197837,28776596,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(c4ccccc4)=CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.02', 'le': '0.15', 'lle': '-2.50', 'sei': '4.36'}",CHEMBL5921534,,CHEMBL5921534,7.50,0,http://www.openphacts.org/units/Nanomolar,4591064,=,37,1,=,,IC50,nM,,32.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,32.0
,1197839,28776602,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC4(CC4)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.44', 'le': '0.20', 'lle': '0.18', 'sei': '5.38'}",CHEMBL6057391,,CHEMBL6057391,9.25,0,http://www.openphacts.org/units/Nanomolar,4591065,=,37,1,=,,IC50,nM,,0.56,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.56
,1197841,28776608,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.23', 'le': '0.19', 'lle': '-0.23', 'sei': '5.28'}",CHEMBL5862801,,CHEMBL5862801,9.09,0,http://www.openphacts.org/units/Nanomolar,4591066,=,37,1,=,,IC50,nM,,0.82,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.82
,1197843,28776614,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC(F)(F)CC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.11', 'le': '0.17', 'lle': '-0.77', 'sei': '4.74'}",CHEMBL5959586,,CHEMBL5959586,8.16,0,http://www.openphacts.org/units/Nanomolar,4591067,=,37,1,=,,IC50,nM,,6.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.9
,1197844,28776617,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CC(C(F)(F)F)CC4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '8.81', 'le': '0.17', 'lle': '-1.57', 'sei': '4.60'}",CHEMBL5813106,,CHEMBL5813106,8.42,0,http://www.openphacts.org/units/Nanomolar,4591068,=,37,1,=,,IC50,nM,,3.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.8
,1197846,28776623,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.33', 'le': '0.22', 'lle': '2.02', 'sei': '5.84'}",CHEMBL5934720,,CHEMBL5934720,10.24,0,http://www.openphacts.org/units/Nanomolar,4591069,=,37,1,=,,IC50,nM,,0.058,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.058
,1197848,28776629,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCOC1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.37', 'le': '0.20', 'lle': '1.58', 'sei': '5.32'}",CHEMBL5914817,,CHEMBL5914817,9.82,0,http://www.openphacts.org/units/Nanomolar,4591070,=,37,1,=,,IC50,nM,,0.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.15
,1197850,28776635,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2C(c4ccccc4C4CC4)CC4CC42)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.12', 'le': '0.19', 'lle': '0.14', 'sei': '5.13'}",CHEMBL5974384,,CHEMBL5974384,8.82,0,http://www.openphacts.org/units/Nanomolar,4591071,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1197851,28776638,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CC4CCCC4C2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.77', 'le': '0.18', 'lle': '-0.52', 'sei': '5.11'}",CHEMBL5987746,,CHEMBL5987746,8.80,0,http://www.openphacts.org/units/Nanomolar,4591072,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1197853,28776644,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1c1ccccc1C1CC1,,,CHEMBL5729271,,2022,"{'bei': '9.87', 'le': '0.19', 'lle': '-0.55', 'sei': '5.10'}",CHEMBL5792180,,CHEMBL5792180,8.77,0,http://www.openphacts.org/units/Nanomolar,4591073,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,1197855,28776650,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.28', 'le': '0.21', 'lle': '2.19', 'sei': '5.72'}",CHEMBL5768701,,CHEMBL5768701,10.03,0,http://www.openphacts.org/units/Nanomolar,4591074,=,37,1,=,,IC50,nM,,0.094,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.094
,1197857,28776656,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@H](c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.07', 'le': '0.21', 'lle': '1.80', 'sei': '5.45'}",CHEMBL6011671,,CHEMBL6011671,10.15,0,http://www.openphacts.org/units/Nanomolar,4591075,=,37,1,=,,IC50,nM,,0.071,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.071
,1197859,28776662,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@@H](c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.12', 'le': '0.21', 'lle': '1.85', 'sei': '5.48'}",CHEMBL5865603,,CHEMBL5865603,10.20,0,http://www.openphacts.org/units/Nanomolar,4591076,=,37,1,=,,IC50,nM,,0.063,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.063
,1197861,28776668,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)N1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.56', 'le': '0.22', 'lle': '1.99', 'sei': '6.05'}",CHEMBL6016510,,CHEMBL6016510,10.60,0,http://www.openphacts.org/units/Nanomolar,4591077,=,37,1,=,,IC50,nM,,0.025,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.025
,1197863,28776674,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(c2ccccc2-c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.02', 'le': '0.17', 'lle': '-2.11', 'sei': '4.64'}",CHEMBL5839129,,CHEMBL5839129,7.82,0,http://www.openphacts.org/units/Nanomolar,4591078,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1197865,28776680,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1C1CCCCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.46', 'le': '0.20', 'lle': '0.11', 'sei': '5.24'}",CHEMBL5992969,,CHEMBL5992969,9.01,0,http://www.openphacts.org/units/Nanomolar,4591079,=,37,1,=,,IC50,nM,,0.97,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.97
,1197867,28776686,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCCCC2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.76', 'le': '0.20', 'lle': '0.09', 'sei': '5.55'}",CHEMBL5836711,,CHEMBL5836711,9.55,0,http://www.openphacts.org/units/Nanomolar,4591080,=,37,1,=,,IC50,nM,,0.28,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.28
,1197869,28776692,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCN2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.79', 'le': '0.17', 'lle': '-0.40', 'sei': '4.32'}",CHEMBL5757679,,CHEMBL5757679,7.57,0,http://www.openphacts.org/units/Nanomolar,4591081,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1197870,28776695,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(C)(=O)=NC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.88', 'le': '0.21', 'lle': '0.79', 'sei': '5.37'}",CHEMBL5967093,,CHEMBL5967093,10.33,0,http://www.openphacts.org/units/Nanomolar,4591082,=,37,1,=,,IC50,nM,,0.047,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.047
,1197872,28776701,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=NC(=O)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1,,,CHEMBL5729271,,2022,"{'bei': '9.88', 'le': '0.19', 'lle': '-1.38', 'sei': '5.46'}",CHEMBL6014192,,CHEMBL6014192,8.48,0,http://www.openphacts.org/units/Nanomolar,4591083,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197874,28776707,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5C6COCC56)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.35', 'le': '0.23', 'lle': '2.22', 'sei': '6.17'}",CHEMBL5523428,,CHEMBL5523428,10.62,0,http://www.openphacts.org/units/Nanomolar,4591084,=,37,1,=,,IC50,nM,,0.024,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.024
,1197876,28776713,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCC(O)(C(F)(F)F)CC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.87', 'le': '0.21', 'lle': '0.50', 'sei': '5.59'}",CHEMBL5931376,,CHEMBL5931376,10.24,0,http://www.openphacts.org/units/Nanomolar,4591085,=,37,1,=,,IC50,nM,,0.058,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.058
,1197878,28776719,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](O)(C(F)(F)F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.80', 'le': '0.21', 'lle': '0.21', 'sei': '5.57'}",CHEMBL5847503,,CHEMBL5847503,10.20,0,http://www.openphacts.org/units/Nanomolar,4591086,=,37,1,=,,IC50,nM,,0.063,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.063
,1197880,28776725,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](O)(C(F)(F)F)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.60', 'le': '0.20', 'lle': '0.02', 'sei': '5.47'}",CHEMBL5887445,,CHEMBL5887445,10.01,0,http://www.openphacts.org/units/Nanomolar,4591087,=,37,1,=,,IC50,nM,,0.098,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.098
,1197882,28776731,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CO[C@]1(C)CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '11.13', 'le': '0.21', 'lle': '-0.04', 'sei': '5.85'}",CHEMBL5561680,,CHEMBL5561680,10.06,0,http://www.openphacts.org/units/Nanomolar,4591088,=,37,1,=,,IC50,nM,,0.087,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.087
,1197884,28776737,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=CC[C@@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C(C)C)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.60', 'le': '0.20', 'lle': '-1.01', 'sei': '5.68'}",CHEMBL5928422,,CHEMBL5928422,9.24,0,http://www.openphacts.org/units/Nanomolar,4591089,=,37,1,=,,IC50,nM,,0.57,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.57
,1197886,28776743,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.55', 'le': '0.22', 'lle': '0.91', 'sei': '5.61'}",CHEMBL5989018,,CHEMBL5989018,10.26,0,http://www.openphacts.org/units/Nanomolar,4591090,=,37,1,=,,IC50,nM,,0.055,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.055
,1197888,28776749,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.28', 'le': '0.21', 'lle': '0.77', 'sei': '5.49'}",CHEMBL5995017,,CHEMBL5995017,10.04,0,http://www.openphacts.org/units/Nanomolar,4591091,=,37,1,=,,IC50,nM,,0.091,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.091
,1197890,28776755,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CC5(CC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '12.42', 'le': '0.24', 'lle': '2.26', 'sei': '5.83'}",CHEMBL5751643,,CHEMBL5751643,10.68,0,http://www.openphacts.org/units/Nanomolar,4591092,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1197892,28776761,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.38', 'le': '0.24', 'lle': '3.44', 'sei': '5.70'}",CHEMBL5956838,,CHEMBL5956838,10.33,0,http://www.openphacts.org/units/Nanomolar,4591093,=,37,1,=,,IC50,nM,,0.047,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.047
,1197894,28776767,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.35', 'le': '0.23', 'lle': '3.41', 'sei': '5.68'}",CHEMBL5991241,,CHEMBL5991241,10.30,0,http://www.openphacts.org/units/Nanomolar,4591094,=,37,1,=,,IC50,nM,,0.05,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.05
,1197896,28776773,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.07', 'le': '0.23', 'lle': '1.75', 'sei': '5.69'}",CHEMBL5766828,,CHEMBL5766828,10.41,0,http://www.openphacts.org/units/Nanomolar,4591095,=,37,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
,1197898,28776779,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4COCCO4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.27', 'le': '0.23', 'lle': '3.12', 'sei': '5.66'}",CHEMBL5921495,,CHEMBL5921495,10.26,0,http://www.openphacts.org/units/Nanomolar,4591096,=,37,1,=,,IC50,nM,,0.055,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.055
,1197900,28776785,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.41', 'le': '0.24', 'lle': '2.42', 'sei': '5.75'}",CHEMBL5953237,,CHEMBL5953237,10.52,0,http://www.openphacts.org/units/Nanomolar,4591097,=,37,1,=,,IC50,nM,,0.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.03
,1197902,28776791,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4COCCO4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.59', 'le': '0.24', 'lle': '3.77', 'sei': '5.71'}",CHEMBL5797193,,CHEMBL5797193,10.35,0,http://www.openphacts.org/units/Nanomolar,4591098,=,37,1,=,,IC50,nM,,0.045,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.045
,1197904,28776797,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(CN4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.04', 'sei': '4.71'}",CHEMBL5565924,,CHEMBL5565924,8.11,0,http://www.openphacts.org/units/Nanomolar,4591099,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,1197906,28776803,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CN(CC4CCCN4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.14', 'le': '0.19', 'lle': '1.70', 'sei': '4.90'}",CHEMBL5899288,,CHEMBL5899288,8.59,0,http://www.openphacts.org/units/Nanomolar,4591100,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1197908,28776809,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(CN2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-0.74', 'sei': '4.76'}",CHEMBL5888815,,CHEMBL5888815,8.19,0,http://www.openphacts.org/units/Nanomolar,4591101,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,1197909,28776812,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.31', 'le': '0.21', 'lle': '0.82', 'sei': '5.75'}",CHEMBL5836404,,CHEMBL5836404,9.89,0,http://www.openphacts.org/units/Nanomolar,4591102,=,37,1,=,,IC50,nM,,0.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.13
,1197911,28776818,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.23', 'le': '0.21', 'lle': '2.23', 'sei': '5.61'}",CHEMBL6023708,,CHEMBL6023708,9.82,0,http://www.openphacts.org/units/Nanomolar,4591103,=,37,1,=,,IC50,nM,,0.15,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.15
,1197913,28776824,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2=O)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.12', 'le': '0.21', 'lle': '2.77', 'sei': '5.14'}",CHEMBL5893372,,CHEMBL5893372,9.89,0,http://www.openphacts.org/units/Nanomolar,4591104,=,37,1,=,,IC50,nM,,0.13,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.13
,1197915,28776830,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2C3COCC23)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.07', 'le': '0.23', 'lle': '2.21', 'sei': '6.02'}",CHEMBL5785112,,CHEMBL5785112,10.36,0,http://www.openphacts.org/units/Nanomolar,4591105,=,37,1,=,,IC50,nM,,0.044,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.044
,1197917,28776836,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC(C)O1,,,CHEMBL5729271,,2022,"{'bei': '11.94', 'le': '0.23', 'lle': '1.14', 'sei': '6.16'}",CHEMBL5920200,,CHEMBL5920200,10.60,0,http://www.openphacts.org/units/Nanomolar,4591106,=,37,1,=,,IC50,nM,,0.025,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.025
,1197919,28776842,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC(C)(C)O1,,,CHEMBL5729271,,2022,"{'bei': '10.95', 'le': '0.21', 'lle': '-0.20', 'sei': '5.83'}",CHEMBL5783645,,CHEMBL5783645,10.04,0,http://www.openphacts.org/units/Nanomolar,4591107,=,37,1,=,,IC50,nM,,0.092,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.092
,1197921,28776848,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.45', 'le': '0.20', 'lle': '0.32', 'sei': '4.99'}",CHEMBL5762885,,CHEMBL5762885,9.13,0,http://www.openphacts.org/units/Nanomolar,4591108,=,37,1,=,,IC50,nM,,0.74,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.74
,1197923,28776854,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CC5(CCC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.95', 'le': '0.21', 'lle': '0.76', 'sei': '5.23'}",CHEMBL5934956,,CHEMBL5934956,9.57,0,http://www.openphacts.org/units/Nanomolar,4591109,=,37,1,=,,IC50,nM,,0.27,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.27
,1197925,28776860,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC[C@@H](N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.13', 'le': '0.19', 'lle': '-0.20', 'sei': '4.92'}",CHEMBL5857353,,CHEMBL5857353,9.00,0,http://www.openphacts.org/units/Nanomolar,4591110,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,1197927,28776866,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC[C@@H](N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.01', 'le': '0.19', 'lle': '-0.31', 'sei': '4.85'}",CHEMBL5857353,,CHEMBL5857353,8.89,0,http://www.openphacts.org/units/Nanomolar,4591110,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,1197929,28776872,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.56', 'le': '0.20', 'lle': '-0.82', 'sei': '5.20'}",CHEMBL5757676,,CHEMBL5757676,9.35,0,http://www.openphacts.org/units/Nanomolar,4591111,=,37,1,=,,IC50,nM,,0.45,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.45
,1197931,28776878,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Nc1ncc(Oc2cc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)cc1Cl,,,CHEMBL5729271,,2022,"{'bei': '11.62', 'le': '0.23', 'lle': '1.68', 'sei': '5.55'}",CHEMBL5809484,,CHEMBL5809484,10.12,0,http://www.openphacts.org/units/Nanomolar,4591112,=,37,1,=,,IC50,nM,,0.076,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.076
,1197933,28776884,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CCO1,,,CHEMBL5729271,,2022,"{'bei': '11.35', 'le': '0.22', 'lle': '0.62', 'sei': '5.86'}",CHEMBL5788757,,CHEMBL5788757,10.08,0,http://www.openphacts.org/units/Nanomolar,4591113,=,37,1,=,,IC50,nM,,0.084,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.084
,1197935,28776890,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(CC1CCOCC1)C(=O)Nc1ccc(S(=O)(=O)NC(=O)c2ccc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)cc2Oc2cnc3[nH]ccc3c2)cc1[N+](=O)[O-],,,CHEMBL5729271,,2022,"{'bei': '10.82', 'le': '0.21', 'lle': '1.18', 'sei': '5.16'}",CHEMBL5758637,,CHEMBL5758637,9.92,0,http://www.openphacts.org/units/Nanomolar,4591114,=,37,1,=,,IC50,nM,,0.12,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.12
,1197937,28776896,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '11.41', 'le': '0.22', 'lle': '1.36', 'sei': '5.29'}",CHEMBL5950945,,CHEMBL5950945,9.68,0,http://www.openphacts.org/units/Nanomolar,4591115,=,37,1,=,,IC50,nM,,0.21,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.21
,1197939,28776902,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.82', 'le': '0.22', 'lle': '2.45', 'sei': '6.09'}",CHEMBL5740596,,CHEMBL5740596,10.68,0,http://www.openphacts.org/units/Nanomolar,4591116,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1197941,28776908,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CC(O)CO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.99', 'le': '0.23', 'lle': '2.93', 'sei': '5.38'}",CHEMBL6035625,,CHEMBL6035625,10.34,0,http://www.openphacts.org/units/Nanomolar,4591117,=,37,1,=,,IC50,nM,,0.046,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.046
,1197943,28776914,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CC(O)CO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.85', 'le': '0.23', 'lle': '2.80', 'sei': '5.31'}",CHEMBL6035625,,CHEMBL6035625,10.21,0,http://www.openphacts.org/units/Nanomolar,4591117,=,37,1,=,,IC50,nM,,0.061,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.061
,1197945,28776920,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CN(C)CCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.63', 'le': '0.20', 'lle': '1.17', 'sei': '5.24'}",CHEMBL6014576,,CHEMBL6014576,9.77,0,http://www.openphacts.org/units/Nanomolar,4591118,=,37,1,=,,IC50,nM,,0.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.17
,1197947,28776926,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CN(C)CCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.78', 'le': '0.22', 'lle': '2.22', 'sei': '5.81'}",CHEMBL5764611,,CHEMBL5764611,10.82,0,http://www.openphacts.org/units/Nanomolar,4591119,=,37,1,=,,IC50,nM,,0.015,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.015
,1197949,28776932,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.31', 'le': '0.20', 'lle': '-0.85', 'sei': '5.09'}",CHEMBL5912155,,CHEMBL5912155,8.59,0,http://www.openphacts.org/units/Nanomolar,4590851,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1197951,28776938,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CCCN1c1ccc(-c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)cc1,,,CHEMBL5729271,,2022,"{'bei': '10.47', 'le': '0.20', 'lle': '-1.05', 'sei': '4.91'}",CHEMBL5765058,,CHEMBL5765058,8.82,0,http://www.openphacts.org/units/Nanomolar,4590858,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1197953,28776944,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.65', 'le': '0.20', 'lle': '-0.66', 'sei': '4.98'}",CHEMBL5901355,,CHEMBL5901355,8.96,0,http://www.openphacts.org/units/Nanomolar,4590859,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1197955,28776950,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.62', 'le': '0.20', 'lle': '-0.38', 'sei': '5.23'}",CHEMBL5928484,,CHEMBL5928484,8.82,0,http://www.openphacts.org/units/Nanomolar,4590863,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1197957,28776956,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.79', 'le': '0.20', 'lle': '0.70', 'sei': '4.94'}",CHEMBL5787701,,CHEMBL5787701,8.80,0,http://www.openphacts.org/units/Nanomolar,4590865,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1197959,28776962,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(OCC2CCC3(CC2)COC3)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '-1.36', 'sei': '5.12'}",CHEMBL5840822,,CHEMBL5840822,8.49,0,http://www.openphacts.org/units/Nanomolar,4591120,=,37,1,=,,IC50,nM,,3.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.2
,1197961,28776968,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COC1(C)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.61', 'le': '0.18', 'lle': '-2.07', 'sei': '4.87'}",CHEMBL5783644,,CHEMBL5783644,8.21,0,http://www.openphacts.org/units/Nanomolar,4591121,=,37,1,=,,IC50,nM,,6.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.1
,1197962,28776971,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,COC1(C)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.52', 'le': '0.18', 'lle': '-2.14', 'sei': '4.82'}",CHEMBL5845004,,CHEMBL5845004,8.14,0,http://www.openphacts.org/units/Nanomolar,4591122,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,1197964,28776977,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1=CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.28', 'le': '0.17', 'lle': '-2.79', 'sei': '4.79'}",CHEMBL6020672,,CHEMBL6020672,7.64,0,http://www.openphacts.org/units/Nanomolar,4591123,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1197966,28776983,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.35', 'le': '0.21', 'lle': '0.71', 'sei': '5.56'}",CHEMBL5871180,,CHEMBL5871180,10.17,0,http://www.openphacts.org/units/Nanomolar,4591124,=,37,1,=,,IC50,nM,,0.068,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.068
,1197968,28776989,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.29', 'le': '0.21', 'lle': '0.96', 'sei': '5.82'}",CHEMBL5769999,,CHEMBL5769999,10.00,0,http://www.openphacts.org/units/Nanomolar,4591125,=,37,1,=,,IC50,nM,,0.099,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.099
,1197970,28776995,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.23', 'le': '0.21', 'lle': '1.83', 'sei': '5.39'}",CHEMBL5910275,,CHEMBL5910275,9.77,0,http://www.openphacts.org/units/Nanomolar,4591126,=,37,1,=,,IC50,nM,,0.17,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.17
,1197972,28777001,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCN(C6COC6)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.65', 'le': '0.20', 'lle': '1.30', 'sei': '5.72'}",CHEMBL5841570,,CHEMBL5841570,10.02,0,http://www.openphacts.org/units/Nanomolar,4591127,=,37,1,=,,IC50,nM,,0.095,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.095
,1197974,28777007,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.44', 'le': '0.22', 'lle': '0.73', 'sei': '5.61'}",CHEMBL5887448,,CHEMBL5887448,10.28,0,http://www.openphacts.org/units/Nanomolar,4591128,=,37,1,=,,IC50,nM,,0.053,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.053
,1197976,28777013,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.67', 'le': '0.18', 'lle': '-0.51', 'sei': '4.48'}",CHEMBL5890230,,CHEMBL5890230,8.96,0,http://www.openphacts.org/units/Nanomolar,4591129,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1197978,28777019,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.53', 'le': '0.20', 'lle': '1.19', 'sei': '5.02'}",CHEMBL5936311,,CHEMBL5936311,10.20,0,http://www.openphacts.org/units/Nanomolar,4591130,=,37,1,=,,IC50,nM,,0.063,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.063
,1197980,28777025,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CNCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.67', 'le': '0.20', 'lle': '1.52', 'sei': '4.81'}",CHEMBL5773439,,CHEMBL5773439,10.19,0,http://www.openphacts.org/units/Nanomolar,4591131,=,37,1,=,,IC50,nM,,0.064,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.064
,1197982,28777031,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '0.68', 'sei': '4.96'}",CHEMBL5981762,,CHEMBL5981762,10.08,0,http://www.openphacts.org/units/Nanomolar,4591132,=,37,1,=,,IC50,nM,,0.084,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.084
,1197984,28777037,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(N)C(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.20', 'le': '0.17', 'lle': '-0.27', 'sei': '3.95'}",CHEMBL5775670,,CHEMBL5775670,8.92,0,http://www.openphacts.org/units/Nanomolar,4591133,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197986,28777043,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.45', 'le': '0.20', 'lle': '-0.02', 'sei': '4.96'}",CHEMBL6002443,,CHEMBL6002443,8.92,0,http://www.openphacts.org/units/Nanomolar,4591134,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1197988,28777049,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)N1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.53', 'le': '0.18', 'lle': '0.13', 'sei': '4.31'}",CHEMBL5885190,,CHEMBL5885190,8.48,0,http://www.openphacts.org/units/Nanomolar,4591135,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1197990,28777055,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCCN2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.71', 'le': '0.18', 'lle': '0.03', 'sei': '4.67'}",CHEMBL5848534,,CHEMBL5848534,8.04,0,http://www.openphacts.org/units/Nanomolar,4591136,=,37,1,=,,IC50,nM,,9.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,9.1
,1197992,28777061,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC2CC3(C2)CN(C2CCOCC2)C3)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.78', 'le': '0.17', 'lle': '-1.47', 'sei': '4.57'}",CHEMBL5824581,,CHEMBL5824581,7.85,0,http://www.openphacts.org/units/Nanomolar,4591137,=,37,1,=,,IC50,nM,,14.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,14.0
,1197993,28777064,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(C)(=O)=NC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.52', 'le': '0.18', 'lle': '-1.38', 'sei': '4.54'}",CHEMBL5837669,,CHEMBL5837669,8.59,0,http://www.openphacts.org/units/Nanomolar,4591138,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1197995,28777070,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(C)(=O)=NC1CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.66', 'le': '0.21', 'lle': '-0.35', 'sei': '5.09'}",CHEMBL5910162,,CHEMBL5910162,9.62,0,http://www.openphacts.org/units/Nanomolar,4591139,=,37,1,=,,IC50,nM,,0.24,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.24
,1197997,28777076,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CC(F)(F)CC5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.03', 'le': '0.19', 'lle': '-1.07', 'sei': '4.89'}",CHEMBL5783794,,CHEMBL5783794,8.80,0,http://www.openphacts.org/units/Nanomolar,4591140,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1197999,28777082,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CC(C(F)(F)F)CC5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '8.68', 'le': '0.17', 'lle': '-2.52', 'sei': '4.39'}",CHEMBL5753873,,CHEMBL5753873,7.89,0,http://www.openphacts.org/units/Nanomolar,4591141,=,37,1,=,,IC50,nM,,13.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,13.0
,1198001,28777088,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cc(F)cc4[nH]ccc34)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '8.52', 'le': '0.16', 'lle': '-3.06', 'sei': '4.38'}",CHEMBL6023387,,CHEMBL6023387,7.31,0,http://www.openphacts.org/units/Nanomolar,4591142,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1198003,28777094,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.90', 'le': '0.21', 'lle': '0.81', 'sei': '5.50'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,9.47,0,http://www.openphacts.org/units/Nanomolar,4591143,=,37,1,=,,IC50,nM,,0.34,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.34
,1198005,28777100,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(=O)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.20', 'lle': '1.63', 'sei': '3.71'}",CHEMBL5820802,,CHEMBL5820802,7.31,0,http://www.openphacts.org/units/Nanomolar,4591144,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1198007,28777106,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(COC2CC3(C2)CN(c2ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c2)C3)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '7.90', 'le': '0.15', 'lle': '-2.44', 'sei': '3.97'}",CHEMBL5775726,,CHEMBL5775726,7.08,0,http://www.openphacts.org/units/Nanomolar,4591145,=,37,1,=,,IC50,nM,,84.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.0
,1198009,28777112,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(Cc2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.68', 'le': '0.18', 'lle': '0.59', 'sei': '4.89'}",CHEMBL5779937,,CHEMBL5779937,8.57,0,http://www.openphacts.org/units/Nanomolar,4590931,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,1198010,28777115,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.17', 'le': '0.19', 'lle': '-0.17', 'sei': '4.93'}",CHEMBL5854463,,CHEMBL5854463,9.03,0,http://www.openphacts.org/units/Nanomolar,4591011,=,37,1,=,,IC50,nM,,0.93,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.93
,1198011,28777118,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.18', 'le': '0.19', 'lle': '0.04', 'sei': '4.87'}",CHEMBL5941957,,CHEMBL5941957,8.92,0,http://www.openphacts.org/units/Nanomolar,4591014,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1198012,28777121,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.53', 'le': '0.20', 'lle': '-0.06', 'sei': '5.12'}",CHEMBL5314951,SONROTOCLAX,CHEMBL5314951,9.38,0,http://www.openphacts.org/units/Nanomolar,4591146,=,37,1,=,,IC50,nM,,0.42,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.42
,1198013,28777124,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.18', 'le': '0.19', 'lle': '0.88', 'sei': '4.85'}",CHEMBL5567138,,CHEMBL5567138,8.80,0,http://www.openphacts.org/units/Nanomolar,4591027,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1198014,28777127,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.75', 'le': '0.19', 'lle': '-0.76', 'sei': '4.74'}",CHEMBL5560668,,CHEMBL5560668,8.68,0,http://www.openphacts.org/units/Nanomolar,4591031,=,37,1,=,,IC50,nM,,2.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.1
,1198015,28777130,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.42', 'le': '0.20', 'lle': '0.89', 'sei': '4.98'}",CHEMBL5806214,,CHEMBL5806214,9.28,0,http://www.openphacts.org/units/Nanomolar,4591046,=,37,1,=,,IC50,nM,,0.52,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.52
,1198016,28777133,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)C1CC(c2ccccc2C2CC2)N(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.84', 'le': '0.19', 'lle': '0.67', 'sei': '5.07'}",CHEMBL5934720,,CHEMBL5934720,8.89,0,http://www.openphacts.org/units/Nanomolar,4591069,=,37,1,=,,IC50,nM,,1.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.3
,1198017,28777136,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.96', 'le': '0.19', 'lle': '1.01', 'sei': '5.05'}",CHEMBL5768701,,CHEMBL5768701,8.85,0,http://www.openphacts.org/units/Nanomolar,4591074,=,37,1,=,,IC50,nM,,1.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.4
,1198018,28777139,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@@H](c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.47', 'le': '0.20', 'lle': '1.25', 'sei': '5.15'}",CHEMBL5865603,,CHEMBL5865603,9.60,0,http://www.openphacts.org/units/Nanomolar,4591076,=,37,1,=,,IC50,nM,,0.25,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.25
,1198019,28777142,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)N1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.88', 'le': '0.19', 'lle': '0.46', 'sei': '5.17'}",CHEMBL6016510,,CHEMBL6016510,9.07,0,http://www.openphacts.org/units/Nanomolar,4591077,=,37,1,=,,IC50,nM,,0.86,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.86
,1198020,28777145,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5C6COCC56)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.00', 'le': '0.19', 'lle': '0.20', 'sei': '5.00'}",CHEMBL5523428,,CHEMBL5523428,8.60,0,http://www.openphacts.org/units/Nanomolar,4591084,=,37,1,=,,IC50,nM,,2.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.5
,1198021,28777148,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CC5(CC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.63', 'le': '0.20', 'lle': '0.72', 'sei': '5.00'}",CHEMBL5751643,,CHEMBL5751643,9.14,0,http://www.openphacts.org/units/Nanomolar,4591092,=,37,1,=,,IC50,nM,,0.72,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.72
,1198022,28777151,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,Nc1ncc(Oc2cc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)cc1Cl,,,CHEMBL5729271,,2022,"{'bei': '9.10', 'le': '0.18', 'lle': '-0.52', 'sei': '4.35'}",CHEMBL5809484,,CHEMBL5809484,7.92,0,http://www.openphacts.org/units/Nanomolar,4591112,=,37,1,=,,IC50,nM,,12.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,12.0
,1198023,28777154,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CN(C)CCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.34', 'le': '0.20', 'lle': '0.91', 'sei': '5.10'}",CHEMBL5764611,,CHEMBL5764611,9.51,0,http://www.openphacts.org/units/Nanomolar,4591119,=,37,1,=,,IC50,nM,,0.31,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.31
,1198024,28777157,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.83', 'le': '0.19', 'lle': '-0.73', 'sei': '4.82'}",CHEMBL5887448,,CHEMBL5887448,8.82,0,http://www.openphacts.org/units/Nanomolar,4591128,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1198025,28777160,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '9.24', 'le': '0.17', 'lle': '-0.05', 'sei': '4.41'}",CHEMBL5936311,,CHEMBL5936311,8.96,0,http://www.openphacts.org/units/Nanomolar,4591130,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1198026,28777163,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '8.70', 'le': '0.17', 'lle': '-1.11', 'sei': '4.39'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,7.55,0,http://www.openphacts.org/units/Nanomolar,4591143,=,37,1,=,,IC50,nM,,28.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,28.0
,1198027,28777166,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.29', 'le': '0.18', 'lle': '-0.91', 'sei': '4.33'}",CHEMBL5828646,,CHEMBL5828646,7.31,0,http://www.openphacts.org/units/Nanomolar,4590623,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1198028,28777169,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.62', 'le': '0.17', 'lle': '-1.80', 'sei': '4.20'}",CHEMBL6057930,,CHEMBL6057930,7.08,0,http://www.openphacts.org/units/Nanomolar,4590624,=,37,1,=,,IC50,nM,,83.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,83.0
,1198029,28777172,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.55', 'le': '0.16', 'lle': '-2.03', 'sei': '4.19'}",CHEMBL5523489,,CHEMBL5523489,7.07,0,http://www.openphacts.org/units/Nanomolar,4590625,=,37,1,=,,IC50,nM,,85.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,85.0
,1198030,28777175,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCN(CC3CCCN3c3ccccc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.87', 'le': '0.17', 'lle': '0.04', 'sei': '4.08'}",CHEMBL5919993,,CHEMBL5919993,7.02,0,http://www.openphacts.org/units/Nanomolar,4590626,=,37,1,=,,IC50,nM,,95.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,95.0
,1198031,28777178,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(CN3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.34', 'le': '0.16', 'lle': '-2.03', 'sei': '4.06'}",CHEMBL5793276,,CHEMBL5793276,6.85,0,http://www.openphacts.org/units/Nanomolar,4590627,=,37,1,=,,IC50,nM,,141.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,141.0
,1198032,28777181,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(Cc2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.03', 'le': '0.17', 'lle': '-2.98', 'sei': '4.69'}",CHEMBL5839944,,CHEMBL5839944,7.77,0,http://www.openphacts.org/units/Nanomolar,4590628,=,37,1,=,,IC50,nM,,17.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,17.0
,1198033,28777184,[],CHEMBL5738378,"Bcl-2-G101V Biochemical Assay : Selected compounds disclosed herein were tested for blocking of Bcl-2-G101 protein with its ligand in an assay based on time-resolved fluorescence resonance energy transfer methodology. 0.05 nM of Recombinant human Bcl-2-G101V protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 10 M, 4-fold serially diluted, 10 points; or maximum concentration is 1 uM, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then 5 nM of the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide and Mab Anti-6His Tb cryptate Gold was added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (ex337 nm, em490 nm/520 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2-G101V interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the ratio of fluorescence at 490 nm to that at 520 nm. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software or Dotmatics.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '10.27', 'le': '0.20', 'lle': '0.26', 'sei': '5.19'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,8.92,0,http://www.openphacts.org/units/Nanomolar,4591143,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1198034,28777187,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2cc3cc(N4CCC[C@@H]4c4ccccc4)ccc3s2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.48', 'le': '0.24', 'lle': '0.91', 'sei': '6.13'}",CHEMBL5742800,,CHEMBL5742800,10.35,0,http://www.openphacts.org/units/Nanomolar,4590783,=,37,1,=,,IC50,nM,,0.045,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.045
,1198035,28777190,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCCC2c2cccc(C4CC4)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.46', 'le': '0.20', 'lle': '0.32', 'sei': '5.23'}",CHEMBL5766570,,CHEMBL5766570,9.00,0,http://www.openphacts.org/units/Nanomolar,4591036,=,37,1,=,,IC50,nM,,1.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.0
,1198036,28777193,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2Cl)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.13', 'le': '0.22', 'lle': '1.05', 'sei': '5.53'}",CHEMBL5565335,,CHEMBL5565335,9.51,0,http://www.openphacts.org/units/Nanomolar,4591038,=,37,1,=,,IC50,nM,,0.31,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.31
,1198037,28777196,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2cccc(Cl)c2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.74', 'le': '0.19', 'lle': '-0.14', 'sei': '4.84'}",CHEMBL5557109,,CHEMBL5557109,8.32,0,http://www.openphacts.org/units/Nanomolar,4591041,=,37,1,=,,IC50,nM,,4.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.8
,1198038,28777199,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccc(Cl)cc2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.50', 'le': '0.18', 'lle': '-0.35', 'sei': '4.72'}",CHEMBL5554998,,CHEMBL5554998,8.11,0,http://www.openphacts.org/units/Nanomolar,4591043,=,37,1,=,,IC50,nM,,7.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.7
,1198039,28777202,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3Cl)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.66', 'le': '0.19', 'lle': '-1.08', 'sei': '4.62'}",CHEMBL5542608,,CHEMBL5542608,7.80,0,http://www.openphacts.org/units/Nanomolar,4590562,=,37,1,=,,IC50,nM,,16.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,16.0
,1198040,28777205,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(Cl)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.56', 'le': '0.17', 'lle': '-1.97', 'sei': '4.10'}",CHEMBL5560077,,CHEMBL5560077,6.91,0,http://www.openphacts.org/units/Nanomolar,4590561,=,37,1,=,,IC50,nM,,122.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,122.0
,1198041,28777208,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(Cl)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.49', 'le': '0.16', 'lle': '-2.03', 'sei': '4.06'}",CHEMBL5560407,,CHEMBL5560407,6.85,0,http://www.openphacts.org/units/Nanomolar,4590560,=,37,1,=,,IC50,nM,,140.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,140.0
,1198042,28777211,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '-0.97', 'sei': '4.82'}",CHEMBL5542692,,CHEMBL5542692,8.14,0,http://www.openphacts.org/units/Nanomolar,4590568,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,1198043,28777214,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3cccc(C4CC4)c3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '7.34', 'le': '0.14', 'lle': '-3.14', 'sei': '3.54'}",CHEMBL6046208,,CHEMBL6046208,5.97,0,http://www.openphacts.org/units/Nanomolar,4590572,=,37,1,=,,IC50,nM,,1075.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1075.0
,1198044,28777217,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccc(C4CC4)cc3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '8.46', 'le': '0.16', 'lle': '-2.23', 'sei': '4.07'}",CHEMBL5878519,,CHEMBL5878519,6.88,0,http://www.openphacts.org/units/Nanomolar,4590576,=,37,1,=,,IC50,nM,,133.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,133.0
,1198045,28777220,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '15.25', 'le': '0.28', 'lle': '0.35', 'sei': '12.06'}",CHEMBL5953429,,CHEMBL5953429,8.14,0,http://www.openphacts.org/units/Nanomolar,4590636,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,1198046,28777223,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.92', 'le': '0.19', 'lle': '-0.77', 'sei': '4.80'}",CHEMBL5841782,,CHEMBL5841782,8.10,0,http://www.openphacts.org/units/Nanomolar,4590637,=,37,1,=,,IC50,nM,,7.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.9
,1198047,28777226,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCCC3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.40', 'le': '0.18', 'lle': '-1.19', 'sei': '4.55'}",CHEMBL6058975,,CHEMBL6058975,7.68,0,http://www.openphacts.org/units/Nanomolar,4590744,=,37,1,=,,IC50,nM,,21.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,21.0
,1198048,28777229,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCCC3c3ccccc3Cl)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.31', 'le': '0.18', 'lle': '-1.17', 'sei': '4.48'}",CHEMBL5766318,,CHEMBL5766318,7.57,0,http://www.openphacts.org/units/Nanomolar,4590749,=,37,1,=,,IC50,nM,,27.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,27.0
,1198049,28777232,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(Cl)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.41', 'le': '0.18', 'lle': '-1.08', 'sei': '4.54'}",CHEMBL5867556,,CHEMBL5867556,7.66,0,http://www.openphacts.org/units/Nanomolar,4590759,=,37,1,=,,IC50,nM,,22.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,22.0
,1198050,28777235,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(Cl)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.39', 'le': '0.18', 'lle': '-1.10', 'sei': '4.53'}",CHEMBL5976482,,CHEMBL5976482,7.64,0,http://www.openphacts.org/units/Nanomolar,4590761,=,37,1,=,,IC50,nM,,23.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,23.0
,1198051,28777238,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.00', 'le': '0.19', 'lle': '-0.77', 'sei': '4.85'}",CHEMBL6009632,,CHEMBL6009632,8.19,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,6.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.5
,1198052,28777241,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3cccc(C4CC4)c3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.56', 'sei': '4.98'}",CHEMBL6059159,,CHEMBL6059159,8.40,0,http://www.openphacts.org/units/Nanomolar,4590753,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,1198053,28777244,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccc(C4CC4)cc3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.55', 'le': '0.18', 'lle': '-1.14', 'sei': '4.64'}",CHEMBL5924557,,CHEMBL5924557,7.82,0,http://www.openphacts.org/units/Nanomolar,4590755,=,37,1,=,,IC50,nM,,15.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,15.0
,1198054,28777247,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCCC3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.02', 'le': '0.19', 'lle': '-0.97', 'sei': '4.82'}",CHEMBL5542692,,CHEMBL5542692,8.14,0,http://www.openphacts.org/units/Nanomolar,4590568,=,37,1,=,,IC50,nM,,7.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.2
,1198056,28777253,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.73', 'le': '0.20', 'lle': '-0.39', 'sei': '5.17'}",CHEMBL5543056,,CHEMBL5543056,8.72,0,http://www.openphacts.org/units/Nanomolar,4590569,=,37,1,=,,IC50,nM,,1.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.9
,1198058,28777259,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.40', 'le': '0.20', 'lle': '-0.88', 'sei': '4.86'}",CHEMBL5901355,,CHEMBL5901355,8.74,0,http://www.openphacts.org/units/Nanomolar,4590859,=,37,1,=,,IC50,nM,,1.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.8
,1198060,28777265,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(-c4ccc(N5CCC[C@@H]5c5ccccc5C5CC5)cc4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.65', 'le': '0.20', 'lle': '-0.66', 'sei': '4.98'}",CHEMBL5901355,,CHEMBL5901355,8.96,0,http://www.openphacts.org/units/Nanomolar,4590859,=,37,1,=,,IC50,nM,,1.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.1
,1198061,28777268,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.31', 'le': '0.20', 'lle': '-0.63', 'sei': '5.08'}",CHEMBL5928484,,CHEMBL5928484,8.57,0,http://www.openphacts.org/units/Nanomolar,4590863,=,37,1,=,,IC50,nM,,2.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.7
,1198063,28777274,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.62', 'le': '0.20', 'lle': '-0.38', 'sei': '5.23'}",CHEMBL5928484,,CHEMBL5928484,8.82,0,http://www.openphacts.org/units/Nanomolar,4590863,=,37,1,=,,IC50,nM,,1.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.5
,1198064,28777277,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.38', 'le': '0.20', 'lle': '0.36', 'sei': '4.75'}",CHEMBL5787701,,CHEMBL5787701,8.46,0,http://www.openphacts.org/units/Nanomolar,4590865,=,37,1,=,,IC50,nM,,3.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.5
,1198066,28777283,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.79', 'le': '0.20', 'lle': '0.70', 'sei': '4.94'}",CHEMBL5787701,,CHEMBL5787701,8.80,0,http://www.openphacts.org/units/Nanomolar,4590865,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1198067,28777286,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(-c2ccc(N3CCC[C@@H]3c3ccccc3C3CC3)cc2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.19', 'lle': '0.21', 'sei': '4.67'}",CHEMBL5828583,,CHEMBL5828583,8.31,0,http://www.openphacts.org/units/Nanomolar,4590866,=,37,1,=,,IC50,nM,,4.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.9
,1198069,28777292,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CC=C(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.35', 'le': '0.21', 'lle': '0.71', 'sei': '5.56'}",CHEMBL5871180,,CHEMBL5871180,10.17,0,http://www.openphacts.org/units/Nanomolar,4591124,=,37,1,=,,IC50,nM,,0.068,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.068
,1198071,28777298,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '11.44', 'le': '0.22', 'lle': '0.73', 'sei': '5.61'}",CHEMBL5887448,,CHEMBL5887448,10.28,0,http://www.openphacts.org/units/Nanomolar,4591128,=,37,1,=,,IC50,nM,,0.053,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.053
,1198073,28777304,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CC(=O)N1CCC(c2ccccc2[C@H]2CCCN2c2ccc(-c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)cc2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.53', 'le': '0.20', 'lle': '1.19', 'sei': '5.02'}",CHEMBL5936311,,CHEMBL5936311,10.20,0,http://www.openphacts.org/units/Nanomolar,4591130,=,37,1,=,,IC50,nM,,0.063,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.063
,1198075,28777310,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,COC(=O)c1ccc(C2=CCC(N3CCCC3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '15.25', 'le': '0.28', 'lle': '0.35', 'sei': '12.06'}",CHEMBL5953429,,CHEMBL5953429,8.14,0,http://www.openphacts.org/units/Nanomolar,4590636,=,37,1,=,,IC50,nM,,7.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.3
,1198077,28777316,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.00', 'le': '0.19', 'lle': '-0.61', 'sei': '4.95'}",CHEMBL5972666,,CHEMBL5972666,8.35,0,http://www.openphacts.org/units/Nanomolar,4590824,=,37,1,=,,IC50,nM,,4.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.5
,1198079,28777322,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.14', 'le': '0.19', 'lle': '-0.49', 'sei': '5.02'}",CHEMBL5856844,,CHEMBL5856844,8.47,0,http://www.openphacts.org/units/Nanomolar,4590823,=,37,1,=,,IC50,nM,,3.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.4
,1198081,28777328,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.85', 'le': '0.19', 'lle': '-1.01', 'sei': '4.71'}",CHEMBL5799821,,CHEMBL5799821,8.34,0,http://www.openphacts.org/units/Nanomolar,4590808,=,37,1,=,,IC50,nM,,4.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.6
,1198083,28777334,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(COc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.07', 'le': '0.19', 'lle': '-0.83', 'sei': '4.82'}",CHEMBL5799821,,CHEMBL5799821,8.52,0,http://www.openphacts.org/units/Nanomolar,4590808,=,37,1,=,,IC50,nM,,3.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.0
,1198085,28777340,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.99', 'le': '0.19', 'lle': '-0.95', 'sei': '4.70'}",CHEMBL5956618,,CHEMBL5956618,8.44,0,http://www.openphacts.org/units/Nanomolar,4590818,=,37,1,=,,IC50,nM,,3.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.6
,1198087,28777346,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(O)CCC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(C4=CCC(N5CCC[C@H]5c5ccccc5C5CC5)CC4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.16', 'le': '0.19', 'lle': '-0.80', 'sei': '4.78'}",CHEMBL5956618,,CHEMBL5956618,8.59,0,http://www.openphacts.org/units/Nanomolar,4590819,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1198089,28777352,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '0.29', 'sei': '4.58'}",CHEMBL5916255,,CHEMBL5916255,8.15,0,http://www.openphacts.org/units/Nanomolar,4590802,=,37,1,=,,IC50,nM,,7.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.1
,1198091,28777358,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.05', 'le': '0.19', 'lle': '0.37', 'sei': '4.62'}",CHEMBL5841596,,CHEMBL5841596,8.23,0,http://www.openphacts.org/units/Nanomolar,4590803,=,37,1,=,,IC50,nM,,5.9,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.9
,1198093,28777364,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.11', 'le': '0.19', 'lle': '0.42', 'sei': '4.65'}",CHEMBL5916255,,CHEMBL5916255,8.28,0,http://www.openphacts.org/units/Nanomolar,4590802,=,37,1,=,,IC50,nM,,5.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.3
,1198095,28777370,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2=CCC(N3CCC[C@@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.22', 'le': '0.19', 'lle': '0.51', 'sei': '4.70'}",CHEMBL5841596,,CHEMBL5841596,8.37,0,http://www.openphacts.org/units/Nanomolar,4590803,=,37,1,=,,IC50,nM,,4.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.3
,1198097,28777376,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.56', 'le': '0.20', 'lle': '-0.27', 'sei': '4.89'}",CHEMBL5740186,,CHEMBL5740186,8.80,0,http://www.openphacts.org/units/Nanomolar,4590876,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1198099,28777382,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.71', 'le': '0.20', 'lle': '-0.15', 'sei': '4.96'}",CHEMBL5762696,,CHEMBL5762696,8.92,0,http://www.openphacts.org/units/Nanomolar,4590877,=,37,1,=,,IC50,nM,,1.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.2
,1198101,28777388,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.31', 'le': '0.20', 'lle': '-0.17', 'sei': '5.02'}",CHEMBL5979382,,CHEMBL5979382,8.48,0,http://www.openphacts.org/units/Nanomolar,4590856,=,37,1,=,,IC50,nM,,3.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.3
,1198103,28777394,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@H]1CCCN1C1CC=C(c2ccc(C(=O)NS(=O)(=O)c3ccc(NCC4(F)CCOCC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c2)CC1,,,CHEMBL5729271,,2022,"{'bei': '10.50', 'le': '0.20', 'lle': '-0.01', 'sei': '5.12'}",CHEMBL5917184,,CHEMBL5917184,8.64,0,http://www.openphacts.org/units/Nanomolar,4590857,=,37,1,=,,IC50,nM,,2.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.3
,1198105,28777400,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.25', 'le': '0.19', 'lle': '-0.56', 'sei': '4.98'}",CHEMBL6009632,,CHEMBL6009632,8.40,0,http://www.openphacts.org/units/Nanomolar,4590751,=,37,1,=,,IC50,nM,,4.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.0
,1198107,28777406,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.19', 'lle': '0.43', 'sei': '4.71'}",CHEMBL5995925,,CHEMBL5995925,8.38,0,http://www.openphacts.org/units/Nanomolar,4590842,=,37,1,=,,IC50,nM,,4.2,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,4.2
,1198109,28777412,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(C2CCC(N3CCC[C@H]3c3ccccc3C3CC3)CC2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.36', 'le': '0.20', 'lle': '0.56', 'sei': '4.78'}",CHEMBL5966228,,CHEMBL5966228,8.51,0,http://www.openphacts.org/units/Nanomolar,4590844,=,37,1,=,,IC50,nM,,3.1,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,3.1
,1198111,28777418,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '9.90', 'le': '0.19', 'lle': '-0.40', 'sei': '4.81'}",CHEMBL5854463,,CHEMBL5854463,8.80,0,http://www.openphacts.org/units/Nanomolar,4591011,=,37,1,=,,IC50,nM,,1.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.6
,1198112,28777421,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '12.00', 'le': '0.23', 'lle': '1.46', 'sei': '5.82'}",CHEMBL5854463,,CHEMBL5854463,10.66,0,http://www.openphacts.org/units/Nanomolar,4591011,=,37,1,=,,IC50,nM,,0.022,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.022
,1198114,28777427,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.99', 'le': '0.19', 'lle': '-0.01', 'sei': '5.10'}",CHEMBL5972266,,CHEMBL5972266,8.77,0,http://www.openphacts.org/units/Nanomolar,4591010,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,1198115,28777430,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2(F)CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.95', 'le': '0.23', 'lle': '1.71', 'sei': '6.10'}",CHEMBL5972266,,CHEMBL5972266,10.49,0,http://www.openphacts.org/units/Nanomolar,4591010,=,37,1,=,,IC50,nM,,0.032,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.032
,1198117,28777436,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.19', 'lle': '0.09', 'sei': '5.10'}",CHEMBL5555281,,CHEMBL5555281,8.77,0,http://www.openphacts.org/units/Nanomolar,4591009,=,37,1,=,,IC50,nM,,1.7,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,1.7
,1198118,28777439,[],CHEMBL5738374,"Bcl-2/Bcl-X Fluorescence Polarization Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-xl protein with its ligand in an assay based on fluorescence polarization methodology. Recombinant human 2.7 nM Bcl-2/1.3 nM Bcl-xl protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 1 M for Bcl-2 assay, and 10 M or 1 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 ml potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK (FITC)INR-amide (1 nM for Bcl-2, 0.82 nM for Bcl-xl) was added to plate and further incubated at room temperature for 0.5 h. The FP signals (485 nm-520 nm-520 nm) were read on BMG PHERAstar FS or BMG PHERAstar FSX instalment. The inhibition percentage of Bcl-2/Bcl-xl interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the FP signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.10', 'le': '0.23', 'lle': '1.73', 'sei': '6.05'}",CHEMBL5555281,,CHEMBL5555281,10.41,0,http://www.openphacts.org/units/Nanomolar,4591009,=,37,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
,1198120,28777445,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.92', 'le': '0.23', 'lle': '1.74', 'sei': '5.88'}",CHEMBL5542719,,CHEMBL5542719,10.11,0,http://www.openphacts.org/units/Nanomolar,4591012,=,37,1,=,,IC50,nM,,0.078,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.078
,1198122,28777451,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.98', 'le': '0.23', 'lle': '1.92', 'sei': '6.03'}",CHEMBL5807781,,CHEMBL5807781,10.38,0,http://www.openphacts.org/units/Nanomolar,4591013,=,37,1,=,,IC50,nM,,0.042,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.042
,1198124,28777457,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.95', 'le': '0.23', 'lle': '1.59', 'sei': '5.72'}",CHEMBL5941957,,CHEMBL5941957,10.47,0,http://www.openphacts.org/units/Nanomolar,4591014,=,37,1,=,,IC50,nM,,0.034,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.034
,1198126,28777463,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.47', 'le': '0.24', 'lle': '2.48', 'sei': '6.03'}",CHEMBL5836554,,CHEMBL5836554,10.38,0,http://www.openphacts.org/units/Nanomolar,4591018,=,37,1,=,,IC50,nM,,0.042,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.042
,1198128,28777469,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.05', 'le': '0.23', 'lle': '2.72', 'sei': '5.73'}",CHEMBL5980890,,CHEMBL5980890,10.39,0,http://www.openphacts.org/units/Nanomolar,4591020,=,37,1,=,,IC50,nM,,0.041,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.041
,1198130,28777475,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NC[C@@H]2COCCO2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '11.78', 'le': '0.22', 'lle': '2.48', 'sei': '5.60'}",CHEMBL5965443,,CHEMBL5965443,10.15,0,http://www.openphacts.org/units/Nanomolar,4591021,=,37,1,=,,IC50,nM,,0.07,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.07
,1198132,28777481,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.17', 'le': '0.23', 'lle': '2.99', 'sei': '5.71'}",CHEMBL5877687,,CHEMBL5877687,10.35,0,http://www.openphacts.org/units/Nanomolar,4591024,=,37,1,=,,IC50,nM,,0.045,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.045
,1198134,28777487,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.03', 'le': '0.23', 'lle': '2.87', 'sei': '5.64'}",CHEMBL5903988,,CHEMBL5903988,10.23,0,http://www.openphacts.org/units/Nanomolar,4591025,=,37,1,=,,IC50,nM,,0.059,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.059
,1198136,28777493,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.16', 'le': '0.23', 'lle': '1.38', 'sei': '5.91'}",CHEMBL5314951,SONROTOCLAX,CHEMBL5314951,10.82,0,http://www.openphacts.org/units/Nanomolar,4591146,=,37,1,=,,IC50,nM,,0.015,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.015
,1198138,28777499,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.94', 'le': '0.23', 'lle': '2.40', 'sei': '5.69'}",CHEMBL5567138,,CHEMBL5567138,10.32,0,http://www.openphacts.org/units/Nanomolar,4591027,=,37,1,=,,IC50,nM,,0.048,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.048
,1198140,28777505,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.11', 'le': '0.23', 'lle': '1.51', 'sei': '6.07'}",CHEMBL5560614,,CHEMBL5560614,10.44,0,http://www.openphacts.org/units/Nanomolar,4591028,=,37,1,=,,IC50,nM,,0.036,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.036
,1198142,28777511,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5(F)CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.69', 'le': '0.22', 'lle': '1.26', 'sei': '5.98'}",CHEMBL5775285,,CHEMBL5775285,10.28,0,http://www.openphacts.org/units/Nanomolar,4591029,=,37,1,=,,IC50,nM,,0.052,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.052
,1198144,28777517,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@@H]5COCCO5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.06', 'le': '0.23', 'lle': '2.50', 'sei': '5.75'}",CHEMBL5556406,,CHEMBL5556406,10.42,0,http://www.openphacts.org/units/Nanomolar,4591030,=,37,1,=,,IC50,nM,,0.038,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.038
,1198146,28777523,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.38', 'le': '0.22', 'lle': '0.69', 'sei': '5.54'}",CHEMBL5560668,,CHEMBL5560668,10.13,0,http://www.openphacts.org/units/Nanomolar,4591031,=,37,1,=,,IC50,nM,,0.074,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.074
,1198148,28777529,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.33', 'le': '0.23', 'lle': '2.77', 'sei': '6.07'}",CHEMBL5560718,,CHEMBL5560718,10.64,0,http://www.openphacts.org/units/Nanomolar,4591045,=,37,1,=,,IC50,nM,,0.023,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.023
,1198150,28777535,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.98', 'le': '0.23', 'lle': '2.29', 'sei': '5.73'}",CHEMBL5806214,,CHEMBL5806214,10.68,0,http://www.openphacts.org/units/Nanomolar,4591046,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1198152,28777541,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.01', 'le': '0.23', 'lle': '2.31', 'sei': '5.74'}",CHEMBL5806214,,CHEMBL5806214,10.70,0,http://www.openphacts.org/units/Nanomolar,4591047,=,37,1,=,,IC50,nM,,0.02,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.02
,1198154,28777547,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.28', 'le': '0.21', 'lle': '2.19', 'sei': '5.72'}",CHEMBL5768701,,CHEMBL5768701,10.03,0,http://www.openphacts.org/units/Nanomolar,4591074,=,37,1,=,,IC50,nM,,0.094,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.094
,1198156,28777553,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NC[C@H]6CC[C@](C)(O)CC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)[C@@H](c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.12', 'le': '0.21', 'lle': '1.85', 'sei': '5.48'}",CHEMBL5865603,,CHEMBL5865603,10.20,0,http://www.openphacts.org/units/Nanomolar,4591076,=,37,1,=,,IC50,nM,,0.063,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.063
,1198158,28777559,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)N1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.56', 'le': '0.22', 'lle': '1.99', 'sei': '6.05'}",CHEMBL6016510,,CHEMBL6016510,10.60,0,http://www.openphacts.org/units/Nanomolar,4591077,=,37,1,=,,IC50,nM,,0.025,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.025
,1198160,28777565,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5C6COCC56)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '12.35', 'le': '0.23', 'lle': '2.22', 'sei': '6.17'}",CHEMBL5523428,,CHEMBL5523428,10.62,0,http://www.openphacts.org/units/Nanomolar,4591084,=,37,1,=,,IC50,nM,,0.024,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.024
,1198162,28777571,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C=C(C)c1ccccc1[C@@H]1CCCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.55', 'le': '0.22', 'lle': '0.91', 'sei': '5.61'}",CHEMBL5989018,,CHEMBL5989018,10.26,0,http://www.openphacts.org/units/Nanomolar,4591090,=,37,1,=,,IC50,nM,,0.055,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.055
,1198164,28777577,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CC5(CC(N6CCC[C@H]6c6ccccc6C6CC6)C5)C4)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '12.42', 'le': '0.24', 'lle': '2.26', 'sei': '5.83'}",CHEMBL5751643,,CHEMBL5751643,10.68,0,http://www.openphacts.org/units/Nanomolar,4591092,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1198166,28777583,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.07', 'le': '0.23', 'lle': '1.75', 'sei': '5.69'}",CHEMBL5766828,,CHEMBL5766828,10.41,0,http://www.openphacts.org/units/Nanomolar,4591095,=,37,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
,1198168,28777589,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCc1ccccc1[C@@H]1CCCN1C1CC2(C1)CN(c1ccc(C(=O)NS(=O)(=O)c3ccc(NC[C@H]4CC[C@](C)(O)CC4)c([N+](=O)[O-])c3)c(Oc3cnc4[nH]ccc4c3)c1)C2,,,CHEMBL5729271,,2022,"{'bei': '12.41', 'le': '0.24', 'lle': '2.42', 'sei': '5.75'}",CHEMBL5953237,,CHEMBL5953237,10.52,0,http://www.openphacts.org/units/Nanomolar,4591097,=,37,1,=,,IC50,nM,,0.03,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.03
,1198170,28777595,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1CC(CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(N4CCC[C@H]4c4ccccc4C4CC4)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC(C)O1,,,CHEMBL5729271,,2022,"{'bei': '11.94', 'le': '0.23', 'lle': '1.14', 'sei': '6.16'}",CHEMBL5920200,,CHEMBL5920200,10.60,0,http://www.openphacts.org/units/Nanomolar,4591106,=,37,1,=,,IC50,nM,,0.025,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.025
,1198172,28777601,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,Nc1ncc(Oc2cc(N3CCC4(CC3)CC(N3CCC[C@H]3c3ccccc3C3CC3)C4)ccc2C(=O)NS(=O)(=O)c2ccc(NCC3CCOCC3)c([N+](=O)[O-])c2)cc1Cl,,,CHEMBL5729271,,2022,"{'bei': '11.62', 'le': '0.23', 'lle': '1.68', 'sei': '5.55'}",CHEMBL5809484,,CHEMBL5809484,10.12,0,http://www.openphacts.org/units/Nanomolar,4591112,=,37,1,=,,IC50,nM,,0.076,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.076
,1198174,28777607,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CCN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.82', 'le': '0.22', 'lle': '2.45', 'sei': '6.09'}",CHEMBL5740596,,CHEMBL5740596,10.68,0,http://www.openphacts.org/units/Nanomolar,4591116,=,37,1,=,,IC50,nM,,0.021,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.021
,1198176,28777613,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)c1ccccc1[C@H]1CN(C)CCN1C1CC2(CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NC[C@H]5CC[C@](C)(O)CC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.78', 'le': '0.22', 'lle': '2.22', 'sei': '5.81'}",CHEMBL5764611,,CHEMBL5764611,10.82,0,http://www.openphacts.org/units/Nanomolar,4591119,=,37,1,=,,IC50,nM,,0.015,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.015
,1198178,28777619,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(CN2CCN(c3ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c3)CC2)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '9.95', 'le': '0.19', 'lle': '-0.02', 'sei': '5.02'}",CHEMBL3137309,VENETOCLAX,CHEMBL3137309,8.64,0,http://www.openphacts.org/units/Nanomolar,4591143,=,37,1,=,,IC50,nM,,2.3,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.3
,1198179,28777622,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(=O)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.20', 'lle': '1.63', 'sei': '3.71'}",CHEMBL5820802,,CHEMBL5820802,7.31,0,http://www.openphacts.org/units/Nanomolar,4591144,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1198181,28777628,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(COC2CC3(C2)CN(c2ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c2)C3)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '7.90', 'le': '0.15', 'lle': '-2.44', 'sei': '3.97'}",CHEMBL5775726,,CHEMBL5775726,7.08,0,http://www.openphacts.org/units/Nanomolar,4591145,=,37,1,=,,IC50,nM,,84.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.0
,1198183,28777634,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(N2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.10', 'le': '0.23', 'lle': '1.73', 'sei': '6.05'}",CHEMBL5555281,,CHEMBL5555281,10.41,0,http://www.openphacts.org/units/Nanomolar,4591009,=,37,1,=,,IC50,nM,,0.039,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.039
,1198184,28777637,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C2CC3(CCN(c4ccc(C(=O)NS(=O)(=O)c5ccc(NCC6CCOCC6)c([N+](=O)[O-])c5)c(Oc5cnc6[nH]ccc6c5)c4)CC3)C2)C(c2ccccc2C2CC2)C1,,,CHEMBL5729271,,2022,"{'bei': '11.28', 'le': '0.21', 'lle': '2.19', 'sei': '5.72'}",CHEMBL5768701,,CHEMBL5768701,10.03,0,http://www.openphacts.org/units/Nanomolar,4591074,=,37,1,=,,IC50,nM,,0.094,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.094
,1198185,28777640,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CCC3(CC2)CC(CN2CCC[C@H]2c2ccccc2C2CC2)C3)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.37', 'le': '0.18', 'lle': '-0.74', 'sei': '4.76'}",CHEMBL5888815,,CHEMBL5888815,8.19,0,http://www.openphacts.org/units/Nanomolar,4591101,=,37,1,=,,IC50,nM,,6.4,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,6.4
,1198186,28777643,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(N4CCC[C@H]4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '12.47', 'le': '0.24', 'lle': '2.48', 'sei': '6.03'}",CHEMBL5836554,,CHEMBL5836554,10.38,0,http://www.openphacts.org/units/Nanomolar,4591018,=,37,1,=,,IC50,nM,,0.042,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,0.042
,1198187,28777646,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CC(CN4CCCC4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '9.58', 'le': '0.18', 'lle': '-0.04', 'sei': '4.71'}",CHEMBL5565924,,CHEMBL5565924,8.11,0,http://www.openphacts.org/units/Nanomolar,4591099,=,37,1,=,,IC50,nM,,7.8,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.8
,1198188,28777649,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(NS(=O)(=O)c1ccc(NCC2CCOCC2)c([N+](=O)[O-])c1)c1ccc(N2CC3(CN(CC4CCCN4c4ccccc4C4CC4)C3)C2)cc1Oc1cnc2[nH]ccc2c1,,,CHEMBL5729271,,2022,"{'bei': '10.14', 'le': '0.19', 'lle': '1.70', 'sei': '4.90'}",CHEMBL5899288,,CHEMBL5899288,8.59,0,http://www.openphacts.org/units/Nanomolar,4591100,=,37,1,=,,IC50,nM,,2.6,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,2.6
,1198189,28777652,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,C[C@]1(O)CC[C@H](CNc2ccc(S(=O)(=O)NC(=O)c3ccc(N4CCC5(CC4)CC(=O)C5)cc3Oc3cnc4[nH]ccc4c3)cc2[N+](=O)[O-])CC1,,,CHEMBL5729271,,2022,"{'bei': '10.20', 'le': '0.20', 'lle': '1.63', 'sei': '3.71'}",CHEMBL5820802,,CHEMBL5820802,7.31,0,http://www.openphacts.org/units/Nanomolar,4591144,=,37,1,=,,IC50,nM,,49.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,49.0
,1198190,28777655,[],CHEMBL5738376,"Bcl-2/Bcl-X TR-FRET Assay: Compounds disclosed herein were tested for blocking of Bcl-2/Bcl-X protein with its ligand in an assay based on Time-Resolved Fluorescence Resonance Energy Transfer (TR-FRET) methodology. Recombinant human 0.05 nM Bcl-2/0.03 nM Bcl-X protein was pre-incubated with a serial dilution of compounds disclosed herein (maximum concentration is 0.1 M for Bcl-2 assay, and 10 M for Bcl-xl assay, 3-fold serially diluted, 10 points; or maximum concentration is 0.02 M for Bcl-2 assay, and 2 M for Bcl-xl assay, 3-fold serially diluted, 10 points) at room temperature for 0.5 hour in an assay buffer containing 20 mM potassium phosphate buffer, pH 7.5, 50 mM NaCl, 1 mM EDTA, 0.05% Tween-20, 0.01% BSA. Then the FITC labeled Bak peptide Ac-GQVGRQLAIIGDK(FITC)INR-amide (0.5 nM for Bcl-2, 0.3 nM for Bcl-xl) and MAb Anti 6His Tb cryptate Gold were added to plate and further incubated at room temperature for 1 hour. The TR-FRET signals (337 nm-520 nm-490 nm) were read on BMG PHERAstar FSX instrument. The inhibition percentage of Bcl-2/Bcl-X interaction with its ligand in presence of increasing concentrations of compounds was calculated based on the TR-FRET signals. The IC50 for each compound was derived from fitting the data to the four-parameter logistic equation by Graphpad Prism software. To improve the assay sensitivity and test more potent compounds in the present application, the bcl-2 concentration was reduced in method B.",B,,,BAO_0000190,BAO_0000357,single protein format,CC1(C)CCC(COC2CC3(C2)CN(c2ccc(C(=O)NS(=O)(=O)c4ccc(NCC5CCOCC5)c([N+](=O)[O-])c4)c(Oc4cnc5[nH]ccc5c4)c2)C3)=C(c2ccc(Cl)cc2)C1,,,CHEMBL5729271,,2022,"{'bei': '7.90', 'le': '0.15', 'lle': '-2.44', 'sei': '3.97'}",CHEMBL5775726,,CHEMBL5775726,7.08,0,http://www.openphacts.org/units/Nanomolar,4591145,=,37,1,=,,IC50,nM,,84.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,84.0
,1293586,29046272,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '11.21', 'le': '0.21', 'lle': '1.45', 'sei': '8.40'}",CHEMBL6003093,,CHEMBL6003093,8.12,0,http://www.openphacts.org/units/Nanomolar,4645959,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293588,29046278,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccccc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL6030598,,CHEMBL6030598,,0,http://www.openphacts.org/units/Nanomolar,4645960,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293590,29046284,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5729797,,2023,"{'bei': '11.00', 'le': '0.20', 'lle': '1.14', 'sei': '8.40'}",CHEMBL5788222,,CHEMBL5788222,8.12,0,http://www.openphacts.org/units/Nanomolar,4645961,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293592,29046290,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5729797,,2023,"{'bei': '11.00', 'le': '0.20', 'lle': '1.14', 'sei': '8.40'}",CHEMBL5856529,,CHEMBL5856529,8.12,0,http://www.openphacts.org/units/Nanomolar,4645962,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293594,29046296,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1F)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5761477,,CHEMBL5761477,,0,http://www.openphacts.org/units/Nanomolar,4645963,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293596,29046302,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccc(F)c1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '10.13', 'le': '0.19', 'lle': '0.71', 'sei': '7.78'}",CHEMBL5995264,,CHEMBL5995264,7.52,0,http://www.openphacts.org/units/Nanomolar,4645964,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293598,29046308,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccc(F)cc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '10.13', 'le': '0.19', 'lle': '0.71', 'sei': '7.78'}",CHEMBL5788840,,CHEMBL5788840,7.52,0,http://www.openphacts.org/units/Nanomolar,4645965,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293600,29046314,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(C)c1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5783154,,CHEMBL5783154,,0,http://www.openphacts.org/units/Nanomolar,4645966,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293601,29046317,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1ccccc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5862464,,CHEMBL5862464,,0,http://www.openphacts.org/units/Nanomolar,4645967,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293603,29046323,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(F)c1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.94', 'le': '0.18', 'lle': '0.40', 'sei': '7.78'}",CHEMBL5837845,,CHEMBL5837845,7.52,0,http://www.openphacts.org/units/Nanomolar,4645968,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293604,29046326,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1Cl)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5876813,,CHEMBL5876813,,0,http://www.openphacts.org/units/Nanomolar,4645969,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293606,29046332,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1c(F)cccc1F)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '10.68', 'le': '0.20', 'lle': '1.17', 'sei': '8.40'}",CHEMBL5853531,,CHEMBL5853531,8.12,0,http://www.openphacts.org/units/Nanomolar,4645970,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293608,29046338,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1C,,,CHEMBL5729797,,2023,,CHEMBL5901855,,CHEMBL5901855,,0,http://www.openphacts.org/units/Nanomolar,4645971,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293610,29046344,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cccc(Cl)c1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL6015564,,CHEMBL6015564,,0,http://www.openphacts.org/units/Nanomolar,4645972,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293612,29046350,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1C(F)(F)F)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5980102,,CHEMBL5980102,,0,http://www.openphacts.org/units/Nanomolar,4645973,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293614,29046356,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccc(C(F)(F)F)c1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.17', 'sei': '7.78'}",CHEMBL5788063,,CHEMBL5788063,7.52,0,http://www.openphacts.org/units/Nanomolar,4645974,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293616,29046362,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccc(C(F)(F)F)cc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.49', 'le': '0.18', 'lle': '-0.17', 'sei': '7.78'}",CHEMBL5941938,,CHEMBL5941938,7.52,0,http://www.openphacts.org/units/Nanomolar,4645975,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293618,29046368,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1c(Cl)ccc(F)c1F)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.46', 'le': '0.18', 'lle': '-0.08', 'sei': '7.78'}",CHEMBL5870017,,CHEMBL5870017,7.52,0,http://www.openphacts.org/units/Nanomolar,4645976,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293621,29046377,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccccc1-c1ccccc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.39', 'le': '0.17', 'lle': '-0.82', 'sei': '7.78'}",CHEMBL5963393,,CHEMBL5963393,7.52,0,http://www.openphacts.org/units/Nanomolar,4645977,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293623,29046383,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1cc(C(F)(F)F)ccc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '10.07', 'le': '0.19', 'lle': '0.12', 'sei': '8.40'}",CHEMBL5983229,,CHEMBL5983229,8.12,0,http://www.openphacts.org/units/Nanomolar,4645978,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293624,29046386,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1ccc(C(F)(F)F)cc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.32', 'le': '0.17', 'lle': '-0.48', 'sei': '7.78'}",CHEMBL5757177,,CHEMBL5757177,7.52,0,http://www.openphacts.org/units/Nanomolar,4645979,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293625,29046389,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccc(OC(F)(F)F)cc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5873413,,CHEMBL5873413,,0,http://www.openphacts.org/units/Nanomolar,4645980,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293627,29046395,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1c(F)cccc1C(F)(F)F)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL6060458,,CHEMBL6060458,,0,http://www.openphacts.org/units/Nanomolar,4645981,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293629,29046401,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccnc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,"{'bei': '11.19', 'le': '0.21', 'lle': '2.05', 'sei': '7.41'}",CHEMBL5929853,,CHEMBL5929853,8.12,0,http://www.openphacts.org/units/Nanomolar,4645982,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293631,29046407,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1ccncc1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5864144,,CHEMBL5864144,,0,http://www.openphacts.org/units/Nanomolar,4645983,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293633,29046413,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,COc1c(C)cnc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1C,,,CHEMBL5729797,,2023,"{'bei': '9.60', 'le': '0.18', 'lle': '0.83', 'sei': '6.33'}",CHEMBL6011142,,CHEMBL6011142,7.52,0,http://www.openphacts.org/units/Nanomolar,4645984,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293635,29046419,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CCOc1ccc(-c2nc(CN(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)c(C)o2)cc1,,,CHEMBL5729797,,2023,,CHEMBL5907696,,CHEMBL5907696,,0,http://www.openphacts.org/units/Nanomolar,4645985,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293637,29046425,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(OCc3ccccc3)cc2)c1,,,CHEMBL5729797,,2023,,CHEMBL6026001,,CHEMBL6026001,,0,http://www.openphacts.org/units/Nanomolar,4645986,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293640,29046434,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCNC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5729797,,2023,,CHEMBL6057180,,CHEMBL6057180,,0,http://www.openphacts.org/units/Nanomolar,4645987,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293642,29046440,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCNC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5729797,,2023,,CHEMBL5900102,,CHEMBL5900102,,0,http://www.openphacts.org/units/Nanomolar,4645988,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293644,29046446,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C(=O)c2cccc(CN(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)c2)CC1,,,CHEMBL5729797,,2023,"{'bei': '9.55', 'le': '0.18', 'lle': '2.06', 'sei': '6.76'}",CHEMBL5763220,,CHEMBL5763220,8.12,0,http://www.openphacts.org/units/Nanomolar,4645989,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293646,29046452,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(OCc3ccccc3)cc2)cc1,,,CHEMBL5729797,,2023,"{'bei': '9.46', 'le': '0.17', 'lle': '-0.12', 'sei': '6.61'}",CHEMBL5941798,,CHEMBL5941798,8.12,0,http://www.openphacts.org/units/Nanomolar,4645990,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293649,29046461,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,COCCNC(=O)c1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5729797,,2023,,CHEMBL5941948,,CHEMBL5941948,,0,http://www.openphacts.org/units/Nanomolar,4645991,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293652,29046470,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CN(C)CCNC(=O)c1ccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cc1,,,CHEMBL5729797,,2023,,CHEMBL6042832,,CHEMBL6042832,,0,http://www.openphacts.org/units/Nanomolar,4645992,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293655,29046479,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CN1CCN(C(=O)c2ccc(CN(C(=O)c3cc(-c4cc5c(cc4C(=O)N4Cc6ccccc6C[C@H]4CN4CCOCC4)OCO5)n4c3CCCC4)c3ccc(O)cc3)cc2)CC1,,,CHEMBL5729797,,2023,"{'bei': '9.55', 'le': '0.18', 'lle': '2.06', 'sei': '6.76'}",CHEMBL5789676,,CHEMBL5789676,8.12,0,http://www.openphacts.org/units/Nanomolar,4645993,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293658,29046488,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CS(=O)(=O)NC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(OCc3ccccc3)cc2)c1,,,CHEMBL5729797,,2023,"{'bei': '8.68', 'le': '0.16', 'lle': '0.89', 'sei': '5.45'}",CHEMBL5857436,,CHEMBL5857436,8.12,0,http://www.openphacts.org/units/Nanomolar,4645994,=,37,1,=,,IC50,nM,,7.5,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,7.5
,1293660,29046494,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5729797,,2023,"{'bei': '9.78', 'le': '0.18', 'lle': '1.15', 'sei': '5.61'}",CHEMBL5949378,,CHEMBL5949378,7.52,0,http://www.openphacts.org/units/Nanomolar,4645995,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293662,29046500,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,CC(C)(C)OC(=O)c1cccc(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)c1,,,CHEMBL5729797,,2023,"{'bei': '9.12', 'le': '0.17', 'lle': '-0.11', 'sei': '6.12'}",CHEMBL6010922,,CHEMBL6010922,7.52,0,http://www.openphacts.org/units/Nanomolar,4645996,=,37,1,=,,IC50,nM,,30.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,30.0
,1293663,29046503,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,N#Cc1ccccc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5998767,,CHEMBL5998767,,0,http://www.openphacts.org/units/Nanomolar,4645997,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293664,29046506,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cn1cnnc1CN(C(=O)c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5941257,,CHEMBL5941257,,0,http://www.openphacts.org/units/Nanomolar,4645998,<,37,1,<,,IC50,nM,,5.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,5.0
,1293666,29046512,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,O=C(c1cc(-c2cc3c(cc2C(=O)N2Cc4ccccc4C[C@H]2CN2CCOCC2)OCO3)n2c1CCCC2)N(Cc1cccc(NO)c1)c1ccc(O)cc1,,,CHEMBL5729797,,2023,,CHEMBL5996892,,CHEMBL5996892,,0,http://www.openphacts.org/units/Nanomolar,4645999,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
,1293668,29046518,[],CHEMBL5739506,"BCL-2 TR-FRET Assay: The following assay concentrations and times were used: 3 ng BCL-2, 5 l of 1:100 anti-His Tb-labeled donor, 5 l of 1:100 Dye-labeled acceptor, 5 l of 1:40 BCL-2 Peptide Ligand, and 2 ul of test compound, with 60 min incubation time. The results of the assay were read using a Clariostar (BMG Labtech) plate reader with the following parameters: TR FRET, 340ex/620 and 665em; 60 sec Delay; and 500 sec integration.",B,,,BAO_0000190,BAO_0000357,single protein format,Cc1c(CN(C(=O)c2cc(-c3cc4c(cc3C(=O)N3Cc5ccccc5C[C@H]3CN3CCOCC3)OCO4)n3c2CCCC3)c2ccc(O)cc2)cccc1NO,,,CHEMBL5729797,,2023,,CHEMBL5931418,,CHEMBL5931418,,0,http://www.openphacts.org/units/Nanomolar,4646000,>,37,1,>,,IC50,nM,,50.0,CHEMBL4860,Homo sapiens,Apoptosis regulator Bcl-2,9606,,,IC50,nM,UO_0000065,,50.0
